1st Q
This section reports quality control (QC) statistics for the personal genotype data, as well as for the reference genotype data.
Sample QC
- The genetically determined sex is: Female
- 7 of 293,013 variants are missing, missing rate is: 0.00%
Variants count in each chromosome:
Minor allele frequency in sample based on MAF reference data:
- 292745 of 293548 variants were found in MAF reference data.
Population stratification analysis:
PCA
UMAP
Concordance check:
- In the current genotype file, 293482 of 293548 (99.98%) variants were found in previous genotype file.
- In these common variants, 199513 of 293482 (67.98%) variants were identical.
Population QC
Minor allele frequency:
Missing genotype rates:
Sex discrepancy:
Cryptic relatedness:
Hardy-Weinberg equilibrium:
Heterozygosity rate:
2nd Q
The traits listed in this section are almost definitely determined by genetics. However, the association with relevant disease outcome is certainly not definite. For example, “FTO related obesity” simply reports one widely cited FTO SNP that is associated with obesity, but obesity itself is certainly not determined by a single SNP.
Qualitative traits
| Name | Result |
|---|---|
| ABO blood type | A |
| APOE type | ε3/ε3: the most common |
| Alcohol flush | A- |
| Altruism | More likely |
| Caffeine metabolism | Normal |
| Earwax Type | Wet |
| FTO related obesity | None allele mutated: wild type |
| Folic Acid metabolism | Slow |
| HIV resistance | Susceptible |
| Lactose metabolism | Lactose tolerance |
| Marital satisfaction | Higher levels of satisfaction |
| Muscle fiber type | Slow muscle type |
| Nicotineaddiction | Wild type |
| Perception of fish odor | Insensitive |
Scientific detail:
ABO blood type
Description:
The ABO blood types were discovered by Karl Landsteiner in 1901. He received the Nobel Prize in Physiology or Medicine in 1930 for this discovery. ABO blood types are also present in other primates such as apes and Old World monkeys. The ABO blood group system is used to denote the presence of one, both, or neither of the A and B antigens on erythrocytes. In human blood transfusions it is the most important of the 38 different blood type (or group) classification systems currently recognized. A mismatch in this, or any other serotype, can cause a potentially fatal adverse reaction after a transfusion, or an unwanted immune response to an organ transplant. The associated anti-A and anti-B antibodies are usually IgM antibodies, produced in the first years of life by sensitization to environmental substances such as food, bacteria, and viruses. Usually, four tag SNPs were used for the main ABO blood group antigens (rs8176746 for B, rs687289 for O, rs507666 for A1 and rs8176704 for A2).
Result:
A
Distribution plot:
Scientific detail:
- rs41302905: C/C
- rs8176719: T/TC
- rs8176746: G/G
Reference:
- PMID: 18604267
APOE type
Description:
The APOE gene provides instructions for making a protein called apolipoprotein E. This protein combines with fats (lipids) in the body to form molecules called lipoproteins. Lipoproteins are responsible for packaging cholesterol and other fats and carrying them through the bloodstream. Maintaining normal levels of cholesterol is essential for the prevention of disorders that affect the heart and blood vessels (cardiovascular diseases), including heart attack and stroke.
Result:
ε3/ε3: the most common
Distribution plot:
Scientific detail:
- rs429358: T/T
- rs7412: C/C
Reference:
- PMID: 9343467
Alcohol flush
Description:
In African and European populations, acetaldehyde is broken down quickly enough to maintain tolerably low concentrations in drinkers. In east Asian populations, there is a common loss-of-function variant of the ALDH2 gene on chromosome 12 (rs671). Even a single copy decreases acetaldehyde breakdown enough for the concentration to become uncomfortably high after drinking alcohol. This variant is an important determinant of the east Asian flushing reaction to alcohol, and of alcohol intake. Less importantly, a genetic variant of the ADH1B gene on chromosome 4 (rs1229984) that is common in east Asia increases alcohol clearance rates. Together, these two single nucleotide polymorphisms strongly affect alcohol exposure, and each has been shown to decrease substantially the incidence of alcoholism. Both variants involve a G→A mutation, with the A allele decreasing alcohol exposure. Each variant has three possible genotypes, AA, AG, and GG, so the two variants define nine possible genotypes. Alcohol intake is affected more by the decreased rate of breakdown of acetaldehyde than by the increased alcohol clearance rate. Hence, when describing these nine genotypes the rs671 genotype is given first and the rs1229984 genotype second, and alphabetic order corresponds to increasing alcohol intake: AA/AA, AA/AG, AA/GG; then AG/AA, AG/AG, AG/GG; then GG/AA, GG/AG, GG/GG. We denote this 9 genotype as A+, A, A-, B+, B, B-, C+, C, C-, respectively.
Result:
A-
Distribution plot:
Scientific detail:
- rs671: G/G
- rs1229984: C/C
Reference:
- PMID: 30955975
- PMID 6582480
Altruism
Description:
William D. Hamilton postulated the existence of ‘genes underlying altruism’, under the rubric of inclusive fitness theory, a half-century ago. Humans are by nature prosocial. Nevertheless, prosocial behavior is greatly variable among individuals. By far the best-studied polymorphism within COMT is the Val158Met polymorphism (rs4680). It has long been known that there is a trimodal distribution of COMT activity in human populations (Floderus et al., 1981), which was subsequently shown to be due to the presence of this polymorphism (Lachman et al., 1996). The polymorphism is an A to G single nucleotide change that results in a valine to methionine substitution at position 158 of the MB-COMT amino acid sequence (position 108 in S-COMT Bertocci et al., 1991; Lundstrom et al., 1991). The Met158 form of COMT has a lower thermostability and therefore a lower activity at 37˚C, compared to the Val158 form (Chen et al., 2004; Lotta et al., 1995). The apparent differences in the magnitude of the Val158Met effect on activity are likely due in part to methodological factors, but could plausibly also be due to tissue-specific effects of other polymorphisms/haplotypes in COMT.
Result:
More likely
Distribution plot:
Scientific detail:
- rs4680: A/G
Reference:
- PMID: 21030481
Caffeine metabolism
Description:
Caffeine (1,3,7-trimethylxanthine) is one of the most widely used drugs in the world and is available in many mediums for consumption. The pharmacokinetics and pharmacodynamics of caffeine have been well studied. Caffeine metabolism occurs primarily in the liver via the cytochrome P450 system (CYP1A2). The CYP1A2 proteins are encoded by the CYP1A2 gene, and CYP1A2 activity is induced when aromatic hydrocarbons bind the aryl hydrocarbon receptor. The CYP1A2 gene encodes a member of the cytochrome p450 family of proteins, which metabolize nutrients and drugs. One well known substrate of CYP1A2 is caffeine. The same amount of caffeine will therefore tend to have more stimulating effect on CYP1A2 slow metabolizers than on CYP1A2 fast metabolizers. The SNP rs762551, also known as -164A>C or -163C>A, encodes the CYP1A2*1F allele of the CYP1A2 gene. The C allele is considered the wild-type, even though it is the rarer allele in most populations. AA = CYP1A2*1F = Fast Metabolizer. CC, AC = CYP1A2*1C = Slow Metabolizer.
Result:
Normal
Distribution plot:
Scientific detail:
- rs762551: A/A
Earwax Type
Description:
Description is unavailable.
Result:
Wet
Distribution plot:
Scientific detail:
- rs17822931: C/C
Reference:
- PMID: 16444273
FTO related obesity
Description:
In 2007, within a time period of three months, two studies claimed the discovery of FTO as the first GWAS-identified obesity-susceptibility gene. FTO was first discovered through a GWAS of type 2 diabetes in Europeans, comparing 1,924 cases and 2,938 controls. A cluster of single nucleotide polymorphisms (SNPs) in the first intron of the gene showed highly significant association with risk of type 2 diabetes. However, after adjusting for BMI, the association with type 2 diabetes completely abolished, suggesting that the FTO - type 2 diabetes association was mediated through FTO’s effect on BMI. Eight weeks after the first discovery, a GWAS for BMI in 4,741 Sardinians observed highly significant associations for SNPs from the same intronic cluster in FTO, which was subsequently replicated in 2,335 European and Hispanic Americans. A third study, published at around the same time as the two GWAS, identified the same FTO locus serendipitously, while testing for population stratification in their case-control obesity data. Together, these studies firmly established FTO as the first gene with common variants that affect obesity susceptibility in the general population. Although the mechanism and function of FTO is not fully understood, possible functional alterations by the gene have been reported in the HPA axis and in the reward system in the brain.
Result:
None allele mutated: wild type
Distribution plot:
Scientific detail:
- rs9939609: A/A
Reference:
- PMID: 17434869
Folic Acid metabolism
Description:
The methylenetetrahydrofolate reductase gene, more commonly known as MTHFR, is the most asked-about gene by DTC customers. Some websites and products have made bold claims that common genetic variants in MTHFR can cause a wide array of health conditions, ranging from blood clots and cancer to autism and migraines. The MTHFR gene contains instructions for making an enzyme that’s important for metabolizing folate (also called folic acid or vitamin B9). MTHFR also helps our cells recycle homocysteine, a chemical in the blood, into methionine, a building block for proteins. there are two common naturally occurring variants in the MTHFR gene, called C677T (rs1801133) and A1298C. When the MTHFR gene has either of these two variants, the resulting MTHFR enzyme is slightly less active, and this can lead to decreased levels of folate and increased levels of homocysteine in the blood. Homozygous rs1801133(T;T) individuals have ~30% of the expected MTHFR enzyme activity, and rs1801133(C;T) heterozygotes have ~65% activity, compared to the most common genotype, rs1801133(C;C).
Result:
Slow
Distribution plot:
Scientific detail:
- rs1801133: A/G
Reference:
- PMID: 8789576
HIV resistance
Description:
Host genetic factors are involved in resistance/susceptibility to HIV-1 infection and progression. The most relevant genetic variant of the gene encoding HIV-1 major co- receptor, CCR5 (chemokine receptor type 5). The CCR5 gene codes for a protein on the cell membrane of white blood cells, specifically T-cells, macrophages, dendritic cells, eosinophils, and microglial cells. It is a part of your immune system’s response to foreign invaders, and it is also an essential part of the way that the HIV virus is able to hijack immune cells. A mutation in CCR5, named Delta 32 (rs333), causes a change in the protein that makes it non-functional. Carrying two copies of the mutation protects most carriers from HIV. The first person in the world to be cured of HIV, the “Berlin Patient“, was Timothy Ray Brown, an American living in Berlin. While HIV positive, he contracted leukemia, and in 2007 he was given a bone marrow transplant from a donor with two copies of the CCR5 Delta32 mutation. After 3 months, he no longer had detectable HIV in his blood. The Delta32 variant is well studied on a variety of immune system topics. It is thought that the mutation first arose in Northern Europe and was preferentially passed on in Caucasian populations due to increasing resistance to smallpox.
Result:
Susceptible
Distribution plot:
Scientific detail:
- Snp (rs333) cannot be found in your genotype file!
- rs113010081: T/T
Reference:
- PMID: 31873311
- PMID: 8898752
Lactose metabolism
Description:
Lactose, a sugar in milk, is broken down by the enzyme lactase which our bodies produce in the small intestines. For some people, the production of the lactase enzyme stops when they become an adult, driven by a genetic variation near the LCT gene. This means some adults are genetically predisposed to not be able to digest larger quantities of milk. Producing lactase as an adult is the most common genotype for Caucasian populations, while in Asian populations, the majority do not produce lactase as an adult. A theory for this occurrence seems to be an adaptation by Caucasian populations in Europe who relied on dairy products as a source of protein. For people with European Caucasian ancestry, the main variant to look at is rs4988235. It is located in the MCM6 gene, which influences the LCT gene. Approximately 90% of Caucasians will have A/A or A/G and still produce lactase to break down milk as an adult. In Asian populations, less than one percent will carry the G allele. People with African ancestry may find that they carry a different variant (rs145946881) in the MCM6 gene that also causes lactase persistence as an adult.
Result:
Lactose tolerance
Distribution plot:
Scientific detail:
- rs4988235: A/A
Reference:
- PMID: 11788828
Marital satisfaction
Description:
Based on a study from Makhanova, A. at el. published in February 2021, a research team from the University of Arkansas, Florida State University, and McGill University collected data from 71 heterosexual newlywed couples (N = 142 participants) in their early 30s. Within three months of getting married, couples completed a series of baseline measures. Over the next three years, both partners completed measures of marital satisfaction every four months, along with saliva samples for DNA extraction. Those who had the rs3796863 CC genotype reported greater marital satisfaction, compared to those with the AC/AA type. In addition, those with the CC genotype also reported more trust, forgiveness, and gratitude toward their relationship partner. These associations were the same for men and women. It’s also important to realize that any genetic marker associated with a behavior — in this case marital satisfaction — isn’t causal. That is, every person with this CC genotype won’t be great at relationships. And every person without it won’t be hopeless when it comes to love. Genes aren’t destiny. But this research does show that there are genetic underpinnings to our behavior.
Result:
Higher levels of satisfaction
Distribution plot:
Scientific detail:
- rs3796863: G/G
Reference:
- PMID: 33536489
Muscle fiber type
Description:
Over the last couple of decades, research has focused on attempting to understand the genetic influence on sports performance. This has led to the identification of a number of candidate genes which may help differentiate between elite and non-elite athletes. One of the most promising genes in that regard is ACTN3, which has commonly been referred to as “a gene for speed”. Recent research has examined the influence of this gene on other performance phenotypes, including exercise adaptation, exercise recovery, and sporting injury risk. ACTN3 is a gene that encodes for alpha-actinin-3, a protein expressed only in type-II muscle fibers (North et al., 1999). A common polymorphism in this gene is R577X (rs1815739), where a C-to-T base substitution results in the transformation of an arginine base (R) to a premature stop codon (X). X allele homozygotes are deficient in the alpha-actinin-3 protein, which is associated with a lower fast-twitch fiber percentage (Vincent et al., 2007), but does not result in disease (MacArthur and North, 2004). The XX genotype frequency differs across ethnic groups, with approximately 25% of Asians, 18% of Caucasians, 11% of Ethiopians, 3% of Jamaican and US African Americans, and 1% of Kenyans and Nigerians possessing the XX genotype (Yang et al., 2007; MacArthur et al., 2008; Scott et al., 2010). ACTN3 genotype is associated with speed and power phenotypes.
Result:
Slow muscle type
Distribution plot:
Scientific detail:
- rs1815739: T/T
Reference:
- PMID: 17828264
Nicotineaddiction
Description:
Abundant data from twin and adoption studies provide evidence for the heritability of habitual cigarette smoking. Hall et al. reviewed twin and adoption data in smoking studies, including five studies of twins reared apart. Taken together, these twin studies suggest that a majority of NA risk is attributable to genetic factors. More recent twin smoking research suggests that the heritability of NA is ∼75%. In 2008, Berrettini et al. described a GWAS of ∼7000 individuals of European origin for CPD, with a P-value ∼10−5, at a CHRNA3 SNP allele. They studied a second population of equal size, for the same phenotype (CPD), reporting association to a second allele in the same haplotype, establishing the common European haplotype as conferring risk for Nicotine addition. The CHRNA5/A3/B4 is a gene cluster on chromosome 15 that encodes the α5, α3, and β4 of the nicotinic acetylcholine receptor subunits (nAChR) (Duga et al., 2001; Eng, Kozak, Beaudet, & Zoghbi, 1991). Genome-wide association studies have shown strong associations between tobacco smoking dependence and genetic variations in the CHRNA5/A3/B4 gene cluster (Saccone et al., 2007; Wen, Yang, Cui, & Li, 2016). One single nucleotide polymorphisms (SNP) that showed strong relation to tobacco smoking behavior/dependence is rs16969968 in exon 5 of CHRNA5.
Result:
Wild type
Distribution plot:
Scientific detail:
- rs429358: T/T
- rs16969968: A/G
Reference:
- https://www.nature.com/articles/nature06846
- PMID: 18519524
Perception of fish odor
Description:
The perception of smell is enabled by olfactory receptors, which are proteins that bind odor molecules. Olfactory senses are one of the oldest and most critical senses for the organism survival that helps in identifying food, potential mating partners, as well as dangers. Due to the variation in the number of olfactory receptors in the species, different species have different olfactory abilities. These olfactory receptors (OR) are encoded by OR genes. In humans out of 855 OR genes, only ~400 were functionally coded for ORs. The genetic variation in the OR genes among individuals provides the personalized olfaction behaviour among individuals. A number of association studies for odor perception with genetic OR loci are reported. Also, a recent genome-wide association study was performed by Gisladottir et al. for odor perception on 9,122 Icelanders. They found three genetic variants i.e. p.Ser95Pro in TAAR5 gene (rs41286168), p.Lys233Asn in OR6C70 (rs60683621) and intergenic variant rs317787 associated with aversion to fish odor, increased intensity of licorice, and cinnamon odor respectively.
Result:
Insensitive
Distribution plot:
Scientific detail:
- rs41286168: A/A
Reference:
- PMID: 33035477
3rd Q
The risk assessment is purely based on polygenic risk score, whose association with various diseases is usually very limited. Furthermore, the information provided here should be in no way treated similarly as information from your physician. Most complex traits are determined by both genetics, lifestyle factors, and many other environmental factors.
According to SNPedia , “population statistics are a bit hard to come by, and furthermore, the more interesting ‘personal genomics’ statistic might be residual lifetime risk in light of your own genome and your current age ... but there isn't enough medical and epidemiological data to actually calculate this yet for any complex disease”. Nevertheless, we list the average lifetime risk for various traits based on SNPedia, unless otherwise specified.
Quantitative traits
| Name | Risk |
|---|---|
| Age related macular degeneration | Normal |
| Atrial fibrillation | Low risk |
| Breast cancer | Normal |
| COVID-19 susceptibility | Normal |
| Colorectal cancer | Normal |
| Coronary artery disease | Low risk |
| Lung cancer | Normal |
| Migraine | Low risk |
| Schizophrenia | Low risk |
Scientific detail:
Age related macular degeneration
Description:
Age-related macular degeneration (AMD) is an eye disease that can blur the sharp, central vision one needs for activities like reading and driving. “Age-related” means that it often happens in older people. “Macular” means it affects a part of the eye called the macula. AMD is a leading cause of vision loss for people age 50 and older. AMD doesn’t cause complete blindness, but losing one’ central vision can make it harder to see faces, drive, or do close-up work like cooking or fixing things around the house. AMD happens very slowly in some people. For some people, AMD may not experience vision loss for a long time. For other people, AMD progresses faster and can lead to central vision loss in one eye or both eyes. AMD is the very first disease that inspired genome-wide association studies (GWAS). Arguably, the best-known and most successful GWAS was on AMD, by Klein et al. in 2005, published on Science Journal.
Standardized genetic risk score:
Mean - 0.15 * SD
Distribution:
N of reference population: 503
N below this sample: 223 (44.33%)
N above this sample: 280 (55.67%)
Distribution plot:
Scientific detail:
- rs10033900: C/T, effect allele: C, beta: 1.15
- rs10781182: G/G, effect allele: G, beta: 1.11
- rs10922109: C/A, effect allele: C, beta: 0.38
- rs11080055: C/A, effect allele: C, beta: 0.91
- rs114092250: G/G, effect allele: G, beta: 0.7
- rs1142: C/T, effect allele: C, beta: 1.11
- Snp (rs116503776) cannot be found in your genotype file!
- rs11884770: C/T, effect allele: C, beta: 0.9
- rs12357257: A/G, effect allele: G, beta: 1.11
- rs140647181: T/T, effect allele: T, beta: 1.59
- Snp (rs142450006) cannot be found in your genotype file!
- rs1626340: G/G, effect allele: G, beta: 0.88
- rs201459901: T/T, effect allele: T, beta: 0.76
- rs2043085: C/T, effect allele: T, beta: 0.87
- rs2230199: G/G, effect allele: C, beta: 1.43
- rs2740488: A/A, effect allele: A, beta: 0.9
- rs3138141: C/C, effect allele: C, beta: 1.16
- rs3750846: T/T, effect allele: T, beta: 2.81
- rs429358: T/T, effect allele: T, beta: 0.7
- rs5754227: T/T, effect allele: T, beta: 0.77
- rs5817082: C/C, effect allele: C, beta: 0.84
- rs61941274: A/G, effect allele: G, beta: 1.51
- rs61985136: T/T, effect allele: T, beta: 0.9
- rs62247658: C/T, effect allele: T, beta: 1.14
- rs62358361: G/G, effect allele: G, beta: 1.8
- rs6565597: C/C, effect allele: C, beta: 1.13
- rs67538026: C/T, effect allele: C, beta: 0.9
- rs71507014: G/C/C/G/C/C, effect allele: GC, beta: 1.1
- rs72802342: C/A, effect allele: C, beta: 0.79
- rs7803454: C/C, effect allele: C, beta: 1.13
- Snp (rs79037040) cannot be found in your genotype file!
- rs8135665: C/C, effect allele: C, beta: 1.14
- rs943080: C/T, effect allele: T, beta: 0.88
- rs9564692: C/C, effect allele: C, beta: 0.89
Reference:
- A large genome-wide association study of age-related macular degeneration highlights contributions of rare and common variants
Atrial fibrillation
Description:
Atrial fibrillation (AF) is the most common heart rhythm disorder worldwide and may have serious cardiovascular health consequences. AF is associated with increased risk of stroke, dementia, heart failure, and death. There are several known robust, clinical risk predictors for AF, such as male sex, increasing age, and hypertension; however, during the last couple of decades, a substantive genetic component has also been established. Over the last 10 years, the discovery of novel AF-related genetic variants has accelerated, increasing our understanding of mechanisms behind AF. Current studies are focusing on mapping the polygenic structure of AF, improving risk prediction, therapeutic development, and patient-specific management. Nevertheless, it is still difficult for clinicians to interpret the role of genetics in AF prediction and management.
Standardized genetic risk score:
Mean - 1.46 * SD
Distribution:
N of reference population: 503
N below this sample: 30 (5.96%)
N above this sample: 473 (94.04%)
Distribution plot:
Scientific detail:
- rs11264280: C/C, effect allele: T, beta: 1.12
- rs1152591: A/G, effect allele: A, beta: 1.09
- rs11598047: A/A, effect allele: G, beta: 1.18
- rs11718898: C/T, effect allele: C, beta: 1.08
- rs12664873: T/G, effect allele: T, beta: 1.08
- rs1997572: A/A, effect allele: G, beta: 1.1
- rs2106261: C/C, effect allele: T, beta: 1.2
- rs2288327: A/A, effect allele: G, beta: 1.09
- rs2540949: A/A, effect allele: A, beta: 1.08
- rs2967791: C/C, effect allele: T, beta: 1.07
- rs337711: C/C, effect allele: T, beta: 1.07
- rs35176054: T/T, effect allele: A, beta: 1.14
- rs3771537: C/C, effect allele: A, beta: 1.09
- rs4499262: C/C, effect allele: A, beta: 1.14
- rs4946333: A/G, effect allele: G, beta: 1.08
- rs520525: A/G, effect allele: A, beta: 1.12
- rs60848348: C/C, effect allele: T, beta: 1.13
- rs6843082: A/G, effect allele: G, beta: 1.45
- rs7026071: C/C, effect allele: T, beta: 1.09
- rs72700118: C/C, effect allele: A, beta: 1.14
- rs7394190: G/G, effect allele: G, beta: 1.15
- rs74022964: C/C, effect allele: T, beta: 1.12
- rs7508: A/G, effect allele: A, beta: 1.09
- rs75190942: C/C, effect allele: A, beta: 1.17
- rs7915134: C/C, effect allele: C, beta: 1.12
- rs883079: T/T, effect allele: T, beta: 1.11
Reference:
- Multi-ethnic genome-wide association study for atrial fibrillation
Breast cancer
Description:
Breast cancer risk is influenced by rare coding variants in susceptibility genes, such as BRCA1, and many common, mostly non-coding variants. However, much of the genetic contribution to breast cancer risk remains unknown.
Standardized genetic risk score:
Mean - 0.31 * SD
Distribution:
N of reference population: 503
N below this sample: 178 (35.39%)
N above this sample: 325 (64.61%)
Distribution plot:
Scientific detail:
- rs2992756: T/T, effect allele: C, beta: 1.03
- rs4233486: C/C, effect allele: T, beta: 0.97
- rs79724016: T/T, effect allele: T, beta: 0.85
- rs1707302: A/A, effect allele: G, beta: 0.97
- rs140850326: C/C, effect allele: I, beta: 0.94
- rs17426269: G/G, effect allele: G, beta: 1.06
- rs7529522: T/T, effect allele: T, beta: 1.06
- rs4971059: A/G, effect allele: G, beta: 1.07
- rs35383942: C/C, effect allele: C, beta: 1.08
- rs11117758: G/G, effect allele: G, beta: 0.95
- rs113577745: C/C, effect allele: C, beta: 1.08
- rs6725517: A/A, effect allele: A, beta: 0.95
- Snp (rs71801447) cannot be found in your genotype file!
- rs12479355: A/A, effect allele: A, beta: 0.94
- rs6805189: C/T, effect allele: T, beta: 0.96
- rs13066793: A/A, effect allele: A, beta: 0.91
- rs9833888: T/G, effect allele: G, beta: 1.06
- Snp (rs34207738) cannot be found in your genotype file!
- rs58058861: G/G, effect allele: G, beta: 1.05
- rs6815814: C/A, effect allele: A, beta: 1.05
- Snp (4:84370124) cannot be found in your genotype file!
- rs10022462: T/T, effect allele: C, beta: 1.07
- rs77528541: G/G, effect allele: G, beta: 0.91
- Snp (rs116095464) cannot be found in your genotype file!
- rs72749841: C/T, effect allele: T, beta: 0.93
- rs35951924: A/T/A/T, effect allele: A, beta: 0.96
- rs6882649: T/G, effect allele: T, beta: 0.94
- rs6596100: C/T, effect allele: C, beta: 0.97
- rs4562056: T/G, effect allele: G, beta: 1.04
- rs3819405: C/C, effect allele: C, beta: 0.93
- rs2223621: T/T, effect allele: C, beta: 1.05
- rs71557345: A/G, effect allele: G, beta: 0.92
- rs12207986: A/G, effect allele: A, beta: 0.95
- rs6569648: C/T, effect allele: T, beta: 0.91
- rs7971: A/A, effect allele: A, beta: 0.97
- rs17156577: T/T, effect allele: T, beta: 1.11
- rs17268829: C/T, effect allele: T, beta: 1.07
- rs71559437: G/G, effect allele: G, beta: 0.96
- rs514192: A/A, effect allele: T, beta: 1.06
- rs12546444: A/A, effect allele: A, beta: 0.94
- rs58847541: G/G, effect allele: G, beta: 1.08
- rs1895062: G/G, effect allele: A, beta: 0.97
- rs10760444: A/A, effect allele: A, beta: 1.08
- Snp (rs8176636) cannot be found in your genotype file!
- rs67958007: T/TG, effect allele: TG, beta: 1.06
- rs140936696: C/C, effect allele: C, beta: 1.07
- rs6597981: A/G, effect allele: G, beta: 0.96
- rs202049448: T/T, effect allele: T, beta: 0.96
- rs206966: C/C, effect allele: C, beta: 1.04
- rs10623258: C/C, effect allele: C, beta: 1.06
- rs28539243: G/G, effect allele: G, beta: 1.05
- rs2432539: A/G, effect allele: G, beta: 1.05
- rs4496150: C/C, effect allele: C, beta: 0.96
- rs72826962: C/C, effect allele: C, beta: 0.99
- Snp (rs2532263) cannot be found in your genotype file!
- rs117618124: T/T, effect allele: T, beta: 0.86
- rs78269692: T/T, effect allele: T, beta: 1.08
- rs2594714: G/G, effect allele: G, beta: 0.94
- rs2965183: A/G, effect allele: G, beta: 1.05
- Snp (rs71338792) cannot be found in your genotype file!
- rs16991615: G/G, effect allele: G, beta: 1.09
- rs6122906: A/A, effect allele: A, beta: 1.08
- rs738321: C/G, effect allele: C, beta: 0.94
- rs73161324: C/T, effect allele: C, beta: 1.14
- rs28512361: G/G, effect allele: G, beta: 1.06
Reference:
- Association analysis identifies 65 new breast cancer risk loci
COVID-19 susceptibility
Description:
While environmental, clinical and social factors play a role in exposure to SARS-CoV-2 and COVID-19 disease severity, host genetics may also be important. Identifying host-specific genetic factors may reveal biological mechanisms of therapeutic relevance and clarify causal relationships of modifiable environmental risk factors for SARS-CoV-2 infection and outcomes. We derive personal susceptibility based on GWAS released by the COVID-19 host genetics initiative. This initiative brings together the human genetics community to generate, share, and analyze data to learn the genetic determinants of COVID-19 susceptibility, severity, and outcomes. Such discoveries could help to generate hypotheses for drug repurposing, identify individuals at unusually high or low risk, and contribute to global knowledge of the biology of SARS-CoV-2 infection and disease.
Standardized genetic risk score:
Mean - 0.58 * SD
Distribution:
N of reference population: 503
N below this sample: 134 (26.64%)
N above this sample: 369 (73.36%)
Distribution plot:
Scientific detail:
- rs2271616: T/G, effect allele: G, beta: 1.155
- rs10490770: T/T, effect allele: T, beta: 1.160
- rs11919389: T/T, effect allele: T, beta: 0.941
- rs1886814: A/A, effect allele: A, beta: 1.106
- Snp (rs912805253) cannot be found in your genotype file!
- rs10774671: G/G, effect allele: G, beta: 1.059
- rs2109069: G/G, effect allele: G, beta: 1.049
- rs4801778: T/G, effect allele: G, beta: 0.946
- rs72711165: C/T, effect allele: T, beta: 1.077
- rs1819040: T/T, effect allele: T, beta: 0.957
- rs77534576: C/C, effect allele: C, beta: 1.084
- rs74956615: T/T, effect allele: T, beta: 1.055
- rs13050728: C/T, effect allele: T, beta: 0.967
Reference:
- PMID：34237774
Colorectal cancer
Description:
Colorectal cancer (CRC) is the third and fourth most common cancer in women and men worldwide, respectively, and the fourth most common cause of cancer death. CRC exhibits global geographic variations in its incidence with multiple factors (social, demographic, environmental, and genetic) playing different roles in its pathogenesis. Diet rich in fat and low in fiber, high levels of triglycerides, physical inactivity, diabetes, alcohol, obesity, and smoking are the identified risk factors of colorectal cancer. Hereditary factors play a definite role as well. CRC is generally sporadic but approximately 25% of the patients have a genetic predisposition. Instability in chromosomes, CpG island methylation, and microsatellite instability have been reported in key genes leading to the developing of CRC. Gene–environment interactions are also important in the pathogenesis.
Standardized genetic risk score:
Mean - 0.49 * SD
Distribution:
N of reference population: 503
N below this sample: 158 (31.41%)
N above this sample: 345 (68.59%)
Distribution plot:
Scientific detail:
- Using "clump" and "score" function in plink to calculate PRS.
- There are 4791 variants for this trait in raw GWAS data.
- After clumping, there are 4792 valid variants for PRS.
- In this sample, there are 4790 loaded to calculate PRS.
Reference:
- Association analyses identify 31 new risk loci for colorectal cancer susceptibility
Coronary artery disease
Description:
Coronary artery disease (CAD) is a leading cause of death worldwide. The major sequelae of CAD include angina, myocardial infarction (MI), arrhythmias, heart failure, and sudden cardiac death. CAD has a complex aetiology, and various environmental factors, including cigarette smoking, sedentary lifestyle, unhealthy diet and obesity, and disease predisposition. These lifestyle-related factors can lead to type 2 diabetes, hypercholesterolaemia and arterial hypertension, which are key risk factors for CAD. In addition, the influence of heritability on CAD susceptibility has been recognized for many years and accounts for 40–50% of cases. Although the inherited CAD risk is particularly evident in large families with multiple affected members, decade ago only mutations in the LDL receptor gene were reproducibly linked to the disease. However, with the emergence of genome-wide association studies (GWAS), large number of common variants displayed strongly reproducible yet small effects and substantially broadened the spectrum of genetic factors recognized as contributing to CAD aetiology.
Standardized genetic risk score:
Mean - 2.04 * SD
Distribution:
N of reference population: 503
N below this sample: 7 (1.39%)
N above this sample: 496 (98.61%)
Distribution plot:
Scientific detail:
- rs10840293: A/G, effect allele: A, beta: 1.06
- rs10947789: C/T, effect allele: T, beta: 1.05
- rs10953541: C/C, effect allele: C, beta: 1.05
- rs11203042: C/T, effect allele: T, beta: 1.04
- rs11206510: T/T, effect allele: T, beta: 1.08
- rs1122608: T/G, effect allele: G, beta: 1.08
- rs11556924: C/C, effect allele: C, beta: 1.08
- rs11830157: T/T, effect allele: G, beta: 1.04
- rs12190287: C/G, effect allele: C, beta: 1.06
- rs12413409: G/G, effect allele: G, beta: 1.08
- rs12526453: C/C, effect allele: C, beta: 1.1
- rs12936587: A/G, effect allele: G, beta: 1.03
- rs12976411: A/A, effect allele: T, beta: 0.95
- rs1412444: T/T, effect allele: T, beta: 1.07
- rs1561198: C/T, effect allele: T, beta: 1.06
- rs16986953: G/G, effect allele: A, beta: 1.09
- rs17087335: G/G, effect allele: T, beta: 1.06
- rs17114036: A/G, effect allele: A, beta: 1.13
- rs17464857: T/T, effect allele: T, beta: 1.06
- rs17465637: C/C, effect allele: C, beta: 1.08
- rs17514846: C/C, effect allele: A, beta: 1.05
- rs180803: G/G, effect allele: G, beta: 1.2
- rs1878406: C/C, effect allele: T, beta: 1.06
- rs2023938: T/T, effect allele: C, beta: 1.06
- rs2047009: T/G, effect allele: G, beta: 1.06
- rs2048327: T/T, effect allele: C, beta: 1.06
- rs2075650: A/A, effect allele: G, beta: 1.07
- rs216172: G/G, effect allele: C, beta: 1.05
- rs2252641: C/C, effect allele: C, beta: 1.03
- rs2505083: C/T, effect allele: C, beta: 1.06
- rs264: G/G, effect allele: G, beta: 1.06
- rs273909: A/A, effect allele: G, beta: 1.06
- rs2895811: C/T, effect allele: C, beta: 1.04
- rs2954029: T/T, effect allele: A, beta: 1.04
- rs3184504: C/T, effect allele: T, beta: 1.07
- rs3217992: C/C, effect allele: T, beta: 1.14
- rs3798220: T/T, effect allele: C, beta: 1.42
- rs3918226: C/C, effect allele: T, beta: 1.14
- rs4252120: C/C, effect allele: T, beta: 1.03
- rs445925: G/G, effect allele: G, beta: 1.09
- rs46522: C/C, effect allele: T, beta: 1.04
- rs4773144: A/A, effect allele: G, beta: 1.05
- rs4845625: C/C, effect allele: T, beta: 1.05
- rs4977574: A/A, effect allele: G, beta: 1.21
- rs501120: T/T, effect allele: T, beta: 1.08
- rs515135: C/C, effect allele: C, beta: 1.07
- rs56062135: C/T, effect allele: C, beta: 1.07
- rs579459: C/T, effect allele: C, beta: 1.08
- rs646776: C/T, effect allele: T, beta: 1.11
- rs6544713: C/C, effect allele: T, beta: 1.05
- rs663129: A/G, effect allele: A, beta: 1.06
- rs6725887: T/T, effect allele: C, beta: 1.14
- rs7136259: C/T, effect allele: T, beta: 1.04
- rs7173743: C/T, effect allele: T, beta: 1.08
- rs7212798: T/T, effect allele: C, beta: 1.08
- rs7692387: A/G, effect allele: G, beta: 1.07
- rs8042271: G/G, effect allele: G, beta: 1.1
- rs9319428: G/G, effect allele: A, beta: 1.04
- rs9515203: T/T, effect allele: T, beta: 1.07
- rs964184: C/C, effect allele: G, beta: 1.05
- rs974819: C/C, effect allele: T, beta: 1.07
- rs9818870: C/C, effect allele: T, beta: 1.07
- rs9982601: C/C, effect allele: T, beta: 1.12
Reference:
- Identification of 64 Novel Genetic Loci Provides an Expanded View on the Genetic Architecture of Coronary Artery Disease
Lung cancer
Description:
Lung cancer is the leading cause of cancer-related deaths worldwide in both men and women. Although it has long been recognized that lung cancer runs strongly in families, the specific genes that are responsible for enhanced risk are just starting to be revealed. Identifying genes responsible for lung cancer before the era of GWAS has been limited. Candidate susceptibility genes coding for enzymes involved in the activation, detoxification and repair of damages caused by tobacco smoke as well as genes in inflammatory and cell-cycle pathways have been extensively studied. Many of these candidate gene studies are either preliminary or controversial. GWAS have evolved from finding lung cancer loci per se, to a more refined search strategy focused on specific subgroups of lung cancer patients. Advances in analysis strategies were also achieved moving from single marker analyses to pathway-based and variant prioritization approaches. GWAS have also been performed to find genetic loci associated with lung cancer survival, response to conventional therapies, and multiple sites of cancer. GWAS by environmental exposures and genome-wide epistasis analyses are also emerging.
Standardized genetic risk score:
Mean - 0.13 * SD
Distribution:
N of reference population: 503
N below this sample: 223 (44.33%)
N above this sample: 280 (55.67%)
Distribution plot:
Scientific detail:
- rs1056562: C/C, effect allele: T, beta: 1.11
- rs11571833: A/A, effect allele: T, beta: 1.6
- rs11591710: A/A, effect allele: C, beta: 1.16
- Snp (rs116822326) cannot be found in your genotype file!
- rs11780471: G/G, effect allele: A, beta: 0.87
- rs13080835: T/G, effect allele: T, beta: 0.9
- rs17879961: A/A, effect allele: G, beta: 0.41
- rs41309931: G/G, effect allele: T, beta: 1.17
- rs4236709: A/G, effect allele: G, beta: 1.13
- rs55781567: C/G, effect allele: G, beta: 1.3
- rs56113850: C/C, effect allele: T, beta: 0.88
- rs66759488: G/G, effect allele: A, beta: 1.07
- rs6920364: G/G, effect allele: C, beta: 1.07
- rs71658797: T/T, effect allele: A, beta: 1.13
- rs7705526: C/C, effect allele: A, beta: 1.25
- rs77468143: T/T, effect allele: G, beta: 0.86
- rs7953330: C/G, effect allele: C, beta: 0.86
- rs885518: A/G, effect allele: G, beta: 1.17
Reference:
- Large-scale association analysis identifies new lung cancer susceptibility loci and heterogeneity in genetic susceptibility across histological subtypes
Migraine
Description:
Migraine affects up to one-fifth of the world population. It persistently ranks among the top 10 causes of disability, and accounts for more than half of the years lived with disability from neurological causes. As such, migraine has a tremendous socioeconomic impact, not to mention lost productivity and human suffering. Despite decades of research, the complex pathophysiology of migraine is still poorly understood. Without understanding the molecular mechanisms, existing therapies are empirical, serendipitous, and of limited efficacy. It has long been recognised that migraine is a disease with a strong genetic component. Migraine runs in families, and epidemiological studies in twins and families have indicated that risk for migraine is conferred by a combination of genetic and environmental factors, both contributing equally. These studies also indicated that the genetic contribution seems stronger in migraine with aura than the more common migraine without aura subtype.
Standardized genetic risk score:
Mean - 0.69 * SD
Distribution:
N of reference population: 503
N below this sample: 120 (23.86%)
N above this sample: 383 (76.14%)
Distribution plot:
Scientific detail:
- rs10155855: A/A, effect allele: T, beta: 1.08
- rs10166942: C/T, effect allele: C, beta: 0.94
- rs10218452: A/A, effect allele: G, beta: 1.11
- rs1024905: G/G, effect allele: G, beta: 1.06
- rs10456100: C/C, effect allele: T, beta: 1.06
- rs10786156: C/C, effect allele: G, beta: 0.95
- rs10895275: A/A, effect allele: A, beta: 1.04
- rs11031122: T/T, effect allele: C, beta: 1.04
- Snp (rs111404218) cannot be found in your genotype file!
- rs11172113: C/T, effect allele: C, beta: 0.9
- rs11624776: C/A, effect allele: C, beta: 0.96
- rs12260159: A/G, effect allele: A, beta: 0.92
- rs1268083: T/T, effect allele: C, beta: 0.96
- rs12845494: C/C, effect allele: G, beta: 0.96
- rs13078967: A/A, effect allele: C, beta: 0.87
- rs138556413: C/C, effect allele: T, beta: 0.88
- Snp (rs140002913) cannot be found in your genotype file!
- rs144017103: C/C, effect allele: T, beta: 0.85
- rs1572668: A/A, effect allele: G, beta: 1.04
- rs17857135: T/T, effect allele: C, beta: 1.06
- rs186166891: A/A, effect allele: T, beta: 1.09
- rs1925950: A/A, effect allele: G, beta: 1.07
- rs2078371: T/T, effect allele: C, beta: 1.11
- rs2223089: G/G, effect allele: C, beta: 0.93
- rs2506142: A/A, effect allele: G, beta: 1.06
- rs28455731: G/G, effect allele: T, beta: 1.06
- rs4081947: G/G, effect allele: G, beta: 1.03
- rs4814864: C/G, effect allele: C, beta: 1.07
- rs4910165: C/G, effect allele: C, beta: 0.94
- rs561561: A/A, effect allele: T, beta: 0.94
- rs6478241: A/G, effect allele: A, beta: 1.05
- rs6693567: T/T, effect allele: C, beta: 1.05
- Snp (rs67338227) cannot be found in your genotype file!
- rs6791480: C/C, effect allele: T, beta: 1.04
- rs75213074: C/C, effect allele: T, beta: 0.89
- rs7684253: T/T, effect allele: C, beta: 0.96
- Snp (rs77505915) cannot be found in your genotype file!
- rs9349379: G/G, effect allele: G, beta: 0.93
- rs10514168: C/C, effect allele: C, beta: 1.05
- rs10752212: A/G, effect allele: G, beta: 1.03
- rs10970305: C/A, effect allele: C, beta: 1.06
- rs11129078: A/G, effect allele: G, beta: 1.06
- rs11713169: A/A, effect allele: C, beta: 1.05
- rs1195218: G/G, effect allele: G, beta: 1.1
- rs1378552: C/T, effect allele: T, beta: 1.03
- rs149951341: C/C, effect allele: C, beta: 1.05
- rs17515225: C/T, effect allele: T, beta: 1.03
- rs1782032: G/G, effect allele: G, beta: 1.03
- rs1847202: T/T, effect allele: T, beta: 1.03
- rs1858111: A/A, effect allele: G, beta: 1.04
- rs2150864: A/G, effect allele: G, beta: 1.04
- rs2153535: G/G, effect allele: G, beta: 1.05
- rs2318131: C/A, effect allele: C, beta: 1.04
- rs2360806: A/A, effect allele: C, beta: 1.05
- rs2551802: G/G, effect allele: G, beta: 1.04
- rs34311235: T/T, effect allele: T, beta: 1.03
- rs34912216: A/G, effect allele: G, beta: 1.04
- rs4076764: T/T, effect allele: T, beta: 1.03
- rs4343996: A/A, effect allele: G, beta: 1.03
- rs56051278: A/A, effect allele: G, beta: 1.07
- rs60464047: T/T, effect allele: T, beta: 1.04
- rs6069325: T/T, effect allele: T, beta: 1.07
- rs61759167: C/C, effect allele: T, beta: 1.05
- rs62018380: C/A, effect allele: C, beta: 1.05
- rs66800491: A/A, effect allele: G, beta: 1.08
- rs6833641: G/G, effect allele: G, beta: 1.05
- rs6946969: A/G, effect allele: G, beta: 1.03
- rs705145: C/A, effect allele: C, beta: 1.05
- rs7170668: T/T, effect allele: T, beta: 1.04
- rs7957589: T/A, effect allele: T, beta: 1.05
- rs9834560: C/A, effect allele: C, beta: 1.04
- rs9906289: C/C, effect allele: T, beta: 1.09
- rs997295: T/T, effect allele: T, beta: 1.03
Reference:
- Meta-analysis of 375
- 000 individuals identifies 38 susceptibility loci for migraine
Schizophrenia
Description:
Schizophrenia is a common and serious psychiatric illness affecting 0.5–1% of the population in early adulthood. The disease remains incurable, with the best outcome being the control of symptoms and preservation of sufficient functionality and independence. Schizophrenia is a disease with remarkable phenotypic heterogeneity. The symptoms are generally divided into three categories: positive symptoms, negative symptoms, and cognitive symptoms. Each patient can have a different mix of the three types of symptoms leading to an overall highly heterogeneous phenotype. Affective symptoms may combine with the classic symptoms of schizophrenia leading to schizoaffective disorder, which some genetic researchers categorize with schizophrenia and others with bipolar disorder (BD). It has long been recognized that schizophrenia runs in families, noted in the first detailed description of the disease by Bleuler in 1911. Formally, the heritability of the disease has been calculated at > 80%, making genetic makeup the most important factor for developing the disease.
Standardized genetic risk score:
Mean - 1.24 * SD
Distribution:
N of reference population: 503
N below this sample: 57 (11.33%)
N above this sample: 446 (88.67%)
Average lifetime risk: 15.2/100,000 persons
Distribution plot:
Scientific detail:
- Snp (chr1_243881945_I) cannot be found in your genotype file!
- Snp (chr1_8424984_D) cannot be found in your genotype file!
- Snp (chr10_104957618_I) cannot be found in your genotype file!
- Snp (chr11_46350213_D) cannot be found in your genotype file!
- Snp (chr18_52749216_D) cannot be found in your genotype file!
- Snp (chr2_146436222_I) cannot be found in your genotype file!
- Snp (chr2_149429178_D) cannot be found in your genotype file!
- Snp (chr2_200825237_I) cannot be found in your genotype file!
- Snp (chr22_39987017_D) cannot be found in your genotype file!
- Snp (chr3_180594593_I) cannot be found in your genotype file!
- Snp (chr5_140143664_I) cannot be found in your genotype file!
- Snp (chr6_84280274_D) cannot be found in your genotype file!
- Snp (chr7_2025096_I) cannot be found in your genotype file!
- Snp (chr7_24747494_D) cannot be found in your genotype file!
- rs10043984: C/C, effect allele: T, beta: 1.069
- rs1023500: T/T, effect allele: T, beta: 1.076
- rs10503253: C/A, effect allele: A, beta: 1.073
- rs10520163: T/T, effect allele: T, beta: 1.065
- rs10791097: T/T, effect allele: T, beta: 1.076
- rs10803138: A/G, effect allele: A, beta: 0.933
- rs10860964: C/C, effect allele: T, beta: 1.06
- rs11027857: A/G, effect allele: A, beta: 1.064
- rs1106568: A/A, effect allele: A, beta: 0.934
- rs111294930: G/G, effect allele: A, beta: 1.094
- rs11139497: A/A, effect allele: A, beta: 1.069
- rs11191419: T/T, effect allele: A, beta: 0.906
- rs11210892: A/A, effect allele: A, beta: 0.934
- Snp (rs115329265) cannot be found in your genotype file!
- rs11682175: C/T, effect allele: T, beta: 0.933
- rs11685299: A/A, effect allele: A, beta: 0.939
- rs11693094: C/T, effect allele: T, beta: 0.929
- rs117074560: C/C, effect allele: T, beta: 0.849
- rs11740474: A/A, effect allele: A, beta: 0.942
- rs12129573: C/A, effect allele: A, beta: 1.078
- rs12148337: T/T, effect allele: T, beta: 1.06
- rs12325245: A/A, effect allele: A, beta: 0.92
- rs12421382: C/T, effect allele: T, beta: 0.941
- rs12522290: C/C, effect allele: C, beta: 1.084
- rs12691307: A/G, effect allele: A, beta: 1.073
- rs12704290: A/G, effect allele: A, beta: 0.904
- rs12826178: G/G, effect allele: T, beta: 0.846
- rs12845396: A/A, effect allele: A, beta: 0.947
- rs12887734: G/G, effect allele: T, beta: 1.088
- rs12903146: A/A, effect allele: A, beta: 1.067
- rs13240464: T/T, effect allele: T, beta: 1.083
- rs1339227: C/T, effect allele: T, beta: 0.942
- rs1378559: T/T, effect allele: T, beta: 1.09
- rs140505938: C/T, effect allele: T, beta: 0.914
- rs14403: C/T, effect allele: T, beta: 0.934
- rs1498232: C/C, effect allele: T, beta: 1.069
- rs1501357: T/T, effect allele: T, beta: 0.926
- rs16867576: A/A, effect allele: A, beta: 1.101
- rs1702294: C/C, effect allele: T, beta: 0.887
- rs17194490: G/G, effect allele: T, beta: 1.101
- Snp (rs190065944) cannot be found in your genotype file!
- rs2007044: A/G, effect allele: A, beta: 0.912
- rs2053079: A/A, effect allele: A, beta: 0.931
- rs2068012: C/T, effect allele: T, beta: 0.933
- rs211829: T/T, effect allele: T, beta: 1.061
- rs215411: T/A, effect allele: A, beta: 1.064
- rs2239063: A/A, effect allele: A, beta: 1.067
- rs2332700: C/G, effect allele: C, beta: 1.073
- rs2514218: C/T, effect allele: T, beta: 0.927
- rs2535627: T/T, effect allele: T, beta: 1.071
- rs2693698: G/G, effect allele: A, beta: 0.939
- rs2851447: C/G, effect allele: C, beta: 0.915
- rs2905426: T/G, effect allele: T, beta: 0.934
- rs2909457: A/G, effect allele: A, beta: 0.944
- rs2973155: C/T, effect allele: T, beta: 0.933
- rs324017: C/A, effect allele: A, beta: 0.938
- rs35518360: A/A, effect allele: A, beta: 0.857
- rs36068923: A/A, effect allele: A, beta: 0.919
- rs3735025: C/C, effect allele: T, beta: 1.066
- rs3768644: G/G, effect allele: A, beta: 0.904
- rs3849046: C/T, effect allele: T, beta: 1.063
- rs4129585: C/C, effect allele: A, beta: 1.087
- rs4240748: C/C, effect allele: C, beta: 0.943
- rs4330281: C/T, effect allele: T, beta: 0.94
- rs4388249: C/C, effect allele: T, beta: 1.076
- rs4391122: A/G, effect allele: A, beta: 0.922
- rs4523957: T/T, effect allele: T, beta: 1.071
- rs4648845: C/C, effect allele: T, beta: 1.072
- rs4702: A/A, effect allele: A, beta: 0.922
- rs4766428: C/C, effect allele: T, beta: 1.068
- rs55661361: G/G, effect allele: A, beta: 0.926
- rs55833108: G/G, effect allele: T, beta: 1.075
- rs56205728: A/G, effect allele: A, beta: 1.074
- rs56873913: T/T, effect allele: T, beta: 1.071
- rs5937157: T/T, effect allele: T, beta: 0.938
- rs59979824: A/A, effect allele: A, beta: 0.937
- rs6002655: C/T, effect allele: T, beta: 1.066
- rs6065094: A/G, effect allele: A, beta: 0.928
- rs6434928: A/G, effect allele: A, beta: 0.929
- rs6466055: C/C, effect allele: A, beta: 1.068
- rs6670165: C/T, effect allele: T, beta: 1.075
- rs6704641: A/A, effect allele: A, beta: 1.081
- rs6704768: A/A, effect allele: A, beta: 0.93
- rs679087: C/C, effect allele: A, beta: 0.941
- rs6984242: A/G, effect allele: A, beta: 0.941
- rs715170: C/C, effect allele: T, beta: 0.935
- rs7267348: T/T, effect allele: T, beta: 0.937
- rs72934570: C/T, effect allele: T, beta: 0.873
- rs73229090: C/A, effect allele: A, beta: 0.908
- rs7405404: C/T, effect allele: T, beta: 1.077
- rs7432375: A/G, effect allele: A, beta: 0.933
- rs75059851: A/A, effect allele: A, beta: 1.091
- rs7523273: A/A, effect allele: A, beta: 1.063
- rs75575209: A/A, effect allele: A, beta: 0.902
- rs75968099: C/C, effect allele: T, beta: 1.085
- rs76869799: C/C, effect allele: C, beta: 0.846
- rs77149735: G/G, effect allele: A, beta: 1.317
- rs77502336: G/G, effect allele: C, beta: 1.066
- rs7801375: G/G, effect allele: A, beta: 0.924
- rs7819570: G/G, effect allele: T, beta: 1.079
- rs78322266: G/G, effect allele: T, beta: 1.188
- rs7893279: T/T, effect allele: T, beta: 1.125
- Snp (rs7907645) cannot be found in your genotype file!
- rs79212538: G/G, effect allele: T, beta: 1.155
- rs8042374: A/G, effect allele: A, beta: 1.093
- rs8044995: G/G, effect allele: A, beta: 1.081
- rs8082590: A/A, effect allele: A, beta: 0.939
- rs832187: C/C, effect allele: T, beta: 0.941
- rs9420: G/G, effect allele: A, beta: 1.068
- rs950169: C/T, effect allele: T, beta: 0.923
- rs9607782: T/T, effect allele: A, beta: 1.087
- rs9636107: A/A, effect allele: A, beta: 0.93
- rs9841616: T/T, effect allele: A, beta: 0.925
- rs9922678: A/A, effect allele: A, beta: 1.067
Reference:
- Biological insights from 108 schizophrenia-associated genetic loci
4th Q
This section uses PharmGKB and ClinVAR as an example, to illustrate how PAGEMENT could query third party genotype-based databases. Right now, only VCF file format is supported. By default, the first five INFO fields are displayed in the output table, unless specified otherwise by the user.
Clinvar
Page:
| Variant | Allele | Allele type | Genotype | Clinvar ID |
|---|---|---|---|---|
| rs10246939 | C | Drug response | CT | 2906 |
| rs1042713 | A | Drug response | AG | 225937 |
| rs10509305 | C | Conflicting interpretations of pathogenicity | CA | 1720 |
| rs10509681 | C | Drug response | CT | 375654 |
| rs1051740 | C | Drug response | CT | 16604 |
| rs16969968 | A | Drug response | AG | 17497 |
| rs1800629 | A | Drug response | AG | 225964 |
| rs1801131 | G | Conflicting interpretations of pathogenicity | TG | 3521 |
| rs1801133 | A | Drug response | AG | 3520 |
| rs1801278 | T | Risk factor | CT | 29761 |
| rs1801394 | G | Drug response | AG | 7029 |
| rs1801700 | A | Conflicting interpretations of pathogenicity | AG | 255981 |
| rs2214102 | C | Drug response | CT | 829326 |
| rs2228001 | T | Drug response | TG | 190215 |
| rs3738888 | A | Conflicting interpretations of pathogenicity | AG | 136500 |
| rs405509 | G | Drug response | TG | 619951 |
| rs4680 | A | Drug response | AG | 17591 |
| rs4961 | T | Drug response | TG | 18274 |
| rs5174 | T | Risk factor | TT | 6996 |
| rs6025 | C | Drug response | CC | 226007 |
| rs716274 | G | Drug response | GG | 226013 |
| rs9332131 | G | Drug response | GAGA | 285601 |
| rs10066882 | A | Conflicting interpretations of pathogenicity | CC | 414373 |
| rs1041983 | T | Drug response | CC | 375653 |
| rs10979599 | T | Conflicting interpretations of pathogenicity | GG | 245634 |
| rs11078699 | T | Conflicting interpretations of pathogenicity | CC | 387361 |
| rs11104729 | C | Conflicting interpretations of pathogenicity | TT | 261849 |
| rs11466016 | A | Conflicting interpretations of pathogenicity | CC | 36516 |
| rs11541998 | T | Conflicting interpretations of pathogenicity | CC | 732303 |
| rs11549709 | A | Conflicting interpretations of pathogenicity | GG | 136294 |
| rs11568360 | A | Conflicting interpretations of pathogenicity | GG | 284547 |
| rs11569534 | T | Conflicting interpretations of pathogenicity | CC | 330292 |
| rs11569541 | G | Conflicting interpretations of pathogenicity | AA | 636934 |
| rs11570255 | A | Conflicting interpretations of pathogenicity | GG | 16646 |
| rs11571640 | C | Conflicting interpretations of pathogenicity | AA | 38258 |
| rs11575936 | T | Conflicting interpretations of pathogenicity | CC | 723758 |
| rs11807956 | A | Conflicting interpretations of pathogenicity | GG | 256741 |
| rs11840224 | A | Conflicting interpretations of pathogenicity | GG | 35723 |
| rs11893228 | T | Conflicting interpretations of pathogenicity | CC | 178627 |
| rs11971167 | A | Drug response | GG | 7164 |
| rs12161733 | A | Conflicting interpretations of pathogenicity | GG | 536220 |
| rs12324002 | G | Conflicting interpretations of pathogenicity | AA | 36133 |
| rs12562058 | A | Conflicting interpretations of pathogenicity | CC | 710715 |
| rs12713843 | T | Conflicting interpretations of pathogenicity | CC | 281142 |
| rs12720763 | A | Conflicting interpretations of pathogenicity | CC | 334059 |
| rs13098532 | G | Conflicting interpretations of pathogenicity | TT | 343746 |
| rs13171868 | C | Conflicting interpretations of pathogenicity | TT | 163597 |
| rs13306187 | T | Conflicting interpretations of pathogenicity | CC | 334146 |
| rs13306505 | T | Conflicting interpretations of pathogenicity | CC | 374957 |
| rs13306523 | T | Conflicting interpretations of pathogenicity | CC | 297984 |
| rs16024 | T | Conflicting interpretations of pathogenicity | CC | 194928 |
| rs16881446 | C | Risk factor | TT | 441163 |
| rs16904791 | A | Conflicting interpretations of pathogenicity | CC | 709941 |
| rs16937932 | T | Conflicting interpretations of pathogenicity | CC | 178767 |
| rs16955859 | G | Conflicting interpretations of pathogenicity | AA | 707596 |
| rs16978578 | C | Conflicting interpretations of pathogenicity | TT | 226712 |
| rs17006082 | G | Conflicting interpretations of pathogenicity | TT | 462965 |
| rs17027133 | C | Conflicting interpretations of pathogenicity | TT | 540408 |
| rs17028450 | T | Conflicting interpretations of pathogenicity | CC | 12707 |
| rs17071686 | A | Conflicting interpretations of pathogenicity | CC | 774331 |
| rs17089782 | A | Conflicting interpretations of pathogenicity | GG | 217689 |
| rs17102066 | T | Conflicting interpretations of pathogenicity | CC | 281057 |
| rs17107315 | C | Conflicting interpretations of pathogenicity | TT | 13760 |
| rs17158558 | T | Conflicting interpretations of pathogenicity | CC | 13938 |
| rs17222674 | G | Conflicting interpretations of pathogenicity | AA | 499389 |
| rs17235409 | A | Risk factor | GG | 9233 |
| rs17354992 | T | Conflicting interpretations of pathogenicity | CC | 46987 |
| rs17500494 | G | Conflicting interpretations of pathogenicity | TT | 359958 |
| rs17514281 | G | Conflicting interpretations of pathogenicity | AA | 294581 |
| rs1762111 | G | Conflicting interpretations of pathogenicity | AA | 99311 |
| rs17860530 | A | Conflicting interpretations of pathogenicity | GG | 196346 |
| rs17878854 | A | Conflicting interpretations of pathogenicity | GG | 366730 |
| rs17879685 | T | Drug response | CC | 633846 |
| rs17879961 | G | Conflicting interpretations of pathogenicity | AA | 5591 |
| rs17883718 | A | Conflicting interpretations of pathogenicity | GG | 618661 |
| rs17885240 | T | Conflicting interpretations of pathogenicity | CC | 134361 |
| rs1799802 | T | Conflicting interpretations of pathogenicity | CC | 134148 |
| rs1799978 | C | Drug response | TT | 225963 |
| rs1800056 | C | Conflicting interpretations of pathogenicity | TT | 132736 |
| rs1800059 | C | Conflicting interpretations of pathogenicity | AA | 127399 |
| rs1800120 | T | Conflicting interpretations of pathogenicity | GG | 256253 |
| rs1800556 | T | Conflicting interpretations of pathogenicity | CC | 3830 |
| rs1800562 | A | Conflicting interpretations of pathogenicity | GG | 9 |
| rs1800888 | T | Drug response | CC | 17744 |
| rs1805007 | T | Conflicting interpretations of pathogenicity | CC | 14312 |
| rs1805008 | T | Conflicting interpretations of pathogenicity | CC | 14310 |
| rs1805322 | T | Conflicting interpretations of pathogenicity | GG | 135946 |
| rs2070074 | G | Conflicting interpretations of pathogenicity | AA | 3613 |
| rs2219594 | A | Conflicting interpretations of pathogenicity | CC | 51695 |
| rs2227434 | T | Conflicting interpretations of pathogenicity | CC | 696149 |
| rs2228241 | A | Conflicting interpretations of pathogenicity | GG | 42334 |
| rs2229152 | T | Conflicting interpretations of pathogenicity | CC | 712435 |
| rs2229843 | T | Conflicting interpretations of pathogenicity | GG | 12690 |
| rs2230234 | T | Conflicting interpretations of pathogenicity | AA | 36014 |
| rs2230516 | T | Conflicting interpretations of pathogenicity | CC | 194960 |
| rs2232078 | T | Conflicting interpretations of pathogenicity | CC | 339211 |
| rs2233218 | A | Conflicting interpretations of pathogenicity | GG | 218640 |
| rs2233328 | G | Conflicting interpretations of pathogenicity | TT | 188374 |
| rs2235019 | A | Drug response | CC | 828595 |
| rs2235075 | G | Drug response | AA | 828561 |
| rs2271305 | C | Conflicting interpretations of pathogenicity | TT | 197782 |
| rs2272707 | A | Conflicting interpretations of pathogenicity | GG | 737320 |
| rs2275601 | C | Conflicting interpretations of pathogenicity | TT | 715943 |
| rs2276263 | A | Conflicting interpretations of pathogenicity | GG | 374733 |
| rs2276278 | T | Conflicting interpretations of pathogenicity | GG | 517205 |
| rs2287617 | T | Conflicting interpretations of pathogenicity | CC | 594929 |
| rs2288326 | T | Conflicting interpretations of pathogenicity | GG | 47548 |
| rs2295947 | A | Conflicting interpretations of pathogenicity | GG | 165063 |
| rs2296928 | G | Conflicting interpretations of pathogenicity | TT | 692098 |
| rs2303603 | A | Conflicting interpretations of pathogenicity | GG | 290657 |
| rs2303834 | G | Conflicting interpretations of pathogenicity | AA | 47086 |
| rs2307440 | A | Conflicting interpretations of pathogenicity | GG | 21313 |
| rs2491080 | A | Conflicting interpretations of pathogenicity | GG | 626489 |
| rs268 | G | Conflicting interpretations of pathogenicity | AA | 1550 |
| rs28363595 | T | Conflicting interpretations of pathogenicity | CC | 713884 |
| rs28364364 | A | Conflicting interpretations of pathogenicity | GG | 92419 |
| rs28364528 | A | Conflicting interpretations of pathogenicity | GG | 468645 |
| rs28364537 | T | Conflicting interpretations of pathogenicity | CC | 254868 |
| rs28369776 | A | Conflicting interpretations of pathogenicity | GG | 377876 |
| rs28377085 | G | Conflicting interpretations of pathogenicity | AA | 236819 |
| rs28383481 | A | Conflicting interpretations of pathogenicity | GG | 38794 |
| rs28399504 | G | Drug response | AA | 16900 |
| rs28562785 | T | Conflicting interpretations of pathogenicity | CC | 159460 |
| rs288326 | A | Risk factor | GG | 5221 |
| rs2884737 | C | Drug response | AA | 225983 |
| rs28897680 | G | Conflicting interpretations of pathogenicity | TT | 37443 |
| rs28903085 | C | Conflicting interpretations of pathogenicity | AA | 128012 |
| rs28903091 | A | Conflicting interpretations of pathogenicity | GG | 37380 |
| rs28909989 | A | Conflicting interpretations of pathogenicity | GG | 331219 |
| rs28910612 | A | Conflicting interpretations of pathogenicity | GG | 786476 |
| rs28990974 | C | Conflicting interpretations of pathogenicity | TT | 302744 |
| rs28990975 | C | Conflicting interpretations of pathogenicity | AA | 302740 |
| rs28991292 | A | Conflicting interpretations of pathogenicity | GG | 256612 |
| rs29000285 | T | Conflicting interpretations of pathogenicity | CC | 361175 |
| rs2915960 | T | Conflicting interpretations of pathogenicity | CC | 329088 |
| rs3087376 | T | Conflicting interpretations of pathogenicity | CC | 317310 |
| rs3087378 | A | Conflicting interpretations of pathogenicity | GG | 317337 |
| rs3092859 | C | Conflicting interpretations of pathogenicity | TT | 135748 |
| rs3212986 | A | Drug response | CC | 225987 |
| rs3212989 | G | Conflicting interpretations of pathogenicity | AA | 235480 |
| rs3213408 | T | Conflicting interpretations of pathogenicity | CC | 464097 |
| rs3218690 | C | Conflicting interpretations of pathogenicity | TT | 132757 |
| rs3219488 | A | Conflicting interpretations of pathogenicity | GG | 132703 |
| rs339097 | G | Drug response | AA | 225988 |
| rs34044544 | A | Conflicting interpretations of pathogenicity | GG | 352970 |
| rs34360255 | A | Conflicting interpretations of pathogenicity | GG | 763904 |
| rs34391943 | T | Conflicting interpretations of pathogenicity | CC | 167378 |
| rs34723289 | G | Conflicting interpretations of pathogenicity | AA | 198818 |
| rs34819316 | A | Conflicting interpretations of pathogenicity | GG | 445491 |
| rs34832477 | A | Conflicting interpretations of pathogenicity | GG | 691859 |
| rs35152987 | A | Conflicting interpretations of pathogenicity | CC | 15070 |
| rs35313315 | A | Conflicting interpretations of pathogenicity | TT | 129596 |
| rs35350960 | A | Conflicting interpretations of pathogenicity | CC | 12274 |
| rs35554630 | A | Conflicting interpretations of pathogenicity | GG | 196576 |
| rs35625882 | T | Conflicting interpretations of pathogenicity | CC | 739302 |
| rs35691292 | A | Conflicting interpretations of pathogenicity | GG | 13135 |
| rs35759430 | A | Conflicting interpretations of pathogenicity | GG | 283585 |
| rs36022183 | T | Conflicting interpretations of pathogenicity | CC | 94111 |
| rs363824 | G | Conflicting interpretations of pathogenicity | TT | 42408 |
| rs3729732 | A | Conflicting interpretations of pathogenicity | GG | 631966 |
| rs3729841 | T | Conflicting interpretations of pathogenicity | CC | 43391 |
| rs3735971 | A | Conflicting interpretations of pathogenicity | GG | 363868 |
| rs3736497 | C | Conflicting interpretations of pathogenicity | AA | 437080 |
| rs3737274 | A | Conflicting interpretations of pathogenicity | GG | 299646 |
| rs3737311 | A | Conflicting interpretations of pathogenicity | GG | 285240 |
| rs3738497 | T | Conflicting interpretations of pathogenicity | GG | 468979 |
| rs3739274 | T | Conflicting interpretations of pathogenicity | CC | 361923 |
| rs3740654 | A | Conflicting interpretations of pathogenicity | GG | 514270 |
| rs3741050 | C | Conflicting interpretations of pathogenicity | GG | 769322 |
| rs3741447 | A | Conflicting interpretations of pathogenicity | GG | 434780 |
| rs3743808 | G | Conflicting interpretations of pathogenicity | AA | 632946 |
| rs3744824 | T | Conflicting interpretations of pathogenicity | CC | 159870 |
| rs3747835 | T | Conflicting interpretations of pathogenicity | CC | 100583 |
| rs3751369 | C | Conflicting interpretations of pathogenicity | TT | 311551 |
| rs3761169 | A | Conflicting interpretations of pathogenicity | GG | 288545 |
| rs3764873 | A | Conflicting interpretations of pathogenicity | CC | 310137 |
| rs3766317 | A | Conflicting interpretations of pathogenicity | GG | 21357 |
| rs3782356 | T | Conflicting interpretations of pathogenicity | CC | 134730 |
| rs3795339 | T | Conflicting interpretations of pathogenicity | CC | 129318 |
| rs3796241 | A | Conflicting interpretations of pathogenicity | TT | 730216 |
| rs3810796 | T | Conflicting interpretations of pathogenicity | CC | 378702 |
| rs3918290 | T | Drug response | CC | 432 |
| rs41428447 | A | Conflicting interpretations of pathogenicity | GG | 214786 |
| rs4148323 | A | Drug response | GG | 12280 |
| rs4148327 | C | Conflicting interpretations of pathogenicity | TT | 160241 |
| rs4148725 | T | Conflicting interpretations of pathogenicity | CC | 411121 |
| rs4149584 | T | Conflicting interpretations of pathogenicity | CC | 217017 |
| rs4150521 | A | Conflicting interpretations of pathogenicity | GG | 134120 |
| rs4151031 | A | Conflicting interpretations of pathogenicity | GG | 256188 |
| rs4253046 | G | Conflicting interpretations of pathogenicity | TT | 300083 |
| rs429358 | C | Conflicting interpretations of pathogenicity | TT | 17864 |
| rs4977574 | G | Risk factor | AA | 812644 |
| rs4986761 | C | Conflicting interpretations of pathogenicity | TT | 128454 |
| rs4987050 | G | Conflicting interpretations of pathogenicity | AA | 136580 |
| rs4988460 | A | Conflicting interpretations of pathogenicity | GG | 597988 |
| rs5029941 | T | Conflicting interpretations of pathogenicity | CC | 135332 |
| rs5122 | A | Conflicting interpretations of pathogenicity | GG | 2582 |
| rs5346 | A | Conflicting interpretations of pathogenicity | GG | 226623 |
| rs5350 | A | Conflicting interpretations of pathogenicity | GG | 255141 |
| rs5352 | T | Conflicting interpretations of pathogenicity | CC | 16638 |
| rs5452 | A | Conflicting interpretations of pathogenicity | GG | 329805 |
| rs5744739 | A | Conflicting interpretations of pathogenicity | GG | 240452 |
| rs5744948 | G | Conflicting interpretations of pathogenicity | TT | 240537 |
| rs5964007 | G | Conflicting interpretations of pathogenicity | AA | 287834 |
| rs5969 | G | Conflicting interpretations of pathogenicity | AA | 627369 |
| rs6035 | C | Conflicting interpretations of pathogenicity | TT | 255189 |
| rs6063 | T | Conflicting interpretations of pathogenicity | CC | 16378 |
| rs6068812 | G | Conflicting interpretations of pathogenicity | AA | 29680 |
| rs607969 | T | Conflicting interpretations of pathogenicity | CC | 41854 |
| rs6161 | T | Conflicting interpretations of pathogenicity | CC | 372354 |
| rs6170 | T | Conflicting interpretations of pathogenicity | GG | 304276 |
| rs6177 | A | Conflicting interpretations of pathogenicity | GG | 281656 |
| rs6267 | T | Drug response | GG | 17592 |
| rs6413438 | T | Drug response | CC | 39353 |
| rs6413500 | T | Conflicting interpretations of pathogenicity | CC | 626118 |
| rs6672843 | A | Conflicting interpretations of pathogenicity | GG | 260015 |
| rs6755258 | A | Conflicting interpretations of pathogenicity | GG | 528460 |
| rs7190978 | T | Conflicting interpretations of pathogenicity | GG | 320070 |
| rs7196804 | T | Conflicting interpretations of pathogenicity | CC | 201068 |
| rs7244681 | C | Conflicting interpretations of pathogenicity | GG | 196054 |
| rs7262506 | C | Conflicting interpretations of pathogenicity | AA | 338234 |
| rs730254 | T | Conflicting interpretations of pathogenicity | CC | 48422 |
| rs7334118 | C | Conflicting interpretations of pathogenicity | TT | 35724 |
| rs7412 | T | Drug response | CC | 17848 |
| rs8099917 | G | Drug response | TT | 226027 |
| rs8187798 | G | Conflicting interpretations of pathogenicity | AA | 256159 |
| rs8187808 | G | Conflicting interpretations of pathogenicity | AA | 498331 |
| rs8190976 | T | Conflicting interpretations of pathogenicity | CC | 810272 |
| rs8191498 | C | Conflicting interpretations of pathogenicity | TT | 321155 |
| rs8191996 | C | Conflicting interpretations of pathogenicity | TT | 736719 |
| rs9282564 | C | Drug response | TT | 829327 |
| rs9332604 | C | Conflicting interpretations of pathogenicity | TT | 293616 |
Page:
PharmGKB
Variants which affect phenotypes:
Page:
| Variant | Alleles | Associations | Genotype | PMID |
|---|---|---|---|---|
| rs10030044 | G | Allele G is associated with increased risk of occurence of breast cancer during SERM (selective estrogen receptor modulators) therapy when treated with raloxifene or tamoxifen in people with Breast Neoplasms as compared to allele T. | TG | 23764426 |
| rs1017860 | CC | Genotype CC is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with hemopoietic stem cell transplant as compared to genotypes CT + TT. | CC | 25425682 |
| rs10248420 | G | Allele G is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele A. | AG | 18215618 |
| rs10267099 | G | Allele G is associated with increased risk of Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele A. | GG | 24116192 |
| rs1042713 | G | Allele G is associated with increased likelihood of Sexual adverse events when treated with risperidone in people with Schizophrenia as compared to allele A. | AG | 22212732 |
| rs1049353 | C | Allele C is associated with increased risk of Weight gain when exposed to risperidone in children with Autism Spectrum Disorder as compared to allele T. | CT | 23799528 |
| rs10509681 | C | Allele C is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to allele T. | CT | 23413280 |
| rs1051740 | T | Allele T is associated with increased risk of Craniofacial Abnormalities when exposed to phenytoin in people with first trimester pregnancy as compared to allele C. | CT | 19952982 |
| rs1051740 | CT | Genotype CT is associated with increased risk of nephrotoxicity grades 1-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype TT. | CT | 24533712 |
| rs10875989 | T | Allele T is associated with increased severity of Anemia, Leukopenia, Neutropenia and Thrombocytopenia when treated with platinum in people with Lung Neoplasms as compared to allele C. | CT | 26358256 |
| rs10876844 | A | Allele A is associated with increased likelihood of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to allele C. | CA | 22310351 |
| rs11212570 | AA + AG | Genotypes AA + AG is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotype GG. | AG | 30430914 |
| rs1138272 | T | Allele T is associated with increased non-inducible thiotepa clearance and decreased tepa clearance when treated with thiotepa. | CT | 19076156 |
| rs1143634 | AA | Genotype AA is associated with decreased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to genotypes AG + GG. | AG | 25560300 |
| rs1152003 | CC | Genotype CC is associated with increased risk of developing osteonecrosis of the jaw when treated with zoledronate in people with Multiple Myeloma as compared to genotypes CG + GG. | CC | 21517810 |
| rs11549467 | AG | Genotype AG is associated with decreased progression-free survival when treated with pazopanib in people with Carcinoma, Renal Cell as compared to genotype GG. | GG | 21576632 |
| rs11549467 | AG | Genotype AG is associated with decreased progression-free survival as compared to genotype GG. | GG | 26641474 |
| rs11563250 | AG + GG | Genotypes AG + GG is associated with decreased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype AA. | AA | 25778466 |
| rs11587213 | AA | Genotype AA is associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotypes AG + GG. | AA | 18595682 |
| rs11739136 | CT + TT | Genotypes CT + TT are associated with decreased risk of Hypertension as compared to genotype CC. | CC | 18496125 |
| rs11739136 | CT + TT | Genotypes CT + TT are associated with decreased blood pressure in men as compared to genotype CC. | CC | 18854753 |
| rs12036333 | AA + AG | Genotypes AA + AG is associated with decreased event-free survival when treated with cytarabine and idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG. | GG | 28570300 |
| rs12210538 | G | Allele G is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to allele A. | AG | 20179710 |
| rs1229984 | T | Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C. | CC | 32451486 |
| rs1229984 | T | Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C. | CC | 15902904 |
| rs1229984 | T | Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C. | CC | 31090166 |
| rs12720067 | T | Allele T is associated with increased likelihood of remission when treated with amitriptyline, citalopram, paroxetine or venlafaxine in people with Depression as compared to allele C. | CT | 18215618 |
| rs12721655 | AG | Genotype AG is associated with decreased survival when treated with cyclophosphamide and doxorubicin in women with Breast Neoplasms as compared to genotype AA. | AA | 20179710 |
| rs12762549 | G | Allele G is associated with increased risk of Leukopenia when treated with docetaxel. | CG | 18294295 |
| rs13181 | GG | Genotype GG is associated with decreased progression-free survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT. | TG | 22026922 |
| rs13181 | G | Allele G is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele T. | TG | 19620936 |
| rs13181 | GG + GT | Genotypes GG + GT is associated with decreased overall survival and progression-free survival when treated with oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT. | TG | 27636246 |
| rs13181 | GG | Genotype GG is associated with decreased overall survival when treated with capecitabine, cisplatin, docetaxel, epirubicin and gemcitabine in people with Pancreatic Neoplasms as compared to genotypes GT + TT. | TG | 22026922 |
| rs13181 | G | Allele G is associated with increased risk of Drug Toxicity when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT. | TG | 20385995 |
| rs1409314 | A | Allele A is associated with increased risk of Anemia, Leukopenia, Thrombocytopenia, Toxic liver disease or Vomiting when exposed to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G. | AG | 25732572 |
| rs1611115 | T | Allele T is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to allele C. | CC | 25096645 |
| rs1634776 | T | Allele T is associated with increased likelihood of severe cutaneous adverse reactions when treated with allopurinol as compared to allele C. | CT | 33356553 |
| rs16969968 | A | Allele A is associated with increased likelihood of Tobacco Use Disorder when exposed to nicotine as compared to allele G. | AG | 19706762 |
| rs16969968 | A | Allele A is associated with increased risk of Tobacco Use Disorder. | AG | 18618000 |
| rs16969968 | A | Allele A is associated with increased likelihood of Schizophrenia. | AG | 21418140 |
| rs16969968 | A | Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G. | AG | 20886544 |
| rs16969968 | A | Allele A is associated with increased severity of smoking when exposed to nicotine in people with smoking as compared to allele G. | AG | 21418140 |
| rs16969968 | G | Allele G is not associated with increased Tobacco Use Disorder when treated with Opium alkaloids and derivatives in people with Pain as compared to allele A. | AG | 20725741 |
| rs16969968 | A | Allele A is associated with increased severity of smoking when exposed to nicotine in people with Schizophrenia who are smokers as compared to allele G. | AG | 21418140 |
| rs16969968 | A | Allele A is associated with increased severity of Substance-Related Disorders due to Opium alkaloids and derivatives in people with Pain as compared to allele G. | AG | 20725741 |
| rs16969968 | A | Allele A is associated with increased likelihood of Tobacco Use Disorder due to nicotine as compared to allele G. | AG | 19132693 |
| rs16969968 | A | Allele A is associated with increased likelihood of Tobacco Use Disorder as compared to allele G. | AG | 27355804 |
| rs16969968 | A | Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine as compared to allele G. | AG | 30453884 |
| rs16969968 | A | Allele A is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele G. | AG | 29196725 |
| rs16969968 | G | Allele G is associated with increased likelihood of Alcoholism due to ethanol as compared to allele A. | AG | 19132693 |
| rs17024608 | A | Allele A is associated with increased likelihood of Osteonecrosis when treated with Bisphosphonates as compared to allele G. | AA | 22267851 |
| rs17091162 | AC + CC | Genotypes AC + CC are associated with decreased survival when treated with antineoplastic agents in people with Pancreatic Neoplasms as compared to genotype AA. | CA | 21487324 |
| rs17128809 | AA | Genotype AA is associated with increased risk of adverse events when treated with ritodrine as compared to genotypes AT + TT. | AA | 31324945 |
| rs17501011 | AA + AG | Genotypes AA + AG is associated with decreased overall survival when treated with FOLFIRI in people with Colorectal Neoplasms as compared to genotype GG. | GG | 31698983 |
| rs17501331 | AG + GG | Genotypes AG + GG are associated with decreased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA. | AA | 27845419 |
| rs17574269 | AG | Genotype AG is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Small Cell as compared to genotype AA. | AA | 23478653 |
| rs17587029 | G | Allele G is associated with decreased likelihood of Amenorrhea when treated with docetaxel, FEC100, gemcitabine, trastuzumab and zoledronate in women with Breast Neoplasms as compared to allele A. | AA | 31371054 |
| rs17655652 | CC | Genotype CC is associated with decreased reduction in LDL-C when treated with pravastatin in women as compared to genotypes CT + TT. | TT | 19752398 |
| rs1799722 | T | Allele T is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele C. | CT | 10904024 |
| rs1799722 | CT + TT | Genotypes CT + TT are associated with increased risk of Cough when treated with enalapril, imidapril and lisinopril in people with Essential hypertension as compared to genotype CC. | CT | 12522467 |
| rs1799836 | CC | Genotype CC is associated with increased risk of Tobacco Use Disorder in women as compared to genotypes CT + TT. | CC | 28858992 |
| rs1799978 | C | Allele C is associated with decreased time until response when treated with olanzapine and risperidone in people with Schizophrenia as compared to genotype TT. | TT | 16513877 |
| rs1800629 | AA + AG | Genotypes AA + AG are associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG. | AG | 18444945 |
| rs1800629 | A | Allele A is associated with increased likelihood of serious hypersensitivity when treated with carbamazepine as compared to allele G. | AG | 11294926 |
| rs1800629 | AA + AG | Genotypes AA + AG are associated with increased likelihood of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype GG. | AG | 22151084 |
| rs1800629 | AG | Genotype AG is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotype GG. | AG | 30430914 |
| rs1800629 | A | Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G. | AG | 31616045 |
| rs1801131 | GG | Genotype GG is associated with decreased event-free survival when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype TT. | TG | 23652803 |
| rs1801131 | G | Allele G is associated with increased progression free survival in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotype TT. | TG | 15385937 |
| rs1801131 | G | Allele G is associated with increased likelihood of clinical response when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT. | TG | 20863444 |
| rs1801131 | T | Allele T is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G. | TG | 16439441 |
| rs1801131 | GG + GT | Genotypes GG + GT are associated with decreased overall survival when treated with cisplatin and pemetrexed in people with Stomach Neoplasms as compared to genotype TT. | TG | 20634689 |
| rs1801131 | G | Allele G is associated with increased likelihood of neurotoxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T. | TG | 19858780 |
| rs1801131 | TT | Genotype TT is associated with decreased Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes GG + GT. | TG | 18245544 |
| rs1801131 | GG | Genotype GG is associated with decreased risk of Myelosuppression when treated with mercaptopurine and methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GT + TT. | TG | 17323057 |
| rs1801131 | G | Allele G is associated with increased risk of side effects when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T. | TG | 16572443 |
| rs1801131 | G | Allele G is associated with increased risk of Graft vs Host Disease when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT. | TG | 16920564 |
| rs1801131 | GG | Genotype GG is associated with decreased severity of oral mucositis when treated with methotrexate in people with hematopoietic-cell-transplantation as compared to genotype TT. | TG | 16501586 |
| rs1801131 | GG | Genotype GG is associated with decreased risk of relapse when treated with methotrexate in people with allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia. as compared to genotype TT. | TG | 15569990 |
| rs1801131 | GG | Genotype GG is associated with decreased event-free survival and overall survival when treated with capecitabine, fluorouracil or oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT. | TG | 25331073 |
| rs1801131 | G | Allele G is associated with increased likelihood of elevated transaminases when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele T. | TG | 20514079 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 18458567 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased risk of discontinuation when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | AG | 11710708 |
| rs1801133 | A | Allele A is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to allele G. | AG | 27992285 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased risk of Toxic liver disease when treated with methotrexate in children with Neoplasms as compared to genotype GG. | AG | 23648444 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased risk of Drug Toxicity when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 25007187 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased Drug Toxicity when treated with methotrexate in children with as compared to genotype GG. | AG | 21644011 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased severity of Folic Acid Deficiency when treated with asparaginase, daunorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 25065700 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased risk of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 25110820 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased risk of Neutropenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 25110820 |
| rs1801133 | GG | Genotype GG is associated with decreased risk of Drug Toxicity when treated with methotrexate in children with Neoplasms as compared to genotypes AA + AG. | AG | 28696419 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype GG. | AG | 29589488 |
| rs1801133 | A | Allele A is associated with graft vs host disease when treated with cyclosporine and methotrexate in people with recipients of HLA-identical hematopoietic stem cell transplantation. | AG | 19005482 |
| rs1801133 | A | Allele A is associated with increased likelihood of Metabolic Syndrome when treated with antipsychotics in people with Schizophrenia. | AG | 17976958 |
| rs1801133 | A | Allele A is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | AG | 20863444 |
| rs1801133 | A | Allele A is associated with increased risk of Recurrence when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G. | AG | 15781665 |
| rs1801133 | AA | Genotype AA is associated with decreased risk of Graft vs Host Disease when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG. | AG | 16920564 |
| rs1801133 | AG | Genotype AG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms. | AG | 20819423 |
| rs1801133 | A | Allele A is associated with increased likelihood of Drug Toxicity when treated with cyclophosphamide and fluorouracil in people with Breast Neoplasms as compared to allele G. | AG | 20638924 |
| rs1801133 | AA + AG | Genotypes AA + AG are not associated with increased risk of Osteonecrosis when treated with dexamethasone in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 18285546 |
| rs1801133 | GG | Genotype GG is associated with decreased severity of Drug Toxicity when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG. | AG | 19384296 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased risk of hematological toxicity when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype GG. | AG | 23488607 |
| rs1801133 | A | Allele A is associated with increased risk of prolonged high concentrations of methotrexate in children with Leukemia as compared to allele G. | AG | 24241962 |
| rs1801133 | G | Allele G is associated with increased Weight gain when treated with antipsychotics in people with schizoaffective disorder and Schizophrenia as compared to allele A. | AG | 24725652 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased risk of Diarrhea, mucositis and Neutropenia when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype GG. | AG | 29134491 |
| rs1801133 | AA | Genotype AA is associated with decreased overall survival when treated with azacitidine in people with Myelodysplastic Syndromes as compared to genotypes AG + GG. | AG | 29205204 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased likelihood of treatment interruptions when treated with mercaptopurine in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 18458567 |
| rs1801133 | AG | Genotype AG is associated with increased risk of Alopecia when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | AG | 18381794 |
| rs1801133 | GG | Genotype GG is associated with decreased likelihood of Coronary Artery Disease and Myocardial Infarction when treated with pravastatin in people with Hypertension. | AG | 18622257 |
| rs1801394 | AG + GG | Genotypes AG + GG are associated with increased likelihood of mucositis when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma. | AG | 18368069 |
| rs1801394 | G | Allele G is associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to allele A. | AG | 29589488 |
| rs1801394 | AG | Genotype AG is associated with increased speed of platelet recovery when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + GG. | AG | 18368069 |
| rs1978153 | C | Allele C is associated with increased severity of Respiratory Insufficiency when treated with morphine in children with Sleep Apnea Syndromes and tonsillectomy as compared to allele G. | CG | 26810133 |
| rs2016848 | A | Allele A is associated with increased risk of Cough when treated with Ace Inhibitors, Plain in people with Hypertension as compared to allele G. | AG | 21052031 |
| rs2144297 | T | Allele T is associated with Hypercholesterolemia due to atenolol in people with Hypertension as compared to allele C. | CT | 24116192 |
| rs2207396 | A | Allele A is associated with increased risk of Oligospermia when treated with Alkylating Agents and cisplatin in people with childhood cancer as compared to genotype GG. | AG | 21430602 |
| rs2227956 | G | Allele G is associated with decreased severity of Hypersensitivity when treated with carbamazepine as compared to allele A. | AA | 16538175 |
| rs2228001 | G | Allele G is associated with increased risk of Ototoxicity when treated with cisplatin in people with Osteosarcoma as compared to allele T. | TG | 19434073 |
| rs2229109 | CC | Genotype CC is associated with increased intracellular and blood concentration of cyclosporine in people with Transplantation as compared to genotypes CT + TT. | CC | 18334915 |
| rs2236418 | AG + GG | Genotypes AG + GG is associated with increased likelihood of methamphetamine dependence, Psychotic Disorders and Substance-Related Disorders when exposed to methamphetamine as compared to genotype AA. | GG | 27967329 |
| rs2246709 | G | Allele G is associated with increased severity of side effects when treated with methadone in people with Heroin Dependence as compared to allele A. | AG | 21902501 |
| rs2273697 | GG | Genotype GG is associated with increased risk of Anemia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AA + AG. | GG | 29507678 |
| rs2278294 | T | Allele T is associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C. | TT | 20679962 |
| rs2291075 | CT + TT | Genotypes CT + TT are associated with increased event-free survival and overall survival when treated with cytarabine, daunorubicin, etoposide and mitoxantrone in children with Leukemia, Myeloid, Acute as compared to genotype CC. | CT | 26663398 |
| rs2305948 | C | Allele C is associated with increased severity of Drug Toxicity when treated with sunitinib in people with Carcinoma, Renal Cell and Gastrointestinal Stromal Tumors as compared to allele T. | CC | 19667267 |
| rs2305948 | CC | Genotype CC is associated with increased overall survival and progression-free survival when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotypes CT + TT. | CC | 24510746 |
| rs2562519 | T | Allele T is associated with increased risk of Exanthema when treated with nevirapine in people with HIV Infections as compared to allele C. | TT | 21810746 |
| rs2720376 | C | Allele C is associated with increased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele T. | CT | 25829401 |
| rs2748249 | A | Allele A is associated with increased severity of Drug Toxicity when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele C. | CA | 24220096 |
| rs28362731 | AG | Genotype AG is associated with increased risk of Thrombocytopenia due to cisplatin in people with Mesothelioma as compared to genotype GG. | AG | 30840592 |
| rs28371685 | CT | Genotype CT is associated with decreased warfarin dose when treated with warfarin as compared to genotype CC. | CC | 15970795 |
| rs28399504 | G | Allele G is associated with decreased platelet inhibition after a clopidogrel 600-mg loading dose when treated with clopidogrel in people with Coronary Artery Disease as compared to allele A. | AA | 19463375 |
| rs2884737 | CC | Genotype CC is associated with decreased warfarin dose requirements on day 14 when treated with warfarin as compared to genotype AA. | AA | 18030307 |
| rs2884737 | AC + CC | Genotypes AC + CC is associated with decreased time to the first INR within the therapeutic range when treated with warfarin as compared to genotype AA. | AA | 18322281 |
| rs2963155 | G | Allele G is associated with increased pain crisis in people with Anemia, Sickle Cell as compared to allele A. | AG | 30079801 |
| rs307826 | CC + CT | Genotypes CC + CT is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotype TT. | TT | 23462807 |
| rs3094188 | A | Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele C. | CA | 21801394 |
| rs3094188 | A | Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele C. | CA | 21801394 |
| rs3212986 | CC | Genotype CC is associated with increased progression-free survival when treated with Platinum compounds in people with Ovarian Neoplasms as compared to genotypes AA + AC. | CC | 19203783 |
| rs3212986 | AA | Genotype AA is associated with decreased likelihood of nephrotoxicity when treated with cisplatin in people with Neoplasms as compared to genotypes AC + CC. | CC | 21902499 |
| rs3212986 | CC | Genotype CC is associated with increased risk of mucositis when treated with docetaxel in women with Breast Neoplasms as compared to genotypes AA + AC. | CC | 25495407 |
| rs3212986 | AC | Genotype AC is associated with decreased disease-free survival and overall survival in people with Carcinoma, Non-Small-Cell Lung as compared to genotype CC. | CC | 19361884 |
| rs3219484 | CT | Genotype CT is associated with decreased risk of neutropenia grade 3-4 when treated with cisplatin and cyclophosphamide in women with Ovarian Neoplasms as compared to genotype CC. | CC | 24533712 |
| rs34399035 | T | Allele T is associated with decreased metformin uptake in HEK-293 cells and reduction in protein expression levels when exposed to metformin as compared to allele C. | CC | 21956618 |
| rs3732218 | GG | Genotype GG is associated with increased glucuronidation of anastrozole in human liver microsomes as compared to genotypes AA + AG. | GG | 23371966 |
| rs3736228 | T | Allele T is associated with increased risk of osteoporotic fracture as compared to allele C. | CT | 18455228 |
| rs3736228 | T | Allele T is associated with increased risk of Osteoporosis. | CT | 18455228 |
| rs3780126 | G | Allele G are associated with increased overall survival when treated with bevacizumab and pemetrexed in people with Lung Neoplasms as compared to allele A. | AG | 19841321 |
| rs3786362 | A | Allele A is associated with increased risk of Hyperprolactinemia when treated with risperidone in children with Autism Spectrum Disorder as compared to allele G. | AA | 29955115 |
| rs3798220 | CT | Genotype CT is associated with decreased risk of Myocardial Infarction when treated with aspirin in women. | TT | 18775538 |
| rs3815087 | A | Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol as compared to allele G. | AG | 21801394 |
| rs3815087 | A | Allele A is associated with increased risk of Epidermal Necrolysis, Toxic and Stevens-Johnson Syndrome when treated with allopurinol, carbamazepine or phenytoin as compared to allele G. | AG | 21801394 |
| rs4133101 | T | Allele T is associated with increased risk of gastrointestinal toxicities when treated with celecoxib in people with Colorectal Neoplasms as compared to allele C. | TT | 23778325 |
| rs4141964 | CT + TT | Genotypes CT + TT is associated with increased risk of Postoperative Nausea and Vomiting when treated with morphine in children as compared to genotype CC. | TT | 25558980 |
| rs4148323 | AA | Genotype AA is associated with decreased progression-free survival when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148323 | AA | Genotype AA is associated with decreased overall survival when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148412 | T | Allele T is associated with increased severity of Respiratory Insufficiency when treated with morphine in children with Sleep Apnea Syndromes and tonsillectomy as compared to allele C. | TT | 26810133 |
| rs4149000 | T | Allele T is associated with increased risk of Muscular Diseases when treated with hmg coa reductase inhibitors as compared to allele C. | CT | 31220337 |
| rs4149118 | G | Allele G is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms. | AG | 21995462 |
| rs429358 | T | Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease. | TT | 20031582 |
| rs429358 | TT | Genotype TT is associated with increased time to achieve stable dose when treated with warfarin as compared to genotypes CC + CT. | TT | 21923605 |
| rs463312 | AC | Genotype AC is associated with decreased progression-free survival when treated with cabazitaxel in people with Carcinoma, Transitional Cell as compared to genotype AA. | AA | 27020167 |
| rs4680 | AA | Genotype AA is associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotypes AG + GG. | AG | 27061230 |
| rs4680 | AG + GG | Genotypes AG + GG is associated with increased likelihood of requiring postoperative intervention with opioids in children with adenotonsillectomy as compared to genotype AA. | AG | 24533707 |
| rs4680 | AA + AG | Genotypes AA + AG is associated with increased diastolic blood pressure and systolic blood pressure when treated with antipsychotics in children as compared to genotype GG. | AG | 25048416 |
| rs4680 | A | Allele A is associated with increased risk of Toxic liver disease when treated with mercaptopurine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele G. | AG | 32265697 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of relapse when treated with nicotine. | AG | 18192898 |
| rs4680 | A | Allele A is associated with increased methylation at sites 1 and 2 in the COMT promoter when treated with antipsychotics in people with Schizophrenia as compared to allele G. | AG | 22391769 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of Exanthema when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AA + GG. | AG | 30549211 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of extrapyramidal symptoms when treated with haloperidol in men with Schizophrenia as compared to genotypes AA + GG. | AG | 23963056 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of somnolence due to fentanyl in healthy individuals as compared to genotype GG. | AG | 30281924 |
| rs4680 | AA + GG | Genotypes AA + GG is associated with decreased libido when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype AG. | AG | 30549211 |
| rs4680 | G | Allele G is associated with increased severity of Pain when treated with propranolol in women with Temporomandibular Joint Disorders and Pain as compared to allele A. | AG | 20216107 |
| rs4680 | AG | Genotype AG is associated with increased likelihood of Hyperalgesia due to opioids in people with Pain as compared to genotypes AA + GG. | AG | 31041874 |
| rs4680 | AA | Genotype AA is associated with decreased likelihood of Headache Disorders and Substance Withdrawal Syndrome in people not taking Analgesics, Antiinflammatory agents, non-steroids, Ergot alkaloids, opioids and sumatriptan as compared to genotypes AG + GG. | AG | 25096645 |
| rs4693570 | C | Allele C is associated with increased risk of Myalgia unspecified when treated with hmg coa reductase inhibitors in people with Hyperlipidemias as compared to allele T. | CC | 21868014 |
| rs4790694 | C | Allele C is associated with increased likelihood of Substance-Related Disorders when exposed to methamphetamine as compared to allele A. | CC | 17233643 |
| rs4888024 | G | Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance when treated with methotrexate as compared to allele A. | GG | 19176441 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with decreased likelihood of Myocardial Infarction when treated with diuretics in people with Hypertension. | TG | 11926892 |
| rs4961 | GG | Genotype GG is associated with decreased risk of Myocardial Infarction when treated with Thiazides, plain in people with Hypertension. | TG | 19145769 |
| rs508448 | GG | Genotype GG is associated with decreased age at onset of Heroin Dependence due to heroin as compared to genotypes AA + AG. | AG | 28692418 |
| rs50872 | GG | Genotype GG is associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AG. | GG | 27498158 |
| rs55781567 | G | Allele G is associated with increased Tobacco Use Disorder when exposed to nicotine as compared to allele C. | CG | 29196725 |
| rs5925720 | T | Allele T is associated with decreased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G. | GG | 26378035 |
| rs598961 | AA | Genotype AA is associated with decreased time to delivery when treated with ritodrine as compared to genotypes AG + GG. | GG | 31324945 |
| rs6002674 | C | Allele C is associated with decreased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele T. | TT | 23508266 |
| rs6088638 | T | Allele T is associated with increased risk of Alcoholism due to ethanol as compared to allele C. | TT | 28550509 |
| rs6090041 | G | Allele G is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele A. | GG | 20032820 |
| rs6090043 | C | Allele C is associated with increased risk of Opioid-Related Disorders when exposed to opioids as compared to allele T. | CC | 20032820 |
| rs6130615 | CC | Genotype CC is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotypes CT + TT. | CC | 31461081 |
| rs6347 | TT | Genotype TT is associated with increased risk of Death when exposed to cocaine in people with Cocaine-Related Disorders as compared to genotypes CC + CT. | TT | 23340505 |
| rs6500843 | G | Allele G is associated with increased risk of Death when treated with antineoplastic agents in women with Breast Neoplasms as compared to allele A. | GG | 25823661 |
| rs6511720 | T | Allele T is associated with baseline LDL cholesterol in people with Vascular Diseases. | TG | 21977987 |
| rs652888 | G | Allele G is associated with increased likelihood of Agranulocytosis when treated with Antithyroid Preparations as compared to allele A. | AG | 27157822 |
| rs671 | GG | Genotype GG is associated with increased risk of Alcoholism due to ethanol as compared to genotypes AA + AG. | GG | 16679777 |
| rs671 | A | Allele A is associated with decreased risk of Alcoholism due to ethanol as compared to allele G. | GG | 15902904 |
| rs683369 | CG + GG | Genotypes CG + GG is associated with decreased event-free survival when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC. | CC | 24589908 |
| rs6920220 | A | Allele A is associated with increased likelihood of discontinuation of methotrexate in people with Arthritis as compared to allele G. | AG | 20921970 |
| rs6962291 | AA | Genotype AA is associated with decreased risk of intolerance when treated with aspirin in people with Asthma as compared to genotype TT. | TT | 21449675 |
| rs7131056 | CC | Genotype CC is associated with decreased likelihood of Weight gain when treated with antipsychotics as compared to genotypes AA + AC. | CA | 27217270 |
| rs716274 | AG + GG | Genotypes AG + GG are associated with increased risk of Death when treated with etoposide and Platinum compounds in people with Carcinoma, Small Cell as compared to genotype AA. | GG | 21118971 |
| rs7242 | T | Allele T is associated with increased likelihood of Depressive Disorder, Major as compared to allele G. | TT | 18794724 |
| rs7259857 | C | Allele C is associated with decreased risk of Esophagitis when treated with radiotherapy as compared to allele T. | TT | 25054431 |
| rs7412 | CC | Genotype CC is associated with increased time to achieve stable dose when treated with warfarin as compared to genotypes CT + TT. | CC | 21923605 |
| rs762551 | CC | Genotype CC is associated with decreased risk of Parkinson Disease when exposed to caffeine in people with coffee consumption as compared to genotype AA. | AA | 21281405 |
| rs762551 | AA | Genotype AA is associated with increased likelihood of insomnia due to caffeine as compared to genotypes AC + CC. | AA | 29668752 |
| rs762551 | AC + CC | Genotypes AC + CC are associated with decreased risk of Breast Neoplasms when exposed to caffeine in people with BRCA1 mutations. | AA | 17507615 |
| rs762551 | A | Allele A is associated with increased risk of Fatigue when treated with paroxetine in people with Depressive Disorder, Major as compared to allele C. | AA | 21121774 |
| rs762551 | AA | Genotype AA is associated with increased likelihood of Metabolic Syndrome when treated with clozapine in people with Schizophrenia and Tobacco Use Disorder as compared to genotypes AC + CC. | AA | 27681143 |
| rs762551 | AA | Genotype AA is associated with increased likelihood of Neural Tube Defects when exposed to caffeine in women who are pregnant as compared to genotypes AC + CC. | AA | 20641098 |
| rs778293 | C | Allele C is associated with increased likelihood of Psychotic Disorders due to methamphetamine as compared to allele T. | CT | 19482054 |
| rs7945189 | CT + TT | Genotypes CT + TT are associated with decreased likelihood of Acute coronary syndrome when exposed to Antiinflammatory agents, non-steroids in people with Acute coronary syndrome as compared to genotype CC. | CC | 20538124 |
| rs8099917 | TT | Genotype TT is associated with increased baseline viral load in people with Hepatitis as compared to genotypes GG + GT. | TT | 21628662 |
| rs8099917 | T | Allele T is associated with increased response (SVR and RVR) in HCV-HIV coinfected patients when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin as compared to allele G. | TT | 23133602 |
| rs8099917 | TT | Genotype TT is associated with increased response (SVR) in HCV genotype 1 patients when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 22438096 |
| rs8099917 | TT | Genotype TT is associated with increased response (SVR) to interferon monotherapy in HCV genotype 1 patients when treated with interferons in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 22438096 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 28261382 |
| rs8099917 | TT | Genotype TT is associated with increased likelihood of cryoglobulinemia when treated with peginterferon alfa-2a in people with. | TT | 28453396 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 29104462 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with daclatasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 30431653 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 27514956 |
| rs8099917 | TT | Genotype TT is associated with increased likelihood of sustained virological response (SVR) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis as compared to genotypes GG + GT. | TT | 21628662 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 24362944 |
| rs8099917 | TT | Genotype TT is associated with increased rapid virological response (rvr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 26699619 |
| rs8099917 | TT | Genotype TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT. | TT | 27561198 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 27027531 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b or ribavirin in people with as compared to genotypes GG + GT. | TT | 25918016 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with ledipasvir and sofosbuvir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 27357737 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 27833958 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 28261382 |
| rs8099917 | G | Allele G is associated with decreased likelihood of sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T. | TT | 28261910 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 28739427 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, ribavirin and simeprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 28506030 |
| rs8099917 | TT | Genotype TT is associated with increased rapid virological response (rvr) and sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 24308755 |
| rs8099917 | TT | Genotype TT is associated with increased sustained virological response (svr) when treated with peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 31803800 |
| rs8124728 | A | Allele A is associated with decreased risk of Peripheral Nervous System Diseases due to stavudine in people with HIV Infections as compared to allele G. | GG | 30273369 |
| rs8176719 | C | Allele C is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele del. | TTC | 28750087 |
| rs877087 | TT | Genotype TT is associated with increased risk of Heart Failure when treated with amlodipine in people with Hypertension. | TT | 22664477 |
| rs879207 | AG | Genotype AG is associated with increased risk of Neurotoxicity Syndromes when treated with carboplatin, docetaxel and paclitaxel in women with Ovarian Neoplasms as compared to genotypes AA + GG. | AG | 23963862 |
| rs9282564 | CC + CT | Genotypes CC + CT are associated with decreased risk of Death due to opioids in people with Opioid-Related Disorders as compared to genotype TT. | TT | 27061230 |
| rs928655 | A | Allele A is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G. | AA | 18615156 |
| rs951439 | CT | Genotype CT is associated with increased likelihood of response when treated with olanzapine in people with Schizophrenia. | CT | 17588543 |
| rs9554320 | AA | Genotype AA is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC. | CA | 23421954 |
| rs9554320 | AA | Genotype AA is associated with decreased overall survival and progression-free survival when treated with sunitinib in people with Carcinoma, Renal Cell as compared to genotypes AC + CC. | CA | 27417418 |
| rs962369 | C | Allele C is associated with increased likelihood of suicidal ideation when treated with escitalopram or nortriptyline in people with Depressive Disorder, Major as compared to allele T. | CT | 19641488 |
| rs989692 | CT + TT | Genotypes CT + TT is associated with increased likelihood of Angioedema when treated with Ace Inhibitors, Plain as compared to genotype CC. | CT | 23838604 |
| rs9981861 | TT | Genotype TT is associated with decreased survival when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes CC + CT. | CT | 21079520 |
| rs1021737 | TT | Genotype TT is associated with increased risk of Hepatic Veno-Occlusive Disease when treated with busulfan and cyclophosphamide in children with hemopoietic stem cell transplant as compared to genotypes GG + GT. | GG | 27779248 |
| rs1041983 | T | Allele T is associated with increased risk of Toxic liver disease when treated with isoniazid, pyrazinamide and rifampin in people with Tuberculosis. | CC | 18421452 |
| rs1041983 | TT | Genotype TT is associated with increased risk of Toxic liver disease when treated with ethambutol, isoniazid, pyrazinamide and rifampin in people with Tuberculosis as compared to genotype CC. | CC | 22506592 |
| rs1041983 | T | Allele T is associated with increased risk of drug-induced liver injury when treated with isoniazid in people with Tuberculosis as compared to allele C. | CC | 29036176 |
| rs1041983 | T | Allele T is associated with increased risk of Drug Toxicity due to isoniazid and phenytoin in people with Tuberculoma of brain or Tuberculous meningitis NOS as compared to allele C. | CC | 27488001 |
| rs1042713 | AA | Genotype AA is associated with increased risk of asthma exacerbations when exposed to salmeterol in children with Asthma as compared to genotype GG. | AG | 16772309 |
| rs1042713 | AA | Genotype AA is associated with increased risk of asthma exacerbations when exposed to salbutamol or salmeterol in children with Asthma as compared to genotype GG. | AG | 19800676 |
| rs1042713 | AA | Genotype AA is associated with increased risk of uncontrolled asthma when treated with corticosteroids in children with Asthma as compared to genotype GG. | AG | 24279851 |
| rs1042713 | GG | Genotype GG is not associated with increased risk of Hypertriglyceridemia due to atenolol or metoprolol in people with Hypertension as compared to genotypes AA + AG. | AG | 16027735 |
| rs1042713 | GG | Genotype GG is associated with increased risk of emergency department and hospital utliization when treated with Ace Inhibitors, Plain, Angiotensin II Antagonists, Beta Blocking Agents, digoxin, diuretics or spironolactone in people with Heart Failure as compared to genotypes AA + AG. | AG | 22543981 |
| rs1042713 | AA | Genotype AA is associated with increased risk of exacerbations when treated with corticosteroids and salmeterol in children with Asthma as compared to genotype GG. | AG | 24279851 |
| rs1045644 | CG + GG | Genotypes CG + GG are associated with decreased likelihood of Peripheral Nervous System Diseases when treated with vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | GG | 30506673 |
| rs10491684 | A | Allele A is associated with increased severity of Thrombocytopenia when treated with carboplatin and gemcitabine in people with Carcinoma, Non-Small-Cell Lung as compared to allele G. | GG | 31616045 |
| rs10517 | GG | Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG. | GG | 30237583 |
| rs1051740 | CC | Genotype CC is associated with increased time above therapeutic range when treated with phenprocoumon as compared to genotype TT. | CT | 21057703 |
| rs1051740 | CC | Genotype CC is associated with increased likelihood of being overanticoagulated due to phenprocoumon as compared to genotypes CT + TT. | CT | 21057703 |
| rs10792367 | G | Allele G is associated with decreased blood pressure (BP) reduction when treated with hydrochlorothiazide in people with Hypertension as compared to genotype CC. | CG | 21164499 |
| rs10841661 | T | Allele T is associated with increased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C. | CC | 19696792 |
| rs10846744 | GG | Genotype GG is associated with decreased sustained virological response (svr) when treated with peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes CC + CG. | GG | 27561198 |
| rs10981694 | GG + GT | Genotypes GG + GT are associated with increased severity of Ototoxicity when treated with cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT. | TT | 22516052 |
| rs11252394 | A | Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G. | GG | 23508266 |
| rs1138272 | CT + TT | Genotypes CT + TT is associated with decreased event-free survival and overall survival when treated with cisplatin in people with Osteosarcoma as compared to genotype CC. | CT | 25592234 |
| rs11587213 | AG + GG | Genotypes AG + GG are associated with increased likelihood of atopy in patients with aspirin-intolerant chronic urticaria as compared to genotype AA. | AA | 18534082 |
| rs11591147 | T | Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease. | GG | 20031582 |
| rs11600347 | A | Allele A is associated with increased likelihood of Diabetes Mellitus when treated with hydrochlorothiazide in people with Hypertension as compared to allele C. | CC | 22907731 |
| rs11710163 | AG | Genotype AG is associated with increased overall survival due to carboplatin, cisplatin, docetaxel, gemcitabine or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA. | AA | 21636554 |
| rs12119882 | AG | Genotype AG is associated with increased likelihood of Hyperbilirubinemia when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype AA. | AA | 28347776 |
| rs1229984 | TT | Genotype TT is associated with increased Vmax of ethanol in healthy individuals as compared to genotypes CC + CT. | CC | 23240771 |
| rs12720066 | AC + CC | Genotypes AC + CC are associated with increased severity of Neutropenia when exposed to irinotecan in people with Colorectal Neoplasms as compared to genotype AA. | AA | 27845419 |
| rs13181 | GG | Genotype GG is associated with increased risk of dying when treated with Platinum compounds in people with Colorectal Neoplasms as compared to genotype TT. | TG | 15213713 |
| rs13181 | G | Allele G is associated with decreased event free survival when treated with cisplatin in people with Osteosarcoma as compared to genotype TT. | TG | 19434073 |
| rs13181 | GG + GT | Genotypes GG + GT are associated with increased risk of Recurrence when treated with fluorouracil and leucovorin in people with Colorectal Neoplasms as compared to genotype TT. | TG | 18267032 |
| rs13181 | GG | Genotype GG is associated with increased event free survival when treated with cisplatin, doxorubicin, ifosfamide and methotrexate in people with Osteosarcoma as compared to genotype TT. | TG | 21826087 |
| rs13181 | GT | Genotype GT is associated with increased progression-free survival when treated with fluorouracil and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GG + TT. | TG | 21449681 |
| rs13181 | TT | Genotype TT is associated with increased risk of Neutropenia when treated with docetaxel in women with Breast Neoplasms as compared to genotypes GG + GT. | TG | 25495407 |
| rs13181 | GG | Genotype GG is associated with increased likelihood of pneumonitis when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT. | TG | 25069034 |
| rs13181 | GG + GT | Genotypes GG + GT are associated with increased risk of Alopecia due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype TT. | TG | 30914949 |
| rs13432159 | G | Allele G is associated with increased general side-effects when treated with sertraline in people with Depressive Disorder, Major as compared to allele T. | TT | 22041458 |
| rs135543 | TT | Genotype TT is associated with increased reduction in fasting LDL-C when treated with fenofibrate as compared to genotypes CC + CT. | CC | 22547144 |
| rs1522113 | A | Allele A is associated with increased bronchodilator response (FEV1) when treated with salbutamol in Asthma as compared to allele G. | GG | 23508266 |
| rs16969968 | A | Allele A is associated with decreased likelihood of abstinence of nicotine in people with Tobacco Use Disorder. | AG | 22648373 |
| rs16969968 | GG | Genotype GG is associated with increased functional MRI reactivity to smoking images due to nicotine in women with nicotine dependence as compared to genotypes AA + AG. | AG | 21764527 |
| rs16969968 | A | Allele A is associated with decreased variance in Tobacco Use Disorder associated with peer smoking when exposed to nicotine as compared to allele G. | AG | 20840187 |
| rs17135437 | T | Allele T is associated with increased hearing and vision-related side-effects when treated with citalopram in people with Depressive Disorder, Major as compared to allele C. | CC | 22760553 |
| rs17655652 | CC | Genotype CC is associated with increased reduction in LDL-C when treated with pravastatin in men as compared to genotypes CT + TT. | TT | 19752398 |
| rs17661089 | AG + GG | Genotypes AG + GG are associated with decreased overall survival due to carboplatin, cisplatin, docetaxel or paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA. | AG | 21636554 |
| rs1799807 | C | Allele C is associated with postanesthesia apnea when exposed to succinylcholine as compared to allele T. | TT | 12724618 |
| rs1799978 | CT | Genotype CT is associated with increased likelihood of Insulin Resistance when treated with risperidone in children with Child Behavior Disorders and Mental Disorders as compared to genotype TT. | TT | 26880915 |
| rs1799978 | C | Allele C is associated with increased risk of Hyperprolactinemia when treated with risperidone as compared to allele T. | TT | 19339912 |
| rs1800629 | GG | Genotype GG is associated with increased bone marrow density in the lumbar spine when treated with atorvastatin in people with Acute coronary syndrome. | AG | 18997459 |
| rs1800629 | GG | Genotype GG is associated with increased risk of hand-foot syndrome when treated with sorafenib in people with Carcinoma, Hepatocellular as compared to genotype AG. | AG | 22736425 |
| rs1800872 | TT | Genotype TT is associated with increased risk of transplant rejection when treated with cyclosporine and mycophenolate mofetil in people with Kidney Transplantation as compared to genotypes GG + GT. | GG | 18444945 |
| rs1800888 | TT | Genotype TT is not associated with increased risk of Hypertriglyceridemia due to atenolol or metoprolol in people with Hypertension as compared to genotypes CC + CT. | CC | 16027735 |
| rs1801123 | C | Allele C is associated with lymph node involvement when treated with in women with Breast Neoplasms as compared to allele T. | TT | 23459444 |
| rs1801131 | GG | Genotype GG is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes GT + TT. | TG | 17488658 |
| rs1801131 | TT | Genotype TT is associated with increased response base on Disease Activity Score in 44 joints improvement at 6 months of treatment when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT. | TG | 16572443 |
| rs1801131 | TT | Genotype TT is associated with increased likelihood of red blood cell transfusions when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT. | TG | 18368069 |
| rs1801131 | GG + GT | Genotypes GG + GT are associated with increased overall survival when treated with bevacizumab, cyanocobalamin, folic acid and pemetrexed in people with Head and Neck Neoplasms as compared to genotype TT. | TG | 21343546 |
| rs1801131 | GG | Genotype GG is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotypes GT + TT. | TG | 17700593 |
| rs1801131 | TT | Genotype TT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Rectal Neoplasms as compared to genotypes GG + GT. | TG | 22045187 |
| rs1801131 | GG | Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Neoplasms. | TG | 23736036 |
| rs1801131 | TT | Genotype TT is associated with increased event free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes GG + GT. | TG | 21747412 |
| rs1801131 | GG | Genotype GG is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype TT. | TG | 18580170 |
| rs1801131 | GT + TT | Genotypes GT + TT is associated with increased risk of mucositis when treated with asparaginase, daunorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | TG | 25065700 |
| rs1801131 | GG | Genotype GG is associated with increased risk of hand-foot syndrome when treated with capecitabine in people with Gastrointestinal Neoplasms as compared to genotypes GT + TT. | TG | 27864592 |
| rs1801131 | GG | Genotype GG is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms. | TG | 20819423 |
| rs1801131 | GG | Genotype GG is associated with increased Weight gain when treated with clozapine or olanzapine in people with schizoaffective disorder and Schizophrenia as compared to genotype GT. | TG | 24725652 |
| rs1801133 | AA | Genotype AA is associated with increased risk of gastrointestinal toxicity, Leukopenia and Toxic liver disease when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 19648163 |
| rs1801133 | AA | Genotype AA is associated with increased progression-free survival when treated with carboplatin and pemetrexed in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | AG | 19307503 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Leukemia as compared to genotypes AG + GG. | AG | 12453860 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of Drug Toxicity when treated with cisplatin, cyclophosphamide, dactinomycin, doxorubicin, methotrexate and vincristine in children with Osteosarcoma as compared to genotypes AG + GG. | AG | 19159907 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with decreased severity of Leukopenia when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 16870553 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with decreased survival when treated with methotrexate in children with Lymphoma, Non-Hodgkin as compared to genotype GG. | AG | 23488607 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of Recurrence when treated with methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG. | AG | 21644011 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of Recurrence when treated with methotrexate in children with Osteosarcoma as compared to genotypes AG + GG. | AG | 28592186 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Thrombocytopenia when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG. | AG | 17488658 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG. | AG | 17488658 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of response to chemotherapy when treated with carboplatin, cisplatin, docetaxel, gemcitabine, paclitaxel and vinorelbine in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | AG | 21605004 |
| rs1801133 | AA | Genotype AA is associated with increased risk of toxicity when treated with methotrexate as compared to genotype GG. | AG | 22143415 |
| rs1801133 | GG | Genotype GG is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Osteosarcoma as compared to genotypes AA + AG. | AG | 25778468 |
| rs1801133 | GG | Genotype GG is associated with increased likelihood of treatment interruptions when treated with capecitabine in people with Colorectal Neoplasms as compared to genotypes AA + AG. | AG | 28745575 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate as compared to genotype GG. | AG | 22143415 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Toxic liver disease when treated with methotrexate in people with Arthritis, Psoriatic as compared to genotypes AG + GG. | AG | 20472929 |
| rs1801133 | AA | Genotype AA is associated with increased overall survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 17512587 |
| rs1801133 | AA | Genotype AA is associated with increased risk of mucositis when treated with busulfan, cyclophosphamide and methotrexate as compared to genotype GG. | AG | 15051775 |
| rs1801133 | A | Allele A is associated with decreased likelihood of event-free survival when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotype GG. | AG | 17488658 |
| rs1801133 | GG | Genotype GG is associated with increased progression free survival when treated with antineoplastic agents in people with Leukemia, Lymphocytic, Chronic, B-Cell as compared to genotypes AA + AG. | AG | 15385937 |
| rs1801133 | AA | Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG. | AG | 17488658 |
| rs1801133 | AA | Genotype AA is associated with increased risk of mucositis when treated with methotrexate in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes AG + GG. | AG | 11418485 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG. | AG | 17512587 |
| rs1801133 | AA | Genotype AA is associated with increased severity of mucositis when treated with methotrexate in people with hematopoietic stem cell transplantation as compared to genotype GG. | AG | 16501586 |
| rs1801133 | GG | Genotype GG is associated with increased event-free survival when treated with methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AA + AG. | AG | 21747412 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | AG | 23095111 |
| rs1801133 | AG + GG | Genotypes AG + GG are associated with decreased severity of Pain when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype AA. | AG | 22926161 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to genotypes AG + GG. | AG | 23314736 |
| rs1801133 | GG | Genotype GG is associated with increased event-free survival and overall survival when treated with fluorouracil in people with Rectal Neoplasms as compared to genotype AA. | AG | 25041994 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with decreased overall survival when treated with pemetrexed in people with Carcinoma, Non-Small-Cell Lung and Mesothelioma as compared to genotype GG. | AG | 24732178 |
| rs1801133 | AA | Genotype AA is associated with increased risk of Drug Toxicity when treated with methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 25303299 |
| rs1801133 | AA | Genotype AA is associated with increased plasma total homocysteine concentrations when exposed to nitrous oxide in people with surgery as compared to genotype GG. | AG | 18580170 |
| rs1801133 | AA | Genotype AA is associated with increased likelihood of adverse events when treated with methotrexate in people with Arthritis, Juvenile Rheumatoid as compared to genotype GG. | AG | 20595278 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with decreased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype GG. | AG | 18299612 |
| rs1801394 | AA | Genotype AA is associated with increased red blood cell folate when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | AG | 20386493 |
| rs1801394 | GG | Genotype GG is associated with increased severity of Stomatitis when treated with leucovorin and tegafur in people with Colorectal Neoplasms as compared to genotypes AA + AG. | AG | 20647221 |
| rs1801394 | AA + AG | Genotypes AA + AG are associated with decreased severity of Pain when treated with folic acid and vitamin b-complex, plain in women with Migraine with Aura as compared to genotype GG. | AG | 22926161 |
| rs1804645 | CT | Genotype CT is associated with increased severity of change in Lumbar Bone Mineral Density when treated with tamoxifen as compared to genotype CC. | CC | 22174377 |
| rs1883112 | AA | Genotype AA is associated with increased risk of cardiotoxicity when treated with doxorubicin in people with Lymphoma, Non-Hodgkin as compared to genotypes AG + GG. | AG | 16330681 |
| rs1883112 | AA | Genotype AA is associated with increased risk of cardiotoxicity when treated with idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG. | AG | 28485375 |
| rs1883112 | AG + GG | Genotypes AG + GG are associated with decreased risk of toxicity when treated with cyclophosphamide, doxorubicin, prednisone, rituximab and vincristine in people with Lymphoma, Large B-Cell, Diffuse as compared to genotype AA. | AG | 19448608 |
| rs2070401 | GG | Genotype GG is associated with increased likelihood of Toxic liver disease when treated with isoniazid and rifampin in people with Tuberculosis as compared to genotypes AA + AG. | AA | 22341855 |
| rs2228001 | GG + GT | Genotypes GG + GT are associated with increased risk of Neutropenia when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT. | TG | 21047201 |
| rs2228001 | GG + GT | Genotypes GG + GT are associated with increased risk of Drug Toxicity when treated with cisplatin in people with Urinary Bladder Neoplasms as compared to genotype TT. | TG | 21047201 |
| rs2229109 | CT | Genotype CT is associated with increased risk of Diarrhea and Vomiting when treated with bleomycin, cyclophosphamide, doxorubicin, prednisone, rituximab, vincristine and vindesine in people with Lymphoma, Non-Hodgkin as compared to genotype CC. | CC | 25637052 |
| rs2229109 | CT | Genotype CT is associated with increased likelihood of progression-free survival when treated with dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC. | CC | 29177954 |
| rs2229109 | CT | Genotype CT is associated with increased risk of Neutropenia when treated with valganciclovir in people with Kidney Transplantation as compared to genotype CC. | CC | 27402191 |
| rs2229109 | CT + TT | Genotypes CT + TT is associated with increased risk of renal transplant failure when treated with tacrolimus in people with Kidney Transplantation as compared to genotype CC. | CC | 29689130 |
| rs2233406 | AG + GG | Genotypes AG + GG are associated with decreased risk of Diarrhea due to gefitinib in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA. | AG | 31664190 |
| rs2241716 | TT | Genotype TT is associated with increased likelihood of Pain when treated with Iodine (131I) compounds and radiotherapy in people with Thyroid Neoplasms as compared to genotypes CC + CT. | CC | 30430914 |
| rs2246709 | A | Allele A is associated with decreased severity of opioid withdrawal symptoms when treated with methadone in people with Heroin Dependence as compared to allele G. | AG | 21902501 |
| rs2273697 | A | Allele A is associated with increased probability of antiepileptic drug response when treated with antiepileptics in children with Epilepsy as compared to allele G. | GG | 21799461 |
| rs2273697 | A | Allele A is associated with increased risk of Bone Marrow Diseases when treated with methotrexate in children with Osteosarcoma as compared to allele G. | GG | 27566582 |
| rs2273697 | A | Allele A is associated with increased residual clearance of intravenous talinolol and lower bioavailablilty of orally administered talinolol when exposed to talinolol as compared to allele G. | GG | 18334920 |
| rs2273697 | AA + AG | Genotypes AA + AG are associated with increased risk of neurological ADR when treated with carbamazepine in people with Epilepsy as compared to genotype GG. | GG | 20216337 |
| rs2273697 | AA | Genotype AA is associated with increased likelihood of Drug Toxicity when treated with methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG. | GG | 18381794 |
| rs2273697 | A | Allele A is associated with increased risk of renal proximal tubulopathy due to tenofovir in people with HIV Infections as compared to allele G. | GG | 17083032 |
| rs2273697 | AG | Genotype AG is associated with increased area under the concentration versus time curve (AUC6-12) level of the acyl glucuronide of mycophenolic acid when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG. | GG | 18946804 |
| rs2273697 | GG | Genotype GG is associated with decreased progression-free survival when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AG. | GG | 30237583 |
| rs2274924 | C | Allele C is associated with increased risk of hypomagnesemia primary when treated with Proton pump inhibitors as compared to allele T. | TT | 27926584 |
| rs2278294 | CT + TT | Genotypes CT + TT is associated with decreased likelihood of Lymphopenia when treated with azathioprine in children with Inflammatory Bowel Diseases as compared to genotype CC. | TT | 26332308 |
| rs2278294 | CT + TT | Genotypes CT + TT are associated with decreased risk of biopsy-proven acute rejection when treated with mycophenolate mofetil in people with kidney transplant as compared to genotype CC. | TT | 17851563 |
| rs2278294 | T | Allele T is associated with decreased risk of transplant rejection when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele C. | TT | 20679962 |
| rs2281617 | CC | Genotype CC is associated with increased Euphoric and Energetic after amphetamine (10 mg) when exposed to amphetamine in healthy individuals as compared to genotypes CT + TT. | CT | 21029375 |
| rs2302821 | C | Allele C is associated with increased risk of cardiovascular toxicity and symptoms when treated with celecoxib in people with Colorectal Neoplasms as compared to allele A. | AA | 23778325 |
| rs2302948 | T | Allele T is associated with decreased likelihood of Fever when treated with cytarabine, fludarabine, gemtuzumab ozogamicin and idarubicin in people with Leukemia, Myeloid, Acute as compared to allele C. | CT | 22584460 |
| rs2305799 | CT + TT | Genotypes CT + TT are not associated with increased risk of Osteonecrosis when treated with dexamethasone in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | CC | 18285546 |
| rs2305948 | TT | Genotype TT is associated with increased risk of Angina Pectoris and Myocardial Infarction when treated with clopidogrel in people with Coronary Disease as compared to genotypes CC + CT. | CC | 25738571 |
| rs2305948 | CC | Genotype CC is associated with decreased overall survival when treated with sunitinib in people with Carcinoma, Renal Cell. | CC | 21882181 |
| rs2307441 | C | Allele C is associated with increased risk of Toxic liver disease when treated with valproic acid as compared to allele T. | TT | 21038416 |
| rs2440390 | T | Allele T is associated with increased Weight gain when treated with olanzapine in people with Mental Disorders as compared to allele C. | CC | 22967772 |
| rs2476601 | AA | Genotype AA is associated with increased likelihood of discontinuation of methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | GG | 20921970 |
| rs2476601 | A | Allele A is associated with increased risk of drug-induced liver injury when treated with amoxicillin and clavulanate as compared to allele G. | GG | 30664875 |
| rs2501873 | CC | Genotype CC is associated with decreased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotypes CT + TT. | CC | 24193570 |
| rs2514218 | CC | Genotype CC is associated with increased severity of Psychomotor Agitation due to aripiprazole in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT. | CT | 26320194 |
| rs2518224 | CC | Genotype CC is associated with increased risk of treatment-emergent suicidal ideation when treated with citalopram in people with Depression. | CA | 17898344 |
| rs28399504 | G | Allele G is associated with increased risk of Death when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A. | AA | 19106084 |
| rs28399504 | G | Allele G is associated with increased risk of cardiovascular events when treated with clopidogrel in people with Myocardial Infarction as compared to genotype AA. | AA | 19106083 |
| rs28399504 | G | Allele G is associated with increased risk of ischaemic events when treated with clopidogrel in people with Acute coronary syndrome as compared to allele A. | AA | 20801498 |
| rs2884737 | CC | Genotype CC is associated with increased risk of over-anticoagulation when treated with warfarin as compared to genotype AA. | AA | 20354686 |
| rs301927 | G | Allele G is associated with increased likelihood of Peripheral Nervous System Diseases when treated with cyclophosphamide, epirubicin and paclitaxel in women with Breast Neoplasms as compared to allele A. | AA | 24599932 |
| rs301927 | AA | Genotype AA is associated with decreased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes AG + GG. | AA | 26133777 |
| rs3087374 | A | Allele A is associated with increased risk of Toxic liver disease when treated with valproic acid as compared to allele C. | CC | 21038416 |
| rs3136228 | GG | Genotype GG is associated with increased severity of Neutropenia when treated with fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to genotypes GT + TT. | TT | 22868256 |
| rs3212191 | TT | Genotype TT is associated with increased risk of Hemorrhage when treated with warfarin as compared to genotypes CC + CT. | CT | 31461081 |
| rs3212986 | AC | Genotype AC is associated with increased risk of nephrotoxicity when treated with cisplatin and cyclophosphamide in people with Ovarian Neoplasms as compared to genotype AA. | CC | 19786980 |
| rs3212986 | AA + AC | Genotypes AA + AC are associated with increased overall survival when treated with platinum in people with Carcinoma, Non-Small-Cell Lung as compared to allele C. | CC | 19362955 |
| rs3212986 | AA + AC | Genotypes AA + AC are not associated with increased risk of recurrence of disease when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype CC. | CC | 22329723 |
| rs3212986 | AA + AC | Genotypes AA + AC are not associated with increased risk of Death when treated with Platinum compounds in women Ovarian Neoplasms as compared to genotype CC. | CC | 22329723 |
| rs3212986 | A | Allele A is associated with increased overall survival and progression-free survival when treated with cisplatin in people with Esophageal Neoplasms as compared to allele C. | CC | 19620936 |
| rs3212986 | AA + AC | Genotypes AA + AC is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype CC. | CC | 25495407 |
| rs3212986 | AA | Genotype AA is associated with increased risk of Neutropenia when treated with cyclophosphamide, doxorubicin and fluorouracil in women with Breast Neoplasms as compared to genotypes AC + CC. | CC | 29507678 |
| rs3212986 | AC + CC | Genotypes AC + CC are associated with decreased risk of Vomiting due to bleomycin, cisplatin and etoposide in men with Testicular Neoplasms as compared to genotype AA. | CC | 30914949 |
| rs3212986 | AA + AC | Genotypes AA + AC are associated with increased overall survival when treated with cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotype CC. | CC | 23962907 |
| rs363341 | TT | Genotype TT is associated with increased risk of Drug Toxicity when treated with antipsychotics in people with Psychotic Disorders as compared to genotypes CC + CT. | CT | 27272046 |
| rs3736228 | T | Allele T is associated with decreased Bone Mineral Density as compared to allele C. | CT | 18455228 |
| rs3764043 | CC | Genotype CC is associated with decreased imatinib clearance when treated with imatinib as compared to genotypes CT + TT. | CC | 21633340 |
| rs3780412 | C | Allele C is associated with increased risk of obsessive-compulsive symptoms when treated with clozapine, olanzapine and risperidone in people with Schizophrenia. | TT | 19884611 |
| rs3784867 | T | Allele T is associated with increased risk of Peripheral Nervous System Diseases when treated with vincristine as compared to allele C. | CC | 29999516 |
| rs3787186 | TT | Genotype TT is associated with increased risk of Graft vs Host Disease when treated with cyclosporine and methotrexate in people with hemopoietic stem cell transplant as compared to genotypes CC + CT. | CT | 25425682 |
| rs3789243 | G | Allele G is associated with increased risk of drug resistance when treated with antiepileptics in people with Epilepsy. | AA | 19450124 |
| rs3789243 | G | Allele G is associated with increased risk of drug resistance when treated with antiepileptics in men with Epilepsy. | AA | 19450124 |
| rs3856806 | TT | Genotype TT is associated with increased decline in FEV 1 after aspirin provocation when exposed to aspirin in people with Asthma as compared to genotypes CC + CT. | CT | 20224667 |
| rs3856806 | TT | Genotype TT is associated with increased risk of aspirin hypersensitivity when treated with aspirin in people with Asthma as compared to genotypes CC + CT. | CT | 20224667 |
| rs3918290 | CT | Genotype CT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms. | CC | 17700593 |
| rs3918290 | CT | Genotype CT is associated with increased Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 30114658 |
| rs3918290 | CT + TT | Genotypes CT + TT is associated with increased severity of hand-foot syndrome when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 24817302 |
| rs3918290 | CT | Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 26099996 |
| rs3918290 | T | Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms. | CC | 23930673 |
| rs3918290 | CT + TT | Genotypes CT + TT is associated with increased severity of Myelosuppression when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 24817302 |
| rs3918290 | CT | Genotype CT is associated with increased Infection and Toxic liver disease when treated with fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | CC | 26846104 |
| rs3918290 | CT | Genotype CT is associated with increased likelihood of mucositis when treated with fluorouracil in women with Neoplasms as compared to genotype CC. | CC | 19473056 |
| rs3918290 | CT | Genotype CT is associated with increased likelihood of Thrombocytopenia when treated with fluorouracil in women with Neoplasms as compared to genotype CC. | CC | 19473056 |
| rs3918290 | CT + TT | Genotypes CT + TT is associated with increased likelihood of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 12360106 |
| rs3918290 | T | Allele T is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to allele C. | CC | 28481884 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 20819423 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity, Leukopenia and mucositis when treated with fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 18299612 |
| rs3918290 | CT | Genotype CT is associated with increased likelihood of Drug Toxicity when treated with capecitabine in people with Colorectal Neoplasms as compared to genotype CC. | CC | 21498394 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 24167597 |
| rs3918290 | CT + TT | Genotypes CT + TT is associated with increased severity of Diarrhea when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 24817302 |
| rs3918290 | CT + TT | Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 30723313 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with capecitabine in women with Breast Neoplasms as compared to genotype CC. | CC | 27454530 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colonic Neoplasms as compared to genotype CC. | CC | 25381393 |
| rs3918290 | CT | Genotype CT is associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 29134491 |
| rs3918290 | CT + TT | Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with capecitabine, fluorouracil or tegafur in people with Neoplasms as compared to genotype CC. | CC | 26603945 |
| rs3918290 | T | Allele T is associated with increased severity of Drug Toxicity when treated with fluorouracil. | CC | 18299612 |
| rs3918290 | T | Allele T is associated with increased likelihood of Drug Toxicity when treated with capecitabine or fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 23603345 |
| rs3918290 | CT + TT | Genotypes CT + TT are associated with increased risk of Drug Toxicity when treated with fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 17121937 |
| rs3918290 | CT | Genotype CT is associated with increased severity of Drug Toxicity when treated with fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 17064846 |
| rs4148323 | AA + AG | Genotypes AA + AG are associated with increased severity of Diarrhea when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG. | GG | 19299905 |
| rs4148323 | AA + AG | Genotypes AA + AG are associated with increased severity of Neutropenia when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG. | GG | 19299905 |
| rs4148323 | AG | Genotype AG is associated with increased risk of Hyperbilirubinemia when treated with indinavir in people with HIV as compared to genotype GG. | GG | 16609363 |
| rs4148323 | AA + AG | Genotypes AA + AG are associated with increased severity of Thrombocytopenia when treated with cisplatin and irinotecan in women with Genital Neoplasms, Female as compared to genotype GG. | GG | 19299905 |
| rs4148323 | AA | Genotype AA is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG. | GG | 19390945 |
| rs4148323 | AG | Genotype AG is associated with increased severity of Neutropenia when treated with irinotecan in people with Neoplasms as compared to genotype GG. | GG | 19390945 |
| rs4148323 | AA | Genotype AA is associated with increased Neutropenia when treated with cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148323 | AA | Genotype AA is associated with increased risk of Neutropenia when treated with irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 18221820 |
| rs4148323 | A | Allele A is associated with increased likelihood of Diarrhea when treated with irinotecan in people with Lung Neoplasms as compared to allele G. | GG | 28367249 |
| rs4148323 | AG | Genotype AG is associated with increased risk of Neutropenia when treated with irinotecan in people with Colorectal Neoplasms as compared to genotype GG. | GG | 26830078 |
| rs4148323 | A | Allele A is associated with increased likelihood of Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to allele G. | GG | 28367249 |
| rs4148323 | AA + AG | Genotypes AA + AG is associated with increased risk of Neutropenia when treated with irinotecan in people with biliary tract neoplasms and Pancreatic Neoplasms as compared to genotype GG. | GG | 26229432 |
| rs4148323 | AA + AG | Genotypes AA + AG is associated with increased likelihood of Diarrhea and Neutropenia when treated with irinotecan in people with Lung Neoplasms as compared to genotype GG. | GG | 28502040 |
| rs429358 | CC | Genotype CC is associated with increased severity of COVID-19 as compared to genotype TT. | TT | 32451547 |
| rs429358 | CC + CT | Genotypes CC + CT are associated with increased non-HDL cholesterol when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV Infections as compared to allele C. | TT | 15809899 |
| rs429358 | C | Allele C is associated with increased likelihood of Hemorrhage when treated with acenocoumarol or warfarin in people with venous thromboembolism as compared to allele T. | TT | 29432897 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with increased Hypertriglyceridemia in people with Coronary Disease or Hypertension as compared to genotype TT. | TT | 31559922 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with increased likelihood of Recurrence when treated with bupropion or nicotine in people with Tobacco Use Disorder as compared to genotype TT. | TT | 23247396 |
| rs429358 | C | Allele C is associated with increased risk of mortality after myocardial infarction, however this can be eliminated when treated with simvastatin as compared to allele T. | TT | 10736278 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with increased reduction in C-reactive protein (CRP) when treated with atorvastatin or pravastatin in people with Acute coronary syndrome. | TT | 19667110 |
| rs445925 | A | Allele A is associated with baseline LDL cholesterol in people with Vascular Diseases. | GG | 21977987 |
| rs4638843 | C | Allele C is associated with decreased progression-free survival when treated with cisplatin and doxorubicin in people with Osteosarcoma as compared to allele G. | CC | 25829401 |
| rs4680 | AG + GG | Genotypes AG + GG are associated with decreased likelihood of treatment with methadone or morphine in infants with Neonatal Abstinence Syndrome as compared to genotype AA. | AG | 23632726 |
| rs4680 | AA | Genotype AA is associated with increased overall mean numerical rating scale (NRS) score for pain when treated with morphine as compared to genotype GG. | AG | 23210659 |
| rs4680 | AG | Genotype AG is associated with decreased likelihood of Exanthema when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AA + GG. | AG | 30549211 |
| rs4680 | G | Allele G is associated with decreased risk of Tobacco Use Disorder due to nicotine in smokers as compared to allele A. | AG | 16395295 |
| rs4680 | GG | Genotype GG is associated with increased severity of withdrawal in people not taking nicotine in women Tobacco Use Disorder as compared to genotypes AA + AG. | AG | 23459442 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with decreased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotype GG. | AG | 18180754 |
| rs4680 | GG | Genotype GG is associated with increased reaction time when treated with tolcapone in abstinent smokers. | AG | 24095246 |
| rs4680 | AA | Genotype AA is associated with increased likelihood of smoking cessation when treated with nicotine as compared to genotypes AG + GG. | AG | 17548664 |
| rs4680 | GG | Genotype GG is associated with increased likelihood of relapse when treated with nicotine. | AG | 18192898 |
| rs4680 | AG | Genotype AG is associated with decreased reaction time when treated with tolcapone in abstinent smokers. | AG | 24095246 |
| rs4680 | AA + GG | Genotypes AA + GG are associated with increased likelihood of adverse events when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotype AG. | AG | 30549211 |
| rs4680 | AA | Genotype AA is associated with increased numerical rating scale (NRS) score for pain during painful procedure when treated with morphine as compared to genotype GG. | AG | 23210659 |
| rs4680 | AG + GG | Genotypes AG + GG are associated with decreased length of hospital stay in infants with Neonatal Abstinence Syndrome as compared to genotype AA. | AG | 23632726 |
| rs4680 | AA | Genotype AA is associated with increased likelihood of cessation when treated with Drugs used in nicotine dependence in people with as compared to genotypes AG + GG. | AG | 26555332 |
| rs4680 | AA + GG | Genotypes AA + GG are associated with increased likelihood of Sexual Dysfunctions, Psychological when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG. | AG | 30549211 |
| rs4680 | AA | Genotype AA is associated with increased likelihood of Vomiting when treated with buprenorphine, fentanyl or tramadol in people with Opioid-Related Disorders as compared to genotypes AG + GG. | AG | 30549211 |
| rs4680 | GG | Genotype GG is associated with increased blood pressure when treated with nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG. | AG | 23459442 |
| rs4790694 | A | Allele A is not associated with increased risk of Tobacco Use Disorder due to nicotine as compared to allele C. | CC | 17579607 |
| rs4790694 | A | Allele A is associated with increased risk of Tobacco Use Disorder due to nicotine as compared to allele C. | CC | 17579607 |
| rs492338 | AA | Genotype AA is associated with increased risk of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotype GG. | GG | 24706167 |
| rs494904 | T | Allele T is associated with decreased risk of Alcoholism due to ethanol as compared to allele C. | CT | 32451486 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased reduction in blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG. | TG | 18591455 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG. | TG | 11882573 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased ambulatory blood pressure in people with Hypertension as compared to genotype GG. | TG | 18591455 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased likelihood of Hypertension as compared to genotype GG. | TG | 9149697 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased likelihood of diuretic unresponsiveness when treated with furosemide and spironolactone in people with Liver Cirrhosis as compared to genotype GG. | TG | 21692745 |
| rs4961 | TT | Genotype TT is associated with increased hydrochlorothiazide induced calcium retention when treated with hydrochlorothiazide in men with Hypertension as compared to genotype GG. | TG | 16450155 |
| rs4961 | GT | Genotype GT is associated with increased reduction in mean arterial pressure when treated with hydrochlorothiazide in people with Essential hypertension as compared to genotype GG. | TG | 9149697 |
| rs4961 | GT + TT | Genotypes GT + TT are associated with increased reduction in mean blood pressure when treated with hydrochlorothiazide in people with Hypertension as compared to genotype GG. | TG | 10523341 |
| rs568408 | A | Allele A is associated with increased risk of time to anemia in patients undergoing living or deceased donor kidney transplant when treated with mycophenolate mofetil as compared to allele G. | GG | 21107304 |
| rs5789 | C | Allele C is associated with decreased likelihood of aspirin-induced asthma when exposed to Antiinflammatory agents, non-steroids in people with Asthma as compared to allele A. | CC | 26067486 |
| rs6021191 | T | Allele T is associated with increased risk of Hypersensitivity when treated with asparaginase in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to allele A. | AA | 25987655 |
| rs6025 | T | Allele T is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to allele C. | CC | 28750087 |
| rs6025 | CT | Genotype CT is associated with increased risk of Venous Thrombosis when treated with hormonal contraceptives for systemic use in women as compared to genotype CC. | CC | 12069454 |
| rs6025 | CT + TT | Genotypes CT + TT is not associated with increased risk of venous thromboembolism when treated with hormonal contraceptives for systemic use in women as compared to genotype CC. | CC | 15208046 |
| rs6025 | CT + TT | Genotypes CT + TT is not associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC. | CC | 15946211 |
| rs6025 | CT | Genotype CT is associated with increased risk of Stroke when treated with hormonal contraceptives for systemic use in women as compared to genotype CC. | CC | 16769590 |
| rs6071980 | C | Allele C is associated with increased risk of non-response when treated with Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele T. | TT | 18615156 |
| rs6130615 | TT | Genotype TT is associated with increased severity of Anemia when treated with docetaxel in people with Nasopharyngeal Neoplasms as compared to genotype CT. | CC | 24193570 |
| rs671 | AA + AG | Genotypes AA + AG are associated with increased Heroin Dependence due to heroin as compared to genotype GG. | GG | 21723677 |
| rs6714486 | A | Allele A is associated with changes in mycophenolic acid exposure-related parameters on day 7 after transplantation (treatment with 2g per day) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T. | TT | 16198654 |
| rs6769511 | C | Allele C is associated with increased likelihood of Disease Progression when treated with epirubicin, fluorouracil and oxaliplatin in people with Stomach Neoplasms as compared to allele T. | TT | 26115082 |
| rs683369 | CG + GG | Genotypes CG + GG is associated with increased overall survival when treated with cisplatin in people with Esophageal Neoplasms as compared to genotype CC. | CC | 32285752 |
| rs683369 | CC | Genotype CC is associated with decreased severity of Drug Toxicity when treated with imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG. | CC | 28289867 |
| rs683369 | CG + GG | Genotypes CG + GG is associated with increased risk of conjunctival hemorrhage when treated with imatinib in people with Gastrointestinal Stromal Tumors as compared to genotype CC. | CC | 28762371 |
| rs686 | A | Allele A is associated with increased risk of Tobacco Use Disorder when exposed to nicotine in smokers as compared to allele G. | GG | 18092181 |
| rs7104613 | T | Allele T is associated with opioids response when treated with fentanyl, morphine, opioids or oxycodone in people with Neoplasms as compared to allele C. | CC | 21622719 |
| rs7170924 | GT + TT | Genotypes GT + TT are associated with increased risk of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype GG. | GG | 27498158 |
| rs7305534 | CC + CT | Genotypes CC + CT is associated with increased severity of Diarrhea, Nausea and Vomiting when treated with platinum in people with Lung Neoplasms as compared to genotype TT. | TT | 26358256 |
| rs7412 | T | Allele T is associated with increased risk of Hypertriglyceridemia when treated with Antivirals for treatment of HIV infections, combinations and ritonavir in people with HIV Infections as compared to allele C. | CC | 15809899 |
| rs7412 | T | Allele T is associated with LDL-C response when treated with atorvastatin in people with Coronary Disease. | CC | 20031582 |
| rs7412 | CT + TT | Genotypes CT + TT is associated with increased Hyperuricemia in people with Coronary Disease or Hypertension as compared to genotype CC. | CC | 31559922 |
| rs7412 | CT + TT | Genotypes CT + TT is associated with increased percent reduction in LDL-cholesterol when treated with atorvastatin or pravastatin in people with Acute coronary syndrome as compared to genotype CC. | CC | 19667110 |
| rs7572857 | AA + AG | Genotypes AA + AG are associated with increased risk of aspirin-intolerant asthma when exposed to aspirin in people with Asthma as compared to genotype GG. | GG | 21072201 |
| rs7572857 | AA | Genotype AA is associated with increased decline of forced expiratory volume in 1s (FEV(1)) by aspirin provocation when exposed to aspirin in people with Asthma as compared to genotypes AG + GG. | GG | 21072201 |
| rs762551 | AA | Genotype AA is associated with decreased risk of Iron Overload when treated with deferasirox in children with Thalassemia as compared to genotypes AC + CC. | AA | 28346059 |
| rs762551 | AC + CC | Genotypes AC + CC are associated with increased risk of Myocardial Infarction in people with increased coffee intake. | AA | 16522833 |
| rs762551 | AA | Genotype AA is associated with decreased plasma concentrations when treated with olanzapine in people with psychiatric disorders as compared to allele C. | AA | 19636338 |
| rs762551 | AA + AC | Genotypes AA + AC are associated with decreased on-treatment platelet reactivity when treated with clopidogrel in people with cigarette smokers as compared to genotype CC. | AA | 21148426 |
| rs762551 | AC + CC | Genotypes AC + CC are associated with increased QT interval when treated with antipsychotics, chlorpromazine, fluphenazine, thioridazine and trifluoperazine in people with Schizophrenia as compared to genotype AA. | AA | 17611010 |
| rs762551 | C | Allele C is associated with increased likelihood of Pulmonary Disease, Chronic Obstructive as compared to allele A. | AA | 20797314 |
| rs762551 | AC + CC | Genotypes AC + CC are associated with increased QT interval when treated with chlorpromazine in people with Schizophrenia as compared to genotype AA. | AA | 17611010 |
| rs762551 | CC | Genotype CC is associated with increased risk of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes AA + AC. | AA | 16490169 |
| rs762551 | AA | Genotype AA is associated with decreased likelihood of Metabolic Syndrome when treated with clozapine in people with Schizophrenia as compared to genotypes AC + CC. | AA | 27681143 |
| rs762551 | CC | Genotype CC is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes AA + AC. | AA | 10889552 |
| rs7929521 | GG | Genotype GG is associated with increased IC50 of daunorubicin. | AG | 18451141 |
| rs806374 | CC | Genotype CC is associated with increased likelihood of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes CT + TT. | CT | 21266946 |
| rs806374 | CC | Genotype CC is associated with increased severity of tardive dyskinesia when treated with antipsychotics in people with Schizophrenia as compared to genotypes CT + TT. | CT | 21266946 |
| rs8099917 | GG + GT | Genotypes GG + GT are associated with increased risk of treatment failure when treated with peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 24355007 |
| rs8099917 | TT | Genotype TT is associated with decreased severity of Hepatitis C when treated with peginterferon alfa-2b and ribavirin as compared to genotypes GG + GT. | TT | 21911885 |
| rs8099917 | GG + GT | Genotypes GG + GT are associated with increased likelihood of retreatment failure when treated with direct acting antivirals, elbasvir / grazoprevir or ledipasvir / sofosbuvir in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 31846553 |
| rs8099917 | GG + GT | Genotypes GG + GT are associated with increased risk of Hypercholesterolemia when treated with asunaprevir, daclatasvir, direct acting antivirals, ledipasvir / sofosbuvir or ombitasvir / paritaprevir / ritonavir in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 31144350 |
| rs8176746 | T | Allele T is associated with increased ACE activity in people with Hypertension. | GG | 20066004 |
| rs894160 | CT + TT | Genotypes CT + TT are associated with decreased Weight gain due to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype CC. | CT | 16732015 |
| rs9282564 | CC + CT | Genotypes CC + CT is associated with increased risk of Respiratory Insufficiency when treated with morphine in children as compared to genotype TT. | TT | 25311385 |
| rs9345389 | G | Allele G is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) and is also associated with greater methotrexate clearance. when treated with methotrexate as compared to allele A. | AA | 19176441 |
| rs9394992 | CT + TT | Genotypes CT + TT are associated with increased risk of neutropenia when treated with gemcitabine in people with Pancreatic Neoplasms as compared to genotype CC. | CC | 20665488 |
| rs940052 | G | Allele G is associated with decreased risk of Esophagitis when treated with radiotherapy as compared to allele A. | AG | 25054431 |
| rs951439 | TT | Genotype TT is associated with increased likelihood of response when treated with risperidone in people with Schizophrenia as compared to genotypes CC + CT. | CT | 17588543 |
| rs951439 | CC | Genotype CC is associated with increased likelihood of positive response when treated with olanzapine and perphenazine in people with Schizophrenia as compared to genotypes CT + TT. | CT | 17588543 |
| rs9922316 | T | Allele T is associated with increased dexmedetomidine ED50 values for drug-induced dorsal hand vein (DHV) constriction when exposed to dexmedetomidine in healthy individuals as compared to allele G. | GG | 23337848 |
Page:
Variants which affect drug dose, response, metabolism, etc.:
Page:
| Variant | Alleles | Associations | Genotype | PMID |
|---|---|---|---|---|
| rs1042389 | TT | Genotype TT is associated with decreased metabolism of efavirenz in healthy individuals as compared to genotype CC. | CT | 28960269 |
| rs1042713 | AA | Genotype AA is associated with decreased response to salmeterol in children with Asthma. | AG | 23126384 |
| rs1042713 | AA | Genotype AA is associated with decreased response to salmeterol in people with Asthma as compared to genotype GG. | AG | 16322642 |
| rs1042713 | AA | Genotype AA is associated with decreased response to methacholine in people with Asthma as compared to genotype GG. | AG | 23384627 |
| rs1042713 | AG + GG | Genotypes AG + GG are associated with increased response to benazepril in people with Essential hypertension as compared to genotype AA. | AG | 15554460 |
| rs10485058 | AA | Genotype AA is associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotypes AG + GG. | AA | 27958381 |
| rs10494227 | A | Allele A is associated with increased response to interferon beta-1a and interferon beta-1b in people with Multiple Sclerosis as compared to allele G. | AA | 27001119 |
| rs10509681 | C | Allele C is associated with increased metabolism of rosiglitazone in healthy individuals as compared to allele T. | CT | 17178266 |
| rs10509681 | C | Allele C is associated with increased metabolism of repaglinide in healthy individuals as compared to allele T. | CT | 14534525 |
| rs1051740 | C | Allele C is associated with increased dose of carbamazepine in people with Epilepsy as compared to allele T. | CT | 19620853 |
| rs1051740 | CT | Genotype CT is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotype TT. | CT | 22188362 |
| rs1051740 | TT | Genotype TT is associated with decreased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CC + CT. | CT | 23252947 |
| rs1051740 | CC | Genotype CC is associated with decreased dose of phenprocoumon as compared to genotypes CT + TT. | CT | 21110013 |
| rs1051740 | C | Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele T. | CT | 15692831 |
| rs10793902 | T | Allele T is associated with increased response to hydroxyurea in people with Anemia, Sickle Cell and beta-Thalassemia as compared to allele C. | CT | 26895070 |
| rs10964552 | AA + AC | Genotypes AA + AC are associated with decreased response to cisplatin in people with Urinary Bladder Neoplasms as compared to genotype CC. | CC | 27150640 |
| rs11126740 | AA | Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotypes AG + GG. | AG | 27670765 |
| rs1126535 | T | Allele T is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to allele C. | CT | 28639493 |
| rs11265572 | GT + TT | Genotypes GT + TT are associated with decreased metabolism of tacrolimus in people with liver transplantation as compared to genotype GG. | GG | 24351870 |
| rs1130864 | AG + GG | Genotypes AG + GG are associated with increased response to adalimumab in people with Inflammatory Bowel Diseases as compared to genotype AA. | GG | 27096233 |
| rs1143634 | GG | Genotype GG is associated with decreased response to infliximab in people with Crohn Disease as compared to genotypes AA + AG. | AG | 22960943 |
| rs1143634 | A | Allele A is associated with increased dose of morphine in women with Pain, Postoperative as compared to allele G. | AG | 27649267 |
| rs11563250 | AG + GG | Genotypes AG + GG is associated with decreased concentrations of bilirubin in people with Colorectal Neoplasms as compared to genotype AA. | AA | 25778466 |
| rs11574077 | TT | Genotype TT is associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype CT. | TT | 29706892 |
| rs11702779 | AG + GG | Genotypes AG + GG are associated with increased response to methacholine chloride in children with Asthma. | GG | 21803869 |
| rs11869731 | CC | Genotype CC is associated with increased response to lithium in people with Bipolar Disorder as compared to genotypes CG + GG. | CC | 21961650 |
| rs11959113 | AA | Genotype AA is associated with increased dose of fentanyl in people with Pain, Postoperative as compared to genotypes AG + GG. | AA | 25615449 |
| rs12067645 | AA + AG | Genotypes AA + AG is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype GG. | AG | 30088438 |
| rs12082710 | TT | Genotype TT is associated with increased response to antidepressants in people with Depression as compared to genotypes CC + CT. | TT | 23092981 |
| rs1232027 | A | Allele A is associated with increased response to methotrexate in people with Arthritis, Psoriatic as compared to allele G. | AG | 20472929 |
| rs12404655 | AG + GG | Genotypes AG + GG is associated with increased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype AA. | GG | 30088438 |
| rs12505410 | G | Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T. | TG | 24123600 |
| rs12505410 | G | Allele G is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to allele T. | TG | 24123600 |
| rs1265138 | AA | Genotype AA is associated with increased response to cladribine and cytarabine in children with Leukemia, Myeloid, Acute as compared to genotypes AG + GG. | AA | 24024897 |
| rs12720066 | AC + CC | Genotypes AC + CC are associated with decreased exposure to SN-38 in people with Colorectal Neoplasms as compared to genotype AA. | AA | 27845419 |
| rs12721655 | G | Allele G is not associated with decreased clearance of nevirapine in people with HIV Infections as compared to allele A. | AA | 22354160 |
| rs1521470 | A | Allele A is associated with decreased response to lithium in people with Bipolar Disorder as compared to allele G. | GG | 29121268 |
| rs16969968 | G | Allele G is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder. | AG | 22648373 |
| rs16969968 | GG | Genotype GG is associated with decreased dose of nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG. | AG | 23358500 |
| rs16969968 | AA + AG | Genotypes AA + AG are associated with increased response to bupropion, nicotine or varenicline in women with Tobacco Use Disorder as compared to genotype GG. | AG | 29621993 |
| rs16969968 | A | Allele A is associated with increased concentrations of cotinine in people with Tobacco Use Disorder as compared to allele G. | AG | 26833182 |
| rs16969968 | AA + AG | Genotypes AA + AG are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype GG. | AG | 26142345 |
| rs16969968 | A | Allele A is associated with increased response to Drugs used in nicotine dependence in people with Tobacco Use Disorder. | AG | 22648373 |
| rs16969968 | A | Allele A is associated with increased dose of nicotine in people with Tobacco Use Disorder as compared to allele G. | AG | 26010901 |
| rs17216198 | T | Allele T is associated with decreased exposure to rosuvastatin in healthy individuals as compared to allele C. | CC | 30100615 |
| rs1741981 | CC | Genotype CC is associated with decreased response to corticosteroids in children with Asthma as compared to genotypes CT + TT. | CT | 24307847 |
| rs1741981 | CC | Genotype CC is associated with decreased response to Corticosteroids For Systemic Use in people with Asthma as compared to genotypes CT + TT. | CT | 24307847 |
| rs1799722 | TT | Genotype TT is associated with decreased response to enalapril in people with Hypertension as compared to genotypes CC + CT. | CT | 22706620 |
| rs1799722 | CT | Genotype CT is associated with increased exposure to atorvastatin in healthy individuals as compared to genotypes CC + TT. | CT | 29250329 |
| rs1799978 | T | Allele T is associated with increased response to risperidone in people with Schizophrenia as compared to allele C. | TT | 17105675 |
| rs1799978 | CC | Genotype CC is associated with decreased dose of methadone in people with Heroin Dependence as compared to genotype TT. | TT | 21902500 |
| rs1799978 | TT | Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotype CT. | TT | 18855532 |
| rs1800562 | A | Allele A is associated with decreased dose of epoetin alfa in people with hemodialysis treatment as compared to allele G. | GG | 18025780 |
| rs1800629 | GG | Genotype GG is associated with decreased response to adalimumab in people with Arthritis, Rheumatoid. | AG | 17673491 |
| rs1800629 | G | Allele G is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Crohn Disease, Inflammatory Bowel Diseases, Psoriasis or Spondylarthropathies as compared to allele A. | AG | 26244882 |
| rs1800629 | AG + GG | Genotypes AG + GG is associated with increased response to adalimumab, etanercept and infliximab in people with Arthritis, Rheumatoid as compared to genotype AA. | AG | 22760475 |
| rs1800629 | AG + GG | Genotypes AG + GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AA. | AG | 18713756 |
| rs1800888 | CT | Genotype CT is associated with decreased response to terbutaline in healthy individuals as compared to genotype CC. | CC | 11222464 |
| rs1801131 | G | Allele G is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele T. | TG | 20078613 |
| rs1801131 | TT | Genotype TT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GG + GT. | TG | 27676277 |
| rs1801131 | GT | Genotype GT is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype TT. | TG | 25618758 |
| rs1801131 | GG | Genotype GG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes GT + TT. | TG | 27992285 |
| rs1801131 | G | Allele G is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major. | TG | 27035272 |
| rs1801133 | AG + GG | Genotypes AG + GG is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype AA. | AG | 24967362 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased exposure to methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 21644011 |
| rs1801133 | AA | Genotype AA is associated with decreased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotypes AG + GG. | AG | 29589488 |
| rs1801133 | AA + AG | Genotypes AA + AG are associated with increased response to disulfiram in people with Cocaine-Related Disorders as compared to genotype GG. | AG | 23335901 |
| rs1801133 | A | Allele A is associated with increased response to fluorouracil, leucovorin and oxaliplatin in people with Colorectal Neoplasms as compared to allele G. | AG | 20078613 |
| rs1801133 | AA | Genotype AA is associated with decreased response to capecitabine, fluorouracil, leucovorin and oxaliplatin in people with Colonic Neoplasms as compared to allele G. | AG | 24980946 |
| rs1801133 | AA | Genotype AA is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AG + GG. | AG | 27676277 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased concentrations of methotrexate in people with Burkitt Lymphoma, Lymphoma, T-Cell or Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG. | AG | 25303299 |
| rs1801133 | AA | Genotype AA is associated with decreased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes AG + GG. | AG | 27995989 |
| rs1801133 | AA | Genotype AA is associated with decreased response to methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG. | AG | 24637499 |
| rs1801133 | AA + AG | Genotypes AA + AG is associated with increased response to fluorouracil in people with Colorectal Neoplasms as compared to genotype GG. | AG | 29134491 |
| rs1801133 | A | Allele A is associated with increased response to Vitamin B-complex, Incl. Combinations in people with Depressive Disorder, Major. | AG | 27035272 |
| rs1801394 | AG + GG | Genotypes AG + GG is associated with increased response to methotrexate in children with Arthritis, Juvenile Rheumatoid as compared to genotype AA. | AG | 29589488 |
| rs1975974 | AG + GG | Genotypes AG + GG is associated with increased response to ustekinumab in people with Psoriasis as compared to genotype AA. | AG | 27977334 |
| rs204047 | GG | Genotype GG is associated with increased dose of methadone as compared to genotypes GT + TT. | GG | 31907389 |
| rs204047 | GG | Genotype GG is associated with increased concentrations of methadone as compared to genotypes GT + TT. | GG | 31907389 |
| rs2071303 | CC + CT | Genotypes CC + CT are associated with increased response to adalimumab in people with Crohn Disease as compared to genotype TT. | CT | 27115882 |
| rs2075650 | G | Allele G is associated with decreased response to hmg coa reductase inhibitors as compared to allele A. | AA | 27045730 |
| rs2177370 | A | Allele A is associated with increased response to donepezil, galantamine or rivastigmine in people with Alzheimer Disease as compared to allele G. | AA | 25730470 |
| rs2230808 | CC | Genotype CC is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype TT. | CC | 20346718 |
| rs2246709 | AG + GG | Genotypes AG + GG are associated with increased response to amlodipine in people with Hypertension as compared to genotype AA. | AG | 19907160 |
| rs2273697 | A | Allele A is associated with decreased exposure to mycophenolic acid in people with Kidney Transplantation as compared to allele G. | GG | 28624888 |
| rs2273697 | A | Allele A is associated with decreased exposure to mycophenolic acid as compared to allele G. | GG | 28624888 |
| rs2284922 | A | Allele A is associated with increased response to carboplatin, docetaxel and trastuzumab in women with Breast Neoplasms. | AG | 30071039 |
| rs2303377 | TT | Genotype TT is associated with increased response to duloxetine in people with Depressive Disorder, Major as compared to genotypes CC + CT. | TT | 28696415 |
| rs2305089 | TT | Genotype TT is associated with increased response to flunisolide in people with Asthma as compared to genotypes CC + CT. | TT | 22538805 |
| rs2305948 | T | Allele T is associated with decreased response to clopidogrel in people with Coronary Disease as compared to allele C. | CC | 25738571 |
| rs2337980 | CC | Genotype CC is associated with increased response to nicotine in women as compared to genotypes CT + TT. | CC | 20231857 |
| rs243865 | T | Allele T is associated with decreased response to ulinastatin in people with Pancreatitis as compared to allele C. | CC | 31192912 |
| rs2461817 | C | Allele C is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to allele A. | CA | 23252947 |
| rs2461817 | AA | Genotype AA is associated with decreased concentrations of voriconazole as compared to genotype AC. | CA | 31932875 |
| rs2477134 | G | Allele G is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T. | TG | 29580174 |
| rs2514218 | T | Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele C. | CT | 26666695 |
| rs2740204 | T | Allele T is associated with increased response to clozapine in people with Schizophrenia as compared to allele G. | TG | 20196918 |
| rs2776546 | A | Allele A is associated with increased response to diuretics, hydrochlorothiazide or Thiazides, plain in people with Hypertension as compared to allele C. | AA | 23753411 |
| rs28371685 | T | Allele T is associated with decreased dose of warfarin as compared to allele C. | CC | 20072124 |
| rs28399504 | G | Allele G is associated with decreased metabolism of mephenytoin as compared to allele A. | AA | 9435198 |
| rs286913 | A | Allele A is associated with increased response to ziprasidone in people with Schizophrenia as compared to allele G. | AG | 21107309 |
| rs2884737 | AA | Genotype AA is associated with increased dose of warfarin as compared to genotype AC. | AA | 24019055 |
| rs2884737 | C | Allele C is associated with decreased dose of warfarin as compared to allele A. | AA | 20072124 |
| rs2884737 | CC | Genotype CC is associated with decreased dose of warfarin as compared to genotype AA. | AA | 18322281 |
| rs2884737 | C | Allele C is associated with decreased dose of warfarin as compared to allele A. | AA | 16611750 |
| rs3184504 | T | Allele T is associated with increased response to candesartan in people with Hypertension as compared to allele C. | CT | 31327267 |
| rs3212986 | CC | Genotype CC is associated with increased response to Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + AC. | CC | 29662106 |
| rs3212986 | A | Allele A is not associated with decreased response to Platinum compounds in women with Ovarian Neoplasms as compared to allele C. | CC | 22329723 |
| rs3212986 | AC + CC | Genotypes AC + CC are associated with increased response to granisetron or palonosetron in people with Nausea and Vomiting as compared to genotype AA. | CC | 29177570 |
| rs3749034 | G | Allele G is associated with increased dose of methadone in people with Heroin Dependence as compared to allele A. | AG | 31866536 |
| rs3761555 | TT | Genotype TT is associated with decreased response to Selective serotonin reuptake inhibitors or venlafaxine in people with Depressive Disorder, Major as compared to genotypes CC + CT. | CT | 23394390 |
| rs3785143 | T | Allele T is associated with decreased response to atomoxetine in children with Attention Deficit Disorder with Hyperactivity as compared to allele C. | CC | 23266789 |
| rs3787429 | TT | Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT. | TT | 21652606 |
| rs3816877 | CC | Genotype CC is associated with increased concentrations of valproic acid in people with Epilepsy as compared to genotype CT. | CC | 27406852 |
| rs3918290 | CC | Genotype CC is associated with increased response to fluorouracil in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CT. | CC | 26846104 |
| rs3918290 | CT | Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 17064846 |
| rs3918290 | CT | Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 18600527 |
| rs3918290 | CT | Genotype CT is associated with decreased clearance of fluorouracil in people with Colorectal Neoplasms as compared to genotype CC. | CC | 11953843 |
| rs3918290 | CT | Genotype CT is associated with decreased response to cisplatin and fluorouracil in men with Head and Neck Neoplasms as compared to genotype CC. | CC | 26792652 |
| rs3918290 | CT | Genotype CT is associated with decreased metabolism of fluorouracil in people with Neoplasms as compared to genotype CC. | CC | 26216193 |
| rs3918290 | CT | Genotype CT is associated with decreased dose of capecitabine in people with Colorectal Neoplasms as compared to genotype CC. | CC | 21498394 |
| rs4148323 | AA | Genotype AA is associated with decreased metabolism of SN-38 in people with Neoplasms as compared to genotype GG. | GG | 17627617 |
| rs4148323 | AA | Genotype AA is associated with decreased metabolism of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148323 | AA | Genotype AA is associated with decreased response to cisplatin and irinotecan in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 16636344 |
| rs4148323 | A | Allele A is associated with decreased metabolism of carvedilol in people with Angina Pectoris as compared to allele G. | GG | 16849011 |
| rs4148386 | AA + AG | Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG. | AG | 23252947 |
| rs4148412 | TT | Genotype TT is associated with increased concentrations of morphine-3-glucuronide in children with tonsillectomy as compared to genotypes CC + CT. | TT | 26810133 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with decreased dose of warfarin as compared to genotype TT. | TT | 25312789 |
| rs429358 | C | Allele C is associated with decreased dose of acenocoumarol in people with venous thromboembolism as compared to allele T. | TT | 29432897 |
| rs429358 | CT | Genotype CT is associated with decreased response to atorvastatin in people with Hypercholesterolemia as compared to genotype TT. | TT | 25860945 |
| rs429358 | CC + CT | Genotypes CC + CT is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to genotype TT. | TT | 24951635 |
| rs4305746 | AA + AG | Genotypes AA + AG are associated with increased response to aripiprazole in people with Schizophrenia as compared to genotype GG. | AA | 19345712 |
| rs4645962 | CT | Genotype CT is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype TT. | TT | 26249541 |
| rs4646450 | GG | Genotype GG is associated with increased dose-adjusted trough concentrations of tacrolimus in people with liver transplantation as compared to genotypes AA + AG. | GG | 29454235 |
| rs4680 | AA + AG | Genotypes AA + AG is associated with increased concentrations of glucose in children as compared to genotype GG. | AG | 25048416 |
| rs4680 | AG + GG | Genotypes AG + GG is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotype AA. | AG | 32459054 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with increased response to opioids in children as compared to genotype GG. | AG | 30704436 |
| rs4680 | AA + AG | Genotypes AA + AG is associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype GG. | AG | 23856854 |
| rs4680 | GG | Genotype GG is associated with decreased response to morphine in infants with Pain as compared to genotypes AA + AG. | AG | 27027462 |
| rs4680 | G | Allele G is associated with increased clearance of methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to allele A. | AG | 18214865 |
| rs4680 | A | Allele A is associated with increased response to morphine in people with Low Back Pain as compared to allele G. | AG | 23773341 |
| rs4680 | AG + GG | Genotypes AG + GG are associated with increased dose of morphine as compared to genotype AA. | AG | 17156920 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with increased response to venlafaxine in people with Anxiety Disorders as compared to genotype GG. | AG | 22417933 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with increased response to morphine or remifentanil in infants with Pain as compared to genotype GG. | AG | 27027462 |
| rs4680 | AA | Genotype AA is associated with decreased dose of morphine in people with Pain, Postoperative as compared to genotypes AG + GG. | AG | 23686330 |
| rs4680 | GG | Genotype GG is associated with decreased response to fluvoxamine in people with Depressive Disorder, Major as compared to allele A. | AG | 20619611 |
| rs4680 | AA + AG | Genotypes AA + AG are associated with increased response to oxycodone as compared to genotype GG. | AG | 31493434 |
| rs4680 | A | Allele A is associated with increased response to paroxetine in people with Depressive Disorder, Major as compared to allele G. | AG | 18989660 |
| rs4680 | AA | Genotype AA is associated with decreased dose of sufentanil in children as compared to genotypes AG + GG. | AG | 28006928 |
| rs4680 | G | Allele G is associated with increased dose of morphine in people with Pain, Postoperative and Coronary Artery Disease as compared to allele A. | AG | 31967515 |
| rs4737771 | C | Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T. | TT | 27091189 |
| rs4795893 | AA + AG | Genotypes AA + AG is associated with increased response to risperidone in people with Schizophrenia as compared to genotype GG. | AG | 24495780 |
| rs4986910 | G | Allele G is associated with decreased dose of tacrolimus in people with Kidney Transplantation as compared to allele A. | AA | 12966368 |
| rs5063 | TT | Genotype TT is associated with decreased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype CC. | CC | 20877298 |
| rs5569 | GG | Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. | GG | 21127421 |
| rs5569 | GG | Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. | GG | 29230023 |
| rs5569 | AG + GG | Genotypes AG + GG are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. | GG | 15322419 |
| rs56113850 | T | Allele T is associated with decreased clearance of nicotine as compared to allele C. | CC | 26407342 |
| rs585719 | CT | Genotype CT is associated with increased response to citalopram in people with Depression as compared to genotype CC. | CT | 23158458 |
| rs5882 | A | Allele A is associated with increased response to simvastatin in people with Hypercholesterolemia as compared to allele G. | AA | 17931083 |
| rs5934731 | C | Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele T. | CT | 21635146 |
| rs6458232 | C | Allele C is associated with response to cisplatin, fluorouracil and mitoxantrone in people with Carcinoma, Hepatocellular as compared to allele A. | CC | 21635146 |
| rs646776 | C | Allele C is associated with increased response to hmg coa reductase inhibitors as compared to allele T. | CT | 25350695 |
| rs6494223 | T | Allele T is associated with increased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C. | CT | 24951635 |
| rs671 | AA + AG | Genotypes AA + AG is associated with decreased response to nitroglycerin in children with Heart Defects, Congenital as compared to genotype GG. | GG | 31250045 |
| rs683369 | CG + GG | Genotypes CG + GG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype CC. | CC | 29427770 |
| rs683369 | CC | Genotype CC is associated with increased clearance of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG. | CC | 24589908 |
| rs686 | G | Allele G is associated with increased response to clozapine in people with Schizophrenia as compared to allele A. | GG | 21332319 |
| rs6908425 | CT + TT | Genotypes CT + TT are associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Psoriasis as compared to genotype CC. | CT | 27670765 |
| rs6920220 | AA | Genotype AA is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Psoriatic or Psoriasis as compared to genotypes AG + GG. | AG | 30653751 |
| rs7121 | CC | Genotype CC is associated with increased response to cisplatin and fluorouracil in people with Esophageal Neoplasms as compared to genotypes CT + TT. | CC | 19274060 |
| rs7405404 | T | Allele T is associated with increased response to lithium in people with Bipolar Disorder as compared to allele C. | CT | 29121268 |
| rs7412 | CC | Genotype CC is associated with increased dose of warfarin in people with Atrial Fibrillation, Pulmonary Embolism or Venous Thrombosis as compared to genotypes CT + TT. | CC | 31854268 |
| rs7412 | T | Allele T is associated with decreased dose of warfarin in people with haplotype epsilon2. | CC | 21228733 |
| rs760370 | AG + GG | Genotypes AG + GG is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype AA. | AG | 28992563 |
| rs762551 | A | Allele A is associated with increased dose of paroxetine in people with Depressive Disorder, Major as compared to allele C. | AA | 21121774 |
| rs762551 | AA | Genotype AA is associated with increased metabolism of caffeine in people with heavy coffee consumption as compared to genotypes AC + CC. | AA | 20390257 |
| rs762551 | AA | Genotype AA is associated with increased metabolism of caffeine in people with Tobacco Use Disorder as compared to genotypes AC + CC. | AA | 17370067 |
| rs762551 | AA | Genotype AA is associated with increased clearance of carbamazepine in children with Epilepsy as compared to genotypes AC + CC. | AA | 26762380 |
| rs762551 | AA | Genotype AA is associated with increased metabolism of caffeine as compared to genotype AC. | AA | 10233211 |
| rs762551 | AA + AC | Genotypes AA + AC is associated with increased metabolism of caffeine as compared to genotype CC. | AA | 29282363 |
| rs762551 | CC | Genotype CC is associated with decreased dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes AA + AC. | AA | 30713339 |
| rs7668282 | CC + CT | Genotypes CC + CT is associated with decreased metabolism of morphine in people with Anemia, Sickle Cell as compared to genotype TT. | TT | 17724700 |
| rs800292 | GG | Genotype GG is associated with decreased response to bevacizumab in people with Macular Degeneration as compared to genotype AA. | AG | 22594510 |
| rs8099917 | T | Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in children with Hepatitis C as compared to allele G. | TT | 26825765 |
| rs8099917 | T | Allele T is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele G. | TT | 19749757 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Hepatitis C, HIV Infections and HIV Infections as compared to genotypes GG + GT. | TT | 22328925 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or simeprevir in people with Hepatitis C as compared to genotypes GG + GT. | TT | 26264253 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21745312 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT. | TT | 21321200 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21254157 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21739446 |
| rs8099917 | GG + GT | Genotypes GG + GT is associated with decreased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. | TT | 25278709 |
| rs8099917 | GG + GT | Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype TT. | TT | 20060832 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin or telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 25393304 |
| rs8099917 | TT | Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 24102823 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 22301466 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 25852275 |
| rs8099917 | GG + GT | Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 21346780 |
| rs8099917 | T | Allele T is associated with increased response to peginterferon alfa-2a or peginterferon alfa-2b in people with Hepatitis B, Chronic as compared to allele G. | TT | 31201901 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21360545 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21112660 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21112660 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT. | TT | 21321200 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21246582 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21048934 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 23142377 |
| rs8099917 | TT | Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21466653 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 21911885 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b, ribavirin and telaprevir in people with Hepatitis C as compared to genotypes GG + GT. | TT | 20648473 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 20434452 |
| rs8099917 | G | Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T. | TT | 19749758 |
| rs8099917 | GT | Genotype GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 19749758 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 24929144 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype GT. | TT | 23281610 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic and Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 26075078 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotype GT. | TT | 23730840 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 21384511 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to genotypes GG + GT. | TT | 21907615 |
| rs8099917 | G | Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C as compared to allele T. | TT | 21931540 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GT + TT. | TT | 21987611 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 26003758 |
| rs8099917 | GG | Genotype GG is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 19749758 |
| rs8099917 | TT | Genotype TT is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21503910 |
| rs8099917 | TT | Genotype TT is associated with increased response to interferon alfa-n1, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 21466653 |
| rs8099917 | GG + GT | Genotypes GG + GT is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C. | TT | 20060832 |
| rs8099917 | TT | Genotype TT is associated with increased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic as compared to genotypes GG + GT. | TT | 24768758 |
| rs9282564 | C | Allele C is associated with decreased concentrations of methadone in people with Opioid-Related Disorders as compared to allele T. | TT | 17178267 |
| rs9282564 | CC + CT | Genotypes CC + CT is associated with decreased dose-adjusted trough concentrations of tacrolimus in people with Kidney Transplantation as compared to genotype TT. | TT | 29603629 |
| rs9332131 | del | Allele del is associated with decreased metabolism of phenytoin in people with no disease as compared to genotype AA. | GAGA | 16220110 |
| rs9332131 | del | Allele del is associated with decreased dose of warfarin. | GAGA | 20072124 |
| rs933271 | C | Allele C is associated with decreased response to risperidone in people with Schizophrenia. | TT | 22935916 |
| rs1002976 | C | Allele C is associated with increased concentrations of uric acid in people with Hypertension as compared to allele T. | TT | 29580174 |
| rs10248420 | A | Allele A is associated with decreased response to clozapine in people with Schizophrenia as compared to allele G. | AG | 22722500 |
| rs1042713 | A | Allele A is associated with decreased response to corticosteroids and selective beta-2-adrenoreceptor agonists in children with Asthma as compared to genotype GG. | AG | 26774659 |
| rs1042713 | AA | Genotype AA is associated with increased response to tiotropium in people with Asthma as compared to genotypes AG + GG. | AG | 19183167 |
| rs1042713 | AA | Genotype AA is associated with increased dose of phenylephrine in women as compared to genotype GG. | AG | 25730298 |
| rs1042713 | GG | Genotype GG is associated with increased response to propranolol in people with Liver Cirrhosis as compared to genotype AA. | AG | 26109805 |
| rs1042713 | AA | Genotype AA is associated with increased response to atenolol or metoprolol in people with Tachycardia as compared to genotypes AG + GG. | AG | 31090079 |
| rs10499563 | CC + CT | Genotypes CC + CT is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Colitis, Ulcerative and Inflammatory Bowel Diseases as compared to genotype TT. | TT | 24776844 |
| rs10514475 | A | Allele A is associated with increased response to Selective serotonin reuptake inhibitors in people with Depression as compared to allele G. | GG | 25649181 |
| rs10517 | AA | Genotype AA is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes AG + GG. | GG | 27740732 |
| rs10517 | GG | Genotype GG is associated with decreased dose of warfarin as compared to genotypes AA + AG. | GG | 26257249 |
| rs1051740 | CC | Genotype CC is associated with increased dose of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. | CT | 22188362 |
| rs1051740 | CC | Genotype CC is associated with increased metabolism of carbamazepine in people with Epilepsy as compared to genotypes CT + TT. | CT | 26555147 |
| rs1059513 | CC + CT | Genotypes CC + CT are associated with increased response to esomeprazole in children with eosinophilic esophagitis as compared to genotype TT. | TT | 31490856 |
| rs10841753 | CT + TT | Genotypes CT + TT are associated with decreased concentrations of methotrexate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | TT | 28525903 |
| rs10954732 | GG | Genotype GG is associated with increased concentrations of voriconazole as compared to genotype AA. | AG | 31932875 |
| rs1143634 | A | Allele A is associated with decreased dose of morphine in women with Pain, Postoperative as compared to allele G. | AG | 27649267 |
| rs11591147 | T | Allele T is associated with increased response to hmg coa reductase inhibitors in people with Hypercholesterolemia as compared to genotype GG. | GG | 26902539 |
| rs11702779 | AA | Genotype AA is associated with increased response to methacholine chloride in children with Asthma as compared to genotypes AG + GG. | GG | 21803869 |
| rs11716445 | A | Allele A is associated with decreased response to pravastatin or simvastatin in people with Hypercholesterolemia as compared to allele G. | AA | 23166513 |
| rs11960832 | TT | Genotype TT is associated with decreased response to olanzapine in people with Schizophrenia as compared to genotypes CC + CT. | TT | 23886675 |
| rs12081765 | G | Allele G is associated with increased response to adalimumab, certolizumab pegol, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A. | AA | 33124499 |
| rs1229984 | CT | Genotype CT is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotypes CC + TT. | CC | 31002879 |
| rs12456693 | T | Allele T is associated with increased response to clopidogrel in people with Coronary Artery Disease as compared to allele C. | CC | 30487649 |
| rs12505410 | GG + GT | Genotypes GG + GT is associated with increased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT. | TG | 24123600 |
| rs12505410 | GG | Genotype GG is associated with increased clearance of methotrexate in people with Osteosarcoma as compared to genotypes GT + TT. | TG | 29791011 |
| rs12566888 | TT | Genotype TT is associated with increased response to ticagrelor in healthy individuals as compared to genotype GT. | GG | 27937053 |
| rs1277733 | TT | Genotype TT is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CC. | CC | 30032160 |
| rs13181 | GG | Genotype GG is associated with increased response to bevacizumab, capecitabine, cisplatin, docetaxel, epirubicin, oxaliplatin or trastuzumab in people with Stomach Neoplasms as compared to genotypes GT + TT. | TG | 27995989 |
| rs1412125 | CC | Genotype CC is associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotypes CT + TT. | CT | 24684392 |
| rs1449683 | CC + CT | Genotypes CC + CT are associated with decreased response to fluvoxamine in people with Depressive Disorder as compared to genotype TT. | CT | 25710119 |
| rs1611115 | CT + TT | Genotypes CT + TT are associated with increased response to levodopa in people with Cocaine-Related Disorders as compared to genotype CC. | CC | 24809448 |
| rs1611115 | CT + TT | Genotypes CT + TT is associated with increased response to naltrexone in men with Alcoholism as compared to genotype CC. | CC | 24724887 |
| rs16873129 | C | Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T. | CC | 27091189 |
| rs17180299 | AG + GG | Genotypes AG + GG are associated with increased concentrations of methadone in people with Opioid-Related Disorders as compared to genotype AA. | AA | 27010727 |
| rs17268282 | T | Allele T is associated with increased response to furosemide in people with Heart Failure as compared to allele G. | GG | 26927285 |
| rs17461620 | C | Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T. | CT | 19749758 |
| rs17584499 | CC | Genotype CC is associated with increased response to pioglitazone in people with Diabetes Mellitus, Type 2 as compared to genotypes CT + TT. | CT | 23147557 |
| rs17798800 | T | Allele T is associated with decreased response to donepezil, galantamine and rivastigmine in people with Alzheimer Disease as compared to allele C. | CT | 23374588 |
| rs1800629 | A | Allele A is associated with decreased response to adalimumab, etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G. | AG | 19365401 |
| rs1800629 | A | Allele A is associated with decreased response to etanercept, infliximab or Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele G. | AG | 16909270 |
| rs1800629 | GG | Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotype AG. | AG | 15834068 |
| rs1800629 | GG | Genotype GG is associated with increased response to adalimumab, etanercept or infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. | AG | 16720636 |
| rs1800629 | GG | Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotype AG. | AG | 18050183 |
| rs1800629 | GG | Genotype GG is associated with increased response to etanercept in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. | AG | 12759288 |
| rs1800629 | GG | Genotype GG is associated with increased response to adalimumab in people with Arthritis, Rheumatoid as compared to genotype AG. | AG | 17343250 |
| rs1800629 | GG | Genotype GG is associated with increased response to infliximab in people with Arthritis, Rheumatoid as compared to genotypes AA + AG. | AG | 12847678 |
| rs1800629 | GG | Genotype GG is associated with increased response to adalimumab or infliximab in people with Spondylitis, Ankylosing as compared to genotype AG. | AG | 16720636 |
| rs1800629 | GG | Genotype GG is associated with increased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Inflammation as compared to genotypes AA + AG. | AG | 24192118 |
| rs1801131 | GT + TT | Genotypes GT + TT is associated with increased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | TG | 26616421 |
| rs1801131 | GG + GT | Genotypes GG + GT are associated with increased response to oxaliplatin in people with Colorectal Neoplasms as compared to genotype TT. | TG | 20385995 |
| rs1801131 | G | Allele G is associated with decreased response to benazepril in people with Hypertension. | TG | 16081343 |
| rs1801133 | AA | Genotype AA is associated with increased response to benazepril in people with Hypertension as compared to genotypes AG + GG. | AG | 15226090 |
| rs1801133 | GG | Genotype GG is associated with increased exposure to capecitabine in people with Neoplasms as compared to genotypes AA + AG. | AG | 26242222 |
| rs1801133 | AG | Genotype AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotypes AA + GG. | AG | 25618758 |
| rs1801133 | G | Allele G is associated with decreased response to benazepril in people with Hypertension. | AG | 16081343 |
| rs1801133 | AA | Genotype AA is associated with increased concentrations of methotrexate in people with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotypes AG + GG. | AG | 17180579 |
| rs1801278 | CT + TT | Genotypes CT + TT is associated with decreased response to Drugs Used In Diabetes in people with Diabetes Mellitus, Type 2 as compared to genotype CC. | CT | 28696414 |
| rs1801394 | AA + AG | Genotypes AA + AG is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to genotype GG. | AG | 27676277 |
| rs1801394 | A | Allele A is associated with decreased response to methotrexate in people with Arthritis, Rheumatoid as compared to allele G. | AG | 29743634 |
| rs1803545 | A | Allele A is associated with increased response to glibenclamide in people with as compared to allele G. | GG | 27403931 |
| rs1883112 | AA | Genotype AA is associated with increased response to idarubicin in people with Leukemia, Myeloid, Acute as compared to genotype GG. | AG | 28485375 |
| rs191190 | CC + CT | Genotypes CC + CT is associated with decreased response to ustekinumab in people with Psoriasis as compared to genotype TT. | CT | 27977334 |
| rs2003569 | A | Allele A is associated with increased response to simvastatin as compared to allele G. | GG | 25493567 |
| rs2071427 | TT | Genotype TT is associated with increased response to lithium in people with Bipolar Disorder. | CC | 21781277 |
| rs2162145 | T | Allele T is associated with increased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele C. | CC | 29650774 |
| rs2229109 | CT | Genotype CT is associated with increased resistance to doxorubicin, methotrexate, prednisolone and vincristine in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype CC. | CC | 25582575 |
| rs2273697 | AG | Genotype AG is associated with increased exposure to deferasirox in children with beta-Thalassemia as compared to genotype GG. | GG | 28346059 |
| rs2273697 | AA + AG | Genotypes AA + AG are associated with increased metabolism of irinotecan in people with Colorectal Neoplasms as compared to genotype GG. | GG | 18981587 |
| rs2273697 | AA + AG | Genotypes AA + AG are associated with increased clearance of carbamazepine in people with Epilepsy as compared to genotype GG. | GG | 23252947 |
| rs2273697 | AG | Genotype AG is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype GG. | GG | 25348619 |
| rs2298805 | AA | Genotype AA is associated with increased response to desloratadine and mizolastine in people with Urticaria as compared to genotypes AG + GG. | GG | 25412950 |
| rs2303070 | T | Allele T is associated with increased response to glibenclamide in people with as compared to allele G. | GG | 27403931 |
| rs2305948 | CT + TT | Genotypes CT + TT is associated with increased response to carfilzomib, dexamethasone and lenalidomide in people with Multiple Myeloma as compared to genotype CC. | CC | 28488026 |
| rs2501873 | TT | Genotype TT is associated with increased dose of warfarin in people with heart valve replacement as compared to genotypes CC + CT. | CC | 25356900 |
| rs2514218 | CC | Genotype CC is associated with increased response to aripiprazole or risperidone in people with Psychotic Disorders, schizoaffective disorder or Schizophrenia as compared to genotypes CT + TT. | CT | 26320194 |
| rs2532560 | G | Allele G is associated with increased response to antidepressants in people with Depressive Disorder, Major as compared to allele A. | AA | 27091189 |
| rs2535629 | AA | Genotype AA is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AG + GG. | GG | 27396837 |
| rs254271 | C | Allele C is associated with decreased response to metformin in people with Diabetes Mellitus, Type 2 as compared to allele G. | CG | 29650774 |
| rs261316 | T | Allele T is associated with decreased response to atenolol and hydrochlorothiazide in people with Hypertension as compared to allele C. | TT | 29097388 |
| rs28371685 | T | Allele T is associated with increased metabolism of phenytoin in people with no disease as compared to genotype CC. | CC | 16220110 |
| rs28371759 | AA | Genotype AA are associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype AG. | AA | 28079798 |
| rs2860905 | A | Allele A is associated with decreased dose of warfarin as compared to allele G. | AG | 19752777 |
| rs2873804 | CC | Genotype CC is associated with increased response to bupropion in people with Depressive Disorder, Major as compared to genotypes CT + TT. | CT | 22947179 |
| rs28898617 | G | Allele G is associated with increased concentrations of valproic acid in children with Epilepsy as compared to allele A. | AA | 28763744 |
| rs3025000 | CT + TT | Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC. | CC | 23149126 |
| rs3025000 | CT + TT | Genotypes CT + TT are associated with increased response to bevacizumab or ranibizumab in people with Macular Degeneration as compared to genotype CC. | CC | 23149126 |
| rs339097 | G | Allele G is associated with increased dose of warfarin. | AA | 20200517 |
| rs339097 | G | Allele G is associated with increased dose of warfarin. | AA | 20200517 |
| rs339097 | G | Allele G is associated with increased dose of warfarin. | AA | 20200517 |
| rs3731722 | G | Allele G is associated with dose of allopurinol or febuxostat in people with Gout as compared to allele A. | AA | 27798726 |
| rs3746544 | GG + GT | Genotypes GG + GT are associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype TT. | TT | 28871191 |
| rs3761847 | G | Allele G is associated with decreased response to Tumor necrosis factor alpha (TNF-alpha) inhibitors in people with Arthritis, Rheumatoid as compared to allele A. | GG | 25834819 |
| rs3768652 | AA + AC | Genotypes AA + AC is associated with increased response to antipsychotics in people with Schizophrenia as compared to genotype CC. | CC | 30032160 |
| rs3787430 | TT | Genotype TT is associated with increased response to risperidone in people with Schizophrenia as compared to genotypes CC + CT. | CT | 21652606 |
| rs405509 | TT | Genotype TT is associated with increased response to Selective serotonin reuptake inhibitors in people with Depressive Disorder, Major as compared to genotypes GG + GT. | TG | 32795354 |
| rs4086116 | T | Allele T is associated with decreased dose of acenocoumarol as compared to allele C. | CT | 19578179 |
| rs4086116 | T | Allele T is associated with decreased dose of phenprocoumon maintenance dosage by 2.2 mg/week as compared to allele C. | CT | 21063236 |
| rs4148323 | AA | Genotype AA is associated with increased concentrations of SN-38 in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG. | GG | 18221820 |
| rs4148323 | AA + AG | Genotypes AA + AG are associated with increased exposure to letermovir as compared to genotype GG. | GG | 31022310 |
| rs4149118 | G | Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms. | AG | 21995462 |
| rs429358 | CC | Genotype CC is associated with increased response to hmg coa reductase inhibitors in people with Alzheimer Disease as compared to genotypes CT + TT. | TT | 28212683 |
| rs429358 | T | Allele T is associated with decreased dose of warfarin in people with haplotype epsilon2. | TT | 21228733 |
| rs4364871 | CT + TT | Genotypes CT + TT is associated with decreased concentrations of ara-CTP in children with Leukemia, Myeloid, Acute as compared to genotype CC. | CT | 30088438 |
| rs4420638 | G | Allele G is associated with decreased response to hmg coa reductase inhibitors in people with Cardiovascular Diseases or Hypercholesterolemia as compared to allele A. | AG | 27648687 |
| rs445925 | A | Allele A is associated with increased response to hmg coa reductase inhibitors as compared to allele G. | GG | 25350695 |
| rs4646450 | A | Allele A is associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G. | GG | 29318894 |
| rs4680 | GG | Genotype GG is associated with increased dose of opioids in women with Breast Neoplasms and Pain, Postoperative as compared to genotypes AA + AG. | AG | 27729204 |
| rs4680 | GG | Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotypes AA + AG. | AG | 29230023 |
| rs4680 | AA | Genotype AA is associated with increased response to remifentanil in infants with Pain as compared to genotypes AG + GG. | AG | 27027462 |
| rs4680 | GG | Genotype GG is associated with increased response to methylphenidate in children with Attention Deficit Disorder with Hyperactivity as compared to genotype AA. | AG | 18214865 |
| rs4680 | A | Allele A is associated with decreased dose of morphine in people with Neoplasms as compared to allele G. | AG | 19094200 |
| rs4680 | GG | Genotype GG is associated with increased response to venlafaxine in people with Depressive Disorder, Major as compared to genotypes AA + AG. | AG | 23706899 |
| rs4680 | GG | Genotype GG is associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotypes AA + AG. | AG | 22695756 |
| rs4680 | GG | Genotype GG is associated with increased dose of opioids in people with Neoplasms and Pain as compared to genotypes AA + AG. | AG | 28745577 |
| rs4680 | GG | Genotype GG is associated with increased response to clozapine in people with Schizophrenia as compared to genotypes AA + AG. | AG | 25560469 |
| rs4680 | AG | Genotype AG is associated with decreased dose of opioids in children as compared to genotype GG. | AG | 30704436 |
| rs4680 | GG | Genotype GG is associated with increased response to entacapone in people with Parkinson Disease as compared to genotype AA. | AG | 21280081 |
| rs4680 | GG | Genotype GG is associated with increased dose of opioids in people with Pain, Postoperative as compared to genotype AA. | AG | 25185591 |
| rs4680 | GG | Genotype GG is associated with increased response to modafinil in people with methamphetamine dependence as compared to genotypes AA + AG. | AG | 22217949 |
| rs4795893 | G | Allele G is associated with decreased response to antipsychotics in people with Schizophrenia as compared to allele A. | AG | 26788534 |
| rs4910008 | CC | Genotype CC is associated with increased response to tocilizumab in people with Arthritis, Rheumatoid as compared to genotypes CT + TT. | CT | 27339827 |
| rs49411 | C | Allele C is associated with decreased response to antidepressants in people with Depressive Disorder, Major as compared to allele T. | CT | 27091189 |
| rs4961 | TT | Genotype TT is associated with increased response to bumetanide, furosemide and torasemide in healthy individuals as compared to genotype GG. | TG | 20877298 |
| rs4986910 | AG | Genotype AG is associated with increased response to fluvastatin as compared to genotype AA. | AA | 16103896 |
| rs5326 | CT + TT | Genotypes CT + TT are associated with increased response to methylphenidate in children with Autism Spectrum Disorder as compared to genotype CC. | CC | 23856854 |
| rs5993883 | T | Allele T is associated with decreased response to quetiapine in people with Schizophrenia as compared to allele G. | TG | 26282453 |
| rs671 | AA + AG | Genotypes AA + AG are associated with increased concentrations of nitroglycerin in children with Heart Defects, Congenital and Hypertension, Pulmonary as compared to genotype GG. | GG | 31250045 |
| rs671 | AG | Genotype AG is associated with increased exposure to ethanol in men as compared to genotype GG. | GG | 25365528 |
| rs671 | AG | Genotype AG is associated with increased concentrations of ethanol in healthy individuals as compared to genotype GG. | GG | 31002879 |
| rs671 | AG | Genotype AG is associated with increased concentrations of acetaldehyde in healthy individuals as compared to genotype GG. | GG | 31002879 |
| rs6806020 | C | Allele C is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele T. | CT | 19749758 |
| rs683369 | CC | Genotype CC is associated with decreased concentrations of imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG. | CC | 24589908 |
| rs683369 | CC | Genotype CC is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotypes CG + GG. | CC | 28289867 |
| rs689466 | CC | Genotype CC is associated with increased response to celecoxib in healthy individuals as compared to genotypes CT + TT. | TT | 29066864 |
| rs6961071 | GG | Genotype GG is associated with increased response to fentanyl in people with Pain, Postoperative as compared to genotypes AA + AG. | AG | 29502940 |
| rs6983267 | GG + GT | Genotypes GG + GT are associated with increased response to Platinum compounds in people with Lung Neoplasms as compared to genotype TT. | TG | 26729200 |
| rs7412 | CT | Genotype CT is associated with increased response to atorvastatin as compared to genotype CC. | CC | 16103896 |
| rs7412 | C | Allele C is associated with decreased response to atorvastatin, pravastatin or simvastatin in people with Hyperlipidemias as compared to allele T. | CC | 20031551 |
| rs7412 | CT + TT | Genotypes CT + TT are associated with increased response to rosuvastatin as compared to genotype CC. | CC | 22331829 |
| rs7412 | CC | Genotype CC is associated with decreased dose of warfarin in people with heart valve replacement as compared to genotype CT. | CC | 28079798 |
| rs7412 | CT | Genotype CT is associated with increased response to fluvastatin as compared to genotype CC. | CC | 30363031 |
| rs7412 | CT + TT | Genotypes CT + TT is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to genotype CC. | CC | 12042669 |
| rs760370 | GG | Genotype GG is associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotypes AA + AG. | AG | 20812847 |
| rs760370 | A | Allele A is associated with decreased response to gemcitabine and paclitaxel in women Breast Neoplasms as compared to allele G. | AG | 24361227 |
| rs7606603 | C | Allele C is associated with decreased response to atenolol in people with Hypertension as compared to allele T. | CC | 29650764 |
| rs762551 | AC + CC | Genotypes AC + CC is associated with increased concentrations of deferasirox in people with beta-Thalassemia as compared to genotype AA. | AA | 25348619 |
| rs762551 | CC | Genotype CC is associated with increased response to nevirapine in people with HIV Infections as compared to genotypes AA + AC. | AA | 26348712 |
| rs762551 | AA | Genotype AA is associated with decreased concentrations of olanzapine in people with Schizophrenia as compared to genotypes AC + CC. | AA | 25090458 |
| rs7750468 | G | Allele G is associated with decreased response to peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to allele A. | GG | 19749758 |
| rs7772821 | GG | Genotype GG is associated with increased response to corticosteroids in people with Asthma as compared to genotypes GT + TT. | TT | 25919112 |
| rs7968606 | CC | Genotype CC is associated with increased response to amisulpride in people with Schizophrenia as compared to genotypes CT + TT. | CT | 28332719 |
| rs8099917 | GG + GT | Genotypes GG + GT are associated with increased response to peginterferon alfa-2a, peginterferon alfa-2b and ribavirin in people with Hepatitis C, Chronic as compared to genotype TT. | TT | 21503910 |
| rs8099917 | GG | Genotype GG is associated with increased response to interferons and ribavirin in people with Hepatitis C as compared to genotypes GT + TT. | TT | 26334898 |
| rs8187692 | A | Allele A is associated with increased exposure to rosuvastatin in healthy individuals as compared to allele G. | GG | 30100615 |
| rs833069 | CC + CT | Genotypes CC + CT are associated with increased response to ranibizumab in people with Macular Degeneration as compared to genotype TT. | TT | 23559864 |
| rs9282564 | CT | Genotype CT is associated with increased concentrations of cyclosporine in people with heart transplantation as compared to genotype TT. | TT | 26107754 |
| rs9282564 | C | Allele C is associated with increased concentrations of methotrexate in children with as compared to allele T. | TT | 27566582 |
| rs928655 | AG + GG | Genotypes AG + GG is associated with increased response to etanercept in people with Psoriasis as compared to genotype AA. | AA | 28470127 |
| rs933271 | CC + CT | Genotypes CC + CT are associated with increased response to methadone in people with Opioid-Related Disorders as compared to genotype TT. | TT | 32407152 |
| rs9394992 | CT + TT | Genotypes CT + TT is associated with increased response to tipiracil hydrochloride and trifluridine in people with Colorectal Neoplasms as compared to genotype CC. | CC | 28992563 |
| rs964184 | G | Allele G is associated with increased response to fenofibrate in people with Hypertriglyceridemia as compared to allele C. | CC | 23119086 |
| rs9939609 | AA + AT | Genotypes AA + AT is associated with decreased response to interferon alfa-2a, recombinant, interferon alfa-2b, recombinant and ribavirin in people with Hepatitis C, Chronic and HIV Infections as compared to genotype TT. | AA | 25367448 |
Page:
Variants which have in vitro functional analysis-type associations:
Page:
| Variant | Alleles | Associations | Genotype | PMID |
|---|---|---|---|---|
| rs1043657 | T | Allele T is associated with decreased enzyme activity of AKR7A2 when assayed with daunorubicin or doxorubicin as compared to allele C. | CC | 20837989 |
| rs1800629 | AA + AG | Genotypes AA + AG is associated with increased activity of TNF as compared to genotype GG. | AG | 18438841 |
| rs1801394 | AG + GG | Genotypes AG + GG are associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients. | AG | 15797993 |
| rs1804645 | T | Allele T is associated with decreased activity of NCOA1 when exposed to tamoxifen. | CC | 22174377 |
| rs2168047 | T | Allele T is associated with increased expression of UGT2B4 in normal breast tissue. | TT | 21358749 |
| rs2229109 | T | Allele T is associated with decreased transport of ABCB1 when assayed with amisulpride, aripiprazole, olanzapine or risperidone in LLC-PK1 cells as compared to allele C. | CC | 29443543 |
| rs35350960 | A | Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38. | CC | 12181437 |
| rs3918290 | CT | Genotype CT is associated with decreased clearance of fluorouracil in peripheral blood mononuclear cells as compared to genotype CC. | CC | 26967565 |
| rs3918290 | CT | Genotype CT is associated with decreased activity of DPYD in peripheral blood mononuclear cells as compared to genotype CC. | CC | 28295243 |
| rs3918290 | CT | Genotype CT is associated with decreased activity of DPYD as compared to genotype CC. | CC | 26804652 |
| rs3918290 | CT | Genotype CT is associated with decreased activity of DPYD as compared to genotype CC. | CC | 8698850 |
| rs4148323 | A | Allele A is associated with decreased enzyme activity of UGT1A1 when assayed with SN-38. | GG | 12181437 |
| rs4148323 | AG | Genotype AG is associated with decreased clearance of SN-38 in human liver microsomes as compared to genotype GG. | GG | 24897286 |
| rs4148323 | AG | Genotype AG is associated with decreased formation of UGT1A1 in human liver microsomes as compared to genotype GG. | GG | 24897286 |
| rs4557343 | T | Allele T is associated with increased expression of UGT2B15 in normal breast tissue. | TT | 21358749 |
| rs4898439 | A | Allele A is associated with increased expression of ABCD1 in HapMap cells. | CA | 21383772 |
| rs56113850 | CC + CT | Genotypes CC + CT are associated with increased activity of CYP2A6 when assayed with nicotine as compared to genotype TT. | CC | 29232328 |
| rs6962291 | AA | Genotype AA is associated with decreased steady-state level of TBX2 in plasma. | TT | 21449675 |
| rs6962291 | AA | Genotype AA is associated with decreased expression of TBXAS1 in PBMCs. | TT | 21449675 |
| rs762551 | A | Allele A is associated with increased activity of CYP1A2. | AA | 21593735 |
| rs9999111 | C | Allele C is associated with decreased expression of ABCG2 in human umbilical cord and T cells as compared to allele A. | AA | 28930109 |
| rs9999111 | C | Allele C is associated with decreased expression of ABCG2 in HepG2 and HEK293 cells as compared to allele A. | AA | 28930109 |
| rs1130169 | T | Allele T is associated with decreased expression of CD38. | CT | 20470215 |
| rs11971167 | T | Allele T is associated with activity of CFTR when treated with ivacaftor in FRT cell lines. | GG | 23891399 |
| rs1229984 | CT + TT | Genotypes CT + TT are associated with increased enzyme activity of ADH1B when exposed to ethanol as compared to genotype CC. | CC | 26863581 |
| rs12701634 | CC | Genotype CC is associated with increased transcription of ABCB1 as compared to genotypes CT + TT. | TT | 28601971 |
| rs17091297 | C | Allele C is associated with increased expression of ABCD1 in HapMap cells. | GG | 21383772 |
| rs1800629 | AG | Genotype AG is associated with decreased steady-state level of TNF when exposed to adalimumab as compared to genotype GG. | AG | 17343250 |
| rs1801131 | GT | Genotype GT is associated with increased catalytic activity of TYMS when treated with methotrexate in lymphoblasts from pediatric ALL patients. | TG | 15797993 |
| rs1801131 | GG + GT | Genotypes GG + GT is associated with increased sensitivity to gemcitabine as compared to genotype TT. | TG | 25560468 |
| rs1804645 | T | Allele T is associated with increased half-life of NCOA1. | CC | 22174377 |
| rs2515629 | G | Allele G is associated with increased expression of ABCA1 in HapMap cells. | AA | 21383772 |
| rs304400 | AA | Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG. | GG | 28601971 |
| rs4773866 | T | Allele T is associated with increased expression of ABCC4 in HapMap cells. | CC | 21383772 |
| rs6021191 | T | Allele T is associated with increased expression of NFATC2 as compared to allele A. | AA | 25987655 |
| rs6569487 | AA | Genotype AA is associated with increased transcription of ABCB1 as compared to genotypes AG + GG. | AG | 28601971 |
| rs731780 | G | Allele G is associated with increased expression of SLC29A1 as compared to allele C. | CC | 16609362 |
| rs841698 | T | Allele T is associated with increased expression of ABCD3 in HapMap cells. | CC | 21383772 |
| rs9357155 | A | Allele A is associated with increased expression of TAP2 in HapMap cells. | GG | 21383772 |
Page:
Third-party DB
Page:
| snp | phewas phenotype | p-value | odds-ratio | gene_name | gwas-associations |
|---|---|---|---|---|---|
| rs10033900 | Lipoid metabolism disorder NOS | 0.0009218 | 0.7521 | CFI | Age-related macular degeneration |
| rs10033900 | Abnormal mammogram | 0.0005789 | 0.8096 | CFI | Age-related macular degeneration |
| rs10033900 | Colon cancer | 0.004222 | 0.7967 | CFI | Age-related macular degeneration |
| rs10033900 | Generalized convulsive epilepsy | 0.004709 | 0.6007 | CFI | Age-related macular degeneration |
| rs10033900 | Aseptic necrosis of bone | 0.005044 | 0.6275 | CFI | Age-related macular degeneration |
| rs10033900 | Poisoning by other anti-infectives | 0.00507 | 0.8071 | CFI | Age-related macular degeneration |
| rs10033900 | Polyneuropathy in diabetes | 0.005194 | 1.196 | CFI | Age-related macular degeneration |
| rs10033900 | Colorectal cancer | 0.005395 | 0.813 | CFI | Age-related macular degeneration |
| rs10033900 | Adverse effects of cardiac rhythm regulators | 0.005963 | 0.5641 | CFI | Age-related macular degeneration |
| rs10033900 | Other hemoglobinopathies | 0.0106 | 0.502 | CFI | Age-related macular degeneration |
| rs10033900 | Osteoporosis | 0.006733 | 0.8851 | CFI | Age-related macular degeneration |
| rs10033900 | Convulsions | 1.595e-05 | 0.7423 | CFI | Age-related macular degeneration |
| rs10033900 | Osteoporosis, NOS or other | 0.00807 | 0.8903 | CFI | Age-related macular degeneration |
| rs10033900 | Poisoning by agents affecting the cardiovascular system | 0.008446 | 0.7698 | CFI | Age-related macular degeneration |
| rs10033900 | Epilepsy, recurrent seizures, convulsions | 3.18e-05 | 0.7614 | CFI | Age-related macular degeneration |
| rs10033900 | Bacterial enteritis | 0.009951 | 1.305 | CFI | Age-related macular degeneration |
| rs10033900 | Sulfonamides | 0.0005884 | 0.7419 | CFI | Age-related macular degeneration |
| rs10033900 | Open wounds of head; neck; and trunk | 0.01125 | 0.8775 | CFI | Age-related macular degeneration |
| rs10033900 | Diseases of the tongue | 0.009885 | 0.7238 | CFI | Age-related macular degeneration |
| rs10033900 | Alcoholism | 0.001593 | 0.7903 | CFI | Age-related macular degeneration |
| rs10033900 | Alcohol-related disorders | 0.001194 | 0.8088 | CFI | Age-related macular degeneration |
| rs10033900 | Epilepsy | 0.001148 | 0.6924 | CFI | Age-related macular degeneration |
| rs10045431 | Esophagitis, GERD and related diseases | 0.00337 | 0.9061 | IL12B | Crohn's disease |
| rs10045431 | Other open wound of head and face | 0.009868 | 1.214 | IL12B | Crohn's disease |
| rs10045431 | Anal and rectal conditions | 0.005696 | 1.159 | IL12B | Crohn's disease |
| rs10045431 | Wheezing and painful respiration | 0.004513 | 0.8691 | IL12B | Crohn's disease |
| rs10045431 | Hypertrophy of female genital organs | 0.01087 | 0.5245 | IL12B | Crohn's disease |
| rs10045431 | Myalgia and myositis NOS | 0.005783 | 0.8816 | IL12B | Crohn's disease |
| rs10045431 | Abnormal sputum | 0.003597 | 0.7034 | IL12B | Crohn's disease |
| rs10045431 | Obstructive sleep apnea | 0.00357 | 0.8477 | IL12B | Crohn's disease |
| rs10045431 | Stomach cancer | 0.00147 | 0.4099 | IL12B | Crohn's disease |
| rs10045431 | Thyroid cancer | 0.01021 | 1.476 | IL12B | Crohn's disease |
| rs10045431 | Cellulitis and abscess of leg | 0.008008 | 1.171 | IL12B | Crohn's disease |
| rs10045431 | Blister | 0.00145 | 0.3544 | IL12B | Crohn's disease |
| rs10045431 | Infertility, male | 0.008549 | 0.4266 | IL12B | Crohn's disease |
| rs10045431 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.002691 | 1.284 | IL12B | Crohn's disease |
| rs10045431 | Diseases of esophagus | 0.00257 | 0.9059 | IL12B | Crohn's disease |
| rs10045431 | Sleep apnea | 0.008115 | 0.8862 | IL12B | Crohn's disease |
| rs10088262 | Osteomyelitis | 0.001277 | 0.6983 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Nonrheumatic pulmonary valve disorders | 0.005686 | 0.5424 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Unspecified osteomyelitis | 0.001005 | 0.6587 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Cancer of other female genital organs | 0.009138 | 1.887 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Breast cancer | 0.0022 | 1.215 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Derangement of joint, non-traumatic | 0.004486 | 0.7662 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Pain in limb | 0.01006 | 0.9155 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Diffuse diseases of connective tissue | 0.001544 | 0.7225 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Open wounds of head; neck; and trunk | 0.005784 | 0.8496 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Breast cancer, including in situ | 0.001212 | 1.225 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Open wounds of extremities | 0.002209 | 0.8684 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Systemic lupus erythematosus | 0.004757 | 0.5983 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Benign neoplasm of uterus | 0.01098 | 1.211 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Other open wound of head and face | 0.002539 | 0.7805 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Eustachian tube disorders | 0.009453 | 1.252 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Eustachian tube disorders | 0.002595 | 1.15 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Arthralgia/ankylosis of temporomandibular joint | 0.007356 | 1.584 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Other pulmonary inflamation or edema | 0.007447 | 0.7238 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Hematemesis | 0.007889 | 1.584 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Infections involving bone | 0.003132 | 0.7451 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Breast cancer | 0.0006859 | 1.235 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Chronic osteomyelitis | 0.008128 | 0.5743 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Discoid lupus erythematosus | 0.001307 | 0.5744 | FAM91A1 | Pancreatic cancer |
| rs10088262 | Renal osteodystrophy | 0.0052 | 0.5918 | FAM91A1 | Pancreatic cancer |
| rs10108954 | Endometrial hyperplasia | 0.008014 | 2.162 | MFHAS1 | Prion diseases |
| rs10108954 | Diseases of sebaceous glands | 0.00697 | 1.328 | MFHAS1 | Prion diseases |
| rs10108954 | Prostatitis | 0.001207 | 0.2639 | MFHAS1 | Prion diseases |
| rs10108954 | Osteoarthrosis; localized, secondary | 0.001684 | 2.997 | MFHAS1 | Prion diseases |
| rs10108954 | Inflammatory diseases of prostate | 0.01068 | 0.5122 | MFHAS1 | Prion diseases |
| rs10108954 | Sebaceous cyst | 0.003224 | 1.44 | MFHAS1 | Prion diseases |
| rs10108954 | Malignant neoplasm of renal pelvis | 0.001616 | 4.243 | MFHAS1 | Prion diseases |
| rs10108954 | Decubitus ulcer | 0.004701 | 1.683 | MFHAS1 | Prion diseases |
| rs10108954 | Type 1 diabetic ketoacidosis | 0.002179 | 2.305 | MFHAS1 | Prion diseases |
| rs1011970 | Calculus of kidney | 0.004814 | 0.7884 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Cardiac arrhythmia NOS | 0.003151 | 0.8138 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Actinic keratosis | 0.01025 | 0.8783 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Hyperosmolality and/or hypernatremia | 0.007251 | 1.55 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Other specified cardiac dysrhythmias | 0.006973 | 0.8457 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Rosacea | 0.002521 | 0.7586 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Cardiac conduction disorders | 0.003454 | 0.8571 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Cardiac dysrhythmias | 0.008813 | 0.9003 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Dyschromia and Vitiligo | 0.0003242 | 0.7015 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Atrial fibrillation | 0.008967 | 0.8564 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Dry eyes | 0.006007 | 0.8359 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Supraventricular premature beats | 0.006424 | 0.6467 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Epistaxis or throat hemorrhage | 0.003898 | 0.7459 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Palpitations | 0.009777 | 0.8482 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Abnormal electrocardiogram | 0.0108 | 0.8414 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Thoracic neuritis/radiculitis | 4.595e-05 | 0.7953 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.005447 | 0.8674 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Chronic lymphocytic thyroiditis | 0.005556 | 1.549 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Osteoarthritis; localized | 0.001681 | 0.8344 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Other disorders of back | 0.01084 | 0.8246 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Pain, swelling or discharge of eye | 0.009409 | 0.6391 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Secondary malignant neoplasm of liver | 0.01129 | 1.424 | CDKN2B-AS1 | Breast cancer |
| rs1011970 | Coagulation defects | 0.002826 | 0.8636 | CDKN2B-AS1 | Breast cancer |
| rs10166942 | Hypotension NOS | 0.009278 | 0.8123 | TRPM8 | Migraine |
| rs10166942 | Myeloid leukemia | 0.006926 | 1.883 | TRPM8 | Migraine |
| rs10166942 | Aplastic anemia | 0.01044 | 1.381 | TRPM8 | Migraine |
| rs10166942 | Disorders of penis | 0.000505 | 1.572 | TRPM8 | Migraine |
| rs10166942 | Chronic prostatitis | 0.009962 | 1.567 | TRPM8 | Migraine |
| rs10166942 | Disturbances of sulphur-bearing amino-acid metabolism | 0.003296 | 0.2848 | TRPM8 | Migraine |
| rs10166942 | Prolapse of vaginal walls | 0.006379 | 0.7865 | TRPM8 | Migraine |
| rs10166942 | Redundant prepuce and phimosis/BXO | 0.006354 | 1.842 | TRPM8 | Migraine |
| rs10166942 | Ileostomy status | 0.0111 | 0.5064 | TRPM8 | Migraine |
| rs10166942 | Disturbances of amino-acid transport | 0.002742 | 0.2784 | TRPM8 | Migraine |
| rs102275 | Lesions of stomach and duodenum | 0.008777 | 1.88 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Malignant neoplasm of kidney and other urinary organs | 0.008437 | 0.5593 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Other specified diseases of the salivary glands | 0.008384 | 0.5355 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Inflammatory disease of breast | 0.008991 | 1.527 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Bipolar | 0.0009503 | 1.502 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Disturbance of salivary secretion | 0.007191 | 0.5543 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Light-headedness and vertigo | 0.001165 | 1.123 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Hypocalcemia | 0.003373 | 1.474 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Abnormal heart sounds | 0.006918 | 0.848 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Inflammatory bowel disease | 0.0002721 | 1.461 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Jaundice | 0.0003079 | 1.64 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Cancer of kidney and urinary organs | 0.01152 | 0.8292 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Crohn's disease | 0.0004158 | 1.622 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Aneurysm of artery of lower extremity | 0.00599 | 0.6 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Vertiginous syndromes and other disorders of vestibular system | 0.0005992 | 1.125 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs102275 | Ulcerative colitis | 0.01135 | 1.419 | C11orf10 | Phospholipid levels in plasma, Docosapentaenoic acid, Crohn's disease, HDL Cholesterol, Alpha-Linolenic acid |
| rs10237118 | Cholangitis | 0.002965 | 2.33 | DENND2A | Optic disc parameters |
| rs10237118 | Injuries to the nervous system | 0.0004609 | 2.233 | DENND2A | Optic disc parameters |
| rs10237118 | Other disorders of biliary tract | 0.001525 | 2.022 | DENND2A | Optic disc parameters |
| rs10237118 | Impetigo | 0.002147 | 2.097 | DENND2A | Optic disc parameters |
| rs10237118 | Conductive hearing loss | 0.004256 | 1.985 | DENND2A | Optic disc parameters |
| rs10237118 | Wheezing | 0.006126 | 1.576 | DENND2A | Optic disc parameters |
| rs10237118 | Mechanical complication due to other implant and internal device | 0.006528 | 1.601 | DENND2A | Optic disc parameters |
| rs10237118 | Alkalosis | 0.006621 | 2.286 | DENND2A | Optic disc parameters |
| rs10237118 | Other disorders of bladder | 0.008791 | 1.295 | DENND2A | Optic disc parameters |
| rs10237118 | Major depressive disorder | 0.001036 | 0.675 | DENND2A | Optic disc parameters |
| rs10237118 | Otitis externa | 0.00299 | 0.6638 | DENND2A | Optic disc parameters |
| rs10237118 | Benign neoplasm of unspecified sites | 0.002912 | 2.811 | DENND2A | Optic disc parameters |
| rs10237118 | Impacted cerumen | 0.005186 | 0.808 | DENND2A | Optic disc parameters |
| rs10237118 | Phosphorus metabolism disorder | 0.005581 | 1.76 | DENND2A | Optic disc parameters |
| rs1024161 | Large cell lymphoma | 0.00794 | 1.91 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Other disorders of bone and cartilage | 0.002293 | 1.245 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Thyrotoxicosis | 9.424e-05 | 1.355 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Other alveolar and parietoalveolar pneumonopathy | 0.01128 | 0.6032 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Osteoarthrosis, generalized | 0.009093 | 1.207 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Extrinsic allergic alveolitis | 0.001979 | 2.237 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Rotator cuff (capsule) sprain | 0.003137 | 1.218 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Ischemic Heart Disease | 0.003839 | 0.9143 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Unstable angina (intermediate coronary syndrome) | 0.007574 | 0.8583 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Abdominal aortic aneurysm | 0.004001 | 0.7909 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Kyphosis (acquired) | 0.01093 | 0.679 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Other aneurysm | 0.004168 | 0.8337 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Hypothyroidism | 0.01144 | 1.097 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Coronary atherosclerosis | 0.006863 | 0.9153 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Atherosclerosis | 0.00681 | 0.8881 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Graves' disease | 0.002473 | 1.538 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Idiopathic fibrosing alveolitis | 0.01079 | 0.5287 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Diseases of hard tissues of teeth | 0.004981 | 0.8294 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Renal dialysis | 0.0104 | 0.7063 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Aortic aneurysm | 0.006306 | 0.8251 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Open wound of nose and sinus | 0.005732 | 0.4277 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Atherosclerosis of the extremities | 0.006519 | 0.8731 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Chronic sinusitis | 0.005705 | 1.123 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Dental caries | 0.006336 | 0.8297 | CTLA4 | Alopecia areata, Graves' disease |
| rs1024161 | Symptomatic artificial menopause | 0.006214 | 1.501 | CTLA4 | Alopecia areata, Graves' disease |
| rs10276619 | Chronic osteomyelitis | 0.008347 | 0.6159 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Atrophy of edentulous alveolar ridge | 0.01012 | 0.6588 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Disorders of parathyroid gland | 0.00801 | 1.281 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Methicillin sensitive Staphylococcus aureus | 0.007986 | 0.7385 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Random mental disorder. Ignored for now | 0.002996 | 0.5998 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Strabismus (not specified as paralytic) | 0.01046 | 0.8121 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Peripheral retinal degenerations | 0.008706 | 1.287 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Hematemesis | 0.004469 | 0.5776 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Type 1 diabetes | 0.006004 | 0.8437 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Chronic sinusitis | 0.006844 | 1.122 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Diabetic retinopathy | 0.009858 | 0.8405 | IKZF1 | Hippocampal atrophy |
| rs10276619 | ASCVD | 0.002769 | 1.405 | IKZF1 | Hippocampal atrophy |
| rs10276619 | Allergic rhinitis | 0.001943 | 1.135 | IKZF1 | Hippocampal atrophy |
| rs1033180 | Other abnormal blood chemistry | 0.002143 | 1.25 | IRF4 | Celiac disease |
| rs1033180 | Malignant neoplasm of kidney and other urinary organs | 0.008762 | 2.05 | IRF4 | Celiac disease |
| rs1033180 | Nonrheumatic mitral valve disorders | 0.008398 | 1.258 | IRF4 | Celiac disease |
| rs1033180 | Psoriasis & related disorders | 0.008392 | 0.636 | IRF4 | Celiac disease |
| rs1033180 | Bladder cancer | 0.003541 | 1.519 | IRF4 | Celiac disease |
| rs1033180 | Cancer of kidney and urinary organs | 0.003841 | 1.399 | IRF4 | Celiac disease |
| rs1033180 | Other hypertrophic and atrophic conditions of skin | 0.01069 | 0.8204 | IRF4 | Celiac disease |
| rs1033180 | Other sprains and strains | 0.002481 | 0.4039 | IRF4 | Celiac disease |
| rs1033180 | Bladder cancer and neoplasms | 0.003541 | 1.503 | IRF4 | Celiac disease |
| rs1033180 | Derangement of joint, non-traumatic | 0.01145 | 0.6317 | IRF4 | Celiac disease |
| rs1043879 | Cystic kidney disease | 0.006752 | 0.5474 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Congenital anomalies of urinary system | 0.01134 | 0.6387 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Persistent mental disorders due to other conditions | 0.00612 | 1.178 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Abnormal sputum | 0.008768 | 1.328 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Premenstrual tension syndromes | 0.008223 | 1.882 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Other specified nonpsychotic and/or transient mental disorders | 0.002277 | 1.274 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Diaphragmatic hernia | 0.007613 | 1.148 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Other disorders of the kidney and ureters | 0.01105 | 0.8881 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Adrenal hyperfunction | 0.01031 | 1.776 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Hallucinations | 0.007229 | 1.82 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Other conditions of brain | 0.003519 | 1.364 | C1orf63 | Erythrocyte sedimentation rate |
| rs1043879 | Other disorders of back | 0.003 | 1.193 | C1orf63 | Erythrocyte sedimentation rate |
| rs10438933 | Glossitis | 0.002598 | 2.327 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Retinal detachments and defects | 0.0005208 | 0.6616 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Sinoatrial node dysfunction | 0.01102 | 1.377 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Wheezing and painful respiration | 0.00808 | 0.8375 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Balanoposthitis | 0.007836 | 1.899 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Macular degeneration | 0.006306 | 0.8355 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Acquired deformities of finger | 0.002647 | 1.685 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Other specified peripheral vascular diseases | 0.003469 | 2.305 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Contact dermatitis and other eczema due to plants [except food] | 0.005304 | 1.988 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10438933 | Hypothyroidism | 0.009487 | 1.14 | B4GALT6 | Amyotrophic lateral sclerosis |
| rs10444502 | Melanoma | 0.0095 | 1.263 | KSR2 | Total Cholesterol |
| rs10444502 | Disease of tricuspid valve | 0.009377 | 0.7808 | KSR2 | Total Cholesterol |
| rs10444502 | Open-angle glaucoma | 0.0006343 | 1.222 | KSR2 | Total Cholesterol |
| rs10444502 | Infertility, male | 0.005632 | 1.909 | KSR2 | Total Cholesterol |
| rs10444502 | Secondary malignant neoplasm | 0.003785 | 1.177 | KSR2 | Total Cholesterol |
| rs10444502 | Chronic cystitis | 0.008675 | 0.6346 | KSR2 | Total Cholesterol |
| rs10444502 | Prurigo | 0.002119 | 1.334 | KSR2 | Total Cholesterol |
| rs10444502 | Ankylosing spondylitis | 0.00683 | 0.3096 | KSR2 | Total Cholesterol |
| rs10444502 | Hematuria | 0.009936 | 0.8957 | KSR2 | Total Cholesterol |
| rs10444502 | Abnormal heart sounds | 0.009046 | 1.167 | KSR2 | Total Cholesterol |
| rs10444502 | Angina pectoris | 0.008152 | 1.133 | KSR2 | Total Cholesterol |
| rs10444502 | Abnormal findings on radiological examination intrathoracic organs | 0.00503 | 1.224 | KSR2 | Total Cholesterol |
| rs10444502 | Male infertility and abnormal spermatozoa | 0.002069 | 1.794 | KSR2 | Total Cholesterol |
| rs10444502 | Benign neoplasm of colon | 0.004908 | 0.9067 | KSR2 | Total Cholesterol |
| rs10444502 | Emphysema | 0.006796 | 0.767 | KSR2 | Total Cholesterol |
| rs10444502 | Fracture of ankle and foot | 0.002354 | 0.8446 | KSR2 | Total Cholesterol |
| rs10444502 | Dysuria | 0.003059 | 0.8397 | KSR2 | Total Cholesterol |
| rs10466868 | Venous embolism & thrombosis | 0.004849 | 0.7675 | GPR133 | Erythropoietin |
| rs10466868 | Cellulitis and abscess of trunk | 0.01147 | 1.426 | GPR133 | Erythropoietin |
| rs10466868 | Valvular heart disease/ heart chambers | 0.009581 | 1.997 | GPR133 | Erythropoietin |
| rs10466868 | Rotator cuff (capsule) sprain | 0.003323 | 1.345 | GPR133 | Erythropoietin |
| rs10466868 | Open wounds of head; neck; and trunk | 0.01022 | 1.233 | GPR133 | Erythropoietin |
| rs10466868 | Unspecified local infection of skin and subcutaneous tissue | 0.003785 | 1.439 | GPR133 | Erythropoietin |
| rs10466868 | Postoperative infection | 0.00485 | 1.334 | GPR133 | Erythropoietin |
| rs10466868 | Inflammatory spondylopathies | 0.008595 | 1.732 | GPR133 | Erythropoietin |
| rs10466868 | Cyst or abscess of Bartholin's gland | 0.001001 | 2.602 | GPR133 | Erythropoietin |
| rs10466868 | Other arthropathies | 0.001589 | 1.228 | GPR133 | Erythropoietin |
| rs10466868 | Ill-defined descriptions and complications of heart disease | 0.002304 | 1.213 | GPR133 | Erythropoietin |
| rs10466868 | Nephritis and nephropathy in diseases classified elsewhere | 0.007359 | 1.431 | GPR133 | Erythropoietin |
| rs10466868 | Heart transplant/surgery | 0.004582 | 1.679 | GPR133 | Erythropoietin |
| rs10466868 | Hemorrhage or hematoma complicating a procedure | 0.009831 | 1.324 | GPR133 | Erythropoietin |
| rs10466868 | Convulsions | 0.002768 | 1.354 | GPR133 | Erythropoietin |
| rs10466868 | Peripheral autonomic neuropathy | 0.007332 | 1.559 | GPR133 | Erythropoietin |
| rs10466868 | Postnasal drip | 0.009435 | 2.014 | GPR133 | Erythropoietin |
| rs10466868 | Epilepsy, recurrent seizures, convulsions | 0.01047 | 1.286 | GPR133 | Erythropoietin |
| rs10466868 | Posttraumatic wound infection | 0.003564 | 2.182 | GPR133 | Erythropoietin |
| rs10466868 | Abnormal heart sounds | 0.0003431 | 1.363 | GPR133 | Erythropoietin |
| rs10466868 | Arthropathy NOS | 0.008652 | 1.284 | GPR133 | Erythropoietin |
| rs10466868 | Localized adiposity | 0.0007145 | 2.625 | GPR133 | Erythropoietin |
| rs10466868 | Noninfectious disorders of lymphatic channels | 0.009535 | 0.5656 | GPR133 | Erythropoietin |
| rs10466868 | Gastroparesis | 0.01054 | 1.917 | GPR133 | Erythropoietin |
| rs10494067 | Strabismus (not specified as paralytic) | 0.006491 | 0.5681 | NTNG1 | Anorexia nervosa |
| rs10494067 | Reflux esophagitis | 0.008196 | 1.437 | NTNG1 | Anorexia nervosa |
| rs10494067 | Chronic lymphocytic thyroiditis | 0.007268 | 0.2084 | NTNG1 | Anorexia nervosa |
| rs10494067 | Disorders of binocular eye movements | 0.002919 | 0.5956 | NTNG1 | Anorexia nervosa |
| rs10494067 | Chronic glomerulonephritis | 0.004249 | 3.096 | NTNG1 | Anorexia nervosa |
| rs10494067 | Other abnormality of urination | 0.008646 | 0.6317 | NTNG1 | Anorexia nervosa |
| rs10494067 | Secondary malignancy of lung | 0.006391 | 1.742 | NTNG1 | Anorexia nervosa |
| rs10494067 | Lymphadenitis | 0.006993 | 0.6613 | NTNG1 | Anorexia nervosa |
| rs10494067 | Gangrene | 0.001445 | 2.358 | NTNG1 | Anorexia nervosa |
| rs10494067 | Rosacea | 0.00892 | 1.382 | NTNG1 | Anorexia nervosa |
| rs10500991 | Prostatitis | 0.0005245 | 1.527 | LUZP2 | Serum transferrin |
| rs10500991 | Disturbance of salivary secretion | 0.00447 | 0.304 | LUZP2 | Serum transferrin |
| rs10500991 | Nerve root lesions | 0.004786 | 1.782 | LUZP2 | Serum transferrin |
| rs10500991 | Abnormal reflex | 0.00377 | 2.408 | LUZP2 | Serum transferrin |
| rs10500991 | Infection of the eye | 0.0016 | 1.247 | LUZP2 | Serum transferrin |
| rs10500991 | Inflammation of eyelids | 0.003979 | 1.199 | LUZP2 | Serum transferrin |
| rs10500991 | Prurigo | 0.00488 | 0.6671 | LUZP2 | Serum transferrin |
| rs10500991 | Chronic kidney disease, Stage I or II | 0.003067 | 1.537 | LUZP2 | Serum transferrin |
| rs10500991 | Unspecified polyarthropathy or polyarthritis | 0.008388 | 1.604 | LUZP2 | Serum transferrin |
| rs10500991 | Conjunctivitis, infectious | 0.002231 | 1.266 | LUZP2 | Serum transferrin |
| rs10500991 | Noninflammatory female genital disorders | 0.007699 | 0.7757 | LUZP2 | Serum transferrin |
| rs10500991 | Sarcoidosis | 0.01151 | 0.4343 | LUZP2 | Serum transferrin |
| rs10500991 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.009609 | 1.244 | LUZP2 | Serum transferrin |
| rs10500991 | Rheumatoid arthritis | 0.002207 | 1.329 | LUZP2 | Serum transferrin |
| rs10500991 | Other disorders of the nervous system | 0.0007137 | 1.852 | LUZP2 | Serum transferrin |
| rs10502868 | Chronic obstructive asthma | 0.004141 | 1.562 | SLC14A2 | Albumin levels |
| rs10502868 | Speech and language disorder | 0.004294 | 1.76 | SLC14A2 | Albumin levels |
| rs10502868 | Appendicitis | 0.007009 | 1.708 | SLC14A2 | Albumin levels |
| rs10502868 | Atrial flutter | 0.0114 | 1.411 | SLC14A2 | Albumin levels |
| rs10502868 | Ill-defined descriptions and complications of heart disease | 0.003668 | 1.244 | SLC14A2 | Albumin levels |
| rs10502868 | Posterior pituitary disorders | 0.009386 | 2.103 | SLC14A2 | Albumin levels |
| rs10502868 | Ptosis of eyelid | 0.007296 | 1.405 | SLC14A2 | Albumin levels |
| rs10502868 | Allergic conjunctivitis | 0.003269 | 1.598 | SLC14A2 | Albumin levels |
| rs10502868 | Cyst of kidney, acquired | 0.007493 | 1.554 | SLC14A2 | Albumin levels |
| rs10502868 | Staphylococcus infections | 0.004476 | 1.489 | SLC14A2 | Albumin levels |
| rs10502868 | Conjunctivitis, noninfectious | 0.00247 | 1.562 | SLC14A2 | Albumin levels |
| rs10502868 | Vascular disorders of penis | 0.008806 | 3.177 | SLC14A2 | Albumin levels |
| rs10502868 | Patellar fracture | 0.008784 | 1.718 | SLC14A2 | Albumin levels |
| rs10502868 | Nephritis and nephropathy in diseases classified elsewhere | 0.008735 | 1.514 | SLC14A2 | Albumin levels |
| rs10502868 | Heart transplant/surgery | 0.002724 | 1.895 | SLC14A2 | Albumin levels |
| rs10502868 | Heart valve replaced | 0.00298 | 1.599 | SLC14A2 | Albumin levels |
| rs10502868 | Other local infections of skin and subcutaneous tissue | 0.005492 | 1.329 | SLC14A2 | Albumin levels |
| rs10502868 | Hx of malignant neoplasm of oral cavity and pharynx | 0.0101 | 1.998 | SLC14A2 | Albumin levels |
| rs10502868 | Other disorders of circulatory system | 0.00116 | 1.342 | SLC14A2 | Albumin levels |
| rs10502868 | Dermatophytosis | 0.01133 | 1.205 | SLC14A2 | Albumin levels |
| rs10502868 | Hypotony of eye | 0.005312 | 2.849 | SLC14A2 | Albumin levels |
| rs10502868 | Methicillin sensitive Staphylococcus aureus | 0.005391 | 1.623 | SLC14A2 | Albumin levels |
| rs10502868 | Renal colic | 0.004687 | 2.162 | SLC14A2 | Albumin levels |
| rs10502868 | Calculus of lower urinary tract | 0.008337 | 2.036 | SLC14A2 | Albumin levels |
| rs10502868 | Circulatory disease NEC | 0.001683 | 1.368 | SLC14A2 | Albumin levels |
| rs10502868 | Localized superficial swelling, mass, or lump | 0.003148 | 1.538 | SLC14A2 | Albumin levels |
| rs10502868 | Hyposmolality and/or hyponatremia | 0.006789 | 1.327 | SLC14A2 | Albumin levels |
| rs10502868 | Exophthalmos | 0.003372 | 2.519 | SLC14A2 | Albumin levels |
| rs10502868 | Allergy to serum or vaccine | 0.0005339 | 2.673 | SLC14A2 | Albumin levels |
| rs10502868 | Antisocial/borderline personality disorder | 0.01146 | 1.977 | SLC14A2 | Albumin levels |
| rs10502868 | Disorders of the autonomic nervous system | 0.006639 | 1.567 | SLC14A2 | Albumin levels |
| rs10502868 | Asthma | 0.0005259 | 1.313 | SLC14A2 | Albumin levels |
| rs10503019 | Chronic pharyngitis and nasopharyngitis | 0.006153 | 0.8212 | ATP8B1 | Vitiligo |
| rs10503019 | Deviated nasal septum | 0.007266 | 0.8116 | ATP8B1 | Vitiligo |
| rs10503019 | Acquired deformities of limbs | 0.006224 | 0.7687 | ATP8B1 | Vitiligo |
| rs10503019 | Nonsenile Cataract | 0.005673 | 0.6497 | ATP8B1 | Vitiligo |
| rs10503019 | Dementia with cerebral degenerations | 0.0002449 | 0.3823 | ATP8B1 | Vitiligo |
| rs10503019 | Other disorders of back | 0.006173 | 0.8324 | ATP8B1 | Vitiligo |
| rs10503019 | Renal failure NOS | 0.002306 | 0.6446 | ATP8B1 | Vitiligo |
| rs10503019 | Osteoporosis, NOS or other | 0.007432 | 0.8632 | ATP8B1 | Vitiligo |
| rs10503019 | Other local infections of skin and subcutaneous tissue | 0.008052 | 0.8233 | ATP8B1 | Vitiligo |
| rs10503019 | Vitamin B12 deficiency anemia | 0.002648 | 1.68 | ATP8B1 | Vitiligo |
| rs10503019 | Hypoglycemia | 0.008738 | 1.505 | ATP8B1 | Vitiligo |
| rs10503019 | Unspecified local infection of skin and subcutaneous tissue | 0.008383 | 0.743 | ATP8B1 | Vitiligo |
| rs10503019 | Schizophrenia | 0.002106 | 1.845 | ATP8B1 | Vitiligo |
| rs10503019 | Swelling, mass, or lump in head and neck | 0.008592 | 0.7658 | ATP8B1 | Vitiligo |
| rs10503253 | Adverse effects of adrenal cortical steroids | 0.006098 | 0.5108 | CSMD1 | Schizophrenia |
| rs10503253 | Disturbances of amino-acid transport | 0.005238 | 1.891 | CSMD1 | Schizophrenia |
| rs10503253 | Senile dementia | 0.003579 | 1.301 | CSMD1 | Schizophrenia |
| rs10503253 | Breast disorder NOS | 0.01135 | 0.1581 | CSMD1 | Schizophrenia |
| rs10503253 | Viral Enteritis | 0.00352 | 1.594 | CSMD1 | Schizophrenia |
| rs10503253 | Disturbances of sulphur-bearing amino-acid metabolism | 0.003504 | 1.954 | CSMD1 | Schizophrenia |
| rs10503253 | Atherosclerosis | 0.01085 | 0.8723 | CSMD1 | Schizophrenia |
| rs10503253 | Pelvic inflammatory disease | 0.002087 | 0.1625 | CSMD1 | Schizophrenia |
| rs10503253 | Fracture of vertebral column without mention of spinal cord injury | 0.004569 | 1.283 | CSMD1 | Schizophrenia |
| rs10503253 | Swelling of limb | 0.001174 | 0.7817 | CSMD1 | Schizophrenia |
| rs10503253 | Hemiplegia | 0.00473 | 0.6502 | CSMD1 | Schizophrenia |
| rs10503253 | Paroxysmal ventricular tachycardia | 0.001803 | 0.6746 | CSMD1 | Schizophrenia |
| rs10503253 | Adverse drug events and drug allergies | 0.005236 | 0.8113 | CSMD1 | Schizophrenia |
| rs10503253 | Unequal leg length (acquired) | 0.01042 | 0.597 | CSMD1 | Schizophrenia |
| rs10503253 | Other signs and symptoms in breast | 0.004438 | 1.442 | CSMD1 | Schizophrenia |
| rs10503253 | Chronic kidney disease, Stage I or II | 0.00922 | 0.6436 | CSMD1 | Schizophrenia |
| rs10503253 | Heartburn | 0.007933 | 1.421 | CSMD1 | Schizophrenia |
| rs10503253 | Genitourinary congenital anomalies | 0.00301 | 0.6032 | CSMD1 | Schizophrenia |
| rs10503253 | Mixed hyperlipidemia | 0.009826 | 0.8232 | CSMD1 | Schizophrenia |
| rs10503253 | Disorders of synovium, tendon, and bursa | 0.01148 | 0.8784 | CSMD1 | Schizophrenia |
| rs10503253 | Macular puckering of retina | 0.0002164 | 1.376 | CSMD1 | Schizophrenia |
| rs10508503 | Hidradenitis | 0.01054 | 2.439 | PTER | Obesity |
| rs10508503 | Cancer of the upper aerodigestive tract | 0.01105 | 0.5096 | PTER | Obesity |
| rs10508503 | Other disorders of prostate | 0.008246 | 0.6119 | PTER | Obesity |
| rs10508503 | Traumatic arthropathy | 0.001501 | 2.087 | PTER | Obesity |
| rs10508503 | Other hypertensive complications | 0.005434 | 0.6308 | PTER | Obesity |
| rs10508503 | Other specified peripheral vascular diseases | 0.01075 | 2.249 | PTER | Obesity |
| rs10508503 | Adverse effects of antirheumatics | 0.01143 | 1.932 | PTER | Obesity |
| rs10508503 | Pseudomonal pneumonia | 0.01043 | 2.465 | PTER | Obesity |
| rs10510102 | Mechanical complication due to other implant and internal device | 0.01147 | 0.667 | ATE1 | Breast cancer |
| rs10510102 | Infections involving bone | 0.005669 | 0.714 | ATE1 | Breast cancer |
| rs10510102 | Gastrointestinal malfunction arising from mental factors | 0.003113 | 2.334 | ATE1 | Breast cancer |
| rs10510102 | Peripheral or central vertigo | 0.00298 | 1.287 | ATE1 | Breast cancer |
| rs10510102 | Allergic reaction to food | 0.008207 | 1.936 | ATE1 | Breast cancer |
| rs10510102 | Psychogenic and somatoform disorders | 0.009836 | 1.321 | ATE1 | Breast cancer |
| rs10510102 | Orchitis and epididymitis | 0.01125 | 0.6097 | ATE1 | Breast cancer |
| rs10510102 | Cyst of kidney, acquired | 0.01011 | 0.7054 | ATE1 | Breast cancer |
| rs10510102 | Other disorders of the kidney and ureters | 0.00473 | 0.8573 | ATE1 | Breast cancer |
| rs10510102 | Open wound of eye or eyelid | 0.0001119 | 2.804 | ATE1 | Breast cancer |
| rs10510102 | Failure to thrive | 0.01113 | 0.6268 | ATE1 | Breast cancer |
| rs10510102 | Empyema and pneumothorax | 0.008261 | 1.351 | ATE1 | Breast cancer |
| rs10510102 | Psychogenic disorder | 0.0002677 | 1.757 | ATE1 | Breast cancer |
| rs10510102 | Alkalosis | 0.008037 | 1.9 | ATE1 | Breast cancer |
| rs10510102 | Congenital anomalies of the eye | 0.003897 | 1.314 | ATE1 | Breast cancer |
| rs10510102 | Purpura and other hemorrhagic conditions | 0.009942 | 0.8259 | ATE1 | Breast cancer |
| rs10516430 | Ovarian cancer | 0.0002133 | 1.828 | RAP1GDS1 | Triglycerides |
| rs10516430 | Cancer of other female genital organs | 0.000343 | 1.663 | RAP1GDS1 | Triglycerides |
| rs10516430 | Corneal opacity | 0.002775 | 1.42 | RAP1GDS1 | Triglycerides |
| rs10516430 | Poisoning by hormones and synthetic substitutes | 0.009046 | 0.6933 | RAP1GDS1 | Triglycerides |
| rs10516430 | Diverticulosis and diverticulitis | 0.01097 | 1.112 | RAP1GDS1 | Triglycerides |
| rs10516430 | Congenital cataract and lens anomalies | 0.01042 | 1.851 | RAP1GDS1 | Triglycerides |
| rs10516430 | Malignant neoplasm of ovary | 0.001978 | 1.799 | RAP1GDS1 | Triglycerides |
| rs10516430 | Adverse effects of cardiac rhythm regulators | 0.01122 | 1.692 | RAP1GDS1 | Triglycerides |
| rs10516430 | Cyst or abscess of Bartholin's gland | 0.006463 | 1.945 | RAP1GDS1 | Triglycerides |
| rs10516430 | Symptoms associated with female genital organs | 0.003936 | 1.218 | RAP1GDS1 | Triglycerides |
| rs10516430 | Bronchopneumonia and lung abscess | 0.006058 | 1.77 | RAP1GDS1 | Triglycerides |
| rs10516430 | Swelling, mass, or lump in head and neck | 0.009221 | 0.7924 | RAP1GDS1 | Triglycerides |
| rs10516430 | Cervical cancer | 0.0005225 | 2.185 | RAP1GDS1 | Triglycerides |
| rs10516430 | Clotting factor deficiency | 0.007321 | 2.047 | RAP1GDS1 | Triglycerides |
| rs10516430 | Hypercoagulable state | 0.01096 | 1.478 | RAP1GDS1 | Triglycerides |
| rs10518025 | Aortic aneurysm | 0.002786 | 0.7389 | CENPC1 | Multiple sclerosis |
| rs10518025 | Cellulitis and abscess of trunk | 0.00151 | 1.462 | CENPC1 | Multiple sclerosis |
| rs10518025 | Leukoplakia of oral mucosa | 0.001894 | 2.129 | CENPC1 | Multiple sclerosis |
| rs10518025 | Other aneurysm | 0.0007918 | 0.7359 | CENPC1 | Multiple sclerosis |
| rs10518025 | Fibroadenosis of breast | 0.0003446 | 3.189 | CENPC1 | Multiple sclerosis |
| rs10518025 | Mastodynia | 0.009463 | 1.352 | CENPC1 | Multiple sclerosis |
| rs10518025 | Cardiomyopathy | 0.01055 | 0.7894 | CENPC1 | Multiple sclerosis |
| rs10518025 | Melanoma | 0.008837 | 1.344 | CENPC1 | Multiple sclerosis |
| rs10518025 | Cancer of other female genital organs | 0.008915 | 2.08 | CENPC1 | Multiple sclerosis |
| rs10518025 | Primary/intrinsic cardiomyopathies | 0.01122 | 0.7852 | CENPC1 | Multiple sclerosis |
| rs10518025 | Other acute and subacute forms of ischemic heart disease | 0.0005549 | 2.337 | CENPC1 | Multiple sclerosis |
| rs10518025 | Abnormal kidney function | 0.007524 | 2.145 | CENPC1 | Multiple sclerosis |
| rs10518025 | Fracture of unspecified bones | 0.0008159 | 0.7608 | CENPC1 | Multiple sclerosis |
| rs10518025 | Sialoadenitis | 0.004464 | 1.63 | CENPC1 | Multiple sclerosis |
| rs10518025 | Cellulitis and abscess of face | 0.005262 | 1.487 | CENPC1 | Multiple sclerosis |
| rs10518025 | Dry eyes | 0.007969 | 1.192 | CENPC1 | Multiple sclerosis |
| rs10518025 | Contact and allergic dermatitis of eyelid | 0.01073 | 1.851 | CENPC1 | Multiple sclerosis |
| rs10518025 | Alopecia Areata | 0.004589 | 2.262 | CENPC1 | Multiple sclerosis |
| rs10518025 | Gastrointestinal complications | 0.006792 | 1.353 | CENPC1 | Multiple sclerosis |
| rs10518765 | Inflammatory conditions of jaw | 0.009415 | 0.5423 | UNC13C | Alkaline phosphatase |
| rs10518765 | Benign neoplasm of brain and other parts of nervous system | 0.00673 | 1.449 | UNC13C | Alkaline phosphatase |
| rs10518765 | Cystitis and urethritis | 0.01062 | 1.227 | UNC13C | Alkaline phosphatase |
| rs10518765 | Microscopic hematuria | 0.004421 | 0.5227 | UNC13C | Alkaline phosphatase |
| rs10518765 | Mucous polyp of cervix | 0.006876 | 0.6338 | UNC13C | Alkaline phosphatase |
| rs10518765 | Ankylosing spondylitis | 0.01036 | 2.14 | UNC13C | Alkaline phosphatase |
| rs10518765 | Other disorders of urethra and urinary tract | 0.007939 | 1.242 | UNC13C | Alkaline phosphatase |
| rs10518765 | Pain in joint | 0.00573 | 0.9034 | UNC13C | Alkaline phosphatase |
| rs10518765 | Bipolar | 0.005614 | 0.6135 | UNC13C | Alkaline phosphatase |
| rs10518765 | Other specified diseases of the salivary glands | 0.003621 | 0.3786 | UNC13C | Alkaline phosphatase |
| rs10518765 | Chronic cystitis | 0.008057 | 1.553 | UNC13C | Alkaline phosphatase |
| rs10518765 | Urethritis and urethral syndrome | 0.008549 | 1.766 | UNC13C | Alkaline phosphatase |
| rs10518765 | Pleurisy; pleural effusion | 0.01151 | 0.8544 | UNC13C | Alkaline phosphatase |
| rs10521222 | Dry eyes | 0.005173 | 0.7158 | SALL1 | C-reactive protein |
| rs10521222 | Sepsis and SIRS | 0.01073 | 1.543 | SALL1 | C-reactive protein |
| rs10521222 | Osteoarthrosis; localized, primary | 0.00455 | 0.4996 | SALL1 | C-reactive protein |
| rs10521222 | Disorders of esophageal motility | 0.004501 | 2.094 | SALL1 | C-reactive protein |
| rs10521222 | Shock | 0.006006 | 1.83 | SALL1 | C-reactive protein |
| rs10521222 | Other infectious diseases | 0.0005891 | 2.934 | SALL1 | C-reactive protein |
| rs10521222 | Malignant neoplasm of renal pelvis | 0.0006622 | 3.763 | SALL1 | C-reactive protein |
| rs10521222 | Atrial fibrillation | 0.01093 | 1.299 | SALL1 | C-reactive protein |
| rs1059513 | Cardiomyopathy | 0.000748 | 1.366 | STAT6 | IgE levels |
| rs1059513 | Jaundice | 0.004649 | 1.696 | STAT6 | IgE levels |
| rs1059513 | Cystic kidney disease | 0.00576 | 1.822 | STAT6 | IgE levels |
| rs1059513 | Dentofacial anomalies, including malocclusion | 0.0003886 | 2.062 | STAT6 | IgE levels |
| rs1059513 | Personality disorders | 0.005954 | 1.414 | STAT6 | IgE levels |
| rs1059513 | Prostatitis | 0.01112 | 1.457 | STAT6 | IgE levels |
| rs1059513 | Vascular disorders of kidney/hypertrophy | 0.003478 | 2.58 | STAT6 | IgE levels |
| rs1059513 | Gingival and periodontal diseases | 0.004483 | 1.324 | STAT6 | IgE levels |
| rs1059513 | Chronic periodontitis | 0.004382 | 1.428 | STAT6 | IgE levels |
| rs1059513 | Anomalies of tooth position/malocclusion | 0.001182 | 2.118 | STAT6 | IgE levels |
| rs1059513 | Primary/intrinsic cardiomyopathies | 0.001185 | 1.362 | STAT6 | IgE levels |
| rs1059513 | Type 2 diabetic peripheral circulatory disorders | 0.0003597 | 1.782 | STAT6 | IgE levels |
| rs1059513 | Type 2 diabetic neuropathy | 0.00695 | 1.278 | STAT6 | IgE levels |
| rs1059513 | Phosphorus metabolism disorder | 0.006973 | 1.63 | STAT6 | IgE levels |
| rs1059513 | Symptoms involving urinary system | 0.007619 | 1.394 | STAT6 | IgE levels |
| rs1059513 | Cholelithiasis with acute cholecystitis | 0.006356 | 1.789 | STAT6 | IgE levels |
| rs1059513 | Periodontitis (acute or chronic) | 0.006328 | 1.358 | STAT6 | IgE levels |
| rs10748128 | Polymyalgia Rheumatica | 0.005432 | 1.283 | FRS2 | Height |
| rs10748128 | Microscopic hematuria | 0.006912 | 0.628 | FRS2 | Height |
| rs10748128 | Dupuytren's disease | 0.0009479 | 1.481 | FRS2 | Height |
| rs10748128 | Stomach cancer | 0.004415 | 1.762 | FRS2 | Height |
| rs10748128 | Hypercoagulable state | 0.009146 | 0.6399 | FRS2 | Height |
| rs10748128 | Polycythemia vera | 0.009937 | 1.712 | FRS2 | Height |
| rs10748128 | Peritoneal or intestinal adhesions | 0.003367 | 1.673 | FRS2 | Height |
| rs10748128 | Congenital anomalies of great vessels | 0.004915 | 0.4108 | FRS2 | Height |
| rs10758593 | Cystitis and urethritis | 0.00522 | 1.211 | GLIS3 | Type 1 diabetes |
| rs10758593 | Esophageal cancer | 0.01139 | 1.702 | GLIS3 | Type 1 diabetes |
| rs10758593 | Nodular lymphoma | 0.009398 | 1.558 | GLIS3 | Type 1 diabetes |
| rs10758593 | Poisoning by primarily systemic agents | 0.005633 | 1.312 | GLIS3 | Type 1 diabetes |
| rs10758593 | Cystitis | 0.006467 | 1.219 | GLIS3 | Type 1 diabetes |
| rs10758593 | Known or suspected fetal abnormality | 0.006558 | 1.655 | GLIS3 | Type 1 diabetes |
| rs10758593 | Inflammatory diseases of female pelvic organs | 0.01065 | 0.8618 | GLIS3 | Type 1 diabetes |
| rs10758593 | Cardiac congenital anomalies | 0.003785 | 1.344 | GLIS3 | Type 1 diabetes |
| rs10758593 | Mental disorders due to brain damage | 0.008368 | 1.219 | GLIS3 | Type 1 diabetes |
| rs10758593 | Seborheic dermatitis | 0.006666 | 0.8433 | GLIS3 | Type 1 diabetes |
| rs10758593 | Cardiac shunt/ heart septal defect | 0.006668 | 1.445 | GLIS3 | Type 1 diabetes |
| rs10758593 | Acute, but ill-defined cerebrovascular disease | 0.004181 | 1.202 | GLIS3 | Type 1 diabetes |
| rs10758593 | Cholelithiasis with other cholecystitis | 0.009065 | 0.7796 | GLIS3 | Type 1 diabetes |
| rs10758593 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.004382 | 1.333 | GLIS3 | Type 1 diabetes |
| rs10758593 | Viral hepatitis | 0.002299 | 0.7508 | GLIS3 | Type 1 diabetes |
| rs10758593 | Late effects of cerebrovascular disease | 0.0009311 | 1.217 | GLIS3 | Type 1 diabetes |
| rs10758593 | Intracerebral hemorrhage | 0.006007 | 1.603 | GLIS3 | Type 1 diabetes |
| rs10758593 | Diseases of the tongue | 0.001066 | 1.491 | GLIS3 | Type 1 diabetes |
| rs10776612 | Abnormal kidney function | 0.002985 | 0.4209 | ARHGAP22 | Conduct disorder |
| rs10776612 | Acquired absence of breast | 0.003951 | 0.7382 | ARHGAP22 | Conduct disorder |
| rs10776612 | Symptoms involving urinary system | 0.005382 | 0.7878 | ARHGAP22 | Conduct disorder |
| rs10776612 | Carditis | 0.0101 | 0.8172 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cardiac dysrhythmias | 0.0001013 | 0.8887 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cholelithiasis and cholecystitis | 0.001854 | 0.8692 | ARHGAP22 | Conduct disorder |
| rs10776612 | Tachycardia NOS | 0.0007473 | 0.8015 | ARHGAP22 | Conduct disorder |
| rs10776612 | Other abnormality of urination | 0.008105 | 0.8276 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cardiac conduction disorders | 0.007863 | 0.8997 | ARHGAP22 | Conduct disorder |
| rs10776612 | Functional disorders of bladder | 0.003591 | 0.7454 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cholelithiasis with acute cholecystitis | 0.0009707 | 0.5675 | ARHGAP22 | Conduct disorder |
| rs10776612 | Chorioretinal scars | 0.006457 | 1.448 | ARHGAP22 | Conduct disorder |
| rs10776612 | Cholelithiasis | 0.00322 | 0.8678 | ARHGAP22 | Conduct disorder |
| rs10781380 | Altered mental status | 0.004157 | 1.311 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Other sprains and strains | 0.01034 | 0.7154 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Lower gastrointestinal congenital anomalies | 0.002558 | 0.3469 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Muscular dystrophies and other myopathies | 0.008921 | 0.636 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Thyrotoxicosis | 0.00617 | 1.251 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Abdominal pain | 0.01001 | 1.086 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Acquired spondylolisthesis | 0.001991 | 1.36 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Subjective visual disturbances | 0.007486 | 1.219 | PRUNE2 | Hippocampal atrophy |
| rs10781380 | Methicillin sensitive Staphylococcus aureus | 0.006625 | 1.356 | PRUNE2 | Hippocampal atrophy |
| rs10794720 | Adverse effects of antibacterials (not penicillins) | 0.002093 | 2.321 | WDR37 | Serum creatinine |
| rs10794720 | Inflammatory and toxic neuropathy | 2.664e-06 | 2.066 | WDR37 | Serum creatinine |
| rs10794720 | Inguinal hernia | 0.01009 | 1.268 | WDR37 | Serum creatinine |
| rs10794720 | Other acquired musculoskeletal deformity | 0.008491 | 0.6352 | WDR37 | Serum creatinine |
| rs10794720 | Cancer of other female genital organs | 0.003474 | 2.508 | WDR37 | Serum creatinine |
| rs10794720 | Obsessive-compulsive disorder | 0.006726 | 2.143 | WDR37 | Serum creatinine |
| rs10794720 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.004977 | 2.717 | WDR37 | Serum creatinine |
| rs10794720 | Peripheral retinal degenerations | 0.01118 | 0.5779 | WDR37 | Serum creatinine |
| rs10794720 | Viral warts & HPV | 0.007214 | 0.7482 | WDR37 | Serum creatinine |
| rs10794720 | Dyschromia and Vitiligo | 0.004639 | 0.6636 | WDR37 | Serum creatinine |
| rs10794720 | Acquired spondylolisthesis | 0.00463 | 0.512 | WDR37 | Serum creatinine |
| rs10794720 | Dry eyes | 0.009581 | 0.7917 | WDR37 | Serum creatinine |
| rs10794720 | Other cardiac conduction disorders | 0.007831 | 2.129 | WDR37 | Serum creatinine |
| rs10794720 | Other cells and casts in urine | 0.005301 | 1.881 | WDR37 | Serum creatinine |
| rs10829156 | Renal colic | 0.006805 | 1.722 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Mitral valve stenosis and/or aortic valve stenosis | 0.007361 | 0.7642 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Chronic obstructive asthma | 0.005966 | 1.339 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Obstructive chronic bronchitis | 0.005005 | 1.262 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Asthma with exacerbation | 0.01011 | 1.407 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Asthma | 0.0001056 | 1.216 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Chronic bronchitis | 0.005684 | 1.23 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Impetigo | 0.00822 | 1.596 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Chronic airway obstruction | 0.001123 | 1.164 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Emphysema | 0.007059 | 1.31 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Type 1 diabetic peripheral circulatory disorders | 0.002442 | 0.1664 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Type 1 diabetic neuropathy | 0.00659 | 0.5928 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Other rheumatic heart disease | 0.009294 | 0.2614 | ARL5B | Sudden cardiac arrest |
| rs10829156 | Poisoning by hormones and synthetic substitutes | 0.01074 | 1.413 | ARL5B | Sudden cardiac arrest |
| rs10841496 | Chronic ischemic heart disease | 0.0009502 | 0.8535 | PDE3A | Azoospermia |
| rs10841496 | Disorders of fluid, electrolyte, and acid-base balance | 0.002716 | 0.9122 | PDE3A | Azoospermia |
| rs10841496 | Toxic multinodular goiter | 0.004438 | 1.937 | PDE3A | Azoospermia |
| rs10841496 | Ileostomy status | 0.005991 | 0.614 | PDE3A | Azoospermia |
| rs10841496 | Cardiac dysrhythmias | 0.006993 | 0.9221 | PDE3A | Azoospermia |
| rs10841496 | Muscular wasting and disuse atrophy | 0.0006477 | 0.5329 | PDE3A | Azoospermia |
| rs10841496 | Other specified nonpsychotic and/or transient mental disorders | 0.008026 | 0.8215 | PDE3A | Azoospermia |
| rs10841496 | Leukemia | 0.001235 | 1.404 | PDE3A | Azoospermia |
| rs10841496 | Insomnia | 0.002908 | 0.8468 | PDE3A | Azoospermia |
| rs10841496 | Hypovolemia | 0.0006205 | 0.8636 | PDE3A | Azoospermia |
| rs10841496 | Failure to thrive | 0.007734 | 0.7189 | PDE3A | Azoospermia |
| rs10841496 | Idiopathic fibrosing alveolitis | 0.01115 | 1.788 | PDE3A | Azoospermia |
| rs10841496 | Alzheimer's disease | 0.002553 | 0.8309 | PDE3A | Azoospermia |
| rs10841496 | Multiple myeloma | 0.0006565 | 1.792 | PDE3A | Azoospermia |
| rs10841496 | Persistent mental disorders due to other conditions | 0.007418 | 0.8662 | PDE3A | Azoospermia |
| rs10841496 | Type 2 diabetic retinopathy | 0.0113 | 0.8435 | PDE3A | Azoospermia |
| rs10841496 | Malaise and fatigue | 0.004231 | 0.9173 | PDE3A | Azoospermia |
| rs10841496 | Sleep disorders | 4.312e-05 | 0.8582 | PDE3A | Azoospermia |
| rs10841496 | Acidosis | 0.002373 | 0.6988 | PDE3A | Azoospermia |
| rs10841496 | Electrolyte imbalance | 0.002106 | 0.8985 | PDE3A | Azoospermia |
| rs10841496 | Hypopotassemia | 0.004154 | 0.8766 | PDE3A | Azoospermia |
| rs10841496 | Acid-base balance disorder | 0.005901 | 0.7611 | PDE3A | Azoospermia |
| rs10841496 | Superficial cellulitis and abscess | 0.004901 | 0.9077 | PDE3A | Azoospermia |
| rs10873876 | Trigeminal nerve disorders | 0.003171 | 1.602 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10873876 | Early complications of trauma or procedure | 0.01001 | 1.757 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10873876 | Hepatomegaly | 0.00372 | 0.2622 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10873876 | Other symptoms involving abdomen and pelvis | 0.007976 | 0.831 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10873876 | Gingival and periodontal diseases | 0.004087 | 1.272 | ST6GALNAC3 | Acute lymphoblastic leukemia |
| rs10882272 | Labyrinthitis | 0.007388 | 0.7141 | O3FAR1 | Vitamin A |
| rs10882272 | Abnormal chest sounds | 0.0083 | 1.43 | O3FAR1 | Vitamin A |
| rs10882272 | Umbilical hernia | 0.007597 | 0.7756 | O3FAR1 | Vitamin A |
| rs10882272 | Atopic or contact dermatitis | 0.004255 | 0.8988 | O3FAR1 | Vitamin A |
| rs10882272 | Hemorrhage NOS | 0.003378 | 1.74 | O3FAR1 | Vitamin A |
| rs10882272 | Fracture of upper limb | 0.008313 | 0.8711 | O3FAR1 | Vitamin A |
| rs10882272 | Osteoporosis | 0.008036 | 1.131 | O3FAR1 | Vitamin A |
| rs10882272 | Respiratory failure | 0.005255 | 1.279 | O3FAR1 | Vitamin A |
| rs10882272 | Abnormal cytological, histological, immunological and DNA test findings | 0.005636 | 1.813 | O3FAR1 | Vitamin A |
| rs10882272 | Fracture of lower limb | 0.00958 | 0.8713 | O3FAR1 | Vitamin A |
| rs10882272 | Adverse effects of antirheumatics | 0.0107 | 0.564 | O3FAR1 | Vitamin A |
| rs10882272 | Voice disturbance | 0.009404 | 1.202 | O3FAR1 | Vitamin A |
| rs10882272 | Emphysema | 0.01124 | 1.25 | O3FAR1 | Vitamin A |
| rs10882272 | Glossitis | 0.01066 | 1.875 | O3FAR1 | Vitamin A |
| rs10882272 | Back pain | 8.473e-05 | 1.127 | O3FAR1 | Vitamin A |
| rs10882272 | Aseptic necrosis of bone | 0.006732 | 1.553 | O3FAR1 | Vitamin A |
| rs10882272 | Disturbances of amino-acid transport | 0.009121 | 0.5285 | O3FAR1 | Vitamin A |
| rs10882272 | Diseases of the larynx and vocal cords | 0.002485 | 1.205 | O3FAR1 | Vitamin A |
| rs10898392 | Disorders of adrenal glands | 0.006413 | 1.327 | DLG2 | Height |
| rs10898392 | Muscle weakness | 0.005104 | 0.7581 | DLG2 | Height |
| rs10898392 | Anal and rectal conditions | 0.007686 | 0.8751 | DLG2 | Height |
| rs10898392 | Peyronie's disease | 0.003078 | 1.946 | DLG2 | Height |
| rs10898392 | Hypertensive heart and/or renal disease | 0.006159 | 1.174 | DLG2 | Height |
| rs10898392 | Viral Enteritis | 0.01129 | 1.449 | DLG2 | Height |
| rs10898392 | Actinic keratosis | 0.003094 | 1.118 | DLG2 | Height |
| rs10898392 | Photodermatitis & sunburn | 0.00152 | 1.21 | DLG2 | Height |
| rs10898392 | Rash and other nonspecific skin eruption | 0.00832 | 1.154 | DLG2 | Height |
| rs10898392 | Benign neoplasm of unspecified sites | 0.00135 | 2.489 | DLG2 | Height |
| rs10898392 | Obesity | 0.01004 | 1.088 | DLG2 | Height |
| rs10898392 | Secondary malignancy of brain/spine | 0.0009536 | 0.5368 | DLG2 | Height |
| rs10898392 | Chronic kidney disease, Stage I or II | 0.0001364 | 0.6268 | DLG2 | Height |
| rs10898392 | Secondary malignant neoplasm of liver | 0.008981 | 0.7336 | DLG2 | Height |
| rs10898392 | Other headache syndromes | 0.002651 | 0.8973 | DLG2 | Height |
| rs10898392 | Abnormal glucose | 0.00319 | 1.124 | DLG2 | Height |
| rs10898392 | Other disorders of testis | 0.007073 | 1.378 | DLG2 | Height |
| rs10898392 | Subarachnoid hemorrhage | 0.002666 | 2.124 | DLG2 | Height |
| rs10898392 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.008742 | 0.8542 | DLG2 | Height |
| rs10937275 | Nodular lymphoma | 0.005593 | 1.807 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Inflammation of the eye | 0.006456 | 0.8451 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Phobia | 0.0103 | 2.19 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Pulmonary collapse; interstitial/compensatory emphysema | 0.001476 | 1.293 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Gastrointestinal complications | 0.00291 | 0.6229 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Abnormal chest sounds | 0.002318 | 1.691 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Synoviopathy | 0.005851 | 1.452 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Graves' disease | 0.00582 | 0.4378 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Contact dermatitis and other eczema due to plants [except food] | 2.686e-05 | 2.684 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937275 | Photodermatitis & sunburn | 0.01087 | 1.24 | ST6GAL1 | Drug-induced liver injury (flucloxacillin) |
| rs10937405 | Lipoma | 0.008787 | 1.192 | TP63 | Lung adenocarcinoma |
| rs10937405 | Plasma protein metabolism disorder | 0.008339 | 0.7732 | TP63 | Lung adenocarcinoma |
| rs10937405 | Breast disorder NOS | 0.007027 | 0.405 | TP63 | Lung adenocarcinoma |
| rs10937405 | Hemoptysis | 0.009069 | 0.7503 | TP63 | Lung adenocarcinoma |
| rs10937405 | Impacted cerumen | 0.008749 | 1.105 | TP63 | Lung adenocarcinoma |
| rs10937405 | Antihypertensive agents causing adverse effects | 0.00977 | 1.516 | TP63 | Lung adenocarcinoma |
| rs10937405 | Cyst and pseudocyst of pancreas | 0.006826 | 1.597 | TP63 | Lung adenocarcinoma |
| rs10953541 | Congenital cataract and lens anomalies | 0.00129 | 2.197 | BCAP29 | Coronary heart disease |
| rs10953541 | Malignant neoplasm of brain and nervous system | 0.007605 | 0.6363 | BCAP29 | Coronary heart disease |
| rs10953541 | Inflammatory diseases of prostate | 0.003663 | 1.296 | BCAP29 | Coronary heart disease |
| rs10953541 | Secondary malignant neoplasm of digestive systems | 0.0045 | 0.5593 | BCAP29 | Coronary heart disease |
| rs10953541 | Orchitis and epididymitis | 0.001675 | 1.601 | BCAP29 | Coronary heart disease |
| rs10953541 | progressive myopia | 0.005386 | 1.797 | BCAP29 | Coronary heart disease |
| rs10953541 | Absent or infrequent menstruation | 0.00274 | 0.541 | BCAP29 | Coronary heart disease |
| rs10953541 | Chronic glomerulonephritis | 0.001597 | 2.429 | BCAP29 | Coronary heart disease |
| rs10953541 | Abdominal aortic aneurysm | 0.005118 | 1.277 | BCAP29 | Coronary heart disease |
| rs10953541 | Prostate cancer | 0.00588 | 1.218 | BCAP29 | Coronary heart disease |
| rs10953541 | Alcoholism | 0.0002363 | 1.345 | BCAP29 | Coronary heart disease |
| rs10953541 | Abnormal function study of cardiovascular system | 0.006882 | 1.198 | BCAP29 | Coronary heart disease |
| rs10953541 | Alcohol-related disorders | 0.0005849 | 1.28 | BCAP29 | Coronary heart disease |
| rs11013962 | Disorders of cornea | 0.01037 | 1.182 | KIAA1217 | Earlobes |
| rs11013962 | Eosinophilia | 0.009667 | 0.5558 | KIAA1217 | Earlobes |
| rs11013962 | Essential hypertension | 0.004281 | 1.089 | KIAA1217 | Earlobes |
| rs11013962 | Eye infection, viral | 0.009939 | 1.367 | KIAA1217 | Earlobes |
| rs11013962 | Dermatophytosis / Dermatomycosis | 0.01013 | 1.101 | KIAA1217 | Earlobes |
| rs11013962 | Mucous polyp of cervix | 0.001168 | 1.499 | KIAA1217 | Earlobes |
| rs11013962 | Open wound of toe(s) | 0.0112 | 0.5781 | KIAA1217 | Earlobes |
| rs11013962 | Hypertension | 0.004967 | 1.087 | KIAA1217 | Earlobes |
| rs11013962 | Ankylosis of joint | 0.006849 | 1.424 | KIAA1217 | Earlobes |
| rs11013962 | Cholelithiasis and cholecystitis | 0.009395 | 0.8908 | KIAA1217 | Earlobes |
| rs11013962 | Adverse effects of cardiac rhythm regulators | 0.008606 | 0.568 | KIAA1217 | Earlobes |
| rs11013962 | Develomental delays and disorders | 0.006192 | 1.279 | KIAA1217 | Earlobes |
| rs11057830 | Colostomy and enterostomy complication | 0.000644 | 2.216 | SCARB1 | Vitamin E |
| rs11057830 | Memory loss | 0.006162 | 0.7208 | SCARB1 | Vitamin E |
| rs11057830 | Generalized anxiety disorder | 0.008018 | 0.6683 | SCARB1 | Vitamin E |
| rs11057830 | Prostatitis | 0.0006235 | 1.515 | SCARB1 | Vitamin E |
| rs11057830 | Eustachian tube disorders | 0.008035 | 0.848 | SCARB1 | Vitamin E |
| rs11057830 | Complication of amputation stump | 0.001077 | 2.257 | SCARB1 | Vitamin E |
| rs11057830 | Otitis media | 0.01123 | 0.8331 | SCARB1 | Vitamin E |
| rs11057830 | Immunity deficiency | 0.0101 | 1.756 | SCARB1 | Vitamin E |
| rs11057830 | Hirsutism | 0.009085 | 1.774 | SCARB1 | Vitamin E |
| rs11057830 | Cancer of larynx | 0.009032 | 0.4946 | SCARB1 | Vitamin E |
| rs11057830 | Deficiency of humoral immunity | 0.004765 | 2.3 | SCARB1 | Vitamin E |
| rs11057830 | Other specified gastritis | 0.00269 | 1.399 | SCARB1 | Vitamin E |
| rs11057830 | Chronic obstructive asthma with exacerbation | 0.004629 | 0.3291 | SCARB1 | Vitamin E |
| rs11057830 | Chronic obstructive asthma | 0.0006173 | 0.5876 | SCARB1 | Vitamin E |
| rs11057830 | Diaphragmatic hernia | 0.007976 | 1.182 | SCARB1 | Vitamin E |
| rs11062040 | Other pulmonary inflamation or edema | 0.00138 | 1.385 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Other hypertrophic and atrophic conditions of skin | 0.01143 | 1.104 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Noninflammatory disorders of ovary, fallopian tube, & broad ligament | 0.001918 | 0.571 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Cerebral atherosclerosis | 0.008596 | 0.6207 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Generalized hyperhidrosis | 0.002301 | 1.383 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Benign neoplasm of ovary | 0.002351 | 0.6034 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Obstruction of bile duct | 0.01005 | 1.559 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Open wound of lip and mouth | 0.006007 | 0.5588 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Nerve root lesions | 0.006443 | 1.622 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Abnormal findings examination of lungs | 0.0107 | 1.157 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Blood vessel replaced | 0.004043 | 1.613 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11062040 | Exophthalmos | 0.003764 | 2.006 | DCP1B | Response to gemcitabine in pancreatic cancer |
| rs11064994 | Acute pancreatitis | 0.003822 | 1.533 | CCDC64 | Cognitive performance |
| rs11064994 | Bacterial enteritis | 0.006509 | 1.56 | CCDC64 | Cognitive performance |
| rs11064994 | Idiopathic fibrosing alveolitis | 0.0001437 | 2.862 | CCDC64 | Cognitive performance |
| rs11064994 | Congenital coagulation defects | 0.003936 | 2.416 | CCDC64 | Cognitive performance |
| rs11064994 | Other alveolar and parietoalveolar pneumonopathy | 0.001539 | 2.196 | CCDC64 | Cognitive performance |
| rs11064994 | Fracture of tibia and fibula | 0.008033 | 0.5705 | CCDC64 | Cognitive performance |
| rs11064994 | Benign neoplasm of lip, oral cavity, and pharynx | 0.008658 | 1.845 | CCDC64 | Cognitive performance |
| rs11064994 | Urinary obstruction | 0.01075 | 1.643 | CCDC64 | Cognitive performance |
| rs11064994 | Other specified diseases of nail | 0.005006 | 0.7362 | CCDC64 | Cognitive performance |
| rs11064994 | Peritonitis and retroperitoneal infections | 0.006722 | 1.703 | CCDC64 | Cognitive performance |
| rs11064994 | Diseases of nail | 0.01005 | 0.764 | CCDC64 | Cognitive performance |
| rs11064994 | Cervical cancer and dysplasia | 0.001855 | 1.583 | CCDC64 | Cognitive performance |
| rs11064994 | Hyperparathyroidism | 0.008489 | 1.509 | CCDC64 | Cognitive performance |
| rs11064994 | Intestinal infection due to C. difficile | 0.0002771 | 1.877 | CCDC64 | Cognitive performance |
| rs11064994 | Clotting factor deficiency | 0.003452 | 2.821 | CCDC64 | Cognitive performance |
| rs11064994 | Other specified nonpsychotic and/or transient mental disorders | 0.01011 | 1.382 | CCDC64 | Cognitive performance |
| rs11064994 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.001134 | 1.671 | CCDC64 | Cognitive performance |
| rs11064994 | Duodenitis | 0.001063 | 1.834 | CCDC64 | Cognitive performance |
| rs11082304 | Chronic ulcer of skin | 0.005919 | 0.8855 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Congenital anomalies of face and neck | 0.002619 | 2.525 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Decreased white blood cell count | 0.004622 | 0.8108 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Other disorders of bone and cartilage | 0.0003868 | 0.777 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Chronic ulcer of unspecified site | 0.0001771 | 0.7123 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Type 2 diabetic retinopathy | 0.006342 | 0.8327 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Other immunological findings | 0.005054 | 0.7486 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Varicose veins of lower extremity, symptomtic | 0.009183 | 0.8286 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Acute pharyngitis | 0.009153 | 0.8748 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Gastritis and duodenitis | 0.007031 | 0.8769 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Septicemia | 0.00494 | 0.8459 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Pulmonary collapse; interstitial/compensatory emphysema | 0.008523 | 0.8607 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Leukemia | 0.009316 | 0.7634 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Other specified gastritis | 0.005138 | 0.7867 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Parkinson's disease | 0.008821 | 1.275 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Psychogenic and somatoform disorders | 0.005583 | 0.782 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Neutropenia | 0.008171 | 0.8154 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Abnormal findings examination of lungs | 0.001408 | 0.8339 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Fracture of tibia and fibula | 0.009469 | 0.7918 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Contact dermatitis and other eczema due to plants [except food] | 0.009701 | 1.7 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs11082304 | Morbid obesity | 0.01064 | 0.8664 | CABLES1 | Platelet counts, Smoking behavior (age of initiation) |
| rs1109670 | Ovarian cancer | 0.0103 | 1.544 | ASAP2 | Multiple sclerosis |
| rs1109670 | Dermatosis NOS | 0.006984 | 1.122 | ASAP2 | Multiple sclerosis |
| rs1109670 | Other disorders of prostate | 0.001168 | 1.469 | ASAP2 | Multiple sclerosis |
| rs1109670 | Abdominal aortic aneurysm | 0.01032 | 0.7831 | ASAP2 | Multiple sclerosis |
| rs1109670 | Malaise and fatigue | 0.01067 | 1.092 | ASAP2 | Multiple sclerosis |
| rs1109670 | Neurological disorders due to brain damage | 0.004657 | 0.8574 | ASAP2 | Multiple sclerosis |
| rs1109670 | Calculus of kidney | 0.004261 | 1.205 | ASAP2 | Multiple sclerosis |
| rs1109670 | Fracture of unspecified bones | 0.003234 | 1.191 | ASAP2 | Multiple sclerosis |
| rs1109670 | Known or suspected fetal abnormality | 0.00881 | 1.702 | ASAP2 | Multiple sclerosis |
| rs1109670 | Pernicious anemia | 0.00511 | 0.5993 | ASAP2 | Multiple sclerosis |
| rs1109670 | Fractur of unspecified part of femur | 0.004199 | 1.473 | ASAP2 | Multiple sclerosis |
| rs1109670 | Carbuncle and furuncle | 0.004685 | 0.5662 | ASAP2 | Multiple sclerosis |
| rs1109670 | Osteopenia | 0.005382 | 1.148 | ASAP2 | Multiple sclerosis |
| rs1109670 | Anxiety, phobic and dissociative disorders | 0.002285 | 1.136 | ASAP2 | Multiple sclerosis |
| rs1109670 | Cancer of other female genital organs | 0.009297 | 1.469 | ASAP2 | Multiple sclerosis |
| rs1109670 | progressive myopia | 0.006716 | 0.4446 | ASAP2 | Multiple sclerosis |
| rs11129295 | Symptoms involving digestive system | 0.01128 | 0.8214 | EOMES | Multiple sclerosis |
| rs11129295 | Psoriasis | 0.01123 | 0.8038 | EOMES | Multiple sclerosis |
| rs11129295 | Psoriasis & related disorders | 0.01122 | 0.8135 | EOMES | Multiple sclerosis |
| rs11129295 | Umbilical hernia | 0.0002798 | 1.382 | EOMES | Multiple sclerosis |
| rs11129295 | Sicca syndrome | 0.004759 | 0.633 | EOMES | Multiple sclerosis |
| rs11129295 | Psoriasis vulgaris | 0.01091 | 0.7987 | EOMES | Multiple sclerosis |
| rs11129295 | Gastritis and duodenitis | 0.0005445 | 1.189 | EOMES | Multiple sclerosis |
| rs11129295 | Hepatomegaly | 0.003837 | 1.795 | EOMES | Multiple sclerosis |
| rs11129295 | Type 1 diabetes nephropathy | 0.01142 | 1.576 | EOMES | Multiple sclerosis |
| rs11129295 | Overweight | 0.01094 | 1.085 | EOMES | Multiple sclerosis |
| rs11129295 | Other acquired musculoskeletal deformity | 0.01092 | 0.8086 | EOMES | Multiple sclerosis |
| rs11129295 | Other anemias | 0.006414 | 1.089 | EOMES | Multiple sclerosis |
| rs11129295 | Type 1 diabetic retinopathy | 0.01107 | 1.385 | EOMES | Multiple sclerosis |
| rs11129295 | Intervertebral disc disorder with myelopathy | 0.009204 | 1.681 | EOMES | Multiple sclerosis |
| rs11129295 | Hypotension | 0.008533 | 1.131 | EOMES | Multiple sclerosis |
| rs11129295 | Lesions of stomach and duodenum | 0.001729 | 2.172 | EOMES | Multiple sclerosis |
| rs11129640 | Sleep apnea | 0.009223 | 1.132 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Behcet's syndrome | 0.003496 | 0.5106 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Heart valve replaced | 0.009139 | 1.311 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Obstructive sleep apnea | 0.006552 | 1.171 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Megaloblastic anemia | 0.0108 | 1.365 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Chronic interstitial cystitis | 0.006236 | 2.13 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Iron deficiency anemia secondary to blood loss | 0.001297 | 1.451 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Aortic aneurysm | 0.001182 | 1.283 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Other aneurysm | 0.009929 | 1.199 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Type 2 diabetes | 0.007727 | 0.9054 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Pathologic fracture | 0.004201 | 1.248 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Hirsutism | 0.01039 | 1.651 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Otitis externa | 0.008499 | 1.209 | ARPP21 | Entorhinal cortical thickness |
| rs11129640 | Nevus, non-neoplastic | 0.003347 | 1.787 | ARPP21 | Entorhinal cortical thickness |
| rs11130874 | Frequency of urination and polyuria | 0.006607 | 1.16 | PTPRG | Schizophrenia |
| rs11130874 | Hyperosmolality and/or hypernatremia | 0.009605 | 1.513 | PTPRG | Schizophrenia |
| rs11130874 | Other disorders of eyelids | 0.001823 | 1.21 | PTPRG | Schizophrenia |
| rs11130874 | Hepatomegaly | 0.002619 | 1.952 | PTPRG | Schizophrenia |
| rs11130874 | Symptoms/disorders of the urinary system | 0.005171 | 1.114 | PTPRG | Schizophrenia |
| rs11130874 | Cancer within the respiratory system | 0.004892 | 0.7402 | PTPRG | Schizophrenia |
| rs11130874 | Sepsis | 0.01109 | 1.302 | PTPRG | Schizophrenia |
| rs11130874 | Secondary malignant neoplasm | 0.004618 | 0.8159 | PTPRG | Schizophrenia |
| rs11130874 | Gingivitis | 7.127e-05 | 2.424 | PTPRG | Schizophrenia |
| rs11130874 | Urethritis and urethral syndrome | 0.01145 | 1.742 | PTPRG | Schizophrenia |
| rs11130874 | Phosphorus metabolism disorder | 0.002227 | 1.583 | PTPRG | Schizophrenia |
| rs11130874 | Dysuria | 0.001214 | 1.241 | PTPRG | Schizophrenia |
| rs11130874 | Adverse effects of hormones and synthetic substitutes | 0.009896 | 2.258 | PTPRG | Schizophrenia |
| rs11130874 | Protein-calorie malnutrition | 0.00761 | 1.201 | PTPRG | Schizophrenia |
| rs11130874 | Cardiac arrest & ventricular fibrillation | 0.00655 | 0.613 | PTPRG | Schizophrenia |
| rs11130874 | Abnormal loss of weight and underweight | 0.005547 | 1.341 | PTPRG | Schizophrenia |
| rs11130874 | Lung cancer | 0.005843 | 0.7417 | PTPRG | Schizophrenia |
| rs11130874 | Simple goiter | 0.008311 | 0.7585 | PTPRG | Schizophrenia |
| rs11141915 | Localized adiposity | 0.009375 | 1.921 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Genital prolapse | 0.008456 | 1.197 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Immune disorders | 0.001694 | 1.353 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | severe protein-calorie malnutrition | 0.001511 | 0.4466 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Thyroid cancer | 0.003042 | 0.5153 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Cervical radiculitis | 0.001393 | 1.251 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Myopia | 0.007799 | 1.151 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Disorders of esophageal motility | 0.01103 | 0.588 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Hypertensive heart and/or renal disease | 0.00971 | 0.8281 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Prolapse of vaginal walls | 0.003654 | 1.259 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Urinary incontinence | 0.004403 | 1.167 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Hypothyroidism | 0.004528 | 1.129 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Concussion | 0.006358 | 1.553 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11141915 | Thyroiditis | 0.004528 | 1.429 | DAPK1 | Response to gemcitabine in pancreatic cancer |
| rs11143230 | Prolapse of vaginal vault after hysterectomy | 0.009543 | 1.456 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Diseases of pulp and periapical tissues | 0.01078 | 1.194 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Sepsis and SIRS | 0.006628 | 1.267 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Plasma protein metabolism disorder | 0.0001924 | 1.433 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Nontoxic multinodular goiter | 0.00384 | 1.283 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Pulmonary collapse; interstitial/compensatory emphysema | 0.0002604 | 1.242 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Hypertension complicating pregnancy | 0.0009324 | 0.3098 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Nontoxic nodular goiter | 0.005004 | 1.196 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Protein plasma/amino-acid transport and metabolism disorder | 0.002445 | 1.307 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Vaginal enterocele, congenital or acquired | 0.01085 | 1.463 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Stomatitis and mucositis | 0.003657 | 1.422 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Other specified diseases of sebaceous glands | 0.003727 | 0.7919 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Hemorrhoids | 0.009504 | 1.113 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Thyrotoxicosis | 0.005552 | 1.247 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Other specified osteoporosis | 0.003262 | 1.735 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Nerve root and plexus disorders | 0.009203 | 1.302 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11143230 | Oral aphthae | 0.01071 | 1.596 | GDA | Suicidal ideation and SSRI class antidepressant Escitalopram, Suicidal ideation |
| rs11144134 | Vitamin deficiency | 0.001431 | 0.6821 | TRPM6 | Magnesium levels |
| rs11144134 | Abnormal reflex | 0.001276 | 2.967 | TRPM6 | Magnesium levels |
| rs11144134 | Mood disorders | 0.01082 | 0.8511 | TRPM6 | Magnesium levels |
| rs11144134 | Purpura and other hemorrhagic conditions | 0.008421 | 0.7492 | TRPM6 | Magnesium levels |
| rs11144134 | Benign neoplasm of colon | 0.009647 | 1.16 | TRPM6 | Magnesium levels |
| rs11144134 | Congenital anomalies of urinary system | 0.009778 | 1.689 | TRPM6 | Magnesium levels |
| rs11144134 | Balanoposthitis | 0.009302 | 2.201 | TRPM6 | Magnesium levels |
| rs11144134 | Pain, swelling or discharge of eye | 0.003963 | 0.4465 | TRPM6 | Magnesium levels |
| rs11144134 | Thrombocytopenia | 0.001797 | 0.6711 | TRPM6 | Magnesium levels |
| rs11144134 | Hydrocele | 0.005035 | 1.962 | TRPM6 | Magnesium levels |
| rs11144134 | Symptoms affecting skin | 0.008636 | 0.8516 | TRPM6 | Magnesium levels |
| rs11144134 | Viral Enteritis | 0.01099 | 0.348 | TRPM6 | Magnesium levels |
| rs11172113 | Aplastic anemia | 0.001001 | 1.437 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Fracture of ribs | 0.005592 | 1.248 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Fracture of pelvis | 0.003732 | 1.366 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | End stage renal disease | 0.00784 | 1.392 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Fracture of ankle and foot | 0.01044 | 1.139 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Fracture of upper limb | 0.002421 | 1.164 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Dermatomycoses | 0.002053 | 0.5168 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Poisoning by agents affecting the cardiovascular system | 0.004701 | 0.7409 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Abnormal function study of cardiovascular system | 0.004637 | 0.8407 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Temporomandibular joint disorders | 0.0007857 | 0.732 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Chronic periodontitis | 0.004828 | 0.7808 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Chronic ulcer of unspecified site | 0.006673 | 0.7755 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Acute bronchitis and bronchiolitis | 0.008704 | 0.8919 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Cardiac defibrillator in situ | 0.004402 | 1.449 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Acute reaction to stress | 0.001894 | 0.7646 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Infection/inflammation of internal prosthetic device, implant or graft | 0.006796 | 1.274 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Other abnormality of urination | 0.0005745 | 0.7778 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Early complications of trauma or procedure | 0.006659 | 1.655 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Mechanical complication due to other implant and internal device | 0.003944 | 1.365 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Symptoms associated with female genital organs | 0.006851 | 0.8402 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Diseases of the jaws | 0.00283 | 0.8182 | LRP1 | Pulmonary function, Migraine |
| rs11172113 | Temporomandibular joint disorder NOS | 0.0004462 | 0.5065 | LRP1 | Pulmonary function, Migraine |
| rs11203203 | Functional digestive disorders | 0.01121 | 1.137 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Nonallopathic lesions NEC | 0.002476 | 1.147 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Spondylosis without myelopathy | 0.01069 | 1.107 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other disorders of back | 0.001229 | 1.199 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Idiopathic fibrosing alveolitis | 0.002517 | 0.4382 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other disorders of pancreatic internal secretion | 0.01005 | 0.5682 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Malunion fracture | 0.005954 | 1.434 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Chronic interstitial cystitis | 0.007913 | 2.033 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Obsessive-compulsive disorder | 0.0104 | 1.674 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Hyperventilation | 0.003607 | 1.76 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other disorders of bone and cartilage | 0.01038 | 1.205 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Thoracic neuritis/radiculitis | 0.003143 | 1.131 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Chronic pharyngitis and nasopharyngitis | 0.002048 | 1.199 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Tension headache | 0.007067 | 1.243 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Acute sinusitis | 0.006648 | 1.145 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Disorders of coccyx | 0.004627 | 1.351 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Chronic sinusitis | 0.007792 | 1.123 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other endocrine disorders | 0.01152 | 1.497 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Intervertebral disc disorders | 3.455e-05 | 1.16 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Other hypertensive complications | 0.0005854 | 1.342 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Back pain | 0.0001058 | 1.125 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11203203 | Degeneration of intervertebral disc | 7.834e-05 | 1.182 | UBASH3A | Vitiligo, Type 1 diabetes, Celiac disease or Rheumatoid arthritis, Rheumatoid arthritis |
| rs11204538 | Prostate cancer | 0.009377 | 0.8509 | TRIM58 | Mean corpuscular volume |
| rs11204538 | Swelling, mass, or lump in head and neck | 0.0007572 | 0.7664 | TRIM58 | Mean corpuscular volume |
| rs11204538 | Schizophrenia | 0.008957 | 0.6021 | TRIM58 | Mean corpuscular volume |
| rs11204538 | Ulcerative stomatitis & mucositis | 0.003142 | 0.5053 | TRIM58 | Mean corpuscular volume |
| rs11204538 | Irregular menstrual bleeding | 0.009469 | 1.637 | TRIM58 | Mean corpuscular volume |
| rs11206510 | Thyroiditis | 0.0004481 | 1.557 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Abnormal weight gain | 0.004094 | 1.425 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Toxic multinodular goiter | 0.004587 | 1.963 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Stress fracture | 0.005591 | 0.242 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Spontaneous ecchymoses | 0.002117 | 0.3899 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Diplopia and disorders of binocular vision | 0.002681 | 0.6644 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Cardiac arrest & ventricular fibrillation | 0.007312 | 1.473 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Hemorrhage or hematoma complicating a procedure | 0.005158 | 0.7547 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Poisoning by other anti-infectives | 0.007824 | 1.285 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Ascites (non malignant) | 0.006818 | 0.6005 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Respiratory failure | 0.006323 | 1.324 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Hemorrhoids | 0.01082 | 1.136 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11206510 | Rhabdomyolysis | 0.01068 | 1.835 | PCSK9 | LDL Cholesterol, Early onset myocardial infarction, Coronary heart disease |
| rs11214606 | Other immunological findings | 0.002087 | 1.745 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Aneurysm of iliac artery | 0.003166 | 2.497 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Dysthymic disorder | 0.001419 | 0.628 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Type 1 diabetic neuropathy | 0.004196 | 1.95 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Mycoses | 0.009217 | 1.987 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Cholesteatoma | 9.689e-05 | 3.179 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Fracture of radius and ulna | 0.01008 | 1.385 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Diseases of hair and hair follicles | 0.003381 | 0.5445 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Methicillin resistant Staphylococcus aureus | 0.004804 | 2.628 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Complication of amputation stump | 0.00109 | 2.907 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Congenital anomalies of great vessels | 0.004541 | 2.796 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Other disorders of middle ear and mastoid | 0.0005852 | 2.195 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Postlaminectomy syndrome | 0.0007134 | 1.997 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Peripheral autonomic neuropathy | 0.006894 | 1.797 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Immune disorders | 0.002456 | 1.601 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Deep vein thrombosis | 0.0066 | 1.576 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Symptoms involving respiratory system | 0.002879 | 0.5473 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11214606 | Diseases of respiratory system | 0.007101 | 0.6737 | DRD2 | Working memory and antipsychotic drug olanzapine |
| rs11221332 | Essential hypertension | 0.001259 | 0.8929 | ETS1 | Celiac disease |
| rs11221332 | Posterior pituitary disorders | 0.001695 | 1.891 | ETS1 | Celiac disease |
| rs11221332 | Allergy to serum or vaccine | 0.01113 | 1.712 | ETS1 | Celiac disease |
| rs11221332 | Osteoarthritis; localized | 0.008838 | 0.8745 | ETS1 | Celiac disease |
| rs11221332 | Hypertension | 0.001071 | 0.8916 | ETS1 | Celiac disease |
| rs11221332 | Other disorders of eye | 0.01065 | 1.13 | ETS1 | Celiac disease |
| rs11221332 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.006984 | 0.7781 | ETS1 | Celiac disease |
| rs11221332 | Other conditions of brain, NOS | 0.002899 | 1.647 | ETS1 | Celiac disease |
| rs11221332 | Osteoarthrosis | 0.005174 | 0.9046 | ETS1 | Celiac disease |
| rs11221332 | Symptoms/disorders of the urinary system | 0.0001749 | 0.8689 | ETS1 | Celiac disease |
| rs11221332 | Cerebrovascular disease | 0.002413 | 0.8842 | ETS1 | Celiac disease |
| rs11221332 | Symptoms involving cardiovascular system | 0.006471 | 0.8339 | ETS1 | Celiac disease |
| rs11221332 | Pituitary hypofunction | 0.009257 | 1.829 | ETS1 | Celiac disease |
| rs11221332 | Open wounds of head; neck; and trunk | 0.005175 | 0.8386 | ETS1 | Celiac disease |
| rs11221332 | Gross hematuria | 0.0009977 | 0.4066 | ETS1 | Celiac disease |
| rs11221332 | Claw toe | 0.01128 | 0.3374 | ETS1 | Celiac disease |
| rs11221332 | Open wounds of extremities | 0.009341 | 0.8802 | ETS1 | Celiac disease |
| rs11221332 | Paralytic strabismus | 0.004072 | 1.577 | ETS1 | Celiac disease |
| rs11221332 | Malignant neoplasm of brain and nervous system | 0.0033 | 1.51 | ETS1 | Celiac disease |
| rs11221332 | Osteoarthrosis NOS | 0.005983 | 0.8992 | ETS1 | Celiac disease |
| rs11221332 | Hypersomnia | 0.01052 | 0.6035 | ETS1 | Celiac disease |
| rs11221332 | Abnormal findings on study of brain, nervous system | 0.008007 | 1.547 | ETS1 | Celiac disease |
| rs11221332 | Cardiac defibrillator in situ | 0.007053 | 0.614 | ETS1 | Celiac disease |
| rs11221332 | Occlusion and stenosis of precerebral arteries | 0.0009581 | 0.8275 | ETS1 | Celiac disease |
| rs11221332 | Seborheic dermatitis | 0.003019 | 1.23 | ETS1 | Celiac disease |
| rs11221332 | Cervical cancer and dysplasia | 0.0001415 | 0.6225 | ETS1 | Celiac disease |
| rs11221332 | Superficial cellulitis and abscess | 0.003528 | 0.8851 | ETS1 | Celiac disease |
| rs11221332 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.0007108 | 0.6369 | ETS1 | Celiac disease |
| rs11221332 | Aneurysm of artery of lower extremity | 0.005158 | 0.5068 | ETS1 | Celiac disease |
| rs11243676 | Stricture of artery | 0.01004 | 0.5396 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Congenital musculoskeletal deformities of spine | 0.006721 | 1.672 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Other disorders of arteries and arterioles | 0.001645 | 0.5322 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Carbuncle and furuncle | 0.0008375 | 2.027 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Develomental delays and disorders | 0.009603 | 1.456 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | AV block | 0.01103 | 0.725 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Symptoms involving respiratory system | 0.002437 | 0.616 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Ptosis of eyelid | 0.001758 | 1.437 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Cervical radiculitis | 0.003516 | 1.33 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Insect bite | 0.001335 | 0.5571 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Anomalies of jaw size/symmetry | 0.003767 | 2.73 | NTNG2 | Systemic lupus erythematosus |
| rs11243676 | Uveitis | 0.01048 | 1.497 | NTNG2 | Systemic lupus erythematosus |
| rs11465804 | Disorders of vitreous body | 0.009976 | 0.7832 | IL23R | Crohn's disease |
| rs11465804 | Mechanical complication due to other implant and internal device | 0.007207 | 1.654 | IL23R | Crohn's disease |
| rs11465804 | Atrophy of edentulous alveolar ridge | 3.18e-05 | 2.638 | IL23R | Crohn's disease |
| rs11465804 | Osteoarthrosis; localized, primary | 0.004315 | 0.5636 | IL23R | Crohn's disease |
| rs11465804 | Other peripheral nerve disorders | 0.0109 | 0.8189 | IL23R | Crohn's disease |
| rs11465804 | Osteochondropathies | 0.004789 | 2.594 | IL23R | Crohn's disease |
| rs11465804 | Hypercholesterolemia | 0.00873 | 0.7989 | IL23R | Crohn's disease |
| rs11465804 | Allergy to serum or vaccine | 0.0007702 | 2.801 | IL23R | Crohn's disease |
| rs11465804 | Unspecified erythematous condition | 0.008822 | 0.154 | IL23R | Crohn's disease |
| rs11465804 | Dental caries | 0.008656 | 1.399 | IL23R | Crohn's disease |
| rs11465804 | Abnormal reflex | 0.007996 | 2.868 | IL23R | Crohn's disease |
| rs11465804 | Other diseases of the teeth and supporting structures | 2.428e-05 | 1.816 | IL23R | Crohn's disease |
| rs11465804 | Fracture of foot | 0.007313 | 0.6203 | IL23R | Crohn's disease |
| rs11465804 | Genitourinary congenital anomalies | 0.01132 | 1.661 | IL23R | Crohn's disease |
| rs11465804 | Cervical cancer | 0.004013 | 2.621 | IL23R | Crohn's disease |
| rs11465804 | Other disorders of eye | 0.005382 | 0.7837 | IL23R | Crohn's disease |
| rs1150754 | Disorders of lipoid metabolism | 0.01132 | 0.8933 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Rosacea | 0.0005574 | 0.712 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Keratitis, infectious | 0.001117 | 0.4812 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Prostatitis | 0.003974 | 0.6584 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetic neuropathy | 1.725e-08 | 2.287 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Hematuria | 0.001119 | 0.8271 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Inflammatory disease of cervix, vagina, and vulva | 0.009757 | 0.7933 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Nephritis and nephropathy in diseases classified elsewhere | 0.004008 | 1.401 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Cyst of kidney, acquired | 0.0004346 | 1.528 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Celiac or tropical sprue | 1.889e-06 | 2.92 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Atrophic gastritis | 0.01088 | 1.567 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Other specified peripheral vascular diseases | 0.002116 | 2.366 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Celiac disease | 6.711e-06 | 2.822 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Ovarian dysfunction | 0.009312 | 0.2627 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Decreased libido | 0.0105 | 2.041 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Urticaria | 0.005234 | 0.7053 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Peripheral autonomic neuropathy | 0.0003163 | 1.663 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Peritoneal or intestinal adhesions | 0.006571 | 1.76 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Congenital anomalies of intestine | 0.002779 | 2.513 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetes nephropathy | 0.0001004 | 2.168 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Stricture and stenosis of esophagus | 0.007385 | 0.6873 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Discoid lupus erythematosus | 0.000417 | 1.762 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Nephritis and nephropathy without mention of glomerulonephritis | 0.005348 | 1.346 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Immune disorders | 0.004881 | 1.352 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Seborheic dermatitis | 0.01086 | 0.7887 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Adverse effects of insulins and antidiabetic agents | 0.0001532 | 2.468 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Diabetic retinopathy | 0.008961 | 1.251 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Adrenal hypofunction | 0.006902 | 1.752 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetic peripheral circulatory disorders | 0.0001084 | 2.712 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Stress fracture | 0.007701 | 2.004 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetic retinopathy | 8.379e-05 | 1.799 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Pilonidal cyst | 0.007682 | 2.247 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Lupus erythematosus | 0.0005656 | 2.396 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Abnormal mammogram | 0.006263 | 0.7838 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Poisoning by psychotropic agents | 0.00886 | 1.878 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Type 1 diabetes | 0.0003616 | 1.313 | TNXB | Systemic lupus erythematosus |
| rs1150754 | Disorders of the autonomic nervous system | 0.0008045 | 1.501 | TNXB | Systemic lupus erythematosus |
| rs11574637 | Benign neoplasm of unspecified sites | 0.01147 | 0.162 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Streptococcus infection | 0.01064 | 0.6653 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Joint/ligament sprain | 0.008831 | 1.38 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Migrain with aura | 0.002359 | 1.624 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Disorders of parathyroid gland | 0.005538 | 1.364 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Other hypertensive complications | 0.002547 | 1.366 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Cellulitis and abscess of foot/toes | 0.008372 | 1.336 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Atherosclerosis of renal artery | 0.001516 | 1.435 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Subjective visual disturbances | 0.006444 | 1.265 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Arterial embolism and thrombosis of lower extremity artery | 0.006578 | 1.421 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Anemia of chronic disease | 0.009621 | 0.7831 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Bladder cancer | 0.01032 | 1.314 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Bacterial infection NOS | 0.008417 | 0.8449 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | E. coli | 0.003269 | 0.6342 | ITGAX | Systemic lupus erythematosus |
| rs11574637 | Acne | 0.003341 | 0.6728 | ITGAX | Systemic lupus erythematosus |
| rs11611208 | Chondrocalcinosis | 0.003031 | 1.814 | PDE3A | Height |
| rs11611208 | Erectile dysfunction | 0.002083 | 1.453 | PDE3A | Height |
| rs11611208 | Other specified disorders of liver | 0.01147 | 0.4416 | PDE3A | Height |
| rs11611208 | Other diseases of the teeth and supporting structures | 0.008428 | 0.5428 | PDE3A | Height |
| rs11611208 | Other disorders of metabolic, endocrine, immunity disorders | 0.0102 | 2.521 | PDE3A | Height |
| rs11611208 | Pruritus and related conditions | 0.003678 | 1.448 | PDE3A | Height |
| rs11611208 | Crystal arthropathies | 0.002217 | 1.832 | PDE3A | Height |
| rs11611208 | Hyperbilirubinemia | 0.0003887 | 2.981 | PDE3A | Height |
| rs11611647 | Heart failure | 0.008316 | 1.139 | CCND2 | Red blood cell count |
| rs11611647 | Valvular heart disease/ heart chambers | 0.006086 | 1.852 | CCND2 | Red blood cell count |
| rs11611647 | Heart failure NOS | 0.002478 | 1.379 | CCND2 | Red blood cell count |
| rs11611647 | Peripheral angiopathy in diseases classified elsewhere | 0.003684 | 1.735 | CCND2 | Red blood cell count |
| rs11611647 | Disorders of the autonomic nervous system | 0.008605 | 1.346 | CCND2 | Red blood cell count |
| rs11611647 | Cellulitis and abscess of face | 0.005084 | 1.43 | CCND2 | Red blood cell count |
| rs11611647 | Hemangioma and lymphangioma, any site | 0.00937 | 1.321 | CCND2 | Red blood cell count |
| rs11611647 | Hypertensive heart and/or renal disease | 0.005872 | 1.211 | CCND2 | Red blood cell count |
| rs11611647 | Hypertensive heart disease | 0.001578 | 1.443 | CCND2 | Red blood cell count |
| rs11611647 | Symptoms involving head and neck | 0.001212 | 0.7596 | CCND2 | Red blood cell count |
| rs11611647 | Respiratory insufficiency | 0.008043 | 1.328 | CCND2 | Red blood cell count |
| rs11611647 | Speech and language disorder | 0.002299 | 0.5707 | CCND2 | Red blood cell count |
| rs11611647 | Scoliosis | 0.001897 | 1.407 | CCND2 | Red blood cell count |
| rs11611647 | Idiopathic fibrosing alveolitis | 0.007807 | 0.3479 | CCND2 | Red blood cell count |
| rs11611647 | Appendiceal conditions | 0.005631 | 1.46 | CCND2 | Red blood cell count |
| rs11611647 | Vascular dementia | 0.005198 | 0.633 | CCND2 | Red blood cell count |
| rs11618202 | Retinal drusen | 0.001845 | 0.6177 | HMGB1 | Total hippocampal volume |
| rs11618202 | Obstructive sleep apnea | 0.002774 | 0.7365 | HMGB1 | Total hippocampal volume |
| rs11618202 | Retinal disorders | 0.005932 | 0.8205 | HMGB1 | Total hippocampal volume |
| rs11618202 | Behcet's syndrome | 0.003406 | 0.2211 | HMGB1 | Total hippocampal volume |
| rs11618202 | Known or suspected fetal abnormality | 0.003132 | 2.195 | HMGB1 | Total hippocampal volume |
| rs11618202 | ASCVD | 0.007269 | 1.638 | HMGB1 | Total hippocampal volume |
| rs11618202 | Sleep apnea | 0.009383 | 0.8135 | HMGB1 | Total hippocampal volume |
| rs11618202 | Ischemic stroke | 0.01077 | 1.329 | HMGB1 | Total hippocampal volume |
| rs11618202 | Stomach cancer | 0.002228 | 2.266 | HMGB1 | Total hippocampal volume |
| rs11618202 | Retinal detachments and defects | 0.005345 | 0.655 | HMGB1 | Total hippocampal volume |
| rs11618202 | Osteoporosis, NOS or other | 0.008108 | 0.8019 | HMGB1 | Total hippocampal volume |
| rs11618202 | Abnormal results of function study of liver | 0.008103 | 1.362 | HMGB1 | Total hippocampal volume |
| rs11618202 | Polyneuropathy in diabetes | 0.005772 | 0.6801 | HMGB1 | Total hippocampal volume |
| rs11712165 | Congenital musculoskeletal deformities of spine | 0.01151 | 1.382 | ARHGAP31 | Celiac disease |
| rs11712165 | Fracture of lower limb | 0.0003032 | 0.828 | ARHGAP31 | Celiac disease |
| rs11712165 | Circumscribed scleroderma | 0.009882 | 1.375 | ARHGAP31 | Celiac disease |
| rs11712165 | Other disorders of peritoneum | 0.002462 | 0.6391 | ARHGAP31 | Celiac disease |
| rs11712165 | Peritoneal adhesions (postoperative) (postinfection) | 0.003249 | 0.5873 | ARHGAP31 | Celiac disease |
| rs11712165 | Fracture of pelvis | 0.000101 | 0.6369 | ARHGAP31 | Celiac disease |
| rs11712165 | Symptoms involving female genital tract | 0.009056 | 1.348 | ARHGAP31 | Celiac disease |
| rs11712165 | Eating disorder | 0.009309 | 1.597 | ARHGAP31 | Celiac disease |
| rs11712165 | Hemorrhage of gastrointestinal tract | 0.006153 | 0.8472 | ARHGAP31 | Celiac disease |
| rs11712165 | Osteoporosis, NOS or other | 0.001438 | 0.8658 | ARHGAP31 | Celiac disease |
| rs11712165 | Fracture of neck of femur | 0.000121 | 0.7587 | ARHGAP31 | Celiac disease |
| rs11712165 | Osteoporosis, osteopenia, & pathological fractures | 0.000694 | 0.8878 | ARHGAP31 | Celiac disease |
| rs11712165 | Anemia in neoplastic disease | 0.004922 | 0.6816 | ARHGAP31 | Celiac disease |
| rs11712165 | Lymphadenitis | 0.004048 | 0.8339 | ARHGAP31 | Celiac disease |
| rs11712165 | Pathologic fracture | 0.009386 | 0.8339 | ARHGAP31 | Celiac disease |
| rs11712165 | Osteoporosis | 0.004118 | 0.8754 | ARHGAP31 | Celiac disease |
| rs11712165 | Osteopenia | 0.003682 | 0.8783 | ARHGAP31 | Celiac disease |
| rs11712165 | Anemia of chronic disease | 0.005743 | 0.8231 | ARHGAP31 | Celiac disease |
| rs11712165 | Pseudoexfoliation glaucoma | 0.009795 | 0.626 | ARHGAP31 | Celiac disease |
| rs11712165 | Peptic ulcer | 0.004238 | 0.8467 | ARHGAP31 | Celiac disease |
| rs11712165 | Tuberculosis | 0.009822 | 0.4881 | ARHGAP31 | Celiac disease |
| rs11712165 | Other diseases of respiratory system | 0.007998 | 0.7178 | ARHGAP31 | Celiac disease |
| rs11712165 | Other disorders of the nervous system | 0.01042 | 0.6439 | ARHGAP31 | Celiac disease |
| rs1175000 | Hypersomnia | 0.002763 | 0.6449 | CDCA7L | Height |
| rs1175000 | Morbid obesity | 0.01016 | 0.8646 | CDCA7L | Height |
| rs1175000 | Emphysema | 0.006171 | 0.7839 | CDCA7L | Height |
| rs1175000 | Iatrogenic hypothyroidism | 0.01066 | 1.31 | CDCA7L | Height |
| rs1175000 | Otorrhea | 0.006267 | 1.975 | CDCA7L | Height |
| rs1175000 | Neutropenia | 0.00175 | 1.269 | CDCA7L | Height |
| rs1175000 | Complication of amputation stump | 0.00785 | 1.869 | CDCA7L | Height |
| rs1175000 | Toxic effect of venom | 0.008116 | 0.6608 | CDCA7L | Height |
| rs1175000 | Viral warts & HPV | 0.01008 | 0.873 | CDCA7L | Height |
| rs1175000 | Reticulosarcoma | 0.003111 | 1.726 | CDCA7L | Height |
| rs1175000 | Decreased white blood cell count | 0.004679 | 1.229 | CDCA7L | Height |
| rs1175000 | Chronic lymphocytic thyroiditis | 0.006552 | 1.435 | CDCA7L | Height |
| rs1175000 | Amblyopia | 0.008942 | 0.7499 | CDCA7L | Height |
| rs1175000 | Abnormal pulmonary function | 0.007247 | 0.4196 | CDCA7L | Height |
| rs11754661 | Scoliosis | 0.009273 | 1.517 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Fracture of foot | 0.001923 | 1.442 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Other disorders of the nervous system | 0.007072 | 1.887 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Anisometropia | 0.008866 | 1.532 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Anorexia | 0.01136 | 0.4401 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Heart transplant/surgery | 0.01028 | 0.3705 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Infertility, female | 0.007205 | 2.508 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Type 2 diabetic ketoacidosis | 0.001195 | 1.315 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Postinflammatory pulmonary fibrosis | 0.003798 | 1.506 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Other disorders of bone and cartilage | 0.007881 | 1.386 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Other specified disorders of liver | 0.009361 | 1.55 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Other specified diseases of hair and hair follicles | 0.001336 | 1.68 | MTHFD1L | Alzheimer's disease |
| rs11754661 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.006136 | 2.853 | MTHFD1L | Alzheimer's disease |
| rs11775334 | Chronic liver disease and cirrhosis | 0.00206 | 0.7761 | MSRA | Hypertension |
| rs11775334 | Hypertensive chronic kidney disease | 0.001433 | 1.242 | MSRA | Hypertension |
| rs11775334 | Type 2 diabetic retinopathy | 0.008601 | 1.198 | MSRA | Hypertension |
| rs11775334 | Pulmonary congestion and hypostasis | 0.001747 | 1.428 | MSRA | Hypertension |
| rs11775334 | Bronchitis | 0.000511 | 0.8377 | MSRA | Hypertension |
| rs11775334 | Congenital deformities of feet | 0.006343 | 0.7382 | MSRA | Hypertension |
| rs11775334 | Anemia of chronic disease | 0.001522 | 1.245 | MSRA | Hypertension |
| rs11775334 | Other open wound of head and face | 0.001515 | 0.7852 | MSRA | Hypertension |
| rs11775334 | Disorders resulting from impaired renal function | 0.006547 | 1.296 | MSRA | Hypertension |
| rs11775334 | Primary pulmonary hypertension | 0.003616 | 1.616 | MSRA | Hypertension |
| rs11775334 | Hypertension | 0.002738 | 1.099 | MSRA | Hypertension |
| rs11775334 | Nephritis and nephropathy in diseases classified elsewhere | 0.01037 | 1.268 | MSRA | Hypertension |
| rs11775334 | Extrapyramidal disease and abnormal movement disorders | 0.003167 | 1.204 | MSRA | Hypertension |
| rs11775334 | Dyspareunia | 0.007913 | 0.5861 | MSRA | Hypertension |
| rs11775334 | Cancer of the digestive organs and peritoneum | 0.009815 | 1.44 | MSRA | Hypertension |
| rs11775334 | Chronic nonalcoholic liver disease | 0.005054 | 0.7841 | MSRA | Hypertension |
| rs11775334 | Pain in limb | 0.004952 | 1.096 | MSRA | Hypertension |
| rs11775334 | Anemia in chronic kidney disease | 0.008989 | 1.297 | MSRA | Hypertension |
| rs11775334 | Congenital anomalies of limbs | 0.005219 | 0.7622 | MSRA | Hypertension |
| rs11775334 | Alkalosis | 0.007192 | 1.792 | MSRA | Hypertension |
| rs11775334 | Type 2 diabetic nephropathy | 0.01123 | 1.203 | MSRA | Hypertension |
| rs11775334 | Thoracic neuritis/radiculitis | 0.01092 | 1.112 | MSRA | Hypertension |
| rs11775334 | Hypertensive heart and/or renal disease | 0.005267 | 1.185 | MSRA | Hypertension |
| rs11775334 | Essential hypertension | 0.003089 | 1.097 | MSRA | Hypertension |
| rs11775334 | Malunion fracture | 0.005261 | 1.441 | MSRA | Hypertension |
| rs11842874 | Cardiomyopathy | 0.002331 | 1.381 | MCF2L | Osteoarthritis |
| rs11842874 | Disturbances of amino-acid transport | 0.009627 | 2.219 | MCF2L | Osteoarthritis |
| rs11842874 | Nonallopathic lesions NEC | 0.008629 | 0.7928 | MCF2L | Osteoarthritis |
| rs11842874 | Hyperosmolality and/or hypernatremia | 0.006622 | 1.796 | MCF2L | Osteoarthritis |
| rs11842874 | Anomalies of pupillary function | 0.006922 | 2.39 | MCF2L | Osteoarthritis |
| rs11842874 | Primary/intrinsic cardiomyopathies | 0.005869 | 1.353 | MCF2L | Osteoarthritis |
| rs11842874 | Other disorders of back | 0.009436 | 0.75 | MCF2L | Osteoarthritis |
| rs11842874 | Systolic/diastolic heart failure | 0.006287 | 1.236 | MCF2L | Osteoarthritis |
| rs11842874 | Disturbances of sulphur-bearing amino-acid metabolism | 0.00755 | 2.281 | MCF2L | Osteoarthritis |
| rs11856323 | Ascites (non malignant) | 0.001599 | 1.736 | CORO2B | Cognitive performance |
| rs11856323 | Periostitis | 0.01067 | 2.144 | CORO2B | Cognitive performance |
| rs11856323 | Anomalies of tooth position/malocclusion | 0.006806 | 2.014 | CORO2B | Cognitive performance |
| rs11856323 | Primary open angle glaucoma | 0.004958 | 0.6422 | CORO2B | Cognitive performance |
| rs11856323 | Cholelithiasis with other cholecystitis | 0.01088 | 0.6037 | CORO2B | Cognitive performance |
| rs11856323 | Eosinophilia | 0.001146 | 2.438 | CORO2B | Cognitive performance |
| rs11856323 | Suppurative and unspecified otitis media | 0.002542 | 1.324 | CORO2B | Cognitive performance |
| rs11856323 | Abnormal sputum | 0.005807 | 1.522 | CORO2B | Cognitive performance |
| rs11856323 | Fever of unknown origin | 0.002796 | 1.214 | CORO2B | Cognitive performance |
| rs11856323 | Chronic sinusitis | 0.01143 | 1.196 | CORO2B | Cognitive performance |
| rs11856323 | Kyphosis (acquired) | 0.001225 | 1.87 | CORO2B | Cognitive performance |
| rs11856323 | Diseases of lips | 0.000973 | 1.927 | CORO2B | Cognitive performance |
| rs11856323 | Peripheral angiopathy in diseases classified elsewhere | 0.006636 | 1.938 | CORO2B | Cognitive performance |
| rs11856323 | Chronic pharyngitis and nasopharyngitis | 0.009534 | 1.272 | CORO2B | Cognitive performance |
| rs11880198 | Open wound of nose and sinus | 0.004353 | 2.163 | GNA15 | Heart failure |
| rs11880198 | Corneal dystrophy | 0.0009915 | 1.444 | GNA15 | Heart failure |
| rs11880198 | Colles' fracture | 0.0008353 | 1.564 | GNA15 | Heart failure |
| rs11880198 | Labyrinthitis | 0.002643 | 1.478 | GNA15 | Heart failure |
| rs11880198 | Inflammatory and toxic neuropathy | 0.002526 | 1.468 | GNA15 | Heart failure |
| rs11880198 | Diseases of pulp and periapical tissues | 0.003206 | 1.27 | GNA15 | Heart failure |
| rs11880198 | Fracture of radius and ulna | 0.003297 | 1.245 | GNA15 | Heart failure |
| rs11880198 | Open wound of hand except finger(s) | 0.005541 | 1.349 | GNA15 | Heart failure |
| rs11880198 | Periapical abscess | 0.00195 | 1.298 | GNA15 | Heart failure |
| rs11880198 | Cramp of limb | 0.003678 | 1.393 | GNA15 | Heart failure |
| rs11880198 | Dystrophy of female genital tract | 0.003401 | 2.135 | GNA15 | Heart failure |
| rs11880198 | Fracture of upper limb | 0.006086 | 1.184 | GNA15 | Heart failure |
| rs11880198 | Frequency of urination and polyuria | 0.009332 | 1.153 | GNA15 | Heart failure |
| rs11880198 | Breast conditions, congenital or relating to hormones | 0.009122 | 1.373 | GNA15 | Heart failure |
| rs11880198 | Pityriasis | 0.001354 | 2.546 | GNA15 | Heart failure |
| rs11898505 | Psoriatic arthropathy | 0.00486 | 1.864 | SPTBN1 | Bone mineral density |
| rs11898505 | Fracture of humerus | 0.000363 | 0.7225 | SPTBN1 | Bone mineral density |
| rs11898505 | Psoriasis & related disorders | 0.01091 | 1.221 | SPTBN1 | Bone mineral density |
| rs11898505 | Dysmetabolic syndrome X | 0.002398 | 1.514 | SPTBN1 | Bone mineral density |
| rs11898505 | Symptoms involving female genital tract | 0.01117 | 0.7264 | SPTBN1 | Bone mineral density |
| rs11898505 | Diseases of lips | 0.004964 | 1.504 | SPTBN1 | Bone mineral density |
| rs11898505 | Scoliosis | 0.01037 | 1.291 | SPTBN1 | Bone mineral density |
| rs11898505 | Depression | 0.0008858 | 0.8861 | SPTBN1 | Bone mineral density |
| rs11898505 | Corneal opacity | 0.01127 | 1.333 | SPTBN1 | Bone mineral density |
| rs11898505 | Mood disorders | 0.0007651 | 0.8872 | SPTBN1 | Bone mineral density |
| rs11898505 | Hemangioma and lymphangioma, any site | 0.001044 | 0.7121 | SPTBN1 | Bone mineral density |
| rs11898505 | Keratoderma, acquired | 0.0008561 | 1.211 | SPTBN1 | Bone mineral density |
| rs11898505 | Pelvic inflammatory disease | 0.01103 | 0.4828 | SPTBN1 | Bone mineral density |
| rs11957313 | Swelling of limb | 0.01097 | 1.214 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Other diseases of the teeth and supporting structures | 0.00246 | 1.376 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Arthropathy associated with infections | 0.006998 | 1.696 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Partial epilepsy | 0.009134 | 1.513 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Type 2 diabetic nephropathy | 0.0115 | 0.7568 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Infertility, male | 0.006035 | 2.17 | KCNIP1 | Multiple sclerosis |
| rs11957313 | CNS infection and poliomyelitis | 0.00412 | 0.2986 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Diseases of pancreas | 0.004549 | 0.729 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Male infertility and abnormal spermatozoa | 0.006109 | 1.906 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Arthralgia/ankylosis of temporomandibular joint | 0.004389 | 1.775 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Precordial pain | 0.008596 | 1.404 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Congenital anomalies of genital organs | 0.007002 | 2.138 | KCNIP1 | Multiple sclerosis |
| rs11957313 | Neurological disorders due to brain damage | 0.005224 | 1.19 | KCNIP1 | Multiple sclerosis |
| rs11984075 | Other hypertrophic and atrophic conditions of skin | 0.007194 | 1.182 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Spondylosis with myelopathy | 0.009788 | 1.519 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Arthropathy NOS involving multiple sites | 0.008244 | 1.837 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Major depressive disorder | 0.008689 | 1.245 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Asthma with exacerbation | 0.00311 | 1.616 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Iron metabolism disorder | 0.001663 | 2.395 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Pituitary hyperfunction | 0.00278 | 2.626 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Benign neoplasm of breast | 0.009804 | 1.776 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Toxic effect of venom | 0.00988 | 1.706 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Depression | 0.009294 | 1.153 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Bundle branch block | 0.002533 | 1.366 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Impaction of intestine | 0.01041 | 2.323 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Parkinson's disease | 0.001387 | 0.5448 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Glomerulonephritis | 0.0003997 | 2.249 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Chronic prostatitis | 0.01059 | 1.756 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Secondary malignancy of brain/spine | 0.004832 | 1.912 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Elevated prostate specific antigen | 0.003694 | 1.329 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Sensorineural hearing loss | 0.002891 | 1.191 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Other disorders of metabolic, endocrine, immunity disorders | 0.002199 | 2.403 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Eustachian tube disorders | 0.0115 | 1.356 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11984075 | Benign neoplasm of other parts of digestive system | 0.002478 | 0.5318 | ELMO1 | Celiac disease or Rheumatoid arthritis |
| rs11989782 | Acute laryngitis and tracheitis | 0.004688 | 0.5991 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Cholangitis | 0.005224 | 1.784 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Other signs and symptoms in breast | 0.002866 | 0.6463 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Cardiac defibrillator in situ | 0.001252 | 0.5649 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Diverticulitis | 0.004399 | 1.261 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Symptoms involving head and neck | 0.01122 | 0.8214 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Osteoporosis, NOS or other | 0.006812 | 0.8694 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Upper gastrointestinal congenital anomalies | 0.005521 | 1.607 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Esophageal atresia/tracheoesophageal fistula | 0.006192 | 1.738 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Restless legs syndrome | 0.005569 | 0.7243 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Atrophy of edentulous alveolar ridge | 0.006333 | 1.526 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Amblyopia | 0.001651 | 1.444 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Osteoporosis | 0.008491 | 0.8698 | SNTB1 | Eosinophilic esophagitis |
| rs11989782 | Other alveolar and parietoalveolar pneumonopathy | 0.003789 | 1.727 | SNTB1 | Eosinophilic esophagitis |
| rs1202199 | Other cerebral degenerations | 0.008161 | 0.4392 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Vascular disorders of penis | 0.002695 | 3.094 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Congenital anomalies of genital organs | 0.01111 | 2.218 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Facial nerve disorders | 0.002898 | 1.686 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Cancer of other lymphoid, histiocytic tissue | 0.009393 | 1.41 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Viral hepatitis | 0.008388 | 1.434 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs1202199 | Hodgkin's disease | 0.007458 | 2.112 | MBOAT1 | Hyperactive-impulsive symptoms |
| rs12141391 | Blindness and low vision | 0.00875 | 1.871 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Abnormal electrocardiogram | 0.01074 | 1.469 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Ingrowing nail | 0.007017 | 1.507 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Atrial fibrillation | 0.003756 | 1.46 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Hemorrhage of rectum and anus | 0.0008837 | 1.752 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Other specified diseases of sebaceous glands | 0.004092 | 1.706 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Fracture of clavicle or scapula | 0.007142 | 2.112 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Other congenital anomalies of skin | 0.004142 | 2.279 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Osteoarthrosis NOS | 0.01083 | 1.282 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Respiratory insufficiency | 0.009869 | 0.2713 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Mechanical complication due to other implant and internal device | 0.009949 | 1.901 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Cystoid macular degeneration of retina | 0.003886 | 2.001 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Conjunctivitis, infectious | 0.005763 | 1.537 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Vitamin deficiency | 0.008013 | 0.5416 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Atrial fibrillation & flutter | 0.003216 | 1.462 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Traumatic arthropathy | 0.006235 | 2.653 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Other diseases of respiratory system | 0.001988 | 2.259 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Premature beats | 0.01079 | 1.574 | NEGR1 | Systemic lupus erythematosus |
| rs12141391 | Lung involvement in conditions classified elsewhere | 0.001438 | 4.298 | NEGR1 | Systemic lupus erythematosus |
| rs12203592 | Actinic keratosis | 4.141e-26 | 1.691 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Benign neoplasm of eye | 1.734e-05 | 1.544 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Skin neoplasm of uncertain behavior | 1.029e-06 | 1.487 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other dermatoses | 1.825e-10 | 1.327 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other specified diseases of sebaceous glands | 0.006917 | 1.316 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Voice disturbance | 0.004223 | 1.297 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Diseases of sebaceous glands | 0.002376 | 1.169 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Carcinoma in situ of skin | 2.068e-10 | 1.874 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other disorders of intestine | 0.009831 | 1.236 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Osteopenia | 6.837e-05 | 1.271 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Inflammation of the eye | 0.004008 | 1.172 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Frequency of urination and polyuria | 0.006087 | 1.176 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other specified erythematous conditions | 0.009986 | 1.406 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other specified nonpsychotic and/or transient mental disorders | 0.00306 | 1.354 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Neoplasm of uncertain behavior | 0.0004348 | 1.317 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Rosacea | 0.00112 | 1.312 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Mental disorders due to brain damage | 0.0007803 | 1.42 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Benign neoplasm of skin | 0.0002758 | 0.8237 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Gastrointestinal complications | 0.01093 | 1.321 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Skin cancer | 1.106e-16 | 1.457 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Celiac disease | 0.008204 | 0.2596 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Sebaceous cyst | 0.008181 | 1.18 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Disorders of the autonomic nervous system | 0.00642 | 0.6435 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Photodermatitis & sunburn | 6.352e-06 | 1.44 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Other acquired musculoskeletal deformity | 0.000281 | 1.433 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Congenital anomalies of intestine | 0.007945 | 2.302 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Brain cancer | 0.006601 | 0.4067 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Erythematous conditions | 0.002257 | 1.201 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Osteoporosis, osteopenia, & pathological fractures | 0.0001521 | 1.195 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Seborrheic keratosis | 3.296e-05 | 1.23 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Patellar fracture | 0.003461 | 0.5029 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Personal history of allergy to medicinal agents | 0.004581 | 1.392 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Celiac or tropical sprue | 0.005924 | 0.2458 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Vitamin B-complex deficiencies | 0.004681 | 1.311 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Chronic tonsillitis and adenoiditis | 0.003334 | 1.948 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Non-melanoma skin cancer | 3.818e-17 | 1.495 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Melanoma | 0.001373 | 1.425 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12203592 | Open wounds of extremities | 0.005778 | 1.167 | IRF4 | Eye color, Hair color, Freckling, Progressive supranuclear palsy |
| rs12210050 | Skin cancer | 1.156e-09 | 1.315 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Disorders of mineral metabolism | 0.004047 | 1.2 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Lipoid metabolism disorder NOS | 0.009263 | 1.349 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Voice disturbance | 0.008658 | 1.26 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Hypercalcemia | 0.0007001 | 1.419 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Carcinoma in situ of skin | 3.348e-08 | 1.713 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Actinic keratosis | 1.937e-08 | 1.318 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Osteoporosis, osteopenia, & pathological fractures | 0.008136 | 1.129 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Failure to thrive | 0.002362 | 1.554 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Non-melanoma skin cancer | 5.952e-09 | 1.318 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Rosacea | 0.002618 | 1.274 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Osteopenia | 0.0001865 | 1.242 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Diseases of the larynx and vocal cords | 0.004636 | 1.243 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Other symptoms referable to back | 0.003584 | 0.6891 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Chronic obstructive asthma | 0.01089 | 1.339 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Herpes simplex | 0.004098 | 1.41 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | H. pylori | 0.00491 | 1.655 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Open wound of nose and sinus | 0.008493 | 2.11 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Neoplasm of uncertain behavior | 0.003933 | 1.252 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Melanoma | 0.00025 | 1.475 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Lack of normal physiological development | 0.009643 | 1.424 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Other dermatoses | 0.0003925 | 1.168 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Skin neoplasm of uncertain behavior | 0.0008494 | 1.322 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Photodermatitis & sunburn | 0.01142 | 1.218 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Benign neoplasm of skin | 0.001212 | 0.8476 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Viral warts & HPV | 0.0005464 | 1.264 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Seborheic dermatitis | 0.003478 | 1.262 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12210050 | Allergy/adverse effect of penicillin | 0.006033 | 1.305 | EXOC2 | Basal cell carcinoma, Tanning |
| rs12212193 | Aneurysm of artery of lower extremity | 0.007234 | 1.53 | BACH2 | Multiple sclerosis |
| rs12212193 | Anemia NOS | 0.002672 | 1.103 | BACH2 | Multiple sclerosis |
| rs12212193 | Hypertrophy of female genital organs | 0.01099 | 0.5868 | BACH2 | Multiple sclerosis |
| rs12212193 | Otorrhea | 0.009137 | 0.5016 | BACH2 | Multiple sclerosis |
| rs12212193 | Cramp of limb | 0.009361 | 0.7685 | BACH2 | Multiple sclerosis |
| rs12212193 | Complications of transplants and reattached limbs | 0.006691 | 0.614 | BACH2 | Multiple sclerosis |
| rs12212193 | Tuberculosis | 0.008879 | 0.5053 | BACH2 | Multiple sclerosis |
| rs12212193 | Hypothyroidism | 0.002722 | 1.113 | BACH2 | Multiple sclerosis |
| rs12212193 | Other anemias | 0.005751 | 1.088 | BACH2 | Multiple sclerosis |
| rs12212193 | Gouty arthropathy | 0.002098 | 1.346 | BACH2 | Multiple sclerosis |
| rs12212193 | Nonrheumatic pulmonary valve disorders | 0.003177 | 0.5785 | BACH2 | Multiple sclerosis |
| rs12251307 | Dyshidrosis | 0.0001473 | 2.257 | IL2RA | Type 1 diabetes |
| rs12251307 | Acute laryngitis and tracheitis | 0.003309 | 1.752 | IL2RA | Type 1 diabetes |
| rs12251307 | Atopic or contact dermatitis | 1.436e-05 | 1.265 | IL2RA | Type 1 diabetes |
| rs12251307 | Congenital anomalies of genital organs | 0.008604 | 2.148 | IL2RA | Type 1 diabetes |
| rs12251307 | Influenza | 0.002002 | 1.542 | IL2RA | Type 1 diabetes |
| rs12251307 | Diverticulosis and diverticulitis | 0.003525 | 1.189 | IL2RA | Type 1 diabetes |
| rs12251307 | Other disorders of soft tissues | 0.007441 | 1.572 | IL2RA | Type 1 diabetes |
| rs12251307 | Diverticulosis | 0.00821 | 1.181 | IL2RA | Type 1 diabetes |
| rs12251307 | Peritonitis and retroperitoneal infections | 0.009657 | 1.543 | IL2RA | Type 1 diabetes |
| rs12251307 | Anisometropia | 0.0005892 | 0.5047 | IL2RA | Type 1 diabetes |
| rs12251307 | Seborheic dermatitis | 0.006841 | 1.278 | IL2RA | Type 1 diabetes |
| rs12279261 | Hydronephrosis | 0.006255 | 1.412 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Cancer of oropharynx | 0.004983 | 2.205 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Symptoms involving respiratory system | 0.007122 | 0.7624 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Polyarteritis nodosa and allied conditions | 0.0029 | 1.466 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Osteoarthrosis, generalized | 0.0009477 | 0.7169 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Disorders of fluid, electrolyte, and acid-base balance | 0.004491 | 0.8881 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Ileostomy status | 0.009083 | 1.671 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Oliguria and anuria | 0.008738 | 2.234 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Giant cell arteritis | 0.002178 | 1.712 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Polycystic ovaries | 0.009025 | 2.133 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Stricture/obstruction of ureter | 0.002027 | 1.649 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Renal colic | 0.001031 | 1.958 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Hypovolemia | 0.01132 | 0.861 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Benign neoplasm of unspecified sites | 0.008078 | 2.152 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Cervical cancer and dysplasia | 0.003715 | 1.402 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Peritoneal or intestinal adhesions | 0.00199 | 1.841 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Abnormal findings on study of brain, nervous system | 0.009693 | 0.5068 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Pituitary hyperfunction | 0.0006351 | 2.621 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Benign neoplasm of colon | 0.0004711 | 1.162 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Diseases of spleen | 0.001776 | 2.119 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Abnormal tumor markers, elevated CEA or CA 125 | 0.0006471 | 2.543 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Nerve plexus lesions | 0.006389 | 1.53 | NCAM1 | Entorhinal cortical thickness |
| rs12279261 | Abnormal cytological, histological, immunological and DNA test findings | 0.002668 | 2.029 | NCAM1 | Entorhinal cortical thickness |
| rs12295638 | Lesions of stomach and duodenum | 0.008739 | 2.233 | ANO3 | Extreme obesity |
| rs12295638 | Cystitis | 0.005688 | 1.363 | ANO3 | Extreme obesity |
| rs12295638 | Acquired foot deformities | 0.004183 | 0.8129 | ANO3 | Extreme obesity |
| rs12295638 | Pituitary hypofunction | 0.0106 | 2.084 | ANO3 | Extreme obesity |
| rs12295638 | Atrophic gastritis | 0.008329 | 1.683 | ANO3 | Extreme obesity |
| rs12295638 | Skin neoplasm of uncertain behavior | 0.004805 | 0.6878 | ANO3 | Extreme obesity |
| rs12295638 | Acquired deformities of ankle and foot | 0.009301 | 0.6965 | ANO3 | Extreme obesity |
| rs12295638 | Cystitis and urethritis | 0.005881 | 1.337 | ANO3 | Extreme obesity |
| rs12295638 | E. coli | 0.0005413 | 1.653 | ANO3 | Extreme obesity |
| rs12295638 | Schizophrenia and other psychotic disorders | 0.009516 | 1.298 | ANO3 | Extreme obesity |
| rs12295638 | Cornea replaced by transplant | 0.0006231 | 2.47 | ANO3 | Extreme obesity |
| rs12295638 | Male genital disorders | 0.001627 | 0.5315 | ANO3 | Extreme obesity |
| rs12295638 | Infections of kidney | 0.0004113 | 1.693 | ANO3 | Extreme obesity |
| rs12413409 | Inflammatory spondylopathies | 0.00197 | 1.905 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Nontoxic uninodular goiter | 0.009767 | 1.363 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Hemorrhage from gastrointestinal ulcer | 0.008573 | 0.48 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Hemangioma and lymphangioma, any site | 0.003919 | 1.504 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Other specified osteoporosis | 0.003042 | 2.101 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Hypotony of eye | 0.005063 | 2.643 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Strabismus (not specified as paralytic) | 0.004401 | 0.6331 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Acute pericarditis | 0.0008842 | 2.895 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Calculus of bile duct | 0.01014 | 1.526 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Arthropathy associated with infections | 0.0015 | 2.016 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Fluid overload | 0.00605 | 1.449 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Blood vessel replaced | 0.01049 | 0.2711 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Cardiomyopathy | 0.0102 | 0.733 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Aplastic anemia | 0.003108 | 1.621 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Cholelithiasis | 0.002114 | 1.266 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Other abnormal blood chemistry | 0.01019 | 1.193 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Fracture of vertebral column without mention of spinal cord injury | 0.001373 | 1.443 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Cholelithiasis and cholecystitis | 0.00924 | 1.209 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Aneurysm of iliac artery | 0.002835 | 2.207 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12413409 | Alopecia | 0.01009 | 1.484 | CNNM2 | Intracranial aneurysm, Coronary heart disease |
| rs12418204 | Fracture of clavicle or scapula | 0.008135 | 1.774 | PDE2A | Optic disc parameters |
| rs12418204 | Nephritis & nephropathy | 0.001678 | 2.413 | PDE2A | Optic disc parameters |
| rs12418204 | Psychogenic and somatoform disorders | 0.008863 | 1.527 | PDE2A | Optic disc parameters |
| rs12418204 | Chronic glomerulonephritis | 0.001699 | 3.494 | PDE2A | Optic disc parameters |
| rs12418204 | Disorders resulting from impaired renal function | 0.00748 | 1.603 | PDE2A | Optic disc parameters |
| rs12418204 | Lower gastrointestinal congenital anomalies | 0.009735 | 2.416 | PDE2A | Optic disc parameters |
| rs12418204 | Osteoarthritis; localized | 0.01063 | 0.7795 | PDE2A | Optic disc parameters |
| rs12418204 | Thrombocytopenia | 0.006571 | 0.6556 | PDE2A | Optic disc parameters |
| rs12418204 | Osteomyelitis | 0.008532 | 1.574 | PDE2A | Optic disc parameters |
| rs12418204 | Osteoarthrosis, generalized | 0.003289 | 0.59 | PDE2A | Optic disc parameters |
| rs12418204 | Anomalies of tooth position/malocclusion | 0.0078 | 2.233 | PDE2A | Optic disc parameters |
| rs12418204 | Dentofacial anomalies, including malocclusion | 0.009606 | 2.011 | PDE2A | Optic disc parameters |
| rs12420464 | Anisometropia | 0.001737 | 1.631 | EIF3F | Depression |
| rs12420464 | Stiffness of joint | 0.007638 | 1.356 | EIF3F | Depression |
| rs12420464 | Congenital anomalies of face and neck | 0.001321 | 3.241 | EIF3F | Depression |
| rs12420464 | Other disorders of adrenal glands | 0.01095 | 1.803 | EIF3F | Depression |
| rs12420464 | Diverticulosis and diverticulitis | 0.008156 | 1.204 | EIF3F | Depression |
| rs12420464 | Eye infection, viral | 0.002174 | 1.778 | EIF3F | Depression |
| rs12423712 | Urinary obstruction | 0.00296 | 1.791 | NCOR2 | Cognitive performance |
| rs12423712 | Encounter for long-term use of antiplatelets/antithrombotics | 0.008917 | 2.719 | NCOR2 | Cognitive performance |
| rs12423712 | Mitral valve stenosis and/or aortic valve stenosis | 0.003523 | 0.5954 | NCOR2 | Cognitive performance |
| rs12423712 | Partial epilepsy | 0.009608 | 1.689 | NCOR2 | Cognitive performance |
| rs12423712 | Secondary malignant neoplasm of digestive systems | 0.008113 | 0.2135 | NCOR2 | Cognitive performance |
| rs12423712 | Large cell lymphoma | 0.002815 | 2.635 | NCOR2 | Cognitive performance |
| rs12423712 | Seborheic dermatitis | 0.01073 | 0.6978 | NCOR2 | Cognitive performance |
| rs12423712 | Trigeminal nerve disorders | 0.00138 | 1.93 | NCOR2 | Cognitive performance |
| rs12423712 | Congenital cataract and lens anomalies | 7.535e-05 | 3.263 | NCOR2 | Cognitive performance |
| rs12423712 | Epilepsy | 0.003954 | 1.663 | NCOR2 | Cognitive performance |
| rs12423712 | Hallux valgus (Bunion) | 0.008342 | 1.345 | NCOR2 | Cognitive performance |
| rs12423712 | Inflammatory and toxic neuropathy | 0.005593 | 1.653 | NCOR2 | Cognitive performance |
| rs12423712 | Open wound of hand except finger(s) | 0.01151 | 1.474 | NCOR2 | Cognitive performance |
| rs12423712 | Essential hypertension | 0.006833 | 0.8573 | NCOR2 | Cognitive performance |
| rs12423712 | Hypertension | 0.005088 | 0.8528 | NCOR2 | Cognitive performance |
| rs12423712 | Multiple sclerosis | 0.01115 | 1.834 | NCOR2 | Cognitive performance |
| rs12423712 | Stiffness of joint | 0.009931 | 1.348 | NCOR2 | Cognitive performance |
| rs12423712 | Subarachnoid hemorrhage | 0.0004281 | 2.98 | NCOR2 | Cognitive performance |
| rs12447690 | Chondrocalcinosis | 0.004989 | 0.7045 | ZNF469 | Central corneal thickness |
| rs12447690 | Crystal arthropathies | 0.005734 | 0.7118 | ZNF469 | Central corneal thickness |
| rs12447690 | Calcium/phosphorus disorders | 0.002786 | 0.8092 | ZNF469 | Central corneal thickness |
| rs12447690 | Abnormal function study of cardiovascular system | 0.002618 | 0.8266 | ZNF469 | Central corneal thickness |
| rs12447690 | Umbilical hernia | 0.001563 | 1.328 | ZNF469 | Central corneal thickness |
| rs12447690 | Excessive or frequent menstruation | 0.01111 | 0.7709 | ZNF469 | Central corneal thickness |
| rs12447690 | Other specified osteoporosis | 0.00313 | 0.5343 | ZNF469 | Central corneal thickness |
| rs12447690 | Disorders of choroid | 0.001068 | 0.7124 | ZNF469 | Central corneal thickness |
| rs12447690 | Premenstrual tension syndromes | 0.005189 | 0.528 | ZNF469 | Central corneal thickness |
| rs12447690 | Adverse effects of hormones and synthetic substitutes | 0.008422 | 0.3764 | ZNF469 | Central corneal thickness |
| rs12447690 | Macular degeneration, wet | 0.004178 | 0.7261 | ZNF469 | Central corneal thickness |
| rs12447690 | Glossitis | 0.01143 | 0.467 | ZNF469 | Central corneal thickness |
| rs12483205 | Peripheral or central vertigo | 0.005088 | 1.242 | DYRK1A | HIV-1 progression |
| rs12483205 | Abnormal findings on examination of urine | 0.009419 | 0.8329 | DYRK1A | HIV-1 progression |
| rs12483205 | Intestinal malabsorption | 0.003505 | 1.442 | DYRK1A | HIV-1 progression |
| rs12483205 | Retinal detachments and defects | 0.007271 | 1.25 | DYRK1A | HIV-1 progression |
| rs12483205 | Primary/intrinsic cardiomyopathies | 0.001924 | 0.7821 | DYRK1A | HIV-1 progression |
| rs12483205 | Cardiomyopathy | 0.00469 | 0.8058 | DYRK1A | HIV-1 progression |
| rs12483205 | Chronic pain syndrome | 0.00714 | 0.4749 | DYRK1A | HIV-1 progression |
| rs12483205 | Other nonspecific findings on examination of urine | 0.001201 | 0.767 | DYRK1A | HIV-1 progression |
| rs12483205 | Symptoms involving female genital tract | 0.002263 | 1.472 | DYRK1A | HIV-1 progression |
| rs12483205 | Acute cystitis | 0.008367 | 0.658 | DYRK1A | HIV-1 progression |
| rs12483205 | Respiratory failure; insufficiency; arrest | 0.003464 | 0.7923 | DYRK1A | HIV-1 progression |
| rs12483205 | Infertility, male | 0.005105 | 2.003 | DYRK1A | HIV-1 progression |
| rs12483205 | Congenital musculoskeletal deformities of spine | 0.005595 | 0.6183 | DYRK1A | HIV-1 progression |
| rs12483205 | Retinal vascular changes and abnomalities | 0.005329 | 0.7738 | DYRK1A | HIV-1 progression |
| rs12483205 | Celiac disease | 0.007278 | 1.798 | DYRK1A | HIV-1 progression |
| rs12483205 | Psoriasis vulgaris | 0.008541 | 1.275 | DYRK1A | HIV-1 progression |
| rs12483205 | Viral warts & HPV | 0.00817 | 1.171 | DYRK1A | HIV-1 progression |
| rs12483205 | Lymphadenitis | 0.005321 | 1.209 | DYRK1A | HIV-1 progression |
| rs12483205 | Memory loss | 0.00858 | 1.254 | DYRK1A | HIV-1 progression |
| rs12531488 | Calculus of kidney | 0.002383 | 1.209 | LOC643308 | Grey matter density |
| rs12531488 | Bundle branch block | 0.007678 | 0.8169 | LOC643308 | Grey matter density |
| rs12531488 | Somatoform disorder | 0.003426 | 1.39 | LOC643308 | Grey matter density |
| rs12531488 | Angina pectoris | 0.009771 | 1.138 | LOC643308 | Grey matter density |
| rs12531488 | Psychogenic and somatoform disorders | 0.005336 | 1.29 | LOC643308 | Grey matter density |
| rs12531488 | Malignant neoplasm of brain and nervous system | 0.0004201 | 0.5526 | LOC643308 | Grey matter density |
| rs12531488 | Myalgia and myositis NOS | 0.0081 | 1.124 | LOC643308 | Grey matter density |
| rs12531488 | Glaucoma | 0.005099 | 1.132 | LOC643308 | Grey matter density |
| rs12531488 | Open wound of eye or eyelid | 0.00544 | 2.019 | LOC643308 | Grey matter density |
| rs12531488 | Cancer of other male genital organs | 0.004635 | 1.801 | LOC643308 | Grey matter density |
| rs12531488 | Left bundle branch block | 0.0002537 | 0.6706 | LOC643308 | Grey matter density |
| rs12531488 | Abnormal movement | 0.007148 | 0.89 | LOC643308 | Grey matter density |
| rs12531488 | Peripheral retinal degenerations | 0.004068 | 1.342 | LOC643308 | Grey matter density |
| rs12531488 | Paroxysmal ventricular tachycardia | 0.007962 | 0.7546 | LOC643308 | Grey matter density |
| rs12559632 | Thyrotoxicosis | 0.0004571 | 0.7007 | PHEX | Fetal hemoglobin |
| rs12559632 | Synoviopathy | 0.01048 | 0.7037 | PHEX | Fetal hemoglobin |
| rs12559632 | Restless legs syndrome | 0.01123 | 0.7221 | PHEX | Fetal hemoglobin |
| rs12559632 | Blood in stool | 0.01042 | 0.8347 | PHEX | Fetal hemoglobin |
| rs12559632 | Cancer of kidney and renal pelvis | 0.00169 | 1.546 | PHEX | Fetal hemoglobin |
| rs12559632 | Type 2 diabetic peripheral circulatory disorders | 0.0003294 | 1.694 | PHEX | Fetal hemoglobin |
| rs12559632 | Sleep related movement disorders | 0.005928 | 0.7368 | PHEX | Fetal hemoglobin |
| rs12559632 | Obesity | 0.00809 | 0.8938 | PHEX | Fetal hemoglobin |
| rs12559632 | Glomerulonephritis | 0.004487 | 1.922 | PHEX | Fetal hemoglobin |
| rs12559632 | Osteoarthrosis, generalized | 0.001689 | 0.75 | PHEX | Fetal hemoglobin |
| rs12559632 | Hemorrhoids | 0.001766 | 0.8509 | PHEX | Fetal hemoglobin |
| rs12559632 | Mastoiditis | 0.0019 | 2.581 | PHEX | Fetal hemoglobin |
| rs12559632 | Renal cell carcinoma | 0.002876 | 1.518 | PHEX | Fetal hemoglobin |
| rs12559632 | Magnesium metabolism disorder | 0.003173 | 1.428 | PHEX | Fetal hemoglobin |
| rs12559632 | Swelling, mass, or lump in head and neck | 0.008488 | 1.281 | PHEX | Fetal hemoglobin |
| rs12569163 | Renal colic | 0.0008711 | 1.921 | WDR64 | Radiation response |
| rs12569163 | Muscular wasting and disuse atrophy | 0.009454 | 1.636 | WDR64 | Radiation response |
| rs12569163 | Pallor and flushing | 0.009736 | 1.441 | WDR64 | Radiation response |
| rs12569163 | Throat pain | 0.0004422 | 1.924 | WDR64 | Radiation response |
| rs12569163 | Other conditions of the mother complicating pregnancy | 0.007506 | 1.72 | WDR64 | Radiation response |
| rs12569163 | Premature beats | 0.007863 | 1.212 | WDR64 | Radiation response |
| rs12569163 | Erectile dysfunction | 0.0003188 | 1.28 | WDR64 | Radiation response |
| rs12569163 | Septicemia | 0.005178 | 1.217 | WDR64 | Radiation response |
| rs12569163 | Hematemesis | 0.005168 | 1.67 | WDR64 | Radiation response |
| rs12569163 | Noninflammatory female genital disorders | 0.00537 | 0.7934 | WDR64 | Radiation response |
| rs12569163 | Thyrotoxicosis | 0.01005 | 1.258 | WDR64 | Radiation response |
| rs12569163 | Disorders of external ear | 0.004096 | 0.4272 | WDR64 | Radiation response |
| rs12569163 | Spondylosis with myelopathy | 0.008678 | 1.414 | WDR64 | Radiation response |
| rs12569163 | Esophageal atresia/tracheoesophageal fistula | 0.001356 | 1.929 | WDR64 | Radiation response |
| rs12569163 | Supraventricular premature beats | 0.007182 | 1.398 | WDR64 | Radiation response |
| rs12569163 | Other forms of chronic heart disease | 0.006201 | 1.23 | WDR64 | Radiation response |
| rs12576239 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.01087 | 1.395 | KCNQ1 | QT interval |
| rs12576239 | Gouty arthropathy | 0.001848 | 1.462 | KCNQ1 | QT interval |
| rs12576239 | Contracture of joint | 0.008848 | 0.568 | KCNQ1 | QT interval |
| rs12576239 | Poisoning by primarily systemic agents | 0.01093 | 1.384 | KCNQ1 | QT interval |
| rs12576239 | Urethral hypermobility/ISD | 0.004367 | 1.808 | KCNQ1 | QT interval |
| rs12576239 | Other symptoms referable to back | 0.009245 | 0.7197 | KCNQ1 | QT interval |
| rs12576239 | Scar conditions and fibrosis of skin | 0.002154 | 1.47 | KCNQ1 | QT interval |
| rs12576239 | Cerebral atherosclerosis | 0.00834 | 1.802 | KCNQ1 | QT interval |
| rs12576239 | Paralysis/spasm of vocal cords or larynx | 0.0006975 | 1.968 | KCNQ1 | QT interval |
| rs12576239 | Thoracic neuritis/radiculitis | 0.006734 | 0.8519 | KCNQ1 | QT interval |
| rs12608932 | Abnormal loss of weight and underweight | 0.007706 | 0.768 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Left bundle branch block | 0.009791 | 1.272 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Frequency of urination and polyuria | 0.003902 | 0.8745 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Secondary malignant neoplasm of liver | 0.008655 | 0.7115 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Adrenal hypofunction | 0.01116 | 1.577 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Stricture of artery | 0.0002466 | 1.454 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Nephritis and nephropathy in diseases classified elsewhere | 0.008629 | 0.768 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Hemangioma and lymphangioma, any site | 0.002266 | 1.338 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Malignant neoplasm of ovary | 0.002285 | 0.5005 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Tachycardia NOS | 0.007242 | 0.8311 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Althete's foot | 8.592e-05 | 0.689 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Bacteremia | 0.001054 | 0.7087 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Obsessive-compulsive disorder | 0.006559 | 0.5163 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Cancer of larynx | 0.01023 | 1.451 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Noninfectious disorders of lymphatic channels | 0.004538 | 0.7208 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Anterior pituitary disorders | 0.0007754 | 1.873 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Other disorders of arteries and arterioles | 0.0009968 | 1.323 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Abnormal movement | 0.00479 | 0.8912 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Seborheic dermatitis | 0.004393 | 0.8272 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Prurigo | 0.0107 | 0.7774 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Lymphadenitis | 0.007198 | 0.8388 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Early or threatened labor; hemorrhage in early pregnancy | 0.003086 | 1.711 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Anisometropia | 0.0101 | 0.7567 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Cancer of connective tissue | 0.00217 | 0.5115 | UNC13A | Amyotrophic lateral sclerosis |
| rs12608932 | Vascular disorders of penis | 0.008888 | 0.3858 | UNC13A | Amyotrophic lateral sclerosis |
| rs12643654 | Hemorrhage NOS | 0.002131 | 2.085 | UNC5C | Phosphorylated tau |
| rs12643654 | Nasal polyps | 0.0008247 | 1.692 | UNC5C | Phosphorylated tau |
| rs12643654 | Bronchitis | 0.004372 | 1.255 | UNC5C | Phosphorylated tau |
| rs12643654 | Lower gastrointestinal congenital anomalies | 0.01127 | 2.082 | UNC5C | Phosphorylated tau |
| rs12643654 | Acute upper respiratory infections | 0.005313 | 1.174 | UNC5C | Phosphorylated tau |
| rs12643654 | Allergic conjunctivitis | 0.002383 | 1.502 | UNC5C | Phosphorylated tau |
| rs12643654 | Urticaria | 0.001106 | 1.482 | UNC5C | Phosphorylated tau |
| rs12643654 | Spinal stenosis of lumbar region | 0.004122 | 1.251 | UNC5C | Phosphorylated tau |
| rs12643654 | Gouty arthropathy | 0.009337 | 1.46 | UNC5C | Phosphorylated tau |
| rs12643654 | Salicylates causing adverse effects in therapeutic use | 0.004916 | 2.373 | UNC5C | Phosphorylated tau |
| rs12643654 | Cataract | 0.001198 | 0.8165 | UNC5C | Phosphorylated tau |
| rs12643654 | Acute pharyngitis | 0.006391 | 1.263 | UNC5C | Phosphorylated tau |
| rs12643654 | Disorders of esophageal motility | 0.002339 | 1.792 | UNC5C | Phosphorylated tau |
| rs12643654 | Noninflammatory disorders of vulva and perineum | 0.01024 | 1.71 | UNC5C | Phosphorylated tau |
| rs12643654 | Lung cancer | 0.0006083 | 1.479 | UNC5C | Phosphorylated tau |
| rs12643654 | Cholelithiasis | 0.003701 | 0.7777 | UNC5C | Phosphorylated tau |
| rs12643654 | Cancer within the respiratory system | 0.0006836 | 1.467 | UNC5C | Phosphorylated tau |
| rs12643654 | Diseases of respiratory system | 0.0002842 | 1.358 | UNC5C | Phosphorylated tau |
| rs12643654 | Cholelithiasis and cholecystitis | 0.003861 | 0.7928 | UNC5C | Phosphorylated tau |
| rs12643654 | Symptoms involving respiratory system | 0.00116 | 1.397 | UNC5C | Phosphorylated tau |
| rs12643654 | Spontaneous ecchymoses | 0.004136 | 1.938 | UNC5C | Phosphorylated tau |
| rs12643654 | Other specified disorders of pancreatic internal secretion | 0.01095 | 1.913 | UNC5C | Phosphorylated tau |
| rs12644284 | Myeloproliferative disease | 0.007692 | 1.367 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Paralytic strabismus | 0.001182 | 1.636 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Sacroiliitis NEC | 0.01009 | 0.4696 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Cholangitis | 0.002933 | 0.4163 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Periodontitis (acute or chronic) | 0.005224 | 1.246 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Hypersomnia | 0.005662 | 0.6053 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Gram negative septicemia | 0.004916 | 0.6468 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Abnormality of red blood cells | 0.005331 | 1.983 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Other disorders of the nervous system | 0.001354 | 1.653 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Mastodynia | 0.01014 | 1.272 | TRIM2 | Multiple sclerosis (severity) |
| rs12644284 | Chronic tonsillitis and adenoiditis | 0.008729 | 1.669 | TRIM2 | Multiple sclerosis (severity) |
| rs12658202 | Mucous polyp of cervix | 0.01017 | 1.37 | GRIA1 | Height |
| rs12658202 | Deficiency of humoral immunity | 0.01019 | 2.014 | GRIA1 | Height |
| rs12658202 | Reticulosarcoma | 0.003716 | 1.706 | GRIA1 | Height |
| rs12658202 | Bladder cancer and neoplasms | 0.008312 | 1.255 | GRIA1 | Height |
| rs12658202 | Gastritis and duodenitis, NOS | 0.004862 | 1.23 | GRIA1 | Height |
| rs12658202 | Hallux rigidus | 0.005851 | 0.7056 | GRIA1 | Height |
| rs12658202 | Inflammatory disease of cervix, vagina, and vulva | 0.006182 | 0.8451 | GRIA1 | Height |
| rs12658202 | Vaginitis and vulvovaginitis | 0.009936 | 0.8362 | GRIA1 | Height |
| rs12658202 | Nonrheumatic aortic valve disorders | 0.009452 | 1.15 | GRIA1 | Height |
| rs12658202 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.01137 | 0.4677 | GRIA1 | Height |
| rs12658202 | Polyp of corpus uteri | 0.004914 | 1.397 | GRIA1 | Height |
| rs12658202 | Other rheumatic heart disease | 0.01138 | 1.867 | GRIA1 | Height |
| rs12658202 | Heart transplant/surgery | 0.01049 | 1.405 | GRIA1 | Height |
| rs12658202 | Polyp of female genital organs | 0.002258 | 1.293 | GRIA1 | Height |
| rs12658202 | Asthma with exacerbation | 0.003962 | 0.7086 | GRIA1 | Height |
| rs12658202 | Bladder cancer | 0.004707 | 1.284 | GRIA1 | Height |
| rs12658202 | Acquired toe deformities | 0.007742 | 0.8567 | GRIA1 | Height |
| rs12720356 | Hypovolemia | 0.006767 | 1.214 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Dyspareunia | 0.009175 | 1.911 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Ileostomy status | 0.00504 | 1.934 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Throat pain | 0.002114 | 2.096 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Neck pain | 0.0007905 | 1.221 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | E. coli | 0.009151 | 1.508 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Localized adiposity | 0.008083 | 2.297 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Sexually transmitted infections | 0.0006784 | 2.824 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Cancer of oropharynx | 0.004373 | 2.544 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Respiratory failure | 0.005926 | 1.451 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Atrophic gastritis | 0.004887 | 1.782 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Benign neoplasm of other endocrine glands | 0.001243 | 0.2893 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Other conditions of brain | 0.007609 | 1.514 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Pneumonia | 0.005838 | 1.193 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Disorders of binocular eye movements | 0.009563 | 0.7065 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Respiratory failure; insufficiency; arrest | 0.0004713 | 1.419 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Disorders of fluid, electrolyte, and acid-base balance | 0.009556 | 1.147 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Septicemia | 0.007053 | 1.299 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Electrolyte imbalance | 0.004446 | 1.185 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Aphakia and other disorders of lens | 0.003716 | 0.5441 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Hyperpotassemia | 0.00144 | 1.387 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12720356 | Polyp of corpus uteri | 0.007218 | 1.622 | TYK2 | Psoriasis vulgaris, Crohn's disease |
| rs12797755 | Blood vessel replaced | 0.01032 | 1.975 | GRIK4 | Cognitive performance |
| rs12797755 | Vascular disorders of kidney/hypertrophy | 0.004558 | 2.817 | GRIK4 | Cognitive performance |
| rs12797755 | Swelling of limb | 0.0008719 | 0.625 | GRIK4 | Cognitive performance |
| rs12797755 | Candidiasis | 0.01028 | 1.359 | GRIK4 | Cognitive performance |
| rs12797755 | Edema | 0.01142 | 0.8177 | GRIK4 | Cognitive performance |
| rs12797755 | Sicca syndrome | 0.004244 | 1.953 | GRIK4 | Cognitive performance |
| rs12797755 | Peripheral enthesopathies | 0.002746 | 0.8099 | GRIK4 | Cognitive performance |
| rs12797755 | Random mental disorder. Ignored for now | 0.007969 | 1.958 | GRIK4 | Cognitive performance |
| rs12807809 | Retention of urine | 0.003914 | 0.824 | NRGN | Schizophrenia |
| rs12807809 | Hypertension | 0.003648 | 0.894 | NRGN | Schizophrenia |
| rs12807809 | Ill-defined descriptions and complications of heart disease | 0.003972 | 0.8584 | NRGN | Schizophrenia |
| rs12807809 | Dementias | 0.007731 | 0.8271 | NRGN | Schizophrenia |
| rs12807809 | Insomnia | 0.009989 | 1.195 | NRGN | Schizophrenia |
| rs12807809 | Cardiac pacemaker/device in situ | 0.009728 | 0.7751 | NRGN | Schizophrenia |
| rs12807809 | Symptoms/disorders of the urinary system | 0.0005583 | 0.8685 | NRGN | Schizophrenia |
| rs12807809 | Conjunctivitis, infectious | 0.004605 | 0.8045 | NRGN | Schizophrenia |
| rs12807809 | Alzheimer's disease | 0.00968 | 0.803 | NRGN | Schizophrenia |
| rs12807809 | Mechanical complication of nervous system device, implant, and graft | 0.003126 | 2.23 | NRGN | Schizophrenia |
| rs12807809 | Systolic/diastolic heart failure | 0.00251 | 0.8452 | NRGN | Schizophrenia |
| rs12807809 | Myocardial infarction | 0.002597 | 0.8318 | NRGN | Schizophrenia |
| rs12807809 | Heart failure | 0.004431 | 0.8586 | NRGN | Schizophrenia |
| rs12807809 | Essential hypertension | 0.003432 | 0.8932 | NRGN | Schizophrenia |
| rs12807809 | Cardiac pacemaker in situ | 0.01069 | 0.7635 | NRGN | Schizophrenia |
| rs12821256 | Allergy to serum or vaccine | 0.01058 | 1.983 | KITLG | Hair color |
| rs12821256 | Appendicitis | 0.01043 | 1.545 | KITLG | Hair color |
| rs12821256 | Hyperglyceridemia | 0.007765 | 0.6942 | KITLG | Hair color |
| rs12821256 | Other congenital anomalies of skin | 0.002333 | 0.4145 | KITLG | Hair color |
| rs12821256 | Angina pectoris | 0.00263 | 0.8003 | KITLG | Hair color |
| rs12821256 | Epiphora | 0.009177 | 0.5731 | KITLG | Hair color |
| rs12821256 | Benign neoplasm of eye | 0.0002035 | 1.503 | KITLG | Hair color |
| rs12821256 | Ill-defined descriptions and complications of heart disease | 0.002331 | 0.8243 | KITLG | Hair color |
| rs12821256 | Diseases of the salivary glands | 0.00879 | 0.6357 | KITLG | Hair color |
| rs12821256 | Disorders of lacrimal system | 0.0005731 | 0.7783 | KITLG | Hair color |
| rs12821256 | Dry eyes | 0.001009 | 0.7796 | KITLG | Hair color |
| rs12821256 | Skin neoplasm of uncertain behavior | 0.01038 | 0.7401 | KITLG | Hair color |
| rs12821256 | Acute appendicitis | 0.004273 | 1.721 | KITLG | Hair color |
| rs12821256 | Other forms of chronic heart disease | 0.008388 | 0.7475 | KITLG | Hair color |
| rs12821256 | Benign neoplasm of brain and other parts of nervous system | 0.006072 | 0.4905 | KITLG | Hair color |
| rs12915189 | Osteoporosis, NOS or other | 0.0009343 | 1.167 | CRTC3 | Cognitive performance |
| rs12915189 | Herpes zoster with nervous system complications | 0.00486 | 0.5869 | CRTC3 | Cognitive performance |
| rs12915189 | Primary pulmonary hypertension | 0.00856 | 0.5881 | CRTC3 | Cognitive performance |
| rs12915189 | Pathologic fracture | 0.007909 | 1.211 | CRTC3 | Cognitive performance |
| rs12915189 | Chronic obstructive asthma | 0.006426 | 1.297 | CRTC3 | Cognitive performance |
| rs12915189 | Attention deficit hyperactivity disorder | 0.0002436 | 1.978 | CRTC3 | Cognitive performance |
| rs12915189 | H. pylori | 0.01084 | 1.468 | CRTC3 | Cognitive performance |
| rs12915189 | Polycystic ovaries | 0.01117 | 1.925 | CRTC3 | Cognitive performance |
| rs12915189 | Osteoporosis, osteopenia, & pathological fractures | 0.006244 | 1.105 | CRTC3 | Cognitive performance |
| rs12915189 | Prostate cancer | 0.007836 | 1.194 | CRTC3 | Cognitive performance |
| rs12915189 | Nasal polyps | 0.003662 | 1.376 | CRTC3 | Cognitive performance |
| rs12915189 | Osteoporosis | 0.004403 | 1.147 | CRTC3 | Cognitive performance |
| rs12915189 | Generalized anxiety disorder | 0.008791 | 1.287 | CRTC3 | Cognitive performance |
| rs12915189 | Fracture of ankle and foot | 0.01001 | 1.148 | CRTC3 | Cognitive performance |
| rs12915189 | Pervasive developmental disorders | 0.0008592 | 1.716 | CRTC3 | Cognitive performance |
| rs12915189 | Ovarian dysfunction | 0.005771 | 1.875 | CRTC3 | Cognitive performance |
| rs12989701 | Optic atrophy | 0.005774 | 0.4927 | BIN1 | Alzheimer's disease |
| rs12989701 | Abnormal kidney function | 0.006662 | 2.192 | BIN1 | Alzheimer's disease |
| rs12989701 | Viral Enteritis | 0.007425 | 1.618 | BIN1 | Alzheimer's disease |
| rs12989701 | Dementia with cerebral degenerations | 0.01057 | 1.648 | BIN1 | Alzheimer's disease |
| rs12989701 | Nephrotic syndrome without mention of glomerulonephritis | 0.01093 | 2.023 | BIN1 | Alzheimer's disease |
| rs12989701 | Joint/ligament sprain | 0.0113 | 0.6644 | BIN1 | Alzheimer's disease |
| rs12989701 | Impetigo | 0.008704 | 1.667 | BIN1 | Alzheimer's disease |
| rs12989701 | Genitourinary congenital anomalies | 0.003504 | 1.529 | BIN1 | Alzheimer's disease |
| rs12989701 | Benign neoplasm of brain and other parts of nervous system | 0.008155 | 1.497 | BIN1 | Alzheimer's disease |
| rs12989701 | Stricture of artery | 0.003525 | 0.6255 | BIN1 | Alzheimer's disease |
| rs12989701 | Bullous dermatoses | 0.002437 | 2.109 | BIN1 | Alzheimer's disease |
| rs12989701 | Hypoglycemia | 0.006557 | 1.587 | BIN1 | Alzheimer's disease |
| rs12989701 | Valvular heart disease/ heart chambers | 0.008573 | 1.892 | BIN1 | Alzheimer's disease |
| rs13088462 | Intervertebral disc disorder with myelopathy | 0.008194 | 2.265 | DOCK3 | Height |
| rs13088462 | Essential hypertension | 0.0001705 | 0.7836 | DOCK3 | Height |
| rs13088462 | Disorders of lipoid metabolism | 0.009792 | 0.8293 | DOCK3 | Height |
| rs13088462 | Hyperlipidemia | 0.006986 | 0.8214 | DOCK3 | Height |
| rs13088462 | Inguinal hernia | 0.002862 | 0.6642 | DOCK3 | Height |
| rs13088462 | Musculoskeletal symptoms referable to limbs | 0.01025 | 1.523 | DOCK3 | Height |
| rs13088462 | Dermatomycoses | 0.0001168 | 2.901 | DOCK3 | Height |
| rs13088462 | Benign neoplasm of eye | 0.0006463 | 1.645 | DOCK3 | Height |
| rs13088462 | Other disorders of eyelids | 0.005795 | 0.7308 | DOCK3 | Height |
| rs13088462 | Mixed hyperlipidemia | 0.001487 | 0.6201 | DOCK3 | Height |
| rs13088462 | Chronic lymphocytic thyroiditis | 0.01146 | 0.2292 | DOCK3 | Height |
| rs13088462 | Anomalies of pupillary function | 0.005295 | 2.69 | DOCK3 | Height |
| rs13088462 | Ingrowing nail | 0.004604 | 0.6721 | DOCK3 | Height |
| rs13088462 | Paralytic ileus | 0.01032 | 0.4635 | DOCK3 | Height |
| rs13088462 | Hypertension | 0.0002191 | 0.7873 | DOCK3 | Height |
| rs13129697 | Retinal vascular changes and abnomalities | 0.002977 | 1.265 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Dupuytren's disease | 0.008395 | 0.6864 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Pleurisy; pleural effusion | 0.004878 | 0.8537 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Muscular dystrophies and other myopathies | 0.002503 | 0.5833 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Other sprains and strains | 0.001239 | 0.6488 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Costochondritis | 0.001116 | 0.3328 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Tinnitus | 0.006338 | 1.222 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Gouty arthropathy | 0.009714 | 0.7425 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Spontaneous ecchymoses | 0.01118 | 0.5698 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | stress incontinence, female | 0.002022 | 1.229 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Gout | 2.414e-07 | 0.716 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Corneal edema | 0.005952 | 1.672 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs13129697 | Gout and other crystal arthropathies | 4.971e-06 | 0.7627 | SLC2A9 | Serum uric acid, Uric acid levels, Serum Urate, Gout |
| rs1317209 | Other alveolar and parietoalveolar pneumonopathy | 0.004791 | 1.786 | RNF186 | Ulcerative colitis |
| rs1317209 | Lung disease due to external agents | 0.008025 | 1.627 | RNF186 | Ulcerative colitis |
| rs1317209 | Benign neoplasm of thyroid glands | 0.01052 | 1.824 | RNF186 | Ulcerative colitis |
| rs1317209 | Back & neck sprains | 0.000987 | 1.203 | RNF186 | Ulcerative colitis |
| rs1317209 | Back pain | 0.002516 | 1.121 | RNF186 | Ulcerative colitis |
| rs1317209 | Sprains and strains | 0.006542 | 1.142 | RNF186 | Ulcerative colitis |
| rs1317209 | Acute, but ill-defined cerebrovascular disease | 0.009444 | 0.7939 | RNF186 | Ulcerative colitis |
| rs1317209 | Chronic laryngitis | 0.01089 | 1.974 | RNF186 | Ulcerative colitis |
| rs1317209 | Neck pain | 0.006796 | 1.128 | RNF186 | Ulcerative colitis |
| rs1317209 | Erectile dysfunction | 0.004801 | 1.231 | RNF186 | Ulcerative colitis |
| rs1317209 | Pain in joint | 0.006763 | 1.112 | RNF186 | Ulcerative colitis |
| rs1317209 | Other headache syndromes | 0.009919 | 1.126 | RNF186 | Ulcerative colitis |
| rs1317209 | Other hemoglobinopathies | 0.003684 | 2.245 | RNF186 | Ulcerative colitis |
| rs1317209 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.004009 | 0.7662 | RNF186 | Ulcerative colitis |
| rs1317209 | Thoracic neuritis/radiculitis | 0.008883 | 1.144 | RNF186 | Ulcerative colitis |
| rs1317209 | Hemorrhage of rectum and anus | 0.001081 | 1.3 | RNF186 | Ulcerative colitis |
| rs1317209 | Skin neoplasm of uncertain behavior | 0.00636 | 1.26 | RNF186 | Ulcerative colitis |
| rs1317209 | Acute prostatitis | 0.0007848 | 2.022 | RNF186 | Ulcerative colitis |
| rs13194491 | Iron metabolism disorder | 3.76e-16 | 7.795 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Malignant neoplasm of kidney and other urinary organs | 0.004521 | 2.065 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Lymphoid leukemia | 0.008482 | 1.85 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Discoid lupus erythematosus | 0.01128 | 1.749 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Adrenal hypofunction | 0.008525 | 1.948 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Lupus erythematosus | 0.007535 | 2.407 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Dystrophy of female genital tract | 0.00351 | 2.607 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Chronic lymphoid leukemia | 0.007584 | 1.896 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Iron deficiency anemias NOS | 0.003885 | 0.7591 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Secondary malignancy of bone | 0.01065 | 1.521 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Bacteremia | 0.00585 | 0.5229 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Flat foot | 0.007046 | 1.515 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Disorders of binocular eye movements | 0.008754 | 0.6824 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Fractur of unspecified part of femur | 0.0107 | 1.636 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Peripheral vascular disease | 0.005205 | 0.7965 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Atherosclerosis of the extremities | 0.0007135 | 0.7173 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Atherosclerosis | 0.002765 | 0.7745 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Iron deficiency anemias | 0.003409 | 0.7403 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.00791 | 0.7268 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Urinary incontinence | 0.007625 | 1.244 | HIST1H2BJ | Transferrin saturation |
| rs13194491 | Peripheral arterial disease | 0.0008221 | 0.7416 | HIST1H2BJ | Transferrin saturation |
| rs13194984 | Fracture of tibia and fibula | 0.003042 | 1.421 | BTN1A1 | Transferrin saturation |
| rs13194984 | Non-melanoma skin cancer | 0.002119 | 1.175 | BTN1A1 | Transferrin saturation |
| rs13194984 | Genu valgum or varum (acquired) | 0.007971 | 0.4974 | BTN1A1 | Transferrin saturation |
| rs13194984 | Disorders of penis | 0.0005132 | 0.5096 | BTN1A1 | Transferrin saturation |
| rs13194984 | Other local infections of skin and subcutaneous tissue | 0.009424 | 1.241 | BTN1A1 | Transferrin saturation |
| rs13194984 | Skin cancer | 0.004782 | 1.152 | BTN1A1 | Transferrin saturation |
| rs13194984 | Other specified cardiac dysrhythmias | 0.008608 | 0.8297 | BTN1A1 | Transferrin saturation |
| rs13194984 | Disorders of binocular eye movements | 0.003817 | 0.7254 | BTN1A1 | Transferrin saturation |
| rs13194984 | Urinary complications | 0.01054 | 0.4915 | BTN1A1 | Transferrin saturation |
| rs13194984 | Acute pancreatitis | 0.007897 | 0.6499 | BTN1A1 | Transferrin saturation |
| rs13194984 | Abnormal findings on radiological examination intrathoracic organs | 0.0106 | 0.7435 | BTN1A1 | Transferrin saturation |
| rs13194984 | Carbuncle and furuncle | 0.006385 | 1.684 | BTN1A1 | Transferrin saturation |
| rs13194984 | Bacteremia | 0.000246 | 0.5187 | BTN1A1 | Transferrin saturation |
| rs13194984 | Fracture of lower limb | 0.002446 | 1.24 | BTN1A1 | Transferrin saturation |
| rs13194984 | Atrial flutter | 0.005735 | 0.7108 | BTN1A1 | Transferrin saturation |
| rs13194984 | Diseases of the oral soft tissues | 0.008177 | 0.7838 | BTN1A1 | Transferrin saturation |
| rs13194984 | Iron metabolism disorder | 5.821e-09 | 4.109 | BTN1A1 | Transferrin saturation |
| rs13194984 | Chronic lymphoid leukemia | 0.006902 | 1.728 | BTN1A1 | Transferrin saturation |
| rs13194984 | Multiple sclerosis | 0.004263 | 1.732 | BTN1A1 | Transferrin saturation |
| rs13194984 | Hypertrophy of breast (Gynecomastia) | 0.005563 | 0.5682 | BTN1A1 | Transferrin saturation |
| rs13194984 | Breast conditions, congenital or relating to hormones | 0.007519 | 0.6188 | BTN1A1 | Transferrin saturation |
| rs13194984 | Biliary cirrhosis | 0.001163 | 2.845 | BTN1A1 | Transferrin saturation |
| rs13194984 | Poisoning by hormones and synthetic substitutes | 0.003387 | 0.5167 | BTN1A1 | Transferrin saturation |
| rs13194984 | Age-related macular degeneration | 0.009419 | 0.761 | BTN1A1 | Transferrin saturation |
| rs13230047 | Noninflammatory female genital disorders | 0.007727 | 0.5083 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Pathological, developmental or recurrent dislocation | 0.0001351 | 4.398 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Otitis media | 0.003049 | 0.5953 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Other hypertrophic and atrophic conditions of skin | 0.007423 | 0.6996 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Gastrointestinal malfunction arising from mental factors | 0.009419 | 3.565 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Suppurative and unspecified otitis media | 0.003673 | 0.5438 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Adjustment reaction | 0.005868 | 1.512 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13230047 | Alopecia Areata | 0.001809 | 4.089 | ELMO1 | Anticoagulant levels (Protein C) |
| rs13278062 | Diaphragmatic hernia | 0.01031 | 1.127 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Other hemoglobinopathies | 0.01063 | 0.4972 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Disturbance of skin sensation | 0.01067 | 1.113 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Circumscribed scleroderma | 0.002845 | 0.6892 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Kidney replaced by transpant | 0.005192 | 0.6804 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Hyperosmolality and/or hypernatremia | 0.002188 | 0.6426 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Symptoms affecting skin | 0.002278 | 1.107 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Congenital anomalies of urinary system | 0.007084 | 0.6826 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Ectropion or entropion | 0.007341 | 0.7933 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Bullous dermatoses | 0.009603 | 1.805 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Bronchiectasis | 0.006436 | 1.391 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Other open wound of head and face | 0.01105 | 1.197 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Pneumonia | 0.005678 | 1.109 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Hereditary hemolytic anemias | 0.009954 | 0.6047 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Aneurysm of other specified artery | 0.00976 | 1.784 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Megaloblastic anemia | 0.001671 | 1.411 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Eating disorder | 0.001766 | 1.78 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Open wounds of head; neck; and trunk | 0.002679 | 1.167 | TNFRSF10A | Age-related macular degeneration |
| rs13278062 | Herpes simplex | 0.004196 | 1.318 | TNFRSF10A | Age-related macular degeneration |
| rs1329428 | Macular degeneration, dry | 1.542e-09 | 0.627 | CFH | Age-related macular degeneration |
| rs1329428 | Nerve root and plexus disorders | 0.001418 | 1.372 | CFH | Age-related macular degeneration |
| rs1329428 | Type 1 diabetic neuropathy | 0.006959 | 1.423 | CFH | Age-related macular degeneration |
| rs1329428 | Encounter for long-term use of anticoagulants/antithrombotics | 0.006078 | 1.265 | CFH | Age-related macular degeneration |
| rs1329428 | Osteoarthrosis; localized, secondary | 0.0008799 | 1.724 | CFH | Age-related macular degeneration |
| rs1329428 | Fracture of vertebral column without mention of spinal cord injury | 0.009076 | 0.8204 | CFH | Age-related macular degeneration |
| rs1329428 | Type 1 diabetes | 0.0001105 | 1.258 | CFH | Age-related macular degeneration |
| rs1329428 | Diabetes mellitus | 3.447e-06 | 1.153 | CFH | Age-related macular degeneration |
| rs1329428 | Left bundle branch block | 0.000674 | 1.363 | CFH | Age-related macular degeneration |
| rs1329428 | Endometrial hyperplasia | 0.0008203 | 1.554 | CFH | Age-related macular degeneration |
| rs1329428 | Osteomyelitis | 0.006309 | 1.287 | CFH | Age-related macular degeneration |
| rs1329428 | Shock | 0.008697 | 1.37 | CFH | Age-related macular degeneration |
| rs1329428 | First degree AV block | 0.00933 | 1.227 | CFH | Age-related macular degeneration |
| rs1329428 | Retinal drusen | 3.168e-06 | 0.6987 | CFH | Age-related macular degeneration |
| rs1329428 | Type 2 diabetes | 6.374e-06 | 1.15 | CFH | Age-related macular degeneration |
| rs1329428 | Macular degeneration, wet | 4.895e-12 | 0.4418 | CFH | Age-related macular degeneration |
| rs1329428 | Type 2 diabetic retinopathy | 0.004349 | 1.208 | CFH | Age-related macular degeneration |
| rs1329428 | Other specified osteoporosis | 0.007802 | 0.5904 | CFH | Age-related macular degeneration |
| rs1329428 | Retinal vascular changes and abnomalities | 2.802e-05 | 0.7319 | CFH | Age-related macular degeneration |
| rs1329428 | Partial epilepsy | 0.005695 | 0.6872 | CFH | Age-related macular degeneration |
| rs1329428 | Bundle branch block | 0.003238 | 1.218 | CFH | Age-related macular degeneration |
| rs1329428 | Type 2 diabetic ketoacidosis | 0.005678 | 1.138 | CFH | Age-related macular degeneration |
| rs1329428 | Sarcoidosis | 0.004161 | 1.634 | CFH | Age-related macular degeneration |
| rs1329428 | Conjunctivitis, noninfectious | 0.008553 | 1.233 | CFH | Age-related macular degeneration |
| rs1329428 | Diabetic retinopathy | 0.002648 | 1.211 | CFH | Age-related macular degeneration |
| rs1329428 | Allergic conjunctivitis | 0.01058 | 1.252 | CFH | Age-related macular degeneration |
| rs1329428 | Retinal disorders | 3.004e-07 | 0.8172 | CFH | Age-related macular degeneration |
| rs1329428 | Encounter for long-term use of aspirin | 0.001615 | 1.349 | CFH | Age-related macular degeneration |
| rs1329428 | Age-related macular degeneration | 7.157e-20 | 0.514 | CFH | Age-related macular degeneration |
| rs1329428 | Macular degeneration | 7.679e-13 | 0.7212 | CFH | Age-related macular degeneration |
| rs13314993 | Acute osteomyelitis | 0.002993 | 1.705 | CCR4 | Celiac disease |
| rs13314993 | Other cerebral degenerations | 0.006494 | 1.412 | CCR4 | Celiac disease |
| rs13314993 | Migrain with aura | 0.008233 | 1.438 | CCR4 | Celiac disease |
| rs13314993 | Testicular hypofunction | 0.007255 | 0.7135 | CCR4 | Celiac disease |
| rs13314993 | Wheezing | 0.009406 | 1.306 | CCR4 | Celiac disease |
| rs13314993 | Chronic prostatitis | 0.004999 | 1.54 | CCR4 | Celiac disease |
| rs13314993 | Cancer of other male genital organs | 0.009176 | 0.5703 | CCR4 | Celiac disease |
| rs13314993 | Drug-resistant infection | 0.0005734 | 1.495 | CCR4 | Celiac disease |
| rs13314993 | Gram positive septicemia | 0.008808 | 1.571 | CCR4 | Celiac disease |
| rs13314993 | Abnormal findings on radiological examination intrathoracic organs | 0.005135 | 1.213 | CCR4 | Celiac disease |
| rs13314993 | Testicular dysfunction | 0.01033 | 0.7299 | CCR4 | Celiac disease |
| rs13314993 | Anaphylactic shock NOS | 0.00951 | 1.456 | CCR4 | Celiac disease |
| rs13314993 | Other symptoms involving abdomen and pelvis | 0.01012 | 0.8837 | CCR4 | Celiac disease |
| rs13314993 | Ventral hernia | 0.001714 | 1.33 | CCR4 | Celiac disease |
| rs13333226 | Other abnormal glucose | 0.007161 | 1.18 | UMOD | Hypertension |
| rs13333226 | Noninflammatory disorders of cervix | 0.001839 | 1.894 | UMOD | Hypertension |
| rs13333226 | Disorders of lacrimal system | 0.006507 | 0.849 | UMOD | Hypertension |
| rs13333226 | Optic atrophy | 0.01073 | 0.5888 | UMOD | Hypertension |
| rs13333226 | Arthropathy associated with infections | 0.004603 | 0.45 | UMOD | Hypertension |
| rs13333226 | Testicular hypofunction | 4.459e-05 | 0.4163 | UMOD | Hypertension |
| rs13333226 | Chronic pharyngitis and nasopharyngitis | 0.003488 | 0.8013 | UMOD | Hypertension |
| rs13333226 | E. coli | 0.00605 | 1.391 | UMOD | Hypertension |
| rs13333226 | Sleep related movement disorders | 0.009949 | 0.7484 | UMOD | Hypertension |
| rs13333226 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.004477 | 1.703 | UMOD | Hypertension |
| rs13333226 | Restless legs syndrome | 0.01009 | 0.7064 | UMOD | Hypertension |
| rs13333226 | Prolapse of vaginal vault after hysterectomy | 0.001911 | 0.4701 | UMOD | Hypertension |
| rs13333226 | Renal failure | 0.002187 | 0.8624 | UMOD | Hypertension |
| rs13333226 | Testicular dysfunction | 0.0001011 | 0.4539 | UMOD | Hypertension |
| rs13333226 | Noninflammatory female genital disorders | 0.006836 | 1.24 | UMOD | Hypertension |
| rs13333226 | Pyogenic arthritis | 0.008109 | 0.415 | UMOD | Hypertension |
| rs13333226 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.006818 | 1.241 | UMOD | Hypertension |
| rs13333226 | Miscarriage; stillbirth | 0.01014 | 1.886 | UMOD | Hypertension |
| rs13333226 | Hereditary and idiopathic peripheral neuropathy | 0.006587 | 0.828 | UMOD | Hypertension |
| rs13333226 | Circumscribed scleroderma | 0.006178 | 1.472 | UMOD | Hypertension |
| rs13333226 | Rheumatoid arthritis | 0.002612 | 1.305 | UMOD | Hypertension |
| rs13333226 | Abnormal involuntary movements | 0.005423 | 0.7263 | UMOD | Hypertension |
| rs13333226 | Diseases of spleen | 0.00907 | 1.888 | UMOD | Hypertension |
| rs13333226 | Encounter for long-term use of anticoagulants/antithrombotics | 0.002008 | 0.6761 | UMOD | Hypertension |
| rs1335532 | Respiratory complications | 0.01086 | 0.3422 | CD58 | Multiple sclerosis |
| rs1335532 | ASCVD | 0.009489 | 1.483 | CD58 | Multiple sclerosis |
| rs1335532 | Nerve root lesions | 0.002181 | 1.948 | CD58 | Multiple sclerosis |
| rs1335532 | Retinal detachments and defects | 0.007403 | 1.31 | CD58 | Multiple sclerosis |
| rs1335532 | Aphakia and other disorders of lens | 0.006154 | 1.428 | CD58 | Multiple sclerosis |
| rs1335532 | Benign neoplasm of colon | 0.008701 | 1.134 | CD58 | Multiple sclerosis |
| rs1335532 | Dysmetabolic syndrome X | 0.001176 | 1.749 | CD58 | Multiple sclerosis |
| rs1335532 | Hereditary and idiopathic peripheral neuropathy | 0.0006694 | 0.7494 | CD58 | Multiple sclerosis |
| rs1335532 | Astigmatism | 0.007245 | 1.205 | CD58 | Multiple sclerosis |
| rs1335532 | Multiple myeloma | 0.004289 | 0.3306 | CD58 | Multiple sclerosis |
| rs1335532 | Diseases of the tongue | 0.002282 | 1.636 | CD58 | Multiple sclerosis |
| rs13429458 | Cholecystitis without cholelithiasis | 0.01123 | 0.6304 | THADA | Polycystic ovary syndrome |
| rs13429458 | Known or suspected fetal abnormality | 0.004956 | 1.996 | THADA | Polycystic ovary syndrome |
| rs13429458 | Acute osteomyelitis | 0.006868 | 1.836 | THADA | Polycystic ovary syndrome |
| rs13429458 | Erectile dysfunction | 0.01032 | 0.7882 | THADA | Polycystic ovary syndrome |
| rs13429458 | Other specified peripheral vascular diseases | 0.009024 | 2.257 | THADA | Polycystic ovary syndrome |
| rs13429458 | Atrophy of edentulous alveolar ridge | 0.001529 | 0.3162 | THADA | Polycystic ovary syndrome |
| rs13429458 | Diseases of hard tissues of teeth | 0.009311 | 0.7522 | THADA | Polycystic ovary syndrome |
| rs13429458 | Endocarditis | 0.0003896 | 1.649 | THADA | Polycystic ovary syndrome |
| rs13429458 | Hallux valgus (Bunion) | 0.005543 | 1.288 | THADA | Polycystic ovary syndrome |
| rs13429458 | Noninflammatory disorders of cervix | 0.007056 | 1.898 | THADA | Polycystic ovary syndrome |
| rs13429458 | Other disorders of arteries and arterioles | 0.01103 | 1.368 | THADA | Polycystic ovary syndrome |
| rs13429458 | Salicylates causing adverse effects in therapeutic use | 0.01023 | 2.085 | THADA | Polycystic ovary syndrome |
| rs13429458 | Nonrheumatic pulmonary valve disorders | 0.006477 | 1.887 | THADA | Polycystic ovary syndrome |
| rs13429458 | Adverse effects of opiates and related narcotics in therapeutic use | 0.003795 | 1.462 | THADA | Polycystic ovary syndrome |
| rs13429458 | Symptoms involving digestive system | 0.002753 | 1.373 | THADA | Polycystic ovary syndrome |
| rs13429458 | Noninfectious dermatoses of eyelid | 0.01115 | 1.829 | THADA | Polycystic ovary syndrome |
| rs13438327 | Other specified disorders of pancreatic internal secretion | 0.005499 | 2.043 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Disturbances in tooth eruption | 0.007772 | 1.575 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Male infertility and abnormal spermatozoa | 0.002382 | 2.266 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Chronic lymphocytic thyroiditis | 0.01013 | 0.4138 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Acquired spondylolisthesis | 0.001253 | 1.608 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Abnormal weight gain | 0.009367 | 1.538 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Other disorders of pancreatic internal secretion | 0.007011 | 1.999 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Prostate cancer | 0.001533 | 1.404 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Infertility, male | 4.129e-05 | 3.467 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Periostitis | 0.01122 | 2.121 | OCM2 | Sudden cardiac arrest |
| rs13438327 | Cystitis and urethritis | 0.01041 | 1.344 | OCM2 | Sudden cardiac arrest |
| rs1354034 | Diffuse diseases of connective tissue | 0.004107 | 1.29 | ARHGEF3 | Platelet counts |
| rs1354034 | Peripheral or central vertigo | 0.00686 | 1.208 | ARHGEF3 | Platelet counts |
| rs1354034 | Thrombocytopenia | 0.0006659 | 1.235 | ARHGEF3 | Platelet counts |
| rs1354034 | Microscopic hematuria | 0.006184 | 0.636 | ARHGEF3 | Platelet counts |
| rs1354034 | Abnormal weight gain | 0.009701 | 1.322 | ARHGEF3 | Platelet counts |
| rs1354034 | Hyperosmolality and/or hypernatremia | 0.008259 | 1.457 | ARHGEF3 | Platelet counts |
| rs1354034 | Hydronephrosis | 0.008031 | 1.319 | ARHGEF3 | Platelet counts |
| rs1354034 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.007869 | 1.324 | ARHGEF3 | Platelet counts |
| rs1354034 | Other conditions of brain, NOS | 0.009519 | 0.6368 | ARHGEF3 | Platelet counts |
| rs1354034 | Diverticulosis | 0.01033 | 1.112 | ARHGEF3 | Platelet counts |
| rs1354034 | Hereditary and idiopathic peripheral neuropathy | 0.0101 | 1.143 | ARHGEF3 | Platelet counts |
| rs1354034 | Poisoning by agents affecting the cardiovascular system | 0.004929 | 1.331 | ARHGEF3 | Platelet counts |
| rs1354034 | Purpura and other hemorrhagic conditions | 0.001391 | 1.195 | ARHGEF3 | Platelet counts |
| rs1354034 | Diseases of nail | 0.0002392 | 1.207 | ARHGEF3 | Platelet counts |
| rs1354034 | Diverticulitis | 0.01144 | 1.21 | ARHGEF3 | Platelet counts |
| rs1354034 | Symptoms involving respiratory system | 0.006747 | 1.207 | ARHGEF3 | Platelet counts |
| rs1354034 | Overweight | 0.01128 | 1.084 | ARHGEF3 | Platelet counts |
| rs1354034 | Urticaria | 0.006772 | 0.7951 | ARHGEF3 | Platelet counts |
| rs1354034 | Anterior pituitary disorders | 0.004997 | 1.686 | ARHGEF3 | Platelet counts |
| rs1354034 | Other specified diseases of nail | 0.0002147 | 1.215 | ARHGEF3 | Platelet counts |
| rs1354034 | Conjunctivitis, infectious | 0.009388 | 1.162 | ARHGEF3 | Platelet counts |
| rs1354034 | Postoperative infection | 0.01072 | 1.194 | ARHGEF3 | Platelet counts |
| rs1354034 | Dermatophytosis / Dermatomycosis | 0.0107 | 1.102 | ARHGEF3 | Platelet counts |
| rs1354034 | Diverticulosis and diverticulitis | 0.009965 | 1.107 | ARHGEF3 | Platelet counts |
| rs1354034 | Derangement of joint, non-traumatic | 0.009443 | 1.233 | ARHGEF3 | Platelet counts |
| rs1354034 | Diseases of respiratory system | 0.005132 | 1.17 | ARHGEF3 | Platelet counts |
| rs1394125 | Purpura and other hemorrhagic conditions | 0.0001733 | 1.238 | UBE2Q2 | Serum creatinine |
| rs1394125 | Reticulosarcoma | 0.001645 | 0.5028 | UBE2Q2 | Serum creatinine |
| rs1394125 | Chronic lymphocytic thyroiditis | 0.009949 | 1.414 | UBE2Q2 | Serum creatinine |
| rs1394125 | Nonsenile Cataract | 0.003799 | 0.6921 | UBE2Q2 | Serum creatinine |
| rs1394125 | Thrombocytopenia | 0.0007112 | 1.238 | UBE2Q2 | Serum creatinine |
| rs1394125 | Other specified disorders of breast | 0.007217 | 0.7904 | UBE2Q2 | Serum creatinine |
| rs1394125 | Intestinal infection due to C. difficile | 0.005364 | 1.389 | UBE2Q2 | Serum creatinine |
| rs1394125 | Temporomandibular joint disorders | 0.009065 | 1.269 | UBE2Q2 | Serum creatinine |
| rs1394125 | Other specified gastritis | 0.007529 | 0.7783 | UBE2Q2 | Serum creatinine |
| rs1394125 | Supraventricular premature beats | 0.001738 | 1.406 | UBE2Q2 | Serum creatinine |
| rs1394125 | Spontaneous ecchymoses | 0.00405 | 1.657 | UBE2Q2 | Serum creatinine |
| rs1394125 | Abnormal coagulation profile | 0.002068 | 1.428 | UBE2Q2 | Serum creatinine |
| rs1394125 | Rheumatoid arthritis | 0.006366 | 0.806 | UBE2Q2 | Serum creatinine |
| rs1394125 | Rheumatic fever / chorea | 0.009521 | 1.92 | UBE2Q2 | Serum creatinine |
| rs1394125 | Thyroiditis | 0.006326 | 1.357 | UBE2Q2 | Serum creatinine |
| rs1394125 | Decreased white blood cell count | 0.002489 | 1.253 | UBE2Q2 | Serum creatinine |
| rs1394125 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.00594 | 0.8247 | UBE2Q2 | Serum creatinine |
| rs1394125 | Bacterial enteritis | 0.003627 | 1.353 | UBE2Q2 | Serum creatinine |
| rs1395479 | Cerebral ischemia | 0.006706 | 0.8581 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Other specified disorders of liver | 0.008908 | 1.324 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Noninflammatory disorders of cervix | 0.005317 | 0.4948 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cancer of connective tissue | 0.007376 | 0.5206 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Transient cerebral ischemia | 0.008831 | 0.8595 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Reticulosarcoma | 0.00145 | 1.786 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Disorders of liver | 0.002156 | 1.137 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Pseudoexfoliation glaucoma | 0.00993 | 1.555 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Palpitations | 0.002155 | 0.8514 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Hydrocele | 0.003749 | 1.58 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cardiac dysrhythmias | 0.01112 | 0.9188 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Alcoholic liver damage | 0.009846 | 1.616 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Gastritis and duodenitis, NOS | 0.009073 | 1.231 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.007182 | 1.59 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cystoid macular degeneration of retina | 0.009284 | 1.314 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cachexia | 0.00583 | 2.038 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Cellulitis and abscess of foot/toes | 0.001505 | 0.7046 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1395479 | Other disorders of lipoid metabolism and hyperalimentation | 0.004594 | 0.7406 | NEIL3 | Heart rate (ratio of low frequency to high frequency power) |
| rs1405069 | Emphysema | 0.007736 | 1.259 | PI16 | Chemerin levels |
| rs1405069 | Ileostomy status | 0.0004943 | 0.519 | PI16 | Chemerin levels |
| rs1405069 | Poisoning by psychotropic agents | 0.003073 | 1.88 | PI16 | Chemerin levels |
| rs1405069 | Gram negative septicemia | 0.006903 | 1.398 | PI16 | Chemerin levels |
| rs1405069 | Alcoholism | 0.004229 | 1.241 | PI16 | Chemerin levels |
| rs1405069 | Chronic ulcer of unspecified site | 0.004507 | 1.291 | PI16 | Chemerin levels |
| rs1405069 | Cardiac arrhythmia NOS | 0.01091 | 1.14 | PI16 | Chemerin levels |
| rs1405069 | Secondary malignancy of brain/spine | 0.004956 | 0.5886 | PI16 | Chemerin levels |
| rs1405069 | Unspecified local infection of skin and subcutaneous tissue | 0.007467 | 1.26 | PI16 | Chemerin levels |
| rs1405069 | Alcohol-related disorders | 0.003932 | 1.21 | PI16 | Chemerin levels |
| rs1405069 | Hallucinations | 0.0007647 | 2.155 | PI16 | Chemerin levels |
| rs1405069 | Urethral stricture (not specified as infectious) | 0.003623 | 1.457 | PI16 | Chemerin levels |
| rs1405069 | Plasma protein metabolism disorder | 0.008044 | 1.288 | PI16 | Chemerin levels |
| rs1412444 | Symptoms involving urinary system | 0.001283 | 1.31 | LIPA | Coronary heart disease |
| rs1412444 | Osteopenia | 0.001949 | 0.8672 | LIPA | Coronary heart disease |
| rs1412444 | Postmenopausal bleeding | 0.006462 | 0.8096 | LIPA | Coronary heart disease |
| rs1412444 | Arteritis NOS | 0.0049 | 1.594 | LIPA | Coronary heart disease |
| rs1412444 | Cholelithiasis | 0.009606 | 1.134 | LIPA | Coronary heart disease |
| rs1412444 | Althete's foot | 0.005683 | 1.264 | LIPA | Coronary heart disease |
| rs1412444 | Menopausal & postmenopausal disorders | 0.001151 | 0.8577 | LIPA | Coronary heart disease |
| rs1412444 | Other pulmonary inflamation or edema | 0.004191 | 1.34 | LIPA | Coronary heart disease |
| rs1412444 | Other hypertensive complications | 0.006778 | 1.262 | LIPA | Coronary heart disease |
| rs1412444 | Polymyalgia Rheumatica | 0.00834 | 0.7764 | LIPA | Coronary heart disease |
| rs1412444 | Calculus of bile duct | 0.00158 | 1.418 | LIPA | Coronary heart disease |
| rs1412444 | Benign neoplasm of breast | 0.007836 | 0.6039 | LIPA | Coronary heart disease |
| rs1412444 | Symptomatic menopause | 0.0005515 | 0.824 | LIPA | Coronary heart disease |
| rs1412444 | Cholelithiasis and cholecystitis | 0.002842 | 1.146 | LIPA | Coronary heart disease |
| rs1436900 | Obstructive sleep apnea | 1.506e-05 | 0.795 | ESRRG | Optic disc parameters |
| rs1436900 | Cystitis | 0.006006 | 0.8114 | ESRRG | Optic disc parameters |
| rs1436900 | Blood in stool | 0.01101 | 0.8699 | ESRRG | Optic disc parameters |
| rs1436900 | Other unspecified back disorders | 0.001124 | 1.684 | ESRRG | Optic disc parameters |
| rs1436900 | Behcet's syndrome | 0.003873 | 1.564 | ESRRG | Optic disc parameters |
| rs1436900 | Dislocation | 0.01107 | 1.111 | ESRRG | Optic disc parameters |
| rs1436900 | Postnasal drip | 0.004375 | 0.4991 | ESRRG | Optic disc parameters |
| rs1436900 | Other nonmalignant breast conditions | 0.000225 | 0.8167 | ESRRG | Optic disc parameters |
| rs1436900 | Diseases of esophagus | 0.008165 | 0.9224 | ESRRG | Optic disc parameters |
| rs1436900 | Urinary tract infection | 0.005249 | 0.9043 | ESRRG | Optic disc parameters |
| rs1436900 | Other disorders of the nervous system | 0.00812 | 1.514 | ESRRG | Optic disc parameters |
| rs1436900 | Sleep apnea | 0.001272 | 0.8718 | ESRRG | Optic disc parameters |
| rs1436900 | Disorders of lacrimal system | 0.008895 | 0.8854 | ESRRG | Optic disc parameters |
| rs1436900 | Macular puckering of retina | 0.00832 | 0.8186 | ESRRG | Optic disc parameters |
| rs1436900 | Other specified disorders of breast | 0.003567 | 0.7821 | ESRRG | Optic disc parameters |
| rs1436900 | Esophagitis, GERD and related diseases | 0.009593 | 0.9222 | ESRRG | Optic disc parameters |
| rs1436900 | Other diseases of lung | 0.008698 | 0.8837 | ESRRG | Optic disc parameters |
| rs1436900 | Labyrinthitis | 0.008364 | 0.7303 | ESRRG | Optic disc parameters |
| rs1436900 | Other disorders of eyelids | 0.009143 | 0.8753 | ESRRG | Optic disc parameters |
| rs1436900 | Cystitis and urethritis | 0.002219 | 0.8038 | ESRRG | Optic disc parameters |
| rs1436900 | Vertiginous syndromes and other disorders of vestibular system | 0.00645 | 0.9117 | ESRRG | Optic disc parameters |
| rs1436900 | Hematuria | 0.003459 | 0.8858 | ESRRG | Optic disc parameters |
| rs1436900 | Seborrheic keratosis | 0.006424 | 0.9035 | ESRRG | Optic disc parameters |
| rs1436900 | Dermatophytosis of nail | 0.006828 | 0.8845 | ESRRG | Optic disc parameters |
| rs1436900 | Nausea and vomiting | 0.009142 | 0.9051 | ESRRG | Optic disc parameters |
| rs1436900 | Secondary thrombocytopenia | 0.008736 | 0.5947 | ESRRG | Optic disc parameters |
| rs1436900 | Hypothyroidism | 0.00538 | 0.9026 | ESRRG | Optic disc parameters |
| rs1436900 | Torticollis | 0.009548 | 1.506 | ESRRG | Optic disc parameters |
| rs1436900 | Restless legs syndrome | 0.005418 | 0.759 | ESRRG | Optic disc parameters |
| rs1437898 | Benign neoplasm of thyroid glands | 0.007397 | 1.758 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Hyperplasia of prostate | 0.01042 | 0.8756 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Bacterial enteritis | 0.01126 | 1.298 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Urethral hypermobility/ISD | 0.003614 | 1.646 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Intestinal infection due to C. difficile | 0.01057 | 1.348 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Viral hepatitis | 0.004614 | 1.295 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Nonspecific findings on examination of blood | 0.006672 | 0.7532 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Acute appendicitis | 0.01148 | 0.6715 | NCKAP5 | Multiple sclerosis |
| rs1437898 | Cervical radiculitis | 0.0105 | 0.8532 | NCKAP5 | Multiple sclerosis |
| rs1445898 | Other derangement of joint | 0.00684 | 1.28 | CAPSL | Type 1 diabetes |
| rs1445898 | Candidiasis | 0.01029 | 0.8495 | CAPSL | Type 1 diabetes |
| rs1445898 | Benign neoplasm of thyroid glands | 0.001694 | 1.953 | CAPSL | Type 1 diabetes |
| rs1445898 | Drug-resistant infection | 0.00862 | 1.355 | CAPSL | Type 1 diabetes |
| rs1445898 | Dermatomycoses | 0.005951 | 0.5759 | CAPSL | Type 1 diabetes |
| rs1445898 | Atopic or contact dermatitis | 0.006268 | 0.9063 | CAPSL | Type 1 diabetes |
| rs1445898 | Pancreatic cancer | 0.001572 | 0.5888 | CAPSL | Type 1 diabetes |
| rs1445898 | Diplopia and disorders of binocular vision | 0.003257 | 0.7546 | CAPSL | Type 1 diabetes |
| rs1445898 | Symptoms involving female genital tract | 0.01025 | 0.7395 | CAPSL | Type 1 diabetes |
| rs1445898 | Acquired hemolytic anemias | 0.003591 | 2.072 | CAPSL | Type 1 diabetes |
| rs1445898 | Neuralgia, neuritis, and radiculitis NOS | 0.008948 | 1.194 | CAPSL | Type 1 diabetes |
| rs1445898 | Corneal edema | 0.000298 | 0.4843 | CAPSL | Type 1 diabetes |
| rs1445898 | Secondary malignant neoplasm of liver | 0.003107 | 0.7005 | CAPSL | Type 1 diabetes |
| rs1457451 | Abnormal mammogram | 0.009583 | 0.7665 | LOC100131818 | Transferrin saturation |
| rs1457451 | Disorders of sweat glands | 0.006577 | 1.414 | LOC100131818 | Transferrin saturation |
| rs1457451 | Methicillin sensitive Staphylococcus aureus | 0.01095 | 0.5685 | LOC100131818 | Transferrin saturation |
| rs1457451 | Malignant neoplasm, other | 0.009444 | 1.344 | LOC100131818 | Transferrin saturation |
| rs1457451 | Degeneration of intervertebral disc | 0.006864 | 0.8281 | LOC100131818 | Transferrin saturation |
| rs1457451 | Other hereditary hemolytic anemias | 0.01119 | 2.41 | LOC100131818 | Transferrin saturation |
| rs1457451 | Jaw disease NOS | 0.01003 | 1.706 | LOC100131818 | Transferrin saturation |
| rs1457451 | Polycythemia vera, secondary | 0.01146 | 1.81 | LOC100131818 | Transferrin saturation |
| rs1457451 | Intervertebral disc disorders | 0.008113 | 0.8563 | LOC100131818 | Transferrin saturation |
| rs1457451 | Osteoarthrosis; localized, primary | 0.008246 | 1.365 | LOC100131818 | Transferrin saturation |
| rs1457451 | Glossodynia | 0.005335 | 2.217 | LOC100131818 | Transferrin saturation |
| rs1471403 | Dysuria | 0.01014 | 1.156 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Spontaneous ecchymoses | 0.009515 | 1.582 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Pathologic fracture | 0.007176 | 0.8228 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Protein plasma/amino-acid transport and metabolism disorder | 0.01025 | 1.256 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Fracture of humerus | 0.004748 | 0.7769 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Sexual and gender identity disorders | 0.006037 | 1.388 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Supraventricular premature beats | 0.004753 | 0.7078 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Epilepsy, recurrent seizures, convulsions | 0.004168 | 0.8173 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Pneumococcal pneumonia | 0.009619 | 1.785 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Carcinoma in situ of skin | 0.00324 | 0.7673 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Chronic cystitis | 0.004328 | 1.544 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Decreased libido | 0.001962 | 2.133 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Salicylates causing adverse effects in therapeutic use | 0.01019 | 1.834 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Mycoses | 0.008796 | 1.526 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Pathologic fracture of vertebrae | 0.004155 | 0.7731 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Convulsions | 0.001465 | 0.7889 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1471403 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.01079 | 2.043 | MEPE | Bone mineral density (hip), Bone mineral density |
| rs1484170 | Nerve root and plexus disorders | 0.01038 | 0.6937 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Methicillin sensitive Staphylococcus aureus | 0.006793 | 1.398 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Type 1 diabetic retinopathy | 0.009381 | 0.6104 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Atrophic gastritis | 0.01088 | 1.519 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Bacterial infection NOS | 0.009155 | 1.16 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Graves' disease | 0.001882 | 1.632 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Sebaceous cyst | 0.009964 | 0.8568 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Somatoform disorder | 0.008994 | 1.394 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Hepatomegaly | 0.002163 | 1.956 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Allergy/adverse effect of penicillin | 0.01001 | 1.26 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Poisoning by antibiotics | 0.009996 | 1.229 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Exophthalmos | 0.0002211 | 2.396 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Crystal arthropathies | 0.009806 | 1.397 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Staphylococcus infections | 0.009872 | 1.289 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Left bundle branch block | 0.005084 | 0.697 | NRG3 | Cardiac hypertrophy |
| rs1484170 | Male infertility and abnormal spermatozoa | 0.008862 | 0.4296 | NRG3 | Cardiac hypertrophy |
| rs1497546 | Macular puckering of retina | 0.008954 | 0.5192 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Joint/ligament sprain | 0.007816 | 1.853 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Hemorrhage or hematoma complicating a procedure | 0.008627 | 0.4451 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Type 2 diabetes | 0.008102 | 1.266 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Osteoarthrosis | 0.00184 | 0.752 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Open wound of ear | 0.009373 | 3.15 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Osteoarthrosis NOS | 0.009995 | 0.777 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Diabetes mellitus | 0.008026 | 1.262 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Mental retardation | 0.001392 | 4.117 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Neoplasm of unspecified nature of digestive system | 0.008413 | 2.106 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Pleurisy; pleural effusion | 0.01048 | 1.41 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Fracture of hand or wrist | 0.01077 | 0.5824 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1497546 | Cerebral atherosclerosis | 0.001679 | 3.128 | OR5H2 | Drug-induced liver injury (flucloxacillin) |
| rs1512268 | Type 1 diabetic peripheral circulatory disorders | 0.00888 | 0.4946 | NKX3-1 | Prostate cancer |
| rs1512268 | Type 1 diabetes | 0.00281 | 0.8328 | NKX3-1 | Prostate cancer |
| rs1512268 | Elevated prostate specific antigen | 0.004165 | 1.201 | NKX3-1 | Prostate cancer |
| rs1512268 | Prostate cancer | 0.00586 | 1.187 | NKX3-1 | Prostate cancer |
| rs1512268 | Trigeminal nerve disorders | 0.004523 | 0.6702 | NKX3-1 | Prostate cancer |
| rs1512268 | Type 2 diabetes | 0.006781 | 0.9187 | NKX3-1 | Prostate cancer |
| rs1512268 | Venous embolism & thrombosis | 0.005742 | 0.859 | NKX3-1 | Prostate cancer |
| rs1512268 | Arthropathy NOS | 0.01127 | 0.8543 | NKX3-1 | Prostate cancer |
| rs1512268 | First degree AV block | 0.007499 | 0.8082 | NKX3-1 | Prostate cancer |
| rs1512268 | Altered mental status | 0.002089 | 0.7487 | NKX3-1 | Prostate cancer |
| rs1512268 | Deep vein thrombosis | 0.002907 | 0.7655 | NKX3-1 | Prostate cancer |
| rs1512268 | Dentofacial anomalies, including malocclusion | 0.00867 | 1.531 | NKX3-1 | Prostate cancer |
| rs1512268 | Nephritis and nephropathy in diseases classified elsewhere | 0.003713 | 0.7611 | NKX3-1 | Prostate cancer |
| rs1512268 | Rash and other nonspecific skin eruption | 0.005393 | 0.8566 | NKX3-1 | Prostate cancer |
| rs1512268 | Fracture of hand or wrist | 0.002299 | 0.8355 | NKX3-1 | Prostate cancer |
| rs1512268 | Diabetes mellitus | 0.007264 | 0.9203 | NKX3-1 | Prostate cancer |
| rs1512268 | Malaise and fatigue | 0.01012 | 0.9247 | NKX3-1 | Prostate cancer |
| rs1512268 | Reticulosarcoma | 0.005449 | 1.66 | NKX3-1 | Prostate cancer |
| rs1512268 | Chronic pharyngitis and nasopharyngitis | 0.008429 | 0.8603 | NKX3-1 | Prostate cancer |
| rs1512268 | Cerebrovascular disease | 0.006967 | 0.9136 | NKX3-1 | Prostate cancer |
| rs1512268 | Bacterial infection NOS | 0.009511 | 0.8847 | NKX3-1 | Prostate cancer |
| rs153091 | Other cerebral degenerations | 0.00552 | 0.6129 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Ischemic stroke | 0.001955 | 0.7696 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Respiratory failure | 0.002487 | 0.7054 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Pathologic fracture of vertebrae | 0.008572 | 1.285 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Mitral valve stenosis and/or aortic valve stenosis | 0.004792 | 0.7612 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Chronic kidney disease, Stage I or II | 0.005024 | 1.449 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Cyst or abscess of Bartholin's gland | 0.00702 | 0.282 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Thyrotoxicosis | 0.007153 | 1.266 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Hearing loss | 0.005308 | 1.11 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Symptoms and disorders of the joints | 0.01008 | 0.879 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Somatoform disorder | 0.01109 | 1.368 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Occlusion of cerebral arteries | 0.003426 | 0.791 | SHISA9 | Response to antipsychotic treatment |
| rs153091 | Posterior pituitary disorders | 0.002212 | 0.36 | SHISA9 | Response to antipsychotic treatment |
| rs1532085 | Thoracic neuritis/radiculitis | 0.004718 | 0.8888 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Disorders of cornea | 0.005818 | 1.198 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Abnormal findings on mammogram or breast exam | 0.009362 | 1.119 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Corneal opacity | 0.009417 | 1.34 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Abnormal mammogram | 0.003387 | 1.198 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Insect bite | 0.009999 | 0.8048 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Sebaceous cyst | 0.005842 | 0.8789 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Type 2 diabetic nephropathy | 0.004697 | 0.81 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | stress incontinence, female | 0.00852 | 1.18 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs1532085 | Secondary malignant neoplasm of liver | 0.006145 | 1.371 | LIPC | Total Cholesterol, HDL Cholesterol, Triglycerides |
| rs153734 | Sprains and strains | 0.009726 | 1.123 | PRICKLE2 | Folate levels |
| rs153734 | Psychogenic disorder | 0.0007665 | 1.645 | PRICKLE2 | Folate levels |
| rs153734 | Disease of tricuspid valve | 0.003837 | 1.324 | PRICKLE2 | Folate levels |
| rs153734 | Psychogenic and somatoform disorders | 0.008653 | 1.302 | PRICKLE2 | Folate levels |
| rs153734 | Althete's foot | 0.001979 | 1.344 | PRICKLE2 | Folate levels |
| rs153734 | Fracture of tibia and fibula | 0.01026 | 0.7332 | PRICKLE2 | Folate levels |
| rs153734 | Osteomyelitis | 0.007202 | 1.323 | PRICKLE2 | Folate levels |
| rs153734 | Chronic lymphocytic thyroiditis | 0.009076 | 1.473 | PRICKLE2 | Folate levels |
| rs153734 | Noninfectious disorders of lymphatic channels | 0.0099 | 0.6942 | PRICKLE2 | Folate levels |
| rs153734 | Strabismus (not specified as paralytic) | 0.005445 | 1.283 | PRICKLE2 | Folate levels |
| rs153734 | Oliguria and anuria | 0.002159 | 2.342 | PRICKLE2 | Folate levels |
| rs153734 | Abnormal loss of weight and underweight | 0.0002369 | 1.452 | PRICKLE2 | Folate levels |
| rs153734 | Benign neoplasm of uterus | 0.01037 | 1.234 | PRICKLE2 | Folate levels |
| rs153734 | Disorders of liver | 0.01137 | 1.121 | PRICKLE2 | Folate levels |
| rs153734 | Extrinsic allergic alveolitis | 0.00261 | 2.201 | PRICKLE2 | Folate levels |
| rs153734 | Anemia NOS | 0.009016 | 1.107 | PRICKLE2 | Folate levels |
| rs153734 | Neck pain | 0.00276 | 1.133 | PRICKLE2 | Folate levels |
| rs153734 | Spondylosis with myelopathy | 0.006723 | 1.427 | PRICKLE2 | Folate levels |
| rs153734 | Elevated C-reactive protein | 0.009445 | 1.923 | PRICKLE2 | Folate levels |
| rs153734 | Primary angle-closure glaucoma | 0.01041 | 0.7887 | PRICKLE2 | Folate levels |
| rs153734 | Spasm of muscle | 0.001907 | 1.294 | PRICKLE2 | Folate levels |
| rs1547374 | Pulmonary collapse; interstitial/compensatory emphysema | 0.002701 | 0.8273 | TFF1 | Pancreatic cancer |
| rs1547374 | Cholecystitis without cholelithiasis | 0.005527 | 0.7364 | TFF1 | Pancreatic cancer |
| rs1547374 | Bladder cancer | 0.006842 | 1.281 | TFF1 | Pancreatic cancer |
| rs1547374 | Hemiplegia | 0.003927 | 0.702 | TFF1 | Pancreatic cancer |
| rs1547374 | Cerebral aneurysm | 0.01006 | 0.5558 | TFF1 | Pancreatic cancer |
| rs1547374 | Multiple myeloma | 0.001593 | 0.5154 | TFF1 | Pancreatic cancer |
| rs1547374 | Nonrheumatic tricuspid valve disorders | 0.003927 | 1.489 | TFF1 | Pancreatic cancer |
| rs1547374 | Anemia of chronic disease | 0.01141 | 0.8275 | TFF1 | Pancreatic cancer |
| rs1547374 | Blindness and low vision | 0.0004335 | 0.6719 | TFF1 | Pancreatic cancer |
| rs1547374 | Herpes zoster with nervous system complications | 0.009382 | 0.6168 | TFF1 | Pancreatic cancer |
| rs1547374 | Other specified diseases of hair and hair follicles | 0.008202 | 1.316 | TFF1 | Pancreatic cancer |
| rs1547374 | Bladder cancer and neoplasms | 0.0104 | 1.257 | TFF1 | Pancreatic cancer |
| rs1547374 | Diverticulosis | 0.008272 | 0.892 | TFF1 | Pancreatic cancer |
| rs1547374 | Joint/ligament sprain | 0.005196 | 1.334 | TFF1 | Pancreatic cancer |
| rs1547374 | Abnormality of red blood cells | 0.003767 | 2.044 | TFF1 | Pancreatic cancer |
| rs1547374 | Diverticulosis and diverticulitis | 0.004917 | 0.8909 | TFF1 | Pancreatic cancer |
| rs1550976 | Lack of normal physiological development | 0.003745 | 0.679 | NTM | Asperger disorder |
| rs1550976 | Osteomyelitis | 0.007643 | 1.294 | NTM | Asperger disorder |
| rs1550976 | Failure to thrive | 0.0005552 | 0.5974 | NTM | Asperger disorder |
| rs1550976 | Dry eyes | 0.01052 | 1.138 | NTM | Asperger disorder |
| rs1550976 | Nonsenile Cataract | 0.009277 | 1.394 | NTM | Asperger disorder |
| rs1550976 | Nonallopathic lesions NEC | 0.005402 | 0.8724 | NTM | Asperger disorder |
| rs1550976 | Duodenal ulcer | 0.007034 | 0.722 | NTM | Asperger disorder |
| rs1550976 | Cataract | 0.007398 | 1.116 | NTM | Asperger disorder |
| rs1550976 | Raynaud's syndrome | 0.008239 | 1.316 | NTM | Asperger disorder |
| rs1550976 | Voice disturbance | 0.0003659 | 1.296 | NTM | Asperger disorder |
| rs1564348 | Other disorders of back | 0.008498 | 0.8147 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Mixed hyperlipidemia | 0.001174 | 1.289 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Diplopia and disorders of binocular vision | 0.001436 | 1.453 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Fracture of ribs | 0.009837 | 0.7327 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Acquired spondylolisthesis | 0.005647 | 0.6537 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Cancer of mouth | 0.005219 | 1.663 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Mammographic microcalcification | 0.01005 | 1.629 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Glaucoma | 0.005533 | 0.8565 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Postlaminectomy syndrome | 0.005822 | 0.5674 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Pulmonary embolism and infarction | 0.003026 | 1.362 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Cysts of the jaws | 0.00986 | 2.318 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Cancer of oropharynx | 0.0004719 | 2.672 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | pulmonary heart disease | 0.0002502 | 1.292 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1564348 | Duodenitis | 0.0004331 | 1.661 | SLC22A1 | Total Cholesterol, LDL Cholesterol |
| rs1566039 | Somatoform disorder | 0.0003603 | 1.494 | PAPD7 | Sphingolipid levels |
| rs1566039 | Other sprains and strains | 0.01022 | 0.737 | PAPD7 | Sphingolipid levels |
| rs1566039 | Infestation | 0.009054 | 0.5516 | PAPD7 | Sphingolipid levels |
| rs1566039 | Effects of radiation NOS | 0.003032 | 1.529 | PAPD7 | Sphingolipid levels |
| rs1566039 | Psychogenic and somatoform disorders | 0.003187 | 1.306 | PAPD7 | Sphingolipid levels |
| rs1566039 | Tension headache | 0.01076 | 1.225 | PAPD7 | Sphingolipid levels |
| rs1566039 | Systemic sclerosis | 0.0005653 | 0.5268 | PAPD7 | Sphingolipid levels |
| rs1566039 | Swelling, mass, or lump in head and neck | 0.004755 | 1.251 | PAPD7 | Sphingolipid levels |
| rs1566039 | Polyarteritis nodosa and allied conditions | 0.0103 | 1.321 | PAPD7 | Sphingolipid levels |
| rs1566039 | Dentofacial anomalies, including malocclusion | 0.003622 | 1.601 | PAPD7 | Sphingolipid levels |
| rs1566039 | Polycythemia vera | 0.002466 | 1.897 | PAPD7 | Sphingolipid levels |
| rs1566039 | Anomalies of tooth position/malocclusion | 0.00478 | 1.685 | PAPD7 | Sphingolipid levels |
| rs1566039 | Contact dermatitis and other eczema due to plants [except food] | 0.007869 | 1.742 | PAPD7 | Sphingolipid levels |
| rs1568679 | Cystic mastopathy | 0.006019 | 0.7497 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Congenital anomalies of lower limb, including pelvic girdle | 9.934e-05 | 2.922 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Cancer of the upper aerodigestive tract | 0.007692 | 0.4527 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Benign mammary dysplasias | 0.00828 | 0.7662 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Blood vessel replaced | 0.01086 | 0.2722 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Myoneural disorders | 0.009559 | 2.212 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Cancer of bone & connective tissue | 0.01045 | 0.3723 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Suicidal ideation or attempt | 0.005794 | 2.136 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Elevated prostate specific antigen | 0.001184 | 1.438 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Spasm of muscle | 0.008143 | 1.364 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Urinary tract infection | 0.005042 | 1.192 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Diseases of nail | 0.009256 | 0.7715 | MEIS2 | Response to antipsychotic treatment |
| rs1568679 | Other unspecified back disorders | 0.00587 | 1.88 | MEIS2 | Response to antipsychotic treatment |
| rs1648707 | Mammographic microcalcification | 0.01073 | 1.514 | ADIPOQ | Adiponectin levels |
| rs1648707 | Hypermetropia | 0.008225 | 0.8771 | ADIPOQ | Adiponectin levels |
| rs1648707 | Impaction of intestine | 0.006627 | 2.106 | ADIPOQ | Adiponectin levels |
| rs1648707 | severe protein-calorie malnutrition | 0.001373 | 0.5404 | ADIPOQ | Adiponectin levels |
| rs1648707 | Other aneurysm | 0.009438 | 1.179 | ADIPOQ | Adiponectin levels |
| rs1648707 | Other disorders of stomach and duodenum | 0.0002897 | 0.6927 | ADIPOQ | Adiponectin levels |
| rs1648707 | Pseudoexfoliation glaucoma | 0.001649 | 0.5407 | ADIPOQ | Adiponectin levels |
| rs1648707 | Nonsenile Cataract | 0.0024 | 0.674 | ADIPOQ | Adiponectin levels |
| rs1648707 | Other specified intestinal malabsorption | 0.005449 | 1.664 | ADIPOQ | Adiponectin levels |
| rs1648707 | Poisoning by psychotropic agents | 0.007502 | 0.5089 | ADIPOQ | Adiponectin levels |
| rs1648707 | Atrophic gastritis | 0.008901 | 0.6505 | ADIPOQ | Adiponectin levels |
| rs1648707 | Nontoxic multinodular goiter | 0.005188 | 1.274 | ADIPOQ | Adiponectin levels |
| rs1668871 | Neck pain | 0.004719 | 1.105 | TMCC2 | Platelet counts |
| rs1668871 | Adverse effects of insulins and antidiabetic agents | 0.0001238 | 0.3452 | TMCC2 | Platelet counts |
| rs1668871 | Osteoarthrosis NOS | 0.005275 | 1.096 | TMCC2 | Platelet counts |
| rs1668871 | Carcinoma in situ of skin | 0.0006356 | 0.7438 | TMCC2 | Platelet counts |
| rs1668871 | Endometriosis | 0.001163 | 1.455 | TMCC2 | Platelet counts |
| rs1668871 | Symptoms involving respiratory system | 0.004915 | 0.8184 | TMCC2 | Platelet counts |
| rs1668871 | Erectile dysfunction | 0.004471 | 1.182 | TMCC2 | Platelet counts |
| rs1668871 | Other benign neoplasm of connective and other soft tissue | 0.01042 | 1.439 | TMCC2 | Platelet counts |
| rs1668871 | Diseases of respiratory system | 0.004001 | 0.8484 | TMCC2 | Platelet counts |
| rs1668871 | Male genital disorders | 0.0004251 | 1.422 | TMCC2 | Platelet counts |
| rs1668871 | Cancer within the respiratory system | 0.01146 | 0.8147 | TMCC2 | Platelet counts |
| rs1668871 | Biliary cirrhosis | 0.0008583 | 2.599 | TMCC2 | Platelet counts |
| rs1668871 | Asthma with exacerbation | 0.007698 | 0.7192 | TMCC2 | Platelet counts |
| rs1668871 | Cirrhosis of liver without mention of alcohol | 0.001033 | 1.532 | TMCC2 | Platelet counts |
| rs1668871 | Osteoarthrosis | 0.006321 | 1.087 | TMCC2 | Platelet counts |
| rs1668871 | Intestinal infection due to C. difficile | 0.004348 | 1.392 | TMCC2 | Platelet counts |
| rs1668871 | Cancer, suspected or other | 0.001256 | 0.8005 | TMCC2 | Platelet counts |
| rs1668871 | Nontoxic uninodular goiter | 0.005446 | 1.233 | TMCC2 | Platelet counts |
| rs1668871 | Malignant neoplasm, other | 0.004162 | 0.7971 | TMCC2 | Platelet counts |
| rs1668871 | Eating disorder | 0.005275 | 1.643 | TMCC2 | Platelet counts |
| rs16826658 | Osteoporosis | 0.007876 | 1.129 | WNT4 | Endometriosis |
| rs16826658 | Glomerulonephritis | 0.0009122 | 1.849 | WNT4 | Endometriosis |
| rs16826658 | Angina pectoris | 0.01151 | 0.8877 | WNT4 | Endometriosis |
| rs16826658 | Other open wound of head and face | 0.009457 | 1.203 | WNT4 | Endometriosis |
| rs16826658 | Skin neoplasm of uncertain behavior | 0.004915 | 0.8218 | WNT4 | Endometriosis |
| rs16826658 | Absent or infrequent menstruation | 0.01141 | 0.6522 | WNT4 | Endometriosis |
| rs16826658 | Nonrheumatic mitral valve disorders | 0.01109 | 0.8768 | WNT4 | Endometriosis |
| rs16826658 | Eating disorder | 0.00233 | 0.537 | WNT4 | Endometriosis |
| rs16826658 | Lesions of stomach and duodenum | 0.008791 | 0.4576 | WNT4 | Endometriosis |
| rs16826658 | Secondary/extrinsic cardiomyopathies | 0.009902 | 1.723 | WNT4 | Endometriosis |
| rs16826658 | Derangement of joint, non-traumatic | 0.007448 | 0.8006 | WNT4 | Endometriosis |
| rs16826658 | Erythematous conditions | 0.007442 | 0.8864 | WNT4 | Endometriosis |
| rs16826658 | Acquired deformities of finger | 0.006395 | 0.6703 | WNT4 | Endometriosis |
| rs16826658 | Dysmenorrhea | 0.00314 | 0.6157 | WNT4 | Endometriosis |
| rs16826658 | Fracture of tibia and fibula | 0.005195 | 1.288 | WNT4 | Endometriosis |
| rs16826658 | Abnormal sputum | 0.005946 | 0.743 | WNT4 | Endometriosis |
| rs16826658 | Cornea replaced by transplant | 0.008585 | 1.716 | WNT4 | Endometriosis |
| rs16861990 | Phlebitis and thrombophlebitis of lower extremities | 0.005728 | 1.453 | NME7 | D-dimer levels |
| rs16861990 | Alkalosis | 0.0103 | 2.227 | NME7 | D-dimer levels |
| rs16861990 | Phlebitis and thrombophlebitis | 0.002011 | 1.446 | NME7 | D-dimer levels |
| rs16861990 | Coagulation defects | 0.0005116 | 1.263 | NME7 | D-dimer levels |
| rs16861990 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.003753 | 1.227 | NME7 | D-dimer levels |
| rs16861990 | Hypercoagulable state | 2e-12 | 3.709 | NME7 | D-dimer levels |
| rs16861990 | Fracture of ribs | 0.005535 | 1.464 | NME7 | D-dimer levels |
| rs16861990 | Clotting factor deficiency | 1.523e-09 | 6.02 | NME7 | D-dimer levels |
| rs16861990 | Mitral valve stenosis and/or aortic valve stenosis | 0.006453 | 0.6231 | NME7 | D-dimer levels |
| rs16861990 | Uterine/Uterovaginal prolapse | 0.002571 | 1.568 | NME7 | D-dimer levels |
| rs16861990 | Venous embolism & thrombosis | 0.001037 | 1.369 | NME7 | D-dimer levels |
| rs16861990 | Light-headedness and vertigo | 0.00543 | 1.203 | NME7 | D-dimer levels |
| rs16861990 | Congenital coagulation defects | 2.069e-11 | 5.429 | NME7 | D-dimer levels |
| rs16861990 | Insect bite | 0.008303 | 1.445 | NME7 | D-dimer levels |
| rs16886165 | Other disorders of back | 0.005962 | 0.8103 | MAP3K1 | Breast cancer |
| rs16886165 | Complication of amputation stump | 0.005658 | 2.012 | MAP3K1 | Breast cancer |
| rs16886165 | Dyspepsia and disorders of function of stomach | 0.01047 | 1.199 | MAP3K1 | Breast cancer |
| rs16886165 | Inflammation of the eye | 0.01003 | 1.15 | MAP3K1 | Breast cancer |
| rs16886165 | Schizophrenia and other psychotic disorders | 0.004554 | 1.262 | MAP3K1 | Breast cancer |
| rs16886165 | Seborrheic keratosis | 0.007964 | 1.137 | MAP3K1 | Breast cancer |
| rs16886165 | Disorders of penis | 0.002588 | 1.488 | MAP3K1 | Breast cancer |
| rs16886165 | Ankylosis of joint | 0.001917 | 1.61 | MAP3K1 | Breast cancer |
| rs16886165 | Mitral stenosis/insufficiency | 0.01106 | 0.2713 | MAP3K1 | Breast cancer |
| rs16886165 | Inflammation of eyelids | 0.001928 | 1.205 | MAP3K1 | Breast cancer |
| rs16886165 | Open wound of foot except toe(s) alone | 0.008004 | 1.608 | MAP3K1 | Breast cancer |
| rs16886165 | Peritoneal adhesions (postoperative) (postinfection) | 0.0115 | 1.623 | MAP3K1 | Breast cancer |
| rs16886165 | Disorders of esophageal motility | 0.002152 | 1.675 | MAP3K1 | Breast cancer |
| rs16892766 | Umbilical hernia | 0.007606 | 1.471 | EIF3H | Colorectal cancer |
| rs16892766 | Protein-calorie malnutrition | 0.002273 | 0.6915 | EIF3H | Colorectal cancer |
| rs16892766 | Ankylosing spondylitis | 0.009873 | 2.582 | EIF3H | Colorectal cancer |
| rs16892766 | Benign neoplasm of other parts of digestive system | 0.0003235 | 1.72 | EIF3H | Colorectal cancer |
| rs16892766 | Chronic tonsillitis and adenoiditis | 0.007839 | 2.062 | EIF3H | Colorectal cancer |
| rs16892766 | Chronic venous hypertension | 0.005815 | 2.632 | EIF3H | Colorectal cancer |
| rs16892766 | Injuries to the nervous system | 0.01148 | 1.809 | EIF3H | Colorectal cancer |
| rs16892766 | Neuralgia, neuritis, and radiculitis NOS | 0.01023 | 1.337 | EIF3H | Colorectal cancer |
| rs16892766 | Respiratory failure; insufficiency; arrest | 0.009411 | 0.7077 | EIF3H | Colorectal cancer |
| rs16892766 | Disorders of the pituitary gland and its hypothalamic control | 0.01104 | 1.554 | EIF3H | Colorectal cancer |
| rs16892766 | Inflammatory spondylopathies | 0.007386 | 1.801 | EIF3H | Colorectal cancer |
| rs16892766 | Acute and chronic tonsillitis | 0.01081 | 1.68 | EIF3H | Colorectal cancer |
| rs16928809 | Torticollis | 0.005481 | 1.855 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Neoplasm of unspecified nature of digestive system | 0.005862 | 1.635 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Benign neoplasm of other parts of digestive system | 0.01029 | 0.5815 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Polyneuropathy in diabetes | 0.01101 | 0.7366 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Seborrhea | 0.008 | 2.228 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Cervical cancer | 0.01024 | 2.109 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Chronic liver disease and cirrhosis | 0.0003976 | 0.5678 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Acquired deformities of finger | 0.005258 | 1.684 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Asthma with exacerbation | 0.004928 | 1.591 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Costochondritis | 0.005696 | 2.143 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Chronic nonalcoholic liver disease | 0.0002762 | 0.5311 | SLC22A18 | Serum bilirubin levels |
| rs16928809 | Cerebral aneurysm | 5.207e-05 | 2.534 | SLC22A18 | Serum bilirubin levels |
| rs16944141 | Asthma | 0.0006431 | 1.309 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Unspecified monoarthritis | 0.00949 | 1.991 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Chronic laryngitis | 0.008406 | 2.465 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Benign neoplasm of skin | 0.009097 | 0.8214 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Excessive or frequent menstruation | 0.008985 | 0.5981 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Discoid lupus erythematosus | 0.008903 | 1.807 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Abnormal pulmonary function | 0.01003 | 2.756 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Dyschromia and Vitiligo | 0.009427 | 0.6686 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Stress fracture | 0.005813 | 2.388 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Emphysema | 0.011 | 1.461 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Chronic prostatitis | 0.005304 | 1.974 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16944141 | Prurigo | 0.007677 | 1.521 | MIR622 | Prostate cancer (gene x gene interaction) |
| rs16991615 | Intestinal malabsorption NOS | 0.01047 | 2.049 | MCM8 | Menopause |
| rs16991615 | Transient cerebral ischemia | 0.007039 | 1.295 | MCM8 | Menopause |
| rs16991615 | Deficiency of humoral immunity | 0.00834 | 2.665 | MCM8 | Menopause |
| rs16991615 | Chronic cystitis | 0.01124 | 1.893 | MCM8 | Menopause |
| rs16991615 | Intracerebral hemorrhage | 0.004037 | 2.147 | MCM8 | Menopause |
| rs16991615 | Cerebral ischemia | 0.01035 | 1.274 | MCM8 | Menopause |
| rs16991615 | Alopecia | 0.004729 | 1.632 | MCM8 | Menopause |
| rs16991615 | Osteitis deformans and osteopathies associated with other disorders | 0.007037 | 2.14 | MCM8 | Menopause |
| rs16991615 | Exostosis of jaw | 0.00266 | 2.959 | MCM8 | Menopause |
| rs16991615 | Hydrocele | 0.009997 | 1.909 | MCM8 | Menopause |
| rs16991615 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.005949 | 1.405 | MCM8 | Menopause |
| rs16991615 | Venous embolism & thrombosis | 0.004174 | 0.7127 | MCM8 | Menopause |
| rs16991615 | Other disorders of testis | 0.006667 | 1.748 | MCM8 | Menopause |
| rs16991615 | Localized adiposity | 0.004673 | 2.571 | MCM8 | Menopause |
| rs16991615 | Viral Enteritis | 0.001201 | 2.066 | MCM8 | Menopause |
| rs16991615 | Other abnormality of urination | 0.005026 | 1.435 | MCM8 | Menopause |
| rs17066096 | Age-related macular degeneration | 0.006957 | 1.228 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Hemoptysis | 0.003212 | 1.406 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Retinal detachment with retinal defect | 0.006982 | 1.424 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Respiratory failure; insufficiency; arrest | 0.01013 | 1.203 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Abnormal sputum | 0.001804 | 1.409 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Cirrhosis of liver without mention of alcohol | 0.006985 | 1.459 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Other symptoms involving abdomen and pelvis | 0.005744 | 1.161 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Portal hypertension | 0.01118 | 1.675 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Chronic liver disease and cirrhosis | 0.00422 | 1.263 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Respiratory abnormalities | 6.109e-05 | 1.535 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Retinal vascular changes and abnomalities | 0.0102 | 1.234 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Hemorrhage of gastrointestinal tract | 0.01054 | 1.183 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Other paralytic syndromes | 0.004714 | 1.539 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Eye infection, viral | 0.007761 | 1.428 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Peripheral or central vertigo | 0.003077 | 1.257 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Pulmonary collapse; interstitial/compensatory emphysema | 0.001325 | 1.227 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Liver abscess and sequelae of chronic liver disease | 0.008834 | 1.552 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.002885 | 1.241 | IL22RA2 | Multiple sclerosis |
| rs17066096 | Rheumatoid arthritis | 0.003025 | 1.271 | IL22RA2 | Multiple sclerosis |
| rs17111394 | Non-melanoma skin cancer | 0.009137 | 0.8799 | TSHR | Optic disc parameters |
| rs17111394 | Diseases of spleen | 0.008828 | 1.91 | TSHR | Optic disc parameters |
| rs17111394 | Retinoschisis and retinal cysts | 0.005901 | 2.215 | TSHR | Optic disc parameters |
| rs17111394 | Nonsenile Cataract | 0.008807 | 1.453 | TSHR | Optic disc parameters |
| rs17111394 | Skin cancer | 0.005905 | 0.8796 | TSHR | Optic disc parameters |
| rs17111394 | Symptoms involving digestive system | 0.01073 | 1.259 | TSHR | Optic disc parameters |
| rs17111394 | Other disorders of gallbladder | 0.01038 | 1.631 | TSHR | Optic disc parameters |
| rs17111394 | Delirium due to conditions classified elsewhere | 0.01117 | 0.6443 | TSHR | Optic disc parameters |
| rs17111394 | Bundle branch block | 0.01071 | 0.7955 | TSHR | Optic disc parameters |
| rs17111394 | Abnormal results of function study of liver | 0.005795 | 1.273 | TSHR | Optic disc parameters |
| rs17111394 | Pulmonary congestion and hypostasis | 0.007712 | 0.6289 | TSHR | Optic disc parameters |
| rs17111394 | Abnormal weight gain | 0.001452 | 1.501 | TSHR | Optic disc parameters |
| rs17277546 | Fibroadenosis of breast | 0.008292 | 3.207 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Bladder cancer | 0.003702 | 0.4074 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Diseases of pulp and periapical tissues | 0.009044 | 1.446 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Malignant neoplasm, other | 0.003915 | 1.578 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Polymyalgia Rheumatica | 0.0008098 | 1.736 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Hemorrhage or hematoma complicating a procedure | 0.0006496 | 1.596 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Fracture of pelvis | 0.003816 | 1.778 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Bladder cancer and neoplasms | 0.001894 | 0.3831 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Periapical abscess | 0.01028 | 1.457 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Impaired fasting glucose | 0.006982 | 1.407 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Aplastic anemia | 0.01151 | 0.3509 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Malunion fracture | 0.01052 | 1.859 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Cancer of kidney and urinary organs | 0.01018 | 0.5927 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17277546 | Fractur of unspecified part of femur | 0.006238 | 1.878 | TRIM4 | Dehydroepiandrosterone sulphate levels, Androsterone sulfate |
| rs17291650 | Fracture of hand or wrist | 0.009486 | 0.7645 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Other derangement of joint | 0.003471 | 0.5697 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of lower limb | 0.003931 | 0.7741 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of unspecified bones | 0.005722 | 0.7717 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Hypovolemia | 0.007208 | 0.8155 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Colles' fracture | 0.009174 | 0.5406 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Ankylosis of joint | 0.0006208 | 0.2903 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of upper limb | 0.0002088 | 0.718 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Genu valgum or varum (acquired) | 0.003074 | 0.4195 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of ribs | 0.008905 | 0.6779 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of foot | 0.009953 | 0.7244 | ATF1 | Sudden cardiac arrest |
| rs17291650 | progressive myopia | 0.01002 | 1.984 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Rheumatoid arthritis | 0.0081 | 0.6885 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Phosphorus metabolism disorder | 0.007451 | 1.642 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.001091 | 0.6592 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Inflammatory conditions of jaw | 0.0041 | 1.893 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Fracture of radius and ulna | 0.004104 | 0.7286 | ATF1 | Sudden cardiac arrest |
| rs17291650 | Acute pericarditis | 0.00657 | 2.424 | ATF1 | Sudden cardiac arrest |
| rs17415853 | Other specified disorders of pancreatic internal secretion | 0.0005846 | 3.142 | EPS8 | Serum ferritin levels |
| rs17415853 | Colles' fracture | 0.006726 | 2.045 | EPS8 | Serum ferritin levels |
| rs17415853 | Cervical cancer and dysplasia | 0.003943 | 1.818 | EPS8 | Serum ferritin levels |
| rs17415853 | Other disorders of pancreatic internal secretion | 0.0007193 | 3.081 | EPS8 | Serum ferritin levels |
| rs17415853 | Allergies, other | 0.00365 | 1.745 | EPS8 | Serum ferritin levels |
| rs17415853 | Varicose veins | 0.007507 | 0.6538 | EPS8 | Serum ferritin levels |
| rs17415853 | Esophageal bleeding | 0.004138 | 2.717 | EPS8 | Serum ferritin levels |
| rs17415853 | Other forms of chronic heart disease | 0.00563 | 1.542 | EPS8 | Serum ferritin levels |
| rs17415853 | E. coli | 0.005473 | 1.84 | EPS8 | Serum ferritin levels |
| rs17415853 | Symptoms involving head and neck | 0.007905 | 1.524 | EPS8 | Serum ferritin levels |
| rs17415853 | Complications of transplants and reattached limbs | 0.003653 | 2.504 | EPS8 | Serum ferritin levels |
| rs17415853 | Osteoarthrosis; localized, secondary | 0.003099 | 2.525 | EPS8 | Serum ferritin levels |
| rs174570 | Other specified diseases of sebaceous glands | 0.01018 | 1.293 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Cyst of kidney, acquired | 0.002403 | 1.459 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Celiac disease | 0.006707 | 1.969 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Celiac or tropical sprue | 0.005255 | 1.98 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Light-headedness and vertigo | 0.006284 | 1.145 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Protein-calorie malnutrition | 0.005215 | 0.7774 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Pleurisy; pleural effusion | 0.009189 | 0.8239 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Abnormal loss of weight and underweight | 0.007752 | 0.6712 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Infertility, female | 0.007218 | 0.3159 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Acute periodontitis | 0.009569 | 1.485 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Open wound of eye or eyelid | 0.01055 | 2.107 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Genitourinary congenital anomalies | 0.0009525 | 1.612 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs174570 | Vertiginous syndromes and other disorders of vestibular system | 0.006411 | 1.139 | FADS2 | Total Cholesterol, LDL Cholesterol, HDL Cholesterol |
| rs17525472 | Chronic periodontitis | 6.318e-05 | 1.559 | SCG3 | Asthma |
| rs17525472 | Dental caries | 0.0009077 | 1.359 | SCG3 | Asthma |
| rs17525472 | Atherosclerosis of aorta | 0.008869 | 1.371 | SCG3 | Asthma |
| rs17525472 | Viral warts & HPV | 0.01009 | 1.215 | SCG3 | Asthma |
| rs17525472 | Carcinoma in situ of skin | 0.009132 | 1.34 | SCG3 | Asthma |
| rs17525472 | Intestinal malabsorption | 0.01035 | 1.496 | SCG3 | Asthma |
| rs17525472 | Periodontitis (acute or chronic) | 0.001854 | 1.372 | SCG3 | Asthma |
| rs17525472 | Retinal vascular changes and abnomalities | 0.001702 | 1.381 | SCG3 | Asthma |
| rs17525472 | Arthropathy NOS involving multiple sites | 0.00491 | 1.841 | SCG3 | Asthma |
| rs17525472 | Circumscribed scleroderma | 0.009693 | 1.537 | SCG3 | Asthma |
| rs17525472 | Symptoms involving digestive system | 0.01126 | 1.307 | SCG3 | Asthma |
| rs17525472 | Allergic reaction to food | 0.009987 | 2.051 | SCG3 | Asthma |
| rs17525472 | Hemoptysis | 0.008111 | 1.472 | SCG3 | Asthma |
| rs17525472 | Abnormal results of function studies | 0.0001375 | 2.2 | SCG3 | Asthma |
| rs17525472 | Acute bronchospasm | 0.005176 | 2.51 | SCG3 | Asthma |
| rs17525472 | Type 1 diabetic ketoacidosis | 0.008222 | 0.5142 | SCG3 | Asthma |
| rs17525472 | Gingival and periodontal diseases | 0.007376 | 1.278 | SCG3 | Asthma |
| rs17525472 | Cancer of the lower GI tract | 0.003296 | 1.551 | SCG3 | Asthma |
| rs17525472 | Abnormal coagulation profile | 0.007619 | 1.493 | SCG3 | Asthma |
| rs17525472 | Abnormal sputum | 0.008627 | 1.442 | SCG3 | Asthma |
| rs17525472 | Diseases of hard tissues of teeth | 0.0004614 | 1.369 | SCG3 | Asthma |
| rs17525472 | Optic atrophy | 0.004119 | 1.667 | SCG3 | Asthma |
| rs1755289 | Pulmonary collapse; interstitial/compensatory emphysema | 0.003926 | 1.181 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Disorders of cervical region | 0.007378 | 0.7319 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Benign neoplasm of bone and articular cartilage | 0.003388 | 1.759 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Varicose veins | 0.009134 | 1.147 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Acquired absence of breast | 0.005707 | 0.7407 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Aseptic necrosis of bone | 7.35e-05 | 1.907 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Disturbances in tooth eruption | 0.008238 | 0.7352 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Lupus erythematosus | 0.003519 | 1.949 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Varicose veins of lower extremity | 0.006078 | 1.162 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Develomental delays and disorders | 0.003267 | 0.7558 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Scoliosis | 0.00785 | 0.7605 | SH3GL2 | Multiple sclerosis |
| rs1755289 | Dermatomycoses | 0.00332 | 1.737 | SH3GL2 | Multiple sclerosis |
| rs17584499 | Gastrointestinal hemorrhage | 0.007917 | 1.129 | PTPRD | Type 2 diabetes |
| rs17584499 | Posttraumatic wound infection | 0.00658 | 0.3412 | PTPRD | Type 2 diabetes |
| rs17584499 | Myocardial infarction | 0.006576 | 0.8553 | PTPRD | Type 2 diabetes |
| rs17584499 | Pleurisy; pleural effusion | 0.001205 | 1.21 | PTPRD | Type 2 diabetes |
| rs17584499 | Urticaria | 0.007303 | 0.7524 | PTPRD | Type 2 diabetes |
| rs17584499 | Intracranial hemorrhage | 0.007321 | 0.6753 | PTPRD | Type 2 diabetes |
| rs17584499 | Ischemic Heart Disease | 0.008935 | 0.9045 | PTPRD | Type 2 diabetes |
| rs17584499 | Coronary atherosclerosis | 0.01042 | 0.9014 | PTPRD | Type 2 diabetes |
| rs17584499 | Photodermatitis & sunburn | 0.00416 | 0.8001 | PTPRD | Type 2 diabetes |
| rs17584499 | Esophageal bleeding | 0.0102 | 1.732 | PTPRD | Type 2 diabetes |
| rs17584499 | Congenital anomalies of great vessels | 0.004277 | 2.096 | PTPRD | Type 2 diabetes |
| rs17584499 | Microscopic hematuria | 0.002993 | 0.5037 | PTPRD | Type 2 diabetes |
| rs17584499 | Portal hypertension | 0.001145 | 1.983 | PTPRD | Type 2 diabetes |
| rs17584499 | Liver abscess and sequelae of chronic liver disease | 0.007552 | 1.614 | PTPRD | Type 2 diabetes |
| rs17584499 | Acute bronchospasm | 0.002386 | 2.451 | PTPRD | Type 2 diabetes |
| rs17638629 | Candidiasis | 0.009611 | 0.6023 | ZNF788 | Cognitive performance |
| rs17638629 | Chronic ulcer of unspecified site | 0.009629 | 0.3951 | ZNF788 | Cognitive performance |
| rs17638629 | Congenital anomalies of great vessels | 0.009083 | 2.841 | ZNF788 | Cognitive performance |
| rs17638629 | Strabismus (not specified as paralytic) | 0.009399 | 0.5036 | ZNF788 | Cognitive performance |
| rs17638629 | Disorders of binocular eye movements | 0.007476 | 0.5566 | ZNF788 | Cognitive performance |
| rs17646946 | Other dyschromia | 0.004592 | 1.311 | TCHHL1 | Hair morphology |
| rs17646946 | Cerebral atherosclerosis | 0.006886 | 0.4693 | TCHHL1 | Hair morphology |
| rs17646946 | Depression | 0.0109 | 0.8961 | TCHHL1 | Hair morphology |
| rs17646946 | Injuries to the nervous system | 0.009361 | 1.582 | TCHHL1 | Hair morphology |
| rs17646946 | Valvular heart disease/ heart chambers | 0.0005515 | 2.095 | TCHHL1 | Hair morphology |
| rs17646946 | Stomatitis and mucositis | 0.01119 | 0.6537 | TCHHL1 | Hair morphology |
| rs17646946 | Diseases of the oral soft tissues | 0.007554 | 0.8231 | TCHHL1 | Hair morphology |
| rs17646946 | Acid-base balance disorder | 0.009158 | 1.341 | TCHHL1 | Hair morphology |
| rs17646946 | Cardiac arrest | 0.001761 | 1.763 | TCHHL1 | Hair morphology |
| rs17646946 | Alopecia Areata | 0.006284 | 2.065 | TCHHL1 | Hair morphology |
| rs17646946 | Parasomnia | 0.0114 | 1.651 | TCHHL1 | Hair morphology |
| rs17646946 | Heart valve replaced | 0.0007095 | 1.433 | TCHHL1 | Hair morphology |
| rs17646946 | Megaloblastic anemia | 0.0006547 | 1.531 | TCHHL1 | Hair morphology |
| rs17646946 | Acidosis | 0.01071 | 1.4 | TCHHL1 | Hair morphology |
| rs17646946 | Subdural hemorrhage (injury) | 0.00478 | 1.754 | TCHHL1 | Hair morphology |
| rs17646946 | Degeneration of intervertebral disc | 0.005125 | 0.8657 | TCHHL1 | Hair morphology |
| rs17646946 | Intracranial hemorrhage (injury) | 0.009332 | 1.505 | TCHHL1 | Hair morphology |
| rs17646946 | Back pain | 0.01086 | 0.912 | TCHHL1 | Hair morphology |
| rs17646946 | Bullous dermatoses | 0.001046 | 2.169 | TCHHL1 | Hair morphology |
| rs17646946 | Spinal stenosis | 0.003173 | 0.8452 | TCHHL1 | Hair morphology |
| rs17662626 | Idiopathic fibrosing alveolitis | 0.002455 | 2.501 | PCGEM1 | Schizophrenia |
| rs17662626 | Vitamin deficiency | 0.008176 | 0.7175 | PCGEM1 | Schizophrenia |
| rs17662626 | Other alveolar and parietoalveolar pneumonopathy | 0.01112 | 1.974 | PCGEM1 | Schizophrenia |
| rs17662626 | Dermatosis NOS | 0.005948 | 0.8183 | PCGEM1 | Schizophrenia |
| rs17662626 | Photodermatitis & sunburn | 0.008769 | 0.7238 | PCGEM1 | Schizophrenia |
| rs17662626 | Malaise and fatigue | 0.006595 | 0.8541 | PCGEM1 | Schizophrenia |
| rs17662626 | Sleep apnea | 0.00474 | 0.79 | PCGEM1 | Schizophrenia |
| rs17662626 | Acute osteomyelitis | 0.01007 | 1.959 | PCGEM1 | Schizophrenia |
| rs17662626 | Irregular menstrual bleeding | 0.01012 | 2.03 | PCGEM1 | Schizophrenia |
| rs17662626 | Renal failure NOS | 0.008119 | 0.4819 | PCGEM1 | Schizophrenia |
| rs17696736 | Anal and rectal polyp | 0.008345 | 0.8028 | NAA25 | Type 1 diabetes |
| rs17696736 | Atherosclerosis | 0.006844 | 1.124 | NAA25 | Type 1 diabetes |
| rs17696736 | Insomnia | 0.006256 | 0.8562 | NAA25 | Type 1 diabetes |
| rs17696736 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.0005808 | 1.234 | NAA25 | Type 1 diabetes |
| rs17696736 | Other aneurysm | 0.00711 | 1.182 | NAA25 | Type 1 diabetes |
| rs17696736 | Retinoschisis and retinal cysts | 0.001274 | 2.43 | NAA25 | Type 1 diabetes |
| rs17696736 | Abdominal aortic aneurysm | 0.006319 | 1.242 | NAA25 | Type 1 diabetes |
| rs17696736 | Atherosclerosis of the extremities | 0.002635 | 1.159 | NAA25 | Type 1 diabetes |
| rs17696736 | Ventricular fibrillation & flutter | 0.001522 | 0.5496 | NAA25 | Type 1 diabetes |
| rs17696736 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.0002792 | 1.335 | NAA25 | Type 1 diabetes |
| rs17696736 | Abnormal findings on mammogram or breast exam | 0.008056 | 1.12 | NAA25 | Type 1 diabetes |
| rs17696736 | Impaired fasting glucose | 0.007954 | 0.8462 | NAA25 | Type 1 diabetes |
| rs17696736 | Type 2 diabetic nephropathy | 0.003832 | 0.81 | NAA25 | Type 1 diabetes |
| rs17696736 | Mastodynia | 0.005788 | 1.283 | NAA25 | Type 1 diabetes |
| rs17696736 | Endometriosis | 0.005688 | 0.7172 | NAA25 | Type 1 diabetes |
| rs17696736 | Hypothyroidism | 0.0006531 | 1.131 | NAA25 | Type 1 diabetes |
| rs17696736 | Peyronie's disease | 0.003004 | 1.938 | NAA25 | Type 1 diabetes |
| rs17696736 | Aortic aneurysm | 0.005149 | 1.212 | NAA25 | Type 1 diabetes |
| rs17696736 | Peripheral arterial disease | 0.005652 | 1.131 | NAA25 | Type 1 diabetes |
| rs17760296 | Chronic sinusitis | 0.002203 | 1.184 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Other disorders of biliary tract | 0.008536 | 1.579 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Rheumatic fever / chorea | 0.0006327 | 2.41 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Chronic venous hypertension | 0.009675 | 2.02 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Acute pericarditis | 0.0009342 | 2.505 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Hypovolemia | 0.006588 | 1.162 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Intracerebral hemorrhage | 0.01148 | 0.4663 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17760296 | Keloid scar | 0.008878 | 1.709 | NOG | Nonsyndromic cleft lip with or without cleft palate |
| rs17763373 | Uterine cancer | 0.0104 | 1.74 | CPEB4 | Prion diseases |
| rs17763373 | Inflammation of eyelids | 0.01001 | 0.7816 | CPEB4 | Prion diseases |
| rs17763373 | Aphasia/speech disturbance | 0.007681 | 1.448 | CPEB4 | Prion diseases |
| rs17763373 | Pathological, developmental or recurrent dislocation | 0.008111 | 2.494 | CPEB4 | Prion diseases |
| rs17763373 | Secondary malignancy of lymph nodes | 0.001742 | 1.588 | CPEB4 | Prion diseases |
| rs17763373 | Contact and allergic dermatitis of eyelid | 0.005346 | 2.374 | CPEB4 | Prion diseases |
| rs17763373 | Arthropathy NOS | 0.009937 | 1.345 | CPEB4 | Prion diseases |
| rs17763373 | Inflammation of the eye | 0.01099 | 0.8042 | CPEB4 | Prion diseases |
| rs17763373 | Arterial embolism and thrombosis | 0.003878 | 0.5507 | CPEB4 | Prion diseases |
| rs17763373 | Abnormal tumor markers, elevated CEA or CA 125 | 0.006017 | 2.766 | CPEB4 | Prion diseases |
| rs17763373 | Other arthropathies | 0.002414 | 1.272 | CPEB4 | Prion diseases |
| rs17763373 | Adverse effects of antibacterials (not penicillins) | 0.003108 | 2.298 | CPEB4 | Prion diseases |
| rs17763373 | Secondary malignant neoplasm | 0.01128 | 1.295 | CPEB4 | Prion diseases |
| rs17774966 | End stage renal disease | 0.01067 | 0.6225 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Disorders of sacrum | 0.005215 | 1.316 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Disorders of synovium, tendon, and bursa | 0.00621 | 1.148 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Chronic ulcer of skin | 0.002683 | 0.8384 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Anal and rectal polyp | 0.008625 | 0.7435 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Urinary tract infection | 0.006185 | 0.8838 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Rotator cuff (capsule) sprain | 0.01038 | 1.23 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Hypertension complicating pregnancy | 0.002259 | 2.332 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Symptoms and disorders of the joints | 0.003629 | 1.16 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Cervicitis and endocervicitis | 0.006101 | 1.704 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Disorders of muscle, ligament, and fascia | 0.003619 | 1.217 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Lipoid metabolism disorder NOS | 0.00149 | 1.423 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Chronic ulcer of leg or foot | 0.00306 | 0.8146 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Cervicocranial/Cervicobrachial syndrome | 0.004695 | 1.329 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Ischemic Heart Disease | 0.009655 | 0.904 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Fasciitis | 0.004428 | 1.218 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Altered mental status | 0.009636 | 0.7221 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Hypertensive chronic kidney disease | 0.004446 | 0.7808 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Vitamin B-complex deficiencies | 0.002933 | 0.7318 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Cancer of the digestive organs and peritoneum | 0.01034 | 1.509 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Osteoarthrosis; localized, secondary | 0.01083 | 1.627 | TUSC1 | Entorhinal cortical thickness |
| rs17774966 | Hypertensive heart and/or renal disease | 0.001057 | 0.7759 | TUSC1 | Entorhinal cortical thickness |
| rs17793829 | Testicular hypofunction | 0.008506 | 1.442 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Meningitis | 0.002636 | 1.889 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Hemangioma and lymphangioma, any site | 0.0008682 | 1.417 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Atrophic gastritis | 0.001398 | 1.636 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Circulatory disease NEC | 0.002247 | 0.806 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Seborrheic keratosis | 0.0007058 | 1.158 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Other dermatoses | 0.003742 | 1.122 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Immunity deficiency | 0.003741 | 0.3998 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Gastritis and duodenitis, NOS | 0.003456 | 1.28 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Other cardiac conduction disorders | 0.009307 | 1.741 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Retinal hemorrhage/ischemia | 0.00211 | 1.507 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Kidney replaced by transpant | 0.005397 | 0.5784 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Retinal disorders | 0.003234 | 1.149 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Gastritis and duodenitis | 9.808e-05 | 1.249 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Benign neoplasm of skin | 0.0008573 | 1.155 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Other disorders of circulatory system | 0.001697 | 0.8208 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Anomalies of jaw size/symmetry | 0.004628 | 2.161 | TTC7B | Cytomegalovirus antibody response |
| rs17793829 | Renal dialysis | 0.009005 | 0.6214 | TTC7B | Cytomegalovirus antibody response |
| rs1800562 | Iron deficiency anemias | 0.001725 | 0.7008 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Iron metabolism disorder | 3.409e-25 | 12.27 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Skin cancer | 0.0003708 | 1.27 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Iron deficiency anemias NOS | 0.001527 | 0.7151 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Disorders of refraction and accommodation | 0.00175 | 1.259 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Eosinophilia | 0.0001859 | 3.002 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Polycythemia vera, secondary | 0.004248 | 2.165 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Other specified diseases of sebaceous glands | 0.00453 | 1.48 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.007556 | 2.913 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Retinoschisis and retinal cysts | 0.009263 | 2.574 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Disorders of cervical region | 6.737e-05 | 2.015 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Traumatic arthropathy | 0.01109 | 2.024 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Other congenital anomalies of skin | 0.0007272 | 2.067 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Disorders of sweat glands | 0.001038 | 1.639 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Diseases of sebaceous glands | 0.004228 | 1.235 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Other disorders of bone and cartilage | 0.003854 | 1.456 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Adrenal hypofunction | 0.007443 | 2.052 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Torticollis | 0.0005442 | 2.321 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Frequency of urination and polyuria | 0.009871 | 1.25 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Other abnormality of urination | 0.0007062 | 1.527 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Hypermetropia | 0.0005697 | 1.403 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | CNS infection and poliomyelitis | 0.005992 | 2.132 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Edema | 0.007657 | 1.211 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800562 | Non-melanoma skin cancer | 0.001005 | 1.262 | HFE | Mean corpuscular hemoglobin, Glycated hemoglobin, LDL Cholesterol, Transferrin saturation, Serum iron, Hematocrit, Total Transferrin, Mean corpuscular volume, Total Cholesterol, Serum transferrin, Ferritin concentration, Serum ferritin |
| rs1800775 | Pervasive developmental disorders | 0.006321 | 0.6371 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Other disorders of urethra and urinary tract | 0.01111 | 0.8361 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Esophageal atresia/tracheoesophageal fistula | 0.001229 | 1.915 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Polyarteritis nodosa and allied conditions | 0.002284 | 1.388 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Mucous polyp of cervix | 0.008911 | 0.7262 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Cerebral aneurysm | 0.005014 | 0.5831 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Retinal disorders | 0.008095 | 1.107 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Congenital deformities of feet | 0.01104 | 0.774 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Swelling of limb | 0.01038 | 1.156 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Macular degeneration | 0.003263 | 1.139 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Chronic lymphocytic thyroiditis | 0.00714 | 0.6972 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Lesions of stomach and duodenum | 0.0101 | 1.905 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Inflammatory bowel disease | 0.007505 | 1.319 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800775 | Other disorders of middle ear and mastoid | 0.0006579 | 1.61 | CETP | HDL Cholesterol, Apolipoprotein A-1 |
| rs1800961 | Extrinsic allergic alveolitis | 0.001435 | 3.656 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Spirochetal infection | 0.005994 | 2.312 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Cachexia | 0.0005511 | 4.02 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Polyp of corpus uteri | 0.003843 | 2.043 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Hypocalcemia | 0.01042 | 1.994 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Optic atrophy | 0.007916 | 2.115 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Sinoatrial node dysfunction | 0.007842 | 0.3716 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Polyp of female genital organs | 0.003143 | 1.749 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Lyme disease | 0.004394 | 2.389 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Other cerebral degenerations | 0.002351 | 2.146 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Intracerebral hemorrhage | 0.004918 | 2.45 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Symptomatic artificial menopause | 0.007998 | 2.42 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Prurigo | 0.002142 | 1.84 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Malignant neoplasm of renal pelvis | 0.002245 | 3.731 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Acidosis | 0.001798 | 2.106 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1800961 | Acid-base balance disorder | 0.004196 | 1.838 | HNF4A | HDL Cholesterol, C-reactive protein, Total Cholesterol |
| rs1801133 | Angina pectoris | 0.007287 | 1.136 | MTHFR | Homocysteine levels |
| rs1801133 | Dystrophy of female genital tract | 0.004088 | 0.3913 | MTHFR | Homocysteine levels |
| rs1801133 | Alzheimer's disease | 0.01097 | 1.178 | MTHFR | Homocysteine levels |
| rs1801133 | Insect bite | 0.00328 | 1.268 | MTHFR | Homocysteine levels |
| rs1801133 | Dementias | 0.0006514 | 1.206 | MTHFR | Homocysteine levels |
| rs1801133 | Gastrointestinal hemorrhage | 0.01048 | 1.105 | MTHFR | Homocysteine levels |
| rs1801133 | Acute bronchitis and bronchiolitis | 0.01085 | 1.122 | MTHFR | Homocysteine levels |
| rs1801133 | Hyperventilation | 0.01038 | 0.5446 | MTHFR | Homocysteine levels |
| rs1801133 | Diffuse diseases of connective tissue | 0.004595 | 1.287 | MTHFR | Homocysteine levels |
| rs1801133 | Delirium dementia and amnestic disorders | 0.0008675 | 1.171 | MTHFR | Homocysteine levels |
| rs1801133 | Senile dementia | 0.004151 | 1.256 | MTHFR | Homocysteine levels |
| rs1801239 | Mental retardation | 0.0005282 | 2.948 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Hallux rigidus | 0.004116 | 1.635 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Cardiomyopathy | 0.008455 | 0.7436 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Sacroiliitis NEC | 0.00945 | 2.039 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Phosphorus metabolism disorder | 0.009053 | 1.609 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Second degree AV block | 0.00783 | 0.3877 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Acute bronchitis and bronchiolitis | 0.001147 | 0.7875 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Schizoid personality disorder | 0.006412 | 1.972 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Benign neoplasm of uterus | 0.005338 | 1.832 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Ptosis of eyelid | 0.003772 | 0.7043 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Other disorders of eyelids | 0.005396 | 0.7886 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Acute posthemorrhagic anemia | 0.007967 | 1.266 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Sialoadenitis | 0.0002518 | 1.962 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Diseases of the salivary glands | 0.0001792 | 1.635 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1801239 | Diseases of blood and blood-forming organs | 0.003802 | 0.6499 | CUBN | Urinary albumin-to-creatinine ratio |
| rs1816002 | Abdominal pain | 0.007697 | 1.08 | ADAMTS14 | Weight |
| rs1816002 | Gestational diabetes | 0.01123 | 0.4785 | ADAMTS14 | Weight |
| rs1816002 | Nervous system congenital anomalies | 0.002044 | 0.6643 | ADAMTS14 | Weight |
| rs1816002 | Cancer of the digestive organs and peritoneum | 0.0007172 | 0.6056 | ADAMTS14 | Weight |
| rs1816002 | Chronic airway obstruction | 0.008105 | 1.109 | ADAMTS14 | Weight |
| rs1816002 | Abnormal thyroid function | 0.005029 | 0.7791 | ADAMTS14 | Weight |
| rs1816002 | Anomalies of pupillary function | 0.00569 | 1.917 | ADAMTS14 | Weight |
| rs1816002 | Chronic pain syndrome | 0.008522 | 0.6014 | ADAMTS14 | Weight |
| rs1816002 | Alzheimer's disease | 0.005636 | 0.8454 | ADAMTS14 | Weight |
| rs1816002 | Megaloblastic anemia | 0.004532 | 0.7271 | ADAMTS14 | Weight |
| rs1816002 | Senile dementia | 0.003049 | 0.8046 | ADAMTS14 | Weight |
| rs1816002 | Other specified erythematous conditions | 0.005171 | 0.7558 | ADAMTS14 | Weight |
| rs1816002 | Neoplasm of unspecified nature of digestive system | 0.002856 | 0.6714 | ADAMTS14 | Weight |
| rs1816002 | Secondary malignancy of lymph nodes | 0.008074 | 0.7962 | ADAMTS14 | Weight |
| rs183266 | Other disorders of bone and cartilage | 0.005169 | 1.332 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Type 1 diabetic neuropathy | 0.00153 | 1.749 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Abnormal pulmonary function | 0.00769 | 2.469 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Osteopenia | 0.008626 | 1.193 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Iron deficiency anemia secondary to blood loss | 0.008198 | 0.573 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Type 1 diabetes nephropathy | 0.0006462 | 2.13 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Allergy to serum or vaccine | 0.004428 | 2.113 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Hyperosmolality and/or hypernatremia | 0.009651 | 1.622 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Secondary hyperparathyroidism (of renal origin) | 0.006541 | 0.5347 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Renal osteodystrophy | 0.009292 | 0.4088 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Type 1 diabetic retinopathy | 0.003159 | 1.664 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Disorders resulting from impaired renal function | 0.002108 | 0.5589 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Gastroparesis | 8.746e-06 | 2.691 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Noninfectious dermatoses of eyelid | 0.007222 | 0.2056 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Acute appendicitis | 0.009954 | 1.637 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Disorders of function of stomach | 0.004817 | 1.248 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Raynaud's syndrome | 0.002172 | 1.51 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs183266 | Anemia in chronic kidney disease | 0.0004849 | 0.4857 | IRF2BPL | Adverse response to lamotrigine and phenytoin |
| rs1837253 | Adjustment reaction | 0.0009504 | 1.215 | TSLP | Asthma |
| rs1837253 | Torsion dystonia | 0.008454 | 1.601 | TSLP | Asthma |
| rs1837253 | Cancer of the lower GI tract | 0.003754 | 1.422 | TSLP | Asthma |
| rs1837253 | Rash and other nonspecific skin eruption | 0.001032 | 1.216 | TSLP | Asthma |
| rs1837253 | Infestation | 0.00371 | 0.4538 | TSLP | Asthma |
| rs1837253 | Symptoms and disorders of the joints | 0.0005815 | 1.169 | TSLP | Asthma |
| rs1837253 | Symptoms affecting skin | 0.009018 | 1.102 | TSLP | Asthma |
| rs1837253 | Colon cancer | 0.000848 | 1.326 | TSLP | Asthma |
| rs1837253 | Hypoventilation | 0.009498 | 0.4905 | TSLP | Asthma |
| rs1837253 | Hypertrophy of breast (Gynecomastia) | 0.006161 | 1.38 | TSLP | Asthma |
| rs1837253 | Colorectal cancer | 0.0004683 | 1.32 | TSLP | Asthma |
| rs1837253 | Stiffness of joint | 0.001602 | 1.26 | TSLP | Asthma |
| rs1853665 | Chronic venous hypertension | 0.000428 | 2.693 | ULBP1 | Radiation response |
| rs1853665 | Open wound of nose and sinus | 0.0005241 | 2.551 | ULBP1 | Radiation response |
| rs1853665 | Nevus, non-neoplastic | 0.001082 | 1.955 | ULBP1 | Radiation response |
| rs1853665 | Hyperlipidemia | 0.009912 | 1.119 | ULBP1 | Radiation response |
| rs1853665 | Disorders of the autonomic nervous system | 0.001279 | 0.5977 | ULBP1 | Radiation response |
| rs1853665 | Loss of teeth or edentulism | 0.01132 | 0.6303 | ULBP1 | Radiation response |
| rs1853665 | Joint effusions | 0.008421 | 1.27 | ULBP1 | Radiation response |
| rs1853665 | Osteoarthrosis of multiple sites | 0.01105 | 0.7757 | ULBP1 | Radiation response |
| rs1853665 | Other disorders of gallbladder | 0.006698 | 0.4274 | ULBP1 | Radiation response |
| rs1853665 | Respiratory complications | 0.007599 | 1.733 | ULBP1 | Radiation response |
| rs1853665 | Anal and rectal conditions | 0.01042 | 1.177 | ULBP1 | Radiation response |
| rs1853665 | Peripheral autonomic neuropathy | 0.01016 | 0.614 | ULBP1 | Radiation response |
| rs1853665 | Primary pulmonary hypertension | 0.0006301 | 1.89 | ULBP1 | Radiation response |
| rs1853665 | Other disorders of testis | 0.001459 | 1.595 | ULBP1 | Radiation response |
| rs1853665 | Bipolar | 0.009544 | 1.452 | ULBP1 | Radiation response |
| rs1869901 | Skin neoplasm of uncertain behavior | 0.008106 | 1.194 | PLCB2 | Schizophrenia |
| rs1869901 | Diseases of the larynx and vocal cords | 0.00784 | 1.173 | PLCB2 | Schizophrenia |
| rs1869901 | Myeloid leukemia | 0.002404 | 1.961 | PLCB2 | Schizophrenia |
| rs1869901 | Other disorders of peritoneum | 0.006632 | 1.438 | PLCB2 | Schizophrenia |
| rs1869901 | Chronic bronchitis | 0.006137 | 1.189 | PLCB2 | Schizophrenia |
| rs1869901 | Alopecia | 0.003003 | 1.345 | PLCB2 | Schizophrenia |
| rs1869901 | Early or threatened labor; hemorrhage in early pregnancy | 0.002324 | 0.5371 | PLCB2 | Schizophrenia |
| rs1869901 | Fracture of pelvis | 0.006776 | 1.332 | PLCB2 | Schizophrenia |
| rs1869901 | Localized superficial swelling, mass, or lump | 0.0092 | 1.251 | PLCB2 | Schizophrenia |
| rs1869901 | Peritoneal adhesions (postoperative) (postinfection) | 0.01096 | 1.504 | PLCB2 | Schizophrenia |
| rs1869901 | Vascular disorders of penis | 0.005359 | 0.3842 | PLCB2 | Schizophrenia |
| rs1869901 | Attention deficit hyperactivity disorder | 0.00536 | 0.5606 | PLCB2 | Schizophrenia |
| rs1869901 | Palpitations | 0.009847 | 1.128 | PLCB2 | Schizophrenia |
| rs1869901 | Multiple sclerosis | 0.006375 | 1.54 | PLCB2 | Schizophrenia |
| rs1869901 | Gingivitis | 0.007284 | 1.763 | PLCB2 | Schizophrenia |
| rs1869901 | Fracture of ribs | 0.009435 | 1.228 | PLCB2 | Schizophrenia |
| rs1888414 | Personality disorders | 0.006833 | 1.251 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Deviated nasal septum | 0.01128 | 0.853 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Inflammatory diseases of female pelvic organs | 0.01005 | 1.164 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Adjustment reaction | 0.002416 | 1.175 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Pyogenic arthritis | 0.0113 | 1.596 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Redundant prepuce and phimosis/BXO | 0.01003 | 1.665 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Inflammatory disease of cervix, vagina, and vulva | 0.007843 | 1.181 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Bronchiectasis | 0.011 | 0.723 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Sleep apnea | 0.005856 | 1.119 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Diseases of lips | 0.006137 | 1.479 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Other specified erythematous conditions | 0.002363 | 1.353 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Other disorders of lipoid metabolism and hyperalimentation | 0.006277 | 0.7744 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Abnormal findings on radiological exam of musculoskeletal system | 0.007651 | 1.568 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Breast disorder NOS | 0.005141 | 2.286 | FDPSP6 | Hippocampal atrophy |
| rs1888414 | Seborheic dermatitis | 0.01144 | 1.171 | FDPSP6 | Hippocampal atrophy |
| rs1923775 | Colostomy and enterostomy complication | 0.004233 | 1.846 | POLN | Alzheimer's disease |
| rs1923775 | Benign neoplasm of uterus | 0.007586 | 1.555 | POLN | Alzheimer's disease |
| rs1923775 | Decubitus ulcer | 0.005408 | 1.247 | POLN | Alzheimer's disease |
| rs1923775 | Visual field defects | 0.01006 | 0.767 | POLN | Alzheimer's disease |
| rs1923775 | Pilonidal cyst | 0.005943 | 2.15 | POLN | Alzheimer's disease |
| rs1923775 | Vaginitis and vulvovaginitis | 0.002859 | 1.243 | POLN | Alzheimer's disease |
| rs1923775 | Fractur of unspecified part of femur | 0.01078 | 1.401 | POLN | Alzheimer's disease |
| rs1923775 | Diseases of the jaws | 0.009082 | 1.202 | POLN | Alzheimer's disease |
| rs1923775 | Diverticulum of esophagus, acquired | 0.0006513 | 2.28 | POLN | Alzheimer's disease |
| rs1926203 | Benign neoplasm of bone and articular cartilage | 0.003572 | 0.4925 | ACTA2 | Lung cancer |
| rs1926203 | Intracerebral hemorrhage | 0.003979 | 0.5529 | ACTA2 | Lung cancer |
| rs1926203 | Renal dialysis | 0.006395 | 0.6727 | ACTA2 | Lung cancer |
| rs1926203 | Graves' disease | 0.007328 | 0.6453 | ACTA2 | Lung cancer |
| rs1926203 | Hypertensive chronic kidney disease | 0.005127 | 0.8205 | ACTA2 | Lung cancer |
| rs1926203 | Premature beats | 0.01114 | 0.8472 | ACTA2 | Lung cancer |
| rs1926203 | End stage renal disease | 0.01055 | 0.6963 | ACTA2 | Lung cancer |
| rs1926203 | Abnormal findings on radiological exam of musculoskeletal system | 7.197e-05 | 1.949 | ACTA2 | Lung cancer |
| rs1927745 | Other unspecified back disorders | 0.005392 | 1.604 | FAM155A | Depression |
| rs1927745 | Open wound of toe(s) | 0.0007496 | 2.005 | FAM155A | Depression |
| rs1927745 | Other signs and symptoms in breast | 0.004624 | 0.6553 | FAM155A | Depression |
| rs1927745 | Ileostomy status | 0.009931 | 1.597 | FAM155A | Depression |
| rs1927745 | Bronchitis | 0.007499 | 1.159 | FAM155A | Depression |
| rs1927745 | Abdominal pain | 0.000678 | 1.12 | FAM155A | Depression |
| rs1927745 | Cervical radiculitis | 0.002414 | 1.225 | FAM155A | Depression |
| rs1927745 | Plasma protein metabolism disorder | 0.00893 | 1.314 | FAM155A | Depression |
| rs1927745 | Subdural hemorrhage | 0.01059 | 0.5537 | FAM155A | Depression |
| rs1927745 | Urethral stricture (not specified as infectious) | 0.009045 | 1.431 | FAM155A | Depression |
| rs1927745 | Keratoconjunctivitis sicca | 0.005866 | 1.666 | FAM155A | Depression |
| rs1980493 | Systemic lupus erythematosus | 0.0005181 | 1.822 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Graves' disease | 0.004545 | 1.612 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Varicose veins of lower extremity | 0.005606 | 1.219 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Disorders of the pituitary gland and its hypothalamic control | 0.004338 | 1.481 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Vaginitis and vulvovaginitis | 0.005346 | 0.7519 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Type 1 diabetic neuropathy | 0.0005468 | 1.705 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Immune disorders | 0.00156 | 1.39 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Other immunological findings | 0.001189 | 1.494 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Peritoneal or intestinal adhesions | 0.006031 | 1.71 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Aneurysm of iliac artery | 0.000348 | 2.192 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Ectropion or entropion | 0.006496 | 1.353 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Disorders of external ear | 0.009116 | 1.741 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Type 1 diabetic retinopathy | 0.01062 | 1.485 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Polycythemia vera, secondary | 0.005948 | 1.735 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Calculus of kidney | 0.007585 | 0.795 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Thyrotoxicosis | 0.003406 | 1.331 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Other specified peripheral vascular diseases | 0.000801 | 2.448 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Gastrointestinal complications | 0.006086 | 1.352 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Rosacea | 0.01036 | 0.7886 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Ingrowing nail | 0.002992 | 1.234 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Adverse effects of insulins and antidiabetic agents | 0.001068 | 2.162 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Celiac or tropical sprue | 9.001e-06 | 2.703 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Allergic rhinitis | 0.00585 | 0.8557 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Urinary calculus | 0.003082 | 0.8005 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Retinoschisis and retinal cysts | 5.049e-05 | 3.006 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Osteoarthrosis; localized, secondary | 0.00932 | 1.691 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Lupus erythematosus | 2.914e-05 | 2.79 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Myeloid leukemia | 0.001783 | 2.124 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Type 1 diabetic ketoacidosis | 0.007371 | 1.504 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Varicose veins of lower extremity, symptomtic | 0.008209 | 1.28 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Varicose veins | 0.003624 | 1.221 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Type 1 diabetes nephropathy | 0.0002289 | 2.088 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Celiac disease | 3.115e-05 | 2.607 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Other infectious diseases | 0.01001 | 0.3384 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Postmenopausal atrophic vaginitis | 0.001043 | 0.6866 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1980493 | Discoid lupus erythematosus | 3.056e-05 | 1.937 | BTNL2 | Anti-cyclic Citrullinated Peptide Antibody |
| rs1992950 | Lack of coordination | 3.314e-05 | 1.442 | SATB2 | Ulcerative colitis |
| rs1992950 | Neutropenia | 0.009636 | 0.7871 | SATB2 | Ulcerative colitis |
| rs1992950 | Bipolar | 0.004069 | 1.449 | SATB2 | Ulcerative colitis |
| rs1992950 | Other conditions of brain, NOS | 5.504e-05 | 1.906 | SATB2 | Ulcerative colitis |
| rs1992950 | Acute sinusitis | 0.01077 | 0.8685 | SATB2 | Ulcerative colitis |
| rs1992950 | Adverse effects of hormones and synthetic substitutes | 0.00215 | 2.441 | SATB2 | Ulcerative colitis |
| rs1992950 | Periapical abscess | 0.007705 | 0.795 | SATB2 | Ulcerative colitis |
| rs1992950 | Diseases of pulp and periapical tissues | 0.001348 | 0.7661 | SATB2 | Ulcerative colitis |
| rs1992950 | Inflammatory and toxic neuropathy | 0.009094 | 0.6935 | SATB2 | Ulcerative colitis |
| rs1992950 | Cancer of brain and nervous system | 0.002922 | 1.703 | SATB2 | Ulcerative colitis |
| rs1992950 | Malignant neoplasm of brain and nervous system | 0.007287 | 1.443 | SATB2 | Ulcerative colitis |
| rs1992950 | Chronic pharyngitis and nasopharyngitis | 0.005651 | 0.8304 | SATB2 | Ulcerative colitis |
| rs1992950 | Acute laryngitis and tracheitis | 0.003792 | 0.5966 | SATB2 | Ulcerative colitis |
| rs1992950 | Brain cancer | 0.002345 | 1.772 | SATB2 | Ulcerative colitis |
| rs2000999 | Hemoptysis | 0.001484 | 1.482 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Chronic lymphocytic thyroiditis | 0.003268 | 1.552 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Other disorders of metabolic, endocrine, immunity disorders | 0.0003333 | 2.378 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Bladder cancer and neoplasms | 0.008147 | 1.306 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Mammographic microcalcification | 7.128e-05 | 1.982 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Abnormal sputum | 0.004466 | 1.402 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Acute upper respiratory infections | 0.005434 | 1.127 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Blindness and low vision | 0.01067 | 0.7053 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Abnormal thyroid function | 0.006292 | 1.331 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Idiopathic fibrosing alveolitis | 0.01088 | 1.844 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Chronic hepatitis | 0.009536 | 1.798 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2000999 | Thyroiditis | 0.0005357 | 1.539 | HPR | Total Cholesterol, LDL Cholesterol, Haptoglobin levels |
| rs2002030 | Wheezing | 0.004743 | 1.593 | C8orf12 | Cognitive performance |
| rs2002030 | Acquired deformities of finger | 0.01135 | 1.706 | C8orf12 | Cognitive performance |
| rs2002030 | Essential tremor | 0.006926 | 1.54 | C8orf12 | Cognitive performance |
| rs2002030 | Carcinoma in situ of skin | 0.002153 | 1.519 | C8orf12 | Cognitive performance |
| rs2002030 | Acquired deformities of limbs | 0.006488 | 1.404 | C8orf12 | Cognitive performance |
| rs2002030 | Pulmonary embolism and infarction | 0.008585 | 1.432 | C8orf12 | Cognitive performance |
| rs2002030 | Torsion dystonia | 0.005581 | 2.007 | C8orf12 | Cognitive performance |
| rs2002030 | Abnormal findings examination of lungs | 0.001527 | 1.376 | C8orf12 | Cognitive performance |
| rs2073643 | Lower gastrointestinal congenital anomalies | 0.008592 | 1.815 | SLC22A5 | Asthma |
| rs2073643 | Non-melanoma skin cancer | 0.001473 | 0.8882 | SLC22A5 | Asthma |
| rs2073643 | Parasomnia | 0.005647 | 0.5849 | SLC22A5 | Asthma |
| rs2073643 | Chronic venous insufficiency | 0.002492 | 0.8225 | SLC22A5 | Asthma |
| rs2073643 | Intracranial hemorrhage | 0.005852 | 1.333 | SLC22A5 | Asthma |
| rs2073643 | Viral warts & HPV | 0.007331 | 0.8666 | SLC22A5 | Asthma |
| rs2073643 | Hyperbilirubinemia | 0.008394 | 0.5463 | SLC22A5 | Asthma |
| rs2073643 | Dermatosis NOS | 0.01045 | 0.9081 | SLC22A5 | Asthma |
| rs2073643 | Bronchiectasis | 0.008063 | 1.378 | SLC22A5 | Asthma |
| rs2073643 | Other disorders of the kidney and ureters | 0.004578 | 1.122 | SLC22A5 | Asthma |
| rs2073643 | Excessive or frequent menstruation | 0.0108 | 1.279 | SLC22A5 | Asthma |
| rs2073643 | Chronic obstructive asthma with exacerbation | 0.008655 | 0.5966 | SLC22A5 | Asthma |
| rs2073643 | Late effects of cerebrovascular disease | 0.001332 | 1.211 | SLC22A5 | Asthma |
| rs2073643 | Skin cancer | 0.0006228 | 0.886 | SLC22A5 | Asthma |
| rs2074404 | Testicular dysfunction | 0.00862 | 1.408 | WNT3 | Celiac disease |
| rs2074404 | Anisometropia | 0.0005536 | 1.449 | WNT3 | Celiac disease |
| rs2074404 | Chronic periodontitis | 0.004423 | 1.303 | WNT3 | Celiac disease |
| rs2074404 | Visual disturbances | 0.00195 | 1.152 | WNT3 | Celiac disease |
| rs2074404 | Spontaneous ecchymoses | 0.008441 | 1.634 | WNT3 | Celiac disease |
| rs2074404 | Psoriasis vulgaris | 0.005256 | 1.293 | WNT3 | Celiac disease |
| rs2074404 | Infection of the eye | 0.001333 | 1.206 | WNT3 | Celiac disease |
| rs2074404 | Unequal leg length (acquired) | 0.008682 | 1.488 | WNT3 | Celiac disease |
| rs2074404 | Abnormal coagulation profile | 0.007325 | 1.396 | WNT3 | Celiac disease |
| rs2074404 | Polycythemia vera, secondary | 0.003677 | 1.704 | WNT3 | Celiac disease |
| rs2074404 | Conjunctivitis, infectious | 0.007218 | 1.191 | WNT3 | Celiac disease |
| rs2074404 | Ulceration of intestine | 0.003826 | 1.729 | WNT3 | Celiac disease |
| rs2074404 | Psychogenic disorder | 0.01106 | 1.432 | WNT3 | Celiac disease |
| rs2074404 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.0003772 | 1.462 | WNT3 | Celiac disease |
| rs2075650 | Glaucoma | 0.007839 | 0.8602 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Deviated nasal septum | 0.004151 | 0.775 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Acute osteomyelitis | 0.004168 | 1.826 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Atopic or contact dermatitis | 0.00197 | 0.8538 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Chronic sinusitis | 0.00057 | 0.8134 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Wheezing and painful respiration | 0.00815 | 0.8433 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Open-angle glaucoma | 0.008523 | 0.8091 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Chronic pharyngitis and nasopharyngitis | 0.002009 | 0.7767 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Diabetes mellitus | 0.00757 | 0.8897 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Dyspepsia and disorders of function of stomach | 0.008148 | 0.8081 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Macular degeneration, dry | 0.0007954 | 0.6921 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Diseases of respiratory system | 6.682e-05 | 0.7078 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Age-related macular degeneration | 6.704e-05 | 0.6658 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Symptoms involving respiratory system | 0.0008009 | 0.6943 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Delirium due to conditions classified elsewhere | 0.003037 | 1.58 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Neoplasm of unspecified nature of digestive system | 0.008922 | 1.517 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Alzheimer's disease | 5.237e-28 | 2.41 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Dry eyes | 0.0006323 | 0.7909 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Aseptic necrosis of bone | 0.01092 | 0.4498 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Vascular dementia | 0.001199 | 1.682 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Develomental delays and disorders | 0.001176 | 1.448 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Diseases of sebaceous glands | 0.00117 | 0.8384 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Subjective visual disturbances | 0.00365 | 0.7349 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Visual disturbances | 0.001152 | 0.8281 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Conduct disorders | 0.004435 | 1.741 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Memory loss | 4.677e-09 | 1.796 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Abnormal findings on mammogram or breast exam | 0.001891 | 0.8279 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Neurological disorders due to brain damage | 4.329e-09 | 1.452 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Mild cognitive impairment | 0.0005436 | 2.194 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Impaction of intestine | 0.003732 | 2.389 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Macular degeneration, wet | 0.001038 | 0.5817 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Hyperlipidemia | 0.01129 | 1.124 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Senile dementia | 1.887e-12 | 2.037 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Persistent mental disorders due to other conditions | 9.183e-16 | 1.775 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Delirium dementia and amnestic disorders | 8.027e-24 | 1.841 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Dementias | 2.409e-26 | 2.114 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Other peripheral nerve disorders | 0.005864 | 0.8692 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Reticulosarcoma | 0.003455 | 1.858 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Allergic rhinitis | 0.0001426 | 0.7998 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Optic atrophy | 0.0002892 | 0.3729 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Type 2 diabetic ketoacidosis | 0.009998 | 0.8385 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Macular degeneration | 0.001732 | 0.8178 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Acute posthemorrhagic anemia | 0.003282 | 1.255 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Epistaxis or throat hemorrhage | 0.003292 | 0.7371 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Asthma | 0.006971 | 0.8465 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Other specified nonpsychotic and/or transient mental disorders | 7.334e-06 | 1.546 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Known or suspected fetal abnormality | 0.004355 | 1.926 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Sebaceous cyst | 0.006628 | 0.8351 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Schizophrenia and other psychotic disorders | 4.897e-05 | 1.41 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Schizoid personality disorder | 0.006963 | 0.3412 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Retinal drusen | 0.009525 | 0.7533 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Disorders of lacrimal system | 0.000856 | 0.8025 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2075650 | Mental disorders due to brain damage | 6.257e-06 | 1.566 | TOMM40 | Alzheimer's disease, Alzheimer's disease biomarkers, Amyloid Beta Peptide 1-42, LDL Cholesterol, C-reactive protein, Total Cholesterol, Grey matter density |
| rs2084385 | Astigmatism | 0.006872 | 0.8307 | PAK2 | Total ventricular volume |
| rs2084385 | Other arthropathies | 0.008915 | 1.17 | PAK2 | Total ventricular volume |
| rs2084385 | Complex regional/central pain syndrome | 0.00215 | 2.112 | PAK2 | Total ventricular volume |
| rs2084385 | Other cerebral degenerations | 0.003577 | 1.622 | PAK2 | Total ventricular volume |
| rs2084385 | Mental retardation | 0.007954 | 2.358 | PAK2 | Total ventricular volume |
| rs2084385 | Diseases of the larynx and vocal cords | 0.00439 | 0.7541 | PAK2 | Total ventricular volume |
| rs2084385 | Osteoarthritis; localized | 0.007644 | 1.184 | PAK2 | Total ventricular volume |
| rs2084385 | Develomental delays and disorders | 0.0001879 | 1.565 | PAK2 | Total ventricular volume |
| rs2084385 | Myoclonus | 0.001314 | 2.057 | PAK2 | Total ventricular volume |
| rs2084385 | Internal derangement of knee | 0.009501 | 1.209 | PAK2 | Total ventricular volume |
| rs2084385 | Bullous dermatoses | 0.002165 | 2.26 | PAK2 | Total ventricular volume |
| rs2084385 | Voice disturbance | 0.005476 | 0.7258 | PAK2 | Total ventricular volume |
| rs2114039 | Primary pulmonary hypertension | 0.004244 | 1.634 | PDGFRA | Corneal curvature |
| rs2114039 | Other disorders of urethra and urinary tract | 0.001323 | 1.274 | PDGFRA | Corneal curvature |
| rs2114039 | Urethral stricture (not specified as infectious) | 0.0001167 | 1.666 | PDGFRA | Corneal curvature |
| rs2114039 | Cardiac pacemaker/device in situ | 0.00432 | 1.239 | PDGFRA | Corneal curvature |
| rs2114039 | Primary angle-closure glaucoma | 0.009113 | 0.7976 | PDGFRA | Corneal curvature |
| rs2114039 | Cardiac pacemaker in situ | 0.001216 | 1.295 | PDGFRA | Corneal curvature |
| rs2114039 | Inflammatory spondylopathies | 0.009024 | 0.6041 | PDGFRA | Corneal curvature |
| rs2114039 | Graves' disease | 0.002158 | 0.5699 | PDGFRA | Corneal curvature |
| rs2114039 | Strabismus (not specified as paralytic) | 0.001319 | 0.7387 | PDGFRA | Corneal curvature |
| rs2114039 | Disorders of binocular eye movements | 0.00496 | 0.7996 | PDGFRA | Corneal curvature |
| rs2114039 | Disorders of the globe | 0.001919 | 0.5766 | PDGFRA | Corneal curvature |
| rs2114039 | Inguinal hernia | 0.008781 | 1.162 | PDGFRA | Corneal curvature |
| rs2114039 | Sinoatrial node dysfunction | 0.002933 | 1.353 | PDGFRA | Corneal curvature |
| rs2114039 | Nonspecific findings on examination of blood | 0.003351 | 1.362 | PDGFRA | Corneal curvature |
| rs2114039 | Acquired absence of breast | 0.007737 | 0.7249 | PDGFRA | Corneal curvature |
| rs2114039 | progressive myopia | 0.006057 | 0.4575 | PDGFRA | Corneal curvature |
| rs2114039 | Symptoms associated with female genital organs | 0.007995 | 0.8216 | PDGFRA | Corneal curvature |
| rs2150702 | Behcet's syndrome | 0.001943 | 0.6094 | MLANA | Multiple sclerosis |
| rs2150702 | Astigmatism | 0.008828 | 0.8881 | MLANA | Multiple sclerosis |
| rs2150702 | Apnea | 0.001235 | 2.344 | MLANA | Multiple sclerosis |
| rs2150702 | Arterial embolism and thrombosis of lower extremity artery | 0.000376 | 1.483 | MLANA | Multiple sclerosis |
| rs2150702 | Heartburn | 0.006781 | 1.378 | MLANA | Multiple sclerosis |
| rs2150702 | Hydrocele | 0.00538 | 0.661 | MLANA | Multiple sclerosis |
| rs2150702 | Arterial embolism and thrombosis | 0.003417 | 1.259 | MLANA | Multiple sclerosis |
| rs2150702 | Temporomandibular joint disorder NOS | 0.005919 | 0.6151 | MLANA | Multiple sclerosis |
| rs2150702 | Dermatomyositis and Polymyositis | 0.005867 | 0.4578 | MLANA | Multiple sclerosis |
| rs2150702 | Dystrophy of female genital tract | 0.001351 | 2.374 | MLANA | Multiple sclerosis |
| rs2150702 | Congenital anomalies of face and neck | 0.0004142 | 0.3106 | MLANA | Multiple sclerosis |
| rs2150702 | Peripheral angiopathy in diseases classified elsewhere | 0.009129 | 1.594 | MLANA | Multiple sclerosis |
| rs2150702 | Iron deficiency anemia secondary to blood loss | 0.008323 | 1.319 | MLANA | Multiple sclerosis |
| rs2150702 | Known or suspected fetal abnormality | 0.004825 | 1.693 | MLANA | Multiple sclerosis |
| rs2150702 | Allergy/adverse effect of penicillin | 0.007109 | 1.227 | MLANA | Multiple sclerosis |
| rs2150702 | Peripheral vascular disease | 0.008627 | 1.111 | MLANA | Multiple sclerosis |
| rs2150702 | Myopia | 0.00164 | 0.8726 | MLANA | Multiple sclerosis |
| rs2166706 | Lipoid metabolism disorder NOS | 0.001912 | 1.318 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Miscarriage; stillbirth | 0.01055 | 1.755 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.001792 | 1.371 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Hyperglyceridemia | 1.159e-05 | 1.425 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Other abnormal glucose | 0.001566 | 1.167 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Prolapse of vaginal vault after hysterectomy | 0.00922 | 0.669 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Abnormal glucose | 0.0002139 | 1.159 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Impaired fasting glucose | 0.00684 | 1.181 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Diabetes mellitus | 0.0002749 | 1.12 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Periodontitis (acute or chronic) | 0.009849 | 1.208 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Intracranial hemorrhage (injury) | 0.005052 | 1.487 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Keratitis | 0.003229 | 0.7371 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Poisoning by primarily systemic agents | 0.002661 | 1.345 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Polycythemia vera, secondary | 0.01062 | 0.6132 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Exostosis of jaw | 0.008836 | 0.4546 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Type 2 diabetes | 0.0004154 | 1.118 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Acute pericarditis | 0.006304 | 0.4127 | MTNR1B | Fasting plasma glucose |
| rs2166706 | Pain, swelling or discharge of eye | 0.008723 | 0.733 | MTNR1B | Fasting plasma glucose |
| rs2237886 | Extrinsic allergic alveolitis | 0.008297 | 2.302 | KCNQ1 | Height |
| rs2237886 | Symptoms involving respiratory system | 0.0009024 | 1.397 | KCNQ1 | Height |
| rs2237886 | Diseases of hair and hair follicles | 0.0004976 | 1.45 | KCNQ1 | Height |
| rs2237886 | Hammer toe | 0.003745 | 0.7071 | KCNQ1 | Height |
| rs2237886 | Generalized convulsive epilepsy | 0.007519 | 1.827 | KCNQ1 | Height |
| rs2237886 | Chronic bronchitis | 0.00451 | 1.313 | KCNQ1 | Height |
| rs2237886 | Bladder cancer and neoplasms | 0.001346 | 1.475 | KCNQ1 | Height |
| rs2237886 | Keratitis, infectious | 0.006926 | 1.588 | KCNQ1 | Height |
| rs2237886 | Age-related macular degeneration | 0.002676 | 0.7032 | KCNQ1 | Height |
| rs2237886 | Diseases of respiratory system | 0.0006816 | 1.326 | KCNQ1 | Height |
| rs2237886 | Obstructive chronic bronchitis | 0.003656 | 1.358 | KCNQ1 | Height |
| rs2237886 | Liver abscess and sequelae of chronic liver disease | 0.004518 | 1.801 | KCNQ1 | Height |
| rs2237886 | Chronic airway obstruction | 0.002879 | 1.2 | KCNQ1 | Height |
| rs2237886 | Esophageal atresia/tracheoesophageal fistula | 0.007891 | 1.978 | KCNQ1 | Height |
| rs2237886 | Alopecia | 0.005466 | 1.502 | KCNQ1 | Height |
| rs2237886 | Bladder cancer | 0.001438 | 1.486 | KCNQ1 | Height |
| rs2237886 | Hemoptysis | 0.003046 | 1.569 | KCNQ1 | Height |
| rs2237886 | Secondary thrombocytopenia | 0.004742 | 1.896 | KCNQ1 | Height |
| rs2237886 | Abnormal sputum | 0.003436 | 1.531 | KCNQ1 | Height |
| rs2237886 | Vascular dementia | 0.009268 | 1.554 | KCNQ1 | Height |
| rs2242073 | Unspecified polyarthropathy or polyarthritis | 0.004502 | 1.664 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Osteoarthrosis of multiple sites | 0.004917 | 1.326 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Early complications of trauma or procedure | 0.004714 | 1.815 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Lump or mass in breast | 0.00483 | 1.227 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Displacement of intervertebral disc | 0.005854 | 0.8072 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Enthesopathy | 0.006927 | 1.159 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Herpes zoster with nervous system complications | 0.003715 | 1.695 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Peritoneal or intestinal adhesions | 0.003662 | 1.817 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Symptomatic artificial menopause | 0.001159 | 1.832 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Chronic tonsillitis and adenoiditis | 0.006749 | 1.822 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Other diseases of respiratory system | 0.006368 | 1.481 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Mental retardation | 0.009809 | 2.195 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Iron deficiency anemias NOS | 0.001957 | 1.208 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Disorders of optic nerve and visual pathways | 0.002537 | 1.385 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Cyst of kidney, acquired | 0.009204 | 0.6811 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Spermatocele | 0.002362 | 2.019 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Generalized hyperhidrosis | 0.008897 | 0.6417 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Optic atrophy | 0.004211 | 1.602 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Iron deficiency anemias | 0.007426 | 1.189 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Fuchs' dystrophy | 0.002557 | 1.653 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Abnormal findings on mammogram or breast exam | 0.001964 | 1.194 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242073 | Herpes zoster | 0.007777 | 1.244 | CRYGC | Attention deficit hyperactivity disorder |
| rs2242944 | Nevus, non-neoplastic | 0.01049 | 1.61 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Respiratory abnormalities | 0.006412 | 0.7418 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Hypercholesterolemia | 0.006965 | 1.118 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Lyme disease | 0.009891 | 1.502 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Unspecified polyarthropathy or polyarthritis | 0.002943 | 0.603 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Eating disorder | 0.00778 | 0.5768 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Functional digestive disorders | 0.009834 | 0.8768 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Open-angle glaucoma | 0.01082 | 0.8623 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Pervasive developmental disorders | 0.001199 | 1.684 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Open wound of ear | 0.004222 | 1.998 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Polyarthropathy or polyarthritis involving multiple sites NOS | 0.002907 | 0.5362 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Attention deficit hyperactivity disorder | 0.0006125 | 1.892 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Bronchitis | 0.008431 | 0.876 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Irritable Bowel Syndrome | 0.01119 | 0.8592 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Hallux rigidus | 0.00554 | 1.403 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Chronic interstitial cystitis | 0.00736 | 2.03 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Malignant neoplasm of renal pelvis | 0.008219 | 2.092 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Mammographic microcalcification | 0.001082 | 0.5411 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Ectropion or entropion | 0.002393 | 0.7545 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Adverse effects of insulins and antidiabetic agents | 0.007177 | 0.5055 | PSMG1 | Ankylosing spondylitis |
| rs2242944 | Paroxysmal supraventricular tachycardia | 0.004154 | 0.759 | PSMG1 | Ankylosing spondylitis |
| rs2252521 | Abnormal serum enzyme levels | 0.00116 | 1.193 | CPVL | Cognitive performance |
| rs2252521 | Cancer of oropharynx | 0.003335 | 2.188 | CPVL | Cognitive performance |
| rs2252521 | Cystic kidney disease | 0.008898 | 0.5717 | CPVL | Cognitive performance |
| rs2252521 | Iron deficiency anemia secondary to blood loss | 0.001623 | 0.6633 | CPVL | Cognitive performance |
| rs2252521 | Cholelithiasis with other cholecystitis | 0.00499 | 0.7266 | CPVL | Cognitive performance |
| rs2252521 | Symptomatic artificial menopause | 0.01068 | 0.6472 | CPVL | Cognitive performance |
| rs2252521 | Disorders of conjunctiva | 0.01027 | 0.7853 | CPVL | Cognitive performance |
| rs2252521 | Genitourinary congenital anomalies | 0.007066 | 0.6808 | CPVL | Cognitive performance |
| rs2274089 | Nontoxic multinodular goiter | 0.009979 | 0.6245 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2274089 | Iron metabolism disorder | 7.032e-14 | 6.178 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2274089 | CNS infection and poliomyelitis | 0.01003 | 1.937 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2274089 | Eosinophilia | 0.003617 | 2.286 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2274089 | Disorders of cervical region | 0.006401 | 1.59 | LRRC16A | Serum transferrin, Serum iron levels, Transferrin saturation |
| rs2275215 | Corneal dystrophy | 0.008652 | 0.7399 | LAMA2 | Body mass index |
| rs2275215 | Breast disorder NOS | 0.003549 | 2.331 | LAMA2 | Body mass index |
| rs2275215 | Vitamin B12 deficiency anemia | 0.004403 | 1.58 | LAMA2 | Body mass index |
| rs2275215 | Sepsis and SIRS | 0.003407 | 1.302 | LAMA2 | Body mass index |
| rs2275215 | Sepsis | 0.003364 | 1.314 | LAMA2 | Body mass index |
| rs2275215 | Other arthropathies | 0.00233 | 1.145 | LAMA2 | Body mass index |
| rs2275215 | Arterial embolism and thrombosis | 0.008738 | 1.246 | LAMA2 | Body mass index |
| rs2275215 | Althete's foot | 0.007771 | 0.7679 | LAMA2 | Body mass index |
| rs2275215 | Open wound of finger(s) | 0.0004499 | 0.787 | LAMA2 | Body mass index |
| rs2277339 | Hypercoagulable state | 0.003759 | 1.807 | PRIM1 | Menopause |
| rs2277339 | Meningitis | 0.001118 | 2.279 | PRIM1 | Menopause |
| rs2277339 | Macular degeneration, wet | 0.005713 | 1.563 | PRIM1 | Menopause |
| rs2277339 | Other disorders of gallbladder | 0.002765 | 1.944 | PRIM1 | Menopause |
| rs2277339 | Aseptic necrosis of bone | 0.01083 | 1.753 | PRIM1 | Menopause |
| rs2277339 | Bipolar | 0.01112 | 1.564 | PRIM1 | Menopause |
| rs2277339 | Cancer of the digestive organs and peritoneum | 0.006006 | 1.701 | PRIM1 | Menopause |
| rs2277339 | Other disorders of adrenal glands | 0.00703 | 1.75 | PRIM1 | Menopause |
| rs2277339 | Atherosclerosis of aorta | 0.008321 | 1.423 | PRIM1 | Menopause |
| rs2277339 | Other disorders of arteries and arterioles | 0.009712 | 1.396 | PRIM1 | Menopause |
| rs2277339 | Diseases of blood and blood-forming organs | 0.007013 | 1.371 | PRIM1 | Menopause |
| rs2277339 | Cataract | 0.001808 | 0.8234 | PRIM1 | Menopause |
| rs2277912 | Symptomatic artificial menopause | 0.001338 | 0.511 | FASTKD2 | Height |
| rs2277912 | Disorders of menstruation | 0.005396 | 0.7794 | FASTKD2 | Height |
| rs2277912 | Other disorders of bone and cartilage | 0.007596 | 0.7624 | FASTKD2 | Height |
| rs2277912 | Chronic tonsillitis and adenoiditis | 0.006544 | 0.366 | FASTKD2 | Height |
| rs2277912 | Acquired hemolytic anemias | 0.01121 | 1.986 | FASTKD2 | Height |
| rs2277912 | Dysphagia | 0.004986 | 0.8485 | FASTKD2 | Height |
| rs2277912 | Otalgia | 0.01123 | 0.7311 | FASTKD2 | Height |
| rs2277912 | Stricture and stenosis of esophagus | 0.0108 | 0.7248 | FASTKD2 | Height |
| rs2277912 | Noninflammatory disorders of vagina | 0.002644 | 0.5897 | FASTKD2 | Height |
| rs2277912 | Urticaria | 0.008754 | 0.7406 | FASTKD2 | Height |
| rs2277912 | Magnesium metabolism disorder | 0.005736 | 0.65 | FASTKD2 | Height |
| rs2277912 | Lymphadenitis | 0.0009825 | 0.7502 | FASTKD2 | Height |
| rs2277912 | Chronic sinusitis | 0.003573 | 0.8482 | FASTKD2 | Height |
| rs2277912 | Infertility, male | 0.000849 | 2.382 | FASTKD2 | Height |
| rs2277912 | Other specified intestinal malabsorption | 0.007329 | 0.4059 | FASTKD2 | Height |
| rs2277912 | Disorders of function of stomach | 0.006971 | 0.8252 | FASTKD2 | Height |
| rs2277912 | Dyspepsia and disorders of function of stomach | 0.003157 | 0.8008 | FASTKD2 | Height |
| rs2279434 | Retinal drusen | 0.001729 | 0.6114 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Genital prolapse | 0.007577 | 1.305 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Elevated prostate specific antigen | 0.0102 | 1.335 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Corneal degenerations | 0.0009277 | 0.3811 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Myalgia and myositis NOS | 0.01058 | 0.8134 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Cystitis | 0.006636 | 0.6512 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Disorders of cornea | 0.00217 | 0.668 | MARCH8 | Mean corpuscular hemoglobin |
| rs2279434 | Macular degeneration | 0.01145 | 0.8082 | MARCH8 | Mean corpuscular hemoglobin |
| rs2281680 | Balanoposthitis | 0.008287 | 1.814 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Infertility, male | 0.006833 | 2.076 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Glycosuria or Acetonuria | 0.01095 | 2.128 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Other specified cardiac dysrhythmias | 0.00148 | 1.201 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Chronic cystitis | 0.01103 | 0.5474 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Dyshidrosis | 0.008753 | 1.667 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Meniere's disease | 0.009681 | 0.4569 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Urinary obstruction | 0.01067 | 1.433 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Cystoid macular degeneration of retina | 0.007542 | 0.6951 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Scar conditions and fibrosis of skin | 0.005628 | 1.37 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | AV block | 0.007767 | 1.237 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Infestation | 0.006378 | 0.3859 | AP1G2 | Sudden cardiac arrest |
| rs2281680 | Abnormal weight gain | 0.004106 | 1.426 | AP1G2 | Sudden cardiac arrest |
| rs2290416 | Abnormal loss of weight and underweight | 0.006029 | 1.468 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Disorders of choroid | 0.001053 | 0.5142 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Congenital anomalies of urinary system | 0.004218 | 1.766 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Elevated white blood cell count | 0.007422 | 1.472 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Genitourinary congenital anomalies | 0.001212 | 1.721 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Mechanical complication due to other implant and internal device | 0.004618 | 1.592 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Cervicocranial/Cervicobrachial syndrome | 0.00767 | 0.6379 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Secondary thrombocytopenia | 0.0004861 | 2.283 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Pallor and flushing | 0.0008359 | 1.807 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Pneumonitis due to inhalation of food or vomitus | 0.009037 | 1.523 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Cystic kidney disease | 0.006852 | 1.873 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Glaucoma | 0.001561 | 0.7961 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Rheumatoid arthritis | 0.004091 | 0.6414 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Choroidal degenerations | 0.006413 | 0.4447 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2290416 | Open-angle glaucoma | 0.00382 | 0.7395 | NAPRT1 | Attention deficit hyperactivity disorder |
| rs2292354 | Random mental disorder. Ignored for now | 0.002187 | 0.5303 | GIT2 | HDL Cholesterol |
| rs2292354 | Polyneuropathy in diabetes | 0.005348 | 0.8085 | GIT2 | HDL Cholesterol |
| rs2292354 | Other disorders of thyroid | 0.007593 | 1.329 | GIT2 | HDL Cholesterol |
| rs2292354 | Disorders of coccyx | 0.01082 | 0.7235 | GIT2 | HDL Cholesterol |
| rs2292354 | Pancreatic cancer | 0.007348 | 1.544 | GIT2 | HDL Cholesterol |
| rs2292354 | Hyperglyceridemia | 0.009552 | 0.7833 | GIT2 | HDL Cholesterol |
| rs2292354 | Type 2 diabetic peripheral circulatory disorders | 0.005046 | 0.6638 | GIT2 | HDL Cholesterol |
| rs2292354 | Periodontitis (acute or chronic) | 0.009334 | 0.7969 | GIT2 | HDL Cholesterol |
| rs2292354 | Other specified erythematous conditions | 0.0008588 | 0.6615 | GIT2 | HDL Cholesterol |
| rs2292354 | Chronic periodontitis | 0.004133 | 0.7484 | GIT2 | HDL Cholesterol |
| rs2294008 | Diseases of esophagus | 0.007232 | 0.9229 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Generalized convulsive epilepsy | 0.007758 | 0.6129 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Hyperpotassemia | 0.005981 | 0.8348 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Acute reaction to stress | 0.01022 | 0.8039 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Reflux esophagitis | 0.009712 | 0.832 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Diaphragmatic hernia | 0.006785 | 0.8806 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Bladder cancer and neoplasms | 0.01029 | 1.248 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Elevated prostate specific antigen | 0.005016 | 1.196 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Other derangement of joint | 0.008387 | 0.7817 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Other nonmalignant breast conditions | 0.005512 | 1.159 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Bladder cancer | 0.0114 | 1.252 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Appendiceal conditions | 0.006297 | 0.7092 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Cellulitis and abscess of foot/toes | 0.007215 | 0.7793 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Acute cystitis | 0.006189 | 0.7106 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Other congenital anomalies | 0.008011 | 0.5487 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Chronic sinusitis | 0.005792 | 0.8901 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.004615 | 0.8283 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Rheumatoid arthritis | 0.007598 | 0.819 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Cystitis | 0.00493 | 0.8106 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Dyspepsia and disorders of function of stomach | 0.005928 | 0.8591 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Cancer of kidney and urinary organs | 0.009563 | 1.198 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Tension headache | 0.009837 | 0.8196 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Disorders of function of stomach | 0.004743 | 0.8619 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | E. coli | 0.007173 | 0.7537 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Peptic ulcer | 0.006217 | 0.856 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Prostate cancer | 0.003843 | 1.197 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Sciatica | 0.002065 | 0.8383 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | GERD | 0.001452 | 0.9027 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Esophagitis, GERD and related diseases | 0.003294 | 0.9139 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Stricture and stenosis of esophagus | 0.002246 | 0.7586 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Age-related macular degeneration | 0.004181 | 0.8239 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Inflammatory disease of breast | 0.001971 | 1.65 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Gastric ulcer | 0.00157 | 0.7485 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Disorders of adrenal glands | 0.004286 | 0.7378 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Bacterial infection NOS | 0.0005492 | 0.8491 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Cystitis and urethritis | 0.003581 | 0.8155 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Pyogenic granuloma | 0.001387 | 0.4628 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294008 | Abnormal function study of cardiovascular system | 0.001431 | 0.8277 | PSCA | Duodenal ulcer, Bladder cancer, Urinary bladder cancer |
| rs2294015 | Urethral stricture (not specified as infectious) | 0.001647 | 0.6492 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Congenital anomalies of face and neck | 0.002287 | 0.3421 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Chronic ulcer of unspecified site | 0.0005603 | 1.359 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Pain in limb | 0.006267 | 1.089 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Fracture of unspecified bones | 0.009956 | 1.145 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Congenital deformities of feet | 0.008592 | 0.7572 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Peripheral arterial disease | 0.00295 | 1.139 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Hammer toe | 0.009214 | 0.8396 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Congenital anomalies of limbs | 0.009077 | 0.7854 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Allergic reaction to food | 0.01121 | 1.777 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Acquired deformities of limbs | 0.007051 | 0.8184 | ANXA13 | Event-related brain oscillations |
| rs2294015 | Subarachnoid hemorrhage | 0.004061 | 0.4518 | ANXA13 | Event-related brain oscillations |
| rs2304130 | Cervicitis and endocervicitis | 0.002375 | 2.057 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Other specified diseases of hair and hair follicles | 0.004196 | 0.5049 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Colles' fracture | 0.004595 | 0.4611 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Arthropathy NOS | 0.0007714 | 0.6546 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Myeloproliferative disease | 0.005799 | 1.592 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Renal osteodystrophy | 0.004043 | 1.83 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Other arthropathies | 0.006601 | 0.8108 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Abnormal cytological, histological, immunological and DNA test findings | 0.004522 | 2.273 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Nonsenile Cataract | 0.00711 | 0.5144 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Hemorrhoids | 0.008686 | 0.8274 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Joint/ligament sprain | 0.003539 | 0.5212 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2304130 | Deep vein thrombosis | 0.00514 | 0.592 | ZNF101 | Total Cholesterol, LDL Cholesterol, Triglycerides, Sphingolipid levels |
| rs2326679 | Polyp of corpus uteri | 0.007023 | 0.6755 | LRRN4 | Menopause |
| rs2326679 | Cerebrovascular disease | 0.003737 | 1.112 | LRRN4 | Menopause |
| rs2326679 | Premature beats | 0.003532 | 0.815 | LRRN4 | Menopause |
| rs2326679 | Cancer of the digestive organs and peritoneum | 0.00375 | 0.59 | LRRN4 | Menopause |
| rs2326679 | Oral aphthae | 0.002824 | 1.746 | LRRN4 | Menopause |
| rs2326679 | Polycythemia vera, secondary | 0.009488 | 0.5555 | LRRN4 | Menopause |
| rs2326679 | Essential tremor | 0.002402 | 1.362 | LRRN4 | Menopause |
| rs2326679 | Symptoms of the muscles | 0.004959 | 1.278 | LRRN4 | Menopause |
| rs2326679 | Appendiceal conditions | 0.009985 | 1.391 | LRRN4 | Menopause |
| rs2326679 | Multiple sclerosis | 0.003415 | 1.597 | LRRN4 | Menopause |
| rs233100 | Heart failure NOS | 0.01139 | 0.7846 | DDAH1 | Multiple sclerosis |
| rs233100 | Benign neoplasm of unspecified sites | 0.003124 | 0.3965 | DDAH1 | Multiple sclerosis |
| rs233100 | Neck pain | 0.008958 | 0.9112 | DDAH1 | Multiple sclerosis |
| rs233100 | Pathologic fracture of vertebrae | 0.004335 | 0.7816 | DDAH1 | Multiple sclerosis |
| rs233100 | Premature menopause and other ovarian failure | 0.003369 | 0.4997 | DDAH1 | Multiple sclerosis |
| rs233100 | Hyperventilation | 0.004094 | 0.5384 | DDAH1 | Multiple sclerosis |
| rs233100 | Paraproteinemia | 0.004642 | 0.7063 | DDAH1 | Multiple sclerosis |
| rs233100 | Altered mental status | 0.0004205 | 0.7158 | DDAH1 | Multiple sclerosis |
| rs233100 | Herpes simplex | 0.004034 | 0.7473 | DDAH1 | Multiple sclerosis |
| rs233100 | Bacterial pneumonia | 0.001448 | 0.732 | DDAH1 | Multiple sclerosis |
| rs233100 | Hereditary and idiopathic peripheral neuropathy | 0.003504 | 0.8577 | DDAH1 | Multiple sclerosis |
| rs233100 | Edema | 0.01143 | 0.9108 | DDAH1 | Multiple sclerosis |
| rs233100 | Adjustment reaction | 0.001888 | 0.8476 | DDAH1 | Multiple sclerosis |
| rs233100 | Nonrheumatic mitral valve disorders | 0.008403 | 0.8738 | DDAH1 | Multiple sclerosis |
| rs233100 | Hemoptysis | 0.01041 | 0.7477 | DDAH1 | Multiple sclerosis |
| rs233100 | Plasma protein metabolism disorder | 0.002685 | 0.7403 | DDAH1 | Multiple sclerosis |
| rs233100 | Chronic prostatitis | 0.00702 | 1.518 | DDAH1 | Multiple sclerosis |
| rs233100 | Spirochetal infection | 0.00224 | 1.61 | DDAH1 | Multiple sclerosis |
| rs233100 | Protein plasma/amino-acid transport and metabolism disorder | 0.0004204 | 0.7256 | DDAH1 | Multiple sclerosis |
| rs233100 | Gastritis and duodenitis, NOS | 0.001879 | 0.7891 | DDAH1 | Multiple sclerosis |
| rs233100 | Lyme disease | 0.001427 | 1.66 | DDAH1 | Multiple sclerosis |
| rs2395029 | Psoriasis & related disorders | 4.113e-07 | 2.203 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Keratoconjunctivitis, noninfectious | 0.0027 | 2.295 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Mitral valve stenosis and/or aortic valve stenosis | 0.006833 | 1.598 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Psoriatic arthropathy | 0.002383 | 3.089 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Chronic hepatitis | 0.008182 | 2.725 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Disorders of cornea | 0.006856 | 1.54 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Voice disturbance | 0.0007985 | 1.682 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Male genital disorders | 0.004361 | 1.872 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Retinal disorders | 0.00593 | 1.334 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Cystic mastopathy | 0.0106 | 1.444 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Substance addiction and disorders | 0.009114 | 0.3411 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Acute laryngitis and tracheitis | 0.005621 | 2.331 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Pseudoexfoliation glaucoma | 0.01111 | 2.299 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Psoriasis vulgaris | 1.939e-07 | 2.344 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Other specified erythematous conditions | 0.011 | 1.756 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Neurological disorders due to brain damage | 0.005282 | 0.6794 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Macular degeneration | 0.008251 | 1.373 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Disorders of cervical region | 0.006257 | 1.886 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Acute sinusitis | 0.005616 | 1.413 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Respiratory failure; insufficiency; arrest | 0.00617 | 0.5394 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Keratoconjunctivitis sicca | 0.01039 | 2.37 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Torticollis | 0.004129 | 2.408 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Fracture of hand or wrist | 0.009025 | 0.6133 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Psoriasis | 4.759e-08 | 2.383 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2395029 | Acute upper respiratory infections | 0.00378 | 1.307 | HCP5 | Psoriasis, HIV-1 progression, AIDS progression, Drug-induced liver injury (flucloxacillin) |
| rs2413583 | Congenital anomalies of posterior segment of eye | 0.01116 | 1.347 | TAB1 | Crohn's disease |
| rs2413583 | Pancytopenia | 0.002965 | 0.4074 | TAB1 | Crohn's disease |
| rs2413583 | Neck pain | 0.001533 | 1.158 | TAB1 | Crohn's disease |
| rs2413583 | Jaundice | 0.00654 | 0.526 | TAB1 | Crohn's disease |
| rs2413583 | Aplastic anemia | 0.004684 | 0.6064 | TAB1 | Crohn's disease |
| rs2413583 | Otorrhea | 0.009171 | 2.039 | TAB1 | Crohn's disease |
| rs2413583 | Neutropenia | 0.01117 | 0.7483 | TAB1 | Crohn's disease |
| rs2413583 | Strabismus (not specified as paralytic) | 0.002845 | 1.348 | TAB1 | Crohn's disease |
| rs2413583 | Type 2 diabetic peripheral circulatory disorders | 0.003264 | 0.5671 | TAB1 | Crohn's disease |
| rs2413583 | Right bundle branch block | 0.008642 | 0.7041 | TAB1 | Crohn's disease |
| rs2413583 | Suppurative and unspecified otitis media | 0.005864 | 1.228 | TAB1 | Crohn's disease |
| rs2413583 | Secondary malignancy of lung | 0.01014 | 0.602 | TAB1 | Crohn's disease |
| rs2413583 | Decreased white blood cell count | 0.01051 | 0.7559 | TAB1 | Crohn's disease |
| rs2413583 | Mastoiditis | 0.0001248 | 2.971 | TAB1 | Crohn's disease |
| rs2413583 | Cerebral atherosclerosis | 0.00974 | 0.4207 | TAB1 | Crohn's disease |
| rs2413583 | Hyperparathyroidism | 0.007157 | 0.6619 | TAB1 | Crohn's disease |
| rs2413583 | Eustachian tube disorders | 0.005186 | 1.171 | TAB1 | Crohn's disease |
| rs2413583 | Simple goiter | 0.005664 | 1.312 | TAB1 | Crohn's disease |
| rs2413583 | Congenital anomalies of urinary system | 0.003578 | 1.606 | TAB1 | Crohn's disease |
| rs2413583 | Salicylates causing adverse effects in therapeutic use | 0.004092 | 2.14 | TAB1 | Crohn's disease |
| rs2413583 | Other disorders of ear | 0.008575 | 1.362 | TAB1 | Crohn's disease |
| rs2413583 | Postlaminectomy syndrome | 0.00413 | 1.541 | TAB1 | Crohn's disease |
| rs2413583 | Complications of transplants and reattached limbs | 0.007699 | 0.4301 | TAB1 | Crohn's disease |
| rs2413583 | Cardiac pacemaker/device in situ | 0.01127 | 0.7805 | TAB1 | Crohn's disease |
| rs2413583 | Migrain with aura | 0.001674 | 0.4557 | TAB1 | Crohn's disease |
| rs2413583 | Dislocation | 0.00583 | 1.159 | TAB1 | Crohn's disease |
| rs2413583 | Diabetic retinopathy | 0.0008239 | 0.7253 | TAB1 | Crohn's disease |
| rs2413583 | Other disorders of middle ear and mastoid | 0.007822 | 1.564 | TAB1 | Crohn's disease |
| rs2413583 | Type 2 diabetic retinopathy | 0.00141 | 0.7288 | TAB1 | Crohn's disease |
| rs2413583 | Thoracic neuritis/radiculitis | 0.003137 | 1.171 | TAB1 | Crohn's disease |
| rs242557 | Conduct disorders | 0.005829 | 1.566 | MAPT | Progressive supranuclear palsy |
| rs242557 | Symptoms involving head and neck | 0.004786 | 1.203 | MAPT | Progressive supranuclear palsy |
| rs242557 | Pain in limb | 0.003048 | 0.9091 | MAPT | Progressive supranuclear palsy |
| rs242557 | Subdural hemorrhage (injury) | 0.0104 | 1.614 | MAPT | Progressive supranuclear palsy |
| rs242557 | Diabetic retinopathy | 0.00244 | 0.8109 | MAPT | Progressive supranuclear palsy |
| rs242557 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.009142 | 0.8039 | MAPT | Progressive supranuclear palsy |
| rs242557 | Shock | 0.01133 | 0.7159 | MAPT | Progressive supranuclear palsy |
| rs242557 | Mental disorders due to brain damage | 0.008543 | 1.224 | MAPT | Progressive supranuclear palsy |
| rs242557 | Superficial cellulitis and abscess | 0.005398 | 0.9057 | MAPT | Progressive supranuclear palsy |
| rs242557 | Schizophrenia and other psychotic disorders | 0.0004327 | 1.262 | MAPT | Progressive supranuclear palsy |
| rs242557 | Diseases of hard tissues of teeth | 0.001662 | 1.23 | MAPT | Progressive supranuclear palsy |
| rs242557 | Nonrheumatic mitral valve disorders | 0.003797 | 1.158 | MAPT | Progressive supranuclear palsy |
| rs242557 | Other hypertrophic and atrophic conditions of skin | 0.009479 | 0.8994 | MAPT | Progressive supranuclear palsy |
| rs242557 | Otalgia | 0.01085 | 0.7937 | MAPT | Progressive supranuclear palsy |
| rs242557 | Chronic pain syndrome | 0.009249 | 0.5823 | MAPT | Progressive supranuclear palsy |
| rs242557 | Cardiomyopathy | 0.007457 | 1.182 | MAPT | Progressive supranuclear palsy |
| rs242557 | Intracranial hemorrhage (injury) | 0.00334 | 1.52 | MAPT | Progressive supranuclear palsy |
| rs242557 | Other disorders of soft tissues | 0.01144 | 0.7132 | MAPT | Progressive supranuclear palsy |
| rs242557 | Decreased libido | 0.00288 | 2.07 | MAPT | Progressive supranuclear palsy |
| rs242557 | Osteoarthrosis, generalized | 0.009315 | 0.8237 | MAPT | Progressive supranuclear palsy |
| rs242557 | Trigeminal nerve disorders | 0.007878 | 0.6718 | MAPT | Progressive supranuclear palsy |
| rs242557 | Dental caries | 0.001387 | 1.241 | MAPT | Progressive supranuclear palsy |
| rs242557 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.0105 | 1.189 | MAPT | Progressive supranuclear palsy |
| rs242557 | Alcoholism | 0.002608 | 1.253 | MAPT | Progressive supranuclear palsy |
| rs242557 | Alcohol-related disorders | 0.000489 | 1.258 | MAPT | Progressive supranuclear palsy |
| rs242557 | Adverse effects of insulins and antidiabetic agents | 0.009056 | 0.5166 | MAPT | Progressive supranuclear palsy |
| rs242557 | Chronic venous hypertension | 0.004473 | 0.3857 | MAPT | Progressive supranuclear palsy |
| rs242557 | Keratitis, infectious | 0.0006616 | 0.6269 | MAPT | Progressive supranuclear palsy |
| rs242557 | Ankylosis of joint | 0.006136 | 0.6759 | MAPT | Progressive supranuclear palsy |
| rs242557 | Other disorders of back | 0.003089 | 0.847 | MAPT | Progressive supranuclear palsy |
| rs242557 | Subdural hemorrhage | 0.01025 | 1.544 | MAPT | Progressive supranuclear palsy |
| rs242557 | Eustachian tube disorders | 0.01051 | 0.8022 | MAPT | Progressive supranuclear palsy |
| rs243021 | Acute bronchospasm | 0.002832 | 0.3842 | BCL11A | Type 2 diabetes |
| rs243021 | ASCVD | 0.006694 | 1.367 | BCL11A | Type 2 diabetes |
| rs243021 | Other abnormal glucose | 0.008745 | 1.136 | BCL11A | Type 2 diabetes |
| rs243021 | Absent or infrequent menstruation | 0.0009403 | 1.706 | BCL11A | Type 2 diabetes |
| rs243021 | Polycythemia vera, secondary | 0.005764 | 0.609 | BCL11A | Type 2 diabetes |
| rs243021 | Gross hematuria | 0.007128 | 0.6197 | BCL11A | Type 2 diabetes |
| rs243021 | Herpes zoster | 0.006857 | 1.183 | BCL11A | Type 2 diabetes |
| rs243021 | Retinal drusen | 0.002649 | 0.7946 | BCL11A | Type 2 diabetes |
| rs243021 | Acute upper respiratory infections | 0.009274 | 1.094 | BCL11A | Type 2 diabetes |
| rs243021 | Aortic aneurysm | 0.00679 | 0.8308 | BCL11A | Type 2 diabetes |
| rs243021 | Abnormal glucose | 0.003096 | 1.123 | BCL11A | Type 2 diabetes |
| rs2430212 | Polycystic ovaries | 0.003749 | 0.3475 | KLHL13 | Serum transferrin |
| rs2430212 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.006636 | 0.802 | KLHL13 | Serum transferrin |
| rs2430212 | Rheumatoid arthritis | 0.004712 | 0.7716 | KLHL13 | Serum transferrin |
| rs2430212 | Arthropathy associated with infections | 0.009414 | 0.528 | KLHL13 | Serum transferrin |
| rs2430212 | Plasma protein metabolism disorder | 0.001877 | 0.6613 | KLHL13 | Serum transferrin |
| rs2430212 | Diseases of the larynx and vocal cords | 0.003928 | 0.7967 | KLHL13 | Serum transferrin |
| rs2430212 | Other alveolar and parietoalveolar pneumonopathy | 0.002492 | 0.3926 | KLHL13 | Serum transferrin |
| rs2430212 | Fracture of humerus | 0.0003679 | 0.6852 | KLHL13 | Serum transferrin |
| rs2430212 | Tachycardia NOS | 0.005244 | 0.7955 | KLHL13 | Serum transferrin |
| rs2430212 | Ovarian dysfunction | 0.002533 | 0.3847 | KLHL13 | Serum transferrin |
| rs2430212 | Voice disturbance | 0.005848 | 0.7781 | KLHL13 | Serum transferrin |
| rs2430212 | Visual disturbances | 0.0008402 | 1.174 | KLHL13 | Serum transferrin |
| rs2430212 | Non-healing surgical wound | 0.004207 | 1.796 | KLHL13 | Serum transferrin |
| rs2430212 | Adverse effects of hormones and synthetic substitutes | 0.008461 | 0.2542 | KLHL13 | Serum transferrin |
| rs2430212 | Vaginitis and vulvovaginitis | 0.003257 | 1.24 | KLHL13 | Serum transferrin |
| rs2430212 | Ectropion or entropion | 0.004383 | 0.72 | KLHL13 | Serum transferrin |
| rs2430212 | Eating disorder | 0.0114 | 1.636 | KLHL13 | Serum transferrin |
| rs2476601 | Retinal edema and hypertensive retinopathy | 0.01085 | 1.48 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Decreased white blood cell count | 0.002305 | 1.4 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Other disorders of gallbladder | 0.004858 | 1.873 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Pernicious anemia | 0.006919 | 1.673 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Ovarian dysfunction | 0.00424 | 2.367 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Supraventricular premature beats | 0.007937 | 1.53 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Vitamin D deficiency | 0.01035 | 1.437 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Congenital deformities of feet | 0.01006 | 1.478 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Hypocalcemia | 0.004849 | 1.674 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Polycystic ovaries | 0.0005011 | 3.149 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Hypothyroidism | 4.02e-07 | 1.334 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Neutropenia | 0.006896 | 1.368 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Hypotony of eye | 0.003949 | 2.638 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Jaundice | 0.00866 | 1.66 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Congenital anomalies of limbs | 0.005418 | 1.453 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Urinary calculus | 0.01121 | 0.7873 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Primary open angle glaucoma | 0.006086 | 1.415 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Malignant neoplasm of renal pelvis | 0.007431 | 2.505 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Chronic lymphocytic thyroiditis | 0.0004169 | 1.909 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Disorders of tooth development | 0.006815 | 1.521 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.009674 | 1.297 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Open-angle glaucoma | 0.008166 | 1.269 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Disorders of liver | 0.002959 | 1.201 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Thyroiditis | 0.0007339 | 1.703 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Macular degeneration, dry | 0.002992 | 1.444 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Thyrotoxicosis | 0.008105 | 1.367 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Glaucoma | 0.009954 | 1.185 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Graves' disease | 0.0004271 | 1.97 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2476601 | Other hypertensive complications | 0.009023 | 1.403 | PTPN22 | Type 1 diabetes, Type 1 diabetes autoantibodies, Vitiligo, Rheumatoid arthritis, Crohn's disease |
| rs2484873 | Malaise and fatigue | 0.00736 | 1.202 | KIAA1217 | Cognitive performance |
| rs2484873 | Anemia NOS | 0.0006997 | 1.281 | KIAA1217 | Cognitive performance |
| rs2484873 | Miscarriage; stillbirth | 0.00607 | 2.521 | KIAA1217 | Cognitive performance |
| rs2484873 | Other forms of chronic heart disease | 0.01057 | 1.413 | KIAA1217 | Cognitive performance |
| rs2484873 | Other disorders of arteries and arterioles | 0.006808 | 1.57 | KIAA1217 | Cognitive performance |
| rs2484873 | Cardiac defibrillator in situ | 0.005462 | 1.995 | KIAA1217 | Cognitive performance |
| rs2484873 | Sexually transmitted infections | 0.01074 | 2.661 | KIAA1217 | Cognitive performance |
| rs2484873 | Perforation of tympanic membrane | 0.008245 | 1.984 | KIAA1217 | Cognitive performance |
| rs2484873 | Other anemias | 0.001584 | 1.24 | KIAA1217 | Cognitive performance |
| rs2484873 | Other aneurysm | 0.003711 | 1.444 | KIAA1217 | Cognitive performance |
| rs2484873 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.006783 | 0.6133 | KIAA1217 | Cognitive performance |
| rs2484873 | Hematemesis | 0.001469 | 2.375 | KIAA1217 | Cognitive performance |
| rs2484873 | Type 1 diabetic peripheral circulatory disorders | 0.003815 | 2.9 | KIAA1217 | Cognitive performance |
| rs2505083 | Disturbances of sulphur-bearing amino-acid metabolism | 0.005529 | 1.839 | KIAA1462 | Coronary heart disease |
| rs2505083 | Empyema and pneumothorax | 0.01047 | 0.7787 | KIAA1462 | Coronary heart disease |
| rs2505083 | Labyrinthitis | 0.008247 | 1.344 | KIAA1462 | Coronary heart disease |
| rs2505083 | Aneurysm of artery of lower extremity | 0.002463 | 1.624 | KIAA1462 | Coronary heart disease |
| rs2505083 | Thyrotoxicosis | 0.003759 | 1.25 | KIAA1462 | Coronary heart disease |
| rs2505083 | Muscular wasting and disuse atrophy | 0.003846 | 0.5814 | KIAA1462 | Coronary heart disease |
| rs2505083 | Respiratory insufficiency | 0.01022 | 0.7811 | KIAA1462 | Coronary heart disease |
| rs2505083 | Disturbances of amino-acid transport | 0.00996 | 1.745 | KIAA1462 | Coronary heart disease |
| rs2505083 | Other benign neoplasm of connective and other soft tissue | 0.0008136 | 0.5993 | KIAA1462 | Coronary heart disease |
| rs2505083 | Aplastic anemia | 0.0005463 | 0.6723 | KIAA1462 | Coronary heart disease |
| rs2505083 | Allergic reaction to food | 0.0065 | 1.863 | KIAA1462 | Coronary heart disease |
| rs2505083 | Herpes zoster with nervous system complications | 0.003633 | 1.552 | KIAA1462 | Coronary heart disease |
| rs2505083 | Disorders of mineral metabolism | 0.003543 | 0.866 | KIAA1462 | Coronary heart disease |
| rs2505083 | Abnormal findings examination of lungs | 0.002547 | 0.8391 | KIAA1462 | Coronary heart disease |
| rs2505083 | Scoliosis | 0.006274 | 0.7632 | KIAA1462 | Coronary heart disease |
| rs2515629 | Arterial embolism and thrombosis | 0.002346 | 1.35 | ABCA1 | HDL Cholesterol |
| rs2515629 | Secondary malignant neoplasm | 0.00133 | 1.243 | ABCA1 | HDL Cholesterol |
| rs2515629 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.001205 | 1.474 | ABCA1 | HDL Cholesterol |
| rs2515629 | Secondary malignant neoplasm of liver | 0.004913 | 1.472 | ABCA1 | HDL Cholesterol |
| rs2515629 | Obesity | 0.001578 | 0.8712 | ABCA1 | HDL Cholesterol |
| rs2515629 | Type 2 diabetes | 0.0007318 | 0.8702 | ABCA1 | HDL Cholesterol |
| rs2515629 | Diabetic retinopathy | 0.008229 | 0.7891 | ABCA1 | HDL Cholesterol |
| rs2515629 | Overweight | 0.004019 | 0.8881 | ABCA1 | HDL Cholesterol |
| rs2515629 | Type 2 diabetic retinopathy | 0.006304 | 0.7745 | ABCA1 | HDL Cholesterol |
| rs2515629 | Thrombocytopenia | 0.003235 | 0.7753 | ABCA1 | HDL Cholesterol |
| rs2515629 | Antihypertensive agents causing adverse effects | 0.00502 | 1.68 | ABCA1 | HDL Cholesterol |
| rs2515629 | Poisoning by other anti-infectives | 0.01091 | 1.277 | ABCA1 | HDL Cholesterol |
| rs2515629 | Glaucoma | 0.01115 | 1.139 | ABCA1 | HDL Cholesterol |
| rs2515629 | Poisoning by primarily systemic agents | 0.001097 | 1.464 | ABCA1 | HDL Cholesterol |
| rs2515629 | Neoplasm of uncertain behavior | 0.001615 | 1.278 | ABCA1 | HDL Cholesterol |
| rs2515629 | Malignant neoplasm, other | 0.004304 | 1.308 | ABCA1 | HDL Cholesterol |
| rs2515629 | Cancer, suspected or other | 0.0005484 | 1.326 | ABCA1 | HDL Cholesterol |
| rs2515629 | Hemorrhage or hematoma complicating a procedure | 0.002554 | 0.7266 | ABCA1 | HDL Cholesterol |
| rs2515629 | Fracture of upper limb | 0.007045 | 0.8327 | ABCA1 | HDL Cholesterol |
| rs2515629 | Diabetes mellitus | 0.0006046 | 0.8698 | ABCA1 | HDL Cholesterol |
| rs2515629 | Candidiasis | 0.003405 | 0.7707 | ABCA1 | HDL Cholesterol |
| rs2515629 | Colles' fracture | 0.001623 | 0.5582 | ABCA1 | HDL Cholesterol |
| rs2515629 | Altered mental status | 0.0004352 | 0.6092 | ABCA1 | HDL Cholesterol |
| rs2517388 | Retinal detachments and defects | 0.007526 | 1.277 | ASH2L | Menopause |
| rs2517388 | Varicose veins | 0.008565 | 0.8318 | ASH2L | Menopause |
| rs2517388 | Varicose veins of lower extremity | 0.006438 | 0.8183 | ASH2L | Menopause |
| rs2517388 | Secondary malignant neoplasm | 0.008831 | 1.192 | ASH2L | Menopause |
| rs2517388 | Diseases of respiratory system | 0.01006 | 0.8212 | ASH2L | Menopause |
| rs2517388 | Bronchopneumonia and lung abscess | 0.007704 | 0.3468 | ASH2L | Menopause |
| rs2523946 | Blood in stool | 0.0008289 | 1.192 | HCG9 | IgA nephropathy |
| rs2523946 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.0008209 | 1.242 | HCG9 | IgA nephropathy |
| rs2523946 | Atrial fibrillation & flutter | 0.008069 | 1.121 | HCG9 | IgA nephropathy |
| rs2523946 | Polyarteritis nodosa and allied conditions | 0.009866 | 1.313 | HCG9 | IgA nephropathy |
| rs2523946 | Conductive hearing loss | 0.006175 | 0.64 | HCG9 | IgA nephropathy |
| rs2523946 | Other and unspecified disc disorder | 0.01029 | 1.441 | HCG9 | IgA nephropathy |
| rs2523946 | Obstructive sleep apnea | 0.001267 | 0.85 | HCG9 | IgA nephropathy |
| rs2523946 | Myalgia and myositis NOS | 0.009668 | 1.112 | HCG9 | IgA nephropathy |
| rs2523946 | Rheumatoid arthritis | 0.000787 | 1.277 | HCG9 | IgA nephropathy |
| rs2523946 | Atrial fibrillation | 0.007812 | 1.124 | HCG9 | IgA nephropathy |
| rs2523946 | Viral warts & HPV | 0.002938 | 0.8531 | HCG9 | IgA nephropathy |
| rs2523946 | Prurigo | 0.005712 | 0.7724 | HCG9 | IgA nephropathy |
| rs2523946 | Arteritis NOS | 0.00168 | 1.69 | HCG9 | IgA nephropathy |
| rs2523946 | Hidradenitis | 0.001209 | 0.3268 | HCG9 | IgA nephropathy |
| rs2523946 | Herpes zoster | 0.01108 | 0.8518 | HCG9 | IgA nephropathy |
| rs2523946 | Other congenital anomalies of skin | 0.009035 | 0.6982 | HCG9 | IgA nephropathy |
| rs2523946 | Congenital anomalies of peripheral vascular system | 0.006391 | 1.801 | HCG9 | IgA nephropathy |
| rs25422 | Cervical cancer and dysplasia | 0.004379 | 1.371 | C6orf204 | Renal cell carcinoma |
| rs25422 | Electrolyte imbalance | 0.005624 | 1.131 | C6orf204 | Renal cell carcinoma |
| rs25422 | Decubitus ulcer | 0.01115 | 1.261 | C6orf204 | Renal cell carcinoma |
| rs25422 | Osteoarthrosis; localized, secondary | 0.005803 | 1.68 | C6orf204 | Renal cell carcinoma |
| rs25422 | Disorders of fluid, electrolyte, and acid-base balance | 0.007599 | 1.11 | C6orf204 | Renal cell carcinoma |
| rs25422 | Macular degeneration, dry | 0.001802 | 1.352 | C6orf204 | Renal cell carcinoma |
| rs25422 | Lesions of stomach and duodenum | 0.004705 | 2.104 | C6orf204 | Renal cell carcinoma |
| rs25422 | Hypovolemia | 0.004039 | 1.168 | C6orf204 | Renal cell carcinoma |
| rs25422 | Wheezing and painful respiration | 0.01086 | 0.8614 | C6orf204 | Renal cell carcinoma |
| rs25422 | Wheezing | 0.0007981 | 0.5954 | C6orf204 | Renal cell carcinoma |
| rs2544390 | Elevated blood pressure reading | 4.067e-05 | 1.228 | LRP2 | Serum urate |
| rs2544390 | Neoplasm of unspecified nature of digestive system | 0.003421 | 1.459 | LRP2 | Serum urate |
| rs2544390 | Gastrointestinal complications | 0.01104 | 1.25 | LRP2 | Serum urate |
| rs2544390 | Injuries to the nervous system | 0.006041 | 0.6046 | LRP2 | Serum urate |
| rs2544390 | Stiffness of joint | 0.005614 | 0.8215 | LRP2 | Serum urate |
| rs2544390 | Abnormal chest sounds | 0.008957 | 0.6805 | LRP2 | Serum urate |
| rs2544390 | Hypertension | 0.003677 | 1.093 | LRP2 | Serum urate |
| rs2544390 | Congenital anomalies of face and neck | 0.007242 | 2.14 | LRP2 | Serum urate |
| rs2544390 | Other disorders of intestine | 0.01087 | 1.176 | LRP2 | Serum urate |
| rs2544390 | Essential hypertension | 0.005537 | 1.088 | LRP2 | Serum urate |
| rs2544390 | Tinnitus | 0.001451 | 1.242 | LRP2 | Serum urate |
| rs2544390 | Unstable angina (intermediate coronary syndrome) | 0.009963 | 1.157 | LRP2 | Serum urate |
| rs255052 | Type 1 diabetic neuropathy | 0.005562 | 1.582 | DPEP2 | HDL Cholesterol |
| rs255052 | Other hypertrophic and atrophic conditions of skin | 0.007788 | 0.86 | DPEP2 | HDL Cholesterol |
| rs255052 | Osteopenia | 0.004463 | 1.184 | DPEP2 | HDL Cholesterol |
| rs255052 | Herpes zoster | 0.007952 | 1.247 | DPEP2 | HDL Cholesterol |
| rs255052 | Fibroadenosis of breast | 0.006911 | 2.426 | DPEP2 | HDL Cholesterol |
| rs255052 | Heart valve replaced | 0.01145 | 1.354 | DPEP2 | HDL Cholesterol |
| rs255052 | Other disorders of the nervous system | 0.01115 | 1.618 | DPEP2 | HDL Cholesterol |
| rs255052 | Vitamin deficiency | 0.005379 | 1.24 | DPEP2 | HDL Cholesterol |
| rs255052 | Balanoposthitis | 0.007714 | 0.3815 | DPEP2 | HDL Cholesterol |
| rs2562519 | Atrial fibrillation | 0.006422 | 0.8677 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Disorders of the pituitary gland and its hypothalamic control | 0.007886 | 1.393 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Osteochondropathies | 0.009033 | 1.891 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Benign neoplasm of other endocrine glands | 0.004916 | 1.461 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Balanoposthitis | 0.004335 | 0.4764 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Heart failure NOS | 0.008241 | 0.7415 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Acute tonsillitis | 0.008243 | 1.629 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Neoplasm of unspecified nature of digestive system | 0.003737 | 1.507 | POLR3G | Nevirapine-induced rash |
| rs2562519 | Atrial fibrillation & flutter | 0.008552 | 0.8741 | POLR3G | Nevirapine-induced rash |
| rs2562784 | Bullous dermatoses | 0.002933 | 2.014 | SH3GL3 | Height |
| rs2562784 | Hematuria | 0.0002749 | 1.183 | SH3GL3 | Height |
| rs2562784 | Random mental disorder. Ignored for now | 0.002856 | 1.614 | SH3GL3 | Height |
| rs2562784 | Speech and language disorder | 0.009224 | 1.427 | SH3GL3 | Height |
| rs2562784 | Hallux valgus (Bunion) | 0.002651 | 1.24 | SH3GL3 | Height |
| rs2562784 | Other specified peripheral vascular diseases | 0.004909 | 2.054 | SH3GL3 | Height |
| rs2562784 | Other congenital anomalies of skin | 0.002734 | 1.54 | SH3GL3 | Height |
| rs2562784 | progressive myopia | 0.01141 | 1.731 | SH3GL3 | Height |
| rs2562784 | Other disorders of bladder | 0.007758 | 1.185 | SH3GL3 | Height |
| rs2562784 | Cancer of bone & connective tissue | 0.01023 | 1.477 | SH3GL3 | Height |
| rs2562784 | Cancer of connective tissue | 0.00112 | 1.864 | SH3GL3 | Height |
| rs2562784 | Urinary calculus | 0.01007 | 1.163 | SH3GL3 | Height |
| rs2562784 | Cancer, suspected or other | 0.00294 | 1.25 | SH3GL3 | Height |
| rs2562784 | Ventral hernia | 0.003288 | 1.349 | SH3GL3 | Height |
| rs2562784 | Disorders of cornea | 0.00687 | 1.222 | SH3GL3 | Height |
| rs2562784 | Intestinal malabsorption | 0.002455 | 1.461 | SH3GL3 | Height |
| rs2562784 | Pneumonia | 0.01131 | 1.117 | SH3GL3 | Height |
| rs2562784 | Abdominal hernia | 0.0008838 | 1.138 | SH3GL3 | Height |
| rs2562784 | Fractur of unspecified part of femur | 0.001224 | 0.5628 | SH3GL3 | Height |
| rs2562784 | Sacroiliitis NEC | 0.00601 | 0.3969 | SH3GL3 | Height |
| rs2562784 | Schizophrenia | 0.007957 | 1.674 | SH3GL3 | Height |
| rs2562784 | Intestinal malabsorption NOS | 0.009014 | 1.673 | SH3GL3 | Height |
| rs2575876 | Angina pectoris | 0.006518 | 0.8633 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Proteinuria | 0.01122 | 1.29 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Cellulitis and abscess of trunk | 0.002326 | 0.6901 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Lupus erythematosus | 0.005514 | 1.923 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Hypoparathyroidism | 0.007189 | 2.121 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Adverse effects of adrenal cortical steroids | 0.005816 | 1.592 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Urethritis and urethral syndrome | 0.007397 | 0.4602 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Labyrinthitis | 5.501e-05 | 0.5299 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Other peripheral nerve disorders | 0.01114 | 0.9001 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Anomalies of jaw size/symmetry | 0.009715 | 1.962 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Diverticulum of esophagus, acquired | 0.009858 | 0.396 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Primary angle-closure glaucoma | 0.0007063 | 1.323 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Cardiac defibrillator in situ | 0.006504 | 1.476 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2575876 | Other infectious diseases | 0.003179 | 0.4027 | ABCA1 | Total cholesterol to Esterified cholesterol ratio |
| rs2597513 | Primary angle-closure glaucoma | 0.006601 | 0.7078 | HDAC11 | Height |
| rs2597513 | Hypotension NOS | 0.001447 | 1.337 | HDAC11 | Height |
| rs2597513 | Type 2 diabetic peripheral circulatory disorders | 0.008129 | 1.535 | HDAC11 | Height |
| rs2597513 | Cancer within the respiratory system | 0.002994 | 1.4 | HDAC11 | Height |
| rs2597513 | Urethral stricture (not specified as infectious) | 0.005133 | 1.654 | HDAC11 | Height |
| rs2597513 | Arthralgia/ankylosis of temporomandibular joint | 0.008107 | 0.2982 | HDAC11 | Height |
| rs2597513 | Hypovolemia | 0.000939 | 1.247 | HDAC11 | Height |
| rs2597513 | Acute laryngitis and tracheitis | 0.01115 | 0.4598 | HDAC11 | Height |
| rs2597513 | Claw toe | 0.0001125 | 3.057 | HDAC11 | Height |
| rs2597513 | Temporomandibular joint disorders | 0.007965 | 0.6294 | HDAC11 | Height |
| rs2597513 | Irritable Bowel Syndrome | 0.004704 | 0.7521 | HDAC11 | Height |
| rs2597513 | Known or suspected fetal abnormality | 0.006491 | 0.238 | HDAC11 | Height |
| rs2597513 | Acidosis | 0.01095 | 1.517 | HDAC11 | Height |
| rs2597513 | Lung cancer | 0.002612 | 1.412 | HDAC11 | Height |
| rs2597513 | Otalgia | 0.001111 | 0.5674 | HDAC11 | Height |
| rs2597513 | Chronic ischemic heart disease | 0.002102 | 1.258 | HDAC11 | Height |
| rs2597513 | Peripheral autonomic neuropathy | 0.006188 | 1.56 | HDAC11 | Height |
| rs2619566 | Acquired spondylolisthesis | 0.004087 | 0.5918 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Coronary atherosclerosis | 0.004506 | 0.8667 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Leukemia | 0.005699 | 1.479 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Seborheic dermatitis | 0.006101 | 0.752 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Heart valve disorders | 0.009972 | 0.8545 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Erythematous conditions | 0.009337 | 0.8327 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Conjunctivitis, infectious | 0.004472 | 0.7662 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Ectropion or entropion | 0.001554 | 0.6164 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Myeloproliferative disease | 0.007584 | 1.5 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Cancer of other female genital organs | 0.008321 | 2.137 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Diffuse diseases of connective tissue | 0.008861 | 0.6679 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Lymphoid leukemia | 0.0004918 | 1.967 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Colostomy and enterostomy complication | 0.01134 | 1.946 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Angina pectoris | 0.002507 | 0.8003 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Other disorders of back | 0.006982 | 0.7849 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Hypercholesterolemia | 0.01073 | 0.852 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Viral Enteritis | 0.003639 | 1.724 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Infection of the eye | 0.006559 | 0.7986 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Ischemic Heart Disease | 0.0004788 | 0.8457 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Fracture of unspecified bones | 0.004441 | 1.251 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2619566 | Chronic lymphoid leukemia | 0.002816 | 1.846 | CNTN4 | Amyotrophic lateral sclerosis |
| rs2651899 | Gram negative septicemia | 0.009643 | 0.7123 | PRDM16 | Migraine |
| rs2651899 | Chronic pancreatitis | 0.003409 | 0.5572 | PRDM16 | Migraine |
| rs2651899 | Toxic erythema | 0.006601 | 2.13 | PRDM16 | Migraine |
| rs2651899 | Methicillin sensitive Staphylococcus aureus | 0.00103 | 0.6882 | PRDM16 | Migraine |
| rs2651899 | Otalgia | 0.006522 | 0.7838 | PRDM16 | Migraine |
| rs2651899 | Synoviopathy | 0.006271 | 0.7477 | PRDM16 | Migraine |
| rs2651899 | Cervical cancer and dysplasia | 0.006404 | 0.7706 | PRDM16 | Migraine |
| rs2651899 | Renal colic | 0.008933 | 0.5888 | PRDM16 | Migraine |
| rs2651899 | Diverticulum of esophagus, acquired | 0.007093 | 0.4899 | PRDM16 | Migraine |
| rs2651899 | Absent or infrequent menstruation | 0.01045 | 0.6615 | PRDM16 | Migraine |
| rs2651899 | Iatrogenic hypotension | 0.006514 | 1.585 | PRDM16 | Migraine |
| rs2651899 | Heart transplant/surgery | 0.004742 | 0.6722 | PRDM16 | Migraine |
| rs2651899 | Type 1 diabetic neuropathy | 0.005028 | 1.454 | PRDM16 | Migraine |
| rs2651899 | Prostatitis | 0.009366 | 0.7766 | PRDM16 | Migraine |
| rs2651899 | Testicular hypofunction | 0.01094 | 1.368 | PRDM16 | Migraine |
| rs2651899 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.008857 | 0.7626 | PRDM16 | Migraine |
| rs2651899 | Atrophy of edentulous alveolar ridge | 0.005239 | 0.6418 | PRDM16 | Migraine |
| rs2651899 | Drug-resistant infection | 0.005704 | 0.7103 | PRDM16 | Migraine |
| rs2651899 | Pyogenic granuloma | 0.006027 | 0.5072 | PRDM16 | Migraine |
| rs2711721 | Fluid overload | 0.008901 | 0.7428 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Degeneration of intervertebral disc | 0.005521 | 1.142 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Microscopic hematuria | 0.003738 | 1.604 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Alcoholic liver damage | 0.009183 | 1.645 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Spondylosis and allied disorders | 0.001392 | 1.149 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Hodgkin's disease | 0.005391 | 0.3781 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Appendicitis | 0.0004454 | 1.596 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Appendiceal conditions | 0.0003871 | 1.586 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Cystic kidney disease | 0.002041 | 0.4619 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Cancer of mouth | 0.006651 | 0.5501 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Spinal stenosis | 0.0005507 | 1.195 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Osteoarthrosis, generalized | 0.008091 | 1.241 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Urethral hypermobility/ISD | 0.001653 | 0.4203 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Abnormal movement | 0.004745 | 1.137 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Abnormal function study of cardiovascular system | 0.01134 | 0.8333 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Deviated nasal septum | 0.006185 | 1.213 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Macular degeneration | 0.004333 | 1.164 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Spondylosis without myelopathy | 0.001622 | 1.152 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Allergies, other | 0.0002106 | 1.419 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Congenital anomalies of urinary system | 0.006089 | 0.5918 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2711721 | Spinal stenosis of lumbar region | 0.004846 | 1.176 | AMIGO2 | Prostate cancer (gene x gene interaction) |
| rs2731672 | Gingival and periodontal diseases | 0.008028 | 0.8137 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Benign neoplasm of uterus | 0.0001215 | 1.353 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Dysmenorrhea | 0.004975 | 1.591 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Early or threatened labor; hemorrhage in early pregnancy | 0.002205 | 1.82 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Keratoconjunctivitis sicca | 0.006667 | 1.653 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Known or suspected fetal abnormality | 0.005593 | 1.732 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Insect bite | 0.002292 | 1.306 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Benign neoplasm of other parts of digestive system | 0.009053 | 0.7175 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Cystic kidney disease | 0.00811 | 0.5471 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Malignant neoplasm of brain and nervous system | 0.005273 | 0.6213 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Inguinal hernia | 0.01141 | 0.8543 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Other conditions of brain | 0.0005574 | 0.6347 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Abnormal results of function study of liver | 0.00586 | 0.7844 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Excessive or frequent menstruation | 0.005196 | 1.355 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Infertility, female | 0.001173 | 2.063 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Uterine leiomyoma | 0.0007545 | 1.324 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2731672 | Abnormal findings on radiological examination intrathoracic organs | 0.01047 | 0.8067 | F12 | Activated partial thromboplastin time, Factor XII levels |
| rs2744148 | Ulcerative stomatitis & mucositis | 0.006022 | 1.932 | SOX8 | Multiple sclerosis |
| rs2744148 | Known or suspected fetal abnormality | 0.003002 | 1.898 | SOX8 | Multiple sclerosis |
| rs2744148 | Macular degeneration | 0.00505 | 0.8446 | SOX8 | Multiple sclerosis |
| rs2744148 | Early or threatened labor; hemorrhage in early pregnancy | 0.0101 | 1.731 | SOX8 | Multiple sclerosis |
| rs2744148 | Atrophy of edentulous alveolar ridge | 0.006236 | 1.604 | SOX8 | Multiple sclerosis |
| rs2744148 | Other conditions of the mother complicating pregnancy | 0.008268 | 1.758 | SOX8 | Multiple sclerosis |
| rs2744148 | Male genital disorders | 0.003081 | 0.6528 | SOX8 | Multiple sclerosis |
| rs2744148 | Optic atrophy | 0.008927 | 1.536 | SOX8 | Multiple sclerosis |
| rs2744148 | Congenital anomalies of the eye | 0.009451 | 0.7446 | SOX8 | Multiple sclerosis |
| rs2744148 | Cholangitis | 0.009404 | 0.3818 | SOX8 | Multiple sclerosis |
| rs2744148 | Spasm of muscle | 0.003333 | 1.303 | SOX8 | Multiple sclerosis |
| rs2744148 | Parasomnia | 0.004719 | 1.802 | SOX8 | Multiple sclerosis |
| rs2744148 | Personal history of allergy to medicinal agents | 0.004432 | 1.358 | SOX8 | Multiple sclerosis |
| rs2744148 | Bone cancer | 0.004474 | 1.811 | SOX8 | Multiple sclerosis |
| rs2744148 | Nevus, non-neoplastic | 0.005419 | 0.3769 | SOX8 | Multiple sclerosis |
| rs2755237 | Alcoholism | 0.007629 | 0.7358 | FOXO1 | Central corneal thickness |
| rs2755237 | Infection/inflammation of internal prosthetic device, implant or graft | 0.000892 | 0.6069 | FOXO1 | Central corneal thickness |
| rs2755237 | Chronic pancreatitis | 0.008008 | 1.766 | FOXO1 | Central corneal thickness |
| rs2755237 | Displacement of intervertebral disc | 0.00365 | 1.233 | FOXO1 | Central corneal thickness |
| rs2755237 | Degenerative disease of the spinal cord | 0.008379 | 1.563 | FOXO1 | Central corneal thickness |
| rs2755237 | Other disorders of bladder | 0.002711 | 1.251 | FOXO1 | Central corneal thickness |
| rs2755237 | Megaloblastic anemia | 0.0008538 | 0.5186 | FOXO1 | Central corneal thickness |
| rs2755237 | Other disorders of stomach and duodenum | 0.001794 | 1.433 | FOXO1 | Central corneal thickness |
| rs2755237 | Noninfectious dermatoses of eyelid | 0.005339 | 1.823 | FOXO1 | Central corneal thickness |
| rs2755237 | Magnesium metabolism disorder | 0.001465 | 0.5698 | FOXO1 | Central corneal thickness |
| rs2755237 | Phobia | 0.009051 | 2.165 | FOXO1 | Central corneal thickness |
| rs2755237 | Vitamin D deficiency | 0.005906 | 0.6618 | FOXO1 | Central corneal thickness |
| rs2755237 | Early or threatened labor; hemorrhage in early pregnancy | 0.01098 | 0.4554 | FOXO1 | Central corneal thickness |
| rs2755237 | pulmonary heart disease | 0.007085 | 1.213 | FOXO1 | Central corneal thickness |
| rs2755237 | Neck pain | 0.00285 | 1.154 | FOXO1 | Central corneal thickness |
| rs2807278 | Chronic glomerulonephritis | 0.006783 | 2.142 | ARG1 | Waist hip ratio |
| rs2807278 | Ulceration of the lower GI tract | 0.003828 | 0.5426 | ARG1 | Waist hip ratio |
| rs2807278 | Sleep related movement disorders | 0.01041 | 1.246 | ARG1 | Waist hip ratio |
| rs2807278 | Myeloproliferative disease | 0.009572 | 1.358 | ARG1 | Waist hip ratio |
| rs2807278 | Coagulation defects | 0.01047 | 0.901 | ARG1 | Waist hip ratio |
| rs2807278 | Ulceration of intestine | 0.008528 | 0.5347 | ARG1 | Waist hip ratio |
| rs2807278 | Other specified erythematous conditions | 0.0002548 | 0.6363 | ARG1 | Waist hip ratio |
| rs2807278 | Hematuria | 0.003174 | 0.8737 | ARG1 | Waist hip ratio |
| rs2807278 | Postnasal drip | 0.005053 | 1.811 | ARG1 | Waist hip ratio |
| rs2807278 | Cancer of connective tissue | 0.006076 | 0.5037 | ARG1 | Waist hip ratio |
| rs2807278 | Parkinson's disease | 0.009717 | 0.7497 | ARG1 | Waist hip ratio |
| rs2807278 | Blister | 0.006632 | 1.823 | ARG1 | Waist hip ratio |
| rs2807278 | Congenital anomalies of the eye | 0.002509 | 0.7526 | ARG1 | Waist hip ratio |
| rs2823455 | Sensorineural hearing loss | 0.003169 | 0.8264 | USP25 | Panic disorder |
| rs2823455 | Hammer toe | 0.002066 | 0.679 | USP25 | Panic disorder |
| rs2823455 | Gouty arthropathy | 0.0108 | 1.45 | USP25 | Panic disorder |
| rs2823455 | Acute bronchitis and bronchiolitis | 0.01126 | 0.8268 | USP25 | Panic disorder |
| rs2823455 | Macular degeneration, dry | 0.004979 | 0.6771 | USP25 | Panic disorder |
| rs2823455 | Hallux valgus (Bunion) | 0.002631 | 0.7077 | USP25 | Panic disorder |
| rs2823455 | Acquired foot deformities | 0.0003448 | 0.7629 | USP25 | Panic disorder |
| rs2823455 | Acquired toe deformities | 0.0002232 | 0.6673 | USP25 | Panic disorder |
| rs2823455 | Other disorders of tympanic membrane | 0.01123 | 1.624 | USP25 | Panic disorder |
| rs2823455 | Disorders of cervical region | 0.00714 | 0.5407 | USP25 | Panic disorder |
| rs2823455 | Other disorders of bone and cartilage | 0.003203 | 0.6597 | USP25 | Panic disorder |
| rs2823455 | Atopic or contact dermatitis | 0.00577 | 0.8421 | USP25 | Panic disorder |
| rs2836878 | Adverse effects of antirheumatics | 0.002622 | 0.4487 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Disorders of tooth development | 0.01131 | 0.7253 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Attention deficit hyperactivity disorder | 0.00153 | 1.816 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Spirochetal infection | 0.002991 | 1.6 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Hemorrhage or hematoma complicating a procedure | 0.002618 | 0.7764 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.009798 | 0.7281 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Lyme disease | 0.001768 | 1.653 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Paroxysmal supraventricular tachycardia | 0.006037 | 0.7496 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Glaucoma | 0.005487 | 0.8834 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Polyarthropathy or polyarthritis involving multiple sites NOS | 0.006408 | 0.5278 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Mammographic microcalcification | 0.002519 | 0.524 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Dysmenorrhea | 0.01139 | 0.6449 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Sciatica | 0.007254 | 0.8415 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Disturbances in tooth eruption | 0.00752 | 0.7041 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Neoplasm of unspecified nature of digestive system | 0.00583 | 1.445 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Other specified diseases of hair and hair follicles | 0.00764 | 0.7238 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Hypercholesterolemia | 0.004137 | 1.134 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Palpitations | 0.008184 | 0.8713 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Hallux rigidus | 0.005998 | 1.412 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Bronchitis | 0.008686 | 0.8683 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Pervasive developmental disorders | 0.01149 | 1.521 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Other disorders of back | 0.01032 | 0.8546 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Respiratory abnormalities | 0.002695 | 0.6938 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Asthma with exacerbation | 0.006987 | 0.6854 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Influenza | 0.01022 | 0.724 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2836878 | Open-angle glaucoma | 0.005438 | 0.8395 | PSMG1 | Inflammatory bowel disease, Ulcerative colitis, C-reactive protein |
| rs2838815 | Traumatic arthropathy | 0.005693 | 1.647 | ADARB1 | Pulmonary function |
| rs2838815 | Abnormal findings on radiological breast exam | 0.01002 | 1.539 | ADARB1 | Pulmonary function |
| rs2838815 | Contracture of joint | 0.003842 | 1.426 | ADARB1 | Pulmonary function |
| rs2838815 | Hydronephrosis | 0.005028 | 0.7412 | ADARB1 | Pulmonary function |
| rs2838815 | Urinary complications | 0.007715 | 1.461 | ADARB1 | Pulmonary function |
| rs2838815 | Abnormal mammogram | 0.002495 | 1.2 | ADARB1 | Pulmonary function |
| rs2839619 | Visual field defects | 0.002464 | 1.304 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Disorders of function of stomach | 0.003007 | 1.167 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Hemorrhage or hematoma complicating a procedure | 0.002699 | 1.239 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Swelling, mass, or lump in head and neck | 0.01058 | 0.8189 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Oliguria and anuria | 0.006024 | 2.178 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Nasal polyps | 0.007441 | 1.323 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Fasciitis | 0.002438 | 1.182 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Disorders of muscle, ligament, and fascia | 0.004664 | 1.164 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Calcaneal spur; Exostosis NOS | 0.01136 | 1.237 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Dyspepsia and disorders of function of stomach | 0.007456 | 1.157 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Pallor and flushing | 0.004285 | 0.6869 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Personal history of allergy to medicinal agents | 0.002515 | 0.768 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2839619 | Ulcerative colitis | 0.006172 | 1.458 | PKNOX1 | Total Cholesterol, LDL Cholesterol |
| rs2853676 | Other forms of chronic heart disease | 0.01123 | 0.8241 | TERT | Glioma |
| rs2853676 | Congenital anomalies of intestine | 0.009352 | 0.2911 | TERT | Glioma |
| rs2853676 | Seborrheic keratosis | 1.563e-07 | 0.804 | TERT | Glioma |
| rs2853676 | Dysmetabolic syndrome X | 0.008192 | 1.451 | TERT | Glioma |
| rs2853676 | Cholelithiasis with acute cholecystitis | 0.003358 | 0.5366 | TERT | Glioma |
| rs2853676 | Balanoposthitis | 0.009542 | 1.661 | TERT | Glioma |
| rs2853676 | Stricture and stenosis of esophagus | 0.005221 | 1.306 | TERT | Glioma |
| rs2853676 | Herpes zoster with nervous system complications | 0.004709 | 0.5674 | TERT | Glioma |
| rs2853676 | Retinal drusen | 0.005417 | 1.262 | TERT | Glioma |
| rs2853676 | Cardiac defibrillator in situ | 0.007326 | 0.6502 | TERT | Glioma |
| rs2853676 | Other hypertrophic and atrophic conditions of skin | 0.002504 | 0.8735 | TERT | Glioma |
| rs2853676 | Postmenopausal hormone replacement | 0.007312 | 1.323 | TERT | Glioma |
| rs2853676 | Central/nonobstroctive sleep apnea | 0.008223 | 0.5215 | TERT | Glioma |
| rs2853676 | Eye infection, viral | 0.008703 | 0.6729 | TERT | Glioma |
| rs2853676 | Paroxysmal ventricular tachycardia | 0.01115 | 0.7582 | TERT | Glioma |
| rs2853676 | Leukoplakia of oral mucosa | 0.0001572 | 2.28 | TERT | Glioma |
| rs2853676 | Fracture of foot | 0.008273 | 0.805 | TERT | Glioma |
| rs2853676 | Costochondritis | 0.002931 | 1.901 | TERT | Glioma |
| rs2853676 | Neoplasm of unspecified nature of digestive system | 0.006993 | 0.6425 | TERT | Glioma |
| rs2853676 | Altered mental status | 0.009799 | 0.7546 | TERT | Glioma |
| rs2853676 | Other dermatoses | 0.001125 | 0.887 | TERT | Glioma |
| rs2857595 | Other disorders of lipoid metabolism and hyperalimentation | 0.004536 | 1.344 | NCR3 | Pulmonary function |
| rs2857595 | Thyrotoxicosis | 0.01033 | 1.26 | NCR3 | Pulmonary function |
| rs2857595 | Varicose veins | 0.0002379 | 1.261 | NCR3 | Pulmonary function |
| rs2857595 | Ectropion or entropion | 0.007973 | 1.324 | NCR3 | Pulmonary function |
| rs2857595 | Varicose veins of lower extremity | 0.0002174 | 1.275 | NCR3 | Pulmonary function |
| rs2857595 | Adverse effects of insulins and antidiabetic agents | 0.003067 | 1.939 | NCR3 | Pulmonary function |
| rs2857595 | Venous embolism & thrombosis | 0.007405 | 1.193 | NCR3 | Pulmonary function |
| rs2857595 | Type 1 diabetic retinopathy | 0.0002628 | 1.671 | NCR3 | Pulmonary function |
| rs2857595 | Other specified peripheral vascular diseases | 0.001371 | 2.28 | NCR3 | Pulmonary function |
| rs2857595 | Poisoning by antibiotics | 0.005472 | 0.7859 | NCR3 | Pulmonary function |
| rs2857595 | Retinoschisis and retinal cysts | 0.005845 | 2.159 | NCR3 | Pulmonary function |
| rs2857595 | Lipoprotein disorders | 0.00728 | 1.409 | NCR3 | Pulmonary function |
| rs2857595 | Peripheral autonomic neuropathy | 0.000128 | 1.647 | NCR3 | Pulmonary function |
| rs2857595 | Celiac disease | 8.504e-05 | 2.385 | NCR3 | Pulmonary function |
| rs2857595 | Cardiac shunt/ heart septal defect | 0.002352 | 0.5295 | NCR3 | Pulmonary function |
| rs2857595 | Celiac or tropical sprue | 3.342e-05 | 2.451 | NCR3 | Pulmonary function |
| rs2857595 | Lymphosarcoma | 0.008797 | 0.1515 | NCR3 | Pulmonary function |
| rs2857595 | Bullous dermatoses | 0.002251 | 2.088 | NCR3 | Pulmonary function |
| rs2857595 | Colon cancer | 0.004484 | 0.7333 | NCR3 | Pulmonary function |
| rs2857595 | Lack of coordination | 0.001541 | 1.353 | NCR3 | Pulmonary function |
| rs2857595 | Prostatitis | 0.001212 | 0.6612 | NCR3 | Pulmonary function |
| rs2857595 | Type 1 diabetes nephropathy | 0.01011 | 1.65 | NCR3 | Pulmonary function |
| rs2857595 | Hyperplasia of prostate | 0.000119 | 0.7836 | NCR3 | Pulmonary function |
| rs2857595 | Inflammatory disease of cervix, vagina, and vulva | 0.005928 | 0.8055 | NCR3 | Pulmonary function |
| rs2857595 | Disorders of the pituitary gland and its hypothalamic control | 0.00862 | 1.407 | NCR3 | Pulmonary function |
| rs2857595 | Disorders of the autonomic nervous system | 0.002434 | 1.406 | NCR3 | Pulmonary function |
| rs2858331 | Type 1 diabetic ketoacidosis | 0.0001121 | 0.572 | HLA-DQA2 | IgE levels |
| rs2858331 | Infections involving bone | 0.007797 | 0.79 | HLA-DQA2 | IgE levels |
| rs2858331 | Adverse effects of insulins and antidiabetic agents | 0.003292 | 0.48 | HLA-DQA2 | IgE levels |
| rs2858331 | Breast conditions, congenital or relating to hormones | 0.006095 | 1.324 | HLA-DQA2 | IgE levels |
| rs2858331 | Other disorders of lipoid metabolism and hyperalimentation | 0.003337 | 0.7581 | HLA-DQA2 | IgE levels |
| rs2858331 | Substance addiction and disorders | 0.002973 | 0.7483 | HLA-DQA2 | IgE levels |
| rs2858331 | Male infertility and abnormal spermatozoa | 0.002949 | 1.8 | HLA-DQA2 | IgE levels |
| rs2858331 | Type 1 diabetic neuropathy | 0.001554 | 0.626 | HLA-DQA2 | IgE levels |
| rs2858331 | Male genital disorders | 0.003596 | 1.34 | HLA-DQA2 | IgE levels |
| rs2858331 | Benign neoplasm of uterus | 0.01113 | 1.199 | HLA-DQA2 | IgE levels |
| rs2858331 | Type 1 diabetes nephropathy | 6.189e-05 | 0.4113 | HLA-DQA2 | IgE levels |
| rs2858331 | Toxic erythema | 0.005248 | 0.3908 | HLA-DQA2 | IgE levels |
| rs2858331 | Hyperpotassemia | 0.009667 | 0.8419 | HLA-DQA2 | IgE levels |
| rs2858331 | Sicca syndrome | 0.005764 | 0.6451 | HLA-DQA2 | IgE levels |
| rs2858331 | Fractur of unspecified part of femur | 0.003753 | 0.6733 | HLA-DQA2 | IgE levels |
| rs2858331 | Claw toe | 0.005153 | 1.975 | HLA-DQA2 | IgE levels |
| rs2858331 | Multiple sclerosis | 0.000626 | 0.5377 | HLA-DQA2 | IgE levels |
| rs2858331 | Occlusion of cerebral arteries, with cerebral infarction | 0.003528 | 0.6268 | HLA-DQA2 | IgE levels |
| rs2858331 | Type 1 diabetes | 0.001715 | 0.8223 | HLA-DQA2 | IgE levels |
| rs2858331 | Deficiency anemias NOS | 0.004491 | 1.428 | HLA-DQA2 | IgE levels |
| rs2858331 | Chronic pancreatitis | 0.0008376 | 1.826 | HLA-DQA2 | IgE levels |
| rs2858331 | Acute laryngitis and tracheitis | 0.009516 | 1.44 | HLA-DQA2 | IgE levels |
| rs2858331 | Disturbances of amino-acid transport | 0.01107 | 1.709 | HLA-DQA2 | IgE levels |
| rs2858331 | Ventral hernia | 0.001532 | 1.334 | HLA-DQA2 | IgE levels |
| rs2858331 | Chronic liver disease and cirrhosis | 0.003031 | 1.249 | HLA-DQA2 | IgE levels |
| rs2858331 | Open wound of finger(s) | 0.005865 | 0.8489 | HLA-DQA2 | IgE levels |
| rs2858331 | Diseases of the tongue | 0.003062 | 1.441 | HLA-DQA2 | IgE levels |
| rs2859631 | Methicillin resistant Staphylococcus aureus | 0.005388 | 3.771 | WWOX | Radiation response |
| rs2859631 | Peptic ulcer | 0.006426 | 1.668 | WWOX | Radiation response |
| rs2859631 | Hemorrhage from gastrointestinal ulcer | 0.0002506 | 3.191 | WWOX | Radiation response |
| rs2859631 | Vascular dementia | 1.127e-06 | 4.531 | WWOX | Radiation response |
| rs2859631 | Other disorders of the kidney and ureters | 0.001191 | 1.571 | WWOX | Radiation response |
| rs2859631 | Poisoning by psychotropic agents | 0.002337 | 3.844 | WWOX | Radiation response |
| rs2859631 | Vertiginous syndromes and other disorders of vestibular system | 0.01071 | 1.363 | WWOX | Radiation response |
| rs2859631 | Glomerulonephritis | 0.01068 | 2.956 | WWOX | Radiation response |
| rs2859631 | Periodontitis (acute or chronic) | 0.0005143 | 2.084 | WWOX | Radiation response |
| rs2859631 | Viral pneumonia | 0.005238 | 4.568 | WWOX | Radiation response |
| rs2859631 | Peyronie's disease | 0.00515 | 4.182 | WWOX | Radiation response |
| rs2859631 | Cystic mastopathy | 0.008417 | 0.5579 | WWOX | Radiation response |
| rs2859631 | Peripheral or central vertigo | 0.0052 | 1.847 | WWOX | Radiation response |
| rs2859631 | Hydronephrosis | 0.002746 | 2.301 | WWOX | Radiation response |
| rs2859631 | Angina pectoris | 0.0006836 | 1.732 | WWOX | Radiation response |
| rs2859631 | Chronic periodontitis | 3.855e-05 | 2.493 | WWOX | Radiation response |
| rs2859631 | Light-headedness and vertigo | 0.009642 | 1.388 | WWOX | Radiation response |
| rs2859631 | Skin neoplasm of uncertain behavior | 0.001238 | 1.935 | WWOX | Radiation response |
| rs2859631 | Unstable angina (intermediate coronary syndrome) | 0.006083 | 1.689 | WWOX | Radiation response |
| rs2859631 | Abnormal findings on radiological examination intrathoracic organs | 0.001913 | 1.985 | WWOX | Radiation response |
| rs2859631 | Gingival and periodontal diseases | 0.0001162 | 2.071 | WWOX | Radiation response |
| rs2859631 | Sleep apnea | 0.009329 | 1.415 | WWOX | Radiation response |
| rs2859631 | Hyposmolality and/or hyponatremia | 0.005685 | 1.672 | WWOX | Radiation response |
| rs286913 | Appendicitis | 0.005801 | 1.848 | EHF | Response to antipsychotic treatment |
| rs286913 | Costochondritis | 0.009114 | 2.465 | EHF | Response to antipsychotic treatment |
| rs286913 | Chronic venous hypertension | 0.009642 | 2.743 | EHF | Response to antipsychotic treatment |
| rs286913 | Allergies, other | 0.009671 | 1.547 | EHF | Response to antipsychotic treatment |
| rs286913 | Apnea | 0.005771 | 2.68 | EHF | Response to antipsychotic treatment |
| rs286913 | Mechanical complication due to other implant and internal device | 0.006715 | 1.701 | EHF | Response to antipsychotic treatment |
| rs286913 | Sleep disorders | 0.01115 | 1.225 | EHF | Response to antipsychotic treatment |
| rs286913 | Dental caries | 0.006079 | 1.452 | EHF | Response to antipsychotic treatment |
| rs286913 | Poisoning by agents primarily affecting blood constituents | 0.00668 | 2.194 | EHF | Response to antipsychotic treatment |
| rs286913 | Immune disorders | 0.003965 | 0.4548 | EHF | Response to antipsychotic treatment |
| rs286913 | Type 1 diabetic peripheral circulatory disorders | 0.006266 | 2.64 | EHF | Response to antipsychotic treatment |
| rs286913 | Diseases of hard tissues of teeth | 0.0112 | 1.405 | EHF | Response to antipsychotic treatment |
| rs286913 | Antihypertensive agents causing adverse effects | 0.006465 | 2.117 | EHF | Response to antipsychotic treatment |
| rs286913 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.002013 | 3.734 | EHF | Response to antipsychotic treatment |
| rs286913 | Althete's foot | 0.001591 | 0.4315 | EHF | Response to antipsychotic treatment |
| rs2870946 | Obsessive-compulsive disorder | 8.316e-05 | 2.912 | IL26 | Ulcerative colitis |
| rs2870946 | Osteoporosis | 0.01066 | 1.25 | IL26 | Ulcerative colitis |
| rs2870946 | Nausea and vomiting | 0.0004139 | 1.284 | IL26 | Ulcerative colitis |
| rs2870946 | Allergic conjunctivitis | 0.004404 | 0.5335 | IL26 | Ulcerative colitis |
| rs2870946 | Psychogenic disorder | 0.001334 | 1.956 | IL26 | Ulcerative colitis |
| rs2870946 | Osteochondropathies | 0.006603 | 2.453 | IL26 | Ulcerative colitis |
| rs2870946 | Raynaud's syndrome | 0.000973 | 1.721 | IL26 | Ulcerative colitis |
| rs2870946 | Electrolyte imbalance | 0.0009436 | 1.256 | IL26 | Ulcerative colitis |
| rs2870946 | Pathologic fracture of vertebrae | 0.004558 | 1.524 | IL26 | Ulcerative colitis |
| rs2870946 | Disorders of fluid, electrolyte, and acid-base balance | 0.001354 | 1.219 | IL26 | Ulcerative colitis |
| rs2870946 | Hyposmolality and/or hyponatremia | 0.01146 | 1.321 | IL26 | Ulcerative colitis |
| rs2870946 | Anomalies of jaw size/symmetry | 0.007764 | 2.687 | IL26 | Ulcerative colitis |
| rs2870946 | Gastrointestinal malfunction arising from mental factors | 0.0001116 | 3.523 | IL26 | Ulcerative colitis |
| rs2870946 | Anemia in neoplastic disease | 0.0006841 | 1.966 | IL26 | Ulcerative colitis |
| rs2870946 | Psychogenic and somatoform disorders | 0.008005 | 1.508 | IL26 | Ulcerative colitis |
| rs2870946 | Disorders of lipoid metabolism | 0.001244 | 1.239 | IL26 | Ulcerative colitis |
| rs2870946 | Conjunctivitis, noninfectious | 0.007277 | 0.6049 | IL26 | Ulcerative colitis |
| rs2870946 | Pathologic fracture | 0.01034 | 1.375 | IL26 | Ulcerative colitis |
| rs2870946 | Intestinal obstruction without mention of hernia | 0.002048 | 1.433 | IL26 | Ulcerative colitis |
| rs2870946 | Pancytopenia | 0.001637 | 2.159 | IL26 | Ulcerative colitis |
| rs2870946 | Gastric ulcer | 0.008141 | 1.536 | IL26 | Ulcerative colitis |
| rs2870946 | Abnormal findings on exam of gastrointestinal tract/abdominal area | 0.008879 | 1.638 | IL26 | Ulcerative colitis |
| rs2870946 | Hypercholesterolemia | 0.001848 | 1.285 | IL26 | Ulcerative colitis |
| rs2870946 | Infestation | 0.009302 | 2.112 | IL26 | Ulcerative colitis |
| rs2870946 | Congenital anomalies of intestine | 0.009928 | 2.687 | IL26 | Ulcerative colitis |
| rs2870946 | Paralytic ileus | 0.006043 | 1.649 | IL26 | Ulcerative colitis |
| rs2870946 | Hypopotassemia | 0.003183 | 1.301 | IL26 | Ulcerative colitis |
| rs2870946 | Other headache syndromes | 0.01107 | 1.194 | IL26 | Ulcerative colitis |
| rs2870946 | Hyperlipidemia | 0.001985 | 1.23 | IL26 | Ulcerative colitis |
| rs2870946 | Postmenopausal hormone replacement | 0.00375 | 1.701 | IL26 | Ulcerative colitis |
| rs2870946 | Central/nonobstroctive sleep apnea | 0.002273 | 2.308 | IL26 | Ulcerative colitis |
| rs2895811 | Fracture of radius and ulna | 0.01056 | 1.171 | HHIPL1 | Coronary heart disease |
| rs2895811 | severe protein-calorie malnutrition | 0.009246 | 0.6433 | HHIPL1 | Coronary heart disease |
| rs2895811 | Hypertensive heart disease | 0.004111 | 0.7337 | HHIPL1 | Coronary heart disease |
| rs2895811 | Renal failure NOS | 0.007223 | 0.7476 | HHIPL1 | Coronary heart disease |
| rs2895811 | Elevated C-reactive protein | 0.003362 | 2.048 | HHIPL1 | Coronary heart disease |
| rs2895811 | Other and unspecified disc disorder | 0.003827 | 0.6462 | HHIPL1 | Coronary heart disease |
| rs2895811 | Testicular hypofunction | 0.003838 | 1.428 | HHIPL1 | Coronary heart disease |
| rs2895811 | Protein-calorie malnutrition | 0.009594 | 0.8605 | HHIPL1 | Coronary heart disease |
| rs2895811 | Femoral hernia | 0.009216 | 0.5237 | HHIPL1 | Coronary heart disease |
| rs2895811 | Claw toe | 0.0008288 | 0.3742 | HHIPL1 | Coronary heart disease |
| rs2895811 | Other forms of chronic heart disease | 0.00306 | 0.8205 | HHIPL1 | Coronary heart disease |
| rs2895811 | Hereditary and idiopathic peripheral neuropathy | 0.009122 | 0.8734 | HHIPL1 | Coronary heart disease |
| rs2895811 | Gram negative septicemia | 0.005449 | 1.413 | HHIPL1 | Coronary heart disease |
| rs2895811 | Pruritus and related conditions | 0.00389 | 0.8243 | HHIPL1 | Coronary heart disease |
| rs2895811 | ASCVD | 0.0006843 | 0.6593 | HHIPL1 | Coronary heart disease |
| rs2901331 | Tobacco use disorder | 0.009482 | 1.104 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Gastrointestinal hemorrhage | 0.01059 | 1.106 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Disturbances of amino-acid transport | 0.003828 | 1.887 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Chronic airway obstruction | 0.01115 | 1.11 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Essential tremor | 0.009373 | 1.295 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Disorders of muscle, ligament, and fascia | 0.009687 | 0.8572 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Disturbances of sulphur-bearing amino-acid metabolism | 0.009054 | 1.789 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Reticulosarcoma | 0.001572 | 1.775 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Congenital musculoskeletal deformities of spine | 0.011 | 0.6852 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Other congenital anomalies | 0.006507 | 1.771 | CNTNAP5 | Response to statin therapy |
| rs2901331 | Secondary thrombocytopenia | 0.003443 | 1.683 | CNTNAP5 | Response to statin therapy |
| rs29232 | Protein plasma/amino-acid transport and metabolism disorder | 0.001316 | 1.32 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Paroxysmal supraventricular tachycardia | 0.003805 | 1.293 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Other acute and subacute forms of ischemic heart disease | 0.001814 | 2.007 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Paraproteinemia | 0.01069 | 1.344 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Suppurative and unspecified otitis media | 0.00614 | 0.8511 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Plasma protein metabolism disorder | 0.001999 | 1.342 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Peripheral vascular disease | 0.006981 | 1.117 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Stricture of artery | 0.001317 | 1.388 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Palpitations | 0.007366 | 1.134 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Extrapyramidal disease and abnormal movement disorders | 0.004028 | 1.194 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Essential tremor | 0.002694 | 1.339 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Sleep apnea | 0.004254 | 1.126 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Dentofacial anomalies, including malocclusion | 0.009204 | 1.506 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Other disorders of arteries and arterioles | 0.004179 | 1.275 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Second degree AV block | 0.001789 | 1.621 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Peripheral arterial disease | 0.00454 | 1.135 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Circumscribed scleroderma | 0.001121 | 1.478 | GABBR1 | Nasopharyngeal carcinoma |
| rs29232 | Other specified erythematous conditions | 0.00122 | 1.372 | GABBR1 | Nasopharyngeal carcinoma |
| rs2925979 | Hypothyroidism | 0.002134 | 0.8853 | CMIP | HDL Cholesterol |
| rs2925979 | Gout and other crystal arthropathies | 0.001456 | 0.8341 | CMIP | HDL Cholesterol |
| rs2925979 | Calcium/phosphorus disorders | 0.0003548 | 0.7613 | CMIP | HDL Cholesterol |
| rs2925979 | Paraproteinemia | 0.002154 | 0.651 | CMIP | HDL Cholesterol |
| rs2925979 | Renal dialysis | 0.01009 | 0.6767 | CMIP | HDL Cholesterol |
| rs2925979 | Dermatophytosis of nail | 0.009571 | 0.8816 | CMIP | HDL Cholesterol |
| rs2925979 | Hemorrhage of rectum and anus | 0.005944 | 0.8154 | CMIP | HDL Cholesterol |
| rs2925979 | Protein plasma/amino-acid transport and metabolism disorder | 0.003681 | 0.7471 | CMIP | HDL Cholesterol |
| rs2925979 | Plasma protein metabolism disorder | 0.003195 | 0.7192 | CMIP | HDL Cholesterol |
| rs2925979 | Crystal arthropathies | 0.00178 | 0.6585 | CMIP | HDL Cholesterol |
| rs2925979 | Chronic renal failure | 0.005572 | 0.8807 | CMIP | HDL Cholesterol |
| rs2925979 | Diaphragmatic hernia | 0.009063 | 0.8732 | CMIP | HDL Cholesterol |
| rs2925979 | Gout | 0.007902 | 0.8506 | CMIP | HDL Cholesterol |
| rs2925979 | Disorders resulting from impaired renal function | 0.0107 | 0.7579 | CMIP | HDL Cholesterol |
| rs2925979 | Early complications of trauma or procedure | 0.01111 | 1.621 | CMIP | HDL Cholesterol |
| rs2925979 | Umbilical hernia | 0.01132 | 0.7749 | CMIP | HDL Cholesterol |
| rs2925979 | Disorders of parathyroid gland | 0.005097 | 0.7369 | CMIP | HDL Cholesterol |
| rs2925979 | Hyperparathyroidism | 0.002822 | 0.7101 | CMIP | HDL Cholesterol |
| rs2925979 | Other local infections of skin and subcutaneous tissue | 0.005208 | 0.8348 | CMIP | HDL Cholesterol |
| rs2925979 | Renal failure | 0.004296 | 0.8911 | CMIP | HDL Cholesterol |
| rs2925979 | Degenerative disease of the spinal cord | 0.008044 | 0.6453 | CMIP | HDL Cholesterol |
| rs2925979 | Disorders of mineral metabolism | 0.01099 | 0.8698 | CMIP | HDL Cholesterol |
| rs2925979 | Graves' disease | 0.01092 | 0.6489 | CMIP | HDL Cholesterol |
| rs2925979 | Disorders of diaphragm | 0.004337 | 0.3921 | CMIP | HDL Cholesterol |
| rs2925979 | Chondrocalcinosis | 0.004078 | 0.68 | CMIP | HDL Cholesterol |
| rs2925979 | Other disorders of the kidney and ureters | 0.002912 | 0.8742 | CMIP | HDL Cholesterol |
| rs2925979 | Carbuncle and furuncle | 0.009017 | 0.6265 | CMIP | HDL Cholesterol |
| rs2925979 | Osteoporosis, osteopenia, & pathological fractures | 0.002245 | 0.8916 | CMIP | HDL Cholesterol |
| rs2934442 | Hemorrhage NOS | 0.00168 | 0.3526 | CGNL1 | Bipolar disorder |
| rs2934442 | Hidradenitis | 0.004548 | 2.331 | CGNL1 | Bipolar disorder |
| rs2934442 | Age-related macular degeneration | 0.003196 | 1.268 | CGNL1 | Bipolar disorder |
| rs2934442 | Macular degeneration, wet | 0.01041 | 1.373 | CGNL1 | Bipolar disorder |
| rs2934442 | Hepatic cancer, primary | 0.007318 | 2.047 | CGNL1 | Bipolar disorder |
| rs2934442 | Anisometropia | 0.00226 | 0.6615 | CGNL1 | Bipolar disorder |
| rs2934442 | Disorders of choroid | 0.007143 | 1.348 | CGNL1 | Bipolar disorder |
| rs2934442 | Peritoneal adhesions (postoperative) (postinfection) | 0.004632 | 1.638 | CGNL1 | Bipolar disorder |
| rs2934442 | Hydrocele | 0.01069 | 0.5876 | CGNL1 | Bipolar disorder |
| rs2934442 | Disorders of coccyx | 0.001581 | 1.452 | CGNL1 | Bipolar disorder |
| rs2934442 | Disorders of mineral metabolism | 0.001121 | 1.206 | CGNL1 | Bipolar disorder |
| rs2934442 | Other disorders of peritoneum | 0.0111 | 1.458 | CGNL1 | Bipolar disorder |
| rs2934442 | Glaucoma | 0.009283 | 1.134 | CGNL1 | Bipolar disorder |
| rs2934442 | Ovarian cyst | 0.009072 | 0.7034 | CGNL1 | Bipolar disorder |
| rs2934442 | Iron metabolism disorder | 0.004874 | 1.941 | CGNL1 | Bipolar disorder |
| rs2957128 | severe protein-calorie malnutrition | 0.005022 | 1.574 | TNFRSF11A | Paget's disease |
| rs2957128 | Gestational diabetes | 0.0009648 | 2.673 | TNFRSF11A | Paget's disease |
| rs2957128 | Chronic pain syndrome | 0.009071 | 1.619 | TNFRSF11A | Paget's disease |
| rs2957128 | Localized superficial swelling, mass, or lump | 0.00372 | 0.774 | TNFRSF11A | Paget's disease |
| rs2957128 | Carbohydrate transport and metabolism disorder | 0.007156 | 1.171 | TNFRSF11A | Paget's disease |
| rs2957128 | Acute renal failure | 0.006821 | 1.158 | TNFRSF11A | Paget's disease |
| rs2957128 | Other conditions of the mother complicating pregnancy | 0.001154 | 1.836 | TNFRSF11A | Paget's disease |
| rs2957128 | Carbuncle and furuncle | 0.00967 | 0.6681 | TNFRSF11A | Paget's disease |
| rs2957128 | Fracture of tibia and fibula | 0.009249 | 1.262 | TNFRSF11A | Paget's disease |
| rs2957128 | Morbid obesity | 0.001417 | 1.196 | TNFRSF11A | Paget's disease |
| rs2957128 | Urinary complications | 0.0108 | 1.441 | TNFRSF11A | Paget's disease |
| rs2957128 | Hypercalcemia | 0.007172 | 0.7939 | TNFRSF11A | Paget's disease |
| rs2957128 | Speech and language disorder | 0.01073 | 0.7175 | TNFRSF11A | Paget's disease |
| rs2957128 | Elevated prostate specific antigen | 0.003359 | 0.8278 | TNFRSF11A | Paget's disease |
| rs2957128 | Cataract | 0.0007919 | 0.8818 | TNFRSF11A | Paget's disease |
| rs296547 | Poisoning by agents affecting the cardiovascular system | 0.00257 | 1.356 | C1orf81 | Celiac disease |
| rs296547 | Stomach cancer | 0.003594 | 1.78 | C1orf81 | Celiac disease |
| rs296547 | Hypercalcemia | 0.002066 | 1.295 | C1orf81 | Celiac disease |
| rs296547 | Anaphylactic shock NOS | 0.0004205 | 1.665 | C1orf81 | Celiac disease |
| rs296547 | Secondary malignancy of lung | 0.01021 | 1.369 | C1orf81 | Celiac disease |
| rs296547 | Bronchiectasis | 1.797e-05 | 1.671 | C1orf81 | Celiac disease |
| rs296547 | Cholesteatoma | 0.003811 | 0.5049 | C1orf81 | Celiac disease |
| rs296547 | Symptoms involving cardiovascular system | 0.00381 | 0.8479 | C1orf81 | Celiac disease |
| rs296547 | Other cerebral degenerations | 0.005455 | 0.677 | C1orf81 | Celiac disease |
| rs296547 | Secondary malignant neoplasm of digestive systems | 0.0001622 | 1.756 | C1orf81 | Celiac disease |
| rs296547 | Muscle weakness | 0.005955 | 0.7525 | C1orf81 | Celiac disease |
| rs296547 | Other upper respiratory disease | 0.006939 | 1.157 | C1orf81 | Celiac disease |
| rs2979481 | Cervical radiculitis | 0.004181 | 1.193 | RBPMS | Heart rate training response |
| rs2979481 | Oral aphthae | 0.002823 | 1.718 | RBPMS | Heart rate training response |
| rs2979481 | Delirium due to conditions classified elsewhere | 0.003574 | 1.414 | RBPMS | Heart rate training response |
| rs2979481 | Stomatitis and mucositis | 0.001684 | 1.46 | RBPMS | Heart rate training response |
| rs2979481 | Hx of malignant neoplasm of oral cavity and pharynx | 0.007572 | 1.623 | RBPMS | Heart rate training response |
| rs2979481 | Cystic kidney disease | 0.008565 | 1.546 | RBPMS | Heart rate training response |
| rs2979481 | Loss of teeth or edentulism | 0.002593 | 1.419 | RBPMS | Heart rate training response |
| rs2979481 | Other diseases of the teeth and supporting structures | 0.007702 | 1.248 | RBPMS | Heart rate training response |
| rs2979481 | Otalgia | 0.005751 | 0.774 | RBPMS | Heart rate training response |
| rs2979481 | Disorders of conjunctiva | 0.002353 | 1.281 | RBPMS | Heart rate training response |
| rs2979481 | Hemorrhage NOS | 0.008302 | 0.5562 | RBPMS | Heart rate training response |
| rs2979481 | Diplopia and disorders of binocular vision | 0.007839 | 1.289 | RBPMS | Heart rate training response |
| rs2979481 | Acute bronchitis and bronchiolitis | 0.002127 | 1.15 | RBPMS | Heart rate training response |
| rs2979481 | Anomalies of pupillary function | 0.009711 | 1.823 | RBPMS | Heart rate training response |
| rs3016539 | Alcoholism | 0.008446 | 1.34 | PARK2 | Pancreatic cancer |
| rs3016539 | Acquired spondylolisthesis | 0.002936 | 1.501 | PARK2 | Pancreatic cancer |
| rs3016539 | Impaired fasting glucose | 0.008017 | 1.278 | PARK2 | Pancreatic cancer |
| rs3016539 | Alcohol-related disorders | 0.007649 | 1.301 | PARK2 | Pancreatic cancer |
| rs3016539 | Chronic kidney disease, Stage I or II | 0.003735 | 1.595 | PARK2 | Pancreatic cancer |
| rs3016539 | Palpitations | 0.007825 | 1.217 | PARK2 | Pancreatic cancer |
| rs3016539 | Postlaminectomy syndrome | 0.002182 | 1.662 | PARK2 | Pancreatic cancer |
| rs3016539 | Abnormal electrocardiogram | 0.006962 | 1.245 | PARK2 | Pancreatic cancer |
| rs3016539 | Stomach cancer | 0.004952 | 2.03 | PARK2 | Pancreatic cancer |
| rs3016539 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.006819 | 0.6143 | PARK2 | Pancreatic cancer |
| rs3016539 | Bundle branch block | 0.009845 | 1.316 | PARK2 | Pancreatic cancer |
| rs3016539 | Hepatic cancer, primary | 0.008311 | 2.294 | PARK2 | Pancreatic cancer |
| rs3016539 | Irregular menstrual bleeding | 0.005518 | 0.252 | PARK2 | Pancreatic cancer |
| rs3027409 | Irregular menstrual cycle/bleeding | 0.008991 | 1.542 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Open-angle glaucoma | 0.001803 | 1.543 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Other acute and subacute forms of ischemic heart disease | 5.536e-05 | 4.716 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Bursitis | 0.004379 | 1.586 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Eating disorder | 0.004345 | 2.576 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Poisoning by agents primarily affecting blood constituents | 0.0105 | 2.426 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Dysmenorrhea | 0.0008892 | 3.031 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Glaucoma | 0.001568 | 1.396 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Cyst and pseudocyst of pancreas | 0.001672 | 2.787 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Abnormal findings on mammogram or breast exam | 0.002595 | 1.354 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Adverse effects of antibacterials (not penicillins) | 0.0003913 | 3.468 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Nerve plexus lesions | 0.00898 | 1.985 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Irregular menstrual cycle | 0.002813 | 2.095 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Cardiac arrest | 0.009138 | 2.524 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Leukoplakia of oral mucosa | 0.002722 | 3.198 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3027409 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.002379 | 2.956 | MAOA | Smoking behavior (10+ cigarettes per day) |
| rs3099950 | Congenital musculoskeletal anomalies | 0.009246 | 2.329 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Polymyalgia Rheumatica | 0.004648 | 1.39 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Acute appendicitis | 0.001742 | 1.754 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Fracture of hand or wrist | 0.01014 | 1.232 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Appendiceal conditions | 0.0005632 | 1.693 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Corneal edema | 0.007623 | 1.807 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Other congenital anomalies of skin | 0.00443 | 1.619 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Other infectious diseases | 0.006946 | 1.917 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Other abnormality of urination | 0.009785 | 1.28 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Rheumatoid arthritis | 0.001623 | 1.364 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Appendicitis | 0.001633 | 1.644 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Cancer of other male genital organs | 0.008376 | 0.1516 | MORN2 | Amyotrophic lateral sclerosis |
| rs3099950 | Muscular wasting and disuse atrophy | 0.005731 | 0.3158 | MORN2 | Amyotrophic lateral sclerosis |
| rs3129882 | Diseases of respiratory system | 0.00146 | 0.8353 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Celiac disease | 0.007223 | 0.5323 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Diabetic retinopathy | 0.002614 | 0.8199 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Pernicious anemia | 0.00095 | 1.583 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Pneumonia | 0.007601 | 0.904 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Pericarditis | 0.001954 | 0.6798 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Symptoms involving respiratory system | 0.004677 | 0.8194 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Asthma | 0.004009 | 0.883 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetic peripheral circulatory disorders | 0.006086 | 0.4722 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 2 diabetes | 0.00283 | 0.9105 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Rheumatoid arthritis & related inflammatory polyarthropathies | 6.048e-07 | 0.7126 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetic ketoacidosis | 1.91e-06 | 0.5052 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Obstructive chronic bronchitis | 0.005899 | 0.8213 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Liver replaced by transplant | 0.005138 | 0.4105 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Respiratory abnormalities | 0.007821 | 0.7578 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Rheumatoid arthritis | 2.796e-06 | 0.6987 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetes | 3.836e-06 | 0.751 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Insulin pump user | 0.002551 | 0.774 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Breast conditions, congenital or relating to hormones | 0.00478 | 1.336 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Cancer of connective tissue | 0.005126 | 1.661 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Hypertrophy of breast (Gynecomastia) | 0.006619 | 1.357 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Rosacea | 0.004203 | 1.198 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Vascular insufficiency of intestine | 0.001303 | 0.6526 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Disorders of the autonomic nervous system | 0.00036 | 0.6931 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Cancer of bone & connective tissue | 0.009467 | 1.434 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Non-Hodgkins lymphoma | 0.01066 | 0.7878 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Diabetes mellitus | 0.00321 | 0.9128 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Celiac or tropical sprue | 0.00546 | 0.5271 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetes nephropathy | 0.000184 | 0.4721 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Secondary/extrinsic cardiomyopathies | 0.006969 | 0.5352 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Cancer of other lymphoid, histiocytic tissue | 0.009819 | 0.79 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 2 diabetic ketoacidosis | 0.000201 | 0.8372 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Hypoglycemia | 0.0003534 | 0.5849 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetic neuropathy | 2.876e-05 | 0.5453 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Peripheral autonomic neuropathy | 0.001604 | 0.6763 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 2 diabetic retinopathy | 0.009657 | 0.838 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Lack of coordination | 0.002721 | 0.779 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Type 1 diabetic retinopathy | 0.001645 | 0.6555 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3129882 | Paraproteinemia | 0.01147 | 0.737 | HLA-DRA | Systemic sclerosis, Parkinson's disease |
| rs3130573 | Uterine leiomyoma | 0.01029 | 0.8147 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Other disorders of intestine | 0.003221 | 1.21 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Benign neoplasm of uterus | 0.009044 | 0.624 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Acidosis | 0.007753 | 1.367 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Gastroparesis | 0.006909 | 0.5363 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Stricture/obstruction of ureter | 0.0007004 | 1.62 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Ovarian cancer | 0.005584 | 1.554 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Benign neoplasm of uterus | 0.009113 | 0.8215 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Chronic bronchitis | 0.01123 | 0.8408 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Sarcoidosis | 0.002197 | 1.702 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Cancer of other female genital organs | 0.002065 | 1.529 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Memory loss | 0.00116 | 0.7598 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Psoriasis | 2.516e-05 | 1.41 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Acute prostatitis | 0.002817 | 0.5259 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Renal failure NOS | 0.007062 | 1.328 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Psoriasis & related disorders | 0.0002078 | 1.333 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Psoriasis vulgaris | 3.463e-05 | 1.414 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Inflammatory diseases of prostate | 0.007808 | 0.801 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Acid-base balance disorder | 0.01034 | 1.293 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Neoplasm of uncertain behavior | 0.00584 | 1.193 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Prostatitis | 0.005541 | 0.7544 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Noninflammatory disorders of ovary, fallopian tube, & broad ligament | 0.001916 | 1.717 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Hydronephrosis | 0.007125 | 1.327 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Graves' disease | 0.00818 | 1.454 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Bullous dermatoses | 0.001419 | 2.033 | PSORS1C1 | Systemic sclerosis |
| rs3130573 | Prostate cancer | 0.0009955 | 0.8032 | PSORS1C1 | Systemic sclerosis |
| rs3131296 | Prostatitis | 0.002896 | 0.6407 | NOTCH4 | Schizophrenia |
| rs3131296 | Benign neoplasm of brain and other parts of nervous system | 0.008106 | 0.5538 | NOTCH4 | Schizophrenia |
| rs3131296 | Celiac disease | 3.647e-07 | 3.185 | NOTCH4 | Schizophrenia |
| rs3131296 | Immune disorders | 0.004789 | 1.364 | NOTCH4 | Schizophrenia |
| rs3131296 | Lupus erythematosus | 0.0005329 | 2.405 | NOTCH4 | Schizophrenia |
| rs3131296 | Testicular hypofunction | 0.008602 | 1.511 | NOTCH4 | Schizophrenia |
| rs3131296 | Sarcoidosis | 0.005101 | 1.805 | NOTCH4 | Schizophrenia |
| rs3131296 | Diabetic retinopathy | 0.002288 | 1.302 | NOTCH4 | Schizophrenia |
| rs3131296 | Testicular dysfunction | 0.004899 | 1.538 | NOTCH4 | Schizophrenia |
| rs3131296 | Multiple sclerosis | 0.01121 | 1.623 | NOTCH4 | Schizophrenia |
| rs3131296 | Type 1 diabetes nephropathy | 0.0001135 | 2.184 | NOTCH4 | Schizophrenia |
| rs3131296 | Stricture and stenosis of esophagus | 0.006982 | 0.6791 | NOTCH4 | Schizophrenia |
| rs3131296 | Discoid lupus erythematosus | 0.0004842 | 1.767 | NOTCH4 | Schizophrenia |
| rs3131296 | Peripheral autonomic neuropathy | 0.0002516 | 1.694 | NOTCH4 | Schizophrenia |
| rs3131296 | Bullous dermatoses | 0.001939 | 2.266 | NOTCH4 | Schizophrenia |
| rs3131296 | Varicose veins | 0.006375 | 1.219 | NOTCH4 | Schizophrenia |
| rs3131296 | Anterior pituitary disorders | 0.006487 | 1.831 | NOTCH4 | Schizophrenia |
| rs3131296 | Hypoglycemia | 0.002659 | 1.661 | NOTCH4 | Schizophrenia |
| rs3131296 | Disorders of the autonomic nervous system | 0.001969 | 1.471 | NOTCH4 | Schizophrenia |
| rs3131296 | Cystic mastopathy | 0.004662 | 0.7932 | NOTCH4 | Schizophrenia |
| rs3131296 | Celiac or tropical sprue | 7.517e-08 | 3.309 | NOTCH4 | Schizophrenia |
| rs3131296 | Rosacea | 0.0004692 | 0.6984 | NOTCH4 | Schizophrenia |
| rs3131296 | Poisoning by hormones and synthetic substitutes | 0.006505 | 1.502 | NOTCH4 | Schizophrenia |
| rs3131296 | Vascular insufficiency of intestine | 0.004101 | 1.571 | NOTCH4 | Schizophrenia |
| rs3131296 | Adverse effects of insulins and antidiabetic agents | 0.0001046 | 2.545 | NOTCH4 | Schizophrenia |
| rs3131296 | Other hereditary hemolytic anemias | 0.007103 | 2.351 | NOTCH4 | Schizophrenia |
| rs3131296 | Abnormal mammogram | 0.01131 | 0.7974 | NOTCH4 | Schizophrenia |
| rs3131296 | Type 1 diabetic retinopathy | 0.0002125 | 1.764 | NOTCH4 | Schizophrenia |
| rs3131296 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.005083 | 1.421 | NOTCH4 | Schizophrenia |
| rs3131296 | Type 1 diabetic neuropathy | 1.605e-05 | 1.952 | NOTCH4 | Schizophrenia |
| rs3131296 | Hematuria | 0.002582 | 0.8369 | NOTCH4 | Schizophrenia |
| rs3131296 | Diseases of sebaceous glands | 0.01049 | 0.8676 | NOTCH4 | Schizophrenia |
| rs3131296 | Benign mammary dysplasias | 0.005418 | 0.8037 | NOTCH4 | Schizophrenia |
| rs3131296 | Abnormal weight gain | 0.00252 | 0.5711 | NOTCH4 | Schizophrenia |
| rs3131296 | Hyperlipidemia | 0.001415 | 0.8618 | NOTCH4 | Schizophrenia |
| rs3131296 | Systemic lupus erythematosus | 0.005399 | 1.642 | NOTCH4 | Schizophrenia |
| rs3131296 | Adrenal hypofunction | 0.006614 | 1.781 | NOTCH4 | Schizophrenia |
| rs3131296 | Hypercholesterolemia | 0.00214 | 0.8371 | NOTCH4 | Schizophrenia |
| rs3131296 | Cyst of kidney, acquired | 0.001231 | 1.484 | NOTCH4 | Schizophrenia |
| rs3131296 | Complication of amputation stump | 0.001337 | 2.258 | NOTCH4 | Schizophrenia |
| rs3131296 | Other specified peripheral vascular diseases | 0.001256 | 2.449 | NOTCH4 | Schizophrenia |
| rs3131296 | Aplastic anemia | 0.01038 | 1.437 | NOTCH4 | Schizophrenia |
| rs3131296 | Posttraumatic wound infection | 0.01142 | 1.877 | NOTCH4 | Schizophrenia |
| rs3131296 | Peripheral angiopathy in diseases classified elsewhere | 0.0106 | 1.733 | NOTCH4 | Schizophrenia |
| rs3131296 | Congenital anomalies of intestine | 0.00175 | 2.657 | NOTCH4 | Schizophrenia |
| rs3131296 | Type 1 diabetic peripheral circulatory disorders | 0.001351 | 2.351 | NOTCH4 | Schizophrenia |
| rs3131296 | Disorders of lipoid metabolism | 0.001294 | 0.8617 | NOTCH4 | Schizophrenia |
| rs3184504 | Open wound of finger(s) | 0.008962 | 0.8594 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Abdominal aortic aneurysm | 0.01139 | 1.22 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Atherosclerosis of the extremities | 0.002085 | 1.16 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Ischemic Heart Disease | 0.007575 | 1.084 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.003074 | 1.264 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Osteoporosis, NOS or other | 0.005418 | 1.13 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Other disorders of gallbladder | 0.001266 | 0.5683 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Arterial embolism and thrombosis | 0.00126 | 1.292 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Abnormal findings on mammogram or breast exam | 0.007769 | 1.119 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Aortic aneurysm | 0.008784 | 1.195 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Essential hypertension | 0.009907 | 1.08 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Hypertension | 0.01107 | 1.078 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Hypothyroidism | 7.655e-06 | 1.174 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Benign neoplasm of uterus | 0.001902 | 0.802 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Phlebitis and thrombophlebitis of lower extremities | 0.0111 | 1.222 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Dentofacial anomalies, including malocclusion | 0.01059 | 0.6601 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Uterine leiomyoma | 0.006447 | 0.8148 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.00686 | 1.296 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Anal and rectal polyp | 0.01057 | 0.8123 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.001846 | 1.204 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Ventricular fibrillation & flutter | 0.01004 | 0.6286 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Arterial embolism and thrombosis of lower extremity artery | 0.007384 | 1.342 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Cancer of the upper aerodigestive tract | 0.006314 | 0.7217 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Morbid obesity | 0.008289 | 0.862 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Other congenital anomalies of skin | 0.006306 | 1.439 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Peyronie's disease | 0.01067 | 1.784 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Peripheral vascular disease | 0.008122 | 1.113 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Empyema and pneumothorax | 0.009123 | 1.284 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Retinoschisis and retinal cysts | 0.003572 | 2.251 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Endometriosis | 0.002769 | 0.7068 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Acute bronchospasm | 0.009458 | 0.4545 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Myocardial infarction | 0.0004043 | 1.171 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Coronary atherosclerosis | 0.006473 | 1.091 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Osteoporosis | 0.006226 | 1.132 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Peripheral arterial disease | 0.004773 | 1.132 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Mastodynia | 0.00819 | 1.264 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Atherosclerosis | 0.001489 | 1.145 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Paranoid disorders | 0.01142 | 1.773 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Anomalies of tooth position/malocclusion | 0.004609 | 0.5834 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs3184504 | Other rheumatic heart disease | 0.005213 | 2.073 | SH2B3 | Diastolic blood pressure, Type 1 diabetes, Coronary heart disease, Eosinophil counts, Systolic blood pressure, Type 1 diabetes autoantibodies, Rheumatoid arthritis |
| rs337847 | Cellulitis and abscess of trunk | 0.006405 | 1.464 | ARSB | Hippocampal atrophy |
| rs337847 | Lipoid metabolism disorder NOS | 0.005597 | 1.535 | ARSB | Hippocampal atrophy |
| rs337847 | Inguinal hernia | 0.002576 | 0.7438 | ARSB | Hippocampal atrophy |
| rs337847 | Psychogenic disorder | 0.0009769 | 1.862 | ARSB | Hippocampal atrophy |
| rs337847 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.001299 | 2.217 | ARSB | Hippocampal atrophy |
| rs337847 | Aplastic anemia | 0.007494 | 1.544 | ARSB | Hippocampal atrophy |
| rs337847 | Esophageal cancer | 0.01091 | 2.002 | ARSB | Hippocampal atrophy |
| rs337847 | Cyst or abscess of Bartholin's gland | 0.001457 | 2.635 | ARSB | Hippocampal atrophy |
| rs337847 | Circumscribed scleroderma | 0.006207 | 0.427 | ARSB | Hippocampal atrophy |
| rs337847 | Hereditary and idiopathic peripheral neuropathy | 0.003629 | 1.27 | ARSB | Hippocampal atrophy |
| rs337847 | Hyperventilation | 0.001574 | 2.195 | ARSB | Hippocampal atrophy |
| rs337847 | Thyroid cancer | 0.01119 | 1.698 | ARSB | Hippocampal atrophy |
| rs363512 | Vascular dementia | 0.002348 | 1.824 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Disorders resulting from impaired renal function | 0.003628 | 1.586 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Mental disorders due to brain damage | 0.00689 | 1.456 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Pneumonitis due to inhalation of food or vomitus | 0.006951 | 1.614 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Abnormal thyroid function | 0.008638 | 1.511 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Lupus erythematosus | 0.009867 | 2.334 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Vitamin B12 deficiency anemia | 0.01114 | 1.838 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.008747 | 2.765 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Fracture of humerus | 0.0021 | 1.547 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Empyema and pneumothorax | 0.00719 | 1.55 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Secondary hyperparathyroidism (of renal origin) | 0.005469 | 1.679 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Macular degeneration, dry | 0.007688 | 1.483 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Other pulmonary inflamation or edema | 0.003437 | 1.644 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Pernicious anemia | 0.007887 | 1.765 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Spondylosis and allied disorders | 0.009657 | 0.8172 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Symptoms involving urinary system | 0.002759 | 1.558 | GRIK1 | Hyperactive-impulsive symptoms |
| rs363512 | Acute, but ill-defined cerebrovascular disease | 0.01007 | 1.344 | GRIK1 | Hyperactive-impulsive symptoms |
| rs368331 | Glaucoma | 0.0003801 | 1.326 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Torsion dystonia | 0.004619 | 2.076 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Open-angle glaucoma | 0.004812 | 1.358 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Other conditions of the mother complicating pregnancy | 0.006307 | 2.319 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Poisoning by agents primarily affecting blood constituents | 0.007023 | 2 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Substance addiction and disorders | 0.01029 | 0.5447 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Labyrinthitis | 0.004109 | 0.3727 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Upper gastrointestinal congenital anomalies | 0.00134 | 2.209 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Diaphragmatic hernia | 0.007445 | 1.263 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Digestive congenital anomalies | 0.00299 | 1.866 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Esophageal atresia/tracheoesophageal fistula | 0.008269 | 2.186 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Mechanical complication of nervous system device, implant, and graft | 0.006324 | 2.599 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs368331 | Macular degeneration | 0.00646 | 1.282 | DNAH11 | Total ventricular volume, Whole-brain volume |
| rs3736228 | Fracture of humerus | 0.007888 | 1.335 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Disaccharide malabsorption | 0.001194 | 0.7337 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Carbohydrate transport and metabolism disorder | 0.001623 | 0.7427 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Type 2 diabetic peripheral circulatory disorders | 0.01111 | 1.453 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Congenital cataract and lens anomalies | 0.0009981 | 2.439 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Skin neoplasm of uncertain behavior | 0.00474 | 1.286 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Subdural hemorrhage | 0.00344 | 1.784 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Other conditions of brain | 0.0007325 | 1.531 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Leukoplakia of oral mucosa | 0.0075 | 1.962 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Stricture and stenosis of esophagus | 0.002798 | 1.417 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Benign mammary dysplasias | 0.003014 | 1.255 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Raynaud's syndrome | 0.01121 | 1.39 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Glycosuria or Acetonuria | 0.0005421 | 2.939 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Congenital anomalies of the eye | 0.006579 | 1.329 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Cystic mastopathy | 0.002402 | 1.273 | LRP5 | Bone mineral density (lumbar spine) |
| rs3736228 | Type 1 diabetic retinopathy | 0.00704 | 1.535 | LRP5 | Bone mineral density (lumbar spine) |
| rs3743200 | Aphasia/speech disturbance | 0.001378 | 0.7424 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Gingival and periodontal diseases | 0.0008792 | 0.7685 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Intracerebral hemorrhage | 0.003571 | 0.4895 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Menopausal & postmenopausal disorders | 0.0112 | 1.141 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Periodontitis (acute or chronic) | 0.009941 | 0.7945 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Early complications of trauma or procedure | 0.0005802 | 0.3608 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Claw toe | 0.004232 | 2.072 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Persistent mental disorders due to other conditions | 0.001186 | 0.8116 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Type 2 diabetic ketoacidosis | 0.002405 | 0.8442 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Dentofacial anomalies, including malocclusion | 0.005454 | 0.5498 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Benign neoplasm of eye | 0.005564 | 1.277 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Neurological disorders due to brain damage | 0.0008965 | 0.8326 | RASGRF1 | RR interval (heart rate) |
| rs3743200 | Jaw disease NOS | 0.005098 | 0.5611 | RASGRF1 | RR interval (heart rate) |
| rs3744064 | Type 2 diabetes | 0.002695 | 1.309 | SEC14L1 | Cognitive performance |
| rs3744064 | Primary open angle glaucoma | 0.000415 | 2.017 | SEC14L1 | Cognitive performance |
| rs3744064 | Other local infections of skin and subcutaneous tissue | 0.001983 | 0.4989 | SEC14L1 | Cognitive performance |
| rs3744064 | Type 2 diabetic retinopathy | 5.223e-05 | 1.946 | SEC14L1 | Cognitive performance |
| rs3744064 | Femoral hernia | 0.009101 | 3.061 | SEC14L1 | Cognitive performance |
| rs3744064 | Retinal edema and hypertensive retinopathy | 2.029e-05 | 2.576 | SEC14L1 | Cognitive performance |
| rs3744064 | Diabetes mellitus | 0.00391 | 1.292 | SEC14L1 | Cognitive performance |
| rs3744064 | Disorders of the globe | 0.0005863 | 2.724 | SEC14L1 | Cognitive performance |
| rs3744064 | Primary angle-closure glaucoma | 0.0008337 | 1.994 | SEC14L1 | Cognitive performance |
| rs3744064 | Hypermetropia | 0.001894 | 0.6367 | SEC14L1 | Cognitive performance |
| rs3744064 | Disorders of refraction and accommodation | 0.006386 | 0.7449 | SEC14L1 | Cognitive performance |
| rs3744064 | Diabetic retinopathy | 0.0003262 | 1.786 | SEC14L1 | Cognitive performance |
| rs3744064 | Type 2 diabetic ketoacidosis | 0.0006928 | 1.541 | SEC14L1 | Cognitive performance |
| rs3744064 | Benign neoplasm of lip, oral cavity, and pharynx | 0.008214 | 2.408 | SEC14L1 | Cognitive performance |
| rs3744064 | Type 2 diabetic nephropathy | 0.00562 | 1.671 | SEC14L1 | Cognitive performance |
| rs3745516 | Other disorders of urethra and urinary tract | 0.007355 | 0.7877 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Open wound of lip and mouth | 0.007484 | 1.779 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Nephritis and nephropathy without mention of glomerulonephritis | 0.005512 | 1.292 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Cardiac complications, not elsewhere classified | 0.0062 | 1.426 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Occlusion and stenosis of precerebral arteries | 0.006509 | 1.157 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Deficiency of humoral immunity | 0.002976 | 2.22 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Sacroiliitis NEC | 0.0097 | 1.77 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Antisocial/borderline personality disorder | 0.005609 | 0.488 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Derangement of joint, non-traumatic | 0.002179 | 1.319 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Type 1 diabetes | 0.008952 | 1.195 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Polyneuropathy in diabetes | 0.003006 | 1.242 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Type 2 diabetic nephropathy | 0.0003054 | 1.331 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Respiratory failure | 0.003866 | 1.321 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Type 2 diabetic neuropathy | 0.004478 | 1.212 | SPIB | Primary biliary cirrhosis |
| rs3745516 | Nephritis and nephropathy in diseases classified elsewhere | 0.001012 | 1.392 | SPIB | Primary biliary cirrhosis |
| rs3757840 | Polymyalgia Rheumatica | 0.0009764 | 1.341 | GCK | Glucose |
| rs3757840 | Anterior pituitary disorders | 0.01139 | 0.6145 | GCK | Glucose |
| rs3757840 | Ingrowing nail | 0.003697 | 0.8526 | GCK | Glucose |
| rs3757840 | Alopecia Areata | 0.007736 | 0.4811 | GCK | Glucose |
| rs3757840 | Ulcer of esophagus | 0.005914 | 0.6959 | GCK | Glucose |
| rs3757840 | Delirium due to conditions classified elsewhere | 0.005482 | 1.387 | GCK | Glucose |
| rs3757840 | Other abnormal glucose | 0.003763 | 0.8683 | GCK | Glucose |
| rs3757840 | Morbid obesity | 0.0113 | 1.152 | GCK | Glucose |
| rs3757840 | Other cells and casts in urine | 0.009316 | 1.407 | GCK | Glucose |
| rs3757840 | Angina pectoris | 0.0008328 | 0.8577 | GCK | Glucose |
| rs3757840 | Malignant neoplasm, other | 0.01046 | 1.216 | GCK | Glucose |
| rs3757840 | Rheumatoid arthritis | 0.0109 | 0.8283 | GCK | Glucose |
| rs3757840 | Alopecia | 0.00705 | 0.759 | GCK | Glucose |
| rs3761847 | Toxic effect of venom | 0.0004227 | 0.5572 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Occlusion and stenosis of precerebral arteries | 0.004511 | 1.141 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Unspecified osteomyelitis | 0.01032 | 1.306 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Testicular hypofunction | 0.007693 | 1.385 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Hallux valgus (Bunion) | 0.005208 | 1.195 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Malunion fracture | 0.0006047 | 0.6185 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Acquired toe deformities | 0.008111 | 1.167 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Testicular dysfunction | 0.00433 | 1.407 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Hammer toe | 0.008102 | 1.194 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Diseases of the tongue | 0.004787 | 0.6906 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Fracture of clavicle or scapula | 0.002317 | 0.6691 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Chronic ischemic heart disease | 0.006746 | 1.141 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Cerebrovascular disease | 0.005419 | 1.098 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Muscular dystrophies and other myopathies | 0.003807 | 1.49 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Infestation | 0.01061 | 0.5874 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Althete's foot | 0.009179 | 1.245 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Right bundle branch block | 0.002508 | 1.321 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Bundle branch block | 0.005257 | 1.208 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.01113 | 1.182 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Acquired foot deformities | 0.01015 | 1.116 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Disorders of esophageal motility | 0.003891 | 0.6425 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Infections involving bone | 0.01132 | 1.24 | TRAF1 | Rheumatoid arthritis |
| rs3761847 | Congenital anomalies of great vessels | 0.006914 | 0.4729 | TRAF1 | Rheumatoid arthritis |
| rs3761959 | Agorophobia, social phobia, and panic disorder | 0.001323 | 0.6751 | FCRL3 | Graves' disease |
| rs3761959 | Costochondritis | 0.001246 | 0.4617 | FCRL3 | Graves' disease |
| rs3761959 | Tension headache | 0.001752 | 0.7829 | FCRL3 | Graves' disease |
| rs3761959 | Chronic pancreatitis | 0.01085 | 0.6098 | FCRL3 | Graves' disease |
| rs3761959 | Urethral stricture (not specified as infectious) | 0.002242 | 0.6605 | FCRL3 | Graves' disease |
| rs3761959 | Disturbance of skin sensation | 0.01093 | 0.8966 | FCRL3 | Graves' disease |
| rs3761959 | Astigmatism | 0.005498 | 1.135 | FCRL3 | Graves' disease |
| rs3761959 | Hypothyroidism | 0.01017 | 1.097 | FCRL3 | Graves' disease |
| rs3761959 | Psychogenic and somatoform disorders | 0.001332 | 0.7507 | FCRL3 | Graves' disease |
| rs3761959 | Abnormal mammogram | 0.003495 | 0.8366 | FCRL3 | Graves' disease |
| rs3761959 | Hypermetropia | 0.003339 | 1.149 | FCRL3 | Graves' disease |
| rs3761959 | Other disorders of adrenal glands | 0.005641 | 0.6394 | FCRL3 | Graves' disease |
| rs3761959 | Disorders of coccyx | 0.008632 | 0.7569 | FCRL3 | Graves' disease |
| rs3761959 | Otitis externa | 0.006037 | 1.191 | FCRL3 | Graves' disease |
| rs3761959 | Inflammatory spondylopathies | 0.01022 | 1.474 | FCRL3 | Graves' disease |
| rs3764640 | Nontoxic multinodular goiter | 0.01003 | 0.7583 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Sialoadenitis | 0.003489 | 0.5475 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Electrolyte imbalance | 0.007636 | 1.117 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Plasma protein metabolism disorder | 0.009357 | 1.318 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Fracture of lower limb | 0.005029 | 1.177 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Glycosuria or Acetonuria | 0.01013 | 2.099 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Other open wound of head and face | 0.004161 | 1.259 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Cardiac shunt/ heart septal defect | 0.002197 | 0.5468 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Immune disorders | 0.003596 | 1.315 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Abnormal reflex | 0.01139 | 2.049 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Urethritis and urethral syndrome | 0.007621 | 1.76 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Anemia NOS | 0.01106 | 0.9043 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.004973 | 1.272 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Viral hepatitis C | 0.009671 | 1.512 | STK11 | Alzheimer's disease with psychosis |
| rs3764640 | Patellar fracture | 0.002757 | 1.512 | STK11 | Alzheimer's disease with psychosis |
| rs3780792 | Bacteremia | 0.008251 | 0.7594 | VAV2 | Multiple sclerosis |
| rs3780792 | Anal and rectal polyp | 0.009709 | 1.236 | VAV2 | Multiple sclerosis |
| rs3780792 | Chronic pain syndrome | 0.004839 | 1.665 | VAV2 | Multiple sclerosis |
| rs3780792 | Type 1 diabetic retinopathy | 0.007643 | 1.403 | VAV2 | Multiple sclerosis |
| rs3780792 | Cramp of limb | 0.01038 | 1.291 | VAV2 | Multiple sclerosis |
| rs3780792 | Ischemic stroke | 0.01135 | 1.187 | VAV2 | Multiple sclerosis |
| rs3780792 | Edema | 0.005375 | 0.8987 | VAV2 | Multiple sclerosis |
| rs3780792 | Back & neck sprains | 0.008225 | 0.8883 | VAV2 | Multiple sclerosis |
| rs3780792 | Hematuria | 0.008725 | 1.115 | VAV2 | Multiple sclerosis |
| rs3780792 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.01064 | 1.588 | VAV2 | Multiple sclerosis |
| rs3780792 | Disorders resulting from impaired renal function | 0.0034 | 1.326 | VAV2 | Multiple sclerosis |
| rs3780792 | Abnormal chest sounds | 0.002103 | 0.6264 | VAV2 | Multiple sclerosis |
| rs3782181 | Swelling of limb | 0.001073 | 1.251 | KITLG | Testicular germ cell cancer |
| rs3782181 | Prostate cancer | 0.001264 | 0.7703 | KITLG | Testicular germ cell cancer |
| rs3782181 | Nevus, non-neoplastic | 0.01021 | 0.4652 | KITLG | Testicular germ cell cancer |
| rs3782181 | H. pylori | 0.008181 | 1.563 | KITLG | Testicular germ cell cancer |
| rs3782181 | Obstruction of bile duct | 0.00171 | 1.79 | KITLG | Testicular germ cell cancer |
| rs3782181 | Chronic interstitial cystitis | 0.001306 | 2.421 | KITLG | Testicular germ cell cancer |
| rs3782181 | Paroxysmal tachycardia, unspecified | 0.006177 | 0.7869 | KITLG | Testicular germ cell cancer |
| rs3782181 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.0003047 | 1.536 | KITLG | Testicular germ cell cancer |
| rs3782181 | Hyperventilation | 0.006181 | 1.791 | KITLG | Testicular germ cell cancer |
| rs3782181 | Disorders of esophageal motility | 0.002719 | 1.636 | KITLG | Testicular germ cell cancer |
| rs3782181 | Congenital musculoskeletal deformities of spine | 0.01063 | 0.6203 | KITLG | Testicular germ cell cancer |
| rs3782181 | Dyschromia and Vitiligo | 0.008253 | 1.235 | KITLG | Testicular germ cell cancer |
| rs3782181 | Chronic hepatitis | 0.004934 | 1.913 | KITLG | Testicular germ cell cancer |
| rs3782181 | Gram positive septicemia | 0.005328 | 1.701 | KITLG | Testicular germ cell cancer |
| rs3782181 | Fracture of unspecified bones | 0.007684 | 0.8302 | KITLG | Testicular germ cell cancer |
| rs3782181 | Hypersomnia | 0.003585 | 1.589 | KITLG | Testicular germ cell cancer |
| rs3782181 | Choroidal degenerations | 0.008934 | 1.49 | KITLG | Testicular germ cell cancer |
| rs3803662 | Postoperative infection | 0.004332 | 0.7927 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Breast cancer | 3.446e-05 | 1.301 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Acute bronchospasm | 0.008189 | 2.131 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Breast cancer | 8.379e-05 | 1.279 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Breast cancer, including in situ | 4.317e-05 | 1.294 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Disorders of esophageal motility | 0.008754 | 1.488 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Skin neoplasm of uncertain behavior | 0.003886 | 0.7954 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803662 | Other benign neoplasm of connective and other soft tissue | 0.001702 | 0.5482 | TOX3 | Breast cancer, ER+ Breast cancer |
| rs3803800 | Shock | 0.004542 | 1.463 | TNFSF13 | IgA nephropathy |
| rs3803800 | Eustachian tube disorders | 0.004502 | 0.8597 | TNFSF13 | IgA nephropathy |
| rs3803800 | Diseases of the tongue | 0.003299 | 1.496 | TNFSF13 | IgA nephropathy |
| rs3803800 | Deep vein thrombosis | 0.009877 | 1.291 | TNFSF13 | IgA nephropathy |
| rs3803800 | Suppurative and unspecified otitis media | 0.006158 | 0.824 | TNFSF13 | IgA nephropathy |
| rs3803800 | Pathological, developmental or recurrent dislocation | 0.009272 | 1.879 | TNFSF13 | IgA nephropathy |
| rs3803800 | Otitis media | 0.01091 | 0.8564 | TNFSF13 | IgA nephropathy |
| rs3803800 | Depression | 0.002257 | 1.135 | TNFSF13 | IgA nephropathy |
| rs3803800 | Acidosis | 0.001146 | 1.519 | TNFSF13 | IgA nephropathy |
| rs3803800 | Hypercalcemia | 0.006009 | 0.7371 | TNFSF13 | IgA nephropathy |
| rs3803800 | Acid-base balance disorder | 0.005278 | 1.364 | TNFSF13 | IgA nephropathy |
| rs3803800 | Sepsis and SIRS | 0.01107 | 1.28 | TNFSF13 | IgA nephropathy |
| rs3803800 | Swelling, mass, or lump in head and neck | 0.01025 | 1.255 | TNFSF13 | IgA nephropathy |
| rs3803800 | Acute laryngitis and tracheitis | 0.008767 | 0.6027 | TNFSF13 | IgA nephropathy |
| rs3803800 | Mood disorders | 0.007724 | 1.114 | TNFSF13 | IgA nephropathy |
| rs3803800 | Exophthalmos | 0.006389 | 0.3135 | TNFSF13 | IgA nephropathy |
| rs3803800 | Vitamin deficiency | 0.01078 | 1.19 | TNFSF13 | IgA nephropathy |
| rs3803800 | Major depressive disorder | 0.002436 | 1.213 | TNFSF13 | IgA nephropathy |
| rs3803800 | Protein-calorie malnutrition | 0.001646 | 1.231 | TNFSF13 | IgA nephropathy |
| rs3803800 | Lymphosarcoma | 0.002169 | 2.317 | TNFSF13 | IgA nephropathy |
| rs3803800 | Generalized anxiety disorder | 0.01044 | 1.316 | TNFSF13 | IgA nephropathy |
| rs3803800 | Agorophobia, social phobia, and panic disorder | 0.006113 | 1.439 | TNFSF13 | IgA nephropathy |
| rs3806156 | Discoid lupus erythematosus | 0.009324 | 0.6744 | BTNL2 | Vitiligo |
| rs3806156 | Intracerebral hemorrhage | 0.007691 | 1.582 | BTNL2 | Vitiligo |
| rs3806156 | Hypoglycemia | 0.008412 | 1.439 | BTNL2 | Vitiligo |
| rs3806156 | Thyrotoxicosis | 0.008399 | 0.804 | BTNL2 | Vitiligo |
| rs3806156 | Atrophy of edentulous alveolar ridge | 0.006682 | 1.482 | BTNL2 | Vitiligo |
| rs3806156 | Ulceration of intestine | 0.01077 | 1.577 | BTNL2 | Vitiligo |
| rs3806156 | Postmenopausal atrophic vaginitis | 0.005083 | 1.254 | BTNL2 | Vitiligo |
| rs3806156 | Acquired deformities of ankle and foot | 0.006846 | 1.229 | BTNL2 | Vitiligo |
| rs3806156 | Eosinophilia | 0.001347 | 1.98 | BTNL2 | Vitiligo |
| rs3806156 | Urethritis and urethral syndrome | 0.00726 | 1.721 | BTNL2 | Vitiligo |
| rs3806156 | Degenerative disease of the spinal cord | 0.00969 | 1.426 | BTNL2 | Vitiligo |
| rs3806156 | Lupus erythematosus | 0.001441 | 0.3884 | BTNL2 | Vitiligo |
| rs3806156 | Shock | 0.004713 | 1.408 | BTNL2 | Vitiligo |
| rs3806156 | Polyarteritis nodosa and allied conditions | 0.002931 | 1.377 | BTNL2 | Vitiligo |
| rs3806156 | Cellulitis and abscess of leg | 0.01028 | 0.8595 | BTNL2 | Vitiligo |
| rs3806156 | Pneumoconiosis | 0.001134 | 0.3714 | BTNL2 | Vitiligo |
| rs3806156 | Atherosclerosis of the extremities | 0.008996 | 1.139 | BTNL2 | Vitiligo |
| rs3806932 | Hereditary and idiopathic peripheral neuropathy | 0.006523 | 0.8701 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other disorders of ear | 0.009304 | 0.7893 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other disorders of back | 0.003675 | 0.8542 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Cardiac dysrhythmias | 0.007603 | 0.9233 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other specified cardiac dysrhythmias | 0.001494 | 0.8648 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other symptoms referable to back | 0.009231 | 0.804 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Cancer of oropharynx | 0.007241 | 2.047 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Congenital anomalies of genital organs | 0.01147 | 0.5099 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Cerebral aneurysm | 0.009811 | 1.607 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Paroxysmal ventricular tachycardia | 0.006004 | 0.776 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Open wound of eye or eyelid | 0.009591 | 0.4859 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Otosclerosis | 0.005555 | 0.661 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Paroxysmal tachycardia, unspecified | 0.002014 | 0.8165 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Delirium dementia and amnestic disorders | 0.0004243 | 1.17 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Chronic lymphoid leukemia | 0.00136 | 0.5792 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Chronic pharyngitis and nasopharyngitis | 0.00906 | 0.8615 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Skin cancer | 0.01108 | 0.9153 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Lymphadenitis | 0.007438 | 0.8493 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Prostate cancer | 0.01118 | 0.8522 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Fracture of clavicle or scapula | 0.003156 | 0.6833 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Cancer of the lower GI tract | 0.0065 | 1.362 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Other diseases of respiratory system | 0.002783 | 1.42 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Posttraumatic wound infection | 0.01008 | 0.5549 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Dementias | 0.009078 | 1.144 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Disorders of sacrum | 0.00561 | 0.797 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Skin neoplasm of uncertain behavior | 0.01024 | 0.8402 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Peyronie's disease | 0.007743 | 0.5314 | TSLP | Eosinophilic esophagitis |
| rs3806932 | Lymphoid leukemia | 0.004278 | 0.6295 | TSLP | Eosinophilic esophagitis |
| rs3807989 | Hepatomegaly | 0.001555 | 1.913 | CAV1 | PR interval |
| rs3807989 | Secondary thrombocytopenia | 0.009235 | 1.581 | CAV1 | PR interval |
| rs3807989 | Iatrogenic hypothyroidism | 0.004178 | 1.351 | CAV1 | PR interval |
| rs3807989 | Abnormal chest sounds | 0.003593 | 0.6587 | CAV1 | PR interval |
| rs3807989 | Glossitis | 0.009806 | 0.4822 | CAV1 | PR interval |
| rs3807989 | Lump or mass in breast | 0.008309 | 0.8622 | CAV1 | PR interval |
| rs3807989 | Muscular wasting and disuse atrophy | 0.0006231 | 0.5134 | CAV1 | PR interval |
| rs3807989 | Other conditions of the mother complicating pregnancy | 0.002789 | 0.5683 | CAV1 | PR interval |
| rs3807989 | Other disorders of metabolic, endocrine, immunity disorders | 0.002712 | 0.436 | CAV1 | PR interval |
| rs3807989 | Posttraumatic stress disorder | 0.01073 | 1.509 | CAV1 | PR interval |
| rs3807989 | Phobia | 0.007839 | 2.016 | CAV1 | PR interval |
| rs3807989 | Adverse effects of opiates and related narcotics in therapeutic use | 0.007821 | 1.291 | CAV1 | PR interval |
| rs3807989 | Stricture/obstruction of ureter | 0.01049 | 1.433 | CAV1 | PR interval |
| rs3807989 | Nephritis and nephropathy in diseases classified elsewhere | 0.003611 | 1.302 | CAV1 | PR interval |
| rs3807989 | Intervertebral disc disorder with myelopathy | 0.00898 | 0.5635 | CAV1 | PR interval |
| rs3807989 | Nonspecific findings on examination of blood | 0.006557 | 1.305 | CAV1 | PR interval |
| rs3815087 | Esophageal cancer | 0.006612 | 1.859 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Althete's foot | 0.000908 | 1.38 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Iron deficiency anemia secondary to blood loss | 0.006844 | 1.381 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Disorders of cornea | 0.003563 | 1.249 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Adverse effects of cardiac rhythm regulators | 0.002743 | 0.3266 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Depression | 0.006715 | 1.122 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Corneal degenerations | 0.0002124 | 1.572 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Psoriasis & related disorders | 1.415e-05 | 1.457 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Prostate cancer | 0.004508 | 0.7924 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Psoriasis vulgaris | 2.448e-07 | 1.608 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Fuchs' dystrophy | 0.0102 | 1.513 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Mood disorders | 0.009784 | 1.114 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Corneal edema | 0.005093 | 1.713 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Malunion fracture | 0.009862 | 1.462 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Psoriasis | 5.549e-07 | 1.571 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Anemia of chronic disease | 0.001312 | 0.7476 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Biliary cirrhosis | 0.006508 | 2.211 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Partial epilepsy | 0.01036 | 0.6239 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Orchitis and epididymitis | 0.007434 | 0.6147 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3815087 | Seborheic dermatitis | 0.0007983 | 1.277 | PSORS1C1 | HIV-1 progression, Stevens-Johnson syndrome and toxic epidermal necrolysis |
| rs3816995 | Anomalies of pupillary function | 0.0009165 | 0.4312 | SDK2 | Panic disorder |
| rs3816995 | Perforation of tympanic membrane | 0.007536 | 0.6633 | SDK2 | Panic disorder |
| rs3816995 | Torticollis | 0.003718 | 1.593 | SDK2 | Panic disorder |
| rs3816995 | Hammer toe | 0.008324 | 0.8411 | SDK2 | Panic disorder |
| rs3816995 | Diverticulitis | 0.007515 | 1.214 | SDK2 | Panic disorder |
| rs3816995 | Disorders of cervical region | 0.003496 | 1.372 | SDK2 | Panic disorder |
| rs3816995 | Other sprains and strains | 0.002289 | 1.389 | SDK2 | Panic disorder |
| rs3816995 | Secondary malignant neoplasm | 0.009643 | 1.148 | SDK2 | Panic disorder |
| rs3816995 | Cardiomegaly | 0.01036 | 0.8743 | SDK2 | Panic disorder |
| rs3816995 | Respiratory insufficiency | 0.0006222 | 0.721 | SDK2 | Panic disorder |
| rs3816995 | Acquired toe deformities | 0.002212 | 0.8397 | SDK2 | Panic disorder |
| rs3818361 | Systolic/diastolic heart failure | 0.007576 | 1.149 | CR1 | Alzheimer's disease |
| rs3818361 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | 0.007775 | 0.3485 | CR1 | Alzheimer's disease |
| rs3818361 | Personality disorders | 0.009632 | 1.287 | CR1 | Alzheimer's disease |
| rs3818361 | Heart valve disorders | 0.0093 | 1.129 | CR1 | Alzheimer's disease |
| rs3818361 | Brain cancer | 0.001152 | 1.911 | CR1 | Alzheimer's disease |
| rs3818361 | Palpitations | 0.005655 | 1.171 | CR1 | Alzheimer's disease |
| rs3818361 | Other aneurysm | 0.002818 | 1.246 | CR1 | Alzheimer's disease |
| rs3818361 | Inflammatory conditions of jaw | 0.007862 | 1.625 | CR1 | Alzheimer's disease |
| rs3818361 | Neutropenia | 0.008149 | 0.7607 | CR1 | Alzheimer's disease |
| rs3818361 | Reticulosarcoma | 0.006953 | 0.4385 | CR1 | Alzheimer's disease |
| rs3818361 | Decreased white blood cell count | 0.002488 | 0.7384 | CR1 | Alzheimer's disease |
| rs3818361 | Cerebral edema and compression of brain | 0.008551 | 1.91 | CR1 | Alzheimer's disease |
| rs3818361 | Posttraumatic wound infection | 0.008176 | 1.825 | CR1 | Alzheimer's disease |
| rs3818361 | Symptoms/disorders of the urinary system | 0.009284 | 1.106 | CR1 | Alzheimer's disease |
| rs3818361 | Congenital anomalies of peripheral vascular system | 0.002923 | 1.98 | CR1 | Alzheimer's disease |
| rs3818361 | Aortic aneurysm | 0.007273 | 1.244 | CR1 | Alzheimer's disease |
| rs3818361 | Loose body in joint | 0.008381 | 0.1494 | CR1 | Alzheimer's disease |
| rs3818361 | Other abnormality of urination | 0.002216 | 1.294 | CR1 | Alzheimer's disease |
| rs3818361 | Senile dementia | 0.008335 | 1.273 | CR1 | Alzheimer's disease |
| rs3818361 | Diseases of pancreas | 0.002091 | 1.294 | CR1 | Alzheimer's disease |
| rs3818361 | Shock | 0.0104 | 1.426 | CR1 | Alzheimer's disease |
| rs3818361 | Myopia | 0.007542 | 0.8648 | CR1 | Alzheimer's disease |
| rs3818361 | Dyschromia and Vitiligo | 0.01079 | 1.225 | CR1 | Alzheimer's disease |
| rs3818361 | Urinary obstruction | 0.002122 | 1.556 | CR1 | Alzheimer's disease |
| rs385893 | Genu valgum or varum (acquired) | 0.007622 | 0.7002 | AK3 | Platelet counts |
| rs385893 | Hirsutism | 0.007201 | 1.664 | AK3 | Platelet counts |
| rs385893 | Other disorders of metabolic, endocrine, immunity disorders | 0.009217 | 1.892 | AK3 | Platelet counts |
| rs385893 | Hypermetropia | 0.007591 | 1.133 | AK3 | Platelet counts |
| rs385893 | Cyst or abscess of Bartholin's gland | 0.009205 | 1.966 | AK3 | Platelet counts |
| rs385893 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.008267 | 1.305 | AK3 | Platelet counts |
| rs385893 | Polyarthropathy or polyarthritis involving multiple sites NOS | 0.002512 | 0.5722 | AK3 | Platelet counts |
| rs385893 | Astigmatism | 0.009969 | 1.123 | AK3 | Platelet counts |
| rs385893 | Herpes zoster with nervous system complications | 0.009865 | 0.6659 | AK3 | Platelet counts |
| rs385893 | Myopia | 0.004188 | 1.131 | AK3 | Platelet counts |
| rs385893 | Symptoms of the muscles | 0.001289 | 0.7649 | AK3 | Platelet counts |
| rs385893 | Cervical cancer and dysplasia | 0.005091 | 1.299 | AK3 | Platelet counts |
| rs385893 | Chronic ulcer of unspecified site | 0.00156 | 1.33 | AK3 | Platelet counts |
| rs385893 | Miscarriage; stillbirth | 0.006612 | 1.851 | AK3 | Platelet counts |
| rs385893 | Unspecified polyarthropathy or polyarthritis | 0.003784 | 0.643 | AK3 | Platelet counts |
| rs385893 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.005694 | 0.4159 | AK3 | Platelet counts |
| rs3885683 | Atrial fibrillation & flutter | 0.0102 | 1.178 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Multiple myeloma | 0.008602 | 1.713 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Personal history of allergy to medicinal agents | 0.006094 | 0.6684 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Other disorders of thyroid | 0.007556 | 0.6174 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Microscopic hematuria | 0.0008606 | 1.846 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Fracture of radius and ulna | 0.004002 | 1.277 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Vascular disorders of penis | 0.001506 | 2.79 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Cardiac defibrillator in situ | 0.01032 | 1.558 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Chronic pancreatitis | 0.008298 | 1.813 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Hemorrhage NOS | 0.005955 | 1.871 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Diseases of pancreas | 0.005878 | 1.307 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Acute pancreatitis | 0.004662 | 1.413 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Dysmenorrhea | 0.005266 | 1.755 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Carbuncle and furuncle | 0.004173 | 1.696 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Paroxysmal ventricular tachycardia | 0.007333 | 1.391 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Dental caries | 0.01001 | 1.268 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3885683 | Paroxysmal tachycardia, unspecified | 0.01149 | 1.26 | DLG2 | Monocyte chemoattractant protein-1 |
| rs3923809 | Traumatic arthropathy | 0.003637 | 1.693 | BTBD9 | Restless legs syndrome |
| rs3923809 | Malignant neoplasm of ovary | 0.002316 | 1.77 | BTBD9 | Restless legs syndrome |
| rs3923809 | Chronic pancreatitis | 0.004237 | 0.515 | BTBD9 | Restless legs syndrome |
| rs3923809 | Extrapyramidal disease and abnormal movement disorders | 0.001653 | 0.806 | BTBD9 | Restless legs syndrome |
| rs3923809 | Mood disorders | 0.005768 | 0.9041 | BTBD9 | Restless legs syndrome |
| rs3923809 | Adverse drug events and drug allergies | 0.004887 | 0.8368 | BTBD9 | Restless legs syndrome |
| rs3923809 | Other alveolar and parietoalveolar pneumonopathy | 9.832e-05 | 2.022 | BTBD9 | Restless legs syndrome |
| rs3923809 | Nonrheumatic aortic valve disorders | 0.003677 | 1.179 | BTBD9 | Restless legs syndrome |
| rs3923809 | Acute bronchospasm | 0.006919 | 2.156 | BTBD9 | Restless legs syndrome |
| rs3923809 | Other diseases of the teeth and supporting structures | 0.005914 | 0.7774 | BTBD9 | Restless legs syndrome |
| rs3923809 | Other disorders of biliary tract | 0.001921 | 0.5641 | BTBD9 | Restless legs syndrome |
| rs3923809 | Incisional hernia | 0.005495 | 1.314 | BTBD9 | Restless legs syndrome |
| rs3923809 | Idiopathic fibrosing alveolitis | 0.003053 | 1.916 | BTBD9 | Restless legs syndrome |
| rs3923809 | Iron deficiency anemias NOS | 0.01012 | 0.8805 | BTBD9 | Restless legs syndrome |
| rs3923809 | Depression | 0.006716 | 0.9039 | BTBD9 | Restless legs syndrome |
| rs398652 | Neoplasm of unspecified nature of digestive system | 0.01009 | 1.52 | PELI2 | Telomere length |
| rs398652 | Osteoarthrosis NOS | 0.01092 | 1.124 | PELI2 | Telomere length |
| rs398652 | Varicose veins | 0.0001513 | 1.304 | PELI2 | Telomere length |
| rs398652 | Postnasal drip | 0.009507 | 1.893 | PELI2 | Telomere length |
| rs398652 | Disorders of the autonomic nervous system | 0.009562 | 1.389 | PELI2 | Telomere length |
| rs398652 | Osteoarthritis; localized | 0.007789 | 1.17 | PELI2 | Telomere length |
| rs398652 | Osteoarthrosis; localized, primary | 0.001516 | 1.384 | PELI2 | Telomere length |
| rs398652 | Varicose veins of lower extremity | 0.001043 | 1.272 | PELI2 | Telomere length |
| rs398652 | Subjective visual disturbances | 0.001818 | 1.334 | PELI2 | Telomere length |
| rs398652 | Hallux valgus (Bunion) | 0.008305 | 1.248 | PELI2 | Telomere length |
| rs398652 | Anomalies of jaw size/symmetry | 0.007244 | 2.185 | PELI2 | Telomere length |
| rs398652 | Congenital anomalies of great vessels | 0.008167 | 2.104 | PELI2 | Telomere length |
| rs398652 | Second degree AV block | 0.007397 | 1.682 | PELI2 | Telomere length |
| rs4086116 | Elevated prostate specific antigen | 0.01086 | 0.8102 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Corneal degenerations | 0.005327 | 0.6504 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Other specified disorders of pancreatic internal secretion | 0.002662 | 0.3318 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Infection/inflammation of internal prosthetic device, implant or graft | 0.002968 | 1.36 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Open wound of lip and mouth | 0.007902 | 1.805 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Nervous system congenital anomalies | 0.007939 | 1.475 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Barrett's esophagus | 0.002944 | 1.488 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Leukoplakia of oral mucosa | 0.00545 | 1.899 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Sprains and strains | 0.007189 | 1.135 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Acute reaction to stress | 0.0001331 | 1.45 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Other disorders of pancreatic internal secretion | 0.002217 | 0.3254 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Calcaneal spur; Exostosis NOS | 0.006637 | 1.317 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Anal and rectal conditions | 0.004318 | 1.188 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Spontaneous ecchymoses | 0.0009734 | 1.892 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Congenital deformities of feet | 0.01033 | 1.357 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Atrial flutter | 0.00986 | 1.262 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Functional disorders of bladder | 0.008576 | 1.346 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Hypotension NOS | 0.006367 | 1.224 | CYP2C9 | Warfarin maintenance dose |
| rs4086116 | Shock | 0.009594 | 1.429 | CYP2C9 | Warfarin maintenance dose |
| rs4132509 | Osteoarthrosis NOS | 0.002842 | 0.8824 | AKT3 | RR interval (heart rate) |
| rs4132509 | Inflammatory spondylopathies | 0.007822 | 0.5224 | AKT3 | RR interval (heart rate) |
| rs4132509 | Other arthropathies | 0.006479 | 0.862 | AKT3 | RR interval (heart rate) |
| rs4132509 | Sacroiliitis NEC | 0.00832 | 0.3522 | AKT3 | RR interval (heart rate) |
| rs4132509 | Viral Enteritis | 0.001015 | 1.702 | AKT3 | RR interval (heart rate) |
| rs4132509 | Hemiplegia | 0.0073 | 0.6584 | AKT3 | RR interval (heart rate) |
| rs4132509 | Benign neoplasm of eye | 0.007167 | 1.294 | AKT3 | RR interval (heart rate) |
| rs4132509 | Impetigo | 0.002789 | 1.714 | AKT3 | RR interval (heart rate) |
| rs4132509 | Osteoarthrosis | 0.007005 | 0.9004 | AKT3 | RR interval (heart rate) |
| rs4132509 | Bursitis | 0.01019 | 0.802 | AKT3 | RR interval (heart rate) |
| rs4132509 | Joint/ligament sprain | 0.008064 | 0.6881 | AKT3 | RR interval (heart rate) |
| rs4132509 | Fracture of humerus | 0.006998 | 0.7322 | AKT3 | RR interval (heart rate) |
| rs4141463 | Acquired deformities of limbs | 0.003372 | 0.8027 | MACROD2 | Autism |
| rs4141463 | Myasthenia gravis | 0.00527 | 0.4382 | MACROD2 | Autism |
| rs4141463 | Mastoiditis | 0.001649 | 2.349 | MACROD2 | Autism |
| rs4141463 | Disorders of the autonomic nervous system | 0.004452 | 1.321 | MACROD2 | Autism |
| rs4141463 | Chronic sinusitis | 0.009532 | 0.8955 | MACROD2 | Autism |
| rs4141463 | Other specified disorders of liver | 0.009817 | 0.7605 | MACROD2 | Autism |
| rs4141463 | Atherosclerosis of the extremities | 0.008411 | 1.138 | MACROD2 | Autism |
| rs4141463 | Gout | 0.007836 | 0.8636 | MACROD2 | Autism |
| rs4141463 | Muscular wasting and disuse atrophy | 0.006082 | 0.5955 | MACROD2 | Autism |
| rs4141463 | Anomalies of tooth position/malocclusion | 0.003148 | 1.732 | MACROD2 | Autism |
| rs4141463 | Muscle weakness | 0.007046 | 0.7642 | MACROD2 | Autism |
| rs4141463 | Sulfonamides | 0.001797 | 0.7559 | MACROD2 | Autism |
| rs4141463 | Poisoning by other anti-infectives | 0.005433 | 0.8031 | MACROD2 | Autism |
| rs4141463 | Thyroiditis | 0.0104 | 0.7432 | MACROD2 | Autism |
| rs4141463 | Pulmonary embolism and infarction | 0.007813 | 0.8006 | MACROD2 | Autism |
| rs4141463 | Streptococcus infection | 0.00533 | 0.7323 | MACROD2 | Autism |
| rs4148441 | Diseases of nail | 0.001539 | 0.7383 | ABCC4 | Platelet counts |
| rs4148441 | Other specified diseases of nail | 0.001319 | 0.7283 | ABCC4 | Platelet counts |
| rs4148441 | Other congenital anomalies | 0.007841 | 2.099 | ABCC4 | Platelet counts |
| rs4148441 | Phlebitis and thrombophlebitis of lower extremities | 0.008666 | 0.6818 | ABCC4 | Platelet counts |
| rs4148441 | Anal and rectal polyp | 0.003254 | 1.457 | ABCC4 | Platelet counts |
| rs4148441 | Osteoarthrosis NOS | 0.0108 | 0.8662 | ABCC4 | Platelet counts |
| rs4148441 | Synoviopathy | 0.01144 | 1.511 | ABCC4 | Platelet counts |
| rs4148441 | Primary angle-closure glaucoma | 0.01033 | 1.374 | ABCC4 | Platelet counts |
| rs4148441 | Polyp of corpus uteri | 0.006863 | 1.608 | ABCC4 | Platelet counts |
| rs4148441 | Nonspecific findings on examination of blood | 5.24e-05 | 0.3614 | ABCC4 | Platelet counts |
| rs4148441 | Acute sinusitis | 0.006261 | 0.7828 | ABCC4 | Platelet counts |
| rs4148441 | Chronic ulcer of skin | 0.008226 | 0.804 | ABCC4 | Platelet counts |
| rs4148441 | Ingrowing nail | 0.005147 | 0.7474 | ABCC4 | Platelet counts |
| rs4148441 | Phlebitis and thrombophlebitis | 0.009332 | 0.7187 | ABCC4 | Platelet counts |
| rs4148441 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.00112 | 2.864 | ABCC4 | Platelet counts |
| rs4148441 | Bone cancer | 0.003345 | 2.09 | ABCC4 | Platelet counts |
| rs4149268 | Acquired hypothyroidism | 0.001073 | 0.4262 | ABCA1 | HDL Cholesterol |
| rs4149268 | Ovarian cyst | 0.004149 | 0.7426 | ABCA1 | HDL Cholesterol |
| rs4149268 | Facial nerve disorders | 0.004807 | 1.412 | ABCA1 | HDL Cholesterol |
| rs4149268 | Light-headedness and vertigo | 0.003644 | 0.901 | ABCA1 | HDL Cholesterol |
| rs4149268 | Chondrocalcinosis | 0.005723 | 1.369 | ABCA1 | HDL Cholesterol |
| rs4149268 | Diverticulum of esophagus, acquired | 0.003017 | 0.4276 | ABCA1 | HDL Cholesterol |
| rs4149268 | Crystal arthropathies | 0.006279 | 1.36 | ABCA1 | HDL Cholesterol |
| rs4149268 | Keloid scar | 0.0007647 | 1.866 | ABCA1 | HDL Cholesterol |
| rs4149268 | Dysmenorrhea | 0.00596 | 0.6453 | ABCA1 | HDL Cholesterol |
| rs4149268 | Congenital anomalies of urinary system | 0.003134 | 1.505 | ABCA1 | HDL Cholesterol |
| rs4149268 | Delirium dementia and amnestic disorders | 0.00773 | 1.13 | ABCA1 | HDL Cholesterol |
| rs4149268 | Cancer of other female genital organs | 0.001357 | 0.6036 | ABCA1 | HDL Cholesterol |
| rs4149268 | Vertiginous syndromes and other disorders of vestibular system | 0.003112 | 0.9036 | ABCA1 | HDL Cholesterol |
| rs4149268 | Myeloid leukemia | 0.006614 | 1.816 | ABCA1 | HDL Cholesterol |
| rs4149268 | Labyrinthitis | 0.0001292 | 0.6121 | ABCA1 | HDL Cholesterol |
| rs4149268 | Sensorineural hearing loss | 0.002958 | 0.8916 | ABCA1 | HDL Cholesterol |
| rs4149268 | Other disorders of eyelids | 0.0111 | 0.8787 | ABCA1 | HDL Cholesterol |
| rs4149268 | Benign neoplasm of bone and articular cartilage | 0.001179 | 0.4683 | ABCA1 | HDL Cholesterol |
| rs4149268 | Ovarian cancer | 0.004677 | 0.5964 | ABCA1 | HDL Cholesterol |
| rs4149268 | Cardiac defibrillator in situ | 0.005247 | 1.454 | ABCA1 | HDL Cholesterol |
| rs4149268 | Constipation | 0.00143 | 1.167 | ABCA1 | HDL Cholesterol |
| rs4149268 | Late effects of cerebrovascular disease | 0.002325 | 0.8271 | ABCA1 | HDL Cholesterol |
| rs4149268 | Malignant neoplasm of ovary | 0.00919 | 0.5716 | ABCA1 | HDL Cholesterol |
| rs4149268 | Symptoms associated with female genital organs | 0.004418 | 0.8242 | ABCA1 | HDL Cholesterol |
| rs4233356 | Internal derangement of knee | 0.009669 | 0.8714 | DUSP23 | Interstitial lung disease |
| rs4233356 | Lymphosarcoma | 0.002898 | 2.215 | DUSP23 | Interstitial lung disease |
| rs4233356 | Benign neoplasm of other parts of digestive system | 0.002006 | 0.707 | DUSP23 | Interstitial lung disease |
| rs4233356 | Pneumococcal pneumonia | 0.005761 | 1.842 | DUSP23 | Interstitial lung disease |
| rs4233356 | Sicca syndrome | 0.0001718 | 1.739 | DUSP23 | Interstitial lung disease |
| rs4233356 | Keratoconjunctivitis, noninfectious | 0.008908 | 0.662 | DUSP23 | Interstitial lung disease |
| rs4233356 | Postmenopausal bleeding | 0.006331 | 1.234 | DUSP23 | Interstitial lung disease |
| rs4233356 | Urethral stricture (not specified as infectious) | 0.004709 | 1.449 | DUSP23 | Interstitial lung disease |
| rs4233356 | Menopausal & postmenopausal disorders | 0.005933 | 1.138 | DUSP23 | Interstitial lung disease |
| rs4233356 | Keratoconjunctivitis sicca | 0.002035 | 0.5218 | DUSP23 | Interstitial lung disease |
| rs4238010 | stress incontinence, female | 0.001716 | 1.309 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Pituitary hypofunction | 0.00251 | 2.175 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Chronic hepatitis | 0.01041 | 1.9 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Premature beats | 0.008158 | 1.258 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Dermatophytosis of the body | 0.005924 | 1.483 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Alcohol-related disorders | 0.008517 | 1.265 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Benign neoplasm of respiratory and intrathoracic organs | 0.004237 | 1.998 | CCND2 | Major depressive disorder (recurrent) |
| rs4238010 | Bladder neck obstruction | 0.001209 | 1.451 | CCND2 | Major depressive disorder (recurrent) |
| rs4295627 | Speech and language disorder | 0.004791 | 1.512 | CCDC26 | Glioma |
| rs4295627 | Benign neoplasm of colon | 0.007497 | 1.117 | CCDC26 | Glioma |
| rs4295627 | Nephritis & nephropathy | 0.0007761 | 1.904 | CCDC26 | Glioma |
| rs4295627 | Seborrhea | 0.008535 | 1.96 | CCDC26 | Glioma |
| rs4295627 | Acute sinusitis | 0.00667 | 1.183 | CCDC26 | Glioma |
| rs4295627 | Cardiac arrest & ventricular fibrillation | 0.01093 | 0.6101 | CCDC26 | Glioma |
| rs4295627 | Fluid overload | 0.006308 | 1.335 | CCDC26 | Glioma |
| rs4295627 | Paroxysmal tachycardia, unspecified | 0.007101 | 0.7831 | CCDC26 | Glioma |
| rs4295627 | Diseases of hair and hair follicles | 0.001939 | 1.312 | CCDC26 | Glioma |
| rs4295627 | Dysphagia | 0.009846 | 1.151 | CCDC26 | Glioma |
| rs4295627 | Diseases of the tongue | 0.001773 | 1.56 | CCDC26 | Glioma |
| rs4295627 | Aphasia/speech disturbance | 0.01028 | 1.271 | CCDC26 | Glioma |
| rs4295627 | Type 1 diabetic peripheral circulatory disorders | 0.00878 | 1.991 | CCDC26 | Glioma |
| rs4295627 | Intracerebral hemorrhage | 0.006102 | 1.698 | CCDC26 | Glioma |
| rs4295627 | Calculus of kidney | 0.006116 | 1.219 | CCDC26 | Glioma |
| rs4295627 | Bacterial enteritis | 0.01019 | 1.368 | CCDC26 | Glioma |
| rs4295627 | Neurological disorders due to brain damage | 0.01065 | 1.162 | CCDC26 | Glioma |
| rs4295627 | Spondylosis with myelopathy | 0.008389 | 0.6187 | CCDC26 | Glioma |
| rs4295627 | Noninfectious gastroenteritis | 0.005909 | 1.206 | CCDC26 | Glioma |
| rs4295627 | Urinary calculus | 0.002658 | 1.211 | CCDC26 | Glioma |
| rs4299376 | Cholelithiasis | 0.0002329 | 0.8246 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Malunion fracture | 0.0006441 | 1.563 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Open wounds of extremities | 0.005969 | 1.126 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Meniere's disease | 0.004909 | 1.663 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Constipation | 0.006202 | 0.8683 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Cellulitis and abscess of hand/fingers | 0.005287 | 0.8232 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Phobia | 0.001748 | 0.2786 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Cholelithiasis and cholecystitis | 6.913e-05 | 0.8227 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Balanoposthitis | 0.00594 | 1.693 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Cancer within the respiratory system | 0.005354 | 0.7835 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Cholelithiasis with other cholecystitis | 0.0004307 | 0.6828 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Calculus of bile duct | 0.005144 | 0.7002 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Hyperlipidemia | 0.009822 | 1.094 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Pulmonary embolism and infarction | 0.002084 | 0.7515 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Secondary malignant neoplasm | 0.001148 | 0.8233 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Contracture of joint | 0.002715 | 1.452 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | pulmonary heart disease | 0.004486 | 0.8438 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Lung cancer | 0.004026 | 0.7738 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Fracture of hand or wrist | 0.005193 | 1.187 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Mammographic microcalcification | 0.00697 | 0.5875 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4299376 | Disorders of lipoid metabolism | 0.008687 | 1.095 | ABCG8 | Total Cholesterol, LDL Cholesterol |
| rs4430796 | Other immunological findings | 0.002555 | 0.729 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Congenital musculoskeletal deformities of spine | 0.003467 | 0.6793 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Nerve root and plexus disorders | 0.01004 | 1.297 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Myocardial infarction | 0.008184 | 1.127 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Back & neck sprains | 0.002733 | 0.8789 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Immune disorders | 0.0003148 | 0.733 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Other disorders of peritoneum | 0.00683 | 0.6866 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Internal derangement of knee | 0.01133 | 0.8784 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Symptoms involving head and neck | 0.01008 | 0.8452 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Drug-resistant infection | 0.01125 | 0.7358 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Lipoid metabolism disorder NOS | 0.007868 | 0.7879 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Periostitis | 0.001938 | 2.003 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Other acquired musculoskeletal deformity | 0.004052 | 0.7947 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Pain, swelling or discharge of eye | 0.0009046 | 0.6748 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Carbuncle and furuncle | 0.01113 | 0.6771 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Prostate cancer | 0.001525 | 0.8192 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Diplopia and disorders of binocular vision | 0.003212 | 1.322 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs4430796 | Bladder neck obstruction | 0.004413 | 0.7792 | HNF1B | Prostate-specific antigen levels (men w/out prostate cancer), Endometrial cancer, Prostate cancer, Type 2 diabetes |
| rs443198 | Aneurysm of iliac artery | 0.00402 | 1.777 | NOTCH4 | Systemic sclerosis |
| rs443198 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.006928 | 1.181 | NOTCH4 | Systemic sclerosis |
| rs443198 | Chronic prostatitis | 0.00682 | 0.6266 | NOTCH4 | Systemic sclerosis |
| rs443198 | Abnormality of red blood cells | 0.01148 | 0.4664 | NOTCH4 | Systemic sclerosis |
| rs443198 | Liver replaced by transplant | 0.002693 | 2.247 | NOTCH4 | Systemic sclerosis |
| rs443198 | Acute tonsillitis | 0.008783 | 0.6178 | NOTCH4 | Systemic sclerosis |
| rs443198 | Aneurysm of artery of lower extremity | 0.001994 | 1.639 | NOTCH4 | Systemic sclerosis |
| rs443198 | Cervicocranial/Cervicobrachial syndrome | 0.005079 | 0.7776 | NOTCH4 | Systemic sclerosis |
| rs443198 | Celiac or tropical sprue | 1.197e-05 | 2.566 | NOTCH4 | Systemic sclerosis |
| rs443198 | Stress fracture | 0.004655 | 1.909 | NOTCH4 | Systemic sclerosis |
| rs443198 | Hemorrhage of gastrointestinal tract | 0.01076 | 1.163 | NOTCH4 | Systemic sclerosis |
| rs443198 | Inflammatory diseases of prostate | 0.002448 | 0.7807 | NOTCH4 | Systemic sclerosis |
| rs443198 | Cellulitis and abscess of face | 0.003281 | 0.6932 | NOTCH4 | Systemic sclerosis |
| rs443198 | Abdominal hernia | 0.002258 | 1.11 | NOTCH4 | Systemic sclerosis |
| rs443198 | Abnormal tumor markers, elevated CEA or CA 125 | 0.0007364 | 2.424 | NOTCH4 | Systemic sclerosis |
| rs443198 | Dental caries | 0.01106 | 1.185 | NOTCH4 | Systemic sclerosis |
| rs443198 | Mitral valve stenosis and/or aortic valve stenosis | 0.0007132 | 1.295 | NOTCH4 | Systemic sclerosis |
| rs443198 | Other benign neoplasm of connective and other soft tissue | 0.005554 | 1.49 | NOTCH4 | Systemic sclerosis |
| rs443198 | Stomatitis and mucositis | 0.01003 | 0.7149 | NOTCH4 | Systemic sclerosis |
| rs443198 | Infertility, female | 0.01049 | 0.5679 | NOTCH4 | Systemic sclerosis |
| rs443198 | Macular degeneration, dry | 0.0004992 | 1.312 | NOTCH4 | Systemic sclerosis |
| rs443198 | Atherosclerosis of the extremities | 0.01143 | 1.134 | NOTCH4 | Systemic sclerosis |
| rs443198 | Celiac disease | 3.545e-05 | 2.478 | NOTCH4 | Systemic sclerosis |
| rs443198 | Prostatitis | 0.001497 | 0.7271 | NOTCH4 | Systemic sclerosis |
| rs443198 | Lymphadenitis | 0.009123 | 1.173 | NOTCH4 | Systemic sclerosis |
| rs443198 | Keratitis | 0.001102 | 0.7097 | NOTCH4 | Systemic sclerosis |
| rs443198 | Stiffness of joint | 0.004576 | 1.212 | NOTCH4 | Systemic sclerosis |
| rs4444235 | Convulsions | 0.01116 | 1.189 | BMP4 | Colorectal cancer |
| rs4444235 | Cerebral edema and compression of brain | 0.00734 | 1.882 | BMP4 | Colorectal cancer |
| rs4444235 | Epilepsy, recurrent seizures, convulsions | 0.007482 | 1.189 | BMP4 | Colorectal cancer |
| rs4444235 | Keratitis, infectious | 0.00267 | 1.449 | BMP4 | Colorectal cancer |
| rs4444235 | Other conditions of brain | 0.0009686 | 1.396 | BMP4 | Colorectal cancer |
| rs4444235 | Nerve root lesions | 0.005469 | 0.6018 | BMP4 | Colorectal cancer |
| rs4444235 | Fracture of pelvis | 0.01068 | 1.316 | BMP4 | Colorectal cancer |
| rs4444235 | Acute reaction to stress | 0.003858 | 0.7808 | BMP4 | Colorectal cancer |
| rs4444235 | Other disorders of prostate | 0.004617 | 0.7471 | BMP4 | Colorectal cancer |
| rs4444235 | Ulceration of the lower GI tract | 0.004628 | 1.57 | BMP4 | Colorectal cancer |
| rs4444235 | Viral Enteritis | 0.0043 | 0.6516 | BMP4 | Colorectal cancer |
| rs4444235 | Superficial cellulitis and abscess | 0.001866 | 1.114 | BMP4 | Colorectal cancer |
| rs4444235 | Temporomandibular joint disorder NOS | 0.0008509 | 0.538 | BMP4 | Colorectal cancer |
| rs4444235 | Ileostomy status | 0.005513 | 1.623 | BMP4 | Colorectal cancer |
| rs4444235 | Anal and rectal conditions | 0.0005056 | 1.187 | BMP4 | Colorectal cancer |
| rs445 | Polymyalgia Rheumatica | 0.008885 | 0.6415 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Arthropathy associated with infections | 0.008869 | 1.757 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Keratoderma, acquired | 0.002489 | 0.7419 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Photodermatitis & sunburn | 0.005656 | 0.7454 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Acne | 0.001394 | 1.526 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Cerebrovascular disease | 0.006187 | 1.157 | CDK6 | White blood cell count, Neutrophil count |
| rs445 | Secondary hyperparathyroidism (of renal origin) | 0.006204 | 1.57 | CDK6 | White blood cell count, Neutrophil count |
| rs4516970 | Sexual and gender identity disorders | 0.005419 | 2.213 | WTAP | Serum ferritin |
| rs4516970 | Myocardial infarction | 0.003639 | 1.478 | WTAP | Serum ferritin |
| rs4516970 | Precordial pain | 0.001992 | 2.148 | WTAP | Serum ferritin |
| rs4516970 | Coronary atherosclerosis | 0.01031 | 1.297 | WTAP | Serum ferritin |
| rs4516970 | Other acute and subacute forms of ischemic heart disease | 0.0009088 | 4.244 | WTAP | Serum ferritin |
| rs4516970 | Congenital cataract and lens anomalies | 0.001265 | 3.989 | WTAP | Serum ferritin |
| rs4516970 | Occlusion of cerebral arteries | 0.00968 | 1.558 | WTAP | Serum ferritin |
| rs4516970 | Dentofacial anomalies, including malocclusion | 0.006756 | 2.62 | WTAP | Serum ferritin |
| rs4516970 | Degeneration of intervertebral disc | 0.01036 | 1.372 | WTAP | Serum ferritin |
| rs4516970 | Aneurysm of iliac artery | 0.009261 | 3.346 | WTAP | Serum ferritin |
| rs4516970 | Spinal stenosis | 0.003469 | 1.456 | WTAP | Serum ferritin |
| rs4516970 | Other disorders of gallbladder | 0.002492 | 2.862 | WTAP | Serum ferritin |
| rs4516970 | Light-headedness and vertigo | 0.002115 | 1.388 | WTAP | Serum ferritin |
| rs4516970 | Mastodynia | 0.008235 | 1.921 | WTAP | Serum ferritin |
| rs4516970 | Sarcoidosis | 0.002498 | 2.816 | WTAP | Serum ferritin |
| rs4516970 | Spinal stenosis of lumbar region | 0.001692 | 1.553 | WTAP | Serum ferritin |
| rs4516970 | Muscular wasting and disuse atrophy | 0.001319 | 2.859 | WTAP | Serum ferritin |
| rs4516970 | Hypocalcemia | 0.003359 | 2.324 | WTAP | Serum ferritin |
| rs4516970 | Angina pectoris | 0.01047 | 1.438 | WTAP | Serum ferritin |
| rs4516970 | Chronic ischemic heart disease | 0.0001755 | 1.68 | WTAP | Serum ferritin |
| rs4516970 | Disorders of cervical region | 0.001669 | 2.25 | WTAP | Serum ferritin |
| rs4516970 | Disorders of liver | 0.007416 | 1.353 | WTAP | Serum ferritin |
| rs4516970 | Congenital anomalies of peripheral vascular system | 0.001627 | 3.377 | WTAP | Serum ferritin |
| rs4516970 | Postmenopausal hormone replacement | 0.00153 | 2.406 | WTAP | Serum ferritin |
| rs4516970 | Ischemic Heart Disease | 0.007942 | 1.291 | WTAP | Serum ferritin |
| rs4528684 | Primary pulmonary hypertension | 0.007917 | 0.2596 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Allergy/adverse effect of penicillin | 0.01089 | 0.688 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Noninflammatory disorders of vulva and perineum | 0.00715 | 1.754 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Acute periodontitis | 0.01109 | 0.516 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Pervasive developmental disorders | 0.0005345 | 2.095 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Other hypertensive complications | 0.006924 | 0.6281 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Type 2 diabetic peripheral circulatory disorders | 0.008459 | 0.4941 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Attention deficit hyperactivity disorder | 0.002645 | 2.108 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Dementia with cerebral degenerations | 0.008054 | 1.811 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Infection/inflammation of internal prosthetic device, implant or graft | 0.006211 | 0.5943 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Hypertrophy of female genital organs | 0.001268 | 2.22 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Cyst or abscess of Bartholin's gland | 0.002311 | 2.52 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Coagulation defects | 0.007026 | 0.8437 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Poisoning by antibiotics | 0.01142 | 0.7258 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Uterine/Uterovaginal prolapse | 0.001519 | 1.54 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Excessive or frequent menstruation | 0.006501 | 1.525 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Peptic ulcer | 0.003065 | 0.7312 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Chronic renal failure | 0.007049 | 0.8182 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.0007754 | 0.7993 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Phlebitis and thrombophlebitis | 0.007079 | 0.7126 | LPHN1 | Mortality among heart failure patients |
| rs4528684 | Curvature of spine | 0.005877 | 0.6418 | LPHN1 | Mortality among heart failure patients |
| rs4537545 | Dystrophy of female genital tract | 0.003714 | 2.073 | IL6R | C-reactive protein |
| rs4537545 | Renal cell carcinoma | 0.01129 | 0.7484 | IL6R | C-reactive protein |
| rs4537545 | Vitamin B12 deficiency anemia | 0.001118 | 1.662 | IL6R | C-reactive protein |
| rs4537545 | Cancer of the upper aerodigestive tract | 0.007393 | 1.366 | IL6R | C-reactive protein |
| rs4537545 | Malignant neoplasm of renal pelvis | 0.005581 | 0.391 | IL6R | C-reactive protein |
| rs4537545 | Dementia with cerebral degenerations | 0.005672 | 1.552 | IL6R | C-reactive protein |
| rs4537545 | Somatoform disorder | 0.00312 | 1.378 | IL6R | C-reactive protein |
| rs4537545 | Diseases of the tongue | 0.005594 | 1.406 | IL6R | C-reactive protein |
| rs4537545 | Bladder cancer | 0.003144 | 1.297 | IL6R | C-reactive protein |
| rs4537545 | Constipation | 0.001219 | 1.166 | IL6R | C-reactive protein |
| rs4537545 | Polycythemia vera, secondary | 0.001701 | 1.72 | IL6R | C-reactive protein |
| rs4537545 | Arthropathy NOS | 0.004482 | 1.189 | IL6R | C-reactive protein |
| rs4537545 | Iron deficiency anemia secondary to blood loss | 0.003672 | 1.35 | IL6R | C-reactive protein |
| rs4537545 | Cancer of larynx | 0.004356 | 1.496 | IL6R | C-reactive protein |
| rs4537545 | Psychogenic and somatoform disorders | 0.007786 | 1.258 | IL6R | C-reactive protein |
| rs4537545 | Bipolar | 0.01095 | 1.363 | IL6R | C-reactive protein |
| rs4537545 | Other specified intestinal malabsorption | 0.005915 | 1.709 | IL6R | C-reactive protein |
| rs4537545 | Morbid obesity | 0.004567 | 1.173 | IL6R | C-reactive protein |
| rs4537545 | Keloid scar | 0.00797 | 0.5823 | IL6R | C-reactive protein |
| rs4537545 | Cerebral edema and compression of brain | 0.003606 | 1.943 | IL6R | C-reactive protein |
| rs4537545 | Disease of capillaries | 0.007804 | 0.7349 | IL6R | C-reactive protein |
| rs454305 | Postmenopausal bleeding | 0.003858 | 1.251 | TGFA | Neutrophil count |
| rs454305 | Nerve plexus lesions | 0.008167 | 1.424 | TGFA | Neutrophil count |
| rs454305 | Epistaxis or throat hemorrhage | 0.005983 | 0.8089 | TGFA | Neutrophil count |
| rs454305 | Hypertensive heart disease | 0.005534 | 1.344 | TGFA | Neutrophil count |
| rs454305 | Valvular heart disease/ heart chambers | 0.009776 | 0.5184 | TGFA | Neutrophil count |
| rs454305 | Sicca syndrome | 0.003847 | 1.526 | TGFA | Neutrophil count |
| rs454305 | Subarachnoid hemorrhage (injury) | 0.005634 | 2.133 | TGFA | Neutrophil count |
| rs454305 | Other biliary tract disease | 0.007369 | 1.269 | TGFA | Neutrophil count |
| rs454305 | Stomach cancer | 0.0003054 | 2.052 | TGFA | Neutrophil count |
| rs454305 | Other disorders of gallbladder | 0.005606 | 1.606 | TGFA | Neutrophil count |
| rs454305 | Deep vein thrombosis | 0.008907 | 1.267 | TGFA | Neutrophil count |
| rs454305 | Abnormal findings on exam of gastrointestinal tract/abdominal area | 0.01089 | 1.33 | TGFA | Neutrophil count |
| rs454305 | Peritoneal or intestinal adhesions | 0.001483 | 1.734 | TGFA | Neutrophil count |
| rs454305 | Functional disorders of bladder | 0.001488 | 1.373 | TGFA | Neutrophil count |
| rs454305 | Occlusion of cerebral arteries, with cerebral infarction | 0.01011 | 1.477 | TGFA | Neutrophil count |
| rs454305 | Disorders of other cranial nerves | 0.008775 | 0.7697 | TGFA | Neutrophil count |
| rs454305 | Intestinal infection due to C. difficile | 0.009541 | 1.364 | TGFA | Neutrophil count |
| rs454305 | Vascular insufficiency of intestine | 0.007803 | 1.41 | TGFA | Neutrophil count |
| rs454305 | Corneal degenerations | 0.006039 | 1.366 | TGFA | Neutrophil count |
| rs454305 | Trigeminal nerve disorders | 0.003451 | 0.6281 | TGFA | Neutrophil count |
| rs454305 | Premature menopause and other ovarian failure | 0.00469 | 1.929 | TGFA | Neutrophil count |
| rs454305 | Hyperosmolality and/or hypernatremia | 0.001888 | 1.552 | TGFA | Neutrophil count |
| rs4649203 | Cardiomegaly | 0.009264 | 1.162 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Renal colic | 0.004719 | 0.4834 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Lupus erythematosus | 0.01054 | 0.4327 | IL28RA | Psoriasis vulgaris |
| rs4649203 | stress incontinence, female | 0.002176 | 1.23 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Syncope and collapse | 0.004206 | 1.139 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Cyst and pseudocyst of pancreas | 0.007696 | 1.617 | IL28RA | Psoriasis vulgaris |
| rs4649203 | Congenital musculoskeletal deformities of spine | 0.009175 | 1.424 | IL28RA | Psoriasis vulgaris |
| rs4650608 | Lack of normal physiological development | 0.01129 | 0.7225 | PTGFR | Bipolar disorder |
| rs4650608 | Type 2 diabetes | 0.007024 | 0.9145 | PTGFR | Bipolar disorder |
| rs4650608 | Corneal dystrophy | 0.008343 | 1.306 | PTGFR | Bipolar disorder |
| rs4650608 | Dysthymic disorder | 0.005749 | 0.84 | PTGFR | Bipolar disorder |
| rs4650608 | Bladder neck obstruction | 0.001552 | 1.325 | PTGFR | Bipolar disorder |
| rs4650608 | Gastroparesis | 0.00357 | 0.4927 | PTGFR | Bipolar disorder |
| rs4650608 | Posttraumatic stress disorder | 0.00633 | 0.5924 | PTGFR | Bipolar disorder |
| rs4650608 | Acid-base balance disorder | 0.009097 | 0.7502 | PTGFR | Bipolar disorder |
| rs4650608 | Diabetes mellitus | 0.01046 | 0.9196 | PTGFR | Bipolar disorder |
| rs4650608 | Genu valgum or varum (acquired) | 0.00286 | 1.484 | PTGFR | Bipolar disorder |
| rs4650608 | Keratoderma, acquired | 0.005149 | 0.8443 | PTGFR | Bipolar disorder |
| rs4650608 | Althete's foot | 0.00278 | 0.7566 | PTGFR | Bipolar disorder |
| rs4650608 | Other specified disorders of breast | 0.0004519 | 1.341 | PTGFR | Bipolar disorder |
| rs4650608 | Labyrinthitis | 0.0002808 | 1.517 | PTGFR | Bipolar disorder |
| rs4650608 | Polyneuropathy in diabetes | 0.0009243 | 0.7915 | PTGFR | Bipolar disorder |
| rs4650608 | Hematemesis | 0.002197 | 0.5246 | PTGFR | Bipolar disorder |
| rs4650608 | Symptoms involving cardiovascular system | 0.006541 | 1.167 | PTGFR | Bipolar disorder |
| rs4650608 | Other abnormal glucose | 0.005284 | 0.8634 | PTGFR | Bipolar disorder |
| rs4650608 | Other disorders of bone and cartilage | 0.001266 | 0.7751 | PTGFR | Bipolar disorder |
| rs4650608 | Type 2 diabetic neuropathy | 0.0111 | 0.8497 | PTGFR | Bipolar disorder |
| rs4650608 | Acidosis | 0.00184 | 0.6584 | PTGFR | Bipolar disorder |
| rs4650608 | Failure to thrive | 0.009219 | 0.6958 | PTGFR | Bipolar disorder |
| rs4656461 | Other hypertrophic and atrophic conditions of skin | 0.00611 | 0.8444 | TMCO1 | Glaucoma |
| rs4656461 | Intestinal obstruction without mention of hernia | 0.007237 | 0.7531 | TMCO1 | Glaucoma |
| rs4656461 | Benign neoplasm of unspecified sites | 0.004004 | 2.433 | TMCO1 | Glaucoma |
| rs4656461 | Paralytic ileus | 0.008707 | 0.6087 | TMCO1 | Glaucoma |
| rs4656461 | Ventral hernia | 0.005013 | 0.6312 | TMCO1 | Glaucoma |
| rs4656461 | Acute pancreatitis | 0.009797 | 1.382 | TMCO1 | Glaucoma |
| rs4656461 | Back pain | 0.007638 | 0.8873 | TMCO1 | Glaucoma |
| rs4656461 | Eating disorder | 0.009317 | 1.811 | TMCO1 | Glaucoma |
| rs4656461 | Heart valve disorders | 0.009751 | 0.8569 | TMCO1 | Glaucoma |
| rs4656461 | Conjunctivitis, noninfectious | 0.003271 | 1.402 | TMCO1 | Glaucoma |
| rs4656461 | Dermatophytosis of the body | 0.009616 | 0.5792 | TMCO1 | Glaucoma |
| rs4656461 | Breast disorder NOS | 0.003761 | 2.651 | TMCO1 | Glaucoma |
| rs4656461 | Noninflammatory disorders of vagina | 0.00707 | 1.487 | TMCO1 | Glaucoma |
| rs4656461 | Heartburn | 0.009822 | 1.502 | TMCO1 | Glaucoma |
| rs4656461 | Ankylosis of joint | 0.004355 | 0.4632 | TMCO1 | Glaucoma |
| rs4656461 | Allergic conjunctivitis | 0.001744 | 1.478 | TMCO1 | Glaucoma |
| rs4656461 | Appendicitis | 0.005743 | 1.574 | TMCO1 | Glaucoma |
| rs4656461 | Cancer of larynx | 0.01065 | 1.604 | TMCO1 | Glaucoma |
| rs4657178 | Degeneration of intervertebral disc | 0.007678 | 1.132 | NOS1AP | QT interval |
| rs4657178 | Elevated prostate specific antigen | 0.005001 | 1.226 | NOS1AP | QT interval |
| rs4657178 | Symptoms involving urinary system | 0.008506 | 1.271 | NOS1AP | QT interval |
| rs4657178 | Disorders of choroid | 0.009449 | 0.7361 | NOS1AP | QT interval |
| rs4657178 | Adverse effects of hormones and synthetic substitutes | 0.008993 | 0.255 | NOS1AP | QT interval |
| rs4657178 | Hallux rigidus | 0.00885 | 1.417 | NOS1AP | QT interval |
| rs4657178 | Septicemia | 0.004198 | 0.8128 | NOS1AP | QT interval |
| rs4657178 | Hypertensive heart disease | 0.0007945 | 1.473 | NOS1AP | QT interval |
| rs4657178 | Malignant neoplasm of ovary | 0.003137 | 0.4375 | NOS1AP | QT interval |
| rs4657178 | Spondylosis with myelopathy | 0.003484 | 1.445 | NOS1AP | QT interval |
| rs4657178 | Cancer of other lymphoid, histiocytic tissue | 0.0009112 | 0.6885 | NOS1AP | QT interval |
| rs4657178 | Ovarian cancer | 0.008385 | 0.5585 | NOS1AP | QT interval |
| rs4657178 | Disaccharide malabsorption | 0.01005 | 1.187 | NOS1AP | QT interval |
| rs4657178 | Non-Hodgkins lymphoma | 0.0003084 | 0.6562 | NOS1AP | QT interval |
| rs4657178 | Lymphosarcoma | 0.002982 | 0.2131 | NOS1AP | QT interval |
| rs4657178 | Hallucinations | 0.001428 | 2.08 | NOS1AP | QT interval |
| rs4676406 | Lump or mass in breast | 0.005704 | 0.8614 | GPR35 | Ulcerative colitis |
| rs4676406 | Aneurysm of other specified artery | 0.005288 | 1.892 | GPR35 | Ulcerative colitis |
| rs4676406 | Open wound of foot except toe(s) alone | 0.003012 | 0.63 | GPR35 | Ulcerative colitis |
| rs4676406 | Nonrheumatic tricuspid valve disorders | 0.007452 | 1.441 | GPR35 | Ulcerative colitis |
| rs4676406 | Labyrinthitis | 0.003291 | 1.402 | GPR35 | Ulcerative colitis |
| rs4676406 | Unspecified monoarthritis | 0.007319 | 1.626 | GPR35 | Ulcerative colitis |
| rs4676406 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.002677 | 0.7998 | GPR35 | Ulcerative colitis |
| rs4676406 | Anomalies of tooth position/malocclusion | 0.005245 | 1.672 | GPR35 | Ulcerative colitis |
| rs4676406 | Right bundle branch block | 0.007062 | 1.281 | GPR35 | Ulcerative colitis |
| rs4676406 | Pruritus and related conditions | 0.009164 | 1.186 | GPR35 | Ulcerative colitis |
| rs4676406 | Late effects of cerebrovascular disease | 0.009645 | 1.166 | GPR35 | Ulcerative colitis |
| rs4676406 | Pneumonitis due to inhalation of food or vomitus | 0.0002181 | 0.6727 | GPR35 | Ulcerative colitis |
| rs4676406 | Chronic prostatitis | 0.002429 | 1.611 | GPR35 | Ulcerative colitis |
| rs4701252 | Fracture of radius and ulna | 0.003816 | 1.248 | CDH12 | Waist circumference |
| rs4701252 | Abdominal aortic aneurysm | 0.005425 | 0.7383 | CDH12 | Waist circumference |
| rs4701252 | Chronic obstructive asthma with exacerbation | 0.005296 | 1.798 | CDH12 | Waist circumference |
| rs4701252 | Aortic aneurysm | 0.003249 | 0.7597 | CDH12 | Waist circumference |
| rs4701252 | Other aneurysm | 0.002689 | 0.7781 | CDH12 | Waist circumference |
| rs4701252 | Behcet's syndrome | 0.006824 | 1.67 | CDH12 | Waist circumference |
| rs4701252 | Agorophobia, social phobia, and panic disorder | 0.006155 | 0.6079 | CDH12 | Waist circumference |
| rs4701252 | Nontoxic multinodular goiter | 0.007647 | 0.7216 | CDH12 | Waist circumference |
| rs4701252 | Osteoporosis, osteopenia, & pathological fractures | 0.006279 | 1.129 | CDH12 | Waist circumference |
| rs4701252 | Nephritis & nephropathy | 0.007313 | 0.429 | CDH12 | Waist circumference |
| rs4701252 | Other immunological findings | 0.008614 | 1.383 | CDH12 | Waist circumference |
| rs4701252 | Polyarthropathy or polyarthritis involving multiple sites NOS | 0.008267 | 0.4335 | CDH12 | Waist circumference |
| rs4701252 | Type 2 diabetic neuropathy | 0.006198 | 0.7977 | CDH12 | Waist circumference |
| rs4701252 | Diseases of lips | 0.008027 | 1.561 | CDH12 | Waist circumference |
| rs4704970 | Personal history of allergy to medicinal agents | 0.005505 | 1.322 | SGCD | Multiple sclerosis |
| rs4704970 | Essential tremor | 0.00653 | 0.6864 | SGCD | Multiple sclerosis |
| rs4704970 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.00792 | 1.231 | SGCD | Multiple sclerosis |
| rs4704970 | Open-angle glaucoma | 0.01046 | 0.8332 | SGCD | Multiple sclerosis |
| rs4704970 | Heart valve replaced | 0.006915 | 1.34 | SGCD | Multiple sclerosis |
| rs4704970 | Valvular heart disease/ heart chambers | 0.01103 | 1.764 | SGCD | Multiple sclerosis |
| rs4704970 | Arthropathy NOS involving multiple sites | 0.008042 | 1.651 | SGCD | Multiple sclerosis |
| rs4704970 | Other acute and subacute forms of ischemic heart disease | 0.01044 | 1.838 | SGCD | Multiple sclerosis |
| rs4704970 | Unspecified local infection of skin and subcutaneous tissue | 0.001281 | 1.373 | SGCD | Multiple sclerosis |
| rs4713693 | Genital prolapse | 0.009546 | 1.157 | HLA-E | Graves' disease |
| rs4713693 | Osteochondropathies | 0.007917 | 0.5109 | HLA-E | Graves' disease |
| rs4713693 | Other hypertrophic and atrophic conditions of skin | 0.0008197 | 1.138 | HLA-E | Graves' disease |
| rs4713693 | Psoriasis & related disorders | 0.00986 | 0.8192 | HLA-E | Graves' disease |
| rs4713693 | Vascular insufficiency of intestine | 0.007236 | 0.7073 | HLA-E | Graves' disease |
| rs4713693 | Plasma protein metabolism disorder | 0.01056 | 1.271 | HLA-E | Graves' disease |
| rs4713693 | Urethral stricture (not specified as infectious) | 0.01039 | 0.7076 | HLA-E | Graves' disease |
| rs4713693 | Viral Enteritis | 0.009568 | 0.6808 | HLA-E | Graves' disease |
| rs4713693 | Gastrointestinal complications | 0.01059 | 1.246 | HLA-E | Graves' disease |
| rs4713693 | Cystitis and urethritis | 0.00907 | 0.8351 | HLA-E | Graves' disease |
| rs4713693 | Late effects of cerebrovascular disease | 0.006263 | 1.173 | HLA-E | Graves' disease |
| rs4713693 | Heart transplant/surgery | 0.002646 | 1.487 | HLA-E | Graves' disease |
| rs4713693 | Secondary malignancy of lymph nodes | 0.006291 | 0.7917 | HLA-E | Graves' disease |
| rs4732812 | Polyp of female genital organs | 0.005818 | 1.282 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Symptoms involving urinary system | 0.0005292 | 1.359 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Ischemic stroke | 0.0008945 | 1.264 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Acute periodontitis | 0.00155 | 1.469 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Other disorders of middle ear and mastoid | 0.0007011 | 1.62 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Influenza | 0.008465 | 1.353 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Peripheral enthesopathies | 0.004598 | 1.109 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Arthropathy NOS | 0.007834 | 1.189 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Blood vessel replaced | 0.008289 | 0.5796 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Late effects of cerebrovascular disease | 0.001831 | 1.218 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Develomental delays and disorders | 0.004398 | 1.311 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Exophthalmos | 0.000282 | 2.286 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Aphasia/speech disturbance | 0.009055 | 1.235 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Gingival and periodontal diseases | 0.001838 | 1.241 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Nonspecific findings on examination of blood | 0.01078 | 1.304 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Allergic conjunctivitis | 0.00392 | 0.7441 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Keratitis, infectious | 0.009175 | 0.6832 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Speech and language disorder | 0.004268 | 1.451 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Hemiplegia | 0.002727 | 1.392 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Mastoiditis | 1.927e-06 | 3.685 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Intracranial hemorrhage (injury) | 0.001721 | 1.584 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Periodontitis (acute or chronic) | 0.00261 | 1.265 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Disorders of parathyroid gland | 0.002589 | 1.346 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Senile dementia | 0.007047 | 1.247 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Dysphagia | 0.002476 | 1.152 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Hematuria | 0.01103 | 1.118 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Lipoid metabolism disorder NOS | 0.0006649 | 0.705 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Occlusion of cerebral arteries | 0.0005604 | 1.261 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Mucous polyp of cervix | 0.003077 | 1.46 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Hyperparathyroidism | 0.008556 | 1.31 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Acute, but ill-defined cerebrovascular disease | 0.009917 | 1.196 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Hallucinations | 0.01147 | 1.778 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Chronic periodontitis | 0.006648 | 1.272 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Abnormal findings on radiological breast exam | 0.002358 | 1.664 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4732812 | Generalized anxiety disorder | 0.003146 | 1.34 | C8orf80 | Suicidal ideation and SSRI class antidepressant Escitalopram |
| rs4764043 | Gastrointestinal complications | 0.005568 | 1.487 | GRIN2B | Aging |
| rs4764043 | Pallor and flushing | 0.01088 | 1.65 | GRIN2B | Aging |
| rs4764043 | Diabetes mellitus | 0.01105 | 0.8572 | GRIN2B | Aging |
| rs4764043 | Type 2 diabetes | 0.005528 | 0.8427 | GRIN2B | Aging |
| rs4764043 | Jaw disease NOS | 0.007498 | 1.826 | GRIN2B | Aging |
| rs4764043 | Abnormal glucose | 0.003081 | 0.7935 | GRIN2B | Aging |
| rs4764043 | Congenital musculoskeletal anomalies | 0.006508 | 2.691 | GRIN2B | Aging |
| rs4764043 | Wheezing and painful respiration | 0.001061 | 0.7423 | GRIN2B | Aging |
| rs4764043 | Schizophrenia and other psychotic disorders | 0.001403 | 0.6285 | GRIN2B | Aging |
| rs4764043 | Retinal detachment with retinal defect | 0.001617 | 1.849 | GRIN2B | Aging |
| rs4789939 | Neoplasm of uncertain behavior | 0.0009312 | 0.7384 | TIMP2 | Dupuytren's disease |
| rs4789939 | Acquired spondylolisthesis | 0.003753 | 1.414 | TIMP2 | Dupuytren's disease |
| rs4789939 | Adverse effects of opiates and related narcotics in therapeutic use | 0.0003853 | 1.531 | TIMP2 | Dupuytren's disease |
| rs4789939 | Abnormal findings examination of lungs | 0.003263 | 1.244 | TIMP2 | Dupuytren's disease |
| rs4789939 | Heart failure | 0.003185 | 1.17 | TIMP2 | Dupuytren's disease |
| rs4789939 | Anemia of chronic disease | 0.0002829 | 1.356 | TIMP2 | Dupuytren's disease |
| rs4789939 | Mastodynia | 0.008119 | 0.7089 | TIMP2 | Dupuytren's disease |
| rs4789939 | Malaise and fatigue | 0.008185 | 0.8977 | TIMP2 | Dupuytren's disease |
| rs4789939 | Spinal stenosis of lumbar region | 0.005828 | 1.194 | TIMP2 | Dupuytren's disease |
| rs4789939 | Carbuncle and furuncle | 0.01047 | 1.571 | TIMP2 | Dupuytren's disease |
| rs4789939 | Systolic/diastolic heart failure | 0.003679 | 1.174 | TIMP2 | Dupuytren's disease |
| rs4789939 | Spinal stenosis | 0.008535 | 1.166 | TIMP2 | Dupuytren's disease |
| rs4789939 | Hyposmolality and/or hyponatremia | 0.001882 | 1.257 | TIMP2 | Dupuytren's disease |
| rs4789939 | Other nonspecific findings on examination of urine | 0.01067 | 1.245 | TIMP2 | Dupuytren's disease |
| rs4789939 | Abnormal kidney function | 0.008781 | 2.075 | TIMP2 | Dupuytren's disease |
| rs4789939 | Type 2 diabetic retinopathy | 0.004156 | 1.275 | TIMP2 | Dupuytren's disease |
| rs4789939 | Anemia in chronic kidney disease | 0.002773 | 1.426 | TIMP2 | Dupuytren's disease |
| rs4789939 | Complications of gastrostomy, colostomy and enterostomy | 0.0006032 | 2.408 | TIMP2 | Dupuytren's disease |
| rs4789939 | Chronic ulcer of leg or foot | 0.01103 | 1.183 | TIMP2 | Dupuytren's disease |
| rs4789939 | Abnormal heart sounds | 0.0009693 | 1.272 | TIMP2 | Dupuytren's disease |
| rs4789939 | Chronic nonalcoholic liver disease | 0.0008139 | 1.388 | TIMP2 | Dupuytren's disease |
| rs4789939 | Other cerebral degenerations | 0.008044 | 0.5744 | TIMP2 | Dupuytren's disease |
| rs4789939 | Decreased libido | 0.001089 | 2.448 | TIMP2 | Dupuytren's disease |
| rs4789939 | Chronic liver disease and cirrhosis | 0.0002251 | 1.406 | TIMP2 | Dupuytren's disease |
| rs4789939 | Chronic ulcer of skin | 0.002307 | 1.189 | TIMP2 | Dupuytren's disease |
| rs4789939 | Open wound of eye or eyelid | 0.003158 | 2.317 | TIMP2 | Dupuytren's disease |
| rs4789939 | Other acquired musculoskeletal deformity | 0.0006204 | 1.397 | TIMP2 | Dupuytren's disease |
| rs4795067 | Benign neoplasm of respiratory and intrathoracic organs | 5.476e-05 | 0.3127 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Dermatomycoses | 0.004875 | 0.5318 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Central/nonobstroctive sleep apnea | 0.007201 | 0.5617 | NOS2 | Psoriasis vulgaris |
| rs4795067 | First degree AV block | 0.006896 | 1.245 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Peritoneal or intestinal adhesions | 0.0076 | 0.5913 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Ulcerative stomatitis & mucositis | 0.007092 | 1.776 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Gingival and periodontal diseases | 0.00166 | 1.231 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Other hemoglobinopathies | 0.005945 | 0.4104 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Eye infection, viral | 0.006636 | 1.402 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Other disorders of soft tissues | 0.01115 | 1.362 | NOS2 | Psoriasis vulgaris |
| rs4795067 | Calculus of bile duct | 0.00732 | 0.7225 | NOS2 | Psoriasis vulgaris |
| rs4815868 | Postmenopausal atrophic vaginitis | 0.009616 | 1.297 | C20orf196 | Cognitive performance |
| rs4815868 | Cancer of kidney and renal pelvis | 0.008592 | 1.41 | C20orf196 | Cognitive performance |
| rs4815868 | Pruritus and related conditions | 0.01012 | 0.7869 | C20orf196 | Cognitive performance |
| rs4815868 | Paraproteinemia | 0.005719 | 1.465 | C20orf196 | Cognitive performance |
| rs4815868 | Disorders of coccyx | 0.008167 | 0.6618 | C20orf196 | Cognitive performance |
| rs4815868 | Perforation of tympanic membrane | 0.004137 | 1.643 | C20orf196 | Cognitive performance |
| rs4815868 | Malignant neoplasm of renal pelvis | 6.331e-05 | 3.148 | C20orf196 | Cognitive performance |
| rs4815868 | Tinnitus | 0.01145 | 1.242 | C20orf196 | Cognitive performance |
| rs4815868 | Cardiac arrhythmia NOS | 0.006197 | 0.829 | C20orf196 | Cognitive performance |
| rs4815868 | Nerve root lesions | 0.008099 | 1.718 | C20orf196 | Cognitive performance |
| rs4815868 | Dyspareunia | 0.008375 | 1.683 | C20orf196 | Cognitive performance |
| rs4815868 | Torsion dystonia | 0.0114 | 1.641 | C20orf196 | Cognitive performance |
| rs4815868 | Paroxysmal tachycardia, unspecified | 0.004369 | 0.7691 | C20orf196 | Cognitive performance |
| rs4815868 | Plasma protein metabolism disorder | 0.005614 | 1.376 | C20orf196 | Cognitive performance |
| rs4815868 | Facial nerve disorders | 0.01142 | 1.457 | C20orf196 | Cognitive performance |
| rs4838605 | Insulin pump user | 0.008954 | 0.7939 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Gout | 0.00672 | 0.8564 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Osteoporosis, osteopenia, & pathological fractures | 0.007129 | 1.099 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Pallor and flushing | 0.005063 | 0.6741 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Other biliary tract disease | 0.01012 | 1.249 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Gout and other crystal arthropathies | 0.006556 | 0.8653 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Benign neoplasm of colon | 0.005343 | 0.9101 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Sacroiliitis NEC | 0.006789 | 0.5079 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Polycystic ovaries | 0.008473 | 0.451 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Thrombocytopenia | 0.007818 | 1.18 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Senile dementia | 0.00665 | 1.226 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Mastoiditis | 0.006568 | 0.4009 | ARHGAP22 | Diabetic retinopathy |
| rs4838605 | Ovarian dysfunction | 0.007584 | 0.4981 | ARHGAP22 | Diabetic retinopathy |
| rs4902642 | Congenital deformities of feet | 0.001674 | 1.376 | ZFP36L1 | Crohn's disease |
| rs4902642 | Intestinal malabsorption | 0.004517 | 0.7118 | ZFP36L1 | Crohn's disease |
| rs4902642 | Heart failure NOS | 0.005187 | 0.7652 | ZFP36L1 | Crohn's disease |
| rs4902642 | Multiple sclerosis | 0.01085 | 0.6545 | ZFP36L1 | Crohn's disease |
| rs4902642 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.004131 | 0.7331 | ZFP36L1 | Crohn's disease |
| rs4902642 | Immune disorders | 0.006565 | 1.257 | ZFP36L1 | Crohn's disease |
| rs4902642 | Cancer of the lower GI tract | 0.009481 | 1.344 | ZFP36L1 | Crohn's disease |
| rs4902642 | Sinoatrial node dysfunction | 0.004996 | 0.7595 | ZFP36L1 | Crohn's disease |
| rs4902642 | Other specified diseases of hair and hair follicles | 0.00139 | 1.384 | ZFP36L1 | Crohn's disease |
| rs4902642 | Meningitis | 0.0001116 | 2.225 | ZFP36L1 | Crohn's disease |
| rs4902642 | Circumscribed scleroderma | 0.007965 | 0.714 | ZFP36L1 | Crohn's disease |
| rs4902642 | Other immunological findings | 0.007842 | 1.313 | ZFP36L1 | Crohn's disease |
| rs4902642 | Other congenital anomalies of skin | 0.0008059 | 1.556 | ZFP36L1 | Crohn's disease |
| rs4902642 | Congenital anomalies of limbs | 0.003665 | 1.296 | ZFP36L1 | Crohn's disease |
| rs4902642 | Ptosis of eyelid | 0.009669 | 0.8379 | ZFP36L1 | Crohn's disease |
| rs4902642 | Cardiac pacemaker in situ | 0.009572 | 0.8232 | ZFP36L1 | Crohn's disease |
| rs4902642 | Psychogenic and somatoform disorders | 0.009567 | 0.7937 | ZFP36L1 | Crohn's disease |
| rs4902642 | Cellulitis and abscess of arm | 0.0009029 | 0.7561 | ZFP36L1 | Crohn's disease |
| rs4917014 | Encounter for long-term use of antiplatelets/antithrombotics | 0.001147 | 0.2666 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Fever of unknown origin | 0.01127 | 0.8974 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Ischemic Heart Disease | 0.001521 | 0.902 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Symptoms/disorders of the urinary system | 0.004528 | 0.9106 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Breast disorder NOS | 0.0006827 | 0.1924 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Chronic ischemic heart disease | 0.006277 | 0.8674 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Premenstrual tension syndromes | 0.005987 | 0.5187 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Hallux rigidus | 0.00888 | 1.387 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Coronary atherosclerosis | 0.00211 | 0.8999 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Pulmonary congestion and hypostasis | 0.007123 | 0.7047 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Stomach cancer | 0.0112 | 0.5354 | IKZF1 | Systemic lupus erythematosus |
| rs4917014 | Cornea replaced by transplant | 0.007342 | 0.5047 | IKZF1 | Systemic lupus erythematosus |
| rs4935969 | Drug-resistant infection | 0.008583 | 1.358 | KIRREL3 | Hair color |
| rs4935969 | Anomalies of pupillary function | 0.004024 | 0.4532 | KIRREL3 | Hair color |
| rs4935969 | Other and unspecified disc disorder | 0.001023 | 1.596 | KIRREL3 | Hair color |
| rs4935969 | Varicose veins of lower extremity, symptomtic | 0.006422 | 1.219 | KIRREL3 | Hair color |
| rs4935969 | Nontoxic nodular goiter | 0.001721 | 0.8175 | KIRREL3 | Hair color |
| rs4935969 | Type 2 diabetic ketoacidosis | 0.004126 | 1.146 | KIRREL3 | Hair color |
| rs4935969 | Cancer of the upper aerodigestive tract | 0.001215 | 1.461 | KIRREL3 | Hair color |
| rs4935969 | Hypermetropia | 0.0089 | 0.8828 | KIRREL3 | Hair color |
| rs4935969 | Protein plasma/amino-acid transport and metabolism disorder | 0.008878 | 1.253 | KIRREL3 | Hair color |
| rs4935969 | Abnormal reflex | 0.01151 | 2.018 | KIRREL3 | Hair color |
| rs4935969 | Duodenal ulcer | 0.01009 | 1.302 | KIRREL3 | Hair color |
| rs4935969 | Allergic rhinitis | 0.005195 | 1.121 | KIRREL3 | Hair color |
| rs4935969 | Cancer of oropharynx | 0.001918 | 2.257 | KIRREL3 | Hair color |
| rs4935969 | Cholecystitis without cholelithiasis | 0.01079 | 0.7703 | KIRREL3 | Hair color |
| rs4935969 | Congenital anomalies of peripheral vascular system | 0.0103 | 1.731 | KIRREL3 | Hair color |
| rs4935969 | Vascular complications of surgery and medical procedures | 0.002377 | 1.639 | KIRREL3 | Hair color |
| rs4935969 | Chronic sinusitis | 0.007823 | 1.119 | KIRREL3 | Hair color |
| rs4935969 | Retinal detachments and defects | 0.01113 | 0.8244 | KIRREL3 | Hair color |
| rs4935969 | Nonrheumatic aortic valve disorders | 0.007598 | 1.155 | KIRREL3 | Hair color |
| rs4935969 | Insulin pump user | 0.009209 | 1.241 | KIRREL3 | Hair color |
| rs4935969 | Acquired deformities of limbs | 0.009249 | 1.21 | KIRREL3 | Hair color |
| rs4935969 | Arteritis NOS | 0.00559 | 1.58 | KIRREL3 | Hair color |
| rs4935969 | Neutropenia | 0.007999 | 1.226 | KIRREL3 | Hair color |
| rs4935969 | Unequal leg length (acquired) | 0.001946 | 1.539 | KIRREL3 | Hair color |
| rs494620 | Colon cancer | 0.007274 | 1.235 | SLC44A4 | Menopause |
| rs494620 | Dermatomyositis and Polymyositis | 0.005836 | 0.4196 | SLC44A4 | Menopause |
| rs494620 | Lymphosarcoma | 0.01047 | 1.985 | SLC44A4 | Menopause |
| rs494620 | Corneal degenerations | 0.002898 | 1.387 | SLC44A4 | Menopause |
| rs494620 | Second degree AV block | 0.008453 | 1.487 | SLC44A4 | Menopause |
| rs494620 | Disorders of lipoid metabolism | 0.005162 | 1.096 | SLC44A4 | Menopause |
| rs494620 | Joint effusions | 0.003457 | 1.235 | SLC44A4 | Menopause |
| rs494620 | Bacteremia | 0.0004042 | 1.392 | SLC44A4 | Menopause |
| rs494620 | Pulmonary collapse; interstitial/compensatory emphysema | 0.001802 | 1.195 | SLC44A4 | Menopause |
| rs494620 | Hyperlipidemia | 0.01045 | 1.088 | SLC44A4 | Menopause |
| rs494620 | Seborheic dermatitis | 0.01055 | 1.171 | SLC44A4 | Menopause |
| rs494620 | Septicemia | 0.001539 | 1.208 | SLC44A4 | Menopause |
| rs494620 | Personal history of allergy to medicinal agents | 0.001868 | 1.31 | SLC44A4 | Menopause |
| rs494620 | Rheumatoid arthritis | 0.002713 | 1.247 | SLC44A4 | Menopause |
| rs494620 | Benign neoplasm of colon | 0.002033 | 1.106 | SLC44A4 | Menopause |
| rs494620 | Stomach cancer | 0.0003761 | 2.05 | SLC44A4 | Menopause |
| rs494620 | Osteoarthrosis | 0.006941 | 1.085 | SLC44A4 | Menopause |
| rs494620 | Esophageal cancer | 0.001345 | 1.95 | SLC44A4 | Menopause |
| rs494620 | Other specified peripheral vascular diseases | 0.006979 | 0.4551 | SLC44A4 | Menopause |
| rs494620 | Adverse effects of adrenal cortical steroids | 0.006425 | 1.553 | SLC44A4 | Menopause |
| rs494620 | Fracture of hand or wrist | 0.0006194 | 1.219 | SLC44A4 | Menopause |
| rs4952590 | Lung disease due to external agents | 0.01132 | 1.692 | PKDCC | Atopy |
| rs4952590 | Osteoarthrosis NOS | 0.003867 | 0.8712 | PKDCC | Atopy |
| rs4952590 | Iron deficiency anemias | 0.01097 | 1.193 | PKDCC | Atopy |
| rs4952590 | Hydrocele | 0.0002061 | 2.028 | PKDCC | Atopy |
| rs4952590 | Myeloproliferative disease | 0.0007342 | 1.615 | PKDCC | Atopy |
| rs4952590 | Pseudomonal pneumonia | 0.009014 | 2.333 | PKDCC | Atopy |
| rs4952590 | Disorders of vitreous body | 0.01137 | 0.8471 | PKDCC | Atopy |
| rs4952590 | Pneumoconiosis | 0.007481 | 2.159 | PKDCC | Atopy |
| rs4952590 | Temporomandibular joint disorder NOS | 0.008709 | 0.3594 | PKDCC | Atopy |
| rs4952590 | Chronic obstructive asthma with exacerbation | 0.004406 | 1.874 | PKDCC | Atopy |
| rs4952590 | Corneal degenerations | 0.01041 | 1.457 | PKDCC | Atopy |
| rs4952590 | Peripheral enthesopathies | 0.01023 | 0.8831 | PKDCC | Atopy |
| rs4952590 | Polycythemia vera | 0.0009457 | 2.227 | PKDCC | Atopy |
| rs4952590 | Pruritus and related conditions | 0.009335 | 0.7564 | PKDCC | Atopy |
| rs4952590 | Otitis externa | 0.005445 | 0.7526 | PKDCC | Atopy |
| rs4952590 | Pleurisy; pleural effusion | 0.008875 | 1.201 | PKDCC | Atopy |
| rs4952590 | Other disorders of testis | 0.003672 | 1.596 | PKDCC | Atopy |
| rs495366 | Chronic pain syndrome | 0.004445 | 1.715 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Cholecystitis without cholelithiasis | 0.007751 | 1.32 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Disorders of other cranial nerves | 0.009795 | 0.7541 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Throat pain | 0.003768 | 1.701 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Disorders of adrenal glands | 0.01034 | 1.329 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Nerve plexus lesions | 0.009235 | 0.6427 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Corneal edema | 0.004206 | 0.4937 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Benign neoplasm of ovary | 0.004355 | 1.61 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Eye infection, viral | 0.0008221 | 1.544 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Respiratory complications | 0.0007254 | 1.866 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Other disorders of gallbladder | 0.006796 | 1.61 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Herpes zoster with nervous system complications | 0.007687 | 0.5819 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.005518 | 1.34 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Voice disturbance | 0.005912 | 1.231 | MMP3 | Matrix metalloproteinase-1 levels |
| rs495366 | Spondylosis and allied disorders | 0.008982 | 0.8936 | MMP3 | Matrix metalloproteinase-1 levels |
| rs4959235 | Osteochondropathies | 0.005101 | 2.448 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Sensorineural hearing loss | 0.007918 | 1.213 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Intervertebral disc disorder with myelopathy | 0.004078 | 2.306 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Conjunctivitis, noninfectious | 0.001777 | 1.536 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Noninfectious disorders of lymphatic channels | 0.01084 | 1.557 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Influenza | 0.001782 | 1.725 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Pernicious anemia | 0.003072 | 1.872 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Poisoning by analgesics, antipyretics, and antirheumatics | 0.006428 | 1.613 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Bronchitis | 0.002463 | 1.324 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4959235 | Asthma | 0.004822 | 1.26 | SLC22A23 | Antipsychotic-induced QTc interval prolongation (Quetiapine) |
| rs4964469 | Noninflammatory disorders of vagina | 0.005035 | 0.72 | LOC100287944 | Parkinson's disease |
| rs4964469 | Other specified diseases of the salivary glands | 0.005088 | 0.5304 | LOC100287944 | Parkinson's disease |
| rs4964469 | Otorrhea | 0.004143 | 0.4293 | LOC100287944 | Parkinson's disease |
| rs4964469 | Aneurysm of artery of lower extremity | 0.002403 | 1.619 | LOC100287944 | Parkinson's disease |
| rs4964469 | Gouty arthropathy | 0.004227 | 1.321 | LOC100287944 | Parkinson's disease |
| rs4964469 | Posttraumatic wound infection | 0.002149 | 1.927 | LOC100287944 | Parkinson's disease |
| rs4964469 | Acute posthemorrhagic anemia | 0.001227 | 1.207 | LOC100287944 | Parkinson's disease |
| rs4964469 | Pneumonia | 0.01017 | 0.9061 | LOC100287944 | Parkinson's disease |
| rs4964469 | Paranoid disorders | 0.006146 | 1.802 | LOC100287944 | Parkinson's disease |
| rs4964469 | Hypercholesterolemia | 0.008947 | 1.111 | LOC100287944 | Parkinson's disease |
| rs4964469 | Cervicocranial/Cervicobrachial syndrome | 0.001704 | 0.7576 | LOC100287944 | Parkinson's disease |
| rs4964469 | Noninflammatory female genital disorders | 0.003741 | 0.8237 | LOC100287944 | Parkinson's disease |
| rs4964469 | Abnormal findings on exam of gastrointestinal tract/abdominal area | 0.01066 | 0.7451 | LOC100287944 | Parkinson's disease |
| rs4964469 | Seborrhea | 0.00669 | 0.4695 | LOC100287944 | Parkinson's disease |
| rs4977574 | Acute, but ill-defined cerebrovascular disease | 0.007128 | 1.19 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac dysrhythmias | 0.004224 | 1.09 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac pacemaker/device in situ | 0.007091 | 1.204 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Polyneuropathy in diabetes | 0.0002201 | 1.273 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Primary thrombocytopenia | 0.009887 | 0.6255 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Type 2 diabetic neuropathy | 0.003474 | 1.191 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Atrial flutter | 0.01122 | 1.209 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Ulcerative colitis | 0.008605 | 0.6942 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Symptoms involving cardiovascular system | 0.006124 | 1.158 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Neurological disorders due to brain damage | 0.005108 | 1.138 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Type 2 diabetic peripheral circulatory disorders | 0.004353 | 1.408 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | stress incontinence, female | 0.007042 | 0.8469 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Ventricular fibrillation & flutter | 0.007578 | 1.612 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Acne | 0.003665 | 0.764 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Central/nonobstroctive sleep apnea | 0.005889 | 1.681 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac arrest & ventricular fibrillation | 0.005456 | 1.421 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Angina pectoris | 4.924e-05 | 1.203 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Paraproteinemia | 0.007277 | 0.7271 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Chronic ischemic heart disease | 7.667e-06 | 1.239 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Costochondritis | 0.002352 | 0.4994 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.003054 | 1.196 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cystitis and urethritis | 0.009029 | 1.197 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac conduction disorders | 0.002514 | 1.126 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Renal failure NOS | 0.005621 | 1.336 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Abdominal aortic aneurysm | 0.001384 | 1.289 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Myocardial infarction | 4.003e-08 | 1.28 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Hemorrhoids | 0.0005759 | 0.8736 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Other infectious diseases | 0.005661 | 1.773 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Disorders of penis | 0.007013 | 0.7483 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Other forms of chronic heart disease | 0.001179 | 1.236 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Pseudomonal pneumonia | 0.009758 | 0.4471 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cystitis | 0.008031 | 1.214 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cerebrovascular disease | 0.00161 | 1.111 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Type 1 diabetic ketoacidosis | 0.005221 | 1.435 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Nephritis; nephrosis; renal sclerosis | 0.002849 | 1.249 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Unstable angina (intermediate coronary syndrome) | 2.164e-09 | 1.396 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Ischemic Heart Disease | 6.335e-10 | 1.207 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Ill-defined descriptions and complications of heart disease | 0.001024 | 1.137 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Symptoms involving digestive system | 0.00818 | 0.8235 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Hypotension NOS | 0.002286 | 1.207 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Other aneurysm | 0.003168 | 1.201 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Mild cognitive impairment | 0.01135 | 1.613 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Hypotension | 0.001051 | 1.162 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Aortic aneurysm | 0.008855 | 1.197 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Occlusion and stenosis of precerebral arteries | 5.597e-05 | 1.205 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Cardiac complications, not elsewhere classified | 0.002296 | 1.433 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Abnormal electrocardiogram | 0.004546 | 1.154 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Coronary atherosclerosis | 1.002e-12 | 1.258 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4977574 | Type 2 diabetic nephropathy | 0.0003253 | 1.296 | CDKN2B-AS1 | Early onset myocardial infarction, Coronary heart disease |
| rs4979906 | Retinal disorders | 0.009923 | 1.134 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Hemorrhage NOS | 0.008112 | 1.73 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Viral hepatitis C | 0.01005 | 1.542 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Prostate cancer | 0.01065 | 1.214 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Respiratory failure | 0.0005051 | 1.414 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Optic neuritis/neuropathy | 0.005318 | 1.426 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Coronary atherosclerosis | 0.008337 | 1.112 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Neck pain | 0.005454 | 1.128 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Pain in limb | 0.01123 | 1.104 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Respiratory insufficiency | 0.001798 | 1.405 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Respiratory failure; insufficiency; arrest | 0.002749 | 1.255 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Arthropathy NOS involving multiple sites | 0.000336 | 1.942 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Otosclerosis | 0.0009807 | 0.4521 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Heartburn | 0.01148 | 1.421 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Osteopenia | 0.001966 | 1.182 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Anemia in neoplastic disease | 0.01141 | 0.6212 | KCNMA1 | Mortality among heart failure patients |
| rs4979906 | Osteoporosis, osteopenia, & pathological fractures | 0.004714 | 1.129 | KCNMA1 | Mortality among heart failure patients |
| rs4986172 | Gout and other crystal arthropathies | 0.0004108 | 1.2 | ACBD4 | Height |
| rs4986172 | Gout | 0.0002388 | 1.225 | ACBD4 | Height |
| rs4986172 | Aneurysm of artery of lower extremity | 0.006454 | 1.554 | ACBD4 | Height |
| rs4986172 | Abnormal results of function study of liver | 0.006834 | 1.219 | ACBD4 | Height |
| rs4986172 | Random mental disorder. Ignored for now | 0.009228 | 1.498 | ACBD4 | Height |
| rs4986172 | Elevated blood pressure reading | 0.009968 | 1.141 | ACBD4 | Height |
| rs4986172 | Gastritis and duodenitis | 0.006877 | 1.146 | ACBD4 | Height |
| rs4986172 | Joint effusions | 0.006893 | 1.224 | ACBD4 | Height |
| rs4986172 | Lichen | 0.005842 | 0.6161 | ACBD4 | Height |
| rs4986172 | Respiratory abnormalities | 0.005016 | 0.7305 | ACBD4 | Height |
| rs4986172 | Hyperventilation | 0.001595 | 0.4617 | ACBD4 | Height |
| rs4986172 | Mitral stenosis/insufficiency | 0.009819 | 0.4939 | ACBD4 | Height |
| rs4986172 | Cystic mastopathy | 0.007459 | 0.8523 | ACBD4 | Height |
| rs4986172 | Alzheimer's disease | 0.004731 | 0.8319 | ACBD4 | Height |
| rs4986172 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | 0.00543 | 1.831 | ACBD4 | Height |
| rs4986172 | Optic neuritis/neuropathy | 0.005076 | 1.362 | ACBD4 | Height |
| rs4986172 | Essential tremor | 0.009729 | 0.7598 | ACBD4 | Height |
| rs4986172 | Unequal leg length (acquired) | 0.0108 | 1.434 | ACBD4 | Height |
| rs4986172 | Ankylosis of joint | 0.01072 | 1.402 | ACBD4 | Height |
| rs4986172 | Vascular dementia | 0.005272 | 0.6933 | ACBD4 | Height |
| rs4986172 | Substance addiction and disorders | 0.007527 | 1.285 | ACBD4 | Height |
| rs4986172 | Dementias | 0.002335 | 0.8445 | ACBD4 | Height |
| rs499697 | Symptoms and disorders of the joints | 0.0002037 | 0.8404 | LCE3E | Hair morphology |
| rs499697 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.01126 | 0.8036 | LCE3E | Hair morphology |
| rs499697 | Cervical cancer and dysplasia | 0.006046 | 0.74 | LCE3E | Hair morphology |
| rs499697 | Decreased libido | 0.009028 | 0.3864 | LCE3E | Hair morphology |
| rs499697 | Fracture of foot | 0.00295 | 0.787 | LCE3E | Hair morphology |
| rs499697 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.00119 | 0.6756 | LCE3E | Hair morphology |
| rs499697 | H. pylori | 0.0003308 | 1.743 | LCE3E | Hair morphology |
| rs499697 | Known or suspected fetal abnormality | 0.005684 | 0.5193 | LCE3E | Hair morphology |
| rs499697 | Stiffness of joint | 0.00508 | 0.8043 | LCE3E | Hair morphology |
| rs499697 | Paralysis/spasm of vocal cords or larynx | 0.003228 | 1.655 | LCE3E | Hair morphology |
| rs499697 | Herpes zoster | 0.007064 | 0.8217 | LCE3E | Hair morphology |
| rs499697 | Temporomandibular joint disorder NOS | 0.005193 | 0.53 | LCE3E | Hair morphology |
| rs499697 | Amblyopia | 0.002468 | 0.6665 | LCE3E | Hair morphology |
| rs499697 | Acquired spondylolisthesis | 0.003311 | 1.351 | LCE3E | Hair morphology |
| rs5015480 | Diseases of nail | 0.008335 | 0.8725 | HHEX | Type 2 diabetes |
| rs5015480 | Hypercholesterolemia | 0.004465 | 0.8917 | HHEX | Type 2 diabetes |
| rs5015480 | Enthesopathy | 0.005141 | 0.8917 | HHEX | Type 2 diabetes |
| rs5015480 | Diabetic retinopathy | 0.001266 | 0.8063 | HHEX | Type 2 diabetes |
| rs5015480 | Type 2 diabetic neuropathy | 0.001707 | 0.826 | HHEX | Type 2 diabetes |
| rs5015480 | Type 2 diabetes | 0.0004393 | 0.8955 | HHEX | Type 2 diabetes |
| rs5015480 | Poisoning by primarily systemic agents | 0.003448 | 0.7383 | HHEX | Type 2 diabetes |
| rs5015480 | Renal failure | 0.004645 | 0.9009 | HHEX | Type 2 diabetes |
| rs5015480 | Hyperparathyroidism | 0.001488 | 0.7217 | HHEX | Type 2 diabetes |
| rs5015480 | Hyperlipidemia | 0.006061 | 0.9138 | HHEX | Type 2 diabetes |
| rs5015480 | Type 2 diabetic retinopathy | 0.0002704 | 0.7756 | HHEX | Type 2 diabetes |
| rs5015480 | Epiphora | 0.01118 | 1.347 | HHEX | Type 2 diabetes |
| rs5015480 | Peripheral enthesopathies | 0.007593 | 0.9153 | HHEX | Type 2 diabetes |
| rs5015480 | Disorders of lipoid metabolism | 0.004905 | 0.9124 | HHEX | Type 2 diabetes |
| rs5015480 | Intervertebral disc disorders | 0.005254 | 1.103 | HHEX | Type 2 diabetes |
| rs5015480 | Type 2 diabetic ketoacidosis | 0.0005544 | 0.8476 | HHEX | Type 2 diabetes |
| rs5015480 | Glomerulonephritis | 0.007899 | 1.624 | HHEX | Type 2 diabetes |
| rs5015480 | Chronic glomerulonephritis | 0.00962 | 2.073 | HHEX | Type 2 diabetes |
| rs5015480 | Postlaminectomy syndrome | 0.009516 | 1.373 | HHEX | Type 2 diabetes |
| rs5015480 | Superficial cellulitis and abscess | 0.008787 | 0.9126 | HHEX | Type 2 diabetes |
| rs5015480 | Type 1 diabetes | 0.0006206 | 0.8098 | HHEX | Type 2 diabetes |
| rs5015480 | Back pain | 0.004757 | 1.087 | HHEX | Type 2 diabetes |
| rs5015480 | Type 1 diabetic retinopathy | 0.004661 | 0.682 | HHEX | Type 2 diabetes |
| rs5015480 | Adverse effects of antineoplastic and immunosuppressive drugs | 0.001289 | 0.7078 | HHEX | Type 2 diabetes |
| rs5015480 | Lipoid metabolism disorder NOS | 3.396e-05 | 0.6934 | HHEX | Type 2 diabetes |
| rs5015480 | Diabetes mellitus | 0.0006201 | 0.8993 | HHEX | Type 2 diabetes |
| rs5015480 | Disorders of parathyroid gland | 0.001433 | 0.7308 | HHEX | Type 2 diabetes |
| rs5015480 | Other specified diseases of nail | 0.003006 | 0.8539 | HHEX | Type 2 diabetes |
| rs5031002 | Other acute and subacute forms of ischemic heart disease | 0.009918 | 3.49 | AR | LDL Cholesterol |
| rs5031002 | Cornea replaced by transplant | 0.008677 | 3.24 | AR | LDL Cholesterol |
| rs5031002 | Fluid overload | 0.001472 | 2.15 | AR | LDL Cholesterol |
| rs5031002 | Pneumonitis due to inhalation of food or vomitus | 0.004286 | 2.221 | AR | LDL Cholesterol |
| rs5031002 | Abnormal findings on study of brain, nervous system | 0.007808 | 2.568 | AR | LDL Cholesterol |
| rs5031002 | Acute pancreatitis | 0.0003742 | 2.291 | AR | LDL Cholesterol |
| rs5031002 | Altered mental status | 0.009851 | 1.959 | AR | LDL Cholesterol |
| rs531676 | Intestinal infection | 0.007695 | 1.21 | CRTAC1 | Type 2 diabetes |
| rs531676 | Schizophrenia | 0.002497 | 1.753 | CRTAC1 | Type 2 diabetes |
| rs531676 | Anticoagulants causing adverse effects | 0.006844 | 1.639 | CRTAC1 | Type 2 diabetes |
| rs531676 | Abnormal coagulation profile | 0.009595 | 1.341 | CRTAC1 | Type 2 diabetes |
| rs531676 | Endometriosis | 0.00896 | 1.357 | CRTAC1 | Type 2 diabetes |
| rs531676 | Acidosis | 0.004528 | 1.39 | CRTAC1 | Type 2 diabetes |
| rs531676 | Jaundice | 0.006278 | 0.6803 | CRTAC1 | Type 2 diabetes |
| rs531676 | Elevated sedimentation rate | 0.01035 | 0.7359 | CRTAC1 | Type 2 diabetes |
| rs531676 | Anxiety disorder | 0.001401 | 1.141 | CRTAC1 | Type 2 diabetes |
| rs531676 | Anxiety, phobic and dissociative disorders | 0.009169 | 1.099 | CRTAC1 | Type 2 diabetes |
| rs531676 | Derangement of joint, non-traumatic | 0.008039 | 1.233 | CRTAC1 | Type 2 diabetes |
| rs544368 | Bacterial infection NOS | 2.454e-05 | 1.316 | SIAE | Bipolar disorder |
| rs544368 | Tachycardia NOS | 0.003218 | 1.302 | SIAE | Bipolar disorder |
| rs544368 | Colles' fracture | 0.005223 | 1.542 | SIAE | Bipolar disorder |
| rs544368 | Cellulitis and abscess of foot/toes | 0.008818 | 1.383 | SIAE | Bipolar disorder |
| rs544368 | Wheezing | 0.00411 | 1.474 | SIAE | Bipolar disorder |
| rs544368 | Retinal drusen | 0.008775 | 1.337 | SIAE | Bipolar disorder |
| rs544368 | Generalized anxiety disorder | 0.002687 | 1.458 | SIAE | Bipolar disorder |
| rs544368 | Urinary incontinence | 0.01128 | 1.185 | SIAE | Bipolar disorder |
| rs544368 | Symptoms/disorders of the urinary system | 2.405e-05 | 1.212 | SIAE | Bipolar disorder |
| rs544368 | Open wounds of extremities | 0.009457 | 1.167 | SIAE | Bipolar disorder |
| rs544368 | Deficiency of humoral immunity | 0.008419 | 2.266 | SIAE | Bipolar disorder |
| rs544368 | Bacteremia | 0.0005032 | 1.54 | SIAE | Bipolar disorder |
| rs544368 | Hyperparathyroidism | 0.004762 | 0.6063 | SIAE | Bipolar disorder |
| rs544368 | Eosinophilia | 0.001134 | 2.248 | SIAE | Bipolar disorder |
| rs544368 | Electrolyte imbalance | 0.001381 | 1.178 | SIAE | Bipolar disorder |
| rs544368 | E. coli | 3.436e-05 | 1.72 | SIAE | Bipolar disorder |
| rs544368 | Phosphorus metabolism disorder | 0.006481 | 1.588 | SIAE | Bipolar disorder |
| rs544368 | Fracture of radius and ulna | 0.005029 | 1.275 | SIAE | Bipolar disorder |
| rs544368 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.0003512 | 1.606 | SIAE | Bipolar disorder |
| rs544368 | Joint/ligament sprain | 0.005827 | 0.6124 | SIAE | Bipolar disorder |
| rs544368 | Acute renal failure | 0.00915 | 1.221 | SIAE | Bipolar disorder |
| rs544368 | Nervous system congenital anomalies | 0.007459 | 1.556 | SIAE | Bipolar disorder |
| rs544368 | Protein-calorie malnutrition | 0.0004058 | 1.319 | SIAE | Bipolar disorder |
| rs544368 | Other disorders of ear | 0.008991 | 1.384 | SIAE | Bipolar disorder |
| rs544368 | Lung disease due to external agents | 0.0005663 | 1.97 | SIAE | Bipolar disorder |
| rs544368 | Hepatic cancer | 0.00757 | 1.888 | SIAE | Bipolar disorder |
| rs544368 | Peritonitis and retroperitoneal infections | 0.0005454 | 1.737 | SIAE | Bipolar disorder |
| rs544368 | Urinary tract infection | 0.00115 | 1.182 | SIAE | Bipolar disorder |
| rs544368 | Mechanical complication due to other implant and internal device | 0.004424 | 1.492 | SIAE | Bipolar disorder |
| rs544368 | Late effects of cerebrovascular disease | 0.005114 | 1.263 | SIAE | Bipolar disorder |
| rs544368 | AV block | 0.01148 | 1.268 | SIAE | Bipolar disorder |
| rs544368 | Atherosclerosis of the extremities | 0.009983 | 1.204 | SIAE | Bipolar disorder |
| rs544368 | Cellulitis and abscess of arm | 0.001151 | 1.425 | SIAE | Bipolar disorder |
| rs544368 | Iron deficiency anemias NOS | 0.008096 | 1.188 | SIAE | Bipolar disorder |
| rs544368 | Hemiplegia | 0.01085 | 1.432 | SIAE | Bipolar disorder |
| rs544368 | Pneumoconiosis | 0.01087 | 2.07 | SIAE | Bipolar disorder |
| rs544368 | Other infectious diseases | 0.008885 | 1.886 | SIAE | Bipolar disorder |
| rs544368 | Open wound of eye or eyelid | 0.00809 | 2.245 | SIAE | Bipolar disorder |
| rs5498 | Blood vessel replaced | 0.008787 | 1.532 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Hemorrhage NOS | 0.004723 | 0.5631 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Seborheic dermatitis | 0.01065 | 1.174 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Hematemesis | 0.008849 | 1.574 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Congenital anomalies of posterior segment of eye | 0.007021 | 1.291 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Irregular menstrual cycle/bleeding | 0.002706 | 0.8056 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Unspecified polyarthropathy or polyarthritis | 0.00207 | 1.595 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Otosclerosis | 0.008949 | 0.6693 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Irregular menstrual cycle | 0.002041 | 0.6936 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Calculus of lower urinary tract | 0.01141 | 0.611 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Prostate cancer | 0.00928 | 0.848 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Complication of amputation stump | 0.003917 | 1.953 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Cardiac complications, not elsewhere classified | 0.00915 | 0.7259 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Adverse effects of antirheumatics | 0.01104 | 1.657 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Phobia | 0.001303 | 2.447 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs5498 | Disorders of menstruation | 0.0009807 | 0.7988 | ICAM1 | Soluble Intercellular Adhesion Molecule 1 |
| rs603424 | Thyroid cancer | 0.01007 | 1.539 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Acquired toe deformities | 0.0002295 | 0.7456 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Corns and callosities | 0.00413 | 0.8109 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Chronic liver disease and cirrhosis | 0.003667 | 1.296 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Secondary thrombocytopenia | 0.004699 | 1.748 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Chronic nonalcoholic liver disease | 0.004944 | 1.303 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Hallux valgus (Bunion) | 0.006218 | 0.7933 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Respiratory failure | 0.002894 | 1.36 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Torticollis | 0.001939 | 0.426 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Hyperlipidemia | 0.0008354 | 1.151 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Disorders of lipoid metabolism | 0.000928 | 1.149 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Complications of transplants and reattached limbs | 0.004043 | 1.722 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Miscarriage; stillbirth | 0.01025 | 1.838 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Dermatomycoses | 0.01013 | 1.713 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Hammer toe | 0.0008791 | 0.7355 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs603424 | Cardiac complications, not elsewhere classified | 0.001893 | 1.526 | PKD2L1 | Phospholipid levels in plasma, Myristate / Myristoleate |
| rs6051520 | Disease of tricuspid valve | 0.008716 | 1.29 | TRIB3 | Cognitive performance |
| rs6051520 | Other specified disorders of plasma protein metabolism | 0.008994 | 0.2578 | TRIB3 | Cognitive performance |
| rs6051520 | Immunity deficiency | 0.004156 | 1.737 | TRIB3 | Cognitive performance |
| rs6051520 | Decreased libido | 0.002934 | 2.16 | TRIB3 | Cognitive performance |
| rs6051520 | Aortic aneurysm | 0.002314 | 1.273 | TRIB3 | Cognitive performance |
| rs6051520 | Atherosclerosis of the extremities | 0.0007311 | 1.213 | TRIB3 | Cognitive performance |
| rs6051520 | Primary/intrinsic cardiomyopathies | 0.008734 | 1.206 | TRIB3 | Cognitive performance |
| rs6051520 | Pityriasis | 0.008907 | 2.116 | TRIB3 | Cognitive performance |
| rs6051520 | Femoral hernia | 0.0002623 | 2.335 | TRIB3 | Cognitive performance |
| rs6051520 | Congenital cataract and lens anomalies | 0.00215 | 2.165 | TRIB3 | Cognitive performance |
| rs6051520 | Periostitis | 0.001055 | 2.078 | TRIB3 | Cognitive performance |
| rs6051520 | Disease of capillaries | 0.0002595 | 1.557 | TRIB3 | Cognitive performance |
| rs6051520 | Internal derangement of knee | 0.008034 | 1.166 | TRIB3 | Cognitive performance |
| rs6051520 | Abdominal aortic aneurysm | 0.003192 | 1.306 | TRIB3 | Cognitive performance |
| rs6051520 | Arterial embolism and thrombosis | 0.006997 | 1.282 | TRIB3 | Cognitive performance |
| rs6051520 | Esophageal cancer | 0.003608 | 0.3606 | TRIB3 | Cognitive performance |
| rs6051520 | Other aneurysm | 0.0005021 | 1.283 | TRIB3 | Cognitive performance |
| rs6051520 | Atherosclerosis | 0.0003399 | 1.197 | TRIB3 | Cognitive performance |
| rs6051520 | Infections involving bone | 0.008096 | 1.285 | TRIB3 | Cognitive performance |
| rs6051520 | Peripheral arterial disease | 0.00153 | 1.177 | TRIB3 | Cognitive performance |
| rs6051520 | Nevus, non-neoplastic | 0.004198 | 1.774 | TRIB3 | Cognitive performance |
| rs6051520 | Bone cancer | 0.01132 | 0.4945 | TRIB3 | Cognitive performance |
| rs6051520 | Noninflammatory disorders of cervix | 0.0008545 | 1.925 | TRIB3 | Cognitive performance |
| rs6051520 | Ventral hernia | 0.004763 | 1.333 | TRIB3 | Cognitive performance |
| rs6051520 | Sarcoidosis | 0.007391 | 1.634 | TRIB3 | Cognitive performance |
| rs6051520 | Peripheral vascular disease | 0.001818 | 1.159 | TRIB3 | Cognitive performance |
| rs6051520 | Aneurysm of artery of lower extremity | 0.01065 | 1.587 | TRIB3 | Cognitive performance |
| rs6051520 | Disorders of the autonomic nervous system | 0.01047 | 1.322 | TRIB3 | Cognitive performance |
| rs6080550 | Cardiac conduction disorders | 0.0005179 | 0.8098 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Cardiac dysrhythmias | 0.0009902 | 0.8591 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Abnormal electrocardiogram | 0.000137 | 0.7393 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Other disorders of eyelids | 0.009772 | 0.8177 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Alcohol-related disorders | 0.008517 | 0.7466 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Other specified cardiac dysrhythmias | 4.763e-05 | 0.7437 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Exostosis of jaw | 0.0008252 | 2.652 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Angina pectoris | 0.003596 | 0.8091 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Cardiac arrhythmia NOS | 0.003137 | 0.7895 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Unstable angina (intermediate coronary syndrome) | 0.001429 | 0.7471 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Large cell lymphoma | 0.00744 | 2.15 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Alcoholism | 0.003962 | 0.6864 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Atrial fibrillation & flutter | 0.00771 | 0.8359 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Atopic or contact dermatitis | 0.005153 | 0.8569 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Atherosclerosis of renal artery | 0.007804 | 0.6526 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Alzheimer's disease | 0.005111 | 1.282 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Musculoskeletal symptoms referable to limbs | 0.007831 | 0.675 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | AV block | 0.01111 | 0.7724 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Atrial flutter | 0.0009198 | 0.6584 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Atrial fibrillation | 0.00804 | 0.8344 | LOC100289473 | Non-obstructive azoospermia |
| rs6080550 | Postmenopausal atrophic vaginitis | 0.00802 | 0.7201 | LOC100289473 | Non-obstructive azoospermia |
| rs6092477 | Alcohol-related disorders | 0.01132 | 1.189 | RBM38 | Mean corpuscular volume |
| rs6092477 | Corneal degenerations | 0.01096 | 1.334 | RBM38 | Mean corpuscular volume |
| rs6092477 | Nevus, non-neoplastic | 0.009491 | 1.617 | RBM38 | Mean corpuscular volume |
| rs6092477 | Dermatophytosis of the body | 0.00104 | 0.6535 | RBM38 | Mean corpuscular volume |
| rs6092477 | Parkinson's disease | 0.01079 | 0.7675 | RBM38 | Mean corpuscular volume |
| rs6092477 | Other disorders of bladder | 0.0007349 | 0.8113 | RBM38 | Mean corpuscular volume |
| rs6092477 | Swelling, mass, or lump in head and neck | 0.007214 | 0.7943 | RBM38 | Mean corpuscular volume |
| rs6092477 | Insect bite | 0.007856 | 0.7906 | RBM38 | Mean corpuscular volume |
| rs6092477 | Perforation of tympanic membrane | 0.00902 | 1.487 | RBM38 | Mean corpuscular volume |
| rs6092477 | Functional disorders of bladder | 0.002757 | 0.7165 | RBM38 | Mean corpuscular volume |
| rs6092477 | Other disorders of tympanic membrane | 0.003906 | 1.48 | RBM38 | Mean corpuscular volume |
| rs6118083 | Mechanical complication due to other implant and internal device | 0.00206 | 0.6088 | PLCB1 | Cognitive performance |
| rs6118083 | Dyspepsia and disorders of function of stomach | 0.000959 | 1.241 | PLCB1 | Cognitive performance |
| rs6118083 | Wheezing and painful respiration | 0.002883 | 0.8425 | PLCB1 | Cognitive performance |
| rs6118083 | Other headache syndromes | 0.004988 | 1.133 | PLCB1 | Cognitive performance |
| rs6118083 | Disorders of function of stomach | 0.000401 | 1.247 | PLCB1 | Cognitive performance |
| rs6118083 | Eustachian tube disorders | 0.0009961 | 1.363 | PLCB1 | Cognitive performance |
| rs6118083 | Symptomatic artificial menopause | 0.00405 | 0.548 | PLCB1 | Cognitive performance |
| rs6118083 | Mitral stenosis/insufficiency | 0.005241 | 0.2757 | PLCB1 | Cognitive performance |
| rs6118083 | Testicular hypofunction | 0.009762 | 1.441 | PLCB1 | Cognitive performance |
| rs6118083 | Other immunological findings | 0.009674 | 1.361 | PLCB1 | Cognitive performance |
| rs6118083 | Gastroparesis | 0.009523 | 1.746 | PLCB1 | Cognitive performance |
| rs6118083 | Memory loss | 0.002279 | 1.319 | PLCB1 | Cognitive performance |
| rs6118083 | Noninfectious disorders of lymphatic channels | 0.002318 | 0.6305 | PLCB1 | Cognitive performance |
| rs6118083 | Dislocation | 0.004121 | 1.154 | PLCB1 | Cognitive performance |
| rs6118083 | Disorders of synovium, tendon, and bursa | 0.009084 | 1.138 | PLCB1 | Cognitive performance |
| rs6118083 | Other rheumatic heart disease | 0.004107 | 0.1272 | PLCB1 | Cognitive performance |
| rs6118083 | Other unspecified back disorders | 0.01011 | 1.59 | PLCB1 | Cognitive performance |
| rs6118083 | Pneumoconiosis | 0.00407 | 2.037 | PLCB1 | Cognitive performance |
| rs613872 | Poisoning by antibiotics | 0.009504 | 0.786 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Cervical radiculitis | 0.006032 | 0.7927 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Appendiceal conditions | 0.0002756 | 1.664 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Corneal dystrophy | 3.156e-05 | 1.63 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Cornea replaced by transplant | 0.005965 | 1.927 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Subarachnoid hemorrhage | 0.003304 | 2.131 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Open wound of toe(s) | 0.003413 | 1.933 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Hemorrhage NOS | 0.006209 | 1.8 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Decreased libido | 0.005864 | 2.149 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Corneal edema | 0.00704 | 1.75 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Enthesopathy | 0.008243 | 0.8643 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Acute appendicitis | 6.013e-06 | 2.045 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Nephritis and nephropathy in diseases classified elsewhere | 0.008845 | 0.6993 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Fuchs' dystrophy | 2.891e-09 | 2.609 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Umbilical hernia | 0.005277 | 0.694 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Type 2 diabetic retinopathy | 0.007472 | 0.7743 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Appendicitis | 0.0005255 | 1.647 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Sialoadenitis | 0.008187 | 1.552 | TCF4 | Fuchs's corneal dystrophy |
| rs613872 | Conjunctivitis, infectious | 0.00411 | 0.7999 | TCF4 | Fuchs's corneal dystrophy |
| rs619865 | Skin cancer | 5.812e-05 | 1.251 | EIF6 | Freckling |
| rs619865 | First degree AV block | 0.006132 | 0.6619 | EIF6 | Freckling |
| rs619865 | Pancreatic cancer | 0.002638 | 1.84 | EIF6 | Freckling |
| rs619865 | Disorders of lipoid metabolism | 0.009332 | 0.8705 | EIF6 | Freckling |
| rs619865 | Hypercholesterolemia | 0.00325 | 0.8203 | EIF6 | Freckling |
| rs619865 | Elevated sedimentation rate | 0.00989 | 1.557 | EIF6 | Freckling |
| rs619865 | Non-melanoma skin cancer | 0.0001073 | 1.254 | EIF6 | Freckling |
| rs619865 | Angina pectoris | 0.006075 | 0.8008 | EIF6 | Freckling |
| rs619865 | Cancer of other female genital organs | 0.009289 | 2.15 | EIF6 | Freckling |
| rs619865 | Iron metabolism disorder | 0.002726 | 2.393 | EIF6 | Freckling |
| rs619865 | Osteoarthrosis; localized, secondary | 0.01082 | 1.866 | EIF6 | Freckling |
| rs619865 | Other endocrine disorders | 0.003666 | 1.845 | EIF6 | Freckling |
| rs619865 | Hyperlipidemia | 0.007508 | 0.8661 | EIF6 | Freckling |
| rs619865 | Phlebitis and thrombophlebitis | 0.006349 | 0.7099 | EIF6 | Freckling |
| rs619865 | Prostatitis | 0.004198 | 1.511 | EIF6 | Freckling |
| rs619865 | Other dermatoses | 0.007435 | 1.155 | EIF6 | Freckling |
| rs619865 | Actinic keratosis | 0.000184 | 1.252 | EIF6 | Freckling |
| rs6437740 | Dermatophytosis / Dermatomycosis | 0.006349 | 0.8868 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Diseases of nail | 0.007003 | 0.8504 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Other nonspecific findings on examination of urine | 0.006351 | 0.8034 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Dermatophytosis of nail | 0.004883 | 0.8637 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Fracture of clavicle or scapula | 0.001502 | 0.5831 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Dermatophytosis | 0.00534 | 0.882 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Schizophrenia | 0.007871 | 0.4825 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Fracture of unspecified bones | 0.01032 | 0.8489 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Neuralgia, neuritis, and radiculitis NOS | 0.002196 | 0.7685 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Adverse effects of adrenal cortical steroids | 0.007243 | 1.555 | BBX | Smoking behavior (cigarettes per day) |
| rs6437740 | Other specified diseases of nail | 0.004193 | 0.8374 | BBX | Smoking behavior (cigarettes per day) |
| rs6457617 | Lupus erythematosus | 0.01132 | 0.5451 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Rheumatoid arthritis | 4.538e-05 | 1.354 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Discoid lupus erythematosus | 0.00178 | 0.6468 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Male genital disorders | 0.002398 | 1.351 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Celiac or tropical sprue | 0.001385 | 0.4885 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Rheumatoid arthritis & related inflammatory polyarthropathies | 5.685e-05 | 1.304 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Conjunctivitis, infectious | 0.01014 | 1.157 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Abnormal electrocardiogram | 0.01027 | 1.137 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Type 1 diabetes | 0.001502 | 1.209 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Multiple sclerosis | 0.000949 | 0.5818 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Psoriasis & related disorders | 0.01093 | 1.214 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Keratoderma, acquired | 0.01083 | 1.154 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hematuria | 0.00217 | 1.131 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Varicose veins | 0.01127 | 0.8779 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Diseases of the larynx and vocal cords | 0.01132 | 1.164 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Toxic multinodular goiter | 0.008756 | 1.813 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Adverse effects of insulins and antidiabetic agents | 0.0008516 | 0.4637 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Polymyalgia Rheumatica | 0.0001792 | 1.394 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hypothyroidism | 0.007327 | 1.1 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Non-melanoma skin cancer | 0.003482 | 1.114 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Congenital anomalies of great vessels | 0.008309 | 0.5043 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Elevated prostate specific antigen | 0.007034 | 1.185 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Sensorineural hearing loss | 0.008088 | 1.103 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hearing loss | 0.0004866 | 1.115 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hyperglyceridemia | 0.00644 | 1.243 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Systemic lupus erythematosus | 0.007172 | 0.6707 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Photodermatitis & sunburn | 0.006967 | 1.172 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Skin cancer | 0.00741 | 1.098 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Infertility, female | 0.003302 | 1.926 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Celiac disease | 0.004203 | 0.5232 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Hyperplasia of prostate | 0.007619 | 1.143 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Acute sinusitis | 0.005204 | 1.143 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs6457617 | Acute upper respiratory infections | 0.003449 | 1.106 | HLA-DQB1 | Graves' disease, Rheumatoid arthritis, Systemic sclerosis |
| rs646776 | Chronic renal failure | 0.00481 | 0.867 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Mixed hyperlipidemia | 0.001525 | 0.7957 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Calcium/phosphorus disorders | 0.009375 | 1.218 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Acute reaction to stress | 0.009428 | 1.283 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Hypocalcemia | 0.003179 | 1.531 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Unstable angina (intermediate coronary syndrome) | 0.009855 | 0.8371 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Scar conditions and fibrosis of skin | 0.01068 | 0.7252 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.008534 | 0.8234 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Osteoarthrosis, generalized | 0.01058 | 1.236 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | ASCVD | 0.007436 | 0.6651 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Hypercholesterolemia | 1.043e-07 | 0.7725 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Renal failure | 0.005301 | 0.8829 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Hypertensive chronic kidney disease | 0.008289 | 0.8062 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Atherosclerosis | 0.002304 | 0.8527 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Disorders of lipoid metabolism | 1.189e-08 | 0.8008 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Hyperlipidemia | 1.743e-08 | 0.8015 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs646776 | Early or threatened labor; hemorrhage in early pregnancy | 0.002246 | 1.878 | CELSR2 | LDL Cholesterol, Total Cholesterol, Progranulin levels, Early onset myocardial infarction, Response to statin therapy, Coronary heart disease |
| rs6499188 | Other paralytic syndromes | 0.003721 | 0.5599 | ZFP90 | Ulcerative colitis |
| rs6499188 | Bladder cancer and neoplasms | 0.009095 | 0.7572 | ZFP90 | Ulcerative colitis |
| rs6499188 | Other nonspecific findings on examination of urine | 0.001977 | 0.7775 | ZFP90 | Ulcerative colitis |
| rs6499188 | Attention deficit hyperactivity disorder | 0.004043 | 1.743 | ZFP90 | Ulcerative colitis |
| rs6499188 | Melanoma | 0.0003239 | 1.41 | ZFP90 | Ulcerative colitis |
| rs6499188 | Bladder cancer | 0.01021 | 0.754 | ZFP90 | Ulcerative colitis |
| rs6499188 | Irregular menstrual cycle/bleeding | 0.002074 | 1.28 | ZFP90 | Ulcerative colitis |
| rs6499188 | Unstable angina (intermediate coronary syndrome) | 0.002252 | 0.8164 | ZFP90 | Ulcerative colitis |
| rs6499188 | Uterine leiomyoma | 0.003104 | 1.281 | ZFP90 | Ulcerative colitis |
| rs6499188 | Secondary malignant neoplasm | 0.009313 | 1.171 | ZFP90 | Ulcerative colitis |
| rs6499188 | Behcet's syndrome | 0.001708 | 0.5233 | ZFP90 | Ulcerative colitis |
| rs6499188 | Subarachnoid hemorrhage | 0.008122 | 1.899 | ZFP90 | Ulcerative colitis |
| rs6499188 | Acid-base balance disorder | 0.005501 | 0.7072 | ZFP90 | Ulcerative colitis |
| rs6499188 | Benign neoplasm of uterus | 0.01076 | 1.225 | ZFP90 | Ulcerative colitis |
| rs6499188 | Pulmonary congestion and hypostasis | 0.01002 | 0.6911 | ZFP90 | Ulcerative colitis |
| rs6499188 | Abnormal findings on examination of urine | 0.001066 | 0.7945 | ZFP90 | Ulcerative colitis |
| rs6499188 | Myocardial infarction | 0.002462 | 0.851 | ZFP90 | Ulcerative colitis |
| rs6499188 | Personal history of allergy to medicinal agents | 0.00855 | 1.284 | ZFP90 | Ulcerative colitis |
| rs6499188 | Malignant neoplasm of kidney and other urinary organs | 0.0001476 | 2.069 | ZFP90 | Ulcerative colitis |
| rs6499188 | Polycystic ovaries | 0.00294 | 2.188 | ZFP90 | Ulcerative colitis |
| rs6499188 | Disorders of menstruation | 0.00216 | 1.262 | ZFP90 | Ulcerative colitis |
| rs6499188 | Strabismus (not specified as paralytic) | 0.01063 | 1.25 | ZFP90 | Ulcerative colitis |
| rs6499640 | Frequency of urination and polyuria | 0.004099 | 0.8773 | FTO | Body mass index, Weight |
| rs6499640 | Cancer of other lymphoid, histiocytic tissue | 0.004358 | 0.7647 | FTO | Body mass index, Weight |
| rs6499640 | End stage renal disease | 0.004562 | 0.6818 | FTO | Body mass index, Weight |
| rs6499640 | Shock | 0.0005104 | 0.6315 | FTO | Body mass index, Weight |
| rs6499640 | Abdominal aortic aneurysm | 0.004234 | 0.7921 | FTO | Body mass index, Weight |
| rs6499640 | Althete's foot | 0.009963 | 1.245 | FTO | Body mass index, Weight |
| rs6499640 | Adverse effects of insulins and antidiabetic agents | 0.008263 | 0.5224 | FTO | Body mass index, Weight |
| rs6499640 | Non-Hodgkins lymphoma | 0.009113 | 0.7785 | FTO | Body mass index, Weight |
| rs6499640 | Aneurysm of iliac artery | 0.009358 | 0.573 | FTO | Body mass index, Weight |
| rs6499640 | Gingivitis | 0.001483 | 0.4508 | FTO | Body mass index, Weight |
| rs651164 | Trigeminal nerve disorders | 0.0007351 | 1.589 | SLC22A1 | Prostate cancer |
| rs651164 | Pain, swelling or discharge of eye | 0.00418 | 1.387 | SLC22A1 | Prostate cancer |
| rs651164 | Osteoporosis, osteopenia, & pathological fractures | 0.007793 | 0.9072 | SLC22A1 | Prostate cancer |
| rs651164 | Acquired foot deformities | 0.008229 | 1.124 | SLC22A1 | Prostate cancer |
| rs651164 | Open wound of lip and mouth | 0.0008366 | 1.938 | SLC22A1 | Prostate cancer |
| rs651164 | Symptoms associated with female genital organs | 0.004743 | 1.208 | SLC22A1 | Prostate cancer |
| rs651164 | Keloid scar | 0.000513 | 1.883 | SLC22A1 | Prostate cancer |
| rs651164 | Mixed hyperlipidemia | 0.009225 | 0.8457 | SLC22A1 | Prostate cancer |
| rs651164 | Vascular insufficiency of intestine | 0.01032 | 0.687 | SLC22A1 | Prostate cancer |
| rs651164 | Oral aphthae | 0.01047 | 1.596 | SLC22A1 | Prostate cancer |
| rs651164 | Essential tremor | 0.008177 | 0.7467 | SLC22A1 | Prostate cancer |
| rs651164 | Periostitis | 0.006529 | 1.796 | SLC22A1 | Prostate cancer |
| rs651164 | Type 2 diabetic nephropathy | 0.0005723 | 0.7586 | SLC22A1 | Prostate cancer |
| rs651164 | Type 2 diabetic peripheral circulatory disorders | 0.0001671 | 0.5877 | SLC22A1 | Prostate cancer |
| rs651164 | Aneurysm of other specified artery | 0.002104 | 1.969 | SLC22A1 | Prostate cancer |
| rs651164 | Peripheral angiopathy in diseases classified elsewhere | 0.004579 | 0.5337 | SLC22A1 | Prostate cancer |
| rs651164 | Other hereditary hemolytic anemias | 0.008584 | 0.3434 | SLC22A1 | Prostate cancer |
| rs6511720 | Abnormal results of function studies | 0.01072 | 1.814 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Allergy to serum or vaccine | 0.0002801 | 2.505 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Diverticulitis | 0.004986 | 1.37 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Mixed hyperlipidemia | 0.00471 | 0.7639 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Diseases of the jaws | 0.006082 | 0.7238 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Allergy/adverse effect of penicillin | 0.003232 | 1.4 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Diseases of white blood cells | 0.01138 | 1.263 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Congenital musculoskeletal anomalies | 0.0002646 | 3.172 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Hyperlipidemia | 6.739e-06 | 0.7948 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Disorders of lipoid metabolism | 4.148e-06 | 0.7919 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Temporomandibular joint disorders | 0.002623 | 0.59 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Other peripheral nerve disorders | 0.00484 | 1.17 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Other arthropathies | 0.004869 | 1.193 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Poisoning by antibiotics | 0.002142 | 1.368 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Cardiac arrhythmia NOS | 0.007568 | 1.237 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Retinal edema and hypertensive retinopathy | 0.004468 | 1.495 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.004911 | 0.6592 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Pain in limb | 0.001092 | 1.174 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Hypercholesterolemia | 2.492e-06 | 0.7387 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Reflux esophagitis | 0.01018 | 1.31 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs6511720 | Corneal edema | 0.008885 | 0.2643 | LDLR | Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Carotid plaque |
| rs652889 | Other disorders of metabolism | 0.0004326 | 0.4359 | PTPRG | QT interval |
| rs652889 | Cellulitis and abscess of arm | 0.0009428 | 0.7298 | PTPRG | QT interval |
| rs652889 | Symptoms involving cardiovascular system | 0.007493 | 1.166 | PTPRG | QT interval |
| rs652889 | Palpitations | 0.01052 | 1.136 | PTPRG | QT interval |
| rs652889 | Arthropathy associated with neurological disorders | 0.005681 | 1.865 | PTPRG | QT interval |
| rs652889 | Cholecystitis without cholelithiasis | 0.002191 | 1.356 | PTPRG | QT interval |
| rs652889 | Dyshidrosis | 0.005466 | 0.533 | PTPRG | QT interval |
| rs652889 | Allergies, other | 0.009609 | 0.7825 | PTPRG | QT interval |
| rs652889 | Atrial fibrillation & flutter | 0.007333 | 1.136 | PTPRG | QT interval |
| rs652889 | Cardiac dysrhythmias | 0.00764 | 1.091 | PTPRG | QT interval |
| rs652889 | Atrial fibrillation | 0.003374 | 1.152 | PTPRG | QT interval |
| rs652889 | Pyogenic granuloma | 0.009351 | 0.4662 | PTPRG | QT interval |
| rs652889 | Disorders of optic nerve and visual pathways | 0.009887 | 0.7785 | PTPRG | QT interval |
| rs652889 | Cerebral edema and compression of brain | 0.001437 | 2.054 | PTPRG | QT interval |
| rs652889 | Hemorrhage or hematoma complicating a procedure | 0.003932 | 1.241 | PTPRG | QT interval |
| rs652889 | Hyperventilation | 0.009978 | 1.656 | PTPRG | QT interval |
| rs652889 | Optic neuritis/neuropathy | 0.009147 | 0.7196 | PTPRG | QT interval |
| rs652889 | Other specified cardiac dysrhythmias | 0.003315 | 1.156 | PTPRG | QT interval |
| rs653178 | Other disorders of gallbladder | 0.001089 | 0.5639 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Ventricular fibrillation & flutter | 0.008967 | 0.6252 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Ischemic Heart Disease | 0.008778 | 1.082 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Retinoschisis and retinal cysts | 0.004073 | 2.223 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Osteoporosis | 0.007409 | 1.129 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Open wound of finger(s) | 0.008721 | 0.8589 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Hypertension | 0.007377 | 1.083 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis of the extremities | 0.002111 | 1.16 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis of renal artery | 0.009476 | 1.275 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Other congenital anomalies of skin | 0.004834 | 1.457 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Hypothyroidism | 4.031e-06 | 1.18 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Cancer of the upper aerodigestive tract | 0.005419 | 0.7174 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.001173 | 1.214 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Myocardial infarction | 0.0004842 | 1.169 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Acute bronchospasm | 0.008823 | 0.4516 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Aortic aneurysm | 0.01004 | 1.191 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.006289 | 1.241 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Uterine leiomyoma | 0.006187 | 0.8137 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Other rheumatic heart disease | 0.005799 | 2.053 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Mastodynia | 0.01011 | 1.256 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Arterial embolism and thrombosis | 0.003545 | 1.261 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Coronary atherosclerosis | 0.006311 | 1.091 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Morbid obesity | 0.01029 | 0.8655 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Peyronie's disease | 0.01148 | 1.772 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Essential hypertension | 0.006539 | 1.084 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.01043 | 1.279 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Endometriosis | 0.003504 | 0.7128 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Anomalies of tooth position/malocclusion | 0.00667 | 0.5976 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Abnormal findings on mammogram or breast exam | 0.006219 | 1.123 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Peripheral vascular disease | 0.01039 | 1.109 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Atherosclerosis | 0.001768 | 1.142 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Osteoporosis, NOS or other | 0.005962 | 1.129 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Peripheral arterial disease | 0.006118 | 1.128 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Disease of tricuspid valve | 0.008312 | 1.247 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs653178 | Benign neoplasm of uterus | 0.001757 | 0.8004 | ATXN2 | Celiac disease, Celiac disease or Rheumatoid arthritis, Serum cystatin C, Diastolic blood pressure, Mean Arterial Pressure |
| rs6544713 | Meniere's disease | 0.008345 | 1.614 | ABCG8 | LDL Cholesterol |
| rs6544713 | Phobia | 0.004104 | 0.3306 | ABCG8 | LDL Cholesterol |
| rs6544713 | Secondary malignant neoplasm | 0.000967 | 0.8205 | ABCG8 | LDL Cholesterol |
| rs6544713 | Malunion fracture | 0.0003264 | 1.601 | ABCG8 | LDL Cholesterol |
| rs6544713 | pulmonary heart disease | 0.009898 | 0.8573 | ABCG8 | LDL Cholesterol |
| rs6544713 | Mammographic microcalcification | 0.004132 | 0.5645 | ABCG8 | LDL Cholesterol |
| rs6544713 | Contracture of joint | 0.001021 | 1.503 | ABCG8 | LDL Cholesterol |
| rs6544713 | Lung cancer | 0.00462 | 0.7766 | ABCG8 | LDL Cholesterol |
| rs6544713 | Calculus of bile duct | 0.007952 | 0.7138 | ABCG8 | LDL Cholesterol |
| rs6544713 | Pulmonary embolism and infarction | 0.001559 | 0.7445 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cholelithiasis and cholecystitis | 8.515e-05 | 0.8245 | ABCG8 | LDL Cholesterol |
| rs6544713 | Diseases of the oral soft tissues | 0.009239 | 0.8498 | ABCG8 | LDL Cholesterol |
| rs6544713 | Hyperlipidemia | 0.008437 | 1.096 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cholelithiasis | 0.00023 | 0.8242 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cancer within the respiratory system | 0.006127 | 0.7864 | ABCG8 | LDL Cholesterol |
| rs6544713 | Fracture of hand or wrist | 0.004027 | 1.193 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cholelithiasis with other cholecystitis | 0.000489 | 0.6853 | ABCG8 | LDL Cholesterol |
| rs6544713 | Cellulitis and abscess of hand/fingers | 0.005621 | 0.824 | ABCG8 | LDL Cholesterol |
| rs6544713 | Disorders of lipoid metabolism | 0.0068 | 1.098 | ABCG8 | LDL Cholesterol |
| rs6544713 | Constipation | 0.006136 | 0.8679 | ABCG8 | LDL Cholesterol |
| rs6544713 | Balanoposthitis | 0.009255 | 1.644 | ABCG8 | LDL Cholesterol |
| rs6554809 | Other specified intestinal malabsorption | 0.004232 | 1.883 | DNAH5 | IgE grass sensitization |
| rs6554809 | Type 2 diabetic ketoacidosis | 0.004451 | 0.8266 | DNAH5 | IgE grass sensitization |
| rs6554809 | Myeloid leukemia | 0.005969 | 1.973 | DNAH5 | IgE grass sensitization |
| rs6554809 | Pityriasis | 0.01043 | 2.218 | DNAH5 | IgE grass sensitization |
| rs6554809 | Hyperpotassemia | 0.01083 | 0.7875 | DNAH5 | IgE grass sensitization |
| rs6554809 | Diabetes mellitus | 0.008727 | 0.8957 | DNAH5 | IgE grass sensitization |
| rs6554809 | Joint/ligament sprain | 0.008877 | 1.397 | DNAH5 | IgE grass sensitization |
| rs6554809 | Type 2 diabetes | 0.007661 | 0.8927 | DNAH5 | IgE grass sensitization |
| rs6554809 | Paralytic strabismus | 0.00326 | 1.674 | DNAH5 | IgE grass sensitization |
| rs6554809 | Asthma | 0.004919 | 1.169 | DNAH5 | IgE grass sensitization |
| rs6554809 | Disorders of vitreous body | 0.005403 | 1.179 | DNAH5 | IgE grass sensitization |
| rs6554809 | Acute posthemorrhagic anemia | 0.008646 | 0.7993 | DNAH5 | IgE grass sensitization |
| rs6554809 | Gross hematuria | 0.01083 | 1.66 | DNAH5 | IgE grass sensitization |
| rs6554809 | Other disorders of eye | 0.01017 | 1.151 | DNAH5 | IgE grass sensitization |
| rs6563943 | Other specified gastritis | 0.007105 | 0.7793 | CDH13 | Height |
| rs6563943 | Systemic sclerosis | 0.01035 | 0.643 | CDH13 | Height |
| rs6563943 | Other disorders of biliary tract | 0.002577 | 0.5965 | CDH13 | Height |
| rs6563943 | Other arthropathies | 0.002388 | 0.8786 | CDH13 | Height |
| rs6563943 | Arthropathy NOS | 0.004595 | 0.8331 | CDH13 | Height |
| rs6563943 | Other disorders of back | 0.007407 | 0.8597 | CDH13 | Height |
| rs6563943 | Muscle/tendon sprain | 0.005316 | 1.92 | CDH13 | Height |
| rs6563943 | Macular degeneration, wet | 0.01066 | 0.7537 | CDH13 | Height |
| rs6563943 | Retinal drusen | 0.004668 | 0.8002 | CDH13 | Height |
| rs6563943 | Abnormal findings on radiological exam of musculoskeletal system | 0.003352 | 1.635 | CDH13 | Height |
| rs6563943 | Secondary malignancy of lymph nodes | 0.005906 | 0.7797 | CDH13 | Height |
| rs6563943 | Viral pneumonia | 0.001407 | 2.329 | CDH13 | Height |
| rs6563943 | Lower gastrointestinal congenital anomalies | 0.003741 | 0.4478 | CDH13 | Height |
| rs6563943 | Anal and rectal polyp | 0.008132 | 1.24 | CDH13 | Height |
| rs6563943 | Atrophic gastritis | 0.006521 | 0.6493 | CDH13 | Height |
| rs6563943 | Macular degeneration, dry | 0.004267 | 0.7992 | CDH13 | Height |
| rs6563943 | Other hemoglobinopathies | 0.008114 | 1.93 | CDH13 | Height |
| rs6563943 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.008892 | 0.8336 | CDH13 | Height |
| rs6564851 | Other local infections of skin and subcutaneous tissue | 0.008236 | 0.8592 | BCMO1 | Beta-carotene |
| rs6564851 | Bronchopneumonia and lung abscess | 0.003982 | 0.542 | BCMO1 | Beta-carotene |
| rs6564851 | Alcohol-related disorders | 0.007935 | 1.186 | BCMO1 | Beta-carotene |
| rs6564851 | Peripheral autonomic neuropathy | 0.009576 | 1.36 | BCMO1 | Beta-carotene |
| rs6564851 | Hypertrophy of breast (Gynecomastia) | 0.0109 | 0.7523 | BCMO1 | Beta-carotene |
| rs6564851 | Scar conditions and fibrosis of skin | 0.01128 | 0.782 | BCMO1 | Beta-carotene |
| rs6564851 | Cerebral edema and compression of brain | 0.005651 | 0.5119 | BCMO1 | Beta-carotene |
| rs6564851 | Angina pectoris | 0.002601 | 1.144 | BCMO1 | Beta-carotene |
| rs6564851 | Chronic glomerulonephritis | 0.002148 | 0.38 | BCMO1 | Beta-carotene |
| rs6564851 | Retinal detachments and defects | 0.01009 | 1.209 | BCMO1 | Beta-carotene |
| rs6564851 | Thyroiditis | 0.005146 | 0.7347 | BCMO1 | Beta-carotene |
| rs6564851 | Primary pulmonary hypertension | 0.003216 | 0.6034 | BCMO1 | Beta-carotene |
| rs6564851 | Anemia NOS | 0.009826 | 1.088 | BCMO1 | Beta-carotene |
| rs6564851 | Pyogenic granuloma | 0.006405 | 0.537 | BCMO1 | Beta-carotene |
| rs6569648 | Dermatophytosis of the body | 0.00585 | 1.4 | L3MBTL3 | Height |
| rs6569648 | Kyphosis (acquired) | 0.01057 | 1.481 | L3MBTL3 | Height |
| rs6569648 | Nontoxic uninodular goiter | 0.003347 | 1.283 | L3MBTL3 | Height |
| rs6569648 | Nonrheumatic mitral valve disorders | 0.004468 | 1.177 | L3MBTL3 | Height |
| rs6569648 | Umbilical hernia | 0.01036 | 1.29 | L3MBTL3 | Height |
| rs6569648 | Abnormal cytological, histological, immunological and DNA test findings | 0.01128 | 1.773 | L3MBTL3 | Height |
| rs6569648 | Stomatitis and mucositis | 0.009334 | 0.66 | L3MBTL3 | Height |
| rs6569648 | Muscular wasting and disuse atrophy | 0.01041 | 0.5217 | L3MBTL3 | Height |
| rs6569648 | Inflammatory conditions of jaw | 0.008628 | 1.573 | L3MBTL3 | Height |
| rs6569648 | Phobia | 0.005358 | 0.2343 | L3MBTL3 | Height |
| rs6569648 | Acute bronchospasm | 0.003265 | 2.376 | L3MBTL3 | Height |
| rs6569648 | Other unspecified back disorders | 0.01028 | 1.559 | L3MBTL3 | Height |
| rs6569648 | Psychogenic and somatoform disorders | 0.007156 | 0.7437 | L3MBTL3 | Height |
| rs6569648 | Open wound of lip and mouth | 0.006077 | 1.78 | L3MBTL3 | Height |
| rs6569648 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.006561 | 1.126 | L3MBTL3 | Height |
| rs6569648 | Abnormal sputum | 0.008047 | 1.345 | L3MBTL3 | Height |
| rs6585827 | Mastodynia | 0.007775 | 1.262 | PLEKHA1 | Height |
| rs6585827 | Rheumatoid arthritis | 2.319e-05 | 1.362 | PLEKHA1 | Height |
| rs6585827 | Macular degeneration | 0.008794 | 1.121 | PLEKHA1 | Height |
| rs6585827 | Hypercholesterolemia | 0.003578 | 1.121 | PLEKHA1 | Height |
| rs6585827 | Blood vessel replaced | 0.006269 | 0.6306 | PLEKHA1 | Height |
| rs6585827 | Corneal dystrophy | 0.0005382 | 1.385 | PLEKHA1 | Height |
| rs6585827 | Rheumatoid arthritis & related inflammatory polyarthropathies | 2.102e-05 | 1.317 | PLEKHA1 | Height |
| rs6585827 | Congenital anomalies of lower limb, including pelvic girdle | 0.01006 | 0.5674 | PLEKHA1 | Height |
| rs6585827 | Contracture of joint | 0.004106 | 0.7017 | PLEKHA1 | Height |
| rs6585827 | Genu valgum or varum (acquired) | 0.006065 | 0.7003 | PLEKHA1 | Height |
| rs6585827 | Acne | 0.003513 | 1.304 | PLEKHA1 | Height |
| rs6585827 | Asthma | 0.009977 | 1.115 | PLEKHA1 | Height |
| rs6585827 | Essential tremor | 0.001274 | 1.367 | PLEKHA1 | Height |
| rs6585827 | Benign neoplasm of other endocrine glands | 0.003487 | 1.441 | PLEKHA1 | Height |
| rs6585827 | Paraproteinemia | 0.005943 | 1.374 | PLEKHA1 | Height |
| rs6585827 | Type 1 diabetic ketoacidosis | 0.006401 | 0.7041 | PLEKHA1 | Height |
| rs6585827 | Cataract | 0.003069 | 1.116 | PLEKHA1 | Height |
| rs6585827 | Other specified osteoporosis | 0.005426 | 1.66 | PLEKHA1 | Height |
| rs6585827 | Aphakia and other disorders of lens | 0.007296 | 1.283 | PLEKHA1 | Height |
| rs6585827 | Macular degeneration, wet | 4.062e-06 | 1.621 | PLEKHA1 | Height |
| rs6585827 | Blister | 0.005723 | 0.5357 | PLEKHA1 | Height |
| rs6585827 | Extrapyramidal disease and abnormal movement disorders | 0.006973 | 1.178 | PLEKHA1 | Height |
| rs6585827 | Age-related macular degeneration | 5.279e-05 | 1.302 | PLEKHA1 | Height |
| rs6585827 | Arterial embolism and thrombosis of lower extremity artery | 0.01062 | 0.7535 | PLEKHA1 | Height |
| rs6585827 | Arterial embolism and thrombosis | 0.001841 | 0.7798 | PLEKHA1 | Height |
| rs6585827 | Symptoms involving respiratory system | 0.003524 | 1.218 | PLEKHA1 | Height |
| rs6586282 | Visual disturbances | 2.3e-06 | 0.7697 | CBS | Homocysteine levels |
| rs6586282 | Benign neoplasm of eye | 0.006038 | 1.307 | CBS | Homocysteine levels |
| rs6586282 | Pyogenic arthritis | 0.0009896 | 1.959 | CBS | Homocysteine levels |
| rs6586282 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.007723 | 0.4586 | CBS | Homocysteine levels |
| rs6586282 | Lung involvement in conditions classified elsewhere | 0.009123 | 2.094 | CBS | Homocysteine levels |
| rs6586282 | Subjective visual disturbances | 0.006147 | 0.764 | CBS | Homocysteine levels |
| rs6586282 | Suppurative and unspecified otitis media | 0.01135 | 1.197 | CBS | Homocysteine levels |
| rs6586282 | Optic neuritis/neuropathy | 0.0009179 | 0.5844 | CBS | Homocysteine levels |
| rs6586282 | Diseases of hard tissues of teeth | 0.007596 | 0.788 | CBS | Homocysteine levels |
| rs6586282 | Keratitis | 0.005564 | 0.6693 | CBS | Homocysteine levels |
| rs6586282 | Mitral stenosis/insufficiency | 0.001313 | 2.171 | CBS | Homocysteine levels |
| rs6586282 | Prolapse of vaginal vault after hysterectomy | 0.0003611 | 1.772 | CBS | Homocysteine levels |
| rs6586282 | Lichen | 0.009038 | 1.601 | CBS | Homocysteine levels |
| rs6586282 | Disorders of optic nerve and visual pathways | 0.002614 | 0.6948 | CBS | Homocysteine levels |
| rs6586282 | Thyrotoxicosis | 0.01079 | 1.275 | CBS | Homocysteine levels |
| rs6586282 | Dyspareunia | 0.00353 | 0.3897 | CBS | Homocysteine levels |
| rs6586282 | Aseptic necrosis of bone | 0.008398 | 1.625 | CBS | Homocysteine levels |
| rs6586282 | Disease of tricuspid valve | 0.01096 | 1.303 | CBS | Homocysteine levels |
| rs6586282 | Noninflammatory disorders of vagina | 0.007844 | 0.6375 | CBS | Homocysteine levels |
| rs6586282 | Chronic rheumatic disease of the heart valves | 0.009085 | 1.194 | CBS | Homocysteine levels |
| rs6586282 | Disturbances in tooth eruption | 0.01001 | 0.6688 | CBS | Homocysteine levels |
| rs6586282 | Prurigo | 0.0068 | 1.355 | CBS | Homocysteine levels |
| rs6610953 | Endometriosis | 0.005403 | 1.497 | FUNDC1 | Personality dimensions |
| rs6610953 | Nausea and vomiting | 0.007462 | 1.154 | FUNDC1 | Personality dimensions |
| rs6610953 | Intestinal obstruction without mention of hernia | 0.007758 | 1.283 | FUNDC1 | Personality dimensions |
| rs6610953 | Carcinoma in situ of skin | 6.656e-05 | 1.568 | FUNDC1 | Personality dimensions |
| rs6610953 | Disorders of mineral metabolism | 0.002257 | 1.238 | FUNDC1 | Personality dimensions |
| rs6610953 | Other specified osteoporosis | 0.009632 | 1.802 | FUNDC1 | Personality dimensions |
| rs6610953 | Otosclerosis | 0.00247 | 1.784 | FUNDC1 | Personality dimensions |
| rs6610953 | Menopausal & postmenopausal disorders | 0.009685 | 1.167 | FUNDC1 | Personality dimensions |
| rs6610953 | Calcium/phosphorus disorders | 0.001798 | 1.341 | FUNDC1 | Personality dimensions |
| rs6610953 | Pseudomonal pneumonia | 7.751e-05 | 4.133 | FUNDC1 | Personality dimensions |
| rs6610953 | Cramp of limb | 0.003626 | 1.467 | FUNDC1 | Personality dimensions |
| rs6610953 | Other specified diseases of the salivary glands | 0.01011 | 1.925 | FUNDC1 | Personality dimensions |
| rs6610953 | Phosphorus metabolism disorder | 0.007641 | 1.633 | FUNDC1 | Personality dimensions |
| rs6610953 | Fracture of vertebral column without mention of spinal cord injury | 0.007304 | 1.316 | FUNDC1 | Personality dimensions |
| rs6610953 | Inflammatory conditions of jaw | 0.01124 | 1.736 | FUNDC1 | Personality dimensions |
| rs6610953 | Pneumonitis due to inhalation of food or vomitus | 0.005377 | 1.504 | FUNDC1 | Personality dimensions |
| rs6610953 | Cancer of other female genital organs | 0.003678 | 2.13 | FUNDC1 | Personality dimensions |
| rs6611365 | Peritoneal adhesions (postoperative) (postinfection) | 0.006202 | 0.4576 | ZNF157 | Optic disc parameters |
| rs6611365 | Benign neoplasm of colon | 0.008087 | 0.8846 | ZNF157 | Optic disc parameters |
| rs6611365 | Otorrhea | 0.002066 | 2.381 | ZNF157 | Optic disc parameters |
| rs6611365 | Uterine/Uterovaginal prolapse | 0.007443 | 0.7221 | ZNF157 | Optic disc parameters |
| rs6611365 | Stricture of artery | 0.01119 | 0.6749 | ZNF157 | Optic disc parameters |
| rs6611365 | Seborrhea | 0.005513 | 2.098 | ZNF157 | Optic disc parameters |
| rs6611365 | Unstable angina (intermediate coronary syndrome) | 0.001808 | 1.272 | ZNF157 | Optic disc parameters |
| rs6611365 | Open wound of lip and mouth | 0.00651 | 0.2818 | ZNF157 | Optic disc parameters |
| rs6611365 | Respiratory failure | 0.004656 | 0.6734 | ZNF157 | Optic disc parameters |
| rs6611365 | Dysmenorrhea | 0.009179 | 0.5865 | ZNF157 | Optic disc parameters |
| rs6708166 | Corns and callosities | 0.01116 | 0.867 | LBH | Factor VIII activity |
| rs6708166 | Keratoderma, acquired | 1.104e-05 | 0.7688 | LBH | Factor VIII activity |
| rs6708166 | Intestinal obstruction without mention of hernia | 0.009572 | 0.839 | LBH | Factor VIII activity |
| rs6708166 | Other hypertrophic and atrophic conditions of skin | 4.908e-06 | 0.8282 | LBH | Factor VIII activity |
| rs6708166 | Disease of capillaries | 0.001506 | 0.6798 | LBH | Factor VIII activity |
| rs6708166 | Infestation | 0.00989 | 0.5629 | LBH | Factor VIII activity |
| rs6708166 | Atherosclerosis of renal artery | 0.00199 | 0.7307 | LBH | Factor VIII activity |
| rs6708166 | Other disorders of lipoid metabolism and hyperalimentation | 0.0104 | 0.7817 | LBH | Factor VIII activity |
| rs6708166 | Cerebrovascular disease | 0.002173 | 0.8985 | LBH | Factor VIII activity |
| rs6708166 | Suicidal ideation or attempt | 0.01035 | 1.667 | LBH | Factor VIII activity |
| rs6708166 | Encounter for long-term use of antiplatelets/antithrombotics | 0.01036 | 0.4374 | LBH | Factor VIII activity |
| rs6708166 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.01054 | 0.8509 | LBH | Factor VIII activity |
| rs6708166 | Other disorders of thyroid | 0.006762 | 0.7434 | LBH | Factor VIII activity |
| rs6708166 | Renal failure | 0.008308 | 0.904 | LBH | Factor VIII activity |
| rs6708166 | Personality disorders | 0.003971 | 0.7754 | LBH | Factor VIII activity |
| rs6708166 | Nevus, non-neoplastic | 0.0008948 | 0.4784 | LBH | Factor VIII activity |
| rs6708166 | Cervicocranial/Cervicobrachial syndrome | 0.007824 | 0.7893 | LBH | Factor VIII activity |
| rs6708166 | Viral pneumonia | 0.008753 | 2.018 | LBH | Factor VIII activity |
| rs6708166 | Acquired deformities of finger | 0.008652 | 1.431 | LBH | Factor VIII activity |
| rs6711606 | Disorders of synovium, tendon, and bursa | 0.003573 | 1.155 | RNF149 | Pancreatic cancer |
| rs6711606 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.000921 | 2.659 | RNF149 | Pancreatic cancer |
| rs6711606 | Gram positive septicemia | 0.001032 | 1.848 | RNF149 | Pancreatic cancer |
| rs6711606 | Infection of the eye | 0.004009 | 1.198 | RNF149 | Pancreatic cancer |
| rs6711606 | Abnormal results of function studies | 0.006981 | 1.685 | RNF149 | Pancreatic cancer |
| rs6711606 | Glomerulonephritis | 0.006733 | 0.4368 | RNF149 | Pancreatic cancer |
| rs6711606 | Osteoarthrosis, generalized | 0.0105 | 0.7857 | RNF149 | Pancreatic cancer |
| rs6711606 | Paroxysmal supraventricular tachycardia | 0.006986 | 0.7192 | RNF149 | Pancreatic cancer |
| rs6711606 | Deviated nasal septum | 0.008871 | 0.8093 | RNF149 | Pancreatic cancer |
| rs6725887 | Gastritis and duodenitis, NOS | 0.007505 | 0.7211 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Benign neoplasm of ovary | 0.005873 | 1.743 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Heart transplant/surgery | 0.005508 | 1.594 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Aortic aneurysm | 0.005209 | 0.7347 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.001883 | 1.89 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Upper gastrointestinal congenital anomalies | 0.009801 | 0.4107 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Other aneurysm | 0.008377 | 0.7719 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Ischemic stroke | 0.009485 | 1.27 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Occlusion of cerebral arteries | 0.007269 | 1.267 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Unspecified erythematous condition | 0.0103 | 1.59 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Neutropenia | 0.01035 | 1.307 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Bacterial enteritis | 0.0007579 | 1.562 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Inflammatory diseases of prostate | 0.003634 | 0.7036 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Psoriasis | 0.005051 | 1.358 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Benign neoplasm of colon | 0.004503 | 0.8698 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Osteitis deformans and osteopathies associated with other disorders | 0.002839 | 1.995 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Disease of tricuspid valve | 0.002742 | 1.398 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Benign neoplasm of bone and articular cartilage | 0.005938 | 1.91 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Psoriasis vulgaris | 0.005267 | 1.366 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Fracture of lower limb | 0.006995 | 1.217 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Alopecia | 0.006896 | 1.436 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Paget's disease of bone | 0.0109 | 2.316 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6725887 | Fracture of neck of femur | 0.006685 | 1.308 | WDR12 | Early onset myocardial infarction, Coronary heart disease |
| rs6782029 | Chronic liver disease and cirrhosis | 0.008633 | 0.7791 | VGLL4 | Anorexia nervosa |
| rs6782029 | Schizoid personality disorder | 0.01046 | 0.4966 | VGLL4 | Anorexia nervosa |
| rs6782029 | Leukoplakia of oral mucosa | 0.009419 | 1.802 | VGLL4 | Anorexia nervosa |
| rs6782029 | Disease of tricuspid valve | 0.001908 | 0.7099 | VGLL4 | Anorexia nervosa |
| rs6782029 | Drug-resistant infection | 0.004362 | 0.6385 | VGLL4 | Anorexia nervosa |
| rs6782029 | Disorders of cervical region | 0.007096 | 0.6843 | VGLL4 | Anorexia nervosa |
| rs6782029 | Methicillin sensitive Staphylococcus aureus | 0.009489 | 0.6959 | VGLL4 | Anorexia nervosa |
| rs6782029 | Posttraumatic stress disorder | 0.003641 | 1.649 | VGLL4 | Anorexia nervosa |
| rs6782029 | Staphylococcus infections | 0.0002317 | 0.6666 | VGLL4 | Anorexia nervosa |
| rs6782029 | Alopecia Areata | 0.0002844 | 2.571 | VGLL4 | Anorexia nervosa |
| rs6782029 | Insulin pump user | 0.006776 | 1.283 | VGLL4 | Anorexia nervosa |
| rs6782029 | Myasthenia gravis | 0.006039 | 2.059 | VGLL4 | Anorexia nervosa |
| rs6782029 | Lymphadenitis | 0.009643 | 0.8248 | VGLL4 | Anorexia nervosa |
| rs6782029 | Bacterial infection NOS | 0.001123 | 0.8293 | VGLL4 | Anorexia nervosa |
| rs6791644 | Cardiac arrest & ventricular fibrillation | 0.0002338 | 1.861 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Cardiac pacemaker in situ | 0.003615 | 1.381 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Congenital anomalies of posterior segment of eye | 0.004698 | 0.608 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Patellar fracture | 0.003294 | 1.649 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Plasma protein metabolism disorder | 0.007443 | 1.434 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Biliary cirrhosis | 0.0004131 | 3.116 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Cirrhosis of liver without mention of alcohol | 0.005864 | 1.621 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Congenital anomalies of the eye | 0.0002848 | 0.5793 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Retinal detachments and defects | 0.01004 | 1.321 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Infestation | 0.003859 | 2.005 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | First degree AV block | 0.0002606 | 1.536 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | AV block | 0.0002882 | 1.421 | FHIT | Attention deficit hyperactivity disorder |
| rs6791644 | Congenital anomalies of peripheral vascular system | 0.007399 | 2.069 | FHIT | Attention deficit hyperactivity disorder |
| rs6807064 | Other conditions of the mother complicating pregnancy | 0.00175 | 0.5011 | ATP2B2 | Phenylalanine |
| rs6807064 | Herpes zoster | 0.006912 | 1.199 | ATP2B2 | Phenylalanine |
| rs6807064 | Nephritis & nephropathy | 0.002468 | 1.717 | ATP2B2 | Phenylalanine |
| rs6807064 | Posttraumatic stress disorder | 0.006929 | 0.5738 | ATP2B2 | Phenylalanine |
| rs6807064 | Abnormal Papanicolaou smear of cervix and cervical HPV | 0.008969 | 0.8025 | ATP2B2 | Phenylalanine |
| rs6807064 | Diseases of pulp and periapical tissues | 0.001094 | 1.267 | ATP2B2 | Phenylalanine |
| rs6807064 | Breast disorder NOS | 0.004864 | 2.232 | ATP2B2 | Phenylalanine |
| rs6807064 | Plasma protein metabolism disorder | 0.01126 | 1.29 | ATP2B2 | Phenylalanine |
| rs6807064 | Renal colic | 0.008716 | 0.5255 | ATP2B2 | Phenylalanine |
| rs6807064 | Periapical abscess | 0.002929 | 1.253 | ATP2B2 | Phenylalanine |
| rs6807064 | Chronic obstructive asthma with exacerbation | 0.0003286 | 1.962 | ATP2B2 | Phenylalanine |
| rs6807064 | Type 2 diabetic peripheral circulatory disorders | 0.01104 | 1.362 | ATP2B2 | Phenylalanine |
| rs6807064 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.0004113 | 1.804 | ATP2B2 | Phenylalanine |
| rs6845865 | Nonrheumatic mitral valve disorders | 0.01095 | 1.181 | ARHGAP10 | QT interval |
| rs6845865 | Cervical cancer | 0.01006 | 1.942 | ARHGAP10 | QT interval |
| rs6845865 | Hematuria | 0.000717 | 0.8283 | ARHGAP10 | QT interval |
| rs6845865 | Torticollis | 0.009877 | 1.616 | ARHGAP10 | QT interval |
| rs6845865 | Polycythemia vera, secondary | 0.009307 | 0.4399 | ARHGAP10 | QT interval |
| rs6845865 | Disorders of tooth development | 0.008774 | 0.6481 | ARHGAP10 | QT interval |
| rs6845865 | Spirochetal infection | 0.00496 | 1.664 | ARHGAP10 | QT interval |
| rs6845865 | Lyme disease | 0.002316 | 1.744 | ARHGAP10 | QT interval |
| rs6845865 | Renal colic | 0.0005439 | 2.035 | ARHGAP10 | QT interval |
| rs6869388 | Other acquired musculoskeletal deformity | 0.003407 | 0.7259 | C5orf36 | Gallbladder cancer |
| rs6869388 | Disorders of uterus, NEC | 0.003707 | 1.956 | C5orf36 | Gallbladder cancer |
| rs6869388 | Hemorrhage from gastrointestinal ulcer | 0.009558 | 1.453 | C5orf36 | Gallbladder cancer |
| rs6869388 | Sensorineural hearing loss | 0.003263 | 1.145 | C5orf36 | Gallbladder cancer |
| rs6869388 | Hyperosmolality and/or hypernatremia | 0.003955 | 1.578 | C5orf36 | Gallbladder cancer |
| rs6869388 | Melanoma | 0.004799 | 0.7033 | C5orf36 | Gallbladder cancer |
| rs6869388 | Hearing loss | 0.001356 | 1.133 | C5orf36 | Gallbladder cancer |
| rs6869388 | Superficial cellulitis and abscess | 0.007667 | 1.121 | C5orf36 | Gallbladder cancer |
| rs6869388 | Hypertrophy of female genital organs | 0.008697 | 1.757 | C5orf36 | Gallbladder cancer |
| rs6869388 | Torticollis | 0.006263 | 1.605 | C5orf36 | Gallbladder cancer |
| rs690037 | Cardiac arrhythmia NOS | 0.002986 | 0.8568 | RFTN1 | Optic disc parameters |
| rs690037 | Psoriasis | 0.005672 | 1.251 | RFTN1 | Optic disc parameters |
| rs690037 | Other diseases of respiratory system | 0.01097 | 1.351 | RFTN1 | Optic disc parameters |
| rs690037 | Psoriasis & related disorders | 0.004388 | 1.244 | RFTN1 | Optic disc parameters |
| rs690037 | Intestinal infection | 0.0001501 | 0.7572 | RFTN1 | Optic disc parameters |
| rs690037 | Abnormal findings on radiological examination intrathoracic organs | 0.008987 | 0.8319 | RFTN1 | Optic disc parameters |
| rs690037 | Anal and rectal polyp | 0.001078 | 0.765 | RFTN1 | Optic disc parameters |
| rs690037 | Intestinal infection due to C. difficile | 0.0002108 | 0.6378 | RFTN1 | Optic disc parameters |
| rs690037 | Spondylosis with myelopathy | 0.004582 | 1.395 | RFTN1 | Optic disc parameters |
| rs690037 | Iatrogenic hypotension | 0.006609 | 0.6256 | RFTN1 | Optic disc parameters |
| rs690037 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.008108 | 0.8106 | RFTN1 | Optic disc parameters |
| rs690037 | Gout | 0.0107 | 1.148 | RFTN1 | Optic disc parameters |
| rs690037 | Gout and other crystal arthropathies | 0.009479 | 1.139 | RFTN1 | Optic disc parameters |
| rs690037 | Retinal edema and hypertensive retinopathy | 0.005349 | 1.329 | RFTN1 | Optic disc parameters |
| rs690037 | Hydrocele | 0.005189 | 1.489 | RFTN1 | Optic disc parameters |
| rs690037 | Bacterial enteritis | 3.684e-06 | 0.608 | RFTN1 | Optic disc parameters |
| rs690037 | Mitral valve stenosis and/or aortic valve stenosis | 0.0006365 | 0.7739 | RFTN1 | Optic disc parameters |
| rs690705 | Other and unspecified disc disorder | 0.008303 | 1.475 | RFC3 | Alzheimer's disease |
| rs690705 | Acute, but ill-defined cerebrovascular disease | 0.00678 | 1.202 | RFC3 | Alzheimer's disease |
| rs690705 | Benign neoplasm of colon | 0.009745 | 0.9133 | RFC3 | Alzheimer's disease |
| rs690705 | Open wound of eye or eyelid | 0.008435 | 1.939 | RFC3 | Alzheimer's disease |
| rs690705 | Known or suspected fetal abnormality | 2.278e-05 | 2.196 | RFC3 | Alzheimer's disease |
| rs690705 | Other disorders of back | 0.002632 | 1.187 | RFC3 | Alzheimer's disease |
| rs690705 | Dislocation | 0.00163 | 1.145 | RFC3 | Alzheimer's disease |
| rs690705 | Hearing loss | 0.008768 | 1.092 | RFC3 | Alzheimer's disease |
| rs690705 | Loose body in joint | 0.003983 | 2.175 | RFC3 | Alzheimer's disease |
| rs690705 | Traumatic arthropathy | 0.01014 | 1.593 | RFC3 | Alzheimer's disease |
| rs690705 | Disorders of sacrum | 0.0003334 | 1.359 | RFC3 | Alzheimer's disease |
| rs6908425 | Stomach cancer | 0.002757 | 1.877 | CDKAL1 | Crohn's disease |
| rs6908425 | Endometrial hyperplasia | 0.008928 | 1.464 | CDKAL1 | Crohn's disease |
| rs6908425 | Urinary obstruction | 0.007454 | 0.6385 | CDKAL1 | Crohn's disease |
| rs6908425 | Premenstrual tension syndromes | 0.00885 | 1.954 | CDKAL1 | Crohn's disease |
| rs6908425 | Adverse drug events and drug allergies | 0.008995 | 0.8279 | CDKAL1 | Crohn's disease |
| rs6908425 | Poisoning by other anti-infectives | 0.009496 | 0.7762 | CDKAL1 | Crohn's disease |
| rs6908425 | Other rheumatic heart disease | 0.002538 | 2.139 | CDKAL1 | Crohn's disease |
| rs6908425 | Emphysema | 0.009057 | 0.7379 | CDKAL1 | Crohn's disease |
| rs6908425 | Cyst or abscess of Bartholin's gland | 0.00155 | 2.208 | CDKAL1 | Crohn's disease |
| rs6908425 | Epiphora | 0.003607 | 0.6216 | CDKAL1 | Crohn's disease |
| rs6908425 | Esophageal cancer | 0.004829 | 1.86 | CDKAL1 | Crohn's disease |
| rs6908425 | Fibroadenosis of breast | 0.002258 | 2.417 | CDKAL1 | Crohn's disease |
| rs6908425 | Non-healing surgical wound | 0.0007508 | 1.859 | CDKAL1 | Crohn's disease |
| rs6908425 | End stage renal disease | 0.003697 | 1.493 | CDKAL1 | Crohn's disease |
| rs6919346 | Spontaneous ecchymoses | 0.002224 | 1.813 | LPA | Lipoprotein(a) levels |
| rs6919346 | Peripheral autonomic neuropathy | 0.006665 | 1.463 | LPA | Lipoprotein(a) levels |
| rs6919346 | Chronic ulcer of skin | 0.007671 | 1.161 | LPA | Lipoprotein(a) levels |
| rs6919346 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.01076 | 1.13 | LPA | Lipoprotein(a) levels |
| rs6919346 | Vascular insufficiency of intestine | 0.002504 | 1.544 | LPA | Lipoprotein(a) levels |
| rs6919346 | Contact dermatitis and other eczema due to plants [except food] | 0.00605 | 1.851 | LPA | Lipoprotein(a) levels |
| rs6919346 | Intestinal malabsorption | 0.00845 | 1.443 | LPA | Lipoprotein(a) levels |
| rs6919346 | Gastrointestinal complications | 0.003519 | 1.357 | LPA | Lipoprotein(a) levels |
| rs6919346 | Hepatomegaly | 0.007022 | 1.836 | LPA | Lipoprotein(a) levels |
| rs6919346 | Acquired deformities of ankle and foot | 0.0001084 | 1.413 | LPA | Lipoprotein(a) levels |
| rs6919346 | Chronic ulcer of leg or foot | 0.007269 | 1.19 | LPA | Lipoprotein(a) levels |
| rs6919346 | Flat foot | 0.0007706 | 1.425 | LPA | Lipoprotein(a) levels |
| rs6919346 | Subdural hemorrhage | 0.008117 | 0.4606 | LPA | Lipoprotein(a) levels |
| rs6919346 | Corns and callosities | 0.008421 | 1.194 | LPA | Lipoprotein(a) levels |
| rs6922632 | Herpes simplex | 0.007937 | 0.6594 | NRSN1 | Cognitive performance |
| rs6922632 | Infection of the eye | 0.01036 | 0.8292 | NRSN1 | Cognitive performance |
| rs6922632 | Spondylosis without myelopathy | 0.003872 | 0.8526 | NRSN1 | Cognitive performance |
| rs6922632 | Periapical abscess | 0.01007 | 0.7631 | NRSN1 | Cognitive performance |
| rs6922632 | Pulmonary collapse; interstitial/compensatory emphysema | 0.007102 | 0.794 | NRSN1 | Cognitive performance |
| rs6922632 | Osteoporosis | 0.002683 | 0.8237 | NRSN1 | Cognitive performance |
| rs6922632 | Lump or mass in breast | 0.009252 | 0.8159 | NRSN1 | Cognitive performance |
| rs6922632 | Mechanical complication due to other implant and internal device | 0.008857 | 0.6215 | NRSN1 | Cognitive performance |
| rs6922632 | Contact dermatitis and other eczema due to plants [except food] | 0.003044 | 0.2194 | NRSN1 | Cognitive performance |
| rs6922632 | Conduct disorders | 0.003594 | 1.759 | NRSN1 | Cognitive performance |
| rs6922632 | Osteoporosis, osteopenia, & pathological fractures | 0.00929 | 0.8817 | NRSN1 | Cognitive performance |
| rs6922632 | Diseases of hard tissues of teeth | 0.001332 | 0.7285 | NRSN1 | Cognitive performance |
| rs6922632 | Benign mammary dysplasias | 0.01022 | 0.8186 | NRSN1 | Cognitive performance |
| rs6922632 | Altered mental status | 0.003542 | 0.6506 | NRSN1 | Cognitive performance |
| rs6922632 | Edema | 0.009248 | 0.8735 | NRSN1 | Cognitive performance |
| rs6922632 | Other sprains and strains | 0.003145 | 0.5848 | NRSN1 | Cognitive performance |
| rs6922632 | Displacement of intervertebral disc | 0.01069 | 0.8155 | NRSN1 | Cognitive performance |
| rs6922632 | Dental caries | 0.00184 | 0.7295 | NRSN1 | Cognitive performance |
| rs6922632 | Atopic or contact dermatitis | 0.009471 | 0.8767 | NRSN1 | Cognitive performance |
| rs6922632 | Open wound of toe(s) | 0.00645 | 1.902 | NRSN1 | Cognitive performance |
| rs6922632 | Gout and other crystal arthropathies | 0.000308 | 0.7566 | NRSN1 | Cognitive performance |
| rs6922632 | Cystic mastopathy | 0.007001 | 0.8039 | NRSN1 | Cognitive performance |
| rs6922632 | Gout | 0.0006442 | 0.7526 | NRSN1 | Cognitive performance |
| rs6922632 | Spondylosis and allied disorders | 0.007504 | 0.8668 | NRSN1 | Cognitive performance |
| rs6922632 | Osteoporosis, NOS or other | 0.001139 | 0.8142 | NRSN1 | Cognitive performance |
| rs6922632 | First degree AV block | 0.006473 | 1.335 | NRSN1 | Cognitive performance |
| rs6922632 | Intracerebral hemorrhage | 0.003696 | 1.806 | NRSN1 | Cognitive performance |
| rs693 | Localized superficial swelling, mass, or lump | 0.009725 | 0.8004 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Conjunctivitis, noninfectious | 0.01097 | 1.226 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Peripheral retinal degenerations | 0.01073 | 0.7856 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Cardiac arrest | 0.008338 | 0.6358 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Fluid overload | 0.007591 | 0.7907 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Renal dialysis | 0.003152 | 0.6845 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Subdural hemorrhage (injury) | 0.003603 | 0.5719 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hypertensive chronic kidney disease | 0.002937 | 0.8236 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Lymphosarcoma | 0.005401 | 2.203 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Cardiac pacemaker/device in situ | 0.007731 | 0.833 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Disorders of lipoid metabolism | 1.813e-07 | 0.8457 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Adverse effects of opiates and related narcotics in therapeutic use | 0.002014 | 1.339 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Celiac disease | 0.001706 | 0.4966 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hyperlipidemia | 8.821e-08 | 0.841 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Mixed hyperlipidemia | 1.348e-05 | 0.7735 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Insect bite | 0.008525 | 0.8119 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Tachycardia NOS | 0.009035 | 0.8471 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hypercholesterolemia | 7.419e-10 | 0.7838 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hypertensive heart and/or renal disease | 0.0002992 | 0.81 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Sensorineural hearing loss | 0.003553 | 0.898 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Celiac or tropical sprue | 0.002167 | 0.5135 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Ileostomy status | 0.007113 | 1.611 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Disturbances of sensation of smell and taste | 0.001655 | 0.5721 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Paralytic strabismus | 0.01076 | 1.461 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs693 | Hearing loss | 0.002005 | 0.9086 | APOB | Total Cholesterol, LDL Cholesterol, Triglycerides |
| rs6959888 | Excessive or frequent menstruation | 0.0003751 | 0.5408 | ZNF804B | Anorexia nervosa |
| rs6959888 | Alzheimer's disease | 0.006078 | 1.281 | ZNF804B | Anorexia nervosa |
| rs6959888 | Disorders of fluid, electrolyte, and acid-base balance | 0.002733 | 1.15 | ZNF804B | Anorexia nervosa |
| rs6959888 | Infections of kidney | 0.01094 | 1.451 | ZNF804B | Anorexia nervosa |
| rs6959888 | Painful respiration | 0.008669 | 1.227 | ZNF804B | Anorexia nervosa |
| rs6959888 | Dysmenorrhea | 0.005335 | 0.4547 | ZNF804B | Anorexia nervosa |
| rs6959888 | Abnormal findings examination of lungs | 0.006636 | 1.253 | ZNF804B | Anorexia nervosa |
| rs6959888 | Chronic pancreatitis | 0.008748 | 0.2644 | ZNF804B | Anorexia nervosa |
| rs6959888 | Hypovolemia | 0.00223 | 1.215 | ZNF804B | Anorexia nervosa |
| rs6959888 | Other diseases of lung | 0.004992 | 1.208 | ZNF804B | Anorexia nervosa |
| rs6959888 | Disorders of menstruation | 0.01091 | 0.7625 | ZNF804B | Anorexia nervosa |
| rs697739 | Hyperglyceridemia | 0.002717 | 0.7672 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Optic neuritis/neuropathy | 0.003933 | 0.7009 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Secondary thrombocytopenia | 0.009126 | 1.594 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Scoliosis | 0.01066 | 0.7552 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Urethral stricture (not specified as infectious) | 0.009476 | 0.6756 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Abnormal kidney function | 0.002836 | 2.1 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Disorders of optic nerve and visual pathways | 0.008513 | 0.7799 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.004561 | 0.8133 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Substance addiction and disorders | 0.00327 | 1.32 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Peripheral vascular disease | 0.00497 | 0.8834 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Viral Enteritis | 0.0003801 | 1.672 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Chronic glomerulonephritis | 0.0002253 | 2.817 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Type 2 diabetic peripheral circulatory disorders | 0.006348 | 0.6879 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Absent or infrequent menstruation | 0.008554 | 1.508 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Spondylosis with myelopathy | 0.009076 | 1.37 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Rheumatoid arthritis | 0.00021 | 0.7321 | ATXN1 | Amyotrophic lateral sclerosis |
| rs697739 | Glomerulonephritis | 0.0009807 | 1.837 | ATXN1 | Amyotrophic lateral sclerosis |
| rs7023329 | Aneurysm of artery of lower extremity | 0.008596 | 0.647 | MTAP | Melanoma |
| rs7023329 | Primary/intrinsic cardiomyopathies | 0.0112 | 1.174 | MTAP | Melanoma |
| rs7023329 | Other upper respiratory disease | 0.005173 | 0.8636 | MTAP | Melanoma |
| rs7023329 | Coronary atherosclerosis | 0.006459 | 1.091 | MTAP | Melanoma |
| rs7023329 | Cardiomyopathy | 0.0111 | 1.169 | MTAP | Melanoma |
| rs7023329 | Memory loss | 0.001782 | 0.7846 | MTAP | Melanoma |
| rs7023329 | progressive myopia | 0.004399 | 1.811 | MTAP | Melanoma |
| rs7023329 | Chronic pharyngitis and nasopharyngitis | 0.006394 | 0.8573 | MTAP | Melanoma |
| rs7023329 | Gastrointestinal malfunction arising from mental factors | 0.006385 | 2.097 | MTAP | Melanoma |
| rs7023329 | Abnormal coagulation profile | 0.002002 | 1.421 | MTAP | Melanoma |
| rs7023329 | Myocardial infarction | 0.009395 | 1.124 | MTAP | Melanoma |
| rs7023329 | Varicose veins of lower extremity | 0.0001925 | 0.8172 | MTAP | Melanoma |
| rs7023329 | Other cells and casts in urine | 0.004948 | 0.6871 | MTAP | Melanoma |
| rs7023329 | Varicose veins | 0.0002104 | 0.8249 | MTAP | Melanoma |
| rs7023329 | Other disorders of biliary tract | 0.009518 | 1.484 | MTAP | Melanoma |
| rs7023329 | Complication of internal orthopedic device | 0.001876 | 1.262 | MTAP | Melanoma |
| rs7023329 | Major depressive disorder | 0.007168 | 0.8645 | MTAP | Melanoma |
| rs7023329 | Varicose veins of lower extremity, symptomtic | 7.985e-05 | 0.7493 | MTAP | Melanoma |
| rs7023329 | Diseases of pulp and periapical tissues | 0.008577 | 0.8375 | MTAP | Melanoma |
| rs7023329 | Mucous polyp of cervix | 0.005542 | 0.7137 | MTAP | Melanoma |
| rs7023329 | Ischemic Heart Disease | 0.004051 | 1.091 | MTAP | Melanoma |
| rs7025486 | Diverticulitis | 0.008381 | 0.7957 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Other alveolar and parietoalveolar pneumonopathy | 0.003259 | 1.722 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Abnormal thyroid function | 0.008552 | 0.7561 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Hyperbilirubinemia | 0.007118 | 0.4339 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Peritonitis and retroperitoneal infections | 0.008623 | 0.6554 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Disorders of other cranial nerves | 0.002475 | 1.333 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Abnormal chest sounds | 0.004568 | 1.505 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Fracture of clavicle or scapula | 0.001956 | 1.499 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Facial nerve disorders | 0.00588 | 1.433 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Mechanical complications of cardiac/vascular device, implant, and graft | 0.004632 | 1.272 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Acute pancreatitis | 0.005876 | 0.7333 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Diseases of pulp and periapical tissues | 0.006532 | 1.227 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Sprains and strains | 0.0008684 | 1.151 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Senile dementia | 0.003066 | 0.7719 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Cystoid macular degeneration of retina | 0.0009133 | 1.42 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Persistent mental disorders due to other conditions | 0.01048 | 0.8537 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Arterial embolism and thrombosis | 0.008812 | 1.253 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Nonrheumatic tricuspid valve disorders | 0.006976 | 1.476 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Arterial embolism and thrombosis of lower extremity artery | 0.009655 | 1.358 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Dermatophytosis of the body | 0.003203 | 1.412 | DAB2IP | Abdominal aortic aneurysm |
| rs7025486 | Other pulmonary inflamation or edema | 0.005744 | 0.709 | DAB2IP | Abdominal aortic aneurysm |
| rs7072268 | Celiac or tropical sprue | 0.01027 | 1.725 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Acid-base balance disorder | 0.008898 | 1.294 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Cancer of oropharynx | 0.004298 | 2.213 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Colostomy and enterostomy complication | 0.003659 | 1.914 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Aphakia and other disorders of lens | 0.008044 | 1.28 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Diseases of hair and hair follicles | 0.01064 | 0.8311 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Diplopia and disorders of binocular vision | 0.007189 | 0.7772 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Keratoderma, acquired | 0.0003726 | 0.8195 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Hypercalcemia | 0.01017 | 1.242 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Myocardial infarction | 0.001723 | 0.8693 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Redundant prepuce and phimosis/BXO | 0.009051 | 0.6048 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Anemia NOS | 0.0005756 | 1.119 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Other anemias | 0.001687 | 1.1 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Abnormal findings on radiological exam of musculoskeletal system | 0.0001351 | 1.967 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Nontoxic nodular goiter | 0.003962 | 1.193 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Celiac disease | 0.009152 | 1.762 | HK1 | Glycated hemoglobin levels |
| rs7072268 | Insulin pump user | 0.001396 | 0.7677 | HK1 | Glycated hemoglobin levels |
| rs7085433 | Anemia in chronic kidney disease | 0.002404 | 0.5606 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Enthesopathy | 0.002847 | 1.205 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Intervertebral disc disorders | 0.005139 | 1.163 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Muscle weakness | 0.007398 | 0.6097 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Disorders of sweat glands | 0.006524 | 1.397 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Sepsis | 0.000126 | 1.578 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Fracture of clavicle or scapula | 0.01031 | 0.5148 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Generalized hyperhidrosis | 0.002175 | 1.565 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Open wound of ear | 0.01065 | 2.161 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Disorders of parathyroid gland | 0.007389 | 0.6194 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Degeneration of intervertebral disc | 0.001094 | 1.226 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Dermatomyositis and Polymyositis | 0.007962 | 2.298 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Synoviopathy | 0.00704 | 1.506 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Contact dermatitis and other eczema due to plants [except food] | 0.0009842 | 2.327 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Other sprains and strains | 0.001629 | 1.58 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Sepsis and SIRS | 0.0001054 | 1.563 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Aortic aneurysm | 0.005939 | 1.317 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Nontoxic uninodular goiter | 0.00666 | 0.6894 | TIMM23 | Mean corpuscular hemoglobin |
| rs7085433 | Disorders of synovium, tendon, and bursa | 0.009295 | 1.174 | TIMM23 | Mean corpuscular hemoglobin |
| rs712039 | Cervical cancer | 0.001839 | 0.3104 | DUSP14 | Tuberculosis |
| rs712039 | Abnormal findings on mammogram or breast exam | 0.01036 | 1.13 | DUSP14 | Tuberculosis |
| rs712039 | Personal history of allergy to medicinal agents | 0.001746 | 0.7181 | DUSP14 | Tuberculosis |
| rs712039 | Partial epilepsy | 0.001758 | 1.516 | DUSP14 | Tuberculosis |
| rs712039 | Retinal vascular changes and abnomalities | 0.006757 | 1.246 | DUSP14 | Tuberculosis |
| rs712039 | Arthropathy NOS | 0.01058 | 0.8303 | DUSP14 | Tuberculosis |
| rs712039 | Ptosis of eyelid | 0.01064 | 1.214 | DUSP14 | Tuberculosis |
| rs712039 | Other specified nonpsychotic and/or transient mental disorders | 0.00159 | 0.7556 | DUSP14 | Tuberculosis |
| rs712039 | Vascular insufficiency of intestine | 0.01051 | 1.402 | DUSP14 | Tuberculosis |
| rs712039 | Poisoning by primarily systemic agents | 0.008595 | 0.7261 | DUSP14 | Tuberculosis |
| rs712039 | Abnormal thyroid function | 0.002771 | 0.7235 | DUSP14 | Tuberculosis |
| rs712039 | Age-related macular degeneration | 0.001228 | 1.276 | DUSP14 | Tuberculosis |
| rs712039 | Nontoxic uninodular goiter | 0.003079 | 0.7613 | DUSP14 | Tuberculosis |
| rs712039 | Subarachnoid hemorrhage | 0.008777 | 1.884 | DUSP14 | Tuberculosis |
| rs712039 | Mental disorders due to brain damage | 0.001045 | 0.7422 | DUSP14 | Tuberculosis |
| rs7136572 | Disorders of refraction and accommodation | 0.007626 | 0.664 | USP44 | Response to antidepressant treatment |
| rs7136572 | Parkinson's disease | 0.003507 | 2.416 | USP44 | Response to antidepressant treatment |
| rs7136572 | Epilepsy, recurrent seizures, convulsions | 0.004803 | 1.87 | USP44 | Response to antidepressant treatment |
| rs7136572 | Hammer toe | 0.002891 | 2.026 | USP44 | Response to antidepressant treatment |
| rs7136572 | Ileostomy status | 0.004687 | 3.345 | USP44 | Response to antidepressant treatment |
| rs7136572 | Symptoms involving cardiovascular system | 0.002799 | 0.3494 | USP44 | Response to antidepressant treatment |
| rs7136572 | Obsessive-compulsive disorder | 0.009435 | 3.628 | USP44 | Response to antidepressant treatment |
| rs7136572 | Functional digestive disorders | 0.004377 | 0.4877 | USP44 | Response to antidepressant treatment |
| rs7136572 | Genital prolapse | 0.01096 | 1.701 | USP44 | Response to antidepressant treatment |
| rs7136572 | Myopia | 0.005327 | 0.5772 | USP44 | Response to antidepressant treatment |
| rs7136572 | Pseudomonal pneumonia | 0.004807 | 5.7 | USP44 | Response to antidepressant treatment |
| rs7136572 | Prolapse of vaginal walls | 0.005276 | 1.922 | USP44 | Response to antidepressant treatment |
| rs7136572 | Extrapyramidal disease and abnormal movement disorders | 0.008763 | 1.786 | USP44 | Response to antidepressant treatment |
| rs7136572 | Ulcerative stomatitis & mucositis | 0.01111 | 3.758 | USP44 | Response to antidepressant treatment |
| rs7136572 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | 0.00916 | 3.966 | USP44 | Response to antidepressant treatment |
| rs7136572 | Pneumonitis due to inhalation of food or vomitus | 0.00758 | 2.271 | USP44 | Response to antidepressant treatment |
| rs7137869 | Temporomandibular joint disorder NOS | 0.007456 | 1.644 | CCDC60 | Aging |
| rs7137869 | Iatrogenic hypothyroidism | 0.006721 | 0.6741 | CCDC60 | Aging |
| rs7137869 | Pneumoconiosis | 0.009809 | 1.897 | CCDC60 | Aging |
| rs7137869 | Malignant neoplasm, other | 0.009379 | 0.7728 | CCDC60 | Aging |
| rs7137869 | Acute pharyngitis | 0.001764 | 0.8204 | CCDC60 | Aging |
| rs7137869 | Sialoadenitis | 0.005172 | 1.535 | CCDC60 | Aging |
| rs7137869 | Angina pectoris | 0.007999 | 1.154 | CCDC60 | Aging |
| rs7137869 | Diseases of the salivary glands | 0.009389 | 1.316 | CCDC60 | Aging |
| rs7137869 | Torsion dystonia | 0.003976 | 1.685 | CCDC60 | Aging |
| rs7137869 | Rash and other nonspecific skin eruption | 0.0112 | 0.8408 | CCDC60 | Aging |
| rs7137869 | Other forms of chronic heart disease | 0.00527 | 1.233 | CCDC60 | Aging |
| rs7137869 | Cardiac congenital anomalies | 0.01117 | 1.343 | CCDC60 | Aging |
| rs7137869 | Malignant neoplasm of brain and nervous system | 0.01139 | 0.6338 | CCDC60 | Aging |
| rs7137869 | Primary pulmonary hypertension | 0.01019 | 1.588 | CCDC60 | Aging |
| rs7137869 | Cancer, suspected or other | 0.008334 | 0.7978 | CCDC60 | Aging |
| rs7140150 | Otalgia | 0.008158 | 1.254 | FRMD6 | Brain structure |
| rs7140150 | Nerve root and plexus disorders | 0.001564 | 1.372 | FRMD6 | Brain structure |
| rs7140150 | Open wound of hand except finger(s) | 0.009842 | 1.263 | FRMD6 | Brain structure |
| rs7140150 | Pathologic fracture | 0.004328 | 1.214 | FRMD6 | Brain structure |
| rs7140150 | Varicose veins of lower extremity, symptomtic | 0.007007 | 0.8187 | FRMD6 | Brain structure |
| rs7140150 | Nerve plexus lesions | 0.000335 | 1.601 | FRMD6 | Brain structure |
| rs7140150 | Other cerebral degenerations | 0.0001451 | 1.624 | FRMD6 | Brain structure |
| rs7140150 | Calcaneal spur; Exostosis NOS | 0.006952 | 1.26 | FRMD6 | Brain structure |
| rs7140150 | Diseases of blood and blood-forming organs | 0.006334 | 0.8047 | FRMD6 | Brain structure |
| rs7140150 | Inflammatory and toxic neuropathy | 0.0006224 | 1.459 | FRMD6 | Brain structure |
| rs7140150 | Viral warts & HPV | 0.007134 | 1.153 | FRMD6 | Brain structure |
| rs7140150 | Secondary malignancy of brain/spine | 0.006181 | 1.622 | FRMD6 | Brain structure |
| rs7140150 | Intracranial hemorrhage | 0.00946 | 0.7552 | FRMD6 | Brain structure |
| rs7157785 | Plasma protein metabolism disorder | 0.001988 | 1.426 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Disorders of penis | 0.008499 | 1.429 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Cancer of oropharynx | 0.002424 | 2.345 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Disorders of choroid | 0.009867 | 0.691 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Peyronie's disease | 0.000789 | 2.312 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Bacterial enteritis | 0.001704 | 1.47 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Patellar fracture | 0.01113 | 1.472 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Conductive hearing loss | 0.001994 | 0.4079 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Peripheral enthesopathies | 0.0006612 | 0.8604 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Noninflammatory disorders of ovary, fallopian tube, & broad ligament | 0.006085 | 1.726 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Other disorders of tympanic membrane | 0.009589 | 0.5679 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Reticulosarcoma | 0.007445 | 0.3958 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Other endocrine disorders | 0.008817 | 0.4795 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Multiple sclerosis | 0.005785 | 1.642 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Uterine cancer | 0.003365 | 0.535 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7157785 | Skin neoplasm of uncertain behavior | 0.003959 | 0.7495 | SGPP1 | Sphingolipid levels - sphingomyelin |
| rs7158173 | Cancer of bone & connective tissue | 0.008412 | 0.6839 | MAX | Waist circumference |
| rs7158173 | Benign neoplasm of brain and other parts of nervous system | 0.005737 | 0.7028 | MAX | Waist circumference |
| rs7158173 | Infertility, male | 0.003538 | 0.47 | MAX | Waist circumference |
| rs7158173 | Intestinal infection due to C. difficile | 0.004395 | 0.7091 | MAX | Waist circumference |
| rs7158173 | Immune disorders | 0.008818 | 0.8003 | MAX | Waist circumference |
| rs7158173 | Other disorders of tympanic membrane | 0.004345 | 1.467 | MAX | Waist circumference |
| rs7158173 | Ovarian cancer | 0.002878 | 0.6032 | MAX | Waist circumference |
| rs7158173 | Perforation of tympanic membrane | 0.007696 | 1.495 | MAX | Waist circumference |
| rs7158173 | Cancer of kidney and urinary organs | 0.01001 | 0.8356 | MAX | Waist circumference |
| rs7158173 | Stricture/obstruction of ureter | 0.005319 | 0.6643 | MAX | Waist circumference |
| rs7158173 | Cancer of other female genital organs | 0.003419 | 0.6544 | MAX | Waist circumference |
| rs7158173 | Intestinal malabsorption | 0.0109 | 1.343 | MAX | Waist circumference |
| rs7158173 | Malignant neoplasm of ovary | 0.006413 | 0.581 | MAX | Waist circumference |
| rs7158173 | Bacterial enteritis | 0.001506 | 0.7146 | MAX | Waist circumference |
| rs7158173 | Anorexia | 0.009069 | 1.336 | MAX | Waist circumference |
| rs7191888 | Nonrheumatic aortic valve disorders | 0.007189 | 0.8172 | C16orf47 | Multiple sclerosis |
| rs7191888 | Other paralytic syndromes | 0.002338 | 1.653 | C16orf47 | Multiple sclerosis |
| rs7191888 | Acute pharyngitis | 0.001218 | 0.7993 | C16orf47 | Multiple sclerosis |
| rs7191888 | Anal and rectal polyp | 0.008768 | 0.7413 | C16orf47 | Multiple sclerosis |
| rs7191888 | Varicose veins of lower extremity | 0.006725 | 0.8177 | C16orf47 | Multiple sclerosis |
| rs7191888 | Acute sinusitis | 0.001828 | 0.8164 | C16orf47 | Multiple sclerosis |
| rs7191888 | Abnormal glucose | 0.009917 | 0.8715 | C16orf47 | Multiple sclerosis |
| rs7191888 | Stricture and stenosis of esophagus | 0.00411 | 1.358 | C16orf47 | Multiple sclerosis |
| rs7191888 | Sialoadenitis | 0.009832 | 1.532 | C16orf47 | Multiple sclerosis |
| rs7191888 | Other abnormal glucose | 0.01138 | 0.8443 | C16orf47 | Multiple sclerosis |
| rs7219585 | Myasthenia gravis | 0.009834 | 2.152 | DNAI2 | Cognitive performance |
| rs7219585 | Secondary malignancy of bone | 1.358e-05 | 1.771 | DNAI2 | Cognitive performance |
| rs7219585 | Adverse effects of sedatives or other central nervous system depressants and anesthetics | 0.001342 | 1.918 | DNAI2 | Cognitive performance |
| rs7219585 | Other disorders of urethra and urinary tract | 0.01081 | 0.7452 | DNAI2 | Cognitive performance |
| rs7219585 | Inguinal hernia | 0.002301 | 0.7813 | DNAI2 | Cognitive performance |
| rs7219585 | Complication of internal orthopedic device | 0.002923 | 0.6861 | DNAI2 | Cognitive performance |
| rs7219585 | Synoviopathy | 0.001766 | 1.539 | DNAI2 | Cognitive performance |
| rs7219585 | Noninflammatory disorders of ovary, fallopian tube, & broad ligament | 0.002824 | 1.864 | DNAI2 | Cognitive performance |
| rs7219585 | Premature menopause and other ovarian failure | 0.003117 | 2.126 | DNAI2 | Cognitive performance |
| rs7219585 | Retinal edema and hypertensive retinopathy | 0.004978 | 1.456 | DNAI2 | Cognitive performance |
| rs7219585 | Subarachnoid hemorrhage | 0.00179 | 2.299 | DNAI2 | Cognitive performance |
| rs7219585 | AV block | 0.003654 | 0.7529 | DNAI2 | Cognitive performance |
| rs7219585 | Malignant neoplasm, other | 0.0113 | 1.304 | DNAI2 | Cognitive performance |
| rs7219585 | Primary angle-closure glaucoma | 0.004873 | 1.343 | DNAI2 | Cognitive performance |
| rs7219585 | Nasal polyps | 0.006501 | 1.468 | DNAI2 | Cognitive performance |
| rs7219585 | Adverse drug events and drug allergies | 0.01076 | 1.227 | DNAI2 | Cognitive performance |
| rs7219585 | Ingrowing nail | 0.006062 | 0.791 | DNAI2 | Cognitive performance |
| rs7219585 | Cancer, suspected or other | 0.01045 | 1.266 | DNAI2 | Cognitive performance |
| rs7253363 | Acute laryngitis and tracheitis | 0.005152 | 2.069 | ACP5 | Multiple sclerosis |
| rs7253363 | Periapical abscess | 0.00739 | 0.569 | ACP5 | Multiple sclerosis |
| rs7253363 | Cholesteatoma | 0.01132 | 2.333 | ACP5 | Multiple sclerosis |
| rs7253363 | Primary pulmonary hypertension | 0.004404 | 2.32 | ACP5 | Multiple sclerosis |
| rs7253363 | Otosclerosis | 0.007092 | 2.015 | ACP5 | Multiple sclerosis |
| rs7253363 | Anisometropia | 0.004249 | 1.74 | ACP5 | Multiple sclerosis |
| rs7253363 | Scleritis and episcleritis | 0.003662 | 2.297 | ACP5 | Multiple sclerosis |
| rs7253363 | Congenital anomalies of peripheral vascular system | 0.007428 | 2.511 | ACP5 | Multiple sclerosis |
| rs7253363 | Sacroiliitis NEC | 0.01052 | 2.365 | ACP5 | Multiple sclerosis |
| rs7253363 | Cramp of limb | 0.01007 | 1.635 | ACP5 | Multiple sclerosis |
| rs7253363 | Paralysis/spasm of vocal cords or larynx | 0.008036 | 2.19 | ACP5 | Multiple sclerosis |
| rs7315438 | Keratitis, infectious | 0.003243 | 0.6835 | MED13L | Colorectal cancer |
| rs7315438 | Disorders resulting from impaired renal function | 0.0043 | 1.308 | MED13L | Colorectal cancer |
| rs7315438 | Nerve plexus lesions | 0.006296 | 0.6877 | MED13L | Colorectal cancer |
| rs7315438 | Other endocrine disorders | 0.002704 | 0.5961 | MED13L | Colorectal cancer |
| rs7315438 | Hyperplasia of prostate | 0.007772 | 0.8742 | MED13L | Colorectal cancer |
| rs7315438 | Oliguria and anuria | 0.005206 | 2.187 | MED13L | Colorectal cancer |
| rs7315438 | Melanoma | 0.0008162 | 0.7349 | MED13L | Colorectal cancer |
| rs7315438 | Cholangitis | 0.008164 | 0.5623 | MED13L | Colorectal cancer |
| rs7315438 | Hypoparathyroidism | 0.007758 | 0.4285 | MED13L | Colorectal cancer |
| rs7315438 | Neoplasm of uncertain behavior | 0.001861 | 0.8191 | MED13L | Colorectal cancer |
| rs735172 | Allergies, other | 0.002665 | 0.7512 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Hepatomegaly | 0.002796 | 0.4305 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Adjustment reaction | 0.002155 | 1.183 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Diseases of pulp and periapical tissues | 0.01083 | 0.8262 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Conduct disorders | 0.01116 | 0.6042 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Periostitis | 0.00649 | 0.4711 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Urethral stricture (not specified as infectious) | 0.008148 | 1.418 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Other disorders of urethra and urinary tract | 0.003487 | 1.239 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Other specified disorders of pancreatic internal secretion | 0.01003 | 0.5358 | EVC | Prostate cancer (gene x gene interaction) |
| rs735172 | Esophageal atresia/tracheoesophageal fistula | 0.01112 | 1.646 | EVC | Prostate cancer (gene x gene interaction) |
| rs735854 | Internal derangement of knee | 0.008326 | 0.8692 | MYH9 | Optic disc parameters |
| rs735854 | Nonspecific findings on examination of blood | 5.266e-05 | 1.492 | MYH9 | Optic disc parameters |
| rs735854 | Angiodysplasia of intestine | 0.0003386 | 0.2548 | MYH9 | Optic disc parameters |
| rs735854 | Enthesopathy | 0.008865 | 0.8961 | MYH9 | Optic disc parameters |
| rs735854 | Varicose veins | 0.0002051 | 0.8175 | MYH9 | Optic disc parameters |
| rs735854 | Disorders of cervical region | 0.007757 | 0.7307 | MYH9 | Optic disc parameters |
| rs735854 | Other disorders of tympanic membrane | 0.002239 | 1.509 | MYH9 | Optic disc parameters |
| rs735854 | Varicose veins of lower extremity | 0.0001414 | 0.8063 | MYH9 | Optic disc parameters |
| rs735854 | Chronic venous insufficiency | 0.006316 | 0.8371 | MYH9 | Optic disc parameters |
| rs735854 | Dental caries | 0.001403 | 1.241 | MYH9 | Optic disc parameters |
| rs735854 | Benign neoplasm of respiratory and intrathoracic organs | 0.005253 | 1.756 | MYH9 | Optic disc parameters |
| rs735854 | Sprains and strains | 0.007508 | 0.9008 | MYH9 | Optic disc parameters |
| rs735854 | Diseases of hard tissues of teeth | 0.0004071 | 1.262 | MYH9 | Optic disc parameters |
| rs735854 | Back & neck sprains | 0.002061 | 0.8719 | MYH9 | Optic disc parameters |
| rs735854 | Chronic obstructive asthma | 0.009424 | 1.273 | MYH9 | Optic disc parameters |
| rs735854 | Ulceration of the lower GI tract | 0.00121 | 0.549 | MYH9 | Optic disc parameters |
| rs735854 | Neurological disorders due to brain damage | 0.005371 | 0.8744 | MYH9 | Optic disc parameters |
| rs735854 | Hypermetropia | 0.007212 | 0.8769 | MYH9 | Optic disc parameters |
| rs735854 | Open wound of lip and mouth | 0.005092 | 0.5128 | MYH9 | Optic disc parameters |
| rs735854 | Diseases of pulp and periapical tissues | 0.002639 | 1.231 | MYH9 | Optic disc parameters |
| rs735854 | Ulceration of intestine | 0.003331 | 0.5434 | MYH9 | Optic disc parameters |
| rs735854 | Osteoarthrosis of multiple sites | 0.0005331 | 0.7695 | MYH9 | Optic disc parameters |
| rs735854 | Symptoms involving female genital tract | 0.00945 | 0.723 | MYH9 | Optic disc parameters |
| rs735854 | Acquired deformities of ankle and foot | 0.00783 | 0.8074 | MYH9 | Optic disc parameters |
| rs735854 | Aphasia/speech disturbance | 0.01072 | 0.8155 | MYH9 | Optic disc parameters |
| rs735854 | Torticollis | 0.001916 | 0.5685 | MYH9 | Optic disc parameters |
| rs735854 | Fractur of unspecified part of femur | 0.001499 | 0.6385 | MYH9 | Optic disc parameters |
| rs735854 | Hemorrhoids | 0.000725 | 0.8705 | MYH9 | Optic disc parameters |
| rs735854 | Acute posthemorrhagic anemia | 0.003807 | 0.8368 | MYH9 | Optic disc parameters |
| rs735854 | Joint/ligament sprain | 0.00473 | 0.7406 | MYH9 | Optic disc parameters |
| rs735854 | Varicose veins of lower extremity, symptomtic | 0.006461 | 0.8138 | MYH9 | Optic disc parameters |
| rs744373 | Adrenal hypofunction | 0.005266 | 1.666 | BIN1 | Alzheimer's disease |
| rs744373 | Menopausal & postmenopausal disorders | 0.0105 | 1.134 | BIN1 | Alzheimer's disease |
| rs744373 | Anal and rectal conditions | 0.001273 | 1.188 | BIN1 | Alzheimer's disease |
| rs744373 | Joint/ligament sprain | 0.006058 | 0.7184 | BIN1 | Alzheimer's disease |
| rs744373 | Postmenopausal hormone replacement | 0.001673 | 1.374 | BIN1 | Alzheimer's disease |
| rs744373 | Vaginitis and vulvovaginitis | 0.01085 | 1.207 | BIN1 | Alzheimer's disease |
| rs744373 | Alopecia Areata | 0.00386 | 2.119 | BIN1 | Alzheimer's disease |
| rs744373 | Diseases of hair and hair follicles | 0.005523 | 1.241 | BIN1 | Alzheimer's disease |
| rs744373 | Cancer of other male genital organs | 0.009824 | 1.727 | BIN1 | Alzheimer's disease |
| rs744373 | Other specified diseases of hair and hair follicles | 0.008096 | 1.328 | BIN1 | Alzheimer's disease |
| rs749005 | Chronic bronchitis | 0.01067 | 1.246 | F13A1 | Entorhinal cortical volume |
| rs749005 | Nervous system congenital anomalies | 0.004634 | 1.57 | F13A1 | Entorhinal cortical volume |
| rs749005 | Altered mental status | 0.005241 | 1.393 | F13A1 | Entorhinal cortical volume |
| rs749005 | Discoid lupus erythematosus | 0.006768 | 0.511 | F13A1 | Entorhinal cortical volume |
| rs749005 | Other specified diseases of nail | 0.01025 | 1.201 | F13A1 | Entorhinal cortical volume |
| rs749005 | Ulceration of the lower GI tract | 0.002165 | 1.808 | F13A1 | Entorhinal cortical volume |
| rs749005 | Systemic lupus erythematosus | 0.007102 | 0.4823 | F13A1 | Entorhinal cortical volume |
| rs749005 | Seborrheic keratosis | 0.003106 | 1.16 | F13A1 | Entorhinal cortical volume |
| rs749005 | Retinal detachments and defects | 0.01072 | 1.288 | F13A1 | Entorhinal cortical volume |
| rs749005 | Phosphorus metabolism disorder | 0.01014 | 0.5385 | F13A1 | Entorhinal cortical volume |
| rs749005 | Chronic prostatitis | 0.01023 | 1.642 | F13A1 | Entorhinal cortical volume |
| rs7495052 | Diseases of pulp and periapical tissues | 0.004955 | 1.215 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Anisometropia | 0.002017 | 0.7284 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Renal colic | 0.01119 | 1.602 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Hypercalcemia | 0.003021 | 0.7723 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Secondary malignancy of lymph nodes | 0.005897 | 1.261 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Nonrheumatic aortic valve disorders | 0.003724 | 0.8508 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Periapical abscess | 0.001731 | 1.254 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Fracture of upper limb | 0.01065 | 0.8788 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Open wound of foot except toe(s) alone | 0.005804 | 1.509 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Disorders of mineral metabolism | 0.0007307 | 0.8439 | SLCO3A1 | Inattentive symptoms |
| rs7495052 | Lymphadenitis | 0.007762 | 1.175 | SLCO3A1 | Inattentive symptoms |
| rs7498403 | Cardiac congenital anomalies | 0.001342 | 1.684 | MAF | Height |
| rs7498403 | Osteoarthrosis | 0.008539 | 1.166 | MAF | Height |
| rs7498403 | Other specified diseases of hair and hair follicles | 0.01006 | 1.545 | MAF | Height |
| rs7498403 | Cardiac shunt/ heart septal defect | 4.076e-05 | 2.235 | MAF | Height |
| rs7498403 | Arthropathy associated with other disorders classified elsewhere | 0.005053 | 2.265 | MAF | Height |
| rs7498403 | Gout and other crystal arthropathies | 0.01093 | 1.261 | MAF | Height |
| rs7498403 | Osteoarthrosis of multiple sites | 0.003129 | 1.505 | MAF | Height |
| rs7498403 | Irritable Bowel Syndrome | 0.009155 | 1.321 | MAF | Height |
| rs7498403 | Cholelithiasis | 0.008811 | 1.254 | MAF | Height |
| rs7498403 | Arthropathy associated with neurological disorders | 0.001419 | 2.66 | MAF | Height |
| rs7498403 | Personality disorders | 0.008863 | 1.498 | MAF | Height |
| rs7498403 | Deviated nasal septum | 0.009722 | 1.348 | MAF | Height |
| rs7498403 | Other upper respiratory disease | 0.0105 | 1.292 | MAF | Height |
| rs7498403 | Cardiac and circulatory congenital anomalies | 0.006922 | 1.507 | MAF | Height |
| rs7498403 | Develomental delays and disorders | 0.00266 | 1.559 | MAF | Height |
| rs750338 | Urticaria | 0.005699 | 0.7516 | PKNOX2 | Alcoholism |
| rs750338 | Disaccharide malabsorption | 0.001519 | 0.7881 | PKNOX2 | Alcoholism |
| rs750338 | Abnormal cytological, histological, immunological and DNA test findings | 0.004171 | 0.3444 | PKNOX2 | Alcoholism |
| rs750338 | Renal colic | 0.004574 | 0.4325 | PKNOX2 | Alcoholism |
| rs750338 | Carbohydrate transport and metabolism disorder | 0.002026 | 0.7951 | PKNOX2 | Alcoholism |
| rs750338 | Chronic airway obstruction | 0.004749 | 1.139 | PKNOX2 | Alcoholism |
| rs750338 | Valvular heart disease/ heart chambers | 0.0007409 | 2.057 | PKNOX2 | Alcoholism |
| rs750338 | Hypertension complicating pregnancy | 0.005583 | 0.2664 | PKNOX2 | Alcoholism |
| rs750338 | Pain in joint | 0.008451 | 1.102 | PKNOX2 | Alcoholism |
| rs750338 | Asthma | 0.009295 | 1.14 | PKNOX2 | Alcoholism |
| rs7517337 | Pulmonary embolism and infarction | 0.001641 | 1.294 | KCNT2 | Total ventricular volume |
| rs7517337 | Osteoporosis, osteopenia, & pathological fractures | 0.006422 | 1.098 | KCNT2 | Total ventricular volume |
| rs7517337 | severe protein-calorie malnutrition | 0.004892 | 1.559 | KCNT2 | Total ventricular volume |
| rs7517337 | Pathologic fracture of vertebrae | 0.000301 | 1.35 | KCNT2 | Total ventricular volume |
| rs7517337 | Other specified disorders of pancreatic internal secretion | 0.01009 | 1.64 | KCNT2 | Total ventricular volume |
| rs7517337 | Prurigo | 0.009059 | 0.7814 | KCNT2 | Total ventricular volume |
| rs7517337 | Hypopotassemia | 0.006026 | 1.135 | KCNT2 | Total ventricular volume |
| rs7517337 | Atrophic gastritis | 0.001166 | 1.591 | KCNT2 | Total ventricular volume |
| rs7517337 | Lymphosarcoma | 0.002892 | 0.3811 | KCNT2 | Total ventricular volume |
| rs7517337 | Meniere's disease | 0.009761 | 1.573 | KCNT2 | Total ventricular volume |
| rs7517337 | Back pain | 0.0005839 | 1.106 | KCNT2 | Total ventricular volume |
| rs7517337 | Functional disorders of bladder | 0.007933 | 1.291 | KCNT2 | Total ventricular volume |
| rs7517337 | Electrolyte imbalance | 0.008596 | 1.096 | KCNT2 | Total ventricular volume |
| rs7517337 | Pathologic fracture | 0.002097 | 1.232 | KCNT2 | Total ventricular volume |
| rs7517337 | Adrenal hyperfunction | 0.003166 | 0.4751 | KCNT2 | Total ventricular volume |
| rs7517337 | Otalgia | 0.009118 | 1.253 | KCNT2 | Total ventricular volume |
| rs755383 | Complications of gastrostomy, colostomy and enterostomy | 0.000743 | 2.312 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Chronic ulcer of unspecified site | 0.006274 | 1.279 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Premature beats | 0.006522 | 0.8385 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Ileostomy status | 0.00648 | 1.603 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.001287 | 1.237 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Patellar fracture | 0.007506 | 1.408 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Multiple sclerosis | 0.002988 | 1.595 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Ankylosing spondylitis | 0.004686 | 2.255 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Injuries to the nervous system | 0.01111 | 1.509 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Calculus of ureter | 0.0005033 | 1.319 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Otorrhea | 0.00918 | 1.897 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Neuralgia, neuritis, and radiculitis NOS | 0.003883 | 1.222 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Jaundice | 0.003429 | 0.64 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Dental caries | 0.01021 | 1.189 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs755383 | Urinary calculus | 0.007675 | 1.149 | DMRT1 | Testicular germ cell cancer, Testicular cancer |
| rs7561317 | Migraine | 0.00129 | 0.7742 | TMEM18 | Body mass index, Weight |
| rs7561317 | Parasomnia | 0.009435 | 1.702 | TMEM18 | Body mass index, Weight |
| rs7561317 | Abnormal findings on radiological exam of musculoskeletal system | 0.002766 | 1.767 | TMEM18 | Body mass index, Weight |
| rs7561317 | Hypopotassemia | 0.01114 | 0.8512 | TMEM18 | Body mass index, Weight |
| rs7561317 | Subarachnoid hemorrhage | 0.007032 | 2.006 | TMEM18 | Body mass index, Weight |
| rs7561317 | Nodular lymphoma | 0.008278 | 1.675 | TMEM18 | Body mass index, Weight |
| rs7561317 | Shock | 0.000504 | 0.4814 | TMEM18 | Body mass index, Weight |
| rs7561317 | Other headache syndromes | 0.008041 | 0.8798 | TMEM18 | Body mass index, Weight |
| rs7561317 | Inflammatory disease of cervix, vagina, and vulva | 0.004938 | 0.7875 | TMEM18 | Body mass index, Weight |
| rs7561317 | Phosphorus metabolism disorder | 0.006869 | 0.5516 | TMEM18 | Body mass index, Weight |
| rs7561317 | Torsion dystonia | 0.008104 | 1.671 | TMEM18 | Body mass index, Weight |
| rs7561317 | Unequal leg length (acquired) | 0.002799 | 0.4911 | TMEM18 | Body mass index, Weight |
| rs7577851 | Unequal leg length (acquired) | 0.0003571 | 0.4047 | AAK1 | Parkinson's disease |
| rs7577851 | Fuchs' dystrophy | 0.004583 | 0.5194 | AAK1 | Parkinson's disease |
| rs7577851 | Other specified diseases of sebaceous glands | 0.008672 | 0.759 | AAK1 | Parkinson's disease |
| rs7577851 | Spinal stenosis of lumbar region | 0.01112 | 0.8387 | AAK1 | Parkinson's disease |
| rs7577851 | Periapical abscess | 0.002733 | 0.7373 | AAK1 | Parkinson's disease |
| rs7577851 | Decreased white blood cell count | 0.001454 | 1.336 | AAK1 | Parkinson's disease |
| rs7577851 | Barrett's esophagus | 0.005988 | 1.491 | AAK1 | Parkinson's disease |
| rs7577851 | Esophageal cancer | 0.008206 | 1.881 | AAK1 | Parkinson's disease |
| rs7577851 | Other disorders of soft tissues | 0.007535 | 0.6138 | AAK1 | Parkinson's disease |
| rs7577851 | Peripheral autonomic neuropathy | 0.008858 | 0.6162 | AAK1 | Parkinson's disease |
| rs7577851 | Ulcer of esophagus | 0.005831 | 1.557 | AAK1 | Parkinson's disease |
| rs7577851 | Psychogenic and somatoform disorders | 0.009514 | 0.7213 | AAK1 | Parkinson's disease |
| rs7577851 | Anemia of chronic disease | 0.003529 | 1.282 | AAK1 | Parkinson's disease |
| rs7577851 | Lymphosarcoma | 0.01098 | 2.103 | AAK1 | Parkinson's disease |
| rs7577851 | Trigeminal nerve disorders | 0.003157 | 1.608 | AAK1 | Parkinson's disease |
| rs7577851 | Crystal arthropathies | 0.01151 | 0.6515 | AAK1 | Parkinson's disease |
| rs7577851 | Acquired deformities of limbs | 0.003243 | 0.7287 | AAK1 | Parkinson's disease |
| rs7577851 | Rash and other nonspecific skin eruption | 0.0046 | 0.8025 | AAK1 | Parkinson's disease |
| rs7577851 | Edema | 0.004849 | 0.8688 | AAK1 | Parkinson's disease |
| rs7577851 | Neutropenia | 0.000975 | 1.364 | AAK1 | Parkinson's disease |
| rs7577851 | Osteoporosis, NOS or other | 0.01069 | 1.159 | AAK1 | Parkinson's disease |
| rs7577851 | Diseases of pulp and periapical tissues | 0.001267 | 0.7296 | AAK1 | Parkinson's disease |
| rs7577851 | Anal and rectal conditions | 0.007581 | 0.8298 | AAK1 | Parkinson's disease |
| rs7577851 | Other disorders of tympanic membrane | 0.004161 | 0.5324 | AAK1 | Parkinson's disease |
| rs7577851 | Other disorders of back | 0.005979 | 0.8125 | AAK1 | Parkinson's disease |
| rs7577851 | Anemia in neoplastic disease | 0.00386 | 1.548 | AAK1 | Parkinson's disease |
| rs7577851 | Spinal stenosis | 0.007004 | 0.845 | AAK1 | Parkinson's disease |
| rs7577851 | Disorders of cornea | 0.009326 | 0.7907 | AAK1 | Parkinson's disease |
| rs7577851 | Enthesopathy | 0.01067 | 0.8699 | AAK1 | Parkinson's disease |
| rs7577851 | Photodermatitis & sunburn | 0.005111 | 0.793 | AAK1 | Parkinson's disease |
| rs7577925 | Irritable Bowel Syndrome | 0.007627 | 0.8481 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Migraine | 0.005978 | 1.171 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Iatrogenic hypotension | 0.001102 | 1.736 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Other diseases of the teeth and supporting structures | 0.008448 | 1.245 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Symptoms involving female genital tract | 0.001642 | 0.6661 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Osteoarthrosis; localized, primary | 0.00613 | 0.7977 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Noninflammatory female genital disorders | 0.002052 | 0.8088 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Optic neuritis/neuropathy | 0.008319 | 0.7344 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Cornea replaced by transplant | 0.009918 | 0.5286 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Bronchitis | 0.004276 | 1.152 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Inflammatory disease of cervix, vagina, and vulva | 0.007149 | 0.8405 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | CNS infection and poliomyelitis | 0.0006833 | 1.877 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Symptoms involving digestive system | 0.005758 | 0.8065 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Skin neoplasm of uncertain behavior | 0.009174 | 0.8277 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Pseudoexfoliation glaucoma | 0.004451 | 1.597 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Benign neoplasm of other parts of digestive system | 0.0092 | 1.307 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Polyneuropathy in diabetes | 0.009368 | 1.188 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Inflammatory diseases of female pelvic organs | 0.01086 | 0.8566 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs7577925 | Renal colic | 0.009983 | 1.613 | NCKAP5 | Attention deficit hyperactivity disorder |
| rs758642 | Disorders of mineral metabolism | 0.01106 | 1.135 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Miscarriage; stillbirth | 0.008393 | 0.4948 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Tuberculosis | 0.003695 | 1.99 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Retinal hemorrhage/ischemia | 0.01044 | 0.7173 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Lump or mass in breast | 0.0002123 | 1.226 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Overweight | 0.006875 | 1.09 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Congenital cataract and lens anomalies | 0.001731 | 2.114 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Phobia | 3.858e-05 | 3.046 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Varicose veins of lower extremity | 0.002561 | 1.183 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Transient cerebral ischemia | 0.005703 | 0.8632 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Benign mammary dysplasias | 0.0003286 | 1.221 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Abnormal findings on mammogram or breast exam | 0.002926 | 1.138 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Congenital musculoskeletal deformities of spine | 0.0002498 | 1.591 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Mastodynia | 0.002618 | 1.306 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | AV block | 0.008983 | 1.188 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Varicose veins | 0.002669 | 1.175 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Cystic mastopathy | 0.0001188 | 1.249 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Cerebral ischemia | 0.001859 | 0.8502 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs758642 | Spondylolisthesis, congenital | 0.002937 | 1.604 | CAMKK1 | Smoking behavior (cigarettes per day) |
| rs7610017 | Other immunological findings | 0.006986 | 1.59 | TP63 | Grey matter density |
| rs7610017 | Mechanical complication of nervous system device, implant, and graft | 0.008756 | 2.712 | TP63 | Grey matter density |
| rs7610017 | Other specified cardiac dysrhythmias | 0.008755 | 1.28 | TP63 | Grey matter density |
| rs7610017 | Rotator cuff (capsule) sprain | 0.003704 | 1.465 | TP63 | Grey matter density |
| rs7610017 | Mixed hyperlipidemia | 0.006565 | 0.6606 | TP63 | Grey matter density |
| rs7610017 | Sprains and strains | 0.005347 | 1.249 | TP63 | Grey matter density |
| rs7610017 | Congenital anomalies of genital organs | 0.006463 | 2.632 | TP63 | Grey matter density |
| rs7610017 | Jaundice | 0.001104 | 2.042 | TP63 | Grey matter density |
| rs7610017 | Spinal stenosis | 0.008547 | 1.267 | TP63 | Grey matter density |
| rs7610017 | Back & neck sprains | 0.003963 | 1.298 | TP63 | Grey matter density |
| rs7610017 | Other disorders of back | 0.008277 | 1.318 | TP63 | Grey matter density |
| rs7610017 | Coagulation defects | 0.0106 | 1.205 | TP63 | Grey matter density |
| rs7610017 | Keratitis | 0.006071 | 1.6 | TP63 | Grey matter density |
| rs7610017 | Atrial fibrillation | 0.008097 | 1.273 | TP63 | Grey matter density |
| rs7610017 | Symptoms involving digestive system | 0.01061 | 1.418 | TP63 | Grey matter density |
| rs7610017 | Bacterial infection NOS | 0.00623 | 1.286 | TP63 | Grey matter density |
| rs7610017 | Urethral stricture (not specified as infectious) | 0.003085 | 1.903 | TP63 | Grey matter density |
| rs7610017 | Muscular wasting and disuse atrophy | 0.008699 | 2.062 | TP63 | Grey matter density |
| rs7610017 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.01145 | 1.211 | TP63 | Grey matter density |
| rs7672826 | Thyroiditis | 0.008853 | 1.344 | MGC45800 | Multiple sclerosis |
| rs7672826 | Disorders of esophageal motility | 0.0001406 | 1.729 | MGC45800 | Multiple sclerosis |
| rs7672826 | Peripheral or central vertigo | 0.003823 | 1.232 | MGC45800 | Multiple sclerosis |
| rs7672826 | Aortic aneurysm | 0.001124 | 0.7839 | MGC45800 | Multiple sclerosis |
| rs7672826 | Nonallopathic lesions NEC | 0.009174 | 1.129 | MGC45800 | Multiple sclerosis |
| rs7672826 | Other aneurysm | 0.003489 | 0.8224 | MGC45800 | Multiple sclerosis |
| rs7672826 | Secondary/extrinsic cardiomyopathies | 0.003044 | 1.865 | MGC45800 | Multiple sclerosis |
| rs7672826 | Inflammation of eyelids | 0.002823 | 1.155 | MGC45800 | Multiple sclerosis |
| rs7672826 | Symptoms of the muscles | 0.003706 | 1.279 | MGC45800 | Multiple sclerosis |
| rs7672826 | Dyspepsia and disorders of function of stomach | 0.01057 | 0.858 | MGC45800 | Multiple sclerosis |
| rs7672826 | Epilepsy, recurrent seizures, convulsions | 0.002547 | 0.8057 | MGC45800 | Multiple sclerosis |
| rs7672826 | Calculus of lower urinary tract | 0.009856 | 0.5715 | MGC45800 | Multiple sclerosis |
| rs7672826 | Noninfectious disorders of lymphatic channels | 0.008838 | 1.32 | MGC45800 | Multiple sclerosis |
| rs7672826 | Disorders of function of stomach | 0.009641 | 0.8627 | MGC45800 | Multiple sclerosis |
| rs7672826 | Inflammation of the eye | 0.003741 | 1.133 | MGC45800 | Multiple sclerosis |
| rs7672826 | Abdominal aortic aneurysm | 0.004699 | 0.783 | MGC45800 | Multiple sclerosis |
| rs7672826 | Other disorders of urethra and urinary tract | 0.00191 | 1.254 | MGC45800 | Multiple sclerosis |
| rs7672826 | Conductive hearing loss | 0.003862 | 1.574 | MGC45800 | Multiple sclerosis |
| rs7672826 | Convulsions | 0.006902 | 0.8166 | MGC45800 | Multiple sclerosis |
| rs7672826 | Hyperbilirubinemia | 0.0002242 | 2.214 | MGC45800 | Multiple sclerosis |
| rs7715811 | Rash and other nonspecific skin eruption | 0.006372 | 0.8427 | DNAH5 | Ankle brachial index |
| rs7715811 | Cystic mastopathy | 0.002138 | 0.8233 | DNAH5 | Ankle brachial index |
| rs7715811 | Other specified disorders of breast | 0.005153 | 0.7718 | DNAH5 | Ankle brachial index |
| rs7715811 | Simple goiter | 0.003957 | 0.7724 | DNAH5 | Ankle brachial index |
| rs7715811 | Toxic effect of venom | 0.003698 | 0.5636 | DNAH5 | Ankle brachial index |
| rs7715811 | Benign mammary dysplasias | 0.002355 | 0.8312 | DNAH5 | Ankle brachial index |
| rs7715811 | Mucous polyp of cervix | 0.001594 | 0.6201 | DNAH5 | Ankle brachial index |
| rs7715811 | Pathologic fracture | 0.006414 | 0.8061 | DNAH5 | Ankle brachial index |
| rs7715811 | Vitamin D deficiency | 0.0105 | 0.7499 | DNAH5 | Ankle brachial index |
| rs7715811 | Postmenopausal hormone replacement | 0.001842 | 0.7252 | DNAH5 | Ankle brachial index |
| rs7715811 | Multiple sclerosis | 0.01033 | 1.511 | DNAH5 | Ankle brachial index |
| rs7715811 | Infertility, male | 0.004781 | 1.988 | DNAH5 | Ankle brachial index |
| rs7715811 | Acute bronchospasm | 0.009412 | 2.033 | DNAH5 | Ankle brachial index |
| rs7715811 | Asthma | 0.007527 | 0.8784 | DNAH5 | Ankle brachial index |
| rs7715811 | Excessive or frequent menstruation | 0.003672 | 0.7259 | DNAH5 | Ankle brachial index |
| rs7715811 | Hypothyroidism | 0.003935 | 0.8897 | DNAH5 | Ankle brachial index |
| rs7742369 | Orchitis and epididymitis | 0.005723 | 1.552 | HMGA1 | Height |
| rs7742369 | Duodenal ulcer | 0.008938 | 0.6642 | HMGA1 | Height |
| rs7742369 | Disorders of uterus, NEC | 0.008388 | 1.877 | HMGA1 | Height |
| rs7742369 | Ptosis of eyelid | 0.01082 | 1.246 | HMGA1 | Height |
| rs7742369 | Benign neoplasm of respiratory and intrathoracic organs | 0.002978 | 1.927 | HMGA1 | Height |
| rs7742369 | Acute, but ill-defined cerebrovascular disease | 0.001626 | 1.289 | HMGA1 | Height |
| rs7742369 | Torsion dystonia | 0.01026 | 1.649 | HMGA1 | Height |
| rs7742369 | Hemorrhage NOS | 0.001434 | 1.961 | HMGA1 | Height |
| rs7742369 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.007016 | 1.764 | HMGA1 | Height |
| rs7742369 | Other disorders of circulatory system | 0.003564 | 1.199 | HMGA1 | Height |
| rs7742369 | Hypertrophy of female genital organs | 0.002587 | 1.943 | HMGA1 | Height |
| rs7742369 | Disorders of esophageal motility | 0.0005785 | 1.747 | HMGA1 | Height |
| rs7742369 | Circulatory disease NEC | 0.004115 | 1.219 | HMGA1 | Height |
| rs7742369 | Neuralgia, neuritis, and radiculitis NOS | 0.003498 | 0.751 | HMGA1 | Height |
| rs7742369 | Nontoxic multinodular goiter | 0.002203 | 0.6836 | HMGA1 | Height |
| rs7774434 | Rheumatoid arthritis | 0.001984 | 1.256 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Vitamin B-complex deficiencies | 0.003554 | 0.7919 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Diplopia and disorders of binocular vision | 0.01028 | 1.274 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Eosinophilia | 0.0006764 | 2.074 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Chronic sinusitis | 0.008639 | 1.12 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Other disorders of adrenal glands | 0.009332 | 0.6447 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Labyrinthitis | 0.01114 | 1.34 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Type 1 diabetic neuropathy | 0.01003 | 1.411 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Other local infections of skin and subcutaneous tissue | 0.006121 | 0.8483 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Discoid lupus erythematosus | 0.004498 | 0.6579 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Lupus erythematosus | 0.003281 | 0.4469 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Rheumatic fever / chorea | 0.009812 | 0.4599 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.004704 | 1.204 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Retinal hemorrhage/ischemia | 0.002346 | 1.448 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Insomnia | 0.008948 | 1.159 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Bullous dermatoses | 0.003318 | 0.4509 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Other specified erythematous conditions | 0.00652 | 0.7513 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Multiple sclerosis | 0.004638 | 0.6061 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Gastroparesis | 0.001771 | 1.828 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7774434 | Allergic rhinitis | 0.009658 | 1.112 | HLA-DQB1 | Primary biliary cirrhosis |
| rs7789197 | Poisoning by anticonvulsants and anti-Parkinsonism drugs | 0.01071 | 1.86 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Otalgia | 3.507e-05 | 1.521 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Periostitis | 0.005115 | 1.916 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Epilepsy | 0.01139 | 1.401 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Noninflammatory disorders of vagina | 0.01057 | 0.6503 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Epilepsy, recurrent seizures, convulsions | 0.00136 | 1.288 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Acute bronchospasm | 0.001731 | 2.526 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Diseases of the jaws | 0.01015 | 1.232 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Adverse effects of insulins and antidiabetic agents | 0.009215 | 1.859 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Dental caries | 0.0009868 | 1.31 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Gastritis and duodenitis | 0.005061 | 1.19 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Diaphragmatic hernia | 0.002318 | 1.192 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Cardiac defibrillator in situ | 0.001109 | 1.605 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Diseases of hard tissues of teeth | 0.004686 | 1.256 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Primary angle-closure glaucoma | 0.007229 | 0.7606 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Convulsions | 0.001052 | 1.311 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Other specified cardiac dysrhythmias | 0.008679 | 1.165 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Other signs and symptoms in breast | 0.01033 | 0.6399 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Other disorders of middle ear and mastoid | 0.008451 | 1.528 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | First degree AV block | 0.003654 | 1.322 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7789197 | Throat pain | 0.009417 | 1.687 | INHBA | Prostate cancer (gene x gene interaction) |
| rs7792939 | Acute cystitis | 0.003734 | 0.5444 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Decubitus ulcer | 0.01076 | 0.7313 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Stress fracture | 0.01057 | 1.99 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Hemiplegia | 0.008644 | 0.6148 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Chronic ulcer of skin | 0.008632 | 0.8354 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Mental retardation | 0.007869 | 2.286 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Chronic cystitis | 0.008979 | 0.4809 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Cystitis and urethritis | 0.004533 | 0.7354 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Cystitis | 0.0005567 | 0.6637 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Fibroadenosis of breast | 0.01135 | 2.232 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Dysuria | 0.007735 | 0.8008 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7792939 | Cachexia | 0.002491 | 2.385 | ZNF498 | Weight, Hip circumference, Brachial circumference |
| rs7804356 | Hallux valgus (Bunion) | 0.005117 | 1.226 | SKAP2 | Type 1 diabetes |
| rs7804356 | Abnormal loss of weight and underweight | 0.01015 | 1.296 | SKAP2 | Type 1 diabetes |
| rs7804356 | Noninfectious dermatoses of eyelid | 0.005505 | 1.77 | SKAP2 | Type 1 diabetes |
| rs7804356 | Renal osteodystrophy | 0.008136 | 1.53 | SKAP2 | Type 1 diabetes |
| rs7804356 | Joint/ligament sprain | 0.006483 | 0.7011 | SKAP2 | Type 1 diabetes |
| rs7804356 | Adverse drug events and drug allergies | 0.001563 | 1.232 | SKAP2 | Type 1 diabetes |
| rs7804356 | Aplastic anemia | 0.006076 | 0.6691 | SKAP2 | Type 1 diabetes |
| rs7865146 | Impetigo | 0.006819 | 0.6179 | ENG | Diastolic blood pressure |
| rs7865146 | Dermatosis NOS | 0.003974 | 0.8942 | ENG | Diastolic blood pressure |
| rs7865146 | Unspecified monoarthritis | 0.007151 | 1.629 | ENG | Diastolic blood pressure |
| rs7865146 | Rhabdomyolysis | 0.009632 | 1.776 | ENG | Diastolic blood pressure |
| rs7865146 | Cardiac shunt/ heart septal defect | 0.002571 | 0.6372 | ENG | Diastolic blood pressure |
| rs7865146 | Retinal vascular changes and abnomalities | 0.0001875 | 0.7475 | ENG | Diastolic blood pressure |
| rs7865146 | Open-angle glaucoma | 0.003521 | 0.8438 | ENG | Diastolic blood pressure |
| rs7865146 | Other disorders of gallbladder | 0.006972 | 1.576 | ENG | Diastolic blood pressure |
| rs7865146 | Occlusion and stenosis of precerebral arteries | 0.01136 | 0.8841 | ENG | Diastolic blood pressure |
| rs7865146 | Secondary malignancy of lymph nodes | 0.01018 | 1.243 | ENG | Diastolic blood pressure |
| rs7865146 | Congenital cataract and lens anomalies | 0.008297 | 0.4675 | ENG | Diastolic blood pressure |
| rs7865146 | Congenital anomalies of peripheral vascular system | 0.008943 | 0.5208 | ENG | Diastolic blood pressure |
| rs7865146 | Cardiac and circulatory congenital anomalies | 0.004 | 0.7534 | ENG | Diastolic blood pressure |
| rs7865146 | Abnormal pulmonary function | 0.007717 | 2.159 | ENG | Diastolic blood pressure |
| rs7866070 | Peptic ulcer | 0.0006551 | 1.215 | PRRX2 | Astigmatism |
| rs7866070 | Abdominal hernia | 0.009863 | 1.094 | PRRX2 | Astigmatism |
| rs7866070 | Barrett's esophagus | 0.009742 | 1.358 | PRRX2 | Astigmatism |
| rs7866070 | Ulcer of esophagus | 0.0008379 | 1.539 | PRRX2 | Astigmatism |
| rs7866070 | Scoliosis | 0.007445 | 1.304 | PRRX2 | Astigmatism |
| rs7866070 | Viral hepatitis | 0.001998 | 0.7322 | PRRX2 | Astigmatism |
| rs7866070 | Crohn's disease | 0.009215 | 1.429 | PRRX2 | Astigmatism |
| rs7866070 | Fasciitis | 0.008844 | 1.163 | PRRX2 | Astigmatism |
| rs7866070 | Curvature of spine | 0.009293 | 1.236 | PRRX2 | Astigmatism |
| rs7866070 | Disorders of synovium, tendon, and bursa | 0.01004 | 1.113 | PRRX2 | Astigmatism |
| rs7866070 | Migraine | 0.01018 | 0.8565 | PRRX2 | Astigmatism |
| rs7866070 | Pseudoexfoliation glaucoma | 0.002382 | 0.5526 | PRRX2 | Astigmatism |
| rs7866070 | Sciatica | 0.003328 | 1.186 | PRRX2 | Astigmatism |
| rs7866070 | Viral hepatitis C | 0.001414 | 0.5753 | PRRX2 | Astigmatism |
| rs7866070 | Pulmonary embolism and infarction | 0.006773 | 1.251 | PRRX2 | Astigmatism |
| rs7866070 | Gastric ulcer | 6.299e-05 | 1.435 | PRRX2 | Astigmatism |
| rs7866070 | Myeloproliferative disease | 0.001948 | 1.415 | PRRX2 | Astigmatism |
| rs786870 | Disorders of adrenal glands | 0.004416 | 1.369 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Paranoid disorders | 0.001664 | 1.973 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Vitamin B12 deficiency anemia | 0.005286 | 1.581 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Disturbance of skin sensation | 0.008544 | 1.133 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Failure to thrive | 0.003099 | 1.468 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Chronic kidney disease, Stage I or II | 0.003108 | 0.6338 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.008386 | 1.212 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Other open wound of head and face | 0.002107 | 0.769 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Orchitis and epididymitis | 0.001429 | 0.5714 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Upper gastrointestinal congenital anomalies | 0.001941 | 1.687 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Hereditary and idiopathic peripheral neuropathy | 0.01114 | 1.155 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Iron metabolism disorder | 0.006679 | 1.871 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs786870 | Muscular dystrophies and other myopathies | 0.0113 | 1.448 | APBB1IP | Response to fenofibrate treatment, Inflammatory biomarkers |
| rs7871764 | Precordial pain | 0.01128 | 0.7464 | DCAF12 | Height |
| rs7871764 | Barrett's esophagus | 0.008599 | 1.375 | DCAF12 | Height |
| rs7871764 | Infections involving bone | 0.007358 | 0.7704 | DCAF12 | Height |
| rs7871764 | Vascular dementia | 0.003768 | 1.436 | DCAF12 | Height |
| rs7871764 | Dermatophytosis of the body | 0.006701 | 0.696 | DCAF12 | Height |
| rs7871764 | Polycystic ovaries | 0.007358 | 0.3874 | DCAF12 | Height |
| rs7871764 | Extrinsic allergic alveolitis | 0.000184 | 2.576 | DCAF12 | Height |
| rs7871764 | Urticaria | 0.007511 | 0.7842 | DCAF12 | Height |
| rs7871764 | Hemorrhagic disorder due to intrinsic circulating anticoagulants | 0.007289 | 1.114 | DCAF12 | Height |
| rs7871764 | Vitamin D deficiency | 0.006313 | 1.308 | DCAF12 | Height |
| rs7871764 | Adverse effects of insulins and antidiabetic agents | 0.005575 | 1.818 | DCAF12 | Height |
| rs7871764 | Age-related macular degeneration | 0.001637 | 1.258 | DCAF12 | Height |
| rs7871764 | Retinal disorders | 0.008983 | 1.116 | DCAF12 | Height |
| rs7873102 | Optic atrophy | 0.002445 | 0.6378 | SHB | Brain structure |
| rs7873102 | Gram negative septicemia | 0.004812 | 1.411 | SHB | Brain structure |
| rs7873102 | Fracture of unspecified bones | 0.006533 | 1.156 | SHB | Brain structure |
| rs7873102 | Symptoms involving nervous and musculoskeletal systems | 0.007016 | 0.7883 | SHB | Brain structure |
| rs7873102 | Acute laryngitis and tracheitis | 0.001482 | 1.562 | SHB | Brain structure |
| rs7873102 | Male infertility and abnormal spermatozoa | 0.01104 | 1.618 | SHB | Brain structure |
| rs7873102 | Other sprains and strains | 0.005416 | 1.348 | SHB | Brain structure |
| rs7873102 | Fasciitis | 0.01039 | 1.15 | SHB | Brain structure |
| rs7873102 | Chronic kidney disease, Stage I or II | 0.003529 | 1.407 | SHB | Brain structure |
| rs7873102 | Cysts of the jaws | 0.001742 | 2.492 | SHB | Brain structure |
| rs7873102 | Diaphragmatic hernia | 0.003623 | 1.147 | SHB | Brain structure |
| rs7873102 | Viral Enteritis | 0.006066 | 1.482 | SHB | Brain structure |
| rs789560 | Emphysema | 0.002829 | 1.426 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Hypercoagulable state | 0.01145 | 1.629 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Uterine leiomyoma | 0.005285 | 1.341 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Disorders of penis | 0.008682 | 1.474 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Develomental delays and disorders | 0.009156 | 1.375 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | severe protein-calorie malnutrition | 0.004332 | 1.783 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Type 2 diabetic peripheral circulatory disorders | 0.009042 | 1.503 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs789560 | Contracture of joint | 0.00112 | 1.664 | C12orf28 | Attention deficit hyperactivity disorder and conduct disorder |
| rs7916697 | Esophageal atresia/tracheoesophageal fistula | 0.00407 | 0.4373 | ATOH7 | Optic disc parameters |
| rs7916697 | Cellulitis and abscess of trunk | 0.006713 | 0.7204 | ATOH7 | Optic disc parameters |
| rs7916697 | Heartburn | 0.005917 | 1.413 | ATOH7 | Optic disc parameters |
| rs7916697 | Melanoma | 0.006393 | 1.299 | ATOH7 | Optic disc parameters |
| rs7916697 | Abnormal reflex | 0.007259 | 2.153 | ATOH7 | Optic disc parameters |
| rs7916697 | Bronchiectasis | 0.006573 | 1.414 | ATOH7 | Optic disc parameters |
| rs7916697 | Nevus, non-neoplastic | 0.0005633 | 0.3604 | ATOH7 | Optic disc parameters |
| rs7916697 | Other rheumatic heart disease | 0.002711 | 2.084 | ATOH7 | Optic disc parameters |
| rs7916697 | Crohn's disease | 0.0006647 | 1.626 | ATOH7 | Optic disc parameters |
| rs7916697 | Toxic erythema | 0.003095 | 2.219 | ATOH7 | Optic disc parameters |
| rs7916697 | Inflammatory bowel disease | 0.008765 | 1.338 | ATOH7 | Optic disc parameters |
| rs7916697 | Inflammatory conditions of jaw | 0.003484 | 1.621 | ATOH7 | Optic disc parameters |
| rs7916697 | Photodermatitis & sunburn | 0.009268 | 0.832 | ATOH7 | Optic disc parameters |
| rs7922491 | Abnormal findings on radiological examination intrathoracic organs | 0.01099 | 1.327 | PRKG1 | Asthma |
| rs7922491 | Spinal stenosis of lumbar region | 0.007157 | 1.236 | PRKG1 | Asthma |
| rs7922491 | Poisoning by other anti-infectives | 0.0005344 | 1.514 | PRKG1 | Asthma |
| rs7922491 | Viral hepatitis | 0.003704 | 1.467 | PRKG1 | Asthma |
| rs7922491 | Hypotension NOS | 0.005857 | 1.297 | PRKG1 | Asthma |
| rs7922491 | Disorders of coccyx | 0.005041 | 1.572 | PRKG1 | Asthma |
| rs7922491 | Diseases of respiratory system | 0.001035 | 1.317 | PRKG1 | Asthma |
| rs7922491 | Abnormal findings on exam of gastrointestinal tract/abdominal area | 0.01144 | 1.51 | PRKG1 | Asthma |
| rs7922491 | Osteoarthrosis of multiple sites | 0.003509 | 1.412 | PRKG1 | Asthma |
| rs7922491 | Herpes zoster with nervous system complications | 0.003419 | 1.863 | PRKG1 | Asthma |
| rs7922491 | Fracture of unspecified bones | 0.00441 | 1.261 | PRKG1 | Asthma |
| rs7922491 | Purpura and other hemorrhagic conditions | 0.01102 | 0.7752 | PRKG1 | Asthma |
| rs7922491 | Cancer within the respiratory system | 5.545e-05 | 1.551 | PRKG1 | Asthma |
| rs7922491 | Lump or mass in breast | 0.008548 | 0.7804 | PRKG1 | Asthma |
| rs7922491 | Sulfonamides | 0.001313 | 1.533 | PRKG1 | Asthma |
| rs7922491 | Chronic pain syndrome | 0.001564 | 2.108 | PRKG1 | Asthma |
| rs7922491 | Deficiency of humoral immunity | 0.01023 | 2.343 | PRKG1 | Asthma |
| rs7922491 | Concussion | 0.00973 | 1.688 | PRKG1 | Asthma |
| rs7922491 | Fuchs' dystrophy | 0.009471 | 1.697 | PRKG1 | Asthma |
| rs7922491 | Lung cancer | 0.0001059 | 1.537 | PRKG1 | Asthma |
| rs7922491 | Hypotension | 0.003752 | 1.231 | PRKG1 | Asthma |
| rs7922491 | Erythematous conditions | 0.01055 | 0.8211 | PRKG1 | Asthma |
| rs7922491 | Other hereditary hemolytic anemias | 0.009381 | 2.437 | PRKG1 | Asthma |
| rs7922491 | Syncope and collapse | 0.004902 | 1.2 | PRKG1 | Asthma |
| rs7922491 | Spondylosis and allied disorders | 0.009143 | 1.171 | PRKG1 | Asthma |
| rs7922491 | Intestinal malabsorption NOS | 0.005418 | 2.023 | PRKG1 | Asthma |
| rs7937 | Diffuse diseases of connective tissue | 0.009626 | 1.254 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Deficiency of humoral immunity | 0.006781 | 2.099 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Osteopenia | 0.006506 | 1.127 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Lack of normal physiological development | 0.008723 | 1.343 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Asthma | 0.003651 | 1.133 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Malaise and fatigue | 0.0114 | 1.08 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Cachexia | 0.003834 | 2.122 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Seborrhea | 0.0114 | 0.523 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Viral infection | 0.0003421 | 1.236 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7937 | Cramp of limb | 9.811e-05 | 1.47 | RAB4B | Chronic obstructive pulmonary disease in current smokers |
| rs7961894 | Posttraumatic stress disorder | 0.008248 | 1.796 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Other diseases of the teeth and supporting structures | 0.003651 | 1.412 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Adjustment reaction | 0.004856 | 1.255 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Cellulitis and abscess of foot/toes | 0.005073 | 1.447 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Colon cancer | 0.006707 | 0.6718 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Peripheral autonomic neuropathy | 0.007981 | 1.543 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Pseudomonal pneumonia | 0.007612 | 2.524 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Enthesopathy | 0.01142 | 1.177 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Generalized anxiety disorder | 0.008896 | 1.431 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Aplastic anemia | 1.931e-05 | 1.85 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Pancytopenia | 0.000773 | 1.996 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Mental retardation | 0.0007206 | 2.968 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Type 1 diabetes | 0.005331 | 1.282 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Multiple myeloma | 0.004376 | 1.845 | WDR66 | Platelet counts, Mean platelet volume |
| rs7961894 | Vitamin B-complex deficiencies | 0.008673 | 1.336 | WDR66 | Platelet counts, Mean platelet volume |
| rs8016947 | Crohn's disease | 0.006783 | 1.448 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Abnormal results of function study of liver | 0.004749 | 1.223 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Mycoses | 0.005324 | 1.562 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Other unspecified back disorders | 0.007313 | 0.6356 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Known or suspected fetal abnormality | 0.001156 | 0.5205 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Cervical cancer | 0.00687 | 0.5087 | NFKBIA | Psoriasis vulgaris |
| rs8016947 | Diaphragmatic hernia | 0.00883 | 0.8836 | NFKBIA | Psoriasis vulgaris |
| rs8017161 | Disorders of parathyroid gland | 0.005431 | 1.299 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Melanoma | 0.01146 | 0.7908 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Jaw disease NOS | 0.0009016 | 1.655 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Hyperparathyroidism | 0.005555 | 1.313 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Other disorders of metabolism | 0.01046 | 0.6144 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Nodular lymphoma | 0.00493 | 0.5816 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Herpes zoster with nervous system complications | 0.004487 | 0.616 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Barrett's esophagus | 0.003283 | 1.411 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Inguinal hernia | 0.006343 | 1.158 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Subarachnoid hemorrhage (injury) | 0.009961 | 0.4293 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Encounter for long-term use of anticoagulants/antithrombotics | 0.000219 | 0.7041 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Nephritis and nephropathy without mention of glomerulonephritis | 0.007486 | 1.249 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Testicular dysfunction | 0.01016 | 0.7172 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Cervical intraepithelial neoplasia (Cervical dysplasia) | 0.003599 | 0.7325 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Bladder neck obstruction | 0.00856 | 0.7891 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Encounter for long-term use of aspirin | 8.282e-05 | 0.6558 | TNFAIP2 | Primary biliary cirrhosis |
| rs8017161 | Cervical cancer and dysplasia | 0.002563 | 0.7427 | TNFAIP2 | Primary biliary cirrhosis |
| rs8023445 | Thrombocytopenia | 0.0037 | 1.296 | SHC4 | Major depressive disorder |
| rs8023445 | Dermatosis NOS | 0.0108 | 0.8591 | SHC4 | Major depressive disorder |
| rs8023445 | Fracture of vertebral column without mention of spinal cord injury | 0.002773 | 1.359 | SHC4 | Major depressive disorder |
| rs8023445 | Fracture of foot | 0.00847 | 1.291 | SHC4 | Major depressive disorder |
| rs8023445 | Secondary malignant neoplasm | 0.007275 | 0.7819 | SHC4 | Major depressive disorder |
| rs8023445 | Pelvic peritoneal adhesions, female (postoperative) (postinfection) | 0.001822 | 2.757 | SHC4 | Major depressive disorder |
| rs8023445 | Hepatomegaly | 0.001031 | 2.268 | SHC4 | Major depressive disorder |
| rs8023445 | Purpura and other hemorrhagic conditions | 0.003701 | 1.265 | SHC4 | Major depressive disorder |
| rs8038465 | Inflammatory bowel disease | 0.01013 | 0.7564 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Ulceration of the lower GI tract | 0.00881 | 0.6347 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Graves' disease | 0.003289 | 0.6352 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Cancer of oropharynx | 0.01105 | 1.953 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Spondylosis and allied disorders | 0.0004319 | 0.8742 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Femoral hernia | 0.003641 | 0.4587 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Other hypertensive complications | 0.004052 | 1.272 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Congenital anomalies of peripheral vascular system | 0.01097 | 0.5377 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Cardiomegaly | 0.001205 | 1.187 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Pneumonia | 0.0009646 | 1.132 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Iatrogenic hypothyroidism | 0.002497 | 0.7122 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Spondylosis without myelopathy | 0.0003026 | 0.8675 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Ulcerative colitis | 0.006626 | 0.6704 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | Balanoposthitis | 0.00666 | 1.665 | CD276 | Gamma-glutamyl transferase |
| rs8038465 | E. coli | 0.004082 | 0.7319 | CD276 | Gamma-glutamyl transferase |
| rs8041675 | Congenital deformities of feet | 2.935e-05 | 1.528 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Disorders of uterus, NEC | 0.01065 | 1.771 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Congenital anomalies of lower limb, including pelvic girdle | 0.008863 | 1.771 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Impaired fasting glucose | 0.003994 | 1.192 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Abnormal glucose | 0.005691 | 1.115 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Chronic tonsillitis and adenoiditis | 0.01059 | 0.595 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Congenital anomalies of limbs | 2.989e-06 | 1.517 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Malignant neoplasm of kidney and other urinary organs | 0.006375 | 1.678 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Malunion fracture | 0.005724 | 1.436 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8041675 | Blindness and low vision | 0.01104 | 1.282 | MEIS2 | Hyperactive-impulsive symptoms |
| rs8042374 | Disorders of parathyroid gland | 0.001375 | 0.6701 | CHRNA3 | Lung cancer |
| rs8042374 | Peripheral arterial disease | 0.002107 | 0.8493 | CHRNA3 | Lung cancer |
| rs8042374 | Type 2 diabetic ketoacidosis | 0.001265 | 1.191 | CHRNA3 | Lung cancer |
| rs8042374 | Chronic nonalcoholic liver disease | 0.005345 | 1.28 | CHRNA3 | Lung cancer |
| rs8042374 | Gouty arthropathy | 0.004039 | 1.364 | CHRNA3 | Lung cancer |
| rs8042374 | Atherosclerosis of native arteries of the extremities with intermittent claudication | 0.006277 | 0.8203 | CHRNA3 | Lung cancer |
| rs8042374 | Cirrhosis of liver without mention of alcohol | 0.004586 | 1.495 | CHRNA3 | Lung cancer |
| rs8042374 | Cancer of other male genital organs | 0.009007 | 1.747 | CHRNA3 | Lung cancer |
| rs8042374 | Gout | 0.0006843 | 1.234 | CHRNA3 | Lung cancer |
| rs8042374 | Pneumonia | 0.005332 | 0.8828 | CHRNA3 | Lung cancer |
| rs8042374 | Gout and other crystal arthropathies | 0.0006565 | 1.218 | CHRNA3 | Lung cancer |
| rs8042374 | Atherosclerosis of the extremities | 0.006508 | 0.8529 | CHRNA3 | Lung cancer |
| rs8042374 | Hyperparathyroidism | 0.002401 | 0.6736 | CHRNA3 | Lung cancer |
| rs8042374 | Peripheral vascular disease | 0.006403 | 0.8754 | CHRNA3 | Lung cancer |
| rs8047014 | Other disorders of soft tissues | 0.006995 | 0.7057 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Morbid obesity | 0.0002051 | 0.8054 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Cancer of kidney and renal pelvis | 0.001569 | 1.415 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Mitral stenosis/insufficiency | 0.003459 | 0.4652 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Urticaria | 0.003144 | 0.7813 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Periapical abscess | 0.01087 | 0.8281 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Cancer of kidney and urinary organs | 0.008696 | 1.201 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Abnormal findings on examination of urine | 0.01103 | 0.8579 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Other biliary tract disease | 0.001084 | 1.324 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Hemorrhage from gastrointestinal ulcer | 0.004385 | 0.6876 | HAS3 | Attention deficit hyperactivity disorder |
| rs8047014 | Renal cell carcinoma | 0.001152 | 1.431 | HAS3 | Attention deficit hyperactivity disorder |
| rs8062326 | Noninflammatory female genital disorders | 0.01076 | 1.475 | SYT17 | Alcoholism |
| rs8062326 | Intestinal malabsorption | 0.001559 | 2.069 | SYT17 | Alcoholism |
| rs8062326 | Hypoglycemia | 0.006774 | 2.087 | SYT17 | Alcoholism |
| rs8062326 | Glossitis | 0.006284 | 3.016 | SYT17 | Alcoholism |
| rs8062326 | Rotator cuff (capsule) sprain | 2.519e-05 | 1.893 | SYT17 | Alcoholism |
| rs8062326 | Peripheral or central vertigo | 0.003693 | 0.4785 | SYT17 | Alcoholism |
| rs8062326 | Sprains and strains | 0.01011 | 1.294 | SYT17 | Alcoholism |
| rs8062326 | Fracture of ribs | 0.001817 | 1.728 | SYT17 | Alcoholism |
| rs8062326 | Ulcerative stomatitis & mucositis | 3.24e-05 | 3.893 | SYT17 | Alcoholism |
| rs8062326 | Otorrhea | 0.008101 | 2.889 | SYT17 | Alcoholism |
| rs8062326 | Fracture of vertebral column without mention of spinal cord injury | 0.008876 | 1.559 | SYT17 | Alcoholism |
| rs8074980 | Secondary malignancy of lymph nodes | 0.004986 | 0.7004 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Respiratory insufficiency | 0.007309 | 0.6819 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Ventral hernia | 0.0005311 | 1.462 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Aphakia and other disorders of lens | 0.007361 | 1.368 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Attention deficit hyperactivity disorder | 0.01052 | 1.72 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Hyperbilirubinemia | 0.001524 | 2.09 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Disease of tricuspid valve | 0.01074 | 0.7362 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Secondary malignancy of bone | 0.003127 | 0.6106 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Calcaneal spur; Exostosis NOS | 0.007386 | 1.336 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Peripheral enthesopathies | 0.00909 | 1.119 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Syncope and collapse | 0.007013 | 0.8587 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Prostate cancer | 0.006267 | 0.7919 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Unspecified erythematous condition | 0.01058 | 0.5495 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Prostatitis | 0.002198 | 0.6615 | CUEDC1 | Multiple sclerosis |
| rs8074980 | Poisoning by water, mineral, and uric acid metabolism drugs | 0.005495 | 1.787 | CUEDC1 | Multiple sclerosis |
| rs8079702 | Other cerebral degenerations | 0.01147 | 1.373 | KCNJ2 | Primary tooth development |
| rs8079702 | Chronic hepatitis | 0.01059 | 1.711 | KCNJ2 | Primary tooth development |
| rs8079702 | Nerve plexus lesions | 0.006641 | 0.6895 | KCNJ2 | Primary tooth development |
| rs8079702 | Fracture of upper limb | 0.00798 | 0.8763 | KCNJ2 | Primary tooth development |
| rs8079702 | Intestinal obstruction without mention of hernia | 0.005702 | 0.8353 | KCNJ2 | Primary tooth development |
| rs8079702 | Loss of teeth or edentulism | 0.003607 | 0.709 | KCNJ2 | Primary tooth development |
| rs8079702 | Disorders of liver | 0.008869 | 0.9042 | KCNJ2 | Primary tooth development |
| rs8079702 | Benign neoplasm of eye | 0.009254 | 1.227 | KCNJ2 | Primary tooth development |
| rs8079702 | Fracture of radius and ulna | 0.005455 | 0.8419 | KCNJ2 | Primary tooth development |
| rs8079702 | Open wound of nose and sinus | 0.01044 | 0.4775 | KCNJ2 | Primary tooth development |
| rs8079702 | Fuchs' dystrophy | 0.002408 | 0.6304 | KCNJ2 | Primary tooth development |
| rs8079702 | Open wounds of head; neck; and trunk | 0.006505 | 0.8679 | KCNJ2 | Primary tooth development |
| rs8079702 | Other diseases of the teeth and supporting structures | 0.002638 | 0.7792 | KCNJ2 | Primary tooth development |
| rs8079702 | Other disorders of intestine | 0.003696 | 0.8299 | KCNJ2 | Primary tooth development |
| rs8083432 | Dupuytren's disease | 0.002948 | 1.497 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Paralytic strabismus | 0.0008719 | 1.722 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Otitis externa | 0.008155 | 1.22 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Peyronie's disease | 0.005804 | 1.965 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Cervicitis and endocervicitis | 0.000601 | 1.883 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Empyema and pneumothorax | 0.00689 | 0.7014 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Psoriasis | 0.008774 | 1.279 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Skin neoplasm of uncertain behavior | 0.006763 | 1.242 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Eustachian tube disorders | 0.001273 | 1.182 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Photodermatitis & sunburn | 0.0001962 | 1.303 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Phobia | 0.003063 | 2.312 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Orchitis and epididymitis | 0.002036 | 1.619 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Occlusion of cerebral arteries, with cerebral infarction | 0.009329 | 0.5668 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Glossodynia | 0.01081 | 0.3625 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Partial epilepsy | 0.009754 | 1.446 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Bladder neck obstruction | 0.009768 | 1.308 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Convulsions | 0.002245 | 1.27 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Intestinal infection | 0.01052 | 0.7827 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8083432 | Epilepsy, recurrent seizures, convulsions | 0.00142 | 1.269 | ZNF521 | Adverse response to lamotrigine and phenytoin |
| rs8099917 | Complications of transplants and reattached limbs | 0.003757 | 1.731 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Anal and rectal polyp | 0.008502 | 0.7466 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Corneal edema | 0.009356 | 1.662 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Adverse effects of hormones and synthetic substitutes | 0.009668 | 2.173 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Other paralytic syndromes | 0.005266 | 1.571 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Dysmetabolic syndrome X | 0.002055 | 1.594 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Arthropathy NOS | 0.005483 | 1.228 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Umbilical hernia | 0.009425 | 1.309 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Anemia of chronic disease | 0.003413 | 1.267 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Renal failure | 0.001055 | 1.159 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Stomatitis and mucositis | 0.01129 | 1.415 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Complication of internal orthopedic device | 0.00766 | 1.268 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Edema | 0.0104 | 1.122 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Conduct disorders | 0.008778 | 0.5003 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Disorders of fluid, electrolyte, and acid-base balance | 0.004118 | 1.117 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8099917 | Chronic renal failure | 0.0009885 | 1.182 | IL28B | Response to hepatitis C treatment, Chronic Hepatitis C infection |
| rs8101881 | Cholelithiasis with other cholecystitis | 0.007278 | 1.29 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Dupuytren's disease | 0.001329 | 1.464 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Cyst or abscess of Bartholin's gland | 0.0104 | 1.898 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Anomalies of tooth position/malocclusion | 0.00739 | 1.644 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Electrolyte imbalance | 0.00552 | 0.9039 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Brain cancer | 0.008901 | 0.584 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Malignant neoplasm of renal pelvis | 0.009278 | 0.4093 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Retinal vascular changes and abnomalities | 0.00152 | 0.7833 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Conduct disorders | 0.007135 | 0.6099 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Bipolar | 0.00446 | 1.421 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Inflammatory spondylopathies | 0.01105 | 0.6552 | SLC7A9 | Lysine/valine ratio |
| rs8101881 | Insect bite | 0.000445 | 1.331 | SLC7A9 | Lysine/valine ratio |
| rs8109578 | Speech and language disorder | 0.007171 | 1.57 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Other benign neoplasm of connective and other soft tissue | 0.0001431 | 1.954 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Amblyopia | 0.007176 | 0.5472 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Thyroiditis | 0.005941 | 0.5298 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Rosacea | 0.005972 | 0.733 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Cerebral ischemia | 0.009414 | 0.8067 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Cancer of connective tissue | 0.01075 | 1.804 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Other disorders of the nervous system | 0.005515 | 1.754 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Femoral hernia | 0.009689 | 2.023 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Magnesium metabolism disorder | 0.01009 | 1.434 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Cerebrovascular disease | 0.004418 | 0.8566 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Cervical cancer and dysplasia | 0.004683 | 0.6094 | ANGPTL6 | Thyroid stimulating hormone |
| rs8109578 | Duodenitis | 0.01015 | 1.513 | ANGPTL6 | Thyroid stimulating hormone |
| rs8111589 | Esophageal atresia/tracheoesophageal fistula | 0.004863 | 0.5535 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Speech and language disorder | 0.002479 | 1.462 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Abdominal pain | 0.0006638 | 0.9056 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Elevated white blood cell count | 0.00712 | 0.7707 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Develomental delays and disorders | 0.002022 | 1.319 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Shock | 0.008638 | 0.7191 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Rheumatic fever / chorea | 0.007455 | 0.472 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Inguinal hernia | 0.001249 | 0.8418 | OPA3 | Depression and alcohol dependence |
| rs8111589 | Diseases of white blood cells | 0.008026 | 0.8454 | OPA3 | Depression and alcohol dependence |
| rs8139900 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.01111 | 1.184 | MYO18B | Uric acid levels |
| rs8139900 | Infection/inflammation of internal prosthetic device, implant or graft | 0.008736 | 1.264 | MYO18B | Uric acid levels |
| rs8139900 | Iatrogenic hypotension | 0.01051 | 1.542 | MYO18B | Uric acid levels |
| rs8139900 | Urethritis and urethral syndrome | 0.005228 | 0.5493 | MYO18B | Uric acid levels |
| rs8139900 | Secondary malignant neoplasm of liver | 0.003873 | 0.7116 | MYO18B | Uric acid levels |
| rs8139900 | Enthesopathy | 0.01117 | 1.107 | MYO18B | Uric acid levels |
| rs8139900 | Polymyalgia Rheumatica | 0.007164 | 1.267 | MYO18B | Uric acid levels |
| rs8139900 | Open wound of hand except finger(s) | 0.006235 | 1.28 | MYO18B | Uric acid levels |
| rs8139900 | Methicillin sensitive Staphylococcus aureus | 0.001335 | 1.414 | MYO18B | Uric acid levels |
| rs8139900 | Abnormal weight gain | 0.007782 | 1.326 | MYO18B | Uric acid levels |
| rs8139900 | Hypotension NOS | 0.004951 | 1.187 | MYO18B | Uric acid levels |
| rs8139900 | Neoplasm of unspecified nature of digestive system | 0.002173 | 1.49 | MYO18B | Uric acid levels |
| rs8139900 | Hypotension | 0.003874 | 1.141 | MYO18B | Uric acid levels |
| rs8139900 | Disorders of synovium, tendon, and bursa | 0.002268 | 1.13 | MYO18B | Uric acid levels |
| rs8139900 | Benign neoplasm of other endocrine glands | 0.009365 | 1.384 | MYO18B | Uric acid levels |
| rs8139900 | Secondary malignancy of lung | 0.006402 | 0.7136 | MYO18B | Uric acid levels |
| rs8139900 | Macular degeneration, dry | 0.009469 | 1.216 | MYO18B | Uric acid levels |
| rs8139900 | Aseptic necrosis of bone | 0.001681 | 1.676 | MYO18B | Uric acid levels |
| rs8139900 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.007869 | 2.103 | MYO18B | Uric acid levels |
| rs8139900 | Staphylococcus infections | 0.003419 | 1.278 | MYO18B | Uric acid levels |
| rs8139900 | Methicillin resistant Staphylococcus aureus | 0.01037 | 1.813 | MYO18B | Uric acid levels |
| rs8139900 | Dysmenorrhea | 0.006894 | 1.486 | MYO18B | Uric acid levels |
| rs8139900 | Acute reaction to stress | 0.00577 | 1.257 | MYO18B | Uric acid levels |
| rs8139900 | Abnormal serum enzyme levels | 0.004583 | 1.153 | MYO18B | Uric acid levels |
| rs8176746 | Breast cancer, including in situ | 0.004371 | 0.701 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Other disorders of thyroid | 0.008681 | 1.511 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Arthropathy associated with neurological disorders | 0.00383 | 2.389 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Back & neck sprains | 0.004221 | 1.247 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Paget's disease of bone | 0.01011 | 2.532 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Other conditions of the mother complicating pregnancy | 0.006168 | 2.187 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Osteitis deformans and osteopathies associated with other disorders | 0.007349 | 2.019 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Chronic lymphocytic thyroiditis | 0.01075 | 1.652 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Depression | 0.01073 | 1.172 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Breast cancer | 0.004212 | 0.7017 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Occlusion of cerebral arteries, with cerebral infarction | 0.0006516 | 2.003 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Osteoarthrosis NOS | 0.004135 | 1.182 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Diseases of pancreas | 0.007903 | 1.361 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Pseudomonal pneumonia | 0.007634 | 2.673 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Breast cancer | 0.004004 | 0.6957 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Thyroiditis | 0.003117 | 1.624 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Peripheral retinal degenerations | 0.002144 | 1.568 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Vascular dementia | 0.008358 | 1.668 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Chronic ulcer of leg or foot | 0.003392 | 1.29 | ABO | Mean corpuscular hemoglobin |
| rs8176746 | Unspecified monoarthritis | 0.005301 | 1.985 | ABO | Mean corpuscular hemoglobin |
| rs8192917 | Abnormal pulmonary function | 0.01057 | 2.094 | GZMB | Vitiligo |
| rs8192917 | Calcium/phosphorus disorders | 0.005639 | 1.228 | GZMB | Vitiligo |
| rs8192917 | Fracture of pelvis | 0.007454 | 1.364 | GZMB | Vitiligo |
| rs8192917 | Abnormal thyroid function | 0.002874 | 1.329 | GZMB | Vitiligo |
| rs8192917 | Internal derangement of knee | 0.01102 | 0.8561 | GZMB | Vitiligo |
| rs8192917 | Nerve root and plexus disorders | 0.005887 | 0.7002 | GZMB | Vitiligo |
| rs8192917 | Primary thrombocytopenia | 0.005753 | 1.669 | GZMB | Vitiligo |
| rs8192917 | Respiratory abnormalities | 0.008919 | 1.335 | GZMB | Vitiligo |
| rs837763 | Abnormal involuntary movements | 0.0005172 | 1.325 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Fuchs' dystrophy | 0.0005885 | 1.646 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Corneal edema | 0.004171 | 1.668 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Adrenal hypofunction | 0.01059 | 1.583 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Benign neoplasm of brain and other parts of nervous system | 0.01048 | 1.372 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Chronic lymphoid leukemia | 0.01112 | 1.507 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Rash and other nonspecific skin eruption | 0.0008157 | 1.202 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Age-related macular degeneration | 0.009504 | 1.189 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Varicose veins of lower extremity | 0.007978 | 1.155 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Disorders of external ear | 0.005102 | 1.68 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Pleurisy; pleural effusion | 0.005902 | 1.146 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Cystoid macular degeneration of retina | 0.007426 | 1.302 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Congenital anomalies of face and neck | 0.001168 | 2.6 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Varicose veins | 0.003839 | 1.163 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Disorders of refraction and accommodation | 0.005912 | 1.105 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Chronic venous insufficiency | 0.0007046 | 1.243 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Cervicocranial/Cervicobrachial syndrome | 0.006653 | 1.258 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Amblyopia | 0.005978 | 1.351 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Corneal dystrophy | 0.001966 | 1.35 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Aneurysm of iliac artery | 0.007729 | 0.567 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Altered mental status | 0.00934 | 1.265 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Appendicitis | 0.009384 | 1.386 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Other symptoms referable to back | 0.01035 | 1.235 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Other hypertrophic and atrophic conditions of skin | 0.009695 | 1.108 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Astigmatism | 0.005956 | 1.136 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Lymphoid leukemia | 0.003934 | 1.569 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Kidney replaced by transpant | 0.0008554 | 0.6218 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Atrophy of edentulous alveolar ridge | 0.003544 | 0.6293 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Lack of coordination | 0.003131 | 1.271 | CDT1 | Mean corpuscular hemoglobin |
| rs837763 | Rosacea | 0.007777 | 1.184 | CDT1 | Mean corpuscular hemoglobin |
| rs855913 | Blindness and low vision | 0.000534 | 1.764 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Other disorders of biliary tract | 0.002992 | 1.975 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Effects of radiation NOS | 0.0001063 | 2.255 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Iatrogenic hypotension | 0.0001761 | 2.402 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Neoplasm of uncertain behavior | 0.002273 | 1.415 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Nephritis; nephrosis; renal sclerosis | 0.002413 | 1.469 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Ischemic Heart Disease | 0.007726 | 0.8484 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Endocarditis | 0.007004 | 0.4193 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Toxic erythema | 0.007626 | 2.695 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Cancer of other male genital organs | 0.004958 | 2.321 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Acute laryngitis and tracheitis | 0.001971 | 2.035 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Antihypertensive agents causing adverse effects | 0.002576 | 2.157 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Diabetic retinopathy | 0.002894 | 1.405 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Degenerative disease of the spinal cord | 0.007604 | 1.797 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Fracture of clavicle or scapula | 0.004786 | 1.774 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Elevated levels of transaminase or lactic acid dehydrogenase | 0.0002453 | 0.5384 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Type 1 diabetes nephropathy | 0.003758 | 2.152 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Hypoglycemia | 0.005995 | 1.837 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Coronary atherosclerosis | 0.005937 | 0.835 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Nonallopathic lesions NEC | 0.009729 | 0.7834 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Scar conditions and fibrosis of skin | 0.0106 | 1.538 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Type 2 diabetic retinopathy | 0.01054 | 1.363 | ZNF746 | Amyotrophic lateral sclerosis |
| rs855913 | Fracture of ribs | 0.009997 | 1.439 | ZNF746 | Amyotrophic lateral sclerosis |
| rs873917 | Spinal stenosis | 0.01069 | 0.8829 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Abnormal findings on radiological breast exam | 0.008752 | 1.544 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Intervertebral disc disorders | 0.003039 | 0.8937 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Congenital anomalies of lower limb, including pelvic girdle | 0.001386 | 0.3816 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Gastrointestinal complications | 0.006622 | 0.7621 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Other specified disorders of pancreatic internal secretion | 0.01114 | 0.5434 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Degeneration of intervertebral disc | 0.003123 | 0.8764 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Ulcerative colitis | 0.003605 | 0.6216 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Vascular insufficiency of intestine | 0.006932 | 0.6721 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Other disorders of intestine | 0.002789 | 0.8083 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Benign neoplasm of uterus | 0.006191 | 1.228 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Posterior pituitary disorders | 0.001094 | 1.902 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Acute sinusitis | 0.01013 | 0.8737 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Spinal stenosis of lumbar region | 0.003559 | 0.8533 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Nontoxic multinodular goiter | 0.003519 | 0.7582 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Inflammatory bowel disease | 0.01022 | 0.7386 | NT5C1A | Amyotrophic lateral sclerosis |
| rs873917 | Other disorders of pancreatic internal secretion | 0.008263 | 0.5309 | NT5C1A | Amyotrophic lateral sclerosis |
| rs908821 | Other specified nonpsychotic and/or transient mental disorders | 0.01132 | 0.8099 | SLC25A36 | Multiple sclerosis |
| rs908821 | Gangrene | 0.0101 | 0.5647 | SLC25A36 | Multiple sclerosis |
| rs908821 | Toxic erythema | 0.009303 | 2.017 | SLC25A36 | Multiple sclerosis |
| rs908821 | Parasomnia | 0.009035 | 1.615 | SLC25A36 | Multiple sclerosis |
| rs908821 | Cancer of the lower GI tract | 0.00694 | 1.382 | SLC25A36 | Multiple sclerosis |
| rs908821 | Nerve plexus lesions | 0.00826 | 1.431 | SLC25A36 | Multiple sclerosis |
| rs908821 | Primary/intrinsic cardiomyopathies | 0.008194 | 1.193 | SLC25A36 | Multiple sclerosis |
| rs908821 | Nerve root and plexus disorders | 0.008554 | 1.316 | SLC25A36 | Multiple sclerosis |
| rs908821 | End stage renal disease | 0.008574 | 1.403 | SLC25A36 | Multiple sclerosis |
| rs908821 | Other disorders of lipoid metabolism and hyperalimentation | 0.009796 | 1.275 | SLC25A36 | Multiple sclerosis |
| rs908821 | Calculus of lower urinary tract | 0.01063 | 1.602 | SLC25A36 | Multiple sclerosis |
| rs908821 | Chronic obstructive asthma | 0.003352 | 0.7284 | SLC25A36 | Multiple sclerosis |
| rs909116 | Open wound of nose and sinus | 0.009958 | 1.975 | TNNT3 | Breast cancer |
| rs909116 | Stomatitis and mucositis | 0.01063 | 0.7343 | TNNT3 | Breast cancer |
| rs909116 | Cellulitis and abscess of trunk | 0.007627 | 1.288 | TNNT3 | Breast cancer |
| rs909116 | Mitral valve stenosis and/or aortic valve stenosis | 0.000823 | 1.285 | TNNT3 | Breast cancer |
| rs909116 | Occlusion and stenosis of precerebral arteries | 0.002158 | 1.153 | TNNT3 | Breast cancer |
| rs909116 | Nonspecific findings on examination of blood | 0.000329 | 0.6976 | TNNT3 | Breast cancer |
| rs909116 | Chronic rheumatic disease of the heart valves | 0.007467 | 1.155 | TNNT3 | Breast cancer |
| rs909116 | Other diseases of the teeth and supporting structures | 0.008643 | 1.235 | TNNT3 | Breast cancer |
| rs909116 | Cerebrovascular disease | 0.0007719 | 1.119 | TNNT3 | Breast cancer |
| rs909116 | Myeloid leukemia | 0.01032 | 0.5499 | TNNT3 | Breast cancer |
| rs9282641 | Chronic lymphocytic thyroiditis | 0.004363 | 1.698 | CD86 | Multiple sclerosis |
| rs9282641 | Polyp of female genital organs | 0.006649 | 1.413 | CD86 | Multiple sclerosis |
| rs9282641 | Chronic rheumatic disease of the heart valves | 0.01094 | 1.255 | CD86 | Multiple sclerosis |
| rs9282641 | Heart transplant/surgery | 0.007215 | 1.709 | CD86 | Multiple sclerosis |
| rs9282641 | Abnormal function study of cardiovascular system | 0.003273 | 1.33 | CD86 | Multiple sclerosis |
| rs9282641 | Systolic/diastolic heart failure | 0.008943 | 1.203 | CD86 | Multiple sclerosis |
| rs9282641 | Benign neoplasm of thyroid glands | 0.007837 | 2.088 | CD86 | Multiple sclerosis |
| rs9282641 | Nonspecific findings on examination of blood | 0.0001777 | 1.718 | CD86 | Multiple sclerosis |
| rs9282641 | Subarachnoid hemorrhage (injury) | 0.0103 | 2.413 | CD86 | Multiple sclerosis |
| rs9282641 | Asthma | 0.0003411 | 1.281 | CD86 | Multiple sclerosis |
| rs9282641 | Malignant neoplasm of renal pelvis | 0.007151 | 2.675 | CD86 | Multiple sclerosis |
| rs9282641 | Symptoms involving urinary system | 0.01019 | 1.403 | CD86 | Multiple sclerosis |
| rs9282641 | Cardiomegaly | 0.003614 | 1.282 | CD86 | Multiple sclerosis |
| rs9282641 | Heart failure | 0.008766 | 1.197 | CD86 | Multiple sclerosis |
| rs9282641 | Chronic obstructive asthma | 0.009075 | 1.448 | CD86 | Multiple sclerosis |
| rs9282641 | Chronic airway obstruction | 0.003855 | 1.207 | CD86 | Multiple sclerosis |
| rs9282641 | Thyroiditis | 0.0003746 | 1.73 | CD86 | Multiple sclerosis |
| rs9282641 | Emphysema | 0.002392 | 1.5 | CD86 | Multiple sclerosis |
| rs9282641 | Chronic ischemic heart disease | 0.0101 | 1.23 | CD86 | Multiple sclerosis |
| rs9282641 | Mitral valve stenosis and/or aortic valve stenosis | 0.0007489 | 1.484 | CD86 | Multiple sclerosis |
| rs9282641 | Primary/intrinsic cardiomyopathies | 0.005555 | 1.323 | CD86 | Multiple sclerosis |
| rs9282641 | Spontaneous ecchymoses | 0.0001681 | 2.39 | CD86 | Multiple sclerosis |
| rs9282641 | Ill-defined descriptions and complications of heart disease | 0.008607 | 1.191 | CD86 | Multiple sclerosis |
| rs9303401 | Acquired spondylolisthesis | 0.004138 | 1.34 | PPM1E | Cognitive performance |
| rs9303401 | Bone cancer | 0.002619 | 0.4536 | PPM1E | Cognitive performance |
| rs9303401 | E. coli | 0.009904 | 0.7285 | PPM1E | Cognitive performance |
| rs9303401 | Persistent mental disorders due to other conditions | 0.002694 | 0.8308 | PPM1E | Cognitive performance |
| rs9303401 | Memory loss | 0.0008662 | 0.7331 | PPM1E | Cognitive performance |
| rs9303401 | Lung involvement in conditions classified elsewhere | 0.003761 | 0.2873 | PPM1E | Cognitive performance |
| rs9303401 | Acne | 0.00994 | 1.283 | PPM1E | Cognitive performance |
| rs9303401 | Alzheimer's disease | 0.003617 | 0.8141 | PPM1E | Cognitive performance |
| rs9303401 | Cancer of bone & connective tissue | 0.007752 | 0.6258 | PPM1E | Cognitive performance |
| rs9303401 | Eustachian tube disorders | 0.006542 | 1.135 | PPM1E | Cognitive performance |
| rs9303401 | Symptoms involving female genital tract | 0.01047 | 1.362 | PPM1E | Cognitive performance |
| rs9303401 | Cellulitis and abscess of hand/fingers | 0.01005 | 1.19 | PPM1E | Cognitive performance |
| rs9303401 | Retinal hemorrhage/ischemia | 0.006506 | 1.429 | PPM1E | Cognitive performance |
| rs9303401 | Peripheral arterial disease | 0.01112 | 1.129 | PPM1E | Cognitive performance |
| rs932316 | Essential hypertension | 0.00341 | 1.119 | SCGN | Transferrin saturation |
| rs932316 | Iron metabolism disorder | 4.153e-07 | 3.215 | SCGN | Transferrin saturation |
| rs932316 | Disorders of esophageal motility | 0.003963 | 0.5068 | SCGN | Transferrin saturation |
| rs932316 | Hypertension | 0.003626 | 1.118 | SCGN | Transferrin saturation |
| rs932316 | Iron deficiency anemias NOS | 0.006995 | 0.8487 | SCGN | Transferrin saturation |
| rs932316 | Other symptoms involving abdomen and pelvis | 0.008722 | 0.8435 | SCGN | Transferrin saturation |
| rs932316 | Cholelithiasis with other cholecystitis | 0.00765 | 0.6963 | SCGN | Transferrin saturation |
| rs932316 | Polymyalgia Rheumatica | 0.009534 | 0.7237 | SCGN | Transferrin saturation |
| rs933688 | Diseases of respiratory system | 0.002113 | 1.24 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Sarcoidosis | 0.01068 | 1.684 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Labyrinthitis | 0.003588 | 1.499 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Nonrheumatic aortic valve disorders | 0.007597 | 0.816 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Obstructive sleep apnea | 0.01 | 1.182 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Symptoms involving digestive system | 0.005309 | 0.7498 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Temporomandibular joint disorder NOS | 0.00126 | 1.875 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Allergic rhinitis | 0.003492 | 1.168 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Other disorders of bladder | 0.01023 | 0.8147 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Other upper respiratory disease | 0.007798 | 1.205 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Primary open angle glaucoma | 0.008009 | 0.7357 | LOC133789 | Smoking behavior (ever vs. never) |
| rs933688 | Precordial pain | 0.003677 | 1.422 | LOC133789 | Smoking behavior (ever vs. never) |
| rs9349379 | Benign neoplasm of uterus | 0.0008352 | 1.713 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Epiphora | 0.002547 | 1.432 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Subjective visual disturbances | 0.008313 | 1.202 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Unstable angina (intermediate coronary syndrome) | 0.0004332 | 1.217 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Other forms of chronic heart disease | 0.003718 | 1.211 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Pancreatic cancer | 0.002941 | 0.6058 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Myocardial infarction | 0.0001591 | 1.188 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Coronary atherosclerosis | 0.001074 | 1.112 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Anorexia | 0.003189 | 1.396 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Uterine/Uterovaginal prolapse | 0.01138 | 0.7862 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Ischemic Heart Disease | 0.005244 | 1.09 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Chronic ischemic heart disease | 0.002944 | 1.156 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Major depressive disorder | 0.01014 | 1.15 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Chronic pain syndrome | 0.002228 | 1.749 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Hyposmolality and/or hyponatremia | 0.006475 | 1.172 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9349379 | Loss of teeth or edentulism | 0.007059 | 1.356 | PHACTR1 | Coronary artery calcification, Coronary heart disease |
| rs9357155 | Osteomyelitis | 0.008361 | 1.399 | PSMB8 | IgA nephropathy |
| rs9357155 | Open-angle glaucoma | 0.001424 | 1.306 | PSMB8 | IgA nephropathy |
| rs9357155 | Symptoms involving cardiovascular system | 0.008615 | 1.232 | PSMB8 | IgA nephropathy |
| rs9357155 | Attention deficit hyperactivity disorder | 0.003151 | 1.94 | PSMB8 | IgA nephropathy |
| rs9357155 | Psoriasis & related disorders | 0.003427 | 1.369 | PSMB8 | IgA nephropathy |
| rs9357155 | Other disorders of soft tissues | 0.0001737 | 1.832 | PSMB8 | IgA nephropathy |
| rs9357155 | Other intestinal obstruction | 0.009584 | 1.341 | PSMB8 | IgA nephropathy |
| rs9357155 | Abnormal findings on examination of urine | 0.003069 | 1.28 | PSMB8 | IgA nephropathy |
| rs9357155 | Psoriasis | 0.002555 | 1.404 | PSMB8 | IgA nephropathy |
| rs9357155 | Unspecified osteomyelitis | 0.01093 | 1.431 | PSMB8 | IgA nephropathy |
| rs9357155 | Rheumatoid arthritis & related inflammatory polyarthropathies | 0.002676 | 1.318 | PSMB8 | IgA nephropathy |
| rs9357155 | Digestive congenital anomalies | 0.01115 | 1.561 | PSMB8 | IgA nephropathy |
| rs9357155 | Exophthalmos | 0.01036 | 1.998 | PSMB8 | IgA nephropathy |
| rs9357155 | Upper gastrointestinal congenital anomalies | 0.005564 | 1.784 | PSMB8 | IgA nephropathy |
| rs9357155 | Type 1 diabetic neuropathy | 0.003863 | 1.652 | PSMB8 | IgA nephropathy |
| rs9357155 | Keratitis | 0.009441 | 1.415 | PSMB8 | IgA nephropathy |
| rs9357155 | Vitamin D deficiency | 0.0005629 | 0.5239 | PSMB8 | IgA nephropathy |
| rs9357155 | Psoriasis vulgaris | 0.004851 | 1.386 | PSMB8 | IgA nephropathy |
| rs9357155 | Glaucoma | 0.004042 | 1.194 | PSMB8 | IgA nephropathy |
| rs9357155 | Heartburn | 0.007602 | 1.524 | PSMB8 | IgA nephropathy |
| rs9357155 | Type 1 diabetic retinopathy | 0.006056 | 1.592 | PSMB8 | IgA nephropathy |
| rs9357155 | Rheumatoid arthritis | 0.001631 | 1.378 | PSMB8 | IgA nephropathy |
| rs9357155 | Arteritis NOS | 0.005744 | 1.791 | PSMB8 | IgA nephropathy |
| rs9357155 | Type 1 diabetes nephropathy | 0.004187 | 1.896 | PSMB8 | IgA nephropathy |
| rs9357155 | Infection/inflammation of internal prosthetic device, implant or graft | 0.001271 | 1.472 | PSMB8 | IgA nephropathy |
| rs9357155 | Hypertrophy of female genital organs | 0.0007655 | 2.17 | PSMB8 | IgA nephropathy |
| rs9357155 | Pervasive developmental disorders | 0.001998 | 1.841 | PSMB8 | IgA nephropathy |
| rs9357155 | Other nonspecific findings on examination of urine | 0.009866 | 1.277 | PSMB8 | IgA nephropathy |
| rs9368699 | Fracture of hand or wrist | 0.003596 | 0.5864 | C6orf48 | HIV-1 progression |
| rs9368699 | Persistent mental disorders due to other conditions | 0.009801 | 0.6707 | C6orf48 | HIV-1 progression |
| rs9368699 | Unspecified local infection of skin and subcutaneous tissue | 0.003022 | 0.3636 | C6orf48 | HIV-1 progression |
| rs9368699 | Respiratory failure; insufficiency; arrest | 0.007797 | 0.5703 | C6orf48 | HIV-1 progression |
| rs9368699 | Pseudoexfoliation glaucoma | 0.004069 | 2.545 | C6orf48 | HIV-1 progression |
| rs9368699 | Acute laryngitis and tracheitis | 0.004556 | 2.29 | C6orf48 | HIV-1 progression |
| rs9368699 | Respiratory failure | 0.008348 | 0.4093 | C6orf48 | HIV-1 progression |
| rs9368699 | Voice disturbance | 0.0009477 | 1.641 | C6orf48 | HIV-1 progression |
| rs9368699 | Vascular disorders of penis | 0.004812 | 4.083 | C6orf48 | HIV-1 progression |
| rs9368699 | Acute upper respiratory infections | 0.001362 | 1.335 | C6orf48 | HIV-1 progression |
| rs9368699 | Rosacea | 0.004853 | 1.507 | C6orf48 | HIV-1 progression |
| rs9368699 | Genital prolapse | 0.003337 | 0.5943 | C6orf48 | HIV-1 progression |
| rs9368699 | Psoriasis & related disorders | 2.557e-06 | 2.068 | C6orf48 | HIV-1 progression |
| rs9368699 | Psoriasis vulgaris | 6.542e-06 | 2.101 | C6orf48 | HIV-1 progression |
| rs9368699 | Cancer of bone & connective tissue | 0.004033 | 2.138 | C6orf48 | HIV-1 progression |
| rs9368699 | Psoriasis | 2.059e-06 | 2.137 | C6orf48 | HIV-1 progression |
| rs9368699 | Neurological disorders due to brain damage | 0.007064 | 0.7019 | C6orf48 | HIV-1 progression |
| rs9368699 | Male genital disorders | 0.00116 | 2.009 | C6orf48 | HIV-1 progression |
| rs9368699 | Corneal dystrophy | 0.00215 | 1.899 | C6orf48 | HIV-1 progression |
| rs9368699 | Stricture/obstruction of ureter | 0.009058 | 2.043 | C6orf48 | HIV-1 progression |
| rs9368699 | Abnormal findings on radiological breast exam | 0.009758 | 2.219 | C6orf48 | HIV-1 progression |
| rs9395066 | Osteoporosis | 0.01048 | 0.8882 | SUPT3H | Height |
| rs9395066 | Cholecystitis without cholelithiasis | 0.001916 | 0.7275 | SUPT3H | Height |
| rs9395066 | Salicylates causing adverse effects in therapeutic use | 0.006797 | 0.4913 | SUPT3H | Height |
| rs9395066 | Epistaxis or throat hemorrhage | 0.005302 | 0.8168 | SUPT3H | Height |
| rs9395066 | pulmonary heart disease | 0.002002 | 0.8411 | SUPT3H | Height |
| rs9395066 | Curvature of spine | 0.004969 | 0.7949 | SUPT3H | Height |
| rs9395066 | Osteoporosis, NOS or other | 0.007445 | 0.8861 | SUPT3H | Height |
| rs9395066 | Lesions of stomach and duodenum | 0.004621 | 2.028 | SUPT3H | Height |
| rs9395066 | Bacterial pneumonia | 0.004863 | 0.7565 | SUPT3H | Height |
| rs9395066 | Umbilical hernia | 0.002939 | 0.7597 | SUPT3H | Height |
| rs9395066 | Restless legs syndrome | 0.01114 | 1.267 | SUPT3H | Height |
| rs9395066 | Periodontitis (acute or chronic) | 0.01065 | 0.8243 | SUPT3H | Height |
| rs9395066 | Adjustment reaction | 0.003738 | 0.8554 | SUPT3H | Height |
| rs9395066 | Hidradenitis | 0.002288 | 0.3255 | SUPT3H | Height |
| rs939876 | Ulceration of the lower GI tract | 0.008716 | 1.664 | TBC1D30 | Cognitive performance |
| rs939876 | Dysthymic disorder | 0.0001123 | 1.363 | TBC1D30 | Cognitive performance |
| rs939876 | Conductive hearing loss | 7.585e-06 | 2.218 | TBC1D30 | Cognitive performance |
| rs939876 | Postmenopausal atrophic vaginitis | 0.005947 | 1.343 | TBC1D30 | Cognitive performance |
| rs939876 | Cholesteatoma | 0.005156 | 1.924 | TBC1D30 | Cognitive performance |
| rs939876 | Essential tremor | 0.009115 | 1.392 | TBC1D30 | Cognitive performance |
| rs939876 | Generalized anxiety disorder | 0.01106 | 1.375 | TBC1D30 | Cognitive performance |
| rs939876 | Somatoform disorder | 0.003594 | 1.521 | TBC1D30 | Cognitive performance |
| rs939876 | Posttraumatic wound infection | 0.004766 | 2.017 | TBC1D30 | Cognitive performance |
| rs939876 | Benign neoplasm of other endocrine glands | 0.002774 | 1.586 | TBC1D30 | Cognitive performance |
| rs939876 | Other disorders of tympanic membrane | 0.01026 | 1.538 | TBC1D30 | Cognitive performance |
| rs939876 | Seborheic dermatitis | 0.001365 | 1.306 | TBC1D30 | Cognitive performance |
| rs939876 | Other disorders of middle ear and mastoid | 0.009452 | 1.561 | TBC1D30 | Cognitive performance |
| rs939876 | Vitamin B12 deficiency anemia | 0.006116 | 1.705 | TBC1D30 | Cognitive performance |
| rs939876 | Intestinal infection due to C. difficile | 0.00952 | 1.47 | TBC1D30 | Cognitive performance |
| rs939876 | Symptoms affecting skin | 0.001914 | 1.156 | TBC1D30 | Cognitive performance |
| rs939876 | Neoplasm of uncertain behavior | 0.006076 | 1.259 | TBC1D30 | Cognitive performance |
| rs939876 | Disturbance of skin sensation | 0.00146 | 1.205 | TBC1D30 | Cognitive performance |
| rs939876 | Urinary incontinence | 0.009711 | 1.179 | TBC1D30 | Cognitive performance |
| rs939876 | Bacterial enteritis | 0.009178 | 1.412 | TBC1D30 | Cognitive performance |
| rs939876 | Type 1 diabetic neuropathy | 0.0008093 | 1.711 | TBC1D30 | Cognitive performance |
| rs939876 | Diseases of sebaceous glands | 0.006087 | 1.154 | TBC1D30 | Cognitive performance |
| rs939876 | Eating disorder | 0.0005518 | 2.075 | TBC1D30 | Cognitive performance |
| rs939876 | Mucous polyp of cervix | 0.005294 | 0.5512 | TBC1D30 | Cognitive performance |
| rs939876 | Mastoiditis | 0.00329 | 2.375 | TBC1D30 | Cognitive performance |
| rs939876 | Atherosclerosis | 0.008159 | 0.8494 | TBC1D30 | Cognitive performance |
| rs939876 | Dermatophytosis of nail | 0.008038 | 1.179 | TBC1D30 | Cognitive performance |
| rs939876 | Hirsutism | 0.005437 | 1.853 | TBC1D30 | Cognitive performance |
| rs939876 | Transient cerebral ischemia | 0.009339 | 0.8197 | TBC1D30 | Cognitive performance |
| rs939876 | Myoclonus | 0.0004994 | 2.111 | TBC1D30 | Cognitive performance |
| rs939876 | Diseases of hair and hair follicles | 0.002062 | 1.349 | TBC1D30 | Cognitive performance |
| rs944260 | Photodermatitis & sunburn | 0.006035 | 0.83 | CDH4 | Sudden cardiac arrest |
| rs944260 | Mixed hyperlipidemia | 0.007162 | 0.8359 | CDH4 | Sudden cardiac arrest |
| rs944260 | Pneumoconiosis | 0.008473 | 1.855 | CDH4 | Sudden cardiac arrest |
| rs944260 | Abnormal pulmonary function | 0.009351 | 2.108 | CDH4 | Sudden cardiac arrest |
| rs944260 | Type 1 diabetes nephropathy | 0.007188 | 0.5285 | CDH4 | Sudden cardiac arrest |
| rs944260 | Fibroadenosis of breast | 0.001684 | 2.461 | CDH4 | Sudden cardiac arrest |
| rs944260 | Mastoiditis | 0.006769 | 2.037 | CDH4 | Sudden cardiac arrest |
| rs944260 | Ankylosis of joint | 0.00983 | 0.663 | CDH4 | Sudden cardiac arrest |
| rs944797 | Type 1 diabetic neuropathy | 0.00811 | 0.6965 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Other infectious diseases | 0.002082 | 0.5213 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Occlusion and stenosis of precerebral arteries | 0.0003023 | 0.846 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Type 1 diabetic ketoacidosis | 0.003658 | 0.683 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Symptoms involving digestive system | 0.003148 | 1.241 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Abnormal electrocardiogram | 0.005819 | 0.87 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Type 2 diabetic nephropathy | 0.0001187 | 0.7566 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Symptoms involving cardiovascular system | 0.002829 | 0.8519 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Plasma protein metabolism disorder | 0.01143 | 1.275 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Ischemic Heart Disease | 9.421e-09 | 0.8398 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Angina pectoris | 8.807e-05 | 0.8367 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Type 2 diabetic neuropathy | 0.008593 | 0.8544 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Occlusion of cerebral arteries | 0.005181 | 0.8377 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Type 2 diabetic peripheral circulatory disorders | 0.003058 | 0.6994 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Nephritis and nephropathy without mention of glomerulonephritis | 0.005272 | 0.7919 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Primary thrombocytopenia | 0.009705 | 1.591 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cardiac complications, not elsewhere classified | 0.0004845 | 0.6579 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cerebrovascular disease | 0.0007004 | 0.8931 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Other forms of chronic heart disease | 0.005053 | 0.8328 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Late effects of cerebrovascular disease | 0.007493 | 0.8538 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Nephritis; nephrosis; renal sclerosis | 0.0005887 | 0.7729 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Peptic ulcer | 0.004881 | 0.8544 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cystitis | 0.004433 | 0.8119 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cardiac arrest & ventricular fibrillation | 0.009289 | 0.7185 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cardiac dysrhythmias | 0.003098 | 0.9149 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Renal failure NOS | 0.009525 | 0.7612 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cardiac conduction disorders | 0.003856 | 0.8925 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Aphasia/speech disturbance | 0.006266 | 0.8147 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Neurological disorders due to brain damage | 0.001325 | 0.8623 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Ulcerative colitis | 0.005244 | 1.472 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Coronary atherosclerosis | 7.283e-11 | 0.8108 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Chronic ischemic heart disease | 4.12e-05 | 0.8212 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Costochondritis | 0.001146 | 2.087 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cerebral ischemia | 0.01109 | 0.8818 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Chronic airway obstruction | 0.002331 | 1.126 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Hypotension | 0.002058 | 0.8683 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Unstable angina (intermediate coronary syndrome) | 1.993e-08 | 0.7309 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Hemorrhoids | 0.002319 | 1.126 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Ischemic stroke | 0.01038 | 0.8435 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Polyneuropathy in diabetes | 0.0002279 | 0.7855 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Gastrointestinal hemorrhage | 0.005379 | 1.109 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Acute, but ill-defined cerebrovascular disease | 0.0008165 | 0.8056 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Mild cognitive impairment | 0.00487 | 0.5834 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Ill-defined descriptions and complications of heart disease | 0.0002053 | 0.8646 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Myocardial infarction | 1.104e-07 | 0.7874 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Cystitis and urethritis | 0.004266 | 0.8214 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Acne | 0.006766 | 1.285 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Hypotension NOS | 0.002939 | 0.8327 | CDKN2B-AS1 | Coronary heart disease |
| rs944797 | Paraproteinemia | 0.003308 | 1.412 | CDKN2B-AS1 | Coronary heart disease |
| rs947583 | Chronic rheumatic disease of the heart valves | 0.01124 | 1.159 | PDE7B | Phosphorus levels |
| rs947583 | Visual disturbances | 0.002944 | 0.8743 | PDE7B | Phosphorus levels |
| rs947583 | Fracture of ribs | 0.0009633 | 1.316 | PDE7B | Phosphorus levels |
| rs947583 | Anisometropia | 0.0003883 | 0.6502 | PDE7B | Phosphorus levels |
| rs947583 | Arteritis NOS | 0.007094 | 0.5574 | PDE7B | Phosphorus levels |
| rs947583 | GERD | 0.009895 | 1.095 | PDE7B | Phosphorus levels |
| rs947583 | Other specified peripheral vascular diseases | 0.001167 | 2.269 | PDE7B | Phosphorus levels |
| rs947583 | Bladder cancer and neoplasms | 0.0037 | 1.298 | PDE7B | Phosphorus levels |
| rs947583 | Osteoarthrosis; localized, primary | 0.007168 | 1.253 | PDE7B | Phosphorus levels |
| rs947583 | Chronic venous hypertension | 0.006176 | 0.3313 | PDE7B | Phosphorus levels |
| rs947583 | Bladder cancer | 0.002721 | 1.318 | PDE7B | Phosphorus levels |
| rs947583 | Esophagitis, GERD and related diseases | 0.00291 | 1.105 | PDE7B | Phosphorus levels |
| rs947583 | Ulceration of the lower GI tract | 0.005889 | 0.5674 | PDE7B | Phosphorus levels |
| rs947583 | Diseases of esophagus | 0.00124 | 1.111 | PDE7B | Phosphorus levels |
| rs9491140 | Streptococcus infection | 0.006095 | 1.35 | NKAIN2 | Personality dimensions |
| rs9491140 | Benign neoplasm of skin | 0.01058 | 0.9046 | NKAIN2 | Personality dimensions |
| rs9491140 | Type 2 diabetic neuropathy | 0.006082 | 1.186 | NKAIN2 | Personality dimensions |
| rs9491140 | Type 2 diabetic peripheral circulatory disorders | 0.001714 | 1.455 | NKAIN2 | Personality dimensions |
| rs9491140 | Obsessive-compulsive disorder | 0.005044 | 1.753 | NKAIN2 | Personality dimensions |
| rs9491140 | Renal dialysis | 0.005356 | 1.436 | NKAIN2 | Personality dimensions |
| rs9502893 | Impacted cerumen | 0.01115 | 1.101 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Other sprains and strains | 0.00454 | 1.356 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Speech and language disorder | 0.001569 | 1.48 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Obstructive chronic bronchitis | 0.0009366 | 1.261 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Develomental delays and disorders | 1.145e-05 | 1.478 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Anomalies of tooth position/malocclusion | 0.01136 | 0.6113 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Dermatophytosis | 0.007056 | 1.108 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Acquired toe deformities | 0.0005214 | 1.219 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Bacterial pneumonia | 0.008056 | 1.282 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Other disorders of eye | 0.004188 | 0.8905 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Abnormal findings examination of lungs | 0.005787 | 1.168 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Acquired foot deformities | 0.009115 | 1.115 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Chronic bronchitis | 0.001236 | 1.225 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Dermatophytosis of nail | 0.0008395 | 1.158 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Obesity | 0.008457 | 0.9174 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Infestation | 0.01102 | 0.5949 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Other diseases of lung | 0.003931 | 1.138 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Hammer toe | 0.006724 | 1.194 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Decubitus ulcer | 0.001281 | 1.271 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Chronic obstructive asthma | 0.01034 | 1.264 | FOXQ1 | Pancreatic cancer |
| rs9502893 | Dermatophytosis / Dermatomycosis | 0.003365 | 1.115 | FOXQ1 | Pancreatic cancer |
| rs951005 | Tachycardia NOS | 0.007707 | 1.246 | CCL21 | Rheumatoid arthritis |
| rs951005 | Aphakia and other disorders of lens | 0.005457 | 1.415 | CCL21 | Rheumatoid arthritis |
| rs951005 | Spirochetal infection | 0.01035 | 0.4949 | CCL21 | Rheumatoid arthritis |
| rs951005 | Stomach cancer | 0.008044 | 0.3273 | CCL21 | Rheumatoid arthritis |
| rs951005 | Ulcerative stomatitis & mucositis | 0.001342 | 2.149 | CCL21 | Rheumatoid arthritis |
| rs951005 | Optic neuritis/neuropathy | 0.0001081 | 1.686 | CCL21 | Rheumatoid arthritis |
| rs951005 | Disorders of cervical region | 0.007033 | 0.6273 | CCL21 | Rheumatoid arthritis |
| rs951005 | Benign neoplasm of thyroid glands | 0.007549 | 1.882 | CCL21 | Rheumatoid arthritis |
| rs951005 | Arthropathy associated with neurological disorders | 0.01087 | 1.906 | CCL21 | Rheumatoid arthritis |
| rs951005 | Generalized anxiety disorder | 0.004385 | 1.403 | CCL21 | Rheumatoid arthritis |
| rs951005 | Claw toe | 0.00889 | 2.082 | CCL21 | Rheumatoid arthritis |
| rs951005 | Disorders of optic nerve and visual pathways | 0.003709 | 1.372 | CCL21 | Rheumatoid arthritis |
| rs951005 | Functional disorders of bladder | 0.004349 | 1.407 | CCL21 | Rheumatoid arthritis |
| rs951005 | Alopecia Areata | 0.003647 | 2.299 | CCL21 | Rheumatoid arthritis |
| rs951005 | Schizoid personality disorder | 0.01099 | 1.821 | CCL21 | Rheumatoid arthritis |
| rs951005 | Posttraumatic stress disorder | 0.008745 | 1.668 | CCL21 | Rheumatoid arthritis |
| rs951005 | Hypotension NOS | 0.007771 | 1.232 | CCL21 | Rheumatoid arthritis |
| rs951005 | Personality disorders | 4.643e-05 | 1.545 | CCL21 | Rheumatoid arthritis |
| rs951005 | Aneurysm of artery of lower extremity | 0.002625 | 0.4121 | CCL21 | Rheumatoid arthritis |
| rs951005 | Adverse effects of antibacterials (not penicillins) | 0.01023 | 1.846 | CCL21 | Rheumatoid arthritis |
| rs951005 | Secondary hyperparathyroidism (of renal origin) | 0.003214 | 1.499 | CCL21 | Rheumatoid arthritis |
| rs9574199 | Diabetes mellitus | 0.009917 | 1.089 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Type 2 diabetes | 0.008505 | 1.092 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Bursitis | 0.007936 | 0.8231 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Open wound of lip and mouth | 0.005726 | 0.4826 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Muscle/tendon sprain | 0.007927 | 0.4278 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Cervical radiculitis | 0.01134 | 0.8424 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Pruritus and related conditions | 0.003827 | 1.225 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Spasm of muscle | 0.01076 | 0.8085 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Nervous system congenital anomalies | 0.001716 | 0.6091 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Scleritis and episcleritis | 0.003754 | 1.657 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Fibroadenosis of breast | 0.0039 | 2.24 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Infections of kidney | 0.006079 | 0.7131 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Obsessive-compulsive disorder | 0.005036 | 0.4827 | POU4F1-AS1 | Total ventricular volume |
| rs9574199 | Methicillin resistant Staphylococcus aureus | 0.008145 | 1.822 | POU4F1-AS1 | Total ventricular volume |
| rs958798 | Cardiac dysrhythmias | 0.006003 | 0.903 | KCNC4 | Self-rated health |
| rs958798 | Adverse effects of antilipemic and antiarteriosclerotic drugs | 0.003541 | 2.342 | KCNC4 | Self-rated health |
| rs958798 | Abnormal sputum | 0.01056 | 1.348 | KCNC4 | Self-rated health |
| rs958798 | Arthralgia/ankylosis of temporomandibular joint | 0.004701 | 1.673 | KCNC4 | Self-rated health |
| rs958798 | Malunion fracture | 0.007753 | 1.479 | KCNC4 | Self-rated health |
| rs958798 | Schizophrenia and other psychotic disorders | 0.004845 | 0.7885 | KCNC4 | Self-rated health |
| rs958798 | Pituitary hyperfunction | 0.0108 | 2.054 | KCNC4 | Self-rated health |
| rs958798 | Polycythemia vera | 0.0106 | 1.787 | KCNC4 | Self-rated health |
| rs958798 | Generalized anxiety disorder | 0.003206 | 0.6828 | KCNC4 | Self-rated health |
| rs958798 | Symptoms/disorders of the urinary system | 0.006502 | 0.9001 | KCNC4 | Self-rated health |
| rs958798 | Alopecia | 0.009928 | 1.349 | KCNC4 | Self-rated health |
| rs958798 | Benign neoplasm of other endocrine glands | 0.007587 | 1.456 | KCNC4 | Self-rated health |
| rs958798 | Disease of tricuspid valve | 0.008942 | 0.7457 | KCNC4 | Self-rated health |
| rs958798 | Cardiomyopathy | 0.0009369 | 0.7607 | KCNC4 | Self-rated health |
| rs958798 | Primary/intrinsic cardiomyopathies | 0.001671 | 0.7658 | KCNC4 | Self-rated health |
| rs958798 | Other derangement of joint | 0.005018 | 1.349 | KCNC4 | Self-rated health |
| rs958798 | Depression | 0.01058 | 0.8952 | KCNC4 | Self-rated health |
| rs9594293 | Joint effusions | 0.00574 | 1.279 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Hypertensive heart disease | 0.009369 | 0.6897 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Postnasal drip | 0.007781 | 1.848 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Other hypertensive complications | 0.003616 | 0.7135 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Other disorders of middle ear and mastoid | 0.008278 | 0.5621 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Elevated blood pressure reading | 0.003163 | 0.8259 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Dysthymic disorder | 0.0001775 | 1.322 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Toxic multinodular goiter | 0.004646 | 2.013 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Other specified erythematous conditions | 0.003482 | 0.6513 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Anxiety, phobic and dissociative disorders | 0.007583 | 1.135 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Depression | 0.00351 | 1.139 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Mood disorders | 0.001527 | 1.147 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Open wound of nose and sinus | 0.0004583 | 2.589 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Uterine leiomyoma | 0.008637 | 1.28 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Chronic venous hypertension | 0.01099 | 0.218 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Suicidal ideation or attempt | 0.00111 | 2.064 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Vascular disorders of penis | 0.001227 | 2.687 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Benign neoplasm of uterus | 0.007219 | 1.27 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Dysuria | 0.005208 | 1.213 | FREM2 | Cytomegalovirus antibody response |
| rs9594293 | Skin neoplasm of uncertain behavior | 0.0006867 | 1.327 | FREM2 | Cytomegalovirus antibody response |
| rs960089 | Skin cancer | 0.002405 | 0.8175 | TOX | Cognitive performance |
| rs960089 | Chronic sinusitis | 0.002363 | 0.7883 | TOX | Cognitive performance |
| rs960089 | Peripheral arterial disease | 0.008268 | 0.8016 | TOX | Cognitive performance |
| rs960089 | Infections involving bone | 0.00869 | 0.608 | TOX | Cognitive performance |
| rs960089 | Biliary cirrhosis | 0.007576 | 2.607 | TOX | Cognitive performance |
| rs960089 | Morbid obesity | 0.009077 | 0.747 | TOX | Cognitive performance |
| rs960089 | Concussion | 0.009524 | 1.735 | TOX | Cognitive performance |
| rs960089 | Other anemias | 0.007661 | 0.8602 | TOX | Cognitive performance |
| rs960089 | Stiffness of joint | 0.009096 | 0.6949 | TOX | Cognitive performance |
| rs960089 | Epistaxis or throat hemorrhage | 0.01096 | 0.7037 | TOX | Cognitive performance |
| rs960089 | Other upper respiratory disease | 0.01046 | 0.7761 | TOX | Cognitive performance |
| rs960089 | Gastrointestinal hemorrhage | 0.00653 | 0.8249 | TOX | Cognitive performance |
| rs960089 | Non-melanoma skin cancer | 0.001392 | 0.7985 | TOX | Cognitive performance |
| rs960089 | Nasal polyps | 0.005 | 0.518 | TOX | Cognitive performance |
| rs960089 | Benign neoplasm of uterus | 0.003155 | 0.6452 | TOX | Cognitive performance |
| rs960089 | Renal failure | 0.007427 | 0.8318 | TOX | Cognitive performance |
| rs960089 | Vaginal enterocele, congenital or acquired | 0.004256 | 1.818 | TOX | Cognitive performance |
| rs964184 | Obsessive-compulsive disorder | 0.008965 | 1.895 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Anomalies of pupillary function | 0.005881 | 2.15 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Sensorineural hearing loss | 0.006686 | 1.159 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Decreased libido | 0.008158 | 2.148 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Peyronie's disease | 0.001247 | 2.328 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Hyperglyceridemia | 5.782e-13 | 2.216 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Urinary complications | 0.008332 | 0.4647 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Cataract | 0.003336 | 1.178 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Delirium due to conditions classified elsewhere | 0.006134 | 1.516 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Phlebitis and thrombophlebitis of lower extremities | 0.003755 | 0.6851 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Anxiety disorder | 0.001142 | 1.219 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Vaginitis and vulvovaginitis | 0.009078 | 1.293 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Lipoprotein disorders | 0.01115 | 0.6116 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Anxiety, phobic and dissociative disorders | 0.005319 | 1.162 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Sexual and gender identity disorders | 0.004895 | 1.546 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Mixed hyperlipidemia | 0.001367 | 1.307 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Hyperlipidemia | 2.532e-05 | 1.226 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Abnormal findings on radiological exam of musculoskeletal system | 0.000233 | 2.085 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Lipoid metabolism disorder NOS | 0.004591 | 1.461 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Disorders of lipoid metabolism | 1.1e-05 | 1.235 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Inflammatory disease of cervix, vagina, and vulva | 0.007259 | 1.266 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Hypercholesterolemia | 7.818e-05 | 1.26 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Other disorders of urethra and urinary tract | 0.004713 | 0.714 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Retinal detachment with retinal defect | 0.006147 | 1.594 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Dysmetabolic syndrome X | 0.001717 | 1.707 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Tinnitus | 0.008866 | 1.283 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Inflammatory diseases of female pelvic organs | 0.002264 | 1.288 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Chronic ischemic heart disease | 0.01069 | 1.197 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs964184 | Coronary atherosclerosis | 0.009791 | 1.13 | ZNF259 | HDL Cholesterol, Total Cholesterol, Lipoprotein-associated phospholipase A2 activity concentrations, LDL Cholesterol, Hypertriglyceridemia, Vitamin E, Triglycerides, Coronary heart disease, Phosphatidylcholines/sphingomyelins ratio |
| rs9642880 | Unspecified local infection of skin and subcutaneous tissue | 0.003616 | 1.283 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Cancer of kidney and urinary organs | 0.009604 | 1.195 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Other specified diseases of the salivary glands | 0.005462 | 1.731 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Bladder cancer and neoplasms | 0.000877 | 1.33 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Cancer of the upper aerodigestive tract | 0.001751 | 1.445 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Abnormal glucose | 0.00345 | 1.121 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Cancer of larynx | 0.008057 | 1.462 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Other local infections of skin and subcutaneous tissue | 0.00261 | 1.19 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Vertiginous syndromes and other disorders of vestibular system | 0.009537 | 0.9181 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Light-headedness and vertigo | 0.007893 | 0.9127 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Secondary malignant neoplasm | 0.009711 | 1.148 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Bladder cancer | 0.0006372 | 1.352 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Other abnormal glucose | 0.007558 | 1.138 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Epiphora | 0.001829 | 0.6914 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9642880 | Hepatic cancer | 0.003936 | 1.752 | MYC | Urinary bladder cancer, Bladder cancer |
| rs9649213 | Other specified diseases of sebaceous glands | 0.0001847 | 1.325 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Muscular dystrophies and other myopathies | 0.0003015 | 1.637 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Anemia in chronic kidney disease | 0.006146 | 0.748 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Anemia of chronic disease | 0.006879 | 0.822 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Contracture of joint | 0.002287 | 1.458 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Hemorrhage of rectum and anus | 0.001636 | 1.232 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Dysphagia | 0.002843 | 0.8723 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Chronic kidney disease, Stage I or II | 0.00824 | 1.367 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Benign neoplasm of other endocrine glands | 0.009097 | 1.385 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Cirrhosis of liver without mention of alcohol | 0.002555 | 0.6309 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Other congenital anomalies of skin | 0.002313 | 1.498 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Other disorders of stomach and duodenum | 0.007897 | 0.7709 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Femoral hernia | 0.0108 | 0.4932 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Lack of normal physiological development | 0.005193 | 0.7001 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Diseases of hair and hair follicles | 0.009026 | 1.214 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs9649213 | Other specified diseases of hair and hair follicles | 0.004488 | 1.336 | BAIAP2L1 | Prostate cancer (gene x gene interaction) |
| rs975334 | Other unspecified back disorders | 0.007312 | 1.532 | CNTN4 | Gallbladder cancer |
| rs975334 | Disorders of synovium, tendon, and bursa | 0.007178 | 0.8945 | CNTN4 | Gallbladder cancer |
| rs975334 | Nervous system congenital anomalies | 0.002423 | 0.6486 | CNTN4 | Gallbladder cancer |
| rs975334 | Chronic pain syndrome | 0.008342 | 0.5793 | CNTN4 | Gallbladder cancer |
| rs975334 | Diseases of pancreas | 0.001581 | 1.254 | CNTN4 | Gallbladder cancer |
| rs975334 | Other disorders of gallbladder | 0.007064 | 1.577 | CNTN4 | Gallbladder cancer |
| rs975334 | Sicca syndrome | 0.0007751 | 1.615 | CNTN4 | Gallbladder cancer |
| rs975334 | Pulmonary collapse; interstitial/compensatory emphysema | 0.007857 | 1.166 | CNTN4 | Gallbladder cancer |
| rs9846480 | Irregular menstrual bleeding | 0.00731 | 1.646 | TXNDC6 | Whole-brain volume |
| rs9846480 | Displacement of intervertebral disc | 0.003395 | 1.176 | TXNDC6 | Whole-brain volume |
| rs9846480 | Chronic prostatitis | 0.00204 | 0.5871 | TXNDC6 | Whole-brain volume |
| rs9846480 | Other specified gastritis | 0.005786 | 0.7746 | TXNDC6 | Whole-brain volume |
| rs9846480 | Other dyschromia | 0.003078 | 0.7691 | TXNDC6 | Whole-brain volume |
| rs9846480 | Other specified disorders of liver | 0.006255 | 0.7408 | TXNDC6 | Whole-brain volume |
| rs9846480 | Cyst or abscess of Bartholin's gland | 0.008183 | 0.4557 | TXNDC6 | Whole-brain volume |
| rs9846480 | Symptoms involving respiratory system | 0.00822 | 0.8265 | TXNDC6 | Whole-brain volume |
| rs9846480 | Uterine leiomyoma | 0.003682 | 0.7958 | TXNDC6 | Whole-brain volume |
| rs9846480 | Benign neoplasm of uterus | 0.002995 | 0.802 | TXNDC6 | Whole-brain volume |
| rs9846480 | Prostatitis | 0.001339 | 0.725 | TXNDC6 | Whole-brain volume |
| rs9846480 | Dyschromia and Vitiligo | 0.01052 | 0.8365 | TXNDC6 | Whole-brain volume |
| rs9846480 | Seborrheic keratosis | 0.007961 | 0.9051 | TXNDC6 | Whole-brain volume |
| rs991316 | Diabetes mellitus | 0.009202 | 0.9232 | ADH7 | Hypertension |
| rs991316 | Abnormal findings on radiological examination intrathoracic organs | 0.001369 | 1.248 | ADH7 | Hypertension |
| rs991316 | Type 2 diabetes | 0.004895 | 0.9162 | ADH7 | Hypertension |
| rs991316 | Postmenopausal atrophic vaginitis | 0.001013 | 0.7674 | ADH7 | Hypertension |
| rs991316 | Keratoderma, acquired | 0.004791 | 1.168 | ADH7 | Hypertension |
| rs991316 | Cancer of other lymphoid, histiocytic tissue | 0.01039 | 1.254 | ADH7 | Hypertension |
| rs991316 | Graves' disease | 0.002899 | 1.535 | ADH7 | Hypertension |
| rs991316 | Impacted cerumen | 0.00947 | 0.9059 | ADH7 | Hypertension |
| rs991316 | Wheezing | 0.01094 | 1.296 | ADH7 | Hypertension |
| rs991316 | Non-Hodgkins lymphoma | 0.006921 | 1.276 | ADH7 | Hypertension |
| rs991316 | Thyrotoxicosis | 0.008031 | 1.229 | ADH7 | Hypertension |
| rs991316 | Acute pharyngitis | 0.009584 | 0.8748 | ADH7 | Hypertension |
| rs9923451 | Hypertrophy of breast (Gynecomastia) | 0.006785 | 2.779 | WWOX | Hip circumference |
| rs9923451 | Hyperglyceridemia | 0.002533 | 2.963 | WWOX | Hip circumference |
| rs9923451 | Calculus of bile duct | 0.008648 | 2.609 | WWOX | Hip circumference |
| rs9923451 | Vitamin deficiency | 0.003332 | 1.925 | WWOX | Hip circumference |
| rs9923451 | Injuries to the nervous system | 0.01042 | 3.254 | WWOX | Hip circumference |
| rs9923451 | Appendiceal conditions | 0.01114 | 2.683 | WWOX | Hip circumference |
| rs9923451 | Seborrheic keratosis | 0.009148 | 1.556 | WWOX | Hip circumference |
| rs9923451 | Bacterial pneumonia | 0.001324 | 2.75 | WWOX | Hip circumference |
| rs9923451 | Infestation | 0.005359 | 4.234 | WWOX | Hip circumference |
| rs9923451 | Vitamin D deficiency | 0.0007964 | 2.708 | WWOX | Hip circumference |
| rs9923451 | Arterial embolism and thrombosis of lower extremity artery | 0.001245 | 3.321 | WWOX | Hip circumference |
| rs9923451 | Benign neoplasm of unspecified sites | 0.01056 | 4.682 | WWOX | Hip circumference |
| rs9929218 | Attention deficit hyperactivity disorder | 0.005562 | 1.685 | CDH1 | Colorectal cancer |
| rs9929218 | Sacroiliitis NEC | 0.01022 | 0.5012 | CDH1 | Colorectal cancer |
| rs9929218 | Bladder cancer and neoplasms | 0.00874 | 0.7712 | CDH1 | Colorectal cancer |
| rs9929218 | Psychogenic and somatoform disorders | 0.01003 | 1.271 | CDH1 | Colorectal cancer |
| rs9929218 | Inflammatory spondylopathies | 0.0109 | 0.6286 | CDH1 | Colorectal cancer |
| rs9929218 | Disorders of menstruation | 0.000429 | 1.288 | CDH1 | Colorectal cancer |
| rs9929218 | Cardiomegaly | 0.01089 | 0.8626 | CDH1 | Colorectal cancer |
| rs9929218 | Constipation | 0.009887 | 0.8748 | CDH1 | Colorectal cancer |
| rs9929218 | Electrolyte imbalance | 0.008484 | 0.9036 | CDH1 | Colorectal cancer |
| rs9929218 | Irregular menstrual cycle/bleeding | 0.000203 | 1.325 | CDH1 | Colorectal cancer |
| rs9929218 | Schizoid personality disorder | 0.003593 | 1.804 | CDH1 | Colorectal cancer |
| rs9929218 | Strabismus (not specified as paralytic) | 0.005674 | 1.258 | CDH1 | Colorectal cancer |
| rs9929218 | Other paralytic syndromes | 0.001882 | 0.5645 | CDH1 | Colorectal cancer |
| rs9929218 | Diseases of respiratory system | 0.009269 | 1.166 | CDH1 | Colorectal cancer |
| rs9943849 | Hypopotassemia | 0.005709 | 0.8595 | CPM | Major depressive disorder |
| rs9943849 | Abnormal findings on study of brain, nervous system | 0.005302 | 0.559 | CPM | Major depressive disorder |
| rs9943849 | Left bundle branch block | 0.008414 | 0.7431 | CPM | Major depressive disorder |
| rs9943849 | Secondary malignancy of bone | 0.002671 | 0.6628 | CPM | Major depressive disorder |
| rs9943849 | Edema | 0.008792 | 0.8952 | CPM | Major depressive disorder |
| rs9943849 | Congenital anomalies of great vessels | 0.003067 | 2.06 | CPM | Major depressive disorder |
| rs9943849 | Open wound of toe(s) | 0.008855 | 0.4558 | CPM | Major depressive disorder |
| rs9943849 | Disorders of fluid, electrolyte, and acid-base balance | 0.007793 | 0.9092 | CPM | Major depressive disorder |
| rs9943849 | Cornea replaced by transplant | 0.000492 | 2.123 | CPM | Major depressive disorder |
| rs9989419 | Atherosclerosis of native arteries of the extremities with ulceration or gangrene | 0.008311 | 1.299 | CETP | HDL Cholesterol |
| rs9989419 | Antisocial/borderline personality disorder | 0.002832 | 1.708 | CETP | HDL Cholesterol |
| rs9989419 | Infection/inflammation of internal prosthetic device, implant or graft | 0.005616 | 1.28 | CETP | HDL Cholesterol |
| rs9989419 | Cardiac congenital anomalies | 0.00687 | 1.319 | CETP | HDL Cholesterol |
| rs9989419 | Psychogenic and somatoform disorders | 0.004174 | 1.284 | CETP | HDL Cholesterol |
| rs9989419 | Staphylococcus infections | 0.003464 | 1.276 | CETP | HDL Cholesterol |
| rs9989419 | Disorders of esophageal motility | 0.001424 | 0.607 | CETP | HDL Cholesterol |
| rs9989419 | Methicillin sensitive Staphylococcus aureus | 0.006514 | 1.337 | CETP | HDL Cholesterol |
| rs9989419 | Anxiety, phobic and dissociative disorders | 0.005667 | 1.108 | CETP | HDL Cholesterol |
| rs9989419 | Lesions of stomach and duodenum | 0.00477 | 0.4442 | CETP | HDL Cholesterol |
| rs9989419 | Major depressive disorder | 0.00304 | 1.175 | CETP | HDL Cholesterol |
| rs9989419 | Posttraumatic stress disorder | 0.002503 | 1.625 | CETP | HDL Cholesterol |
| rs9989419 | Somatoform disorder | 0.002438 | 1.39 | CETP | HDL Cholesterol |
| rs9989419 | Astigmatism | 0.01137 | 0.8907 | CETP | HDL Cholesterol |
| rs999943 | Cystitis and urethritis | 0.008749 | 1.216 | ITPR3 | Extreme obesity |
| rs999943 | Electrolyte imbalance | 0.005746 | 0.8984 | ITPR3 | Extreme obesity |
| rs999943 | Hydronephrosis | 0.007266 | 1.336 | ITPR3 | Extreme obesity |
| rs999943 | Arthropathy NOS involving multiple sites | 0.009153 | 1.579 | ITPR3 | Extreme obesity |
| rs999943 | Bladder cancer | 0.002103 | 1.326 | ITPR3 | Extreme obesity |
| rs999943 | Abdominal pain | 0.007678 | 1.088 | ITPR3 | Extreme obesity |
| rs999943 | Hyperpotassemia | 0.00385 | 0.8098 | ITPR3 | Extreme obesity |
| rs999943 | Other acquired musculoskeletal deformity | 0.006801 | 0.783 | ITPR3 | Extreme obesity |
| rs999943 | Type 2 diabetic nephropathy | 0.01128 | 0.8135 | ITPR3 | Extreme obesity |
| rs999943 | Other disorders of peritoneum | 0.009955 | 0.6563 | ITPR3 | Extreme obesity |
| rs999943 | Somatoform disorder | 0.008947 | 1.342 | ITPR3 | Extreme obesity |
| rs999943 | Iatrogenic hypotension | 0.003041 | 0.5256 | ITPR3 | Extreme obesity |
| rs999943 | Nephritis; nephrosis; renal sclerosis | 0.003786 | 0.7808 | ITPR3 | Extreme obesity |
| rs999943 | Postoperative infection | 0.0007167 | 0.7637 | ITPR3 | Extreme obesity |
| rs999943 | Heart transplant/surgery | 0.001423 | 0.5902 | ITPR3 | Extreme obesity |
| rs999943 | Nephritis and nephropathy in diseases classified elsewhere | 0.006239 | 0.7469 | ITPR3 | Extreme obesity |
| rs999943 | Benign neoplasm of other endocrine glands | 0.007089 | 1.416 | ITPR3 | Extreme obesity |
| rs999943 | Polycystic ovaries | 0.006605 | 0.3667 | ITPR3 | Extreme obesity |
| rs999943 | Salicylates causing adverse effects in therapeutic use | 0.006516 | 1.894 | ITPR3 | Extreme obesity |
| rs999943 | Non-healing surgical wound | 0.002519 | 0.4993 | ITPR3 | Extreme obesity |
| rs999943 | Bladder cancer and neoplasms | 0.003274 | 1.301 | ITPR3 | Extreme obesity |
Page:
5th Q
QR Code
This section allows users to specify a relatively concise list of SNPs freely and to generate a QR code. This feature is expected to facilitate genetic data transmission and encryption, while increasing the possibility to maintain individual privacy.
SNP list QR code:
User QR code:
Decrypted user genotype:
rs970973: NN, rs1874045: NN, rs7514102: GG, rs1801274: NN, rs2274064: TT, rs2297950: CC, rs7527925: NN, rs3811445: GG, rs935172: CC, rs3739014: NN, rs1545133: NN, rs10206850: NN, rs9646748: NN, rs3732083: NN, rs6756597: CT, rs6765537: NN, rs2289247: NN, rs571391: NN, rs9851180: NN, rs6788448: NN, rs898500: NN, rs931606: NN, rs13146272: NN, rs737154: NN, rs1531545: NN, rs285599: NN, rs160632: NN, rs2304054: NN, rs315717: NN, rs1052486: NN, rs2229848: NN, rs9390459: NN, rs2236313: NN, rs7793096: AG, rs3823646: NN, rs10246939: CT, rs12919: NN, rs2301963: NN, rs1800392: NN, rs4870723: NN, rs2294008: CT, rs301430: NN, rs1539172: AG, rs1043836: CT, rs10901333: GG, rs3136618: CC, rs2185724: CT, rs3818876: NN, rs1891110: GG, rs12781609: NN, rs1025412: NN, rs1064005: NN, rs4453265: NN, rs1852450: NN, rs703842: NN, rs11558556: NN, rs495680: NN, rs4942848: NN, rs1135641: NN, rs1060570: NN, rs3825569: CT, rs863980: NN, rs4077410: NN, rs1800775: CA, rs2159132: AG, rs2586514: NN, rs1292053: GG, rs1026128: NN, rs1805034: NN, rs888930: NN, rs2363956: NN, rs3745298: NN, rs2296241: AA, rs4680: AG
Running Log
Input file:
./personal_genome/HG001.vcf.gz
Database directory:
- ./algorithm/Qualitative\Qualitative_traits
- ./algorithm/Quantitative\Quantitative_traits
Reference population data:
- ['D:\\Users\\Sheng\\Documents\\Github\\pageant\\population_genome\\G1K.vcf.gz']
Log:
2021-10-06 16:58:18,209 - INFO: Logging start.
2021-10-06 16:58:18,209 - INFO: Recode and sex impute start
2021-10-06 16:58:20,172 - INFO: Recode and sex impute used time: 1.96s
2021-10-06 16:58:20,172 - INFO: Progress of the analysis: 5.0%
2021-10-06 16:58:21,010 - INFO: Sample QC start
2021-10-06 16:58:47,896 - INFO: Sample QC used time: 26.89s
2021-10-06 16:58:47,897 - INFO: Progress of the analysis: 14.0%
2021-10-06 16:58:47,897 - INFO: Reference data QC start
2021-10-06 16:58:59,164 - INFO: Reference data QC used time: 11.27s
2021-10-06 16:58:59,165 - INFO: Progress of the analysis: 23.0%
2021-10-06 16:58:59,165 - INFO: Initial reference data start
2021-10-06 16:58:59,166 - INFO: Get reference result data start
2021-10-06 16:58:59,353 - INFO: Get reference result data used time: 0.19s
2021-10-06 16:58:59,358 - INFO: Initial reference data used time: 0.19s
2021-10-06 16:58:59,358 - INFO: Progress of the analysis: 38.0%
2021-10-06 16:58:59,373 - INFO: Load sample vcf start
2021-10-06 16:58:59,620 - INFO: Load sample vcf used time: 0.25s
2021-10-06 16:58:59,620 - INFO: Progress of the analysis: 48.0%
2021-10-06 16:58:59,620 - INFO: Load indicator data start
2021-10-06 16:58:59,635 - WARNING: Snp (rs333) cannot be found in your genotype file!
2021-10-06 16:58:59,635 - WARNING: Snp (rs333) cannot be found in your genotype file!
2021-10-06 16:58:59,644 - WARNING: Snp (rs116503776) cannot be found in your genotype file!
2021-10-06 16:58:59,644 - WARNING: Snp (rs142450006) cannot be found in your genotype file!
2021-10-06 16:58:59,646 - WARNING: Snp (rs79037040) cannot be found in your genotype file!
2021-10-06 16:58:59,647 - WARNING: There are duplicate snps (rs11264280) when calculate the quantitative trait!
2021-10-06 16:58:59,649 - WARNING: There are duplicate snps (rs6843082) when calculate the quantitative trait!
2021-10-06 16:58:59,652 - WARNING: Snp (rs71801447) cannot be found in your genotype file!
2021-10-06 16:58:59,652 - WARNING: Snp (rs34207738) cannot be found in your genotype file!
2021-10-06 16:58:59,653 - WARNING: Snp (4:84370124) cannot be found in your genotype file!
2021-10-06 16:58:59,653 - WARNING: Snp (rs116095464) cannot be found in your genotype file!
2021-10-06 16:58:59,656 - WARNING: Snp (rs8176636) cannot be found in your genotype file!
2021-10-06 16:58:59,657 - WARNING: Snp (rs2532263) cannot be found in your genotype file!
2021-10-06 16:58:59,657 - WARNING: Snp (rs71338792) cannot be found in your genotype file!
2021-10-06 16:58:59,659 - WARNING: Snp (rs912805253) cannot be found in your genotype file!
2021-10-06 16:59:00,396 - WARNING: Snp (rs116822326) cannot be found in your genotype file!
2021-10-06 16:59:00,399 - WARNING: Snp (rs111404218) cannot be found in your genotype file!
2021-10-06 16:59:00,400 - WARNING: Snp (rs140002913) cannot be found in your genotype file!
2021-10-06 16:59:00,402 - WARNING: Snp (rs67338227) cannot be found in your genotype file!
2021-10-06 16:59:00,402 - WARNING: Snp (rs77505915) cannot be found in your genotype file!
2021-10-06 16:59:00,407 - WARNING: Snp (chr1_243881945_I) cannot be found in your genotype file!
2021-10-06 16:59:00,407 - WARNING: Snp (chr1_8424984_D) cannot be found in your genotype file!
2021-10-06 16:59:00,407 - WARNING: Snp (chr10_104957618_I) cannot be found in your genotype file!
2021-10-06 16:59:00,407 - WARNING: Snp (chr11_46350213_D) cannot be found in your genotype file!
2021-10-06 16:59:00,407 - WARNING: Snp (chr18_52749216_D) cannot be found in your genotype file!
2021-10-06 16:59:00,407 - WARNING: Snp (chr2_146436222_I) cannot be found in your genotype file!
2021-10-06 16:59:00,408 - WARNING: Snp (chr2_149429178_D) cannot be found in your genotype file!
2021-10-06 16:59:00,408 - WARNING: Snp (chr2_200825237_I) cannot be found in your genotype file!
2021-10-06 16:59:00,408 - WARNING: Snp (chr22_39987017_D) cannot be found in your genotype file!
2021-10-06 16:59:00,408 - WARNING: Snp (chr3_180594593_I) cannot be found in your genotype file!
2021-10-06 16:59:00,408 - WARNING: Snp (chr5_140143664_I) cannot be found in your genotype file!
2021-10-06 16:59:00,408 - WARNING: Snp (chr6_84280274_D) cannot be found in your genotype file!
2021-10-06 16:59:00,409 - WARNING: Snp (chr7_2025096_I) cannot be found in your genotype file!
2021-10-06 16:59:00,409 - WARNING: Snp (chr7_24747494_D) cannot be found in your genotype file!
2021-10-06 16:59:00,410 - WARNING: Snp (rs115329265) cannot be found in your genotype file!
2021-10-06 16:59:00,412 - WARNING: Snp (rs190065944) cannot be found in your genotype file!
2021-10-06 16:59:00,418 - WARNING: Snp (rs7907645) cannot be found in your genotype file!
2021-10-06 16:59:00,420 - INFO: Load indicator data used time: 0.80s
2021-10-06 16:59:00,420 - INFO: Progress of the analysis: 58.0%
2021-10-06 16:59:00,420 - INFO: Add population distribution start
2021-10-06 16:59:12,112 - INFO: Add population distribution used time: 11.69s
2021-10-06 16:59:12,113 - INFO: Progress of the analysis: 62.5%
2021-10-06 16:59:12,113 - INFO: Query database start
2021-10-06 16:59:20,085 - INFO: Progress of the analysis: 71.5%
2021-10-06 16:59:20,087 - INFO: Progress of the analysis: 80.5%
2021-10-06 16:59:20,668 - INFO: Query database used time: 8.55s
2021-10-06 16:59:20,668 - INFO: Load sample vcf start
2021-10-06 16:59:20,909 - INFO: Load sample vcf used time: 0.24s
2021-10-06 16:59:20,909 - INFO: Progress of the analysis: 90.5%
2021-10-06 16:59:20,909 - INFO: Produce QR code start
2021-10-06 16:59:21,377 - INFO: Produce QR code used time: 0.47s
2021-10-06 16:59:21,378 - INFO: Progress of the analysis: 95.0%
2021-10-06 16:59:21,378 - INFO: Export report result start
2021-10-06 16:59:21,686 - INFO: Export report result used time: 0.31s
2021-10-06 16:59:21,686 - INFO: Progress of the analysis: 105.0%
2021-10-06 16:59:21,686 - INFO: Analysis runs successfully!